01300000000000481000450099100020000070000020000270600020000470100020000609100090
00081300053000174210020000701510024000902300053001140350010001674800047001770300
02000224031000300244032000200247036000600249930000600255042000200261117000600263
08500030026920000020027206500090027412200030028304800140028604800140030004800240
03140490038003380490023003760490051003990490037004500490027004870490043005140490
04200557043006500599043006500664043006800729300000700797300000700804300000700811
#1#0#i#1#20080623#Brazilian Journal of Medical and Biological Research#Braz J Me
d Biol Res#Braz. j. med. biol. res#Revista brasileira de pesquisas médicas e bio
lógicas#0100-879X#Associação Brasileira de Divulgação Científica#Braz J Med Biol
 Res#41#1#20081#BJMBR#1#other#nd#0#20080100#12#^les^hSumario#^lpt^hSumário#^len^
hTable of Contents#^len^cBJMBR030^tConcepts and Comments#^len^cBJMBR090^tReview#
^len^cBJMBR010^tBiochemistry and Molecular Biology#^len^cBJMBR040^tExperimental 
Biology#^len^cBJMBR050^tImmunology#^len^cBJMBR060^tNeurosciences and Behavior#^l
en^cBJMBR080^tPhysiology and Biophysics#^les^tBraz J Med Biol Res^vv.41^nn.1^cRi
beirão Preto^mene.^a2008#^lpt^tBraz J Med Biol Res^vv.41^nn.1^cRibeirão Preto^mj
an.^a2008#^len^tBraz J Med Biol Res^vvol.41^nno.1^cRibeirão Preto^mJan.^a2008#^t
^les#^t^lpt#^t^len##
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#o#1#1#article#1#20
080623#161455#6758.htm#170##
02292000000000529000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000300104030002000107
03100030012703200020013006500090013201400080014103500100014922300090015901201380
01680100022003060100026003280700052003540831117004060850008015230850038015310850
02901569085003401598085003601632117000601668072000301674112000901677111001801686
114000901704113001601713881002401729002000901753#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6758.htm#S#h#2#1#article#1#ra#en#bjmbr#1#3.1#ILUS#02#BJMBR090#nd#Braz
 J Med Biol Res#41#1#20080100#^f5^l11#0100-879X#20071217#Impairment of cytomegal
ovirus-specific cellular immune response as a risk factor for cytomegalovirus di
sease in transplant recipients^len#^rND^1A01^nV.N^sMotta#^rND^1A01^nS.L.R^sMarti
ns#Fleury Medicina e Saúde^iA01^cSão Paulo^sSP^pBrasil#^len^aHuman cytomegalovir
us (CMV) infection is common in most people but nearly asymptomatic in immunocom
petent individuals. After primary infection the virus persists throughout life i
n a latent form in a variety of tissues, particularly in precursor cells of the 
monocytic lineage. CMV reinfection and occurrence of disease are associated with
 immunosuppressive conditions. Solid organ and bone marrow transplant patients a
re at high risk for CMV disease as they undergo immunosuppression. Antiviral tre
atment is effective in controlling viremia, but 10-15% of infected patients can 
experience CMV disease by the time the drug is withdrawn. In addition, long-term
 antiviral treatment leads to bone marrow ablation and renal toxicity. Furthermo
re, control of chronic CMV infection in transplant recipients appears to be depe
ndent on the proper recovery of cellular immunity. Recent advances in the charac
terization of T-cell functions and identification of distinct functional signatu
res of T-cell viral responses have opened new perspectives for monitoring transp
lant individuals at risk of developing CMV disease.#^dnd^i1#^tm^len^kCytomegalov
irus infection^i1#^tm^len^kT-cell responses^i1#^tm^len^kTransplant recipients^i1
#^tm^len^kIntracellular cytokines^i1#other#60#20061220#December 20, 2006#2007082
7#August 27, 2007#S0100-879X2006005000193#6758.htm##
02256000000000517000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000300104030002000107
03100030012703200020013006500090013201400080014103500100014922300090015901201380
01680100022003060100026003280700052003540831117004060850008015230850038015310850
02901569085003401598085003601632117000601668072000301674112000901677111001801686
114000901704113001601713002000901729#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
758.htm#S#f#3#1#article#1#ra#en#bjmbr#1#3.1#ILUS#02#BJMBR090#nd#Braz J Med Biol 
Res#41#1#20080100#^f5^l11#0100-879X#20071217#Impairment of cytomegalovirus-speci
fic cellular immune response as a risk factor for cytomegalovirus disease in tra
nsplant recipients^len#^rND^1A01^nV.N^sMotta#^rND^1A01^nS.L.R^sMartins#Fleury Me
dicina e Saúde^iA01^cSão Paulo^sSP^pBrasil#^len^aHuman cytomegalovirus (CMV) inf
ection is common in most people but nearly asymptomatic in immunocompetent indiv
iduals. After primary infection the virus persists throughout life in a latent f
orm in a variety of tissues, particularly in precursor cells of the monocytic li
neage. CMV reinfection and occurrence of disease are associated with immunosuppr
essive conditions. Solid organ and bone marrow transplant patients are at high r
isk for CMV disease as they undergo immunosuppression. Antiviral treatment is ef
fective in controlling viremia, but 10-15% of infected patients can experience C
MV disease by the time the drug is withdrawn. In addition, long-term antiviral t
reatment leads to bone marrow ablation and renal toxicity. Furthermore, control 
of chronic CMV infection in transplant recipients appears to be dependent on the
 proper recovery of cellular immunity. Recent advances in the characterization o
f T-cell functions and identification of distinct functional signatures of T-cel
l viral responses have opened new perspectives for monitoring transplant individ
uals at risk of developing CMV disease.#^dnd^i1#^tm^len^kCytomegalovirus infecti
on^i1#^tm^len^kT-cell responses^i1#^tm^len^kTransplant recipients^i1#^tm^len^kIn
tracellular cytokines^i1#other#60#20061220#December 20, 2006#20070827#August 27,
 2007#6758.htm##
02398000000000541000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000500100121000300105049000900108158000300117
03000240012003100030014403200020014706500090014901400080015803500100016622300090
01760120138001850100023003230100028003460700054003740831124004280850008015520850
03801560085002901598085003401627085003601661117000601697072000301703112000901706
111001801715114000901733113001601742002000901758008008901767#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6758.htm#S#l#4#1#article#1#^mJan.^a2008#ra#en#bjmbr#1#3.1
#ilus#02#BJMBR090#nd#Braz. j. med. biol. res#41#1#20080100#^f5^l11#0100-879X#200
71217#Impairment of cytomegalovirus-specific cellular immune response as a risk 
factor for cytomegalovirus disease in transplant recipients^len#^rND^1A01^nV. N^
sMotta#^rND^1A01^nS. L. R^sMartins#^iA01^1Fleury Medicina e Saúde^cSão Paulo^sSP
^pBrasil#^len^aHuman cytomegalovirus (CMV) infection is common in most people bu
t nearly asymptomatic in immunocompetent individuals. After primary infection th
e virus persists throughout life in a latent form in a variety of tissues, parti
cularly in precursor cells of the monocytic lineage. CMV reinfection and occurre
nce of disease are associated with immunosuppressive conditions. Solid organ and
 bone marrow transplant patients are at high risk for CMV disease as they underg
o immunosuppression. Antiviral treatment is effective in controlling viremia, bu
t 10-15 percent of infected patients can experience CMV disease by the time the 
drug is withdrawn. In addition, long-term antiviral treatment leads to bone marr
ow ablation and renal toxicity. Furthermore, control of chronic CMV infection in
 transplant recipients appears to be dependent on the proper recovery of cellula
r immunity. Recent advances in the characterization of T-cell functions and iden
tification of distinct functional signatures of T-cell viral responses have open
ed new perspectives for monitoring transplant individuals at risk of developing 
CMV disease.#^dnd^i1#^tm^len^kCytomegalovirus infection^i1#^tm^len^kT-cell respo
nses^i1#^tm^len^kTransplant recipients^i1#^tm^len^kIntracellular cytokines^i1#ot
her#60#20061220#December 20, 2006#20070827#August 27, 2007#6758.htm#Internet^iht
tp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2008000100002##
00398000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704017200071002000900243#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#5#1#article#106#<P class="style4"> <A NA
ME="Home"></A><B>Braz J Med Biol Res, <font face="Arial, Helvetica, sans-serif">
January    2008, Volume 41(1) 5-11 </font> (Review)</B></P>     ^cY#6758.htm##
00462000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704023600071002000900307#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#6#2#article#106#<P class="style2"><B><fo
nt size="5" face="Arial, Helvetica, sans-serif">Impairment    of cytomegalovirus
-specific cellular immune response as a risk factor for cytomegalovirus    disea
se in transplant recipients</font></B> </P>     ^cY#6758.htm##
00646000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704042000071002000900491#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#7#3#article#106#<P><font face="Arial, He
lvetica, sans-serif"><span class="style4"><a href="#Correspondence"><img src="/i
mg/revistas/bjmbr/v41n1/recor.gif" width="15" height="14" border="0"></a>    <a 
href="mailto:vinicius.n.motta@gmail.com"><img src="/img/revistas/bjmbr/v41n1/ema
il-ca.gif" width="14" height="11" border="0"></a></span></font>    <font face="A
rial, Helvetica, sans-serif">V.N. Motta and S.L.R. Martins </font>      ^cY#6758
.htm##
00351000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704012500071002000900196#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#8#4#article#106#<P><font face="Arial, He
lvetica, sans-serif">Fleury Medicina e Sa&uacute;de, S&atilde;o    Paulo, SP, Br
asil</font>      ^cY#6758.htm##
00435000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704020900071002000900280#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#9#5#article#106#<P class="style4"> <A HR
EF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM WIDTH=
12 HEIGHT=12 BORDER=0 VSPACE=0 HSPACE=0></A>    <A HREF="#Abstract"><strong>Abst
ract</strong></A>    ^cY#6758.htm##
00416000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704018900072002000900261#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#10#6#article#106#<BR>   <A HREF="#Text">
<IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSP
ACE=0 width="12" height="12"></A>    <A HREF="#Text"><strong>Text</strong></A>  
  ^cY#6758.htm##
00421000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704019400072002000900266#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#11#7#article#106#<BR>   <A HREF="#Refere
nces"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#References"><strong>Referen
ces    ^cY#6758.htm##
00476000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704024900072002000900321#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#12#8#article#106#<br>   </strong></A> <A
 HREF="#Correspondence"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTT
OM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Correspon
dence"><strong>Correspondence and Footnotes</strong></a>      ^cY#6758.htm##
00289000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704006200072002000900134#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#13#9#article#106#<P class="style4">  <HR
 ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6758.htm##
00561000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704033300073002000900406#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#14#10#article#106#<P class="style4"> <A 
NAME="Abstract"></A><span class="style3"><FONT COLOR=#00007F>Abstract    </FONT>
</span><A HREF="#Home"><FONT SIZE=4><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.
gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0" width="12" height="12"></B
></FONT></A>  </P> <font face="Arial, Helvetica, sans-serif">      ^cY#6758.htm#
#
01390000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704116200073002000901235#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#15#11#article#106#<P>Human cytomegalovir
us (CMV) infection is common in most people but nearly asymptomatic    in immuno
competent individuals. After primary infection the virus persists throughout    
life in a latent form in a variety of tissues, particularly in precursor cells  
  of the monocytic lineage. CMV reinfection and occurrence of disease are associ
ated    with immunosuppressive conditions. Solid organ and bone marrow transplan
t patients    are at high risk for CMV disease as they undergo immunosuppression
. Antiviral    treatment is effective in controlling viremia, but 10-15% of infe
cted patients    can experience CMV disease by the time the drug is withdrawn. I
n addition, long-term    antiviral treatment leads to bone marrow ablation and r
enal toxicity. Furthermore,    control of chronic CMV infection in transplant re
cipients appears to be dependent    on the proper recovery of cellular immunity.
 Recent advances in the characterization    of T-cell functions and identificati
on of distinct functional signatures of    T-cell viral responses have opened ne
w perspectives for monitoring transplant    individuals at risk of developing CM
V disease.      ^cY#6758.htm##
00389000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704016100073002000900234#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#16#12#article#106#<P>Key words: Cytomega
lovirus infection; T-cell responses; Transplant recipients;    Intracellular cyt
okines  </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6758.htm##
00552000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704032400073002000900397#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#17#13#article#106#<P class="style4"><A N
AME="Text"></A><span class="style3"><FONT COLOR=#00007F>Text    </FONT></span><A
 HREF="#Home"><FONT SIZE=4><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIG
N=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0" width="12" height="12"></B></FONT><
/A>  </P> <font face="Arial, Helvetica, sans-serif">      ^cY#6758.htm##
00861000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704063300073002000900706#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#18#14#article#106#<P>Cytomegalovirus (CM
V) is a genus of the &szlig;-herpes virinae subfamily of    Herpesviridae, a dou
ble-strand DNA 230-kb virus that produces more than 200    proteins. These prote
ins are produced in three overlapping phases: immediate    early (IE), early, an
d late (1). Human infection usually peaks first during    childhood and results 
from both vertical and horizontal transmission after virus    shedding in urine 
and in respiratory secretions. The next peak occurs in young    adults, mostly b
y sexual transmission and 50 to more than 90% of the worldwide    population bec
ome seropositive for CMV throughout life.      ^cY#6758.htm##
00954000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704072600073002000900799#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#19#15#article#106#<P>Primary CMV infecti
on is commonly asymptomatic in healthy and immunocompetent    individuals but ca
n produce fever, myalgia, pharyngitis, cervical lymphadenopathy,    mild hepatit
is, and spleen enlargement as a mononucleosis-like illness (2).    After primary
 infection, CMV is not completely eliminated from the host but    remains latent
 in a variety of tissues, particularly within macrophages, granulocytes    and d
endritic cell precursors (3). In contrast, reactivation of the virus with    sev
ere clinical symptoms is commonly observed in immunocompromised hosts (4,5).    
Leukopenia, pneumonitis, retinitis, encephalitis, and gastrointestinal problems 
   are frequently observed in these patients.  </font>      ^cY#6758.htm##
00648000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704042000073002000900493#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#20#16#article#106#<P><font face="Arial, 
Helvetica, sans-serif">Reactivation of CMV is not completely    understood but a
 series of mechanisms, which have in common the cAMP and NF<font face="Symbol">k
</font>B    pathways, are likely to play a role, such as stress, inflammation an
d some cAMP-elevating    drugs. These mechanisms lead to activation of the CMV I
E enhancer/promoter that    initiates virus replication (6). </font>      ^cY#67
58.htm##
00692000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704046400073002000900537#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#21#17#article#106#<P><font face="Arial, 
Helvetica, sans-serif">Immunologic control of CMV replication    includes severa
l distinct categories of effector cells: natural killer cells,    macrophages, B
 cells, g<font face="Symbol">d</font> and <font face="Symbol">a</font>&szlig;   
 T cells. In most circumstances, however, virus-specific CD8<SUP>+</SUP> and    
CD4<SUP>+</SUP> T cells appear to play a pivotal role (7-9). </font>  <font face
="Arial, Helvetica, sans-serif">      ^cY#6758.htm##
00318000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704009000073002000900163#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#22#18#article#106#<P><B>The risk for CMV
 reactivation and reinfection in transplant recipients</B>      ^cY#6758.htm##
01056000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704082800073002000900901#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#23#19#article#106#<P>Transplant recipien
ts usually are immunosuppressed and are at high risk of    developing CMV diseas
es. The risk is associated with the degree of T-cell functional    impairment an
d the mode and magnitude of immunosuppression. The serological    CMV status of 
pretransplant donor and recipient (D/R) also correlates with both    the inciden
ce and severity of disease. Seronegative recipients of a CMV-positive    organ (
D<SUP>+</SUP>/R<SUP>-</SUP>) will develop primary infection. Despite    successf
ul treatment, CMV infection recurs in one third of solid organ recipients    (10
). Of note, the secondary consequences of CMV infection are: enhanced susceptibi
lity    to post-transplant Epstein Barr virus-related lymphoproliferation (11), 
acute    chronic allograft rejection (12), and opportunistic infections (4).    
  ^cY#6758.htm##
01524000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704129600073002000901369#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#24#20#article#106#<P>The relationship be
tween the risk for CMV disease and the serologic CMV status    of D/R is the rev
erse in stem cell and bone marrow transplants (BMT). Seronegative    recipients 
of CMV-positive donor bone marrow (D<SUP>+</SUP>/R<SUP>-</SUP>) are    not at hi
gher risk of developing CMV disease, while seropositive recipients    of seroneg
ative bone marrow donors (D<SUP>-</SUP>/R<SUP>+</SUP>) are at an increased    ri
sk for reinfection (13,14). The least risk for CMV infections in BMT occurs    w
hen both donor and recipient are CMV seronegative pre-transplant (D<SUP>-</SUP>/
R<SUP>-</SUP>)    (15). It is thought that the remaining CMV-specific T cells tr
ansferred along    with the bone marrow of seropositive (D<SUP>+</SUP>) but not 
with seronegative    (D<SUP>-</SUP>) donors confer protection against the recipi
ent's (R<SUP>+</SUP>)    own CMV reactivation (14,16,17). The risk of developing
 CMV disease is also    higher for stem cell transplant and BMT recipients from 
unrelated and haplo-identical    donors (18,19). In this case, the risk for CMV-
disease is likely to be linked    to the predisposition for graft-versus-host-di
sease complications. Graft-versus-host-disease    culminates with T-cell functio
nal impairment, as also does CMV-specific cell    immunity (14).      ^cY#6758.h
tm##
00326000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704009800073002000900171#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#25#21#article#106#<P><B>Clinical managem
ent of transplant recipients at risk of developing CMV disease</B>      ^cY#6758
.htm##
00678000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704045000073002000900523#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#26#22#article#106#<P>Before the era of a
ntiviral drugs the only treatment for CMV infection was    reduction of immunosu
ppression in transplant recipients. The development of    drugs able to inhibit 
the viral DNA polymerase activity (Forscanet), or nucleoside    analogues (acycl
ovir, valganciclovir and ganciclovir) that inhibit the incorporation    of dGTP 
terminating the elongation of viral DNA (20,21) has led to improved    anti-CMV 
disease therapies.      ^cY#6758.htm##
01240000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704101200073002000901085#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#27#23#article#106#<P>The prophylaxis str
ategy, in which all transplant recipients are treated with    antiviral drugs be
fore and up to 3 months after transplantation, has significantly    decreased th
e incidence of disease as compared with placebo or no treatment    (22). However
, long-term prophylaxis with antiviral drugs is myeloablative and    nephrotoxic
, and can be associated with delayed CMV-specific T-cell immunity    recovery, d
rug resistance and late-onset CMV disease (9,23,24). Besides, unnecessary    tre
atment of individuals that may not develop disease is not desired. Hence,    the
 role of prophylaxis has been questioned in favor of pre-emptive therapy    (25)
. This approach involves antiviral drug therapy for patients known to be    at r
isk for active or severe disease on the basis of an epidemiological or biologica
l    marker. Instead of being administered to all transplant recipients, anti-CM
V    drugs can be selectively given to the at-risk population saving costs and r
educing    toxicity.      ^cY#6758.htm##
01524000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704129600073002000901369#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#28#24#article#106#<P>Biomarkers able to 
identify patients at risk of developing CMV disease before    the onset of the d
isease are crucial for preemptive therapy. Early on, shell    vial cultures of b
ronchoalveolar lavage for CMV detection were used as a strategy    to identify C
MV-positive transplant recipients at risk (26). The preemptive    approach has b
enefited enormously from advances in CMV diagnosis. The pp65 antigenemia    and 
the widespread application of PCR methodology have provided clinicians with    t
he means of monitoring CMV activity more accurately and to identify groups    of
 patients at risk of developing disease (5,13,27). One weakness of the preemptiv
e    therapy, however, is that CMV activity may be detected just before, at the 
same    time as or after the manifestation of disease and the treatment may not 
be efficient.    In addition, CMV viral load is not universally associated with 
disease and some    patients may develop CMV disease without testing positive fo
r CMV (26,28,29).    An explanation might be linked to the status of the host's 
antiviral cellular    immunity (30). As we shall discuss next, there is evidence
 that the pattern    of CMV-specific T-cell immunity is an independent risk fact
or for CMV disease    in transplant recipients (31,32).  </font>      ^cY#6758.h
tm##
00372000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704014400073002000900217#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#29#25#article#106#<P>  <font face="Arial
, Helvetica, sans-serif"><B>T-cell phenotype and functional signatures  for the 
clinical monitoring setting </B>      ^cY#6758.htm##
01351000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704112300073002000901196#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#30#26#article#106#<P>The role of T cells
 in anti-viral immunity has been known for a long time (8).    T lymphocytes are
 important in the early and late stages of virus infections    (7,33). Upon vira
l infection the host responds with both the innate and adaptive    arms of the i
mmune system. The adaptive immune response is characterized by    activation of 
viral specific T-cell clones that differentiate into effector    and memory T ce
lls. Memory T cells play an important role in secondary infections    when they 
quickly differentiate into effector cells promoting faster, stronger    and more
 efficient responses against the infectious agent. In the absence of    memory T
 cells, the host is at risk of developing viral disease and severe clinical    s
ymptoms. Over the past 5-10 years, conceptual and technical advances have substa
ntially    improved T-cell assays for the determination of the phenotypes and fu
nctional    signatures of memory and effector T cells. It is now possible to fun
ctionally    characterize T-cell immunity that might be suitable for both diagno
sis and clinical    monitoring (30,34,35).  </font>      ^cY#6758.htm##
01431000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704120300073002000901276#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#31#27#article#106#<P><font face="Arial, 
Helvetica, sans-serif">In their landmark paper, Sallusto    et al. (36) characte
rized two phenotypically and functionally distinct memory    T cells for both CD
4 and CD8 T cells. CCR7<SUP>-</SUP> T cells preferentially    secrete cytokines 
IL-4, IL-5 and IFN-<font face="Symbol">g</font>, and because    they lose the ex
pression of CCR7 (a receptor homing to lymph nodes) are prone    to circulate in
to inflamed tissues, and CCR7<SUP>+</SUP> memory T cells that    secrete IL-2 an
d seed lymph nodes and spleen. They were classified as effector    memory T cell
s (CCR7<SUP>-</SUP>) and central memory T cells (CCR7<SUP>+</SUP>).    CD57, CD6
2L, CD28, CD27, and CD45RA surface markers have also been used to characterize  
  these distinct memory T-cell subpopulations and the CD45RA<SUP>+</SUP> CD27<SU
P>-</SUP>    T-cell phenotypes are thought to be fully differentiated cells exhi
biting shorter    telomere length (37,38). Loss of CD27 and expression of CD45RA
 in a varying    proportion of CMV-specific CD8 T cells are associated with spon
taneous IFN-<font face="Symbol">g</font>    secretion and may be a correlate wit
h <I>in vivo</I> virus activity (38,39).    </font>      ^cY#6758.htm##
01563000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704133500073002000901408#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#32#28#article#106#<P><font face="Arial, 
Helvetica, sans-serif">Early studies measured intracellular    cytokines in resp
onse to CMV viral lysates and revealed percentages of cytokine-secreting    T ce
lls in seropositive but not in seronegative individuals (40), though with    gre
at variation among the seropositive individuals (41). A hierarchy of cytokine-po
sitive    T cells (TNF-<font face="Symbol">a</font></font> <font face="Arial, He
lvetica, sans-serif">&gt;    IFN-<font face="Symbol">g</font>&gt; IL-2) can be s
een in chronic CMV infection    (42,43). Interestingly, high TNF-<font face="Sym
bol">a</font>-secreting cells    are also high IFN-<font face="Symbol">g</font>-
producing cells, but this correlation    is not observed for IL-2-secreting cell
s (30). Indeed, a distinct role in viral    immunity related to the ability of T
 cells to secrete IL-2 and/or IFN-<font face="Symbol">g</font>    has been propo
sed. The presence of viral specific IFN-<font face="Symbol">g</font>-secreting  
  cells alone defines an acute infection with a high viral antigen load; convers
ely,    the existence of cells producing IL-2 alone, IFN-<font face="Symbol">g</
font>    alone or IL-2 plus IFN-<font face="Symbol">g</font> correlates with chr
onic    infection with low levels of viral antigen. </font>  <font face="Arial, 
Helvetica, sans-serif">      ^cY#6758.htm##
00785000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704055700073002000900630#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#33#29#article#106#<P>Using tetramer conj
ugated peptide, Bunde et al. (44) have recently suggested    that protection fro
m CMV infection is correlated with IE-1-specific but not    with pp65-specific C
D8 T cells in transplant recipients. However, other studies    have shown pp65-s
pecific T cells as independent risk factor for CMV disease    and long-term viru
s control in such patients (16,45-49). Transplant recipients    with levels of C
MV-specific CD8<SUP>+</SUP> T lymphocytes above 0.2-1 x 10<SUP>7</SUP>    cells 
per liter do not develop CMV disease (16,45).      ^cY#6758.htm##
00421000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704019300073002000900266#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#34#30#article#106#<P>CD4 T cells, on the
 other hand, are necessary to initiate and maintain CMV    CD8-effector immune r
esponse as clearly demonstrated on adoptive cellular immunotherapy    (16,32,48)
.      ^cY#6758.htm##
01614000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704138600073002000901459#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#35#31#article#106#<P>Functional analysis
 of the cell immune response appears, however, to be a better    biomarker for d
isease risk than the number of CMV-specific T cells (48,50).    Quinnan et. al. 
(8) showed as early as in the 1980's the correlation between    the presence of 
CMV-specific cytotoxic T cells and protection from CMV infection.    Absence of 
lymphocyte proliferation in response to CMV antigens <I>in vitro</I>    was anot
her risk factor for disease (31). Until recently, it has been difficult    to as
sess T-cell functional immunity given the complexity of T-cell manipulation,    
which involves isolation of mononuclear cells from large volumes of biological  
  specimens and careful storage of viable samples. Thus, there has been limited 
   interest in assessing the use and importance of measuring T-cell function in 
   diagnostic and clinical monitoring settings. However, the possibility of asse
ssing    T-cell functionality within just about 6 h directly on a fresh whole bl
ood specimen    (42) has increased the interest in studying the CMV-specific imm
une response    as a risk factor for CMV disease in transplant recipients (16,45
-49). In parallel,    a relatively simple procedure for the isolation,<I> in vit
ro</I> expansion and    transfer of CMV-specific T cells into patients has been 
pursued as therapy for    patients at risk of developing CMV disease (51).      
^cY#6758.htm##
00298000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704007000073002000900143#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#36#32#article#106#<P><B>Methodological a
dvances in cytokine flow cytometry</B>      ^cY#6758.htm##
02158000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704193000073002000902003#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#37#33#article#106#<P>CMV-specific T cell
s can be functionally assessed by cytokine and chemokine    release, cytotoxic p
otential and T-cell proliferation. Enzyme-linked immunosorbent    spot can enume
rate cytokine-secreting CMV-specific T cells upon <I>in vitro</I>    stimulation
 with viral antigens (46,52). However, assessment of CMV-specific    T-cell func
tion by polychromatic flow cytometry enables simultaneously assessment    of sev
eral functions, including cytokine secretion (intracellular staining),    cytoto
xic potential (as measured by perforin expression and degranulation activity)   
 and permits the visualization of proliferating T cells based on the use of a   
 dye, carboxyfluorescein succinimidyl ester. Besides, flow cytometry allows to  
  phenotype the T-cell population responding to the stimulus. Over the past 5   
 years, there has been great interest in the quantification of cytokine producti
on    by flow cytometry, referred to as cytokine flow cytometry, which is now in
 advanced    stages of standardization (53). Important achievement is the possib
ility to    use fresh whole blood or frozen peripheral blood mononuclear cells, 
which allows    direct processing with minimal manipulation, sample shipment, st
orage, and latter    processing (54). In addition, 96-well plate-based assays, r
ather than 15-mL    tubes, allow high throughput of samples and are suitable for
 the clinical settings    (55). Moreover, whole blood samples can be processed i
n 96-deep-well plates    (2 mL), in which the entire staining procedure can be p
erformed, including the    lysis of red cells, without the need of sample transf
erring. Stimulation is    usually performed for short time, 6-8 h that allows sa
mple collection, processing    and analysis on a single day. Besides, automate w
ater bath can be set up to    cool samples down to 4&#176;C overnight, by which 
samples can be processed on    the next day (42).  </font>      ^cY#6758.htm##
01273000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704104500073002000901118#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#38#34#article#106#<P><font face="Arial, 
Helvetica, sans-serif">Briefly, cytokine flow cytometry    consists of activatin
g whole blood or peripheral blood mononuclear cells <I>in    vitro</I> for 6 h t
o induce the production of effector cytokines such as IFN-<font face="Symbol">g<
/font>    or TNF-<font face="Symbol">a</font>. The antigen may be a single pepti
de or    a pool of peptides (56,57), purified virus antigenic polypeptides (58) 
or even    virus-infected cell lysates (43). The addition of a transport inhibit
or such    as Brefeldin A prevents secretion and causes cytokine accumulation in
 the cytoplasm    (59). Then, intracellular cytokine staining is performed and c
ells are analyzed    by flow cytometry (<a href="#Fig1">Figure 1</a>). This allo
ws a qualitative    and quantitative assessment of CMV immunity in patients. Co-
staining with CD4,    CD8 and MHC-tetramers makes it possible to determine the p
roportion of tetramer-binding    T-cell subsets that respond to stimulation (47)
. </font>  <font face="Arial, Helvetica, sans-serif">      ^cY#6758.htm##
00678000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704045000073002000900523#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#39#35#article#106#<P>CD4 T-cell response
 to CMV is more effective when viral lysates are used, whereas    the use of pep
tides permits a more consistent detection of CD8 T-cell responses    (56,57,60).
 However, protein-spanning pools of overlapping peptides have been    shown to s
timulate both CD4 and CD8 T-cell responses to CMV in the same sample    when pep
tides of the appropriate length (15 amino acids) and overlap (11 amino    acids)
 are used (57,60).      ^cY#6758.htm##
00266000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704003800073002000900111#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#40#36#article#106#<P><B>Concluding remar
ks</B>      ^cY#6758.htm##
01192000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704096400073002000901037#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#41#37#article#106#<P>At present, prophyl
axis and preemptive antiviral drug treatment are the most    reliable treatment 
for the prevention of CMV disease in transplant recipients.    However, these tr
eatments appear to act as a double-edged sword, leading to    a decrease in infe
ction but also to an increase in late-onset drug-resistant    CMV disease. Besid
es, long-term drug treatment has adverse side effects and    5-10% of transplant
 recipients progress to end-organ CMV disease. Therefore,    cell-based immunoth
erapy and alternative clinical monitoring are desired to    manage not only CMV-
infected patients but also patients at risk for other viral    diseases. The pre
sence of CMV-specific CD4 and CD8 multifunctional T-cell responses    indicates 
efficient control of virus replication. Furthermore, alterations in    functiona
l signatures of T cells may detect subtle changes of virus replication    activi
ty before detectable levels are reached in the host.      ^cY#6758.htm##
01729000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704150100073002000901574#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#42#38#article#106#<P>The use of cytokine
 flow cytometry in clinical settings is expected to be cost-effective.    Flow c
ytometry is already a well-established method widely applied in leukemia    diag
nosis and immunophenotyping. The costs of cytokine flow cytometry should    not 
be higher than those of other T-cell functional assays, such as the measurement 
   of cell proliferation by thymidine incorporation. In addition, this procedure
    does not require duplicate or triplicate samples, being very sensitive and s
pecific.    The possibility of directly processing whole blood for T-cell stimul
ation makes    the assay less time consuming, with just one additional step in c
omparison to    conventional intracellular leukemia panels, such as TDT, CD3 and
 immunoglobulin    light/heavy chains. Nonetheless, we lack well-designed studie
s comparing the    cost effectiveness of cytokine flow cytometry with other meth
odologies for monitoring    patients at risk of developing CMV disease. Furtherm
ore, standardization of    cytokine flow cytometry and well-designed and control
led studies are necessary    for a better understanding of the correlation of ce
rtain functional T-cell signatures    with protection from CMV disease. At prese
nt, quantification of IFN-g-secreting    T cells has been associated with risk o
f developing CMV disease in transplant    recipients. However, additional inform
ation on distinct T-cell functional signatures    might improve diagnosis and de
serves further investigation.      ^cY#6758.htm##
01833000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704160500073002000901678#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#43#39#article#106#<P>In conclusion, func
tional signatures of T-cell responses can represent sensitive    measures of vir
al activity and may be useful tools for monitoring CMV-associated    disease act
ivity in clinical settings.  </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2> <table w
idth="100%"  border="0">   <tr align="left" valign="top">      <td width="13%"><
a href="/img/revistas/bjmbr/v41n1/html/6758i01.htm"><img src="/img/revistas/bjmb
r/v41n1/6758i01peq.jpg" width="120" height="126" border="2"></a></td>     <td wi
dth="87%"><font face="Arial, Helvetica, sans-serif"><a name="Fig1"></a>Figure   
     1. Intracellular cytokine flow cytometry. <I>A</I>, Schematic illustration 
       and estimated time for each step required for stimulation and detection  
      of intracellular cytokine in whole blood samples. Lysing buffer is added  
      directly to blood (adapted from Ref. 57, with permission). <I>B</I>, Typic
al        quantitative assay of cytomegalovitus (CMV)-specific IFN-<font face="S
ymbol">g</font>-secreting        CD8<SUP>+</SUP> T cells. Whole blood samples we
re left unstimulated (negative        control) or were stimulated with SEB (posi
tive control) or with a mixture        of 15-amino acid and 11-amino acid peptid
es with overlaps spanning the CMV        glycoprotein pp65. Specificity and sens
itivity for the detection of CMV-specific        activated T cells are shown by 
the absence of IFN-<font face="Symbol">g</font><SUP>+</SUP>        cells in the 
seronegative donor, and by low-, medium- and high-responder        seropositive 
donors (B, lower panel). </font></td>   </tr> </table>     ^cY#6758.htm##
00379000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704015100073002000900224#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#44#40#article#106#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image    (170 K JPG file)]</
font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6758.htm##
00553000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704032500073002000900398#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#45#41#article#106#<P class="style4"> <A 
NAME="References"></A><FONT color="#00007F" SIZE=4><B>References</B></FONT>    <
A HREF="#Home"><FONT SIZE=4><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALI
GN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0" width="12" height="12"></B></FONT>
</A>  </P> <font face="Arial, Helvetica, sans-serif">      ^cY#6758.htm##
00414000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704017200075002000900247#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#46#42#article#106#1#<P>1. Mc
Donough SH, Spector DH. Transcription in human fibroblasts permissively    infec
ted by human cytomegalovirus strain AD169. <I>Virology</I> 1983; 125: 31-46.    
^cY#6758.htm##
00380000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704013800075002000900213#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#47#43#article#106#2#<P>2. Si
ssons JG, Carmichael AJ. Clinical aspects and management of cytomegalovirus    i
nfection. <I>J Infect</I> 2002; 44: 78-83.    ^cY#6758.htm##
00429000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704018700075002000900262#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#48#44#article#106#3#<P>3. Ha
hn G, Jores R, Mocarski ES. Cytomegalovirus remains latent in a common    precur
sor of dendritic and myeloid cells. <I>Proc Natl Acad Sci U S A</I> 1998;    95:
 3937-3942.    ^cY#6758.htm##
00364000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704012200075002000900197#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#49#45#article#106#4#<P>4. Fi
shman JA, Rubin RH. Infection in organ-transplant recipients. <I>N Engl    J Med
</I> 1998; 338: 1741-1751.    ^cY#6758.htm##
00566000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704032400075002000900399#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#50#46#article#106#5#<P>5. Ya
kushiji K, Gondo H, Kamezaki K, Shigematsu K, Hayashi S, Kuroiwa M, et    al. Mo
nitoring of cytomegalovirus reactivation after allogeneic stem cell transplantat
ion:    comparison of an antigenemia assay and quantitative real-time polymerase
 chain    reaction. <I>Bone Marrow Transplant</I> 2002; 29: 599-606.    ^cY#6758
.htm##
00445000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704020300075002000900278#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#51#47#article#106#6#<P>6. Re
inke P, Prosch S, Kern F, Volk HD. Mechanisms of human cytomegalovirus    (HCMV)
 (re)activation and its impact on organ transplant patients. <I>Transpl    Infec
t Dis</I> 1999; 1: 157-164.    ^cY#6758.htm##
00423000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704018100075002000900256#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#52#48#article#106#7#<P>7. Do
herty PC, Allan W, Eichelberger M, Carding SR. Roles of alpha beta and    gamma 
delta T cell subsets in viral immunity. <I>Annu Rev Immunol</I> 1992;    10: 123
-151.    ^cY#6758.htm##
00596000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704035400075002000900429#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#53#49#article#106#8#<P>8. Qu
innan GV Jr, Kirmani N, Rook AH, Manischewitz JF, Jackson L, Moreschi    G, et a
l. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte  
  and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomega
lovirus    infection in bone-marrow-transplant recipients. <I>N Engl J Med</I> 1
982; 307:    7-13.    ^cY#6758.htm##
00529000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704028700075002000900362#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#54#50#article#106#9#<P>9. Re
usser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response   
 to cytomegalovirus after human allogeneic bone marrow transplantation: pattern 
   of recovery and correlation with cytomegalovirus infection and disease. <I>Bl
ood</I>    1991; 78: 1373-1380.    ^cY#6758.htm##
00407000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704016400076002000900240#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#55#51#article#106#10#<P>10. 
Speich R, van der Bij W. Epidemiology and management of infections after    lung
 transplantation. <I>Clin Infect Dis</I> 2001; 33 (Suppl 1): S58-S65.    ^cY#675
8.htm##
00464000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704022100076002000900297#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#56#52#article#106#11#<P>11. 
Walker RC, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, Habermann    TM, et
 al. Pretransplantation assessment of the risk of lymphoproliferative    disorde
r. <I>Clin Infect Dis</I> 1995; 20: 1346-1353.    ^cY#6758.htm##
00406000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704016300076002000900239#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#57#53#article#106#12#<P>12. 
Cainelli F, Vento S. Infections and solid organ transplant rejection: a    cause
-and-effect relationship? <I>Lancet Infect Dis</I> 2002; 2: 539-549.    ^cY#6758
.htm##
00560000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704031700076002000900393#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#58#54#article#106#13#<P>13. 
Gor D, Sabin C, Prentice HG, Vyas N, Man S, Griffiths PD, et al. Longitudinal   
 fluctuations in cytomegalovirus load in bone marrow transplant patients: relati
onship    between peak virus load, donor/recipient serostatus, acute GVHD and CM
V disease.    <I>Bone Marrow Transplant</I> 1998; 21: 597-605.    ^cY#6758.htm##
00521000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704027800076002000900354#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#59#55#article#106#14#<P>14. 
Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier    C. Don
or CMV serologic status and outcome of CMV-seropositive recipients after    unre
lated donor stem cell transplantation: an EBMT megafile analysis. <I>Blood</I>  
  2003; 102: 4255-4260.    ^cY#6758.htm##
00573000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704033000076002000900406#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#60#56#article#106#15#<P>15. 
Hebart H, Brugger W, Grigoleit U, Gscheidle B, Loeffler J, Schafer H, et    al. 
Risk for cytomegalovirus disease in patients receiving polymerase chain    react
ion-based preemptive antiviral therapy after allogeneic stem cell transplantatio
n    depends on transplantation modality. <I>Blood</I> 2001; 97: 2183-2185.    ^
cY#6758.htm##
00589000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704034600076002000900422#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#61#57#article#106#16#<P>16. 
Gratama JW, van Esser JW, Lamers CH, Tournay C, Lowenberg B, Bolhuis RL,    et a
l. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+    T lym
phocytes in T-cell-depleted stem cell grafts and after transplantation    may id
entify patients at risk for progressive CMV infection. <I>Blood</I> 2001;    98:
 1358-1364.    ^cY#6758.htm##
00469000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704022600076002000900302#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#62#58#article#106#17#<P>17. 
Grob JP, Grundy JE, Prentice HG, Griffiths PD, Hoffbrand AV, Hughes MD,    et al
. Immune donors can protect marrow-transplant recipients from severe cytomegalov
irus    infections. <I>Lancet</I> 1987; 1: 774-776.    ^cY#6758.htm##
00476000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704023300076002000900309#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#63#59#article#106#18#<P>18. 
Enright H, Haake R, Weisdorf D, Ramsay N, McGlave P, Kersey J, et al. Cytomegalo
virus    pneumonia after bone marrow transplantation. Risk factors and response 
to therapy.    <I>Transplantation</I> 1993; 55: 1339-1346.    ^cY#6758.htm##
00413000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704017000076002000900246#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#64#60#article#106#19#<P>19. 
Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection    
after human marrow transplantation. <I>J Infect Dis</I> 1986; 153: 478-488.    ^
cY#6758.htm##
00433000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704019000076002000900266#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#65#61#article#106#20#<P>20. 
Noble S, Faulds D. Ganciclovir. An update of its use in the prevention    of cyt
omegalovirus infection and disease in transplant recipients. <I>Drugs</I>    199
8; 56: 115-146.    ^cY#6758.htm##
00437000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704019400076002000900270#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#66#62#article#106#21#<P>21. 
O'Brien JJ, Campoli-Richards DM. Acyclovir. An updated review of its antiviral  
  activity, pharmacokinetic properties and therapeutic efficacy. <I>Drugs</I>   
 1989; 37: 233-309.    ^cY#6758.htm##
00484000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704024100076002000900317#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#67#63#article#106#22#<P>22. 
Meyers JD, Reed EC, Shepp DH, Thornquist M, Dandliker PS, Vicary CA, et    al. A
cyclovir for prevention of cytomegalovirus infection and disease after    alloge
neic marrow transplantation. <I>N Engl J Med</I> 1988; 318: 70-75.    ^cY#6758.h
tm##
00452000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704020900076002000900285#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#68#64#article#106#23#<P>23. 
Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resi
stant    cytomegalovirus disease among recipients of solid-organ transplants. <I
>Lancet</I>    2000; 356: 645-649.    ^cY#6758.htm##
00542000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704029900076002000900375#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#69#65#article#106#24#<P>24. 
Moretti S, Zikos P, Van Lint MT, Tedone E, Occhini D, Gualandi F, et al.    Fors
carnet <I>vs</I> ganciclovir for cytomegalovirus (CMV) antigenemia after    allo
geneic hemopoietic stem cell transplantation (HSCT): a randomised study.    <I>B
one Marrow Transplant</I> 1998; 22: 175-180.    ^cY#6758.htm##
00403000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704016000076002000900236#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#70#66#article#106#25#<P>25. 
Emery VC. Prophylaxis for CMV should not now replace pre-emptive therapy    in s
olid organ transplantation. <I>Rev Med Virol</I> 2001; 11: 83-86.    ^cY#6758.ht
m##
00574000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704033100076002000900407#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#71#67#article#106#26#<P>26. 
Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA. A randomized,   
 controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infe
ction    in recipients of allogeneic bone marrow transplants; The City of Hope-S
tanford-Syntex    CMV Study Group. <I>N Engl J Med</I> 1991; 324: 1005-1011.    
^cY#6758.htm##
00594000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704035100076002000900427#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#72#68#article#106#27#<P>27. 
Tanabe K, Tokumoto T, Ishikawa N, Koyama I, Takahashi K, Fuchinoue S, et    al. 
Comparative study of cytomegalovirus (CMV) antigenemia assay, polymerase    chai
n reaction, serology, and shell vial assay in the early diagnosis and monitoring
    of CMV infection after renal transplantation. <I>Transplantation</I> 1997; 6
4:    1721-1725.    ^cY#6758.htm##
00508000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704026500076002000900341#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#73#69#article#106#28#<P>28. 
Humar A, Paya C, Pescovitz MD, Dominguez E, Washburn K, Blumberg E, et    al. Cl
inical utility of cytomegalovirus viral load testing for predicting CMV    disea
se in D+/R- solid organ transplant recipients. <I>Am J Transplant</I> 2004;    4
: 644-649.    ^cY#6758.htm##
00413000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704017000076002000900246#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#74#70#article#106#29#<P>29. 
Ljungman P. Would monitoring CMV immune responses allow improved control    of C
MV in stem cell transplant patients. <I>J Clin Virol</I> 2006; 35: 493-495.    ^
cY#6758.htm##
00416000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704017300076002000900249#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#75#71#article#106#30#<P>30. 
Pantaleo G, Harari A. Functional signatures in antiviral T-cell immunity    for 
monitoring virus-associated diseases. <I>Nat Rev Immunol</I> 2006; 6: 417-423.  
  ^cY#6758.htm##
00528000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704028500076002000900361#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#76#72#article#106#31#<P>31. 
Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, et    al. La
te cytomegalovirus disease and mortality in recipients of allogeneic hematopoiet
ic    stem cell transplants: importance of viral load and T-cell immunity. <I>Bl
ood</I>    2003; 101: 407-414.    ^cY#6758.htm##
00531000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704028800076002000900364#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#77#73#article#106#32#<P>32. 
Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED,    et al.
 Reconstitution of cellular immunity against cytomegalovirus in recipients    of
 allogeneic bone marrow by transfer of T-cell clones from the donor. <I>N    Eng
l J Med</I> 1995; 333: 1038-1044.    ^cY#6758.htm##
00553000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704031000076002000900386#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#78#74#article#106#33#<P>33. 
Reddehase MJ, Keil GM, Koszinowski UH. The cytolytic T lymphocyte response    to
 the murine cytomegalovirus. II. Detection of virus replication stage-specific  
  antigens by separate populations of <I>in vivo</I> active cytolytic T lymphocy
te    precursors. <I>Eur J Immunol</I> 1984; 14: 56-61.    ^cY#6758.htm##
00475000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704023200076002000900308#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#79#75#article#106#34#<P>34. 
Martins SL, St John LS, Champlin RE, Wieder ED, McMannis J, Molldrem JJ,    et a
l. Functional assessment and specific depletion of alloreactive human T    cells
 using flow cytometry. <I>Blood</I> 2004; 104: 3429-3436.    ^cY#6758.htm##
00501000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704025800076002000900334#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#80#76#article#106#35#<P>35. 
Stanzani M, Orciuolo E, Lewis R, Kontoyiannis DP, Martins SL, St John LS,    et 
al. <I>Aspergillus fumigatus</I> suppresses the human cellular immune response  
  via gliotoxin-mediated apoptosis of monocytes. <I>Blood</I> 2005; 105: 2258-22
65.    ^cY#6758.htm##
00445000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704020200076002000900278#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#81#77#article#106#36#<P>36. 
Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of    memory
 T lymphocytes with distinct homing potentials and effector functions.    <I>Nat
ure</I> 1999; 401: 708-712.    ^cY#6758.htm##
00491000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704024800076002000900324#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#82#78#article#106#37#<P>37. 
Hamann D, Kostense S, Wolthers KC, Otto SA, Baars PA, Miedema F, et al.    Evide
nce that human CD8+CD45RA+ CD27- cells are induced by antigen and evolve    thro
ugh extensive rounds of division. <I>Int Immunol</I> 1999; 11: 1027-1033.    ^cY
#6758.htm##
00493000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704025000076002000900326#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#83#79#article#106#38#<P>38. 
Kern F, Khatamzas E, Surel I, Frommel C, Reinke P, Waldrop SL, et al. Distributi
on    of human CMV-specific memory T cells among the CD8pos. subsets defined by 
CD57,    CD27, and CD45 isoforms. <I>Eur J Immunol</I> 1999; 29: 2908-2915.    ^
cY#6758.htm##
00467000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704022400076002000900300#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#84#80#article#106#39#<P>39. 
Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno L, et    al. Me
mory CD8+ T cells vary in differentiation phenotype in different persistent    v
irus infections. <I>Nat Med</I> 2002; 8: 379-385.    ^cY#6758.htm##
00427000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704018400076002000900260#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#85#81#article#106#40#<P>40. 
Suni MA, Picker LJ, Maino VC. Detection of antigen-specific T cell cytokine    e
xpression in whole blood by flow cytometry. <I>J Immunol Methods</I> 1998;    21
2: 89-98.    ^cY#6758.htm##
00512000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704026900076002000900345#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#86#82#article#106#41#<P>41. 
Sinclair E, Black D, Epling CL, Carvidi A, Josefowicz SZ, Bredt BM, et    al. CM
V antigen-specific CD4+ and CD8+ T cell IFNgamma expression and proliferation   
 responses in healthy CMV-seropositive individuals. <I>Viral Immunol</I> 2004;  
  17: 445-454.    ^cY#6758.htm##
00409000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704016600076002000900242#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#87#83#article#106#42#<P>42. 
Nomura LE, Walker JM, Maecker HT. Optimization of whole blood antigen-specific  
  cytokine assays for CD4(+) T cells. <I>Cytometry</I> 2000; 40: 60-68.    ^cY#6
758.htm##
00556000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704031300076002000900389#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#88#84#article#106#43#<P>43. 
Waldrop SL, Pitcher CJ, Peterson DM, Maino VC, Picker LJ. Determination    of an
tigen-specific memory/effector CD4+ T cell frequencies by flow cytometry:    evi
dence for a novel, antigen-specific homeostatic mechanism in HIV-associated    i
mmunodeficiency. <I>J Clin Invest</I> 1997; 99: 1739-1750.    ^cY#6758.htm##
00493000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704025000076002000900326#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#89#85#article#106#44#<P>44. 
Bunde T, Kirchner A, Hoffmeister B, Habedank D, Hetzer R, Cherepnev G,    et al.
 Protection from cytomegalovirus after transplantation is correlated with    imm
ediate early 1-specific CD8 T cells. <I>J Exp Med</I> 2005; 201: 1031-1036.    ^
cY#6758.htm##
00490000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704024700076002000900323#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#90#86#article#106#45#<P>45. 
Cwynarski K, Ainsworth J, Cobbold M, Wagner S, Mahendra P, Apperley J,    et al.
 Direct visualization of cytomegalovirus-specific T-cell reconstitution    after
 allogeneic stem cell transplantation. <I>Blood</I> 2001; 97: 1232-1240.    ^cY#
6758.htm##
00624000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704038100076002000900457#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#91#87#article#106#46#<P>46. 
Hebart H, Daginik S, Stevanovic S, Grigoleit U, Dobler A, Baur M, et al.    Sens
itive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte
    responses by interferon-gamma-enzyme-linked immunospot assay and flow cytome
try    in healthy individuals and in patients after allogeneic stem cell transpl
antation.    <I>Blood</I> 2002; 99: 3830-3837.    ^cY#6758.htm##
00546000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704030300076002000900379#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#92#88#article#106#47#<P>47. 
Lacey SF, Gallez-Hawkins G, Crooks M, Martinez J, Senitzer D, Forman SJ,    et a
l. Characterization of cytotoxic function of CMV-pp65-specific CD8+ T-lymphocyte
s    identified by HLA tetramers in recipients and donors of stem-cell transplan
ts.    <I>Transplantation</I> 2002; 74: 722-732.    ^cY#6758.htm##
00543000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704030000076002000900376#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#93#89#article#106#48#<P>48. 
Ozdemir E, St John LS, Gillespie G, Rowland-Jones S, Champlin RE, Molldrem    JJ
, et al. Cytomegalovirus reactivation following allogeneic stem cell transplanta
tion    is associated with the presence of dysfunctional antigen-specific CD8+ T
 cells.    <I>Blood</I> 2002; 100: 3690-3697.    ^cY#6758.htm##
00526000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704028300076002000900359#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#94#90#article#106#49#<P>49. 
Sester M, Sester U, Gartner B, Heine G, Girndt M, Mueller-Lantzsch N, et    al. 
Levels of virus-specific CD4 T cells correlate with cytomegalovirus control    a
nd predict virus-induced disease after renal transplantation. <I>Transplantation
</I>    2001; 71: 1287-1294.    ^cY#6758.htm##
00545000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704030200076002000900378#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#95#91#article#106#50#<P>50. 
Engstrand M, Lidehall AK, Totterman TH, Herrman B, Eriksson BM, Korsgren    O. C
ellular responses to cytomegalovirus in immunosuppressed patients: circulating  
  CD8+ T cells recognizing CMVpp65 are present but display functional impairment
.    <I>Clin Exp Immunol</I> 2003; 132: 96-104.    ^cY#6758.htm##
00518000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704027500076002000900351#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#96#92#article#106#51#<P>51. 
Rauser G, Einsele H, Sinzger C, Wernet D, Kuntz G, Assenmacher M, et al.    Rapi
d generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive   
 transfer into recipients of allogeneic stem cell transplants. <I>Blood</I> 2004
;    103: 3565-3572.    ^cY#6758.htm##
00479000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704023600076002000900312#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#97#93#article#106#52#<P>52. 
Hutchings PR, Cambridge G, Tite JP, Meager T, Cooke A. The detection and    enum
eration of cytokine-secreting cells in mice and man and the clinical application
    of these assays. <I>J Immunol Methods</I> 1989; 120: 1-8.    ^cY#6758.htm##
00397000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704015400076002000900230#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#98#94#article#106#53#<P>53. 
Ghanekar SA, Maecker HT. Cytokine flow cytometry: multiparametric approach    to
 immune function analysis. <I>Cytotherapy</I> 2003; 5: 1-6.    ^cY#6758.htm##
00412000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704016900076002000900245#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#99#95#article#106#54#<P>54. 
Maecker HT, Rinfret A, D'Souza P, Darden J, Roig E, Landry C, et al. Standardiza
tion    of cytokine flow cytometry assays. <I>BMC Immunol</I> 2005; 6: 13.    ^c
Y#6758.htm##
00445000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704020100077002000900278#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#100#96#article#106#55#<P>55.
 Suni MA, Dunn HS, Orr PL, de Laat R, Sinclair E, Ghanekar SA, et al. Performanc
e    of plate-based cytokine flow cytometry with automated data analysis. <I>BMC
    Immunol</I> 2003; 4: 9.    ^cY#6758.htm##
00406000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704016200077002000900239#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#101#97#article#106#56#<P>56.
 Kern F, Surel IP, Brock C, Freistedt B, Radtke H, Scheffold A, et al. T-cell   
 epitope mapping by flow cytometry. <I>Nat Med</I> 1998; 4: 975-978.    ^cY#6758
.htm##
00395000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704015100077002000900228#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#102#98#article#106#57#<P>57.
 Maecker HT, Maino VC. Analyzing T-cell responses to cytomegalovirus by    cytok
ine flow cytometry. <I>Hum Immunol</I> 2004; 65: 493-499.    ^cY#6758.htm##
00606000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704036200077002000900439#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#103#99#article#106#58#<P>58.
 Vaz-Santiago J, Lule J, Rohrlich P, Jacquier C, Gibert N, Le Roy E, et    al. <
I>Ex vivo</I> stimulation and expansion of both CD4(+) and CD8(+) T cells    fro
m peripheral blood mononuclear cells of human cytomegalovirus-seropositive    bl
ood donors by using a soluble recombinant chimeric protein, IE1-pp65. <I>J    Vi
rol</I> 2001; 75: 7840-7847.    ^cY#6758.htm##
00532000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704028700078002000900365#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#104#100#article#106#59#<P>59
. Nylander S, Kalies I. Brefeldin A, but not monensin, completely blocks    CD69
 expression on mouse lymphocytes: efficacy of inhibitors of protein secretion   
 in protocols for intracellular cytokine staining by flow cytometry. <I>J Immuno
l    Methods</I> 1999; 224: 69-76.    ^cY#6758.htm##
00456000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704021100078002000900289#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#p#105#101#article#106#60#<P>60
. Maecker HT, Dunn HS, Suni MA, Khatamzas E, Pitcher CJ, Bunde T, et al.    Use 
of overlapping peptide mixtures as antigens for cytokine flow cytometry.    <I>J
 Immunol Methods</I> 2001; 255: 27-40.    ^cY#6758.htm##
00283000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704005300075002000900128#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#106#102#article#106#  </font>  <HR ALIGN
=LEFT WIDTH=100% SIZE=2>     ^cY#6758.htm##
00530000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704030000075002000900375#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#107#103#article#106#<P class="style4"><A
 NAME="Correspondence"></A><FONT color="#00007F" SIZE=4><B>Correspondence    and
 Footnotes</B></FONT> <A HREF="#Home"><FONT SIZE=4><B><IMG SRC="/img/revistas/bj
mbr/v41n1/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0" width="12" 
height="12"></B></FONT></A></P>     ^cY#6758.htm##
00627000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704039700075002000900472#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#108#104#article#106#<P class="style4"><B
><a href="#Home"><img src="/img/revistas/bjmbr/v41n1/recor.gif" width="15" heigh
t="14" border="0"></a>    Address for correspondence:</B> <font face="Arial, Hel
vetica, sans-serif"> V.N.    Motta, Instituto Fleury, Rua Gen. Valdomiro Lima, 5
08, 04344-903 S&atilde;o    Paulo, SP, Brasil. E-mail: <a href="mailto:vinicius.
n.motta@gmail.com">vinicius.n.motta@gmail.com</a>    ^cY#6758.htm##
00294000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704006400075002000900139#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#109#105#article#106#<br>   </font><font 
face="Arial, Helvetica, sans-serif">    ^cY#6758.htm##
00348000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704011800075002000900193#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6758.htm#S#p#110#106#article#106#<br>   Publication s
upported by FAPESP. Received December 20, 2006. Accepted August    27, 2007. </f
ont> </P>     ^cY#6758.htm##
00559000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100020000740100018000940120
09900112030000900211065000900220064000500229031000400234014000600238865000900244
002000900253035001000262801000900272#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
758.htm#S#c#111#1#article#60#1#^rND^sMcDonough^nSH#^rND^sSpector^nDH#Transcripti
on in human fibroblasts permissively infected by human cytomegalovirus strain AD
169^len#Virology#19830000#1983#125#31-46#20080100#6758.htm#0042-6822#Virology##
00525000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100021000920120
06500113030000900178065000900187064000500196031000300201014000600204865000900210
002000900219035001000228801000900238#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
758.htm#S#c#112#2#article#60#2#^rND^sSissons^nJG#^rND^sCarmichael^nAJ#Clinical a
spects and management of cytomegalovirus infection^len#J Infect#20020000#2002#44
#78-83#20080100#6758.htm#0163-4453#J Infect##
00605000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100014000740100015000880100
01900103012008800122030002500210065000900235064000500244031000300249014001000252
865000900262002000900271035001000280801002500290#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6758.htm#S#c#113#3#article#60#3#^rND^sHahn^nG#^rND^sJores^nR#^rND^sMo
carski^nES#Cytomegalovirus remains latent in a common precursor of dendritic and
 myeloid cells^len#Proc Natl Acad Sci U S A#19980000#1998#95#3937-3942#20080100#
6758.htm#0027-8424#Proc Natl Acad Sci U S A##
00513000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100016000920120
04500108030001300153065000900166064000500175031000400180014001000184865000900194
002000900203035001000212801001300222#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
758.htm#S#c#114#4#article#60#4#^rND^sFishman^nJA#^rND^sRubin^nRH#Infection in or
gan-transplant recipients^len#N Engl J Med#19980000#1998#338#1741-1751#20080100#
6758.htm#0028-4793#N Engl J Med##
00802000000000337000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100019000740100015000930100
01800108010002000126010001700146010001700163810000600180012017900186030002300365
06500090038806400050039703100030040201400080040586500090041300200090042203500100
0431801002300441#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#115#5#ar
ticle#60#5#^rND^sYakushiji^nK#^rND^sGondo^nH#^rND^sKamezaki^nK#^rND^sShigematsu^
nK#^rND^sHayashi^nS#^rND^sKuroiwa^nM#et al#Monitoring of cytomegalovirus reactiv
ation after allogeneic stem cell transplantation: comparison of an antigenemia a
ssay and quantitative real-time polymerase chain reaction^len#Bone Marrow Transp
lant#20020000#2002#29#599-606#20080100#6758.htm#0268-3369#Bone marrow transplant
##
00594000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100016000740100016000900100
01400106010001500120012010600135030001900241710000200260065000900262064000500271
031000200276014000800278865000900286002000900295#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6758.htm#S#c#116#6#article#60#6#^rND^sReinke^nP#^rND^sProsch^nS#^rND^
sKern^nF#^rND^sVolk^nHD#Mechanisms of human cytomegalovirus (HCMV) (re)activatio
n and its impact on organ transplant patients^len#Transpl Infect Dis#2#19990000#
1999#1#157-164#20080100#6758.htm##
00609000000000301000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100015000920100
02200107010001800129012007300147030001700220065000900237064000500246031000300251
014000800254865000900262002000900271035001000280801001700290#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6758.htm#S#c#117#7#article#60#7#^rND^sDoherty^nPC#^rND^sA
llan^nW#^rND^sEichelberger^nM#^rND^sCarding^nSR#Roles of alpha beta and gamma de
lta T cell subsets in viral immunity^len#Annu Rev Immunol#19920000#1992#10#123-1
51#20080100#6758.htm#0732-0582#Annu Rev Immunol##
00819000000000337000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100021000740100017000950100
01500112010002300127010001700150010001800167810000600185012021300191030001300404
06500090041706400050042603100040043101400050043586500090044000200090044903500100
0458801001300468#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#118#8#ar
ticle#60#8#^rND^sQuinnan^nGV Jr#^rND^sKirmani^nN#^rND^sRook^nAH#^rND^sManischewi
tz^nJF#^rND^sJackson^nL#^rND^sMoreschi^nG#et al#Cytotoxic T cells in cytomegalov
irus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic respo
nses correlate with recovery from cytomegalovirus infection in bone-marrow-trans
plant recipients^len#N Engl J Med#19820000#1982#307#7-13#20080100#6758.htm#0028-
4793#N Engl J Med##
00701000000000301000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740100018000910100
01700109010002000126012018600146030000600332065000900338064000500347031000300352
014001000355865000900365002000900374035001000383801000600393#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6758.htm#S#c#119#9#article#60#9#^rND^sReusser^nP#^rND^sRi
ddell^nSR#^rND^sMeyers^nJD#^rND^sGreenberg^nPD#Cytotoxic T-lymphocyte response t
o cytomegalovirus after human allogeneic bone marrow transplantation: pattern of
 recovery and correlation with cytomegalovirus infection and disease^len#Blood#1
9910000#1991#78#1373-1380#20080100#6758.htm#0006-4971#Blood##
00565000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100021000920120
07300113030001600186065000900202064000500211031000300216032000400219014000800223
865000900231002000900240035001000249801001600259#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6758.htm#S#c#120#10#article#60#10#^rND^sSpeich^nR#^rND^svan der Bij^n
W#Epidemiology and management of infections after lung transplantation^len#Clin 
Infect Dis#20010000#2001#33#^s1#S58-S65#20080100#6758.htm#1058-4838#Clin Infect 
Dis##
00696000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100019000930100
02000112010001800132010001700150010002000167810000600187012007800193030001600271
06500090028706400050029603100030030101400100030486500090031400200090032303500100
0332801001600342#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#121#11#a
rticle#60#11#^rND^sWalker^nRC#^rND^sMarshall^nWF#^rND^sStrickler^nJG#^rND^sWiesn
er^nRH#^rND^sVelosa^nJA#^rND^sHabermann^nTM#et al#Pretransplantation assessment 
of the risk of lymphoproliferative disorder^len#Clin Infect Dis#19950000#1995#20
#1346-1353#20080100#6758.htm#1058-4838#Clin Infect Dis##
00523000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100015000940120
08600109030001800195710000200213065000900215064000500224031000200229014000800231
865000900239002000900248#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#
122#12#article#60#12#^rND^sCainelli^nF#^rND^sVento^nS#Infections and solid organ
 transplant rejection: a cause-and-effect relationship?^len#Lancet Infect Dis#2#
20020000#2002#2#539-549#20080100#6758.htm##
00796000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100013000760100015000890100
01900104010001400123010001300137010002000150810000600170012018300176030002300359
06500090038206400050039103100030039601400080039986500090040700200090041603500100
0425801002300435#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#123#13#a
rticle#60#13#^rND^sGor^nD#^rND^sSabin^nC#^rND^sPrentice^nHG#^rND^sVyas^nN#^rND^s
Man^nS#^rND^sGriffiths^nPD#et al#Longitudinal fluctuations in cytomegalovirus lo
ad in bone marrow transplant patients: relationship between peak virus load, don
or/recipient serostatus, acute GVHD and CMV disease^len#Bone Marrow Transplant#1
9980000#1998#21#597-605#20080100#6758.htm#0268-3369#Bone marrow transplant##
00729000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100015000940100
01700109010001800126010002200144010002000166012014900186030000600335065000900341
06400050035003100040035501400100035986500090036900200090037803500100038780100060
0397#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#124#14#article#60#14
#^rND^sLjungman^nP#^rND^sBrand^nR#^rND^sEinsele^nH#^rND^sFrassoni^nF#^rND^sNiede
rwieser^nD#^rND^sCordonnier^nC#Donor CMV serologic status and outcome of CMV-ser
opositive recipients after unrelated donor stem cell transplantation: an EBMT me
gafile analysis^len#Blood#20030000#2003#102#4255-4260#20080100#6758.htm#0006-497
1#Blood##
00792000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100017000920100
01900109010001900128010001800147010001700165810000600182012019900188030000600387
06500090039306400050040203100030040701400100041086500090042000200090042903500100
0438801000600448#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#125#15#a
rticle#60#15#^rND^sHebart^nH#^rND^sBrugger^nW#^rND^sGrigoleit^nU#^rND^sGscheidle
^nB#^rND^sLoeffler^nJ#^rND^sSchafer^nH#et al#Risk for cytomegalovirus disease in
 patients receiving polymerase chain reaction-based preemptive antiviral therapy
 after allogeneic stem cell transplantation depends on transplantation modality^
len#Blood#20010000#2001#97#2183-2185#20080100#6758.htm#0006-4971#Blood##
00805000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100020000940100
01700114010001700131010001900148010001800167810000600185012020900191030000600400
06500090040606400050041503100030042001400100042386500090043300200090044203500100
0451801000600461#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#126#16#a
rticle#60#16#^rND^sGratama^nJW#^rND^svan^nEsser JW#^rND^sLamers^nCH#^rND^sTourna
y^nC#^rND^sLowenberg^nB#^rND^sBolhuis^nRL#et al#Tetramer-based quantification of
 cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell 
grafts and after transplantation may identify patients at risk for progressive C
MV infection^len#Blood#20010000#2001#98#1358-1364#20080100#6758.htm#0006-4971#Bl
ood##
00692000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100017000910100
01900108010002000127010002000147010001700167810000600184012009800190030000700288
06500090029506400050030403100020030901400080031186500090031900200090032803500100
0337801000700347#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#127#17#a
rticle#60#17#^rND^sGrob^nJP#^rND^sGrundy^nJE#^rND^sPrentice^nHG#^rND^sGriffiths^
nPD#^rND^sHoffbrand^nAV#^rND^sHughes^nMD#et al#Immune donors can protect marrow-
transplant recipients from severe cytomegalovirus infections^len#Lancet#19870000
#1987#1#774-776#20080100#6758.htm#0099-5355#Lancet##
00708000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100015000930100
01800108010001600126010001700142010001600159810000600175012010200181030001600283
06500090029906400050030803100030031301400100031686500090032600200090033503500100
0344801001600354#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#128#18#a
rticle#60#18#^rND^sEnright^nH#^rND^sHaake^nR#^rND^sWeisdorf^nD#^rND^sRamsay^nN#^
rND^sMcGlave^nP#^rND^sKersey^nJ#et al#Cytomegalovirus pneumonia after bone marro
w transplantation: Risk factors and response to therapy^len#Transplantation#1993
0000#1993#55#1339-1346#20080100#6758.htm#0041-1337#Transplantation##
00580000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100018000930100
01700111012008200128030001300210065000900223064000500232031000400237014000800241
865000900249002000900258035001000267801001300277#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6758.htm#S#c#129#19#article#60#19#^rND^sMeyers^nJD#^rND^sFlournoy^nN#
^rND^sThomas^nED#Risk factors for cytomegalovirus infection after human marrow t
ransplantation^len#J Infect Dis#19860000#1986#153#478-488#20080100#6758.htm#0022
-1899#J Infect Dis##
00572000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100016000910120
12200107030000600229065000900235064000500244031000300249014000800252865000900260
002000900269035001000278801000600288#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
758.htm#S#c#130#20#article#60#20#^rND^sNoble^nS#^rND^sFaulds^nD#Ganciclovir: An 
update of its use in the prevention of cytomegalovirus infection and disease in 
transplant recipients^len#Drugs#19980000#1998#56#115-146#20080100#6758.htm#0012-
6667#Drugs##
00576000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100027000940120
11200121030000600233065000900239064000500248031000300253014000800256865000900264
002000900273035001000282801000600292#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
758.htm#S#c#131#21#article#60#21#^rND^sO'Brien^nJJ#^rND^sCampoli-Richards^nDM#Ac
yclovir: An updated review of its antiviral activity, pharmacokinetic properties
 and therapeutic efficacy^len#Drugs#19890000#1989#37#233-309#20080100#6758.htm#0
012-6667#Drugs##
00713000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100015000930100
01600108010002000124010002000144010001700164810000600181012011000187030001300297
06500090031006400050031903100040032401400060032886500090033400200090034303500100
0352801001300362#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#132#22#a
rticle#60#22#^rND^sMeyers^nJD#^rND^sReed^nEC#^rND^sShepp^nDH#^rND^sThornquist^nM
#^rND^sDandliker^nPS#^rND^sVicary^nCA#et al#Acyclovir for prevention of cytomega
lovirus infection and disease after allogeneic marrow transplantation^len#N Engl
 J Med#19880000#1988#318#70-75#20080100#6758.htm#0028-4793#N Engl J Med##
00646000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100015000930100
01700108010001600125010001600141012010700157030000700264065000900271064000500280
031000400285014000800289865000900297002000900306035001000315801000700325#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#133#23#article#60#23#^rND^sLimay
e^nAP#^rND^sCorey^nL#^rND^sKoelle^nDM#^rND^sDavis^nCL#^rND^sBoeckh^nM#Emergence 
of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ
 transplants^len#Lancet#20000000#2000#356#645-649#20080100#6758.htm#0099-5355#La
ncet##
00771000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100015000930100
01900108010001600127010001700143010001800160810000600178012015000184030002300334
06500090035706400050036603100030037101400080037486500090038200200090039103500100
0400801002300410#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#134#24#a
rticle#60#24#^rND^sMoretti^nS#^rND^sZikos^nP#^rND^sVan^nLint MT#^rND^sTedone^nE#
^rND^sOcchini^nD#^rND^sGualandi^nF#et al#Forscarnet vs ganciclovir for cytomegal
ovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation 
(HSCT): a randomised study^len#Bone Marrow Transplant#19980000#1998#22#175-180#2
0080100#6758.htm#0268-3369#Bone marrow transplant##
00535000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760120098000920300
01400190065000900204064000500213031000300218014000600221865000900227002000900236
035001000245801001400255#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#
135#25#article#60#25#^rND^sEmery^nVC#Prophylaxis for CMV should not now replace 
pre-emptive therapy in solid organ transplantation^len#Rev Med Virol#20010000#20
01#11#83-86#20080100#6758.htm#1052-9276#Rev Med Virol##
00789000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100016000940100
01700110010001700127010001700144010001500161012020500176030001300381065000900394
06400050040303100040040801400100041286500090042200200090043103500100044080100130
0450#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#136#26#article#60#26
#^rND^sSchmidt^nGM#^rND^sHorak^nDA#^rND^sNiland^nJC#^rND^sDuncan^nSR#^rND^sForma
n^nSJ#^rND^sZaia^nJA#A randomized, controlled trial of prophylactic ganciclovir 
for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow 
transplants; The City of Hope-Stanford-Syntex CMV Study Group^len#N Engl J Med#1
9910000#1991#324#1005-1011#20080100#6758.htm#0028-4793#N Engl J Med##
00820000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100018000920100
01800110010001600128010001900144010001900163810000600182012020700188030001600395
06500090041106400050042003100030042501400100042886500090043800200090044703500100
0456801001600466#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#137#27#a
rticle#60#27#^rND^sTanabe^nK#^rND^sTokumoto^nT#^rND^sIshikawa^nN#^rND^sKoyama^nI
#^rND^sTakahashi^nK#^rND^sFuchinoue^nS#et al#Comparative study of cytomegaloviru
s (CMV) antigenemia assay, polymerase chain reaction, serology, and shell vial a
ssay in the early diagnosis and monitoring of CMV infection after renal transpla
ntation^len#Transplantation#19970000#1997#64#1721-1725#20080100#6758.htm#0041-13
37#Transplantation##
00701000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100014000910100
02000105010001900125010001800144010001800162810000600180012012900186030001600315
71000020033106500090033306400050034203100020034701400080034986500090035700200090
0366#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#138#28#article#60#28
#^rND^sHumar^nA#^rND^sPaya^nC#^rND^sPescovitz^nMD#^rND^sDominguez^nE#^rND^sWashb
urn^nK#^rND^sBlumberg^nE#et al#Clinical utility of cytomegalovirus viral load te
sting for predicting CMV disease in D+/R- solid organ transplant recipients^len#
Am J Transplant#2#20040000#2004#4#644-649#20080100#6758.htm##
00544000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760120105000940300
01300199065000900212064000500221031000300226014000800229865000900237002000900246
035001000255801001300265#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#
139#29#article#60#29#^rND^sLjungman^nP#Would monitoring CMV immune responses all
ow improved control of CMV in stem cell transplant patients^len#J Clin Virol#200
60000#2006#35#493-495#20080100#6758.htm#0928-0197#J Clin Virol##
00532000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100016000940120
09600110030001600206710000200222065000900224064000500233031000200238014000800240
865000900248002000900257#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#
140#30#article#60#30#^rND^sPantaleo^nG#^rND^sHarari^nA#Functional signatures in 
antiviral T-cell immunity for monitoring virus-associated diseases^len#Nat Rev I
mmunol#2#20060000#2006#6#417-423#20080100#6758.htm##
00747000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100020000920100
01800112010001700130010001600147010001700163810000600180012015700186030000600343
06500090034906400050035803100040036301400080036786500090037500200090038403500100
0393801000600403#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#141#31#a
rticle#60#31#^rND^sBoeckh^nM#^rND^sLeisenring^nW#^rND^sRiddell^nSR#^rND^sBowden^
nRA#^rND^sHuang^nML#^rND^sMyerson^nD#et al#Late cytomegalovirus disease and mort
ality in recipients of allogeneic hematopoietic stem cell transplants: importanc
e of viral load and T-cell immunity^len#Blood#20030000#2003#101#407-414#20080100
#6758.htm#0006-4971#Blood##
00764000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100020000930100
01800113010001600131010001900147010001700166010001300183012014800196030001300344
06500090035706400050036603100040037101400100037586500090038500200090039403500100
0403801001300413#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#142#32#a
rticle#60#32#^rND^sWalter^nEA#^rND^sGreenberg^nPD#^rND^sGilbert^nMJ#^rND^sFinch^
nRJ#^rND^sWatanabe^nKS#^rND^sThomas^nED#^rND^set^nal#Reconstitution of cellular 
immunity against cytomegalovirus in recipients of allogeneic bone marrow by tran
sfer of T-cell clones from the donor^len#N Engl J Med#19950000#1995#333#1038-104
4#20080100#6758.htm#0028-4793#N Engl J Med##
00674000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100015000960100
02200111012007400133030014600207710000200353065000900355064000500364031000300369
014000600372865000900378002000900387#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
758.htm#S#c#143#33#article#60#33#^rND^sReddehase^nMJ#^rND^sKeil^nGM#^rND^sKoszin
owski^nUH#The cytolytic T lymphocyte response to the murine cytomegalovirus: II^
len#Detection of virus replication stage-specific antigens by separate populatio
ns of in vivo active cytolytic T lymphocyte precursors. Eur J Immunol#2#19840000
#1984#14#56-61#20080100#6758.htm##
00697000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100018000940100
01900112010001700131010001800148010001900166810000600185012010000191030000600291
06500090029706400050030603100040031101400100031586500090032500200090033403500100
0343801000600353#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#144#34#a
rticle#60#34#^rND^sMartins^nSL#^rND^sSt^nJohn LS#^rND^sChamplin^nRE#^rND^sWieder
^nED#^rND^sMcMannis^nJ#^rND^sMolldrem^nJJ#et al#Functional assessment and specif
ic depletion of alloreactive human T cells using flow cytometry^len#Blood#200400
00#2004#104#3429-3436#20080100#6758.htm#0006-4971#Blood##
00716000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100018000940100
01500112010002300127010001800150010001800168810000600186012011800192030000600310
06500090031606400050032503100040033001400100033486500090034400200090035303500100
0362801000600372#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#145#35#a
rticle#60#35#^rND^sStanzani^nM#^rND^sOrciuolo^nE#^rND^sLewis^nR#^rND^sKontoyiann
is^nDP#^rND^sMartins^nSL#^rND^sSt^nJohn LS#et al#Aspergillus fumigatus suppresse
s the human cellular immune response via gliotoxin-mediated apoptosis of monocyt
es^len#Blood#20050000#2005#105#2258-2265#20080100#6758.htm#0006-4971#Blood##
00639000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100015000940100
01700109010001400126010002200140012009500162030000700257065000900264064000500273
031000400278014000800282865000900290002000900299035001000308801000700318#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#146#36#article#60#36#^rND^sSallu
sto^nF#^rND^sLenig^nD#^rND^sForster^nR#^rND^sLipp^nM#^rND^sLanzavecchia^nA#Two s
ubsets of memory T lymphocytes with distinct homing potentials and effector func
tions^len#Nature#19990000#1999#401#708-712#20080100#6758.htm#0028-0836#Nature##
00719000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100018000920100
01900110010001500129010001600144010001700160810000600177012011900183030001200302
06500090031406400050032303100030032801400100033186500090034100200090035003500100
0359801001200369#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#147#37#a
rticle#60#37#^rND^sHamann^nD#^rND^sKostense^nS#^rND^sWolthers^nKC#^rND^sOtto^nSA
#^rND^sBaars^nPA#^rND^sMiedema^nF#et al#Evidence that human CD8+CD45RA+ CD27- ce
lls are induced by antigen and evolve through extensive rounds of division^len#I
nt Immunol#19990000#1999#11#1027-1033#20080100#6758.htm#0953-8178#Int Immunol##
00723000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100019000900100
01500109010001700124010001600141010001800157810000600175012012100181030001400302
06500090031606400050032503100030033001400100033386500090034300200090035203500100
0361801001400371#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#148#38#a
rticle#60#38#^rND^sKern^nF#^rND^sKhatamzas^nE#^rND^sSurel^nI#^rND^sFrommel^nC#^r
ND^sReinke^nP#^rND^sWaldrop^nSL#et al#Distribution of human CMV-specific memory 
T cells among the CD8pos: subsets defined by CD57, CD27, and CD45 isoforms^len#E
ur J Immunol#19990000#1999#29#2908-2915#20080100#6758.htm#0014-2980#Eur J Immuno
l##
00691000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100017000910100
01600108010001900124010002000143010001700163810000600180012009900186030000800285
06500090029306400050030203100020030701400080030986500090031700200090032603500100
0335801000800345#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#149#39#a
rticle#60#39#^rND^sAppay^nV#^rND^sDunbar^nPR#^rND^sCallan^nM#^rND^sKlenerman^nP#
^rND^sGillespie^nGM#^rND^sPapagno^nL#et al#Memory CD8+ T cells vary in different
iation phenotype in different persistent virus infections^len#Nat Med#20020000#2
002#8#379-385#20080100#6758.htm#1078-8956#Nat Med##
00596000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100017000910100
01600108012009400124030001800218065000900236064000500245031000400250014000600254
865000900260002000900269035001000278801001800288#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6758.htm#S#c#150#40#article#60#40#^rND^sSuni^nMA#^rND^sPicker^nLJ#^rN
D^sMaino^nVC#Detection of antigen-specific T cell cytokine expression in whole b
lood by flow cytometry^len#J Immunol Methods#19980000#1998#212#89-98#20080100#67
58.htm#0022-1759#J Immunol Methods##
00739000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100015000940100
01700109010001700126010002100143010001600164810000600180012013400186030001400320
06500090033406400050034303100030034801400080035186500090035900200090036803500100
0377801001400387#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#151#41#a
rticle#60#41#^rND^sSinclair^nE#^rND^sBlack^nD#^rND^sEpling^nCL#^rND^sCarvidi^nA#
^rND^sJosefowicz^nSZ#^rND^sBredt^nBM#et al#CMV antigen-specific CD4+ and CD8+ T 
cell IFNgamma expression and proliferation responses in healthy CMV-seropositive
 individuals^len#Viral Immunol#20040000#2004#17#445-454#20080100#6758.htm#0882-8
245#Viral Immunol##
00573000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100017000930100
01800110012008400128030001000212065000900222064000500231031000300236014000600239
865000900245002000900254035001000263801001000273#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6758.htm#S#c#152#42#article#60#42#^rND^sNomura^nLE#^rND^sWalker^nJM#^
rND^sMaecker^nHT#Optimization of whole blood antigen-specific cytokine assays fo
r CD4(+) T cells^len#Cytometry#20000000#2000#40#60-68#20080100#6758.htm#0196-476
3#Cytometry##
00754000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100018000940100
01900112010001600131010001700147012019300164030001400357065000900371064000500380
031000300385014001000388865000900398002000900407035001000416801001400426#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#153#43#article#60#43#^rND^sWaldr
op^nSL#^rND^sPitcher^nCJ#^rND^sPeterson^nDM#^rND^sMaino^nVC#^rND^sPicker^nLJ#Det
ermination of antigen-specific memory/effector CD4+ T cell frequencies by flow c
ytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-as
sociated immunodeficiency^len#J Clin Invest#19970000#1997#99#1739-1750#20080100#
6758.htm#0021-9738#J Clin Invest##
00719000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100018000910100
02100109010001800130010001600148010001900164810000600183012011600189030001000305
06500090031506400050032403100040032901400100033386500090034300200090035203500100
0361801001000371#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#154#44#a
rticle#60#44#^rND^sBunde^nT#^rND^sKirchner^nA#^rND^sHoffmeister^nB#^rND^sHabedan
k^nD#^rND^sHetzer^nR#^rND^sCherepnev^nG#et al#Protection from cytomegalovirus af
ter transplantation is correlated with immediate early 1-specific CD8 T cells^le
n#J Exp Med#20050000#2005#201#1031-1036#20080100#6758.htm#0022-1007#J Exp Med##
00712000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100019000950100
01700114010001600131010001800147010001800165810000600183012011800189030000600307
06500090031306400050032203100030032701400100033086500090034000200090034903500100
0358801000600368#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#155#45#a
rticle#60#45#^rND^sCwynarski^nK#^rND^sAinsworth^nJ#^rND^sCobbold^nM#^rND^sWagner
^nS#^rND^sMahendra^nP#^rND^sApperley^nJ#et al#Direct visualization of cytomegalo
virus-specific T-cell reconstitution after allogeneic stem cell transplantation^
len#Blood#20010000#2001#97#1232-1240#20080100#6758.htm#0006-4971#Blood##
00840000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100017000920100
02000109010001900129010001600148010001400164810000600178012025100184030000600435
06500090044106400050045003100030045501400100045886500090046800200090047703500100
0486801000600496#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#156#46#a
rticle#60#46#^rND^sHebart^nH#^rND^sDaginik^nS#^rND^sStevanovic^nS#^rND^sGrigolei
t^nU#^rND^sDobler^nA#^rND^sBaur^nM#et al#Sensitive detection of human cytomegalo
virus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzy
me-linked immunospot assay and flow cytometry in healthy individuals and in pati
ents after allogeneic stem cell transplantation^len#Blood#20020000#2002#99#3830-
3837#20080100#6758.htm#0006-4971#Blood##
00775000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100024000920100
01600116010001800132010001800150010001700168810000600185012016100191030001600352
06500090036806400050037703100030038201400080038586500090039300200090040203500100
0411801001600421#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#157#47#a
rticle#60#47#^rND^sLacey^nSF#^rND^sGallez-Hawkins^nG#^rND^sCrooks^nM#^rND^sMarti
nez^nJ#^rND^sSenitzer^nD#^rND^sForman^nSJ#et al#Characterization of cytotoxic fu
nction of CMV-pp65-specific CD8+ T-lymphocytes identified by HLA tetramers in re
cipients and donors of stem-cell transplants^len#Transplantation#20020000#2002#7
4#722-732#20080100#6758.htm#0041-1337#Transplantation##
00762000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100018000930100
01900111010002300130010001900153010001900172810000600191012015900197030000600356
06500090036206400050037103100040037601400100038086500090039000200090039903500100
0408801000600418#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#158#48#a
rticle#60#48#^rND^sOzdemir^nE#^rND^sSt^nJohn LS#^rND^sGillespie^nG#^rND^sRowland
-Jones^nS#^rND^sChamplin^nRE#^rND^sMolldrem^nJJ#et al#Cytomegalovirus reactivati
on following allogeneic stem cell transplantation is associated with the presenc
e of dysfunctional antigen-specific CD8+ T cells^len#Blood#20020000#2002#100#369
0-3697#20080100#6758.htm#0006-4971#Blood##
00755000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100016000920100
01700108010001500125010001600140010002600156810000600182012014200188030001600330
06500090034606400050035503100030036001400100036386500090037300200090038203500100
0391801001600401#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#159#49#a
rticle#60#49#^rND^sSester^nM#^rND^sSester^nU#^rND^sGartner^nB#^rND^sHeine^nG#^rN
D^sGirndt^nM#^rND^sMueller-Lantzsch^nN#et al#Levels of virus-specific CD4 T cell
s correlate with cytomegalovirus control and predict virus-induced disease after
 renal transplantation^len#Transplantation#20010000#2001#71#1287-1294#20080100#6
758.htm#0041-1337#Transplantation##
00764000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100019000950100
02000114010001700134010001900151010001800170012016300188030001700351065000900368
06400050037703100040038201400070038686500090039300200090040203500100041180100170
0421#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#160#50#article#60#50
#^rND^sEngstrand^nM#^rND^sLidehall^nAK#^rND^sTotterman^nTH#^rND^sHerrman^nB#^rND
^sEriksson^nBM#^rND^sKorsgren^nO#Cellular responses to cytomegalovirus in immuno
suppressed patients: circulating CD8+ T cells recognizing CMVpp65 are present bu
t display functional impairment^len#Clin Exp Immunol#20030000#2003#132#96-104#20
080100#6758.htm#0009-9104#Clin Exp Immunol##
00737000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100017000920100
01700109010001600126010001500142010002100157810000600178012014700184030000600331
06500090033706400050034603100040035101400100035586500090036500200090037403500100
0383801000600393#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#161#51#a
rticle#60#51#^rND^sRauser^nG#^rND^sEinsele^nH#^rND^sSinzger^nC#^rND^sWernet^nD#^
rND^sKuntz^nG#^rND^sAssenmacher^nM#et al#Rapid generation of combined CMV-specif
ic CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogenei
c stem cell transplants^len#Blood#20040000#2004#103#3565-3572#20080100#6758.htm#
0006-4971#Blood##
00684000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100019000960100
01500115010001600130010001500146012012300161030001800284065000900302064000500311
031000400316014000400320865000900324002000900333035001000342801001800352#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#162#52#article#60#52#^rND^sHutch
ings^nPR#^rND^sCambridge^nG#^rND^sTite^nJP#^rND^sMeager^nT#^rND^sCooke^nA#The de
tection and enumeration of cytokine-secreting cells in mice and man and the clin
ical application of these assays^len#J Immunol Methods#19890000#1989#120#1-8#200
80100#6758.htm#0022-1759#J Immunol Methods##
00513000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100018000950120
08200113030001200195710000200207065000900209064000500218031000200223014000400225
865000900229002000900238#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#
163#53#article#60#53#^rND^sGhanekar^nSA#^rND^sMaecker^nHT#Cytokine flow cytometr
y: multiparametric approach to immune function analysis^len#Cytotherapy#2#200300
00#2003#5#1-6#20080100#6758.htm##
00611000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940100
01700111010001600128010001400144010001600158810000600174012005400180030001200234
71000020024606500090024806400050025703100020026201400030026486500090026700200090
0276#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#164#54#article#60#54
#^rND^sMaecker^nHT#^rND^sRinfret^nA#^rND^sD'Souza^nP#^rND^sDarden^nJ#^rND^sRoig^
nE#^rND^sLandry^nC#et al#Standardization of cytokine flow cytometry assays^len#B
MC Immunol#2#20050000#2005#6#13#20080100#6758.htm##
00640000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100015000910100
01400106010001700120010001800137010001900155810000600174012008400180030001200264
71000020027606500090027806400050028703100020029201400020029486500090029600200090
0305#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#165#55#article#60#55
#^rND^sSuni^nMA#^rND^sDunn^nHS#^rND^sOrr^nPL#^rND^sde^nLaat R#^rND^sSinclair^nE#
^rND^sGhanekar^nSA#et al#Performance of plate-based cytokine flow cytometry with
 automated data analysis^len#BMC Immunol#2#20030000#2003#4#9#20080100#6758.htm##
00632000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100016000900100
01500106010001900121010001600140010001900156810000600175012004500181030000800226
06500090023406400050024303100020024801400080025086500090025800200090026703500100
0276801000800286#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#166#56#a
rticle#60#56#^rND^sKern^nF#^rND^sSurel^nIP#^rND^sBrock^nC#^rND^sFreistedt^nB#^rN
D^sRadtke^nH#^rND^sScheffold^nA#et al#T-cell epitope mapping by flow cytometry^l
en#Nat Med#19980000#1998#4#975-978#20080100#6758.htm#1078-8956#Nat Med##
00542000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100016000940120
07700110030001200187065000900199064000500208031000300213014000800216865000900224
002000900233035001000242801001200252#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
758.htm#S#c#167#57#article#60#57#^rND^sMaecker^nHT#^rND^sMaino^nVC#Analyzing T-c
ell responses to cytomegalovirus by cytokine flow cytometry^len#Hum Immunol#2004
0000#2004#65#493-499#20080100#6758.htm#0198-8859#Hum Immunol##
00816000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100022000760100014000980100
01800112010001800130010001600148010001600164810000600180012022100186030000800407
06500090041506400050042403100030042901400100043286500090044200200090045103500100
0460801000800470#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#168#58#a
rticle#60#58#^rND^sVaz-Santiago^nJ#^rND^sLule^nJ#^rND^sRohrlich^nP#^rND^sJacquie
r^nC#^rND^sGibert^nN#^rND^sLe^nRoy E#et al#Ex vivo stimulation and expansion of 
both CD4(+) and CD8(+) T cells from peripheral blood mononuclear cells of human 
cytomegalovirus-seropositive blood donors by using a soluble recombinant chimeri
c protein, IE1-pp65^len#J Virol#20010000#2001#75#7840-7847#20080100#6758.htm#002
2-538X#J Virol##
00678000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100016000940120
20200110030001800312065000900330064000500339031000400344014000600348865000900354
002000900363035001000372801001800382#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
758.htm#S#c#169#59#article#60#59#^rND^sNylander^nS#^rND^sKalies^nI#Brefeldin A, 
but not monensin, completely blocks CD69 expression on mouse lymphocytes: effica
cy of inhibitors of protein secretion in protocols for intracellular cytokine st
aining by flow cytometry^len#J Immunol Methods#19990000#1999#224#69-76#20080100#
6758.htm#0022-1759#J Immunol Methods##
00688000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100015000940100
01500109010001900124010001800143010001500161810000600176012008000182030001800262
06500090028006400050028903100040029401400060029886500090030400200090031303500100
0322801001800332#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6758.htm#S#c#170#60#a
rticle#60#60#^rND^sMaecker^nHT#^rND^sDunn^nHS#^rND^sSuni^nMA#^rND^sKhatamzas^nE#
^rND^sPitcher^nCJ#^rND^sBunde^nT#et al#Use of overlapping peptide mixtures as an
tigens for cytokine flow cytometry^len#J Immunol Methods#20010000#2001#255#27-40
#20080100#6758.htm#0022-1759#J Immunol Methods##
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#o#1#1#article#1#20
080623#161459#6811.htm#122##
03463000000000637000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000400087121000300091049000900094158000300103030002000106
03100030012603200020012906500090013101400090014003500100014922300090015901200580
01680100027002260100025002530100024002780100024003020100021003260100024003470700
12000371070009800491083197700589085000802566085002202574085002602596085003202622
08500210265408500280267511700060270307200030270905800070271206000130271905800050
2732112000902737111001802746114000902764113001902773881002402792002000902816#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#h#2#1#article#1#oa#en#bjmbr#1#
3.1#TAB#10#BJMBR060#nd#Braz J Med Biol Res#41#1#20080100#^f60^l67#0100-879X#2007
1217#Attention in schizophrenia and in epileptic psychosis^len#^rND^1A01^nI.C.J^
sKairalla#^rND^1A02^nP.E.L^sMattos#^rND^1A01^nM.Q^sHoexter#^rND^1A01^nR.A^sBress
an#^rND^1A01^nJ.J^sMari#^rND^1A01^nI^sShirakawa#Universidade Federal de São Paul
o^iA01^1Escola Paulista de Medicina^2Departamento de Psiquiatria^cSão Paulo^sSP^
pBrasil#Universidade Federal do Rio de Janeiro^iA02^1Instituto de Psiquiatria^cR
io de Janeiro^sRJ^pBrasil#^len^aThe adaptive behavior of human beings is usually
 supported by rapid monitoring of outstanding events in the environment. Some in
vestigators have suggested that a primary attention deficit might trigger sympto
ms of schizophrenia. In addition, researchers have long discussed the relationsh
ip between schizophrenia and the schizophrenia-like psychosis of epilepsy (SLPE)
. On the basis of these considerations, the objective of the present study was t
o investigate attention performance of patients with both disorders. Patient age
 was 18 to 60 years, and all patients had received formal schooling for at least
 four years. Patients were excluded if they had any systemic disease with neurol
ogic or psychiatric comorbidity, or a history of brain surgery. The computer-ass
isted TAVIS-2R test was applied to all patients and to a control group to evalua
te and discriminate between selective, alternating and sustained attention. The 
TAVIS-2R test is divided into three parts: one for selective attention (5 min), 
the second for alternating attention (5 min), and the third for the evaluation o
f vigilance or sustained attention (10 min). The same computer software was used
 for statistical analysis of reaction time, omission errors, and commission erro
rs. The sample consisted of 36 patients with schizophrenia, 28 with interictal S
LPE, and 47 healthy controls. The results of the selective attention tests for b
oth patient groups were significantly lower than that for controls. The patients
 with schizophrenia and SLPE performed differently in the alternating and sustai
ned attention tests: patients with SLPE had alternating attention deficits, wher
eas patients with schizophrenia showed deficits in sustained attention. These qu
antitative results confirmed the qualitative clinical observations for both pati
ent groups, that is, that patients with schizophrenia had difficulties in focusi
ng attention, whereas those with epilepsy showed perseveration in attention focu
s.#^dnd^i1#^tm^len^kAttention^i1#^tm^len^kSchizophrenia^i1#^tm^len^kPsychotic di
sorders^i1#^tm^len^kEpilepsy^i1#^tm^len^kNeuropsychology^i1#other#25#FAPESP#1998
/04099-0#CNPq#20070222#February 22, 2007#20070921#September 21, 2007#S0100-879X2
006005000188#6811.htm##
03448000000000625000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000400087121000300091049000900094158000300103030002000106
03100030012603200020012906500090013101400090014003500100014922300090015901200650
01680100027002330100025002600100024002850100024003090100021003330100024003540700
12000378070009800498083197700596085000802573085002202581085002602603085003202629
08500210266108500280268211700060271007200030271605800070271906000130272605800050
2739112000902744111002502753114000902778113002602787002000902813#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#f#3#1#article#1#oa#en#bjmbr#1#3.1#TAB#10#B
JMBR060#nd#Braz J Med Biol Res#41#1#20080100#^f60^l67#0100-879X#20071217#<B>Atte
ntion in schizophrenia and in epileptic psychosis</B>^len#^rND^1A01^nI.C.J^sKair
alla#^rND^1A02^nP.E.L^sMattos#^rND^1A01^nM.Q^sHoexter#^rND^1A01^nR.A^sBressan#^r
ND^1A01^nJ.J^sMari#^rND^1A01^nI^sShirakawa#Universidade Federal de São Paulo^iA0
1^1Escola Paulista de Medicina^2Departamento de Psiquiatria^cSão Paulo^sSP^pBras
il#Universidade Federal do Rio de Janeiro^iA02^1Instituto de Psiquiatria^cRio de
 Janeiro^sRJ^pBrasil#^len^aThe adaptive behavior of human beings is usually supp
orted by rapid monitoring of outstanding events in the environment. Some investi
gators have suggested that a primary attention deficit might trigger symptoms of
 schizophrenia. In addition, researchers have long discussed the relationship be
tween schizophrenia and the schizophrenia-like psychosis of epilepsy (SLPE). On 
the basis of these considerations, the objective of the present study was to inv
estigate attention performance of patients with both disorders. Patient age was 
18 to 60 years, and all patients had received formal schooling for at least four
 years. Patients were excluded if they had any systemic disease with neurologic 
or psychiatric comorbidity, or a history of brain surgery. The computer-assisted
 TAVIS-2R test was applied to all patients and to a control group to evaluate an
d discriminate between selective, alternating and sustained attention. The TAVIS
-2R test is divided into three parts: one for selective attention (5 min), the s
econd for alternating attention (5 min), and the third for the evaluation of vig
ilance or sustained attention (10 min). The same computer software was used for 
statistical analysis of reaction time, omission errors, and commission errors. T
he sample consisted of 36 patients with schizophrenia, 28 with interictal SLPE, 
and 47 healthy controls. The results of the selective attention tests for both p
atient groups were significantly lower than that for controls. The patients with
 schizophrenia and SLPE performed differently in the alternating and sustained a
ttention tests: patients with SLPE had alternating attention deficits, whereas p
atients with schizophrenia showed deficits in sustained attention. These quantit
ative results confirmed the qualitative clinical observations for both patient g
roups, that is, that patients with schizophrenia had difficulties in focusing at
tention, whereas those with epilepsy showed perseveration in attention focus.#^d
nd^i1#^tm^len^kAttention^i1#^tm^len^kSchizophrenia^i1#^tm^len^kPsychotic disorde
rs^i1#^tm^len^kEpilepsy^i1#^tm^len^kNeuropsychology^i1#other#25#FAPESP#1998/0409
9-0#CNPq#20070222#<I>February 22, 2007</I>#20070921#<I>September 21, 2007</I>#68
11.htm##
03568000000000649000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000400100121000300104049000900107158000300116
03000240011903100030014303200020014606500090014801400090015703500100016622300090
01760120058001850100029002430100027002720100025002990100025003240100022003490100
02400371070012200395070010000517083197700617085000802594085002202602085002602624
08500320265008500210268208500280270311700060273107200030273705800070274006000130
27470580005027601120009027651110018027741140009027921130019028010020009028200080
08902829#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#l#4#1#article#1#^m
Jan.^a2008#oa#en#bjmbr#1#3.1#tab#10#BJMBR060#nd#Braz. j. med. biol. res#41#1#200
80100#^f60^l67#0100-879X#20071217#Attention in schizophrenia and in epileptic ps
ychosis^len#^rND^1A01^nI. C. J^sKairalla#^rND^1A02^nP. E. L^sMattos#^rND^1A01^nM
. Q^sHoexter#^rND^1A01^nR. A^sBressan#^rND^1A01^nJ. J^sMari#^rND^1A01^nI^sShirak
awa#^iA01^1Universidade Federal de São Paulo^2Escola Paulista de Medicina^3Depar
tamento de Psiquiatria^cSão Paulo^sSP^pBrasil#^iA02^1Universidade Federal do Rio
 de Janeiro^2Instituto de Psiquiatria^cRio de Janeiro^sRJ^pBrasil#^len^aThe adap
tive behavior of human beings is usually supported by rapid monitoring of outsta
nding events in the environment. Some investigators have suggested that a primar
y attention deficit might trigger symptoms of schizophrenia. In addition, resear
chers have long discussed the relationship between schizophrenia and the schizop
hrenia-like psychosis of epilepsy (SLPE). On the basis of these considerations, 
the objective of the present study was to investigate attention performance of p
atients with both disorders. Patient age was 18 to 60 years, and all patients ha
d received formal schooling for at least four years. Patients were excluded if t
hey had any systemic disease with neurologic or psychiatric comorbidity, or a hi
story of brain surgery. The computer-assisted TAVIS-2R test was applied to all p
atients and to a control group to evaluate and discriminate between selective, a
lternating and sustained attention. The TAVIS-2R test is divided into three part
s: one for selective attention (5 min), the second for alternating attention (5 
min), and the third for the evaluation of vigilance or sustained attention (10 m
in). The same computer software was used for statistical analysis of reaction ti
me, omission errors, and commission errors. The sample consisted of 36 patients 
with schizophrenia, 28 with interictal SLPE, and 47 healthy controls. The result
s of the selective attention tests for both patient groups were significantly lo
wer than that for controls. The patients with schizophrenia and SLPE performed d
ifferently in the alternating and sustained attention tests: patients with SLPE 
had alternating attention deficits, whereas patients with schizophrenia showed d
eficits in sustained attention. These quantitative results confirmed the qualita
tive clinical observations for both patient groups, that is, that patients with 
schizophrenia had difficulties in focusing attention, whereas those with epileps
y showed perseveration in attention focus.#^dnd^i1#^tm^len^kAttention^i1#^tm^len
^kSchizophrenia^i1#^tm^len^kPsychotic disorders^i1#^tm^len^kEpilepsy^i1#^tm^len^
kNeuropsychology^i1#other#25#FAPESP#1998/04099-0#CNPq#20070222#February 22, 2007
#20070921#September 21, 2007#6811.htm#Internet^ihttp://www.scielo.br/scielo.php?
script=sci_arttext&pid=S0100-879X2008000100010##
00374000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704014900070002000900219#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#5#1#article#93#<P> <font face="Arial, He
lvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med    Biol Res, January 2008,
 Volume 41(1) 60-67</B> </font></P>     ^cY#6811.htm##
00359000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704013400070002000900204#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#6#2#article#93#<P><font size="5" face="A
rial, Helvetica, sans-serif"><B>Attention in schizophrenia    and in epileptic p
sychosis</B></font>      ^cY#6811.htm##
00704000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704047900070002000900549#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#7#3#article#93#<P><font face="Arial, Hel
vetica, sans-serif"><b><a href="#Correspondence"><img src="/img/revistas/bjmbr/v
41n1/recor.gif" width="15" height="14" border="0"></a></b>    <a href="mailto:iv
ettek@osite.com.br"><img src="/img/revistas/bjmbr/v41n1/email-ca.gif" width="14"
 height="11" border="0"></a>    I.C.J. Kairalla<SUP>1</SUP>, P.E.L. Mattos<SUP>2
</SUP>, M.Q. Hoexter<SUP>1</SUP>,    R.A. Bressan<SUP>1</SUP>, J.J. Mari<SUP>1</
SUP> and I. Shirakawa<SUP>1</SUP>    </font>      ^cY#6811.htm##
00425000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704020000070002000900270#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#8#4#article#93#<p><font face="Arial, Hel
vetica, sans-serif"><SUP>1</SUP>Departamento de Psiquiatria,    Escola Paulista 
de Medicina, Universidade Federal de S&atilde;o Paulo, S&atilde;o    Paulo, SP, 
Brasil     ^cY#6811.htm##
00359000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704013400070002000900204#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#9#5#article#93#<br>   <SUP>2</SUP>Instit
uto de Psiquiatria, Universidade Federal do Rio de Janeiro,    Rio de Janeiro, R
J, Brasil</font></p>     ^cY#6811.htm##
00442000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704021600071002000900287#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#10#6#article#93#<P> <font face="Arial, H
elvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v41n1/do
wn.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12">    <stro
ng>Abstract</strong></A>    ^cY#6811.htm##
00439000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704021300071002000900284#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#11#7#article#93#<BR>   <A HREF="#Introdu
ction"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Introduction"><strong>Intr
oduction</strong></A>    ^cY#6811.htm##
00439000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704021300071002000900284#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#12#8#article#93#<BR>   <A HREF="#Materia
l"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0 width="12" height="12"></A>    <A HREF="#Material"><strong>Material and
 Methods</strong></A>    ^cY#6811.htm##
00424000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704019800071002000900269#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#13#9#article#93#<BR>   <A HREF="#Results
"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 H
SPACE=0 width="12" height="12"></A>    <A HREF="#Results"><strong>Results</stron
g></A>    ^cY#6811.htm##
00434000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704020700072002000900279#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#14#10#article#93#<BR>   <A HREF="#Discus
sion"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Discussion"><strong>Discuss
ion</strong></A>    ^cY#6811.htm##
00421000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704019400072002000900266#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#15#11#article#93#<BR>   <A HREF="#Refere
nces"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#References"><strong>Referen
ces    ^cY#6811.htm##
00462000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704023500072002000900307#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#16#12#article#93#<br>   </strong></A><A 
HREF="#Acknowledgments"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTT
OM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Acknowled
gments"><strong>Acknowledgments</strong></A>    ^cY#6811.htm##
00473000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704024600072002000900318#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#17#13#article#93#<BR>   <A HREF="#Corres
pondence"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Correspondence"><strong
>Correspondence and Footnotes</strong></A>    </font>      ^cY#6811.htm##
00274000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704004700072002000900119#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#18#14#article#93#<P>  <HR ALIGN=LEFT WID
TH=100% SIZE=2>     ^cY#6811.htm##
00562000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033500072002000900407#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#19#15#article#93#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F><
B>Abstract    </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/
back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A
></FONT></font></P> <font face="Arial, Helvetica, sans-serif">      ^cY#6811.htm
##
02282000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704205500072002000902127#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#20#16#article#93#<P>The adaptive behavio
r of human beings is usually supported by rapid monitoring    of outstanding eve
nts in the environment. Some investigators have suggested    that a primary atte
ntion deficit might trigger symptoms of schizophrenia. In    addition, researche
rs have long discussed the relationship between schizophrenia    and the schizop
hrenia-like psychosis of epilepsy (SLPE). On the basis of these    consideration
s, the objective of the present study was to investigate attention    performanc
e of patients with both disorders. Patient age was 18 to 60 years,    and all pa
tients had received formal schooling for at least four years. Patients    were e
xcluded if they had any systemic disease with neurologic or psychiatric    comor
bidity, or a history of brain surgery. The computer-assisted TAVIS-2R test    wa
s applied to all patients and to a control group to evaluate and discriminate   
 between selective, alternating and sustained attention. The TAVIS-2R test is   
 divided into three parts: one for selective attention (5 min), the second for  
  alternating attention (5 min), and the third for the evaluation of vigilance  
  or sustained attention (10 min). The same computer software was used for stati
stical    analysis of reaction time, omission errors, and commission errors. The
 sample    consisted of 36 patients with schizophrenia, 28 with interictal SLPE,
 and 47    healthy controls. The results of the selective attention tests for bo
th patient    groups were significantly lower than that for controls. The patien
ts with schizophrenia    and SLPE performed differently in the alternating and s
ustained attention tests:    patients with SLPE had alternating attention defici
ts, whereas patients with    schizophrenia showed deficits in sustained attentio
n. These quantitative results    confirmed the qualitative clinical observations
 for both patient groups, that    is, that patients with schizophrenia had diffi
culties in focusing attention,    whereas those with epilepsy showed perseverati
on in attention focus.      ^cY#6811.htm##
00376000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704014900072002000900221#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#21#17#article#93#<P><B>Key words: </B>At
tention; Schizophrenia; Psychotic disorders; Epilepsy;    Neuropsychology  </fon
t>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6811.htm##
00616000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038900072002000900461#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#22#18#article#93#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Introduction"></A><FONT color="#00007F" SIZE=4><B
>Introduction</B></FONT></font>    <font size="4" face="Arial, Helvetica, sans-s
erif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIGN=BOT
TOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A></font></P> <font 
face="Arial, Helvetica, sans-serif">      ^cY#6811.htm##
01050000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704082300072002000900895#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#23#19#article#93#<P>Human beings are exp
osed to different types of stimuli that must be detected    and selected for lat
er processing and for the generation of responses. Therefore,    individuals mus
t pay careful attention to the environment, as well as to internal    physical a
nd psychological stimuli. Attention is associated with alertness because    cert
ain situations require immediate and accurate responses. Several researchers    
have suggested that attention underlies all other cognitive functions (1-3).    
An excessive amount of information, which results from dispersive attention,    
makes it impossible or difficult to understand facts or to identify what is    r
elevant. Also, prolonged focus on one fact rather than on others may lead to    
distorted conclusions or loss of useful and interesting opportunities.      ^cY#
6811.htm##
01356000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704112900072002000901201#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#24#20#article#93#<P>Lezak (2) referred t
o attention as a set of several capabilities or different    processes that are 
associated with how the human organism becomes receptive    to stimuli and how i
t processes and responds to either internal or external    stimuli. According to
 that study, four types of attention were defined: a) selective    attention: th
e capacity to select one stimulus, either external or internal,    from among se
veral others (including the absence of stimuli). It is the capacity    to focus 
on one or two stimuli or ideas while suppressing other stimuli that    competiti
vely disperse attention; b) sustained attention (or vigilance): the    capacity 
to keep the focus of attention for a period of time. It refers to readiness    a
nd to the ability to detect the next input signal, which may not occur for    a 
long period of time (4); c) divided attention: the ability to respond to more   
 than one stimulus at the same time, or to multiple elements or operations withi
n    one activity, such as a complex mental activity; d) alternating attention: 
the    capacity to respond to repeated changes in focus.      ^cY#6811.htm##
01526000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704129900072002000901371#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#25#21#article#93#<P>Butler and Braff (5)
 suggested that a primary attention deficit might trigger    symptoms of schizop
hrenia, such as paranoid-type delusions, which may be understood    as inadequat
e attempts to integrate abnormal experiences. The adaptive behavior    of human 
beings is usually supported by rapid monitoring of outstanding events    in the 
environment, which include threatening stimuli. Patients with persecutory    del
usions, however, show a marked bias towards detecting stimuli associated    with
 threats and towards recalling threatening episodes (6,7). Excessive attention  
  is directed at threatening stimuli when the individual is experiencing delusio
ns,    but not after recovery (8). When stimuli in the form of photographs of ne
utral,    threatening or ambiguous social scenes were presented to patients with
 schizophrenia    and persecutory delusion, they rapidly identified the threaten
ing stimuli on    the photographs. When photographs with ambiguous scenes were u
sed, patients    with schizophrenia and persecutory delusions took less time to 
identify threatening    scenes than patients with schizophrenia and non-persecut
ory delusions or healthy    individuals (9). The slower response of patients wit
h schizophrenia may be associated    with a decrease in alertness.      ^cY#6811
.htm##
01308000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704108100072002000901153#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#26#22#article#93#<P>In 1963, Slater et a
l. (10) reviewed a number of cases that became landmarks    in the studies of ps
ychoses in patients with epilepsy. In 1968, Reynolds (11)    conducted an analys
is of clinical aspects and referred to the three most important    hypotheses fo
und in the literature: 1) that the two disorders are biologically    antagonisti
c; 2) that they have a biological affinity, or 3) that any association    betwee
n the two is completely fortuitous. In 1991, Toone (12) summarized some    gener
ally accepted characteristics of what has been called schizophrenia-like    psyc
hosis of epilepsy (SLPE)<I>.</I> In the literature, SLPE is described as    chro
nic and/or recurrent interictal psychotic episodes of a schizophreniform    type
 with delusions, hallucinations, thought disorder, disorganized behavior,    rel
ative absence of catatonic symptoms, mood swings, avolition, affective flattenin
g    (less intense than in schizophrenia), persistence of psychotic symptoms, su
icide    attempts, multiple hospitalizations, and generalized impaired functioni
ng (13).      ^cY#6811.htm##
00423000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704019600072002000900268#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#27#23#article#93#<P>These two diseases h
ave different prevalence rates: schizophrenia affects about    1% of the general
 population, whereas the rate of epileptic psychoses ranges    from 3 to 7.1% (1
3).      ^cY#6811.htm##
00614000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038700072002000900459#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#28#24#article#93#<P>Several investigator
s have studied attention and attention performance in either    schizophrenia or
 epilepsy, but few have focused on the comparison of these two    diseases. Mell
ers et al. (14) studied the neuropsychological profiles of schizophrenia    and 
SLPE in comparison with healthy controls, and their results will be presented   
 in the discussion of our results.      ^cY#6811.htm##
00637000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704041000072002000900482#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#29#25#article#93#<P>The purpose of the p
resent study was to investigate the selective, sustained    and alternating atte
ntion performance of patients with schizophrenia and patients    with SLPE compa
red to healthy control subjects. Our initial hypothesis was that    the attentio
nal capacity of patients with schizophrenia would be similar to    that of patie
nts with SLPE.  </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6811.htm##
00620000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704039300072002000900465#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#30#26#article#93#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Material"></A><FONT color="#00007F" SIZE=4><B>Pat
ients    and Methods</B></FONT></font> <font size="4" face="Arial, Helvetica, sa
ns-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIGN
=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A></font></P> <f
ont face="Arial, Helvetica, sans-serif">      ^cY#6811.htm##
00890000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704066300072002000900735#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#31#27#article#93#<P>Patients included in
 the study had a confirmed diagnosis of schizophrenia or    of partial or genera
lized epilepsy associated with interictal SLPE for longer    than six months; al
l patients were stable at the time of inclusion. Patient    age was 18 to 60 yea
rs, and all patients had received formal schooling for at    least four years. P
atients were excluded if they had any systemic disease with    neurologic or psy
chiatric comorbidity, or a history of brain surgery. Healthy    control subjects
 were 18 to 60 years old, had at least four years of schooling    and did not ha
ve a history of psychiatric disorders or organic or systemic diseases.      ^cY#
6811.htm##
01121000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704089400072002000900966#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#32#28#article#93#<P>Schizophrenia was di
agnosed according to the criteria established in the Diagnostic    and Statistic
al Manual of Mental Disorders, 4th edition (DSM-IV) (15). The diagnosis    of sc
hizophrenia was confirmed by the presentation of 36 vignettes to two independent
    psychiatrists experienced in the treatment of schizophrenia. Epilepsy was di
agnosed    according to the criteria established in the Classification of Epilep
tic Seizures    (16), and the Classification of Epilepsies and Epileptic Syndrom
es (17) of the    Commission on Classification and Terminology of the Internatio
nal League Against    Epilepsy. Interictal SLPE was diagnosed according to the P
ond Classification    (18). All the healthy controls underwent psychiatric evalu
ation conducted by    one of the authors to exclude a history of psychiatric sym
ptoms according to    the criteria established in the DSM-IV.      ^cY#6811.htm#
#
00437000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704021000072002000900282#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#33#29#article#93#<P>The research protoco
l was approved by the Research Ethics Committee of Universidade    Federal de S&
atilde;o Paulo (EPM, UNIFESP) and written informed consent was    obtained from 
all participants.      ^cY#6811.htm##
01226000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704099900072002000901071#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#34#30#article#93#<P>Patients with schizo
phrenia were recruited in the outpatient service of the    Schizophrenia Program
 of the Department of Psychiatry of the Universidade Federal    de S&atilde;o Pa
ulo (UNIFESP), S&atilde;o Paulo, SP, Brazil. Patients with epilepsy    were recr
uited at two services: a) the outpatient clinic of the Service of Investigation 
   and Treatment of Epilepsies of the Neurology and Neurosurgery Department of  
  UNIFESP, and b) the outpatient service of the Epilepsy and Psychiatry Project 
   (PROJEPSI) of the Institute of Psychiatry at Hospital de Cl&iacute;nicas, Sch
ool    of Medicine, Universidade de S&atilde;o Paulo, S&atilde;o Paulo, SP, Braz
il.    Healthy controls were selected from two groups of volunteers: firefighter
s of    different ranks from the Fire Department of S&atilde;o Paulo, and parent
s of    students in a S&atilde;o Paulo school. Firefighters were examined when n
ot on    duty call, when their attention was not particularly increased by their
 work.      ^cY#6811.htm##
00398000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704017100072002000900243#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#35#31#article#93#<P>All participants too
k the computer-assisted TAVIS-2R test to evaluate attention    (19) and the Rave
n's Progressive Matrices test (20) to assess intelligence.      ^cY#6811.htm##
01608000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704138100072002000901453#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#36#32#article#93#<P>The computer-assiste
d TAVIS-2R test is divided into three parts: one for selective    attention (5 m
in), the second for alternating attention (5 min), and the third    for the eval
uation of vigilance or sustained attention (10 min). In this test,    all symbol
s are familiar: tic-tac-toe symbols in task 1 (selective attention);    colors a
nd basic geometric shapes in task 2 (alternating attention), and a small    soli
d circle in task 3 (sustained attention). In task 1, geometric shapes successive
ly    appear one by one at 1-s intervals and remain on the screen until the scre
en    is full. The test-taker should press a joystick button each time the shape
 previously    agreed upon with the examiner appears on the screen. In task 2, p
airs of geometric    shapes (squares, triangles or circles in yellow, red or blu
e) appear on the    screen at random and the test-taker receives alternate order
s to press the button    when either a pair of equal shapes or a pair of equal c
olors appears on the    screen. In task 3, the screen is black for 10 min, and t
he test-taker is told    to press the button only when a small solid red circle 
appears on the screen,    which happens sporadically and unpredictably on differ
ent parts of the screen.    The same computer software was used for statistical 
analysis of reaction time,    omission errors and commission errors.      ^cY#68
11.htm##
00759000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704053200072002000900604#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#37#33#article#93#<P>The Raven test evalu
ates the capacity to establish adequate strategies to solve    problems accordin
g to an essentially visual (nonverbal) pattern of functioning.    Test results a
re not affected by the patient's educational background and do    not include ve
rbal aspects that may lead to translation distortions or biases    secondary to 
vocabulary, which is dependent on socioeconomic status. This test    is widely u
sed to evaluate intelligence (21,22) and is the standard tool used    to validat
e associated tests.      ^cY#6811.htm##
01115000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704088800072002000900960#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#38#34#article#93#<P>The following questi
onnaire was applied for the evaluation of all healthy controls.    1) Have you e
ver received treatment for any mental disorder? 2) Have you experienced    or ar
e you currently experiencing moments of psychological tension that have    compr
omised or interrupted your daily life activities? 3) Do you have any difficulty 
   to pay attention to or focus attention on what you are doing? 4) Do you have 
   any memory problems? 5) Healthy controls also answered questions evaluating  
  symptoms of depressive or hypomanic syndromes. 6) Neurologic and clinical hist
ory    was recorded. 7) A free conversation was established to identify possible
 current    psychopathologic symptoms. If any of these items pointed to positive
 answers    (symptom or treatment), the individual was excluded from the study, 
even when    that made the volunteer feel disappointed.      ^cY#6811.htm##
01077000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704085000072002000900922#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#39#35#article#93#<P>One-way ANOVA was us
ed for descriptive statistical analysis of the data, followed    by Bonferroni c
orrection to identify significant differences between variables.    The Student 
<I>t</I>-test or the Mann-Whitney test was used for some of the    variables. So
me variables were compared according to crude score percentiles    in the popula
tion (Raven test), and the other variables were compared according    to their c
rude scores. Next, univariate linear regression was used for all scores    befor
e multiple linear regression analysis. Further statistical analyses were    cond
ucted using multiple linear regression, a stepwise linear analysis, adjusting   
 for age, schooling and intelligence. The socioeconomic status of all patients  
  and healthy controls was middle or low-middle class.  </font>  <HR ALIGN=LEFT 
WIDTH=100% SIZE=2>     ^cY#6811.htm##
00606000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704037900072002000900451#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#40#36#article#93#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Results"></A><FONT color="#00007F" SIZE=4><B>Resu
lts</B></FONT></font>    <font size="4" face="Arial, Helvetica, sans-serif"><A H
REF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIGN=BOTTOM BORDER
=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A></font></P> <font face="Aria
l, Helvetica, sans-serif">      ^cY#6811.htm##
00892000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704066500072002000900737#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#41#37#article#93#<P>The study sample con
sisted of 111 subjects, 36 with schizophrenia, 28 with    interictal SLPE, and 4
7 healthy controls. <a href="#Tab1">Table 1</a> shows    that patients with epil
epsy were significantly older than patients with schizophrenia    and healthy co
ntrols and that their educational and intelligence levels were    lower. Age and
 schooling of patients with schizophrenia did not differ significantly    from t
hose of healthy controls, but their intelligence level was lower. Levels    of i
ntelligence established according to the Raven test are different from those    
established by the IQ test, and the highest possible score is 50 points.      ^c
Y#6811.htm##
00575000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704034800072002000900420#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#42#38#article#93#<P>Multiple regression 
analysis of the results of the attention tests was used    to compare both patie
nt groups and healthy controls (<a href="#Tab2">Tables    2</a> and <a href="#Ta
b3">3</a>), as well as patient groups to each other (<a href="#Tab4">Table    4<
/a>). All analyses were adjusted for age, schooling and intelligence level.     
 ^cY#6811.htm##
00484000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704025700072002000900329#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#43#39#article#93#<P><a href="#Tab2">Tabl
e 2</a> shows that patients with schizophrenia had selective    and sustained at
tention deficits compared to the healthy population. The number    of omission e
rrors was higher in the selective and sustained attention tasks.      ^cY#6811.h
tm##
00622000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704039500072002000900467#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#44#40#article#93#<P><a href="#Tab3">Tabl
e 3</a> describes the comparison between patients with    epilepsy and healthy c
ontrols. Patients with epilepsy had alternating and selective    attention defic
its, and omission errors were more frequent in the group of patients    with epi
lepsy in the three evaluations. The number of commission errors was    different
 in all but the sustained attention tasks.      ^cY#6811.htm##
00997000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704077000072002000900842#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#45#41#article#93#<P>The comparison of pa
tients with epilepsy and patients with schizophrenia (<a href="#Tab4">Table    4
</a>) revealed that there was no statistically significant difference in the    
three measurements of reaction times or in the frequency of commission errors.  
  A statistically significant difference was found for omission errors in the   
 alternating and sustained attention tasks. Equivalent results were found for   
 the two patient groups in the selective attention task: both groups had a great
er    number of omission and commission errors than healthy controls (<a href="#
Tab2">Tables    2</a> and <a href="#Tab3">3</a>), with no significant difference
 between patients    with schizophrenia and patients with epilepsy (<a href="#Ta
b4">Table 4</a>).      ^cY#6811.htm##
01214000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704098700072002000901059#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#46#42#article#93#<P>The frequency of com
mission and omission errors made by patients with schizophrenia    in the altern
ating attention task was not significantly different from those    made by healt
hy controls (<a href="#Tab2">Table 2</a>). Patients in the epilepsy    group had
 a greater number of omission errors than healthy controls, whereas    the diffe
rence in the number of commission errors was marginally significant    (P &lt; 0
.06). The number of omission errors for the alternating attention was    signifi
cantly greater in the epilepsy group than in the schizophrenia group    (<a href
="#Tab4">Table 4</a>). For sustained attention, patients with schizophrenia    m
ade more omission and commission errors than healthy controls (<a href="#Tab2">T
able    2</a>). No statistically significant difference was found between patien
ts with    epilepsy and healthy controls in this task, although the difference i
n the frequency    of omission errors bordered significance (P &lt; 0.07).      
^cY#6811.htm##
01171000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704094400072002000901016#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#47#43#article#93#<P>Age at psychosis ons
et (mean: schizophrenia = 24.4 (7.6); epilepsy = 28.7 (11.3))    and duration of
 psychosis (mean: schizophrenia = 10.2 (7.3); epilepsy = 11.2    (10.1)) were si
milar in the two groups of patients. Among the 28 patients with    epilepsy, the
 development of psychotic symptoms preceded the onset of seizures    in only 2 p
atients: for 1 of them by 15 years, and for the other by 5 years.    For all oth
er patients in this group, epileptic seizures preceded psychotic    symptoms by 
a mean number of 15 years. Mean number of hospitalizations was similar    in the
 schizophrenia and epilepsy groups (1.6 (2.1) and 1.7 (3.4)). The analysis    of
 distribution according to gender showed that 1/3 of the patients were women    
in the schizophrenia group, 53.6% were women in the epilepsy group, and 38.3%   
 in the control group. The association between gender and affective deficit was 
   not evaluated in this study.      ^cY#6811.htm##
01011000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704078400072002000900856#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#48#44#article#93#<P>Some patients were r
eceiving monotherapy, but most were also taking 2 or 3    psychotropic drugs; pa
tients with schizophrenia were being treated with typical    or atypical neurole
ptic drugs, sometimes together with antianxiety medication.    Patients with epi
leptic psychosis were taking one neuroleptic drug and one anticonvulsant    drug
, sometimes together with antianxiety medication. No patient was taking    topir
amate.  </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2> <table width="100%"  border="
0">   <tr align="left" valign="top">      <td width="12%"><a href="/img/revistas
/bjmbr/v41n1/html/6811t01.htm"><img src="/img/revistas/bjmbr/v41n1/table.jpg" wi
dth="100" height="65" border="2"></a></td>     <td width="88%"><font face="Arial
, Helvetica, sans-serif">            ^cY#6811.htm##
00480000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704025300072002000900325#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#49#45#article#93#<P><a name="Tab1"></a>T
able 1. Age, schooling and intelligence level of          patients with schizoph
renia, patients with interictal schizophrenia-like          psychosis of epileps
y, and healthy controls.        </font></td>   </tr> </table>     ^cY#6811.htm##
00683000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704045600072002000900528#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#50#46#article#93#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table    (114 K JPG file)]</f
ont></P> <HR ALIGN=LEFT WIDTH=100% SIZE=2> <table width="100%"  border="0">   <t
r align="left" valign="top">      <td width="12%"><a href="/img/revistas/bjmbr/v
41n1/html/6811t02.htm"><img src="/img/revistas/bjmbr/v41n1/table.jpg" width="100
" height="65" border="2"></a></td>     <td width="88%"><font face="Arial, Helvet
ica, sans-serif">            ^cY#6811.htm##
00448000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704022100072002000900293#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#51#47#article#93#<P><a name="Tab2"></a>T
able 2. Comparison of TAVIS-2R scores for patients          with schizophrenia a
nd controls adjusted for age, schooling and intelligence          level.        
</font></td>   </tr> </table>     ^cY#6811.htm##
00683000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704045600072002000900528#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#52#48#article#93#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table    (147 K JPG file)]</f
ont></P> <HR ALIGN=LEFT WIDTH=100% SIZE=2> <table width="100%"  border="0">   <t
r align="left" valign="top">      <td width="12%"><a href="/img/revistas/bjmbr/v
41n1/html/6811t03.htm"><img src="/img/revistas/bjmbr/v41n1/table.jpg" width="100
" height="65" border="2"></a></td>     <td width="88%"><font face="Arial, Helvet
ica, sans-serif">            ^cY#6811.htm##
00442000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704021500072002000900287#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#53#49#article#93#<P><a name="Tab3"></a>T
able 3. Comparison of TAVIS-2R scores for patients          with epilepsy and co
ntrols adjusted for age, schooling and intelligence          level.       </font
></td>   </tr> </table>     ^cY#6811.htm##
00888000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704066100072002000900733#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#54#50#article#93#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table    (141 K JPG file)]</f
ont></P> <HR ALIGN=LEFT WIDTH=100% SIZE=2> <table width="100%"  border="0">   <t
r align="left" valign="top">      <td width="12%"><a href="/img/revistas/bjmbr/v
41n1/html/6811t04.htm"><img src="/img/revistas/bjmbr/v41n1/table.jpg" width="100
" height="65" border="2"></a></td>     <td width="88%"><font face="Arial, Helvet
ica, sans-serif"><a name="Tab4"></a>Table        4. Comparison of TAVIS-2R score
s for patients with schizophrenia and patients        with epilepsy adjusted for
 age, schooling and intelligence level. </font></td>   </tr> </table>     ^cY#68
11.htm##
00347000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704012000072002000900192#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#55#51#article#93#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table    (146 K JPG file)]</f
ont></P>     ^cY#6811.htm##
00274000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704004700072002000900119#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#56#52#article#93#<P>  <HR ALIGN=LEFT WID
TH=100% SIZE=2>     ^cY#6811.htm##
00566000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033900072002000900411#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#57#53#article#93#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007F
><B>Discussion    </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v4
1n1/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B
></A></FONT></font></P> <font face="Arial, Helvetica, sans-serif">      ^cY#6811
.htm##
01848000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704162100072002000901693#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#58#54#article#93#<P>In the tests of sele
ctive attention, both patient groups made more omission    and commission errors
 and had significantly worse results than healthy controls,    with no differenc
e between patient groups. Both groups showed deficits in selective    attention 
and, therefore, are likely to face difficulties in adapting to their    environm
ent, as discussed in the introduction of this study. They may reach    wrong con
clusions and distort reality, or may have great difficulty in responding    to e
xternal demands. In the alternating attention tests, patients in the epilepsy   
 group made more omission errors than healthy controls, and the difference in   
 the number of commission errors bordered significance (P &lt; 0.06), perhaps   
 due to a type II error. In this case, the difficulty in alternating the focus  
  of attention may contribute to problems in interpersonal verbal interactions  
  and may slow the rhythm of fluency when discussing a certain topic. In the sus
tained    attention tasks, patients with schizophrenia had worse results than he
althy    controls both in numbers of omission and commission errors. As a result
 of constant    changes of attentional focus, perhaps one of the factors respons
ible for poor    persistence in activities, patients are unable to start and mai
ntain an activity,    or interpersonal verbal interactions, until completion of 
the activity. Patients    with epilepsy showed a significantly greater number of
 omission errors in the    alternating attention task but fewer omission errors 
in the sustained attention    task than patients with schizophrenia.      ^cY#68
11.htm##
00660000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704043300072002000900505#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#59#55#article#93#<P>The results were obt
ained after multiple regression analysis to rule out the    effect of confoundin
g factors: patients with epilepsy had a significantly greater    mean age and fe
wer schooling years than those with schizophrenia or healthy    controls. Howeve
r, these differences were found in a clinically non-significant    age bracket (
mean age = 34 to 39 years), and schooling was equivalent to secondary    school.
      ^cY#6811.htm##
00858000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704063100072002000900703#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#60#56#article#93#<P>The intelligence lev
el of patients with epilepsy was significantly lower than    that of patients wi
th schizophrenia or healthy controls; patients with schizophrenia    also had si
gnificantly lower intelligence scores than healthy controls. Low    intelligence
 levels have been frequently described in samples of nonpsychotic    patients wi
th epilepsy (23). If patients with epilepsy but no associated psychosis    tend 
to have a poorer intellectual performance, it is reasonable to expect that    th
ose with psychosis may have an even poorer performance. Chronic epilepsy is    u
sually associated with less schooling.      ^cY#6811.htm##
01007000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704078000072002000900852#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#61#57#article#93#<P>Almost all patients 
were taking neuroleptic drugs, and patients with epilepsy    and psychosis were 
also taking antiepileptic drugs. One of the limitations of    our study was that
 we were not able to reduce individual medication doses to    equivalent doses o
f one single standard psychotropic drug (chlorpromazine) because    no data abou
t the equivalence of atypical neuroleptic drugs are available, and    no compari
sons with antiepileptic drugs have been established. Moreover, these    are the 
medications and doses necessary to make patients more balanced and clinically   
 stable, and their cognitive profiles will reflect the use of such medication   
 when they present to a cognitive rehabilitation team. No patient was taking    
a toxic dose of medication.      ^cY#6811.htm##
00767000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704054000072002000900612#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#62#58#article#93#<P>Another limitation o
f our study was the use of the TAVIS-2R test, which is    still not a well-known
 and widely accepted method, but which has the necessary    basic factors for go
od performance as a visual attention test: all symbols are    familiar (24), and
 the test differentiates types of attention in each of its    task more clearly 
than other validated and widely used tests. The problem of    lack of validation
 was mitigated by the comparison of results with a control    group, as proposed
 by Engelberts et al. (25).      ^cY#6811.htm##
01008000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704078100072002000900853#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#63#59#article#93#<P>The results reportd 
by Mellers et al. (14) are similar to our findings. These    investigators studi
ed the neuropsychological profiles of similar groups of patients    compared wit
h normal controls and nonpsychotic patients with epilepsy and found    almost id
entical profiles: psychotic patients had attention deficits, whereas    nonpsych
otic patients with epilepsy did not. Other cognitive functions, such    as intel
ligence level, memory and executive functions, did not differ between    groups.
 Nathaniel-James et al. (22) compared similar groups and found that patients    
had almost the same cognitive performance profile. However, our results, which  
  separated different types of attention, revealed differences between the diagn
ostic    groups under study.      ^cY#6811.htm##
00983000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704075600072002000900828#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#64#60#article#93#<P>The sustained and al
ternating attention performances differed between the groups    of patients with
 schizophrenia and with epilepsy and psychosis, whereas selective    attention d
eficits were equally found in both clinical conditions. The comparison    of qua
litative clinical observations for both patient groups revealed that these    qu
antitative results were coherent, that is, that patients with schizophrenia    h
ad difficulties in focusing attention, whereas those with epilepsy showed persev
eration    in the same focus. Moreover, these results point to the fact that alt
ernating    attention is the opposite of sustained attention, that is, the great
er the alternating    attention, the lower the sustained attention, and vice ver
sa.      ^cY#6811.htm##
00721000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704049400072002000900566#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#65#61#article#93#<P>Our findings suggest
 several new paths for this line of research: their correlation    with positive
 or negative symptoms of psychoses or with the different types    of epilepsy, i
nvestigation of psychological and neurophysiological phenomena    in these condi
tions, and comparisons with other mental, cognitive or affective    functions. T
hey also indicate the need to validate the TAVIS-3R test (current    version) fo
r use with adults.  </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6811.htm#
#
00612000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038500072002000900457#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#66#62#article#93#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><B>R
eferences</B></FONT></font>    <font size="4" face="Arial, Helvetica, sans-serif
"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIGN=BOTTOM 
BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A></font></P> <font face
="Arial, Helvetica, sans-serif">      ^cY#6811.htm##
00401000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704016000074002000900234#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#p#67#63#article#93#1#<P>1. Lur
ia AR. <I>Curso de psicologia geral. Aten&ccedil;&atilde;o e mem&oacute;ria</I>.
    Rio de Janeiro: Civiliza&ccedil;&atilde;o Brasileira; 1979.    ^cY#6811.htm#
#
00398000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704015700074002000900231#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#p#68#64#article#93#2#<P>2. Lez
ak MD. Basic concepts. In: Lezak MD (Editor), <I>Neuropsychological assessment</
I>.    3rd edn. London: Oxford University Press; 1995. p 39.    ^cY#6811.htm##
00521000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704028000074002000900354#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#p#69#65#article#93#3#<P>3. Len
t R. Mentes emocionais, mentes racionais: as bases neurais da emo&ccedil;&atilde
;o    e da raz&atilde;o. In: Lent R (Editor), <I>Cem bilh&otilde;es de neur&ocir
c;nios:    conceitos fundamentais de neuroci&ecirc;ncia</I>. S&atilde;o Paulo: A
theneu;    2001. p 676.    ^cY#6811.htm##
00450000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704020900074002000900283#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#p#70#66#article#93#4#<P>4. Par
asuraman R, Warm JS, Dember WN. Vigilance: taxonomy and utility. In:    Mark LS,
 Warm JS, Huston RL (Editors), <I>Ergonomics and human factors</I>.    New York:
 Springer Verlag; 1987. p 11-32.    ^cY#6811.htm##
00356000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704011500074002000900189#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#p#71#67#article#93#5#<P>5. But
ler RW, Braff DL. Delusions: a review and integration. <I>Schizophr Bull</I>    
1991; 17: 633-647.    ^cY#6811.htm##
00414000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704017300074002000900247#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#p#72#68#article#93#6#<P>6. Kan
ey S, Wolfenden M, Dewey ME, Bentall RP. Persecutory delusions and recall    of 
threatening propositions. <I>Br J Clin Psychol</I> 1992; 31 (Part 1): 85-87.    
^cY#6811.htm##
00428000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704018700074002000900261#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#p#73#69#article#93#7#<P>7. Ben
tall RP, Kaney S, Bowen-Jones K. Persecutory delusions and recall of    threat-r
elated, depression-related and neutral words. <I>Cognit Ther Res</I>    1995; 19
: 331-343.    ^cY#6811.htm##
00366000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704012500074002000900199#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#p#74#70#article#93#8#<P>8. Lea
fhead KM, Young AW, Szulecka TK. Delusions demand attention. <I>Cognit    Neurop
sychiatry</I> 1996; 1: 5-16.    ^cY#6811.htm##
00414000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704017300074002000900247#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#p#75#71#article#93#9#<P>9. Phi
llips ML, Senior C, David AS. Abnormal processing of ambiguity in paranoid    sc
hizophrenia: a visual scan path study. <I>Psychol Med</I> 2000; 30: 157-167.    
^cY#6811.htm##
00379000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704013700075002000900212#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#p#76#72#article#93#10#<P>10. S
later E, Beard AW, Glithero E. The schizophrenia-like psychoses of epilepsy.    
<I>Br J Psychiatry</I> 1963; 109: 95-150.    ^cY#6811.htm##
00363000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704012100075002000900196#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#p#77#73#article#93#11#<P>11. R
eynolds EH. Epilepsy and schizophrenia: relationship and biochemistry.    <I>Lan
cet</I> 1968; 1: 398-401.    ^cY#6811.htm##
00331000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704008900075002000900164#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#p#78#74#article#93#12#<P>12. T
oone BK. The psychoses of epilepsy. <I>J R Soc Med</I> 1991; 84: 457-459.    ^cY
#6811.htm##
00469000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022700075002000900302#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#p#79#75#article#93#13#<P>13. M
archetti RL, Damasceno BP. Epilepsia: psicopatologia e comportamento.    In: Gue
rreiro CAM, Guerreiro MM, Cendes F, Lopes-Cendes I (Editors), <I>Epilepsias</I>.
    S&atilde;o Paulo: Lemos Editorial; 2000. p 231.    ^cY#6811.htm##
00426000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704018400075002000900259#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#p#80#76#article#93#14#<P>14. M
ellers JD, Toone BK, Lishman WA. A neuropsychological comparison of schizophreni
a    and schizophrenia-like psychosis of epilepsy. <I>Psychol Med</I> 2000; 30: 
325-335.    ^cY#6811.htm##
00398000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704015600075002000900231#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#p#81#77#article#93#15#<P>15. A
nonymous. <I>American Psychiatric Association. Diagnostic and statistical    man
ual of mental disorders</I>. 4th edn. Washington: APA; 1994.    ^cY#6811.htm##
00485000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704024300075002000900318#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#p#82#78#article#93#16#<P>16. C
ommission on Classification and Terminology of the International League    Again
st Epilepsy. Proposal for revised clinical and electroencephalographic    classi
fication of epileptic seizures. <I>Epilepsia</I> 1981; 22: 489-501.    ^cY#6811.
htm##
00464000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022200075002000900297#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#p#83#79#article#93#17#<P>17. C
ommission on Classification and Terminology of the International League    Again
st Epilepsy. Proposal for revised classification of epilepsies and epileptic    
syndromes. <I>Epilepsia</I> 1989; 30: 389-399.    ^cY#6811.htm##
00343000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704010100075002000900176#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#p#84#80#article#93#18#<P>18. P
ond DA. Psychiatric aspects of epilepsy. <I>J Ind Med Prof</I> 1957; 3:    1441-
1451.    ^cY#6811.htm##
00387000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704014500075002000900220#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#p#85#81#article#93#19#<P>19. D
uchesne M, Mattos P. Normalization of a computerized visual attention    test (T
AVIS). <I>Arq Neuropsiquiatr</I> 1997; 55: 62-69.    ^cY#6811.htm##
00542000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704030000075002000900375#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#p#86#82#article#93#20#<P>20. R
aven JC. <I>Testes das matrizes progressivas - escala geral, s&eacute;ries    A,
 B, C, D e E. </I>Tradu&ccedil;&atilde;o e adapta&ccedil;&atilde;o de Francisco 
   Campos, revis&atilde;o de Suzana Ezequiel da Cunha. Rio de Janeiro: Centro Ed
itor    de Psicologia Aplicada (CEPA); 1999.    ^cY#6811.htm##
00483000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704024100075002000900316#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#p#87#83#article#93#21#<P>21. B
erman KF, Weinberger D. Functional localization in the brain in schizophrenia.  
  In: Tasman A, Goldfinger SM (Editors), <I>American psychiatric press review   
 of psychiatry</I>. Washington: American Psychiatric Press; 1991.    ^cY#6811.ht
m##
00474000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023200075002000900307#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#p#88#84#article#93#22#<P>22. N
athaniel-James DA, Brown RG, Maier M, Mellers J, Toone B, Ron MA. Cognitive    a
bnormalities in schizophrenia and schizophrenia-like psychosis of epilepsy.    <
I>J Neuropsychiatry Clin Neurosci</I> 2004; 16: 472-479.    ^cY#6811.htm##
00372000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704013000075002000900205#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#p#89#85#article#93#23#<P>23. R
eynolds EH. Mental effects of antiepileptic medication: a review. <I>Epilepsia</
I>    1983; 24 (Suppl 2): S85-S95.    ^cY#6811.htm##
00400000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704015800075002000900233#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#p#90#86#article#93#24#<P>24. K
anda PAM. Estudo da aten&ccedil;&atilde;o na epilepsia parcial criptog&ecirc;nic
a.    [Master's thesis]. S&atilde;o Paulo; EPM, UNIFESP; 1993.    ^cY#6811.htm##
00492000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704025000075002000900325#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#p#91#87#article#93#25#<P>25. E
ngelberts NH, Klein M, Ader HJ, Heimans JJ, Trenite DG, van der Ploeg    HM. The
 effectiveness of cognitive rehabilitation for attention deficits in    focal se
izures: a randomized controlled study. <I>Epilepsia</I> 2002; 43: 587-595.    ^c
Y#6811.htm##
00280000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704005300072002000900125#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#92#88#article#93#  </font>  <HR ALIGN=LE
FT WIDTH=100% SIZE=2>     ^cY#6811.htm##
00631000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704040400072002000900476#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#93#89#article#93#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT color="#00007F" SIZE=4
><B>Acknowledgments</B></FONT></font>    <font size="4" face="Arial, Helvetica, 
sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALI
GN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0" width="12" height="12"></B></A></f
ont></P> <font face="Arial, Helvetica, sans-serif">      ^cY#6811.htm##
00520000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704029300072002000900365#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#94#90#article#93#<P>The authors thank Ke
lsy Catherina Nema Areco, Universidade Federal de S&atilde;o    Paulo, and Ronir
 Raggio Luiz and Antonio Jos&eacute; Leal Costa, Universidade    Federal do Rio 
de Janeiro, for assistance with the statistical analyses.  </font>  <HR ALIGN=LE
FT WIDTH=100% SIZE=2>     ^cY#6811.htm##
00588000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704036100072002000900433#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#95#91#article#93#<P><FONT SIZE=4 face="A
rial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F><B
>Correspondence    and Footnotes</B></FONT></FONT> <font size="4" face="Arial, H
elvetica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A></
font></P>     ^cY#6811.htm##
00602000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704037500072002000900447#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#96#92#article#93#<p><font face="Arial, H
elvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v41n1/rec
or.gif" width="15" height="14" border="0"></a>    Address for correspondence:</b
> I.C.J. Kairalla, Rua Heitor Peixoto, 325/133,    01543-000 S&atilde;o Paulo, S
P, Brasil. Fax: +55-11-5579-7693. E-mail: <a href="mailto:ivettek@osite.com.br">
ivettek@osite.com.br</a>    ^cY#6811.htm##
00438000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704021100072002000900283#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6811.htm#S#p#97#93#article#93#<br>   Research support
ed by FAPESP (No. 1998/04099-0). J.J. Mari is the recipient    of a CNPq IB prod
uctivity fellowship. <I>Received February 22, 2007. Accepted    September 21, 20
07</I>. </font></p>     ^cY#6811.htm##
00438000000000229000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710160016000730180049000890660
01500138062002300153065000900176064000500185865000900190002000900199#v41n1#v:\sc
ielo\serial\bjmbr\v41n1\markup\6811.htm#S#c#98#1#article#25#1#^rND^sLuria^nAR#Cu
rso de psicologia geral. Atenção e memória^len#Rio de Janeiro#Civilização Brasil
eira#19790000#1979#20080100#6811.htm##
00504000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100016000730120019000890160
01600108018003400124063000200158066000700160062002400167065000900191064000500200
014000300205865000900208002000900217#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
811.htm#S#c#99#2#article#25#2#^rND^sLezak^nMD#Basic concepts^len#^rND^sLezak^nMD
#Neuropsychological assessment^len#3#London#Oxford University Press#19950000#199
5#39#20080100#6811.htm##
00570000000000265000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100014000740120079000880160
01400167018006900181066001000250062000800260065000900268064000500277014000400282
865000900286002000900295#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#c#
100#3#article#25#3#^rND^sLent^nR#Mentes emocionais, mentes racionais: as bases n
eurais da emoção e da razão^lpt#^rND^sLent^nR#Cem bilhões de neurônios: conceito
s fundamentais de neurociência^lpt#São Paulo#Atheneu#20010000#2001#676#20080100#
6811.htm##
00620000000000313000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100021000740100015000950100
01700110012003600127016001500163016001500178016001700193018003300210066000900243
062001600252065000900268064000500277014000600282865000900288002000900297#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#c#101#4#article#25#4#^rND^sParasur
aman^nR#^rND^sWarm^nJS#^rND^sDember^nWN#Vigilance: taxonomy and utility^len#^rND
^sMark^nLS#^rND^sWarm^nJS#^rND^sHuston^nRL#Ergonomics and human factors^len#New 
York#Springer Verlag#19870000#1987#11-32#20080100#6811.htm##
00508000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740100016000910120
04000107030001500147065000900162064000500171031000300176014000800179865000900187
002000900196035001000205801001500215#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
811.htm#S#c#102#5#article#25#5#^rND^sButler^nRW#^rND^sBraff^nDL#Delusions: a rev
iew and integration^len#Schizophr Bull#19910000#1991#17#633-647#20080100#6811.ht
m#0586-7614#Schizophr Bull##
00610000000000313000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100015000740100019000890100
01600108010001800124012006500142030001800207065000900225064000500234031000300239
032000200242014000600244865000900250002000900259035001000268801001800278#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#c#103#6#article#25#6#^rND^sKaney^n
S#^rND^sWolfenden^nM#^rND^sDewey^nME#^rND^sBentall^nRP#Persecutory delusions and
 recall of threatening propositions^len#Br J Clin Psychol#19920000#1992#31#1#85-
87#20080100#6811.htm#0144-6657#Br J Clin Psychol##
00596000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100015000920100
02100107012009300128030001600221065000900237064000500246031000300251014000800254
865000900262002000900271035001000280801001600290#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6811.htm#S#c#104#7#article#25#7#^rND^sBentall^nRP#^rND^sKaney^nS#^rND
^sBowen-Jones^nK#Persecutory delusions and recall of threat-related, depression-
related and neutral words^len#Cognit Ther Res#19950000#1995#19#331-343#20080100#
6811.htm#0147-5916#Cognit Ther Res##
00501000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100019000740100016000930100
01900109012003100128030002300159710000200182065000900184064000500193031000200198
014000500200865000900205002000900214#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
811.htm#S#c#105#8#article#25#8#^rND^sLeafhead^nKM#^rND^sYoung^nAW#^rND^sSzulecka
^nTK#Delusions demand attention^len#Cognit Neuropsychiatry#2#19960000#1996#1#5-1
6#20080100#6811.htm##
00581000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100019000740100016000930100
01600109012008900125030001200214065000900226064000500235031000300240014000800243
865000900251002000900260035001000269801001200279#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6811.htm#S#c#106#9#article#25#9#^rND^sPhillips^nML#^rND^sSenior^nC#^r
ND^sDavid^nAS#Abnormal processing of ambiguity in paranoid schizophrenia: a visu
al scan path study^len#Psychol Med#20000000#2000#30#157-167#20080100#6811.htm#00
33-2917#Psychol Med##
00550000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100016000920100
01800108012004900126030001600175065000900191064000500200031000400205014000700209
865000900216002000900225035001000234801001600244#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6811.htm#S#c#107#10#article#25#10#^rND^sSlater^nE#^rND^sBeard^nAW#^rN
D^sGlithero^nE#The schizophrenia-like psychoses of epilepsy^len#Br J Psychiatry#
19630000#1963#109#95-150#20080100#6811.htm#0007-1250#Br J Psychiatry##
00489000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760120062000950300
00700157065000900164064000500173031000200178014000800180865000900188002000900197
035001000206801000700216#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#c#
108#11#article#25#11#^rND^sReynolds^nEH#Epilepsy and schizophrenia: relationship
 and biochemistry^len#Lancet#19680000#1968#1#398-401#20080100#6811.htm#0099-5355
#Lancet##
00465000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760120030000920300
01200122065000900134064000500143031000300148014000800151865000900159002000900168
035001000177801001200187#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#c#
109#12#article#25#12#^rND^sToone^nBK#The psychoses of epilepsy^len#J R Soc Med#1
9910000#1991#84#457-459#20080100#6811.htm#0141-0768#J R Soc Med##
00632000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100020000960120
04600116016002100162016002000183016001600203016002200219018001500241066001000256
062001600266065000900282064000500291014000400296865000900300002000900309#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#c#110#13#article#25#13#^rND^sMarch
etti^nRL#^rND^sDamasceno^nBP#Epilepsia: psicopatologia e comportamento^lpt#^rND^
sGuerreiro^nCAM#^rND^sGuerreiro^nMM#^rND^sCendes^nF#^rND^sLopes-Cendes^nI#Epilep
sias^lpt#São Paulo#Lemos Editorial#20000000#2000#231#20080100#6811.htm##
00593000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100016000940100
01800110012009800128030001200226065000900238064000500247031000300252014000800255
865000900263002000900272035001000281801001200291#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6811.htm#S#c#111#14#article#25#14#^rND^sMellers^nJD#^rND^sToone^nBK#^
rND^sLishman^nWA#A neuropsychological comparison of schizophrenia and schizophre
nia-like psychosis of epilepsy^len#Psychol Med#20000000#2000#30#325-335#20080100
#6811.htm#0033-2917#Psychol Med##
00486000000000253000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730160005000760160010000810180
09200091063000200183066001100185062000400196065000900200064000500209865000900214
002000900223#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#c#112#15#artic
le#25#15#^rND#Anonymous#American Psychiatric Association. Diagnostic and statist
ical manual of mental disorders^len#4#Washington#APA#19940000#1994#20080100#6811
.htm##
00604000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730110090000760120099001660300
01000265065000900275064000500284031000300289014000800292865000900300002000900309
035001000318801001000328#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#c#
113#16#article#25#16#Commission on Classification and Terminology of the Interna
tional League Against Epilepsy#Proposal for revised clinical and electroencephal
ographic classification of epileptic seizures^len#Epilepsia#19810000#1981#22#489
-501#20080100#6811.htm#0013-9580#Epilepsia##
00583000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730110090000760120078001660300
01000244065000900254064000500263031000300268014000800271865000900279002000900288
035001000297801001000307#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#c#
114#17#article#25#17#Commission on Classification and Terminology of the Interna
tional League Against Epilepsy#Proposal for revised classification of epilepsies
 and epileptic syndromes^len#Epilepsia#19890000#1989#30#389-399#20080100#6811.ht
m#0013-9580#Epilepsia##
00442000000000253000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760120036000910300
01500127710000200142065000900144064000500153031000200158014001000160865000900170
002000900179#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#c#115#18#artic
le#25#18#^rND^sPond^nDA#Psychiatric aspects of epilepsy^len#J Ind Med Prof#2#195
70000#1957#3#1441-1451#20080100#6811.htm##
00543000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100016000940120
06600110030001900176065000900195064000500204031000300209014000600212865000900218
002000900227035001000236801001900246#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
811.htm#S#c#116#19#article#25#19#^rND^sDuchesne^nM#^rND^sMattos^nP#Normalization
 of a computerized visual attention test (TAVIS)^len#Arq Neuropsiquiatr#19970000
#1997#55#62-69#20080100#6811.htm#0004-282X#Arq Neuropsiquiatr##
00567000000000229000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730160016000760180154000920660
01500246062004400261065000900305064000500314865000900319002000900328#v41n1#v:\sc
ielo\serial\bjmbr\v41n1\markup\6811.htm#S#c#117#20#article#25#20#^rND^sRaven^nJC
#Testes das matrizes progressivas - escala geral, séries A, B, C, D e E: Traduçã
o e adaptação de Francisco Campos, revisão de Suzana Ezequiel da Cunha^lpt#Rio d
e Janeiro#Centro Editor de Psicologia Aplicada (CEPA)#19990000#1999#20080100#681
1.htm##
00608000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100020000930120
05800113016001600171016002100187018005200208066001100260062002700271065000900298
064000500307865000900312002000900321#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
811.htm#S#c#118#21#article#25#21#^rND^sBerman^nKF#^rND^sWeinberger^nD#Functional
 localization in the brain in schizophrenia^len#^rND^sTasman^nA#^rND^sGoldfinger
^nSM#American psychiatric press review of psychiatry^len#Washington#American Psy
chiatric Press#19910000#1991#20080100#6811.htm##
00712000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100026000760100016001020100
01500118010001700133010001500150010001400165012009000179030003200269065000900301
06400050031003100030031501400080031886500090032600200090033503500100034480100320
0354#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#c#119#22#article#25#22
#^rND^sNathaniel-James^nDA#^rND^sBrown^nRG#^rND^sMaier^nM#^rND^sMellers^nJ#^rND^
sToone^nB#^rND^sRon^nMA#Cognitive abnormalities in schizophrenia and schizophren
ia-like psychosis of epilepsy^len#J Neuropsychiatry Clin Neurosci#20040000#2004#
16#472-479#20080100#6811.htm#0895-0172#J Neuropsychiatry Clin Neurosci##
00507000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760120057000950300
01000152065000900162064000500171031000300176032000400179014000800183865000900191
002000900200035001000209801001000219#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
811.htm#S#c#120#23#article#25#23#^rND^sReynolds^nEH#Mental effects of antiepilep
tic medication: a review^len#Epilepsia#19830000#1983#24#^s2#S85-S95#20080100#681
1.htm#0013-9580#Epilepsia##
00462000000000241000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730160017000760180056000930510
01600149046001000165050001300175045000900188044000500197865000900202002000900211
#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#c#121#24#article#25#24#^rN
D^sKanda^nPAM#Estudo da atenção na epilepsia parcial criptogênica^lpt#Master's t
hesis#São Paulo#UNIFESP^dEPM#19930000#1993#20080100#6811.htm##
00708000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100021000760100015000970100
01500112010001800127010001800145010002400163012012200187030001000309065000900319
06400050032803100030033301400080033686500090034400200090035303500100036280100100
0372#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6811.htm#S#c#122#25#article#25#25
#^rND^sEngelberts^nNH#^rND^sKlein^nM#^rND^sAder^nHJ#^rND^sHeimans^nJJ#^rND^sTren
ite^nDG#^rND^svan^nder Ploeg HM#The effectiveness of cognitive rehabilitation fo
r attention deficits in focal seizures: a randomized controlled study^len#Epilep
sia#20020000#2002#43#587-595#20080100#6811.htm#0013-9580#Epilepsia##
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#o#1#1#article#1#20
080623#161503#6846.htm#204##
03167000000000685000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000300108
03000200011103100030013103200020013406500090013601400090014503500100015422300090
01640120164001730100024003370100025003610100032003860100022004180100022004400100
02000462010002400482010002300506070013300529083151600662085000802178085003702186
08500230222308500280224608500220227408500250229611700060232107200030232705800050
23300580006023350580007023410580042023480580007023901120009023971110014024061140
00902420113001902429881002402448002000902472#v41n1#v:\scielo\serial\bjmbr\v41n1\
markup\6846.htm#S#h#2#1#article#1#oa#en#bjmbr#1#3.1#ILUS#TAB#04#BJMBR010#nd#Braz
 J Med Biol Res#41#1#20080100#^f18^l25#0100-879X#20071217#Purification, partial 
characterization and role in lipid transport to developing oocytes of a novel li
pophorin from the cowpea weevil, Callosobruchus maculatus^len#^rND^1A01^nA.A^sXi
menes#^rND^1A01^nG.A^sOliveira#^rND^1A01^nP^sBittencourt-Cunha#^rND^1A01^nM^sTom
okyo#^rND^1A01^nD.B^sLeite#^rND^1A01^nE^sFolly#^rND^1A01^nD.M^sGolodne#^rND^1A01
^nG.C^sAtella#Universidade Federal do Rio de Janeiro^iA01^1Centro de Ciências da
 Saúde^2Instituto de Bioquímica Médica^cRio de Janeiro^sRJ^pBrasil#^len^aLipid t
ransport in arthropods is achieved by highly specialized lipoproteins, which res
emble those described in vertebrate blood. Here we describe purification and cha
racterization of the lipid-apolipoprotein complex, lipophorin (Lp), from adults 
and larvae of the cowpea weevil Callosobruchus maculatus. We also describe the L
p-mediated lipid transfer to developing oocytes. Lps were isolated from homogena
tes of C. maculatus larvae and adults by potassio bromide gradient and character
ized with respect to physicochemical properties and lipid content. The weevil Lp
 (465 kDa) and larval Lp (585 kDa), with hydrated densities of 1.22 and 1.14 g/m
L, contained 34 and 56% lipids and 9 and 7% carbohydrates, respectively. In both
 Lps, mannose was the predominant monosaccharide detected by paper chromatograph
y. SDS-PAGE revealed two apolipoproteins in each Lp with molecular masses of 225
 kDa (apolipoprotein-I) and 79 kDa (apolipoprotein-II). The lipids were extracte
d and analyzed by thin-layer chromatography. The major phospholipids found were 
phosphatidylserine, phosphatidylcholine and phosphatidylethanolamine in adult Lp
, and phosphatidylcholine, phosphatidylethanolamine and sphingomyelin in larval 
Lp. Hydrocarbons, fatty acids and triacylglycerol were the major neutral lipids 
found in both Lps. Lps labeled in the protein moiety with radioactive iodine (12
5I-iodine) or in the lipid moiety with fluorescent lipids revealed direct eviden
ce of endocytic uptake of Lps in live oocytes of C. maculatus.#^dnd^i1#^tm^len^k
Callosobruchus maculatus^i1#^tm^len^kLipophorin^i1#^tm^len^kLipid transport^i1#^
tm^len^kOogenesis^i1#^tm^len^kHydrocarbons^i1#other#40#CNPq#PADCT#Pronex#Interna
tional Foudation for Science (IFS)#FAPERJ#20070402#April 2, 2007#20070924#Septem
ber 24, 2007#S0100-879X2006005000191#6846.htm##
03184000000000673000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000300108
03000200011103100030013103200020013406500090013601400090014503500100015422300090
01640120178001730100024003510100025003750100032004000100022004320100022004540100
02000476010002400496010002300520070013300543083154800676085000802224085004402232
08500230227608500280229908500220232708500250234911700060237407200030238005800050
23830580006023880580007023940580042024010580007024431120009024501110014024591140
00902473113001902482002000902501#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.
htm#S#f#3#1#article#1#oa#en#bjmbr#1#3.1#ILUS#TAB#04#BJMBR010#nd#Braz J Med Biol 
Res#41#1#20080100#^f18^l25#0100-879X#20071217#<B>Purification, partial character
ization and role in lipid transport to developing oocytes of a novel lipophorin 
from the cowpea weevil, <I>Callosobruchus maculatus</B></I>^len#^rND^1A01^nA.A^s
Ximenes#^rND^1A01^nG.A^sOliveira#^rND^1A01^nP^sBittencourt-Cunha#^rND^1A01^nM^sT
omokyo#^rND^1A01^nD.B^sLeite#^rND^1A01^nE^sFolly#^rND^1A01^nD.M^sGolodne#^rND^1A
01^nG.C^sAtella#Universidade Federal do Rio de Janeiro^iA01^1Centro de Ciências 
da Saúde^2Instituto de Bioquímica Médica^cRio de Janeiro^sRJ^pBrasil#^len^aLipid
 transport in arthropods is achieved by highly specialized lipoproteins, which r
esemble those described in vertebrate blood. Here we describe purification and c
haracterization of the lipid-apolipoprotein complex, lipophorin (Lp), from adult
s and larvae of the cowpea weevil <I>Callosobruchus maculatus</I>. We also descr
ibe the Lp-mediated lipid transfer to developing oocytes. Lps were isolated from
 homogenates of <I>C. maculatus</I> larvae and adults by potassio bromide gradie
nt and characterized with respect to physicochemical properties and lipid conten
t. The weevil Lp (465 kDa) and larval Lp (585 kDa), with hydrated densities of 1
.22 and 1.14 g/mL, contained 34 and 56% lipids and 9 and 7% carbohydrates, respe
ctively. In both Lps, mannose was the predominant monosaccharide detected by pap
er chromatography. SDS-PAGE revealed two apolipoproteins in each Lp with molecul
ar masses of 225 kDa (apolipoprotein-I) and 79 kDa (apolipoprotein-II). The lipi
ds were extracted and analyzed by thin-layer chromatography. The major phospholi
pids found were phosphatidylserine, phosphatidylcholine and phosphatidylethanola
mine in adult Lp, and phosphatidylcholine, phosphatidylethanolamine and sphingom
yelin in larval Lp. Hydrocarbons, fatty acids and triacylglycerol were the major
 neutral lipids found in both Lps. Lps labeled in the protein moiety with radioa
ctive iodine (<SUP>125</SUP>I-iodine) or in the lipid moiety with fluorescent li
pids revealed direct evidence of endocytic uptake of Lps in live oocytes of <I>C
. maculatus</I>.#^dnd^i1#^tm^len^k<I>Callosobruchus maculatus</I>^i1#^tm^len^kLi
pophorin^i1#^tm^len^kLipid transport^i1#^tm^len^kOogenesis^i1#^tm^len^kHydrocarb
ons^i1#other#40#CNPq#PADCT#Pronex#International Foudation for Science (IFS)#FAPE
RJ#20070402#April 2, 2007#20070924#September 24, 2007#6846.htm##
03282000000000697000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000500100038000400105121000300109049000900112
15800030012103000240012403100030014803200020015106500090015301400090016203500100
01712230009001810120164001900100025003540100026003790100032004050100022004370100
02300459010002000482010002500502010002400527070013500551083153000686085000802216
08500370222408500230226108500280228408500220231208500250233411700060235907200030
23650580005023680580006023730580007023790580042023860580007024281120009024351110
01402444114000902458113001902467002000902486008008902495#v41n1#v:\scielo\serial\
bjmbr\v41n1\markup\6846.htm#S#l#4#1#article#1#^mJan.^a2008#oa#en#bjmbr#1#3.1#ilu
s#tab#04#BJMBR010#nd#Braz. j. med. biol. res#41#1#20080100#^f18^l25#0100-879X#20
071217#Purification, partial characterization and role in lipid transport to dev
eloping oocytes of a novel lipophorin from the cowpea weevil, Callosobruchus mac
ulatus^len#^rND^1A01^nA. A^sXimenes#^rND^1A01^nG. A^sOliveira#^rND^1A01^nP^sBitt
encourt-Cunha#^rND^1A01^nM^sTomokyo#^rND^1A01^nD. B^sLeite#^rND^1A01^nE^sFolly#^
rND^1A01^nD. M^sGolodne#^rND^1A01^nG. C^sAtella#^iA01^1Universidade Federal do R
io de Janeiro^2Centro de Ciências da Saúde^3Instituto de Bioquímica Médica^cRio 
de Janeiro^sRJ^pBrasil#^len^aLipid transport in arthropods is achieved by highly
 specialized lipoproteins, which resemble those described in vertebrate blood. H
ere we describe purification and characterization of the lipid-apolipoprotein co
mplex, lipophorin (Lp), from adults and larvae of the cowpea weevil Callosobruch
us maculatus. We also describe the Lp-mediated lipid transfer to developing oocy
tes. Lps were isolated from homogenates of C. maculatus larvae and adults by pot
assio bromide gradient and characterized with respect to physicochemical propert
ies and lipid content. The weevil Lp (465 kDa) and larval Lp (585 kDa), with hyd
rated densities of 1.22 and 1.14 g/mL, contained 34 and 56 percent lipids and 9 
and 7 percent carbohydrates, respectively. In both Lps, mannose was the predomin
ant monosaccharide detected by paper chromatography. SDS-PAGE revealed two apoli
poproteins in each Lp with molecular masses of 225 kDa (apolipoprotein-I) and 79
 kDa (apolipoprotein-II). The lipids were extracted and analyzed by thin-layer c
hromatography. The major phospholipids found were phosphatidylserine, phosphatid
ylcholine and phosphatidylethanolamine in adult Lp, and phosphatidylcholine, pho
sphatidylethanolamine and sphingomyelin in larval Lp. Hydrocarbons, fatty acids 
and triacylglycerol were the major neutral lipids found in both Lps. Lps labeled
 in the protein moiety with radioactive iodine (125I-iodine) or in the lipid moi
ety with fluorescent lipids revealed direct evidence of endocytic uptake of Lps 
in live oocytes of C. maculatus.#^dnd^i1#^tm^len^kCallosobruchus maculatus^i1#^t
m^len^kLipophorin^i1#^tm^len^kLipid transport^i1#^tm^len^kOogenesis^i1#^tm^len^k
Hydrocarbons^i1#other#40#CNPq#PADCT#Pronex#International Foudation for Science (
IFS)#FAPERJ#20070402#April 2, 2007#20070924#September 24, 2007#6846.htm#Internet
^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2008000100004
##
00375000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704014900071002000900220#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#5#1#article#160#<P> <font face="Arial, H
elvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med    Biol Res, January 2008
, Volume 41(1) 18-25</B> </font></P>     ^cY#6846.htm##
00476000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704025000071002000900321#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#6#2#article#160#<P><B><font size="5" fac
e="Arial, Helvetica, sans-serif">Purification, partial    characterization and r
ole in lipid transport to developing oocytes of a novel    lipophorin from the c
owpea weevil, <I>Callosobruchus maculatus</I></font></B>      ^cY#6846.htm##
00659000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704043300071002000900504#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#7#3#article#160#<P><font face="Arial, He
lvetica, sans-serif">A.A. Ximenes, G.A. Oliveira, P. Bittencourt-Cunha,    M. To
mokyo, D.B. Leite, E. Folly, D.M. Golodne and <b><a href="#Correspondence"><img 
src="/img/revistas/bjmbr/v41n1/recor.gif" width="15" height="14" border="0"></a>
</b>    <a href="mailto:atella@Bioqmed.ufrj.br"><img src="/img/revistas/bjmbr/v4
1n1/email-ca.gif" width="14" height="11" border="0"></a>    G.C. Atella </font> 
     ^cY#6846.htm##
00448000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704022200071002000900293#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#8#4#article#160#<P><font face="Arial, He
lvetica, sans-serif">Instituto de Bioqu&iacute;mica M&eacute;dica,    Centro de 
Ci&ecirc;ncias da Sa&uacute;de, Universidade Federal do Rio de Janeiro,    Rio d
e Janeiro, RJ, Brasil</font>      ^cY#6846.htm##
00442000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704021600071002000900287#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#9#5#article#160#<P> <font face="Arial, H
elvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v41n1/do
wn.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12">    <stro
ng>Abstract</strong></A>    ^cY#6846.htm##
00440000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704021300072002000900285#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#10#6#article#160#<BR>   <A HREF="#Introd
uction"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPA
CE=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Introduction"><strong>Int
roduction</strong></A>    ^cY#6846.htm##
00440000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704021300072002000900285#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#11#7#article#160#<BR>   <A HREF="#Materi
al"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0
 HSPACE=0 width="12" height="12"></A>    <A HREF="#Material"><strong>Material an
d Methods</strong></A>    ^cY#6846.htm##
00425000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704019800072002000900270#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#12#8#article#160#<BR>   <A HREF="#Result
s"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0 width="12" height="12"></A>    <A HREF="#Results"><strong>Results</stro
ng></A>    ^cY#6846.htm##
00434000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704020700072002000900279#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#13#9#article#160#<BR>   <A HREF="#Discus
sion"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Discussion"><strong>Discuss
ion</strong></A>    ^cY#6846.htm##
00422000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704019400073002000900267#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#14#10#article#160#<BR>   <A HREF="#Refer
ences"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#References"><strong>Refere
nces    ^cY#6846.htm##
00463000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704023500073002000900308#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#15#11#article#160#<br>   </strong></A><A
 HREF="#Acknowledgments"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOT
TOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Acknowle
dgments"><strong>Acknowledgments</strong></A>    ^cY#6846.htm##
00474000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704024600073002000900319#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#16#12#article#160#<BR>   <A HREF="#Corre
spondence"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 V
SPACE=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Correspondence"><stron
g>Correspondence and Footnotes</strong></A>    </font>      ^cY#6846.htm##
00275000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704004700073002000900120#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#17#13#article#160#<P>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>     ^cY#6846.htm##
00563000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704033500073002000900408#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#18#14#article#160#<P> <font face="Arial,
 Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F>
<B>Abstract    </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1
/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></
A></FONT></font></P> <font face="Arial, Helvetica, sans-serif">      ^cY#6846.ht
m##
01839000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704161100073002000901684#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#19#15#article#160#<P>Lipid transport in 
arthropods is achieved by highly specialized lipoproteins,    which resemble tho
se described in vertebrate blood. Here we describe purification    and character
ization of the lipid-apolipoprotein complex, lipophorin (Lp), from    adults and
 larvae of the cowpea weevil <I>Callosobruchus maculatus</I>. We also    describ
e the Lp-mediated lipid transfer to developing oocytes. Lps were isolated    fro
m homogenates of <I>C. maculatus</I> larvae and adults by potassio bromide    gr
adient and characterized with respect to physicochemical properties and lipid   
 content. The weevil Lp (465 kDa) and larval Lp (585 kDa), with hydrated densiti
es    of 1.22 and 1.14 g/mL, contained 34 and 56% lipids and 9 and 7% carbohydra
tes,    respectively. In both Lps, mannose was the predominant monosaccharide de
tected    by paper chromatography. SDS-PAGE revealed two apolipoproteins in each
 Lp with    molecular masses of 225 kDa (apolipoprotein-I) and 79 kDa (apolipopr
otein-II).    The lipids were extracted and analyzed by thin-layer chromatograph
y. The major    phospholipids found were phosphatidylserine, phosphatidylcholine
 and phosphatidylethanolamine    in adult Lp, and phosphatidylcholine, phosphati
dylethanolamine and sphingomyelin    in larval Lp. Hydrocarbons, fatty acids and
 triacylglycerol were the major neutral    lipids found in both Lps. Lps labeled
 in the protein moiety with radioactive    iodine (<SUP>125</SUP>I-iodine) or in
 the lipid moiety with fluorescent lipids    revealed direct evidence of endocyt
ic uptake of Lps in live oocytes of <I>C.    maculatus</I>.      ^cY#6846.htm##
00383000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704015500073002000900228#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#20#16#article#160#<P>Key words: <I>Callo
sobruchus maculatus</I>; Lipophorin; Lipid transport; Oogenesis;    Hydrocarbons
  </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6846.htm##
00617000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038900073002000900462#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#21#17#article#160#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Introduction"></A><FONT color="#00007F" SIZE=4><
B>Introduction</B></FONT></font>    <font size="4" face="Arial, Helvetica, sans-
serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A></font></P> <font
 face="Arial, Helvetica, sans-serif">      ^cY#6846.htm##
01111000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704088300073002000900956#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#22#18#article#160#<P>Cowpea (<I>Vigna un
guiculata</I>) is a leguminous crop cultivated in most tropical    regions, wher
e its seeds contribute to human and animal diets as an important    source of ca
rbohydrates and protein. Insects from the order Coleoptera (family    Bruchidae)
 cause serious losses of cowpea and other seeds in storage. One of    the most i
mportant insect pests of the cowpea is the larva of<I> Callosobruchus    maculat
us</I> (Coleoptera: Bruchidae), which avidly attacks the seeds during    storage
. Studies of Coleoptera in general and bruchids in particular are underrepresent
ed    in insect biochemistry, despite the fact that Coleoptera is the largest in
sect    order. Additionally, most biochemical research on beetles has concentrat
ed on    the description of digestive enzymes (1). A detailed description of the
 lipid    metabolism of these organisms is lacking.      ^cY#6846.htm##
00848000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704062000073002000900693#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#23#19#article#160#<P>In insects, lipopho
rins (Lps) are the major hemolymphatic lipoproteins, which    carry and distribu
te lipids of many classes among the tissues involved in lipid    absorption, sto
rage and utilization (2). Lps contain two apolipoproteins, apolipophorin    I (a
poLp-I, <SUB>~</SUB>250 kDa) and apolipophorin II (apoLp-II, <SUB>~</SUB>80    k
Da), which comprise about 60% of the mass of the particle (3). A third apoprotei
n    (apolipophorin III, apoLp-III), of molecular mass about 17 kDa, is present 
in    adults of some species in a molecular ratio that depends on physiological 
state    of the insects (4).      ^cY#6846.htm##
00679000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704045100073002000900524#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#24#20#article#160#<P>Lps have been sugge
sted to function as a shuttle for the transport of most    of the lipid classes 
in the hemolymph (5). The best-known transport system is    that of diacylglycer
ol (6). Insects capable of sustained flight use lipids as    their main energy s
ource. Lp particles transfer diacylglycerols to flight muscles    and can then r
eturn to the fat body to be reloaded with diacylglycerol, thus    acting as a re
usable shuttle (5).      ^cY#6846.htm##
01271000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704104300073002000901116#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#25#21#article#160#<P>Insect oogenesis is
 another physiological process that also requires lipids.    This process is cha
racterized by a rapid accumulation of proteins and lipids    by the growing oocy
tes and the production of a great number of eggs in a relatively    short period
 of time. This process is very complex and the involvement of several    organs 
coordinated by hormones has been recognized (7). In this process, Lp    is the m
ain lipoprotein responsible for lipid delivery to oocytes. Evidence    for the r
ole of Lp as the major vehicle for lipid transport to the oocytes was    first p
rovided by Chino et al. (8) in <I>Philosamia cynthia </I>(Lepidoptera)<I>.    </
I>In<I> Manduca sexta </I>(Lepidoptera), Kawooya and Law (9) showed that low-den
sity    lipophorin unloads its lipids to the ovaries and then returns to the hem
olymph.    In addition, high-density lipophorin was also found to transfer lipid
s, resulting    in its conversion to very high-density lipophorin, but without a
 recycling of    apoproteins to the hemolymph (10).      ^cY#6846.htm##
00506000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704027800073002000900351#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#26#22#article#160#<P>In the present stud
y, we purified and characterized the lipophorin from adults    and larvae of the
 cowpea weevil <I>C. maculatus</I>. The biochemical role of    this lipoprotein 
in the lipid transfer process is discussed.  </font>  <HR ALIGN=LEFT WIDTH=100% 
SIZE=2>     ^cY#6846.htm##
00621000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704039300073002000900466#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#27#23#article#160#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Material"></A><FONT color="#00007F" SIZE=4><B>Ma
terial    and Methods</B></FONT></font> <font size="4" face="Arial, Helvetica, s
ans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIG
N=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A></font></P> <
font face="Arial, Helvetica, sans-serif">      ^cY#6846.htm##
00264000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704003600073002000900109#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#28#24#article#160#<P><b>Insects</b>  </f
ont>      ^cY#6846.htm##
00465000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704023700073002000900310#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#29#25#article#160#<P><font face="Arial, 
Helvetica, sans-serif">A <I>C. maculatus</I> colony was    maintained on cowpea 
seeds under standard conditions (28&#176;C and 80% relative    humidity, with a 
photoperiod of 12-h light/12-h dark). </font>      ^cY#6846.htm##
00331000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704010300073002000900176#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#30#26#article#160#<P><font face="Arial, 
Helvetica, sans-serif"><B>Lipophorin</B> <B>purification</B>    </font>      ^cY
#6846.htm##
01583000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704135500073002000901428#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#31#27#article#160#<P><font face="Arial, 
Helvetica, sans-serif">Adults or larvae (4 g) were homogenized    using a tissue
 grinder (Thomas Scientific, Swedesboro, NJ, USA) in an ice bath    in the prese
nce of 20 mM glutathione, 5 mM EDTA, 2 mM PMSF, 0.5 &#181;g/&#181;L    antipain,
 5 &#181;M pepstatin, and 0.5 &#181;g/&#181;L leupeptin in PBS (10    mM phospha
te, 0.15 M NaCl, pH 7.4). The homogenate was then centrifuged at 100,000    <I>g
</I> for 30 min at 4&#176;C in a Beckman ultracentrifuge (Optima L-90 ultracentr
ifuge,    Beckman Coulter, Palo Alto, CA, USA) to remove insoluble material. Pot
assium    bromide (KBr) was added to the supernatant to a final concentration of
 0.4 g/mL    and this mixture was again centrifuged at 125,000 <I>g</I> in a Bec
kman ultracentrifuge    (Optima L-90 ultracentrifuge, Beckman Coulter) with a fi
xed-angle Beckman rotor    (Ti 50.2) at 4&#176;C for 20 h. The gradient of KBr w
as fractionated from the    top to the bottom and Lp fractions (1-4 from the top
) were pooled, extensively    dialyzed against PBS and stored under liquid nitro
gen until use. The degree    of purification was monitored by SDS-PAGE and prote
in concentration was estimated    by the method of Lowry et al. (11) and the mic
ro-BCA Kit (Pierce, Rockford,    IL, USA) in the presence of 0.5% SDS, using bov
ine serum albumin as a standard.    </font>      ^cY#6846.htm##
00368000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704014000073002000900213#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#32#28#article#160#<P><font face="Arial, 
Helvetica, sans-serif"><B>Polyacrylamide gel electrophoresis    and molecular ma
ss determination</B> </font>      ^cY#6846.htm##
00705000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704047700073002000900550#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#33#29#article#160#<P><font face="Arial, 
Helvetica, sans-serif">Polyacrylamide slab gels were run    under both denaturin
g (with SDS) (12) and nondenaturing conditions (13). Electrophoresis    was perf
ormed at constant voltage (100 V) on Tris-glycine gradient gels of 3-20%    acry
lamide, and the protein bands were stained with Coomassie blue. For molecular   
 mass determinations, the molecular weight standard Rainbow Kit from Amersham   
 (Buckinghamshire, England) was used. </font>      ^cY#6846.htm##
00797000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704056900073002000900642#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#34#30#article#160#<P><font face="Arial, 
Helvetica, sans-serif">The molecular mass of Lp was determined    by a pore-limi
ting gradient PAGE (3-20%) as described by Nichols et al. (14).    The gels were
 run at 100 V for 24 h. Calibration standards used were thyroglobulin    (669 kD
a), apoferritin (440 kDa), catalase (232 kDa), and bovine serum albumin    (66 k
Da). The size calibration was based on nonhydrated particle sizes of the    stan
dard proteins calculated from the molecular weight and partial specific    volum
e of the proteins, assuming spherical shape (14). </font>      ^cY#6846.htm##
00312000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704008400073002000900157#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#35#31#article#160#<P><font face="Arial, 
Helvetica, sans-serif"><B>Lipid analysis</B> </font>      ^cY#6846.htm##
01545000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704131700073002000901390#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#36#32#article#160#<P><font face="Arial, 
Helvetica, sans-serif">Lipid extraction was performed by    the method of Bligh 
and Dyer (15) for 2 h in a stoppered tube in 5 mL chloroform-methanol-water    s
olution (2:1:0.8, v/v), with intermittent shaking. The mixture was centrifuged  
  at 1500 <I>g</I> for 30 min at 4&#176;C in a Sorvall RC-5b preparative centrif
uge    (Sorvall Centrifuge, Newtown, CT, USA), the supernatant was collected and
 the    pellet subjected to a second lipid extraction (1 h). To the pooled super
natants,    5 mL water and 5 mL chloroform were added, the mixture was shaken an
d, after    centrifugation, the organic phase was removed and dried under nitrog
en. The    content of total lipids was determined gravimetrically. Extracted lip
ids were    analyzed by one-dimensional thin-layer chromatography (TLC) for neut
ral lipids    (16), or by two-dimensional TLC for phospholipids (17). To visuali
ze the lipids,    the plates were immersed for 10 s in a charring solution consi
sting of 3% CuSO<SUB>4    </SUB>and 8% H<SUB>3</SUB>PO<SUB>4 </SUB>(v/v) and hea
ted to 110&#176;C for    10 min (18). The charred TLC plates were then subjected
 to densitometric analysis.    Each lipid spot was identified by comparison with
 lipid standards (Sigma Aldrich    Co., St. Louis, MO, USA), run in parallel. </
font>      ^cY#6846.htm##
00319000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704009100073002000900164#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#37#33#article#160#<P><font face="Arial, 
Helvetica, sans-serif"><B>Carbohydrate analysis</B> </font>      ^cY#6846.htm##
00994000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704076600073002000900839#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#38#34#article#160#<P><font face="Arial, 
Helvetica, sans-serif">Total carbohydrate was determined    colorimetrically by 
the sulfuric acid/phenol method (19) using glucose as a    standard. To a 400-&#
181;L solution, 20 &#181;L 80% phenol (w/v) was added.    Then, 1 mL concentrate
d sulfuric acid was added rapidly and the tubes were allowed    to stand for 10 
min. The absorbance was measured at 490 nm for hexoses and compared    to a stan
dard curve prepared with various amounts of a 1-mg/mL glucose solution.    The c
arbohydrate composition was analyzed by descending paper chromatography    in is
obutyric acid-ammonium hydroxide-water (3:2:1, v/v) using Whatman No. 1T    pape
r. Subsequently, the chromatograms were dried and stained with silver nitrate   
 (20). </font>      ^cY#6846.htm##
00333000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704010500073002000900178#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#39#35#article#160#<P><font face="Arial, 
Helvetica, sans-serif"><B>Lipophorin density determination</B>    </font>      ^
cY#6846.htm##
00784000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704055600073002000900629#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#40#36#article#160#<P><font face="Arial, 
Helvetica, sans-serif">The density of Lps was determined    by the method of Coe
lho et al. (21). The purified Lp was added to a PBS solution    containing 44% (
w/v) KBr, to a final volume of 5 mL. This solution was transferred    to a centr
ifuge tube, overlaid with 5 mL PBS and centrifuged for 20 h in a Beckman    40 T
i apparatus at 125,000 <I>g</I> at 4&#176;C. After centrifugation, the gradient 
   was fractionated and the density of each fraction was measured using the refr
active    index of KBr at 25&#176;C. </font>      ^cY#6846.htm##
00318000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704009000073002000900163#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#41#37#article#160#<P><font face="Arial, 
Helvetica, sans-serif"><B>Lipophorin labeling </B> </font>      ^cY#6846.htm##
00644000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704041600073002000900489#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#42#38#article#160#<P><font face="Arial, 
Helvetica, sans-serif">Purified Lp was labeled with fluorescent    fatty acid (B
ODIPY<SUP>&#174; </SUP>FL C<SUB>16</SUB>) or phospholipids (TRITC-DHPE;    Molec
ular Probes Inc., Eugene, OR, USA) using the method described by Martin-Nizard  
  et al. (22). Distribution of the fluorescent lipids and Lp was observed using 
   the methods described by Atella and Shahabuddin (23). </font>      ^cY#6846.h
tm##
00639000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704041100073002000900484#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#43#39#article#160#<P><font face="Arial, 
Helvetica, sans-serif">Following manufacturer instructions    for radiolabeling 
(Sigma, St. Louis, MO, USA), purified Lp was iodinated with    <SUP>125</SUP>I-i
odine (100 mCi/mL; Amersham, Piscataway, NJ, USA), using 200    mCi/mg protein. 
The iodogen (Pierce) was used at a concentration of 100 mg/mg    protein. Free i
odine was removed using Sephadex G-50 spin columns. </font>      ^cY#6846.htm##
00329000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704010100073002000900174#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#44#40#article#160#<P><font face="Arial, 
Helvetica, sans-serif"><B>Lipophorin uptake by ovaries</B>    </font>      ^cY#6
846.htm##
01180000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704095200073002000901025#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#45#41#article#160#<P><font face="Arial, 
Helvetica, sans-serif">Radio<SUP> 125</SUP>I-iodine-labeled    Lp was injected (
1 &#181;g/insect) into the hemolymph of one-day-old vitellogenic    females at 2
8&#176; or 4&#176;C using a PLI-100 microinjector (Harvard Apparatus,    Hollist
on, MA, USA). At the desired time, the ovaries were dissected in medium    199 (
Sigma-Aldrich Co.), washed and incubated for 30 min at 28&#176;C in 1 mL    of t
he same culture medium. The radioactive ovaries were homogenized in 0.15    M Na
Cl and the radioactivity was estimated by gamma counting. Alternatively,    Lp l
abeled with either fluorescent fatty acids or fluorescent phospholipids    was i
njected (10 &#181;g/insect) into the hemolymph of vitellogenic females    at 28&
#176;C. One day after injection, the oocytes were dissected and examined    with
 a fluorescent Axioscope microscope (Carl Zeiss, Inc., Thornwood, NJ, USA).    <
/font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6846.htm##
00563000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704033500073002000900408#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#46#42#article#160#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Results"></A><FONT color="#00007F" SIZE=4><B>Res
ults</B></FONT></font>    <font size="4" face="Arial, Helvetica, sans-serif"><A 
HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIGN=BOTTOM BORDE
R=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A></font></P>     ^cY#6846.ht
m##
00958000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704073000073002000900803#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#47#43#article#160#<P><font face="Arial, 
Helvetica, sans-serif">The soluble protein fraction from    homogenates of larva
e and adults of <I>C. maculatus</I> was subjected to a KBr    gradient ultracent
rifugation and the fractions were analyzed by SDS-PAGE (<a href="#Fig1">Figure  
  1</a>). The fractions at the top in both gradients contained only Lp, consisti
ng    of two apolipoproteins, apoLp-I and apoLp-II, with molecular masses of 225
 and    79 kDa, respectively. ApoLp-III (18 kDa) was visualized in larvae but no
t in    adults (<a href="#Fig2">Figure 2D</a>). Pore-limiting gradient PAGE expe
riments    indicated a molecular mass of 480 kDa for adult Lp and of 585 kDa for
 larval    Lp (<a href="#Fig2">Figure 2C</a>). </font> </P>     ^cY#6846.htm##
00875000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704064700073002000900720#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#48#44#article#160#<P><font face="Arial, 
Helvetica, sans-serif"><a href="#Tab1">Table 1</a> shows    the biochemical comp
osition of the purified <I>C. maculatus</I> Lps. The adult    Lp contained 57% p
rotein and 34% lipid and had a high sugar content (9%). The    total lipid conte
nt of larval Lp (56%) was much higher than that of adult Lp,    but the carbohyd
rate content was similar (7%). The <I>C. maculatus </I>Lps stained    positively
 with the periodic acid-Schiff reagent for the presence of carbohydrates    (dat
a not shown) and mannose was the only sugar detected by paper chromatography    
in either case (<a href="#Fig2">Figure 2B</a>). </font>      ^cY#6846.htm##
00593000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704036500073002000900438#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#49#45#article#160#<P><font face="Arial, 
Helvetica, sans-serif">Lp purified from adults showed a    density of 1.22 g/mL,
 whereas larval Lp had a density of 1.14 g/mL (<a href="#Fig2">Figure    2A</a>)
. These values were based on the density of KBr, calculated from the    refracti
ve index of each fraction of a KBr gradient, as described in Material    and Met
hods. </font>      ^cY#6846.htm##
01010000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704078200073002000900855#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#50#46#article#160#<P><font face="Arial, 
Helvetica, sans-serif">The lipid composition of adult <I>C.    maculatus</I> Lp 
is given in <a href="#Fig3">Figure 3</a>. Hydrocarbons, triacylglycerol,    free
 fatty acids, and 1,3-diacylglycerol were the main neutral lipids (<a href="#Fig
3">Figure    3A</a>), whereas phosphatidylserine, phosphatidylcholine and phosph
atidylethanolamine    were the major phospholipids (<a href="#Fig3">Figure 3B</a
>). The lipid composition    of larval Lp showed slight differences compared to 
adult Lp. In the larval Lp,    we observed free fatty acids, triacylglycerol and
 hydrocarbons (<a href="#Fig3">Figure    3A</a>), and the major phospholipids we
re phosphatidylcholine, phosphatidylethanolamine    and sphingomyelin (<a href="
#Fig3">Figure 3B</a>). </font>      ^cY#6846.htm##
00860000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704063200073002000900705#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#51#47#article#160#<P><font face="Arial, 
Helvetica, sans-serif">In order to determine the source    of the relatively ele
vated hydrocarbon content found in both Lps, the total    lipid contents of the 
larval homogenate and of the cowpea seeds were analyzed    (<a href="#Fig4">Figu
re 4</a>). TLC revealed that triacylglycerol, fatty acids    and diacylglycerol 
were the most abundant lipids in the larval homogenate (<a href="#Fig4">Figure  
  4B</a>). In cowpea seeds, triacylglycerol, sterols, phospholipids, and fatty  
  acids predominated. Diacylglycerol was also detected, but in minor amounts (<a
 href="#Fig4">Figure    4A</a>). </font>      ^cY#6846.htm##
00814000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704058600073002000900659#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#52#48#article#160#<P><font face="Arial, 
Helvetica, sans-serif">Receptor-mediated internalization    of molecules is an e
nergy-dependent active process and is significantly reduced    at lower temperat
ures (24). We examined the uptake of <SUP>125</SUP>I-labeled    Lp in adults at 
28&#176; and 4&#176;C. At 28&#176;C, the ovaries were able to    take up Lp. At 
4&#176;C, no lipid uptake was observed (<a href="#Fig5">Figure    5</a>). Taken 
together, these results demonstrate that Lp internalization by    developing egg
s in <I>C. maculatus</I> is an energy-dependent active process.    </font>      
^cY#6846.htm##
01090000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704086200073002000900935#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#53#49#article#160#<P><font face="Arial, 
Helvetica, sans-serif">To confirm the lipid transfer to    ovaries, vitellogenic
 females were injected with lipophorin fluorescently labeled    with phospholipi
ds (Texas Red-PE; <a href="#Fig6">Figure 6B</a>) or a fatty-acid    analog (BODI
PY-FA; <a href="#Fig6">Figure 6C</a>). One day later the ovaries    were excised
 and the fluorescence distribution was determined. In agreement    with the resu
lts obtained using <SUP>125</SUP>I-Lp, we found that the ovaries    of <I>C. mac
ulatus</I> were able to take up lipophorin.</font>  <HR ALIGN=LEFT WIDTH=100% SI
ZE=2> <table width="100%"  border="0">   <tr align="left" valign="top">      <td
 width="12%"><a href="/img/revistas/bjmbr/v41n1/html/6846i01.htm"><img src="/img
/revistas/bjmbr/v41n1/6846i01peq.jpg" width="120" height="129" border="2"></a></
td>     <td width="88%">            ^cY#6846.htm##
00762000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704053400073002000900607#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#54#50#article#160#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig1"></a>Figure 1.          Purification of <I>
Callosobruchus maculatus </I>lipophorin (Lp). Adults          (A) or larvae (B) 
were homogenized and Lp was purified by KBr gradient          ultracentrifugatio
n as described in Material and Methods. The fractions          (1 to 10) were su
bjected to SDS-PAGE (3-20%) and the proteins stained          with Coomassie blu
e. ApoLp-I = apolipophorin I; apoLp-II = apolipophorin          II. </font>     
 </td>   </tr> </table>     ^cY#6846.htm##
00647000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704041900073002000900492#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#55#51#article#160#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image    (39 K JPG file)]</f
ont></P> <HR ALIGN=LEFT WIDTH=100% SIZE=2> <table width="100%"  border="0">   <t
r align="left" valign="top">      <td width="12%"><a href="/img/revistas/bjmbr/v
41n1/html/6846i02.htm"><img src="/img/revistas/bjmbr/v41n1/6846i02peq.jpg" width
="120" height="103" border="2"></a></td>     <td width="88%">            ^cY#684
6.htm##
01390000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704116200073002000901235#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#56#52#article#160#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig2"></a>Figure 2.          Biochemical propert
ies of <I>Callosobruchus maculatus </I>lipophorin (Lp).          <I>A</I>, Deter
mination of Lp density. Lp from adults (filled circles)          and larvae (ope
n circles) was purified using KBr gradient ultracentrifugation.          The den
sity (d) of each Lp was measured with a refractometer (red line)          and th
e amount of protein estimated at 280 nm. <I>B</I>, Carbohydrate          analysi
s of Lp. The carbohydrate composition of adult (A) and larval (L)          Lp wa
s analyzed using paper chromatography. or = origem.<I> C</I>, Determination     
     of Lp molecular mass. Lp (30 &#181;g) obtained from adults (A) and larvae  
        (L) was subjected to a pore-limiting PAGE. Thyroglobulin (T), apoferriti
n          (F), catalase (C), and bovine serum albumin (A) were used as molecula
r          mass standards. <I>D</I>, Analysis of apolipophorin-III amounts of la
rval          and adult Lp by a gradient SDS-PAGE (6-22.5%). Other experimental 
details          are described in Material and Methods. </font>      </td>   </t
r> </table>     ^cY#6846.htm##
00647000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704041900073002000900492#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#57#53#article#160#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image    (59 K JPG file)]</f
ont></P> <HR ALIGN=LEFT WIDTH=100% SIZE=2> <table width="100%"  border="0">   <t
r align="left" valign="top">      <td width="12%"><a href="/img/revistas/bjmbr/v
41n1/html/6846i03.htm"><img src="/img/revistas/bjmbr/v41n1/6846i03peq.jpg" width
="120" height="162" border="2"></a></td>     <td width="88%">            ^cY#684
6.htm##
01284000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704105600073002000901129#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#58#54#article#160#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig3"></a>Figure 3.          Lipid analysis of <
I>Callosobruchus maculatus</I> lipophorins (Lps). Two          milligrams of pur
ified Lp from adults (dark gray columns) and larvae (light          gray columns
) were subjected to lipid extraction. The neutral lipids (A)          and phosph
olipids (B) were analyzed by thin-layer chromatography as described          in 
Material and Methods. The content of each class of lipid was estimated          
by densitometry and plotted as a percentage. The vertical bars represent        
  the SEM for four determinations. CHOE = cholesterol-ester; 1,2-DG = 1,2-diacyl
glycerol;          1,3-DG = 1,3-diacylglycerol; FA = fatty acids; H = hydrocarbo
ns; MG =          monoacylglycerol; ND = non-determined; PA = phosphatidic acid;
 PC = phosphatidylcholine;          PE = phosphatidylethanolamine; PI = phosphat
idylinositol; PL = phospholipids;          PS = phosphatidylserine; SM = sphingo
myelin; TG = triacylglycerol. </font>      </td>   </tr> </table>     ^cY#6846.h
tm##
00647000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704041900073002000900492#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#59#55#article#160#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image    (44 K JPG file)]</f
ont></P> <HR ALIGN=LEFT WIDTH=100% SIZE=2> <table width="100%"  border="0">   <t
r align="left" valign="top">      <td width="12%"><a href="/img/revistas/bjmbr/v
41n1/html/6846i04.htm"><img src="/img/revistas/bjmbr/v41n1/6846i04peq.jpg" width
="120" height="141" border="2"></a></td>     <td width="88%">            ^cY#684
6.htm##
01000000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704077200073002000900845#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#60#56#article#160#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig4"></a>Figure 4.          Lipid composition o
f total homogenates of cowpea seeds (A) and <I>Callosobruchus          maculatus
</I> larvae (B). Two milligrams of total homogenates was subjected          to l
ipid extraction as described in Material and Methods. The extracted          lip
ids were separated by thin-layer chromatography and the content of          each
 lipid was measured by densitometry. The vertical bars represent the          SE
M for four determinations. DG = total diacylglycerol (1,2-DG + 1,3-DG);         
 FA = fatty acids; H = hydrocarbons; MG = monoacylglycerol; ND = non-determined;
          PL = phospholipids; ST = sterols; TG = triacylglycerol. </font>      <
/td>   </tr> </table>     ^cY#6846.htm##
00646000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704041800073002000900491#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#61#57#article#160#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image    (39 K JPG file)]</f
ont></P> <HR ALIGN=LEFT WIDTH=100% SIZE=2> <table width="100%"  border="0">   <t
r align="left" valign="top">      <td width="12%"><a href="/img/revistas/bjmbr/v
41n1/html/6846i05.htm"><img src="/img/revistas/bjmbr/v41n1/6846i05peq.jpg" width
="120" height="87" border="2"></a></td>     <td width="88%">            ^cY#6846
.htm##
00821000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704059300073002000900666#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#62#58#article#160#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig5"></a>Figure 5.          <SUP>125</SUP>I-lip
ophorin uptake by <I>Callosobruchus maculatus </I>ovaries.          Vitellogenic
 females were injected with <SUP>125</SUP>I-lipophorin at          28&#176; or 4
&#176;C. After 1 and 24 h, the ovaries were isolated and          the radioactiv
ity was estimated by gamma counting. The vertical bars represent          the SE
M for four determinations. Other experimental details are described          in 
Material and Methods. CPM = counts per minute. </font>      </td>   </tr> </tabl
e>     ^cY#6846.htm##
00646000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704041800073002000900491#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#63#59#article#160#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image    (24 K JPG file)]</f
ont></P> <HR ALIGN=LEFT WIDTH=100% SIZE=2> <table width="100%"  border="0">   <t
r align="left" valign="top">      <td width="12%"><a href="/img/revistas/bjmbr/v
41n1/html/6846i06.htm"><img src="/img/revistas/bjmbr/v41n1/6846i06peq.jpg" width
="120" height="89" border="2"></a></td>     <td width="88%">            ^cY#6846
.htm##
00906000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704067800073002000900751#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#64#60#article#160#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig6"></a>Figure 6.          Visualization of li
pid uptake by <I>Callosobruchus maculatus</I> ovary.          Vitellogenic femal
es were injected with lipoprotein labeled with fluorescent          fatty acids 
(green) or phospholipids (red) shortly after emergence. After          24 h, the
 developing oocytes were dissected and examined with a confocal          microsc
ope. Scale bar = 100 &#181;m. <I>A</I>, Phase-contrast of an ovarian          fo
llicle; <I>B</I>, localization of phospholipids; <I>C</I>, localization         
 of fatty acids; <I>D</I>, merged image of B and C. </font>      </td>   </tr> <
/table>     ^cY#6846.htm##
00864000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704063600073002000900709#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#65#61#article#160#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image    (25 K JPG file)]</f
ont></P> <HR ALIGN=LEFT WIDTH=100% SIZE=2> <table width="100%"  border="0">   <t
r align="left" valign="top">      <td width="12%"><a href="/img/revistas/bjmbr/v
41n1/html/6846t01.htm"><img src="/img/revistas/bjmbr/v41n1/table.jpg" width="100
" height="65" border="2"></a></td>     <td width="88%"><font face="Arial, Helvet
ica, sans-serif"><a name="Tab1"></a>Table        1. Chemical composition (%, w/w
) of adult and larval lipophorins from the        cowpea weevil <I>Callosobruchu
s maculatus</I>.</font></td>   </tr> </table>     ^cY#6846.htm##
00347000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704011900073002000900192#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#66#62#article#160#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this table    (43 K JPG file)]</f
ont></P>     ^cY#6846.htm##
00275000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704004700073002000900120#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#67#63#article#160#<P>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>     ^cY#6846.htm##
00523000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704029500073002000900368#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#68#64#article#160#<P> <font face="Arial,
 Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007
F><B>Discussion    </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v
41n1/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></
B></A></FONT></font></P>     ^cY#6846.htm##
00640000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704041200073002000900485#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#69#65#article#160#<P><font face="Arial, 
Helvetica, sans-serif">The biochemical characterization    of purified Lps is an
 important step toward understanding the process of lipid    utilization in inse
cts. In the present study, we purified and partially characterized    two Lps fr
om the cowpea weevil <I>C. maculatus</I>. Radio- and fluorescent-labeled    Lp w
as used to investigate its transport to the ovaries. </font>      ^cY#6846.htm##
01383000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704115500073002000901228#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#70#66#article#160#<P><font face="Arial, 
Helvetica, sans-serif">Lps from adults and larvae of <I>C.    maculatu</I>s were
 isolated by a single-step KBr gradient ultracentrifugation.    In this gradient
, both Lps floated to the top of each tube, free of contaminants    (<a href="#F
ig1">Figure 1</a>). The Lps obtained from adults and larvae consisted    of two 
apoproteins (apoLp-I and apoLp-II) of molecular masses similar to those    from 
other species (25). Larval Lp contains little of the smallest apolipoprotein    
(apoLp-III; <a href="#Fig2">Figure 2D</a>) while adult Lp contains none of this 
   form. ApoLp-III has been found in adults of various insect species (26,27).  
  In <I>Manduca sexta</I> and <I>Locusta migratoria</I>, this apolipophorin is  
  involved in the molecular changes that Lp undergoes during flight; as a result
,    Lp particles acquire a greater capacity for carrying lipids from fat body t
o    flight muscles (2,6,28). These changes are regulated by the adipokinetic ho
rmone    (5). Adults of <I>C. maculatus</I> seldom fly, and never for long dista
nces;    this could be the reason for the absence of apoLp-III in adult Lp. </fo
nt>      ^cY#6846.htm##
01003000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704077500073002000900848#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#71#67#article#160#<P><font face="Arial, 
Helvetica, sans-serif">A second KBr gradient ultracentrifugation    using the Lp
 samples showed a density of 1.12 g/mL for adult Lp and of 1.14    g/mL for larv
al Lp (<a href="#Fig2">Figure 2A</a>). These densities are close    to the value
s reported for high-density Lp in other insect species (26). The    Lp from adul
ts is especially poor in lipids, which make up only about 34% of    its total ma
ss, whereas to the larval Lp was 55% (<a href="#Tab1">Table 1</a>).    This diff
erence in lipid content could be responsible for the higher molecular    mass (<
a href="#Fig2">Figure 2C</a>) and the lower density (<a href="#Fig2">Figure    2
A</a>) of the larval Lp compared to the adult, since no apoLp-III was detected  
  in either Lp. </font>      ^cY#6846.htm##
00724000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704049600073002000900569#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#72#68#article#160#<P><font face="Arial, 
Helvetica, sans-serif">Interestingly, our study indicates    the presence of hyd
rocarbons associated with <I>C. maculatus</I> Lp. However,    no significant amo
unt of hydrocarbons was found in total larval homogenate or    in cowpea seeds, 
supporting the concept that hydrocarbons are mostly synthesized    during adulth
ood, presumably at the oenocyte level, and transported by Lp to    the sites of 
deposition, including the epicuticle and ovaries (3,29). </font>      ^cY#6846.h
tm##
00599000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704037100073002000900444#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#73#69#article#160#<P><font face="Arial, 
Helvetica, sans-serif">In the malaria vector <I>Anopheles    gambiae </I>(30), i
n the cockroaches <I>Blattella germanica</I> (31) and<I>    Periplaneta american
a</I> (32) and in the Colorado potato beetle <I>Leptinotarsa    decemlineata </I
>(33), hydrocarbons are also the major lipid class associated    with lipophorin
 particles. </font>      ^cY#6846.htm##
00765000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704053700073002000900610#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#74#70#article#160#<P><font face="Arial, 
Helvetica, sans-serif">A structural model of cockroach and    locust lipophorins
 has already been proposed (34). It is composed of three radially    symmetrical
 layers. The outer surface contains phospholipids and apoLp-I, the    middle lay
er consists of diacylglycerol and apoLp-II and the central core is    composed o
f hydrocarbons. Based on its low diacylglycerol content, it would    be interest
ing to study lipophorin by physical methods in order to determine    its structu
ral organization. </font>      ^cY#6846.htm##
00949000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704072100073002000900794#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#75#71#article#160#<P><font face="Arial, 
Helvetica, sans-serif"><I>C. maculatus </I>Lp stains positively    with the peri
odic acid-Schiff reagent for the presence of carbohydrates (data    not shown), 
and mannose is present as the main monosaccharide in the particle    (<a href="#
Fig2">Figure 2B</a>). It is possible that glycosylation of Lp has    an importan
t role in folding and subunit assembly to achieve the mature protein    in the h
emolymph and ovary. Glycosylation is known to increase the solubility    of prot
eins (35). Thus, the mannose content of <I>C. maculatus</I> Lp could    have a s
ignificant role in keeping this large, hydrophobic protein in the hemolymph,    
improving lipid transport to the tissues. </font>      ^cY#6846.htm##
00755000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704052700073002000900600#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#76#72#article#160#<P><font face="Arial, 
Helvetica, sans-serif">During insect oogenesis, oocytes    accumulate large amou
nts of lipids, which are supplied by means of Lp-selective    lipid transport (9
,30). However, during lipid transfer to <I>Anopheles gambiae</I>    oocytes by L
p, lipid accumulation occurs simultaneously with the deposition    of the protei
n moiety inside yolk granules through endocytosis (30). This finding    is not i
n agreement with the general idea of Lp as a reusable shuttle for lipids    in i
nsects. </font>      ^cY#6846.htm##
00912000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704068400073002000900757#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#77#73#article#160#<P><font face="Arial, 
Helvetica, sans-serif">Receptor-mediated lipoprotein endocytosis    has been stu
died in mammals and insects. In mammals, LDL particles are internalized    upon 
binding to LDL receptors, which are transmembrane proteins (36). Genes    for si
milar receptors have been cloned and sequenced from <I>L. migratoria</I>    (37)
, <I>Galleria mellonella</I> (38) and <I>A. aegypti</I> (39). Recently,    by tr
ansforming the human LDL receptor gene into insect cells, Van Hoof et al.    (40
) demonstrated that an endocytic pathway for Lp uptake does exist in insects.   
 However, no endocytic uptake of Lp has been directly observed in insect oocytes
.    </font>      ^cY#6846.htm##
01140000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704091200073002000900985#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#78#74#article#160#<P><font face="Arial, 
Helvetica, sans-serif">Here we provide direct evidence of    endocytic uptake of
 Lp in live oocytes of <I>C. maculatus</I>. Clearly, lipids    from Lp accumulat
ed in the yolk granules (<a href="#Fig6">Figure 6</a>). During    Lp endocytosis
 by oocytes, we observed a staining pattern which is similar to    the LDL recep
tor-transfected insect cells (40). This result, together with the    temperature
 dependence of the process, indicates Lp endocytic uptake by <I>C.    maculatus<
/I> oocytes. Whether Lp-mediated lipid transfer to <I>C. maculatus</I>    oocyte
s acts as a reusable shuttle remains to be investigated. Further investigation  
  of the mechanism of lipid delivery to the insect oocytes may lead to the ident
ification    of targets that can control the density of pest insects and their i
mpact on    losses of seeds in storage.</font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2
>     ^cY#6846.htm##
00569000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704034100073002000900414#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#79#75#article#160#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><B>
References</B></FONT></font>    <font size="4" face="Arial, Helvetica, sans-seri
f"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIGN=BOTTOM
 BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A></font></P>     ^cY#6
846.htm##
00529000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704028700075002000900362#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#80#76#article#160#1#<P><font
 face="Arial, Helvetica, sans-serif">1. Silva CP, Terra WR, Lima RM. Differences
    in midgut serine proteinases from larvae of the bruchid beetles <I>Callosobr
uchus    maculatus</I> and <I>Zabrotes subfasciatus</I>. <I>Arch Insect Biochem 
Physiol</I>    2001; 47: 18-28.    ^cY#6846.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#81#77#article#160# </font>      ^cY#6846
.htm##
00468000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704022600075002000900301#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#82#78#article#160#2#<P><font
 face="Arial, Helvetica, sans-serif">2. van der Horst DJ, van Hoof D,    van Mar
rewijk WJ, Rodenburg KW. Alternative lipid mobilization: the insect shuttle    s
ystem. <I>Mol Cell Biochem</I> 2002; 239: 113-119.    ^cY#6846.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#83#79#article#160# </font>      ^cY#6846
.htm##
00468000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704022600075002000900301#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#84#80#article#160#3#<P><font
 face="Arial, Helvetica, sans-serif">3. Chino H. <I>Lipid transport: biochemistr
y    of hemolymph lipophorin. Comprehensive insect physiology, biochemistry and 
pharmacology</I>.    Pergamon Press, Oxford: 1985.    ^cY#6846.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#85#81#article#160# </font>      ^cY#6846
.htm##
00466000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704022400075002000900299#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#86#82#article#160#4#<P><font
 face="Arial, Helvetica, sans-serif">4. Kawooya JK, Keim PS, Ryan RO,    Shapiro
 JP, Samaraweera P, Law JH. Insect apolipophorin III. Purification and    proper
ties. <I>J Biol Chem</I> 1984; 259: 10733-10737.    ^cY#6846.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#87#83#article#160# </font>      ^cY#6846
.htm##
00400000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704015800075002000900233#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#88#84#article#160#5#<P><font
 face="Arial, Helvetica, sans-serif">5. Blacklock BJ, Ryan RO. Hemolymph    lipi
d transport. <I>Insect Biochem Mol Biol</I> 1994; 24: 855-873.    ^cY#6846.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#89#85#article#160# </font>      ^cY#6846
.htm##
00468000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704022600075002000900301#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#90#86#article#160#6#<P><font
 face="Arial, Helvetica, sans-serif">6. Soulages JL, Wells MA. Metabolic    fate
 and turnover rate of hemolymph free fatty acids in adult <I>Manduca sexta</I>. 
   <I>Insect Biochem Mol Biol</I> 1994; 24: 79-86.    ^cY#6846.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#91#87#article#160# </font>      ^cY#6846
.htm##
00438000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704019600075002000900271#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#92#88#article#160#7#<P><font
 face="Arial, Helvetica, sans-serif">7. Engelmann F. Insect vitellogenin:    ide
ntification, biosynthesis and role in vitellogenesis. <I>Adv Insect Physiol</I> 
   1979; 14: 49-108.    ^cY#6846.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#93#89#article#160# </font>      ^cY#6846
.htm##
00483000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704024100075002000900316#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#94#90#article#160#8#<P><font
 face="Arial, Helvetica, sans-serif">8. Chino H, Downer RG, Takahashi    K. The 
role of diacylglycerol-carrying lipoprotein I in lipid transport during    insec
t vitellogenesis. <I>Biochim Biophys Acta</I> 1977; 487: 508-516.    ^cY#6846.ht
m##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#95#91#article#160# </font>      ^cY#6846
.htm##
00418000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704017600075002000900251#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#96#92#article#160#9#<P><font
 face="Arial, Helvetica, sans-serif">9. Kawooya JK, Law JH. Role of lipophorin  
  in lipid transport to the insect egg. <I>J Biol Chem</I> 1988; 263: 8748-8753.
    ^cY#6846.htm##
00249000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704002100073002000900094#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#97#93#article#160#    </font>      ^cY#6
846.htm##
00459000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704021600076002000900292#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#98#94#article#160#10#<P><fon
t face="Arial, Helvetica, sans-serif">10. Kawooya JK, Osir EO, Law JH.    Uptake
 of the major hemolymph lipoprotein and its transformation in the insect    egg.
 <I>J Biol Chem</I> 1988; 263: 8740-8747.    ^cY#6846.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#99#95#article#160# </font>      ^cY#6846
.htm##
00443000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704019900077002000900276#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#100#96#article#160#11#<P><fo
nt face="Arial, Helvetica, sans-serif">11. Lowry OH, Rosenbrough NJ, Farr    AL,
 Randall RJ. Protein measurement with the Folin phenol reagent. <I>J Biol    Che
m</I> 1951; 193: 265-275.    ^cY#6846.htm##
00247000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070704001800074002000900092#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#101#97#article#160# </font>      ^cY#684
6.htm##
00437000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704019300077002000900270#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#102#98#article#160#12#<P><fo
nt face="Arial, Helvetica, sans-serif">12. Laemmli UK. Cleavage of structural   
 proteins during the assembly of the head of bacteriophage T4. <I>Nature</I>    
1970; 227: 680-685.    ^cY#6846.htm##
00247000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070704001800074002000900092#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#103#99#article#160# </font>      ^cY#684
6.htm##
00435000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704019000078002000900268#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#104#100#article#160#13#<P><f
ont face="Arial, Helvetica, sans-serif">13. Davis BJ. Disc electrophoresis    II
. Methods and application to human serum proteins. <I>Ann N Y Acad Sci</I>    19
64; 124: 404-427.    ^cY#6846.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#105#101#article#160# </font>      ^cY#68
46.htm##
00445000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704020000078002000900278#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#106#102#article#160#14#<P><f
ont face="Arial, Helvetica, sans-serif">14. Nichols AV, Krauss RM, Musliner    T
A. Nondenaturing polyacrylamide gradient gel electrophoresis. <I>Methods Enzymol
</I>    1986; 128: 417-431.    ^cY#6846.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#107#103#article#160# </font>      ^cY#68
46.htm##
00433000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704018800078002000900266#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#108#104#article#160#15#<P><f
ont face="Arial, Helvetica, sans-serif">15. Bligh EG, Dyer WJ. A rapid method   
 of total lipid extraction and purification. <I>Can J Biochem Physiol</I> 1959; 
   37: 911-917.    ^cY#6846.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#109#105#article#160# </font>      ^cY#68
46.htm##
00465000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704022000078002000900298#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#110#106#article#160#16#<P><f
ont face="Arial, Helvetica, sans-serif">16. Vogel CW, Doizaki WM, Zieve L.    Ra
pid thin-layer chromatographic separation of phospholipids and neutral lipids   
 of serum. <I>J Lipid Res</I> 1962; 3: 138-140.    ^cY#6846.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#111#107#article#160# </font>      ^cY#68
46.htm##
00532000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704028700078002000900365#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#112#108#article#160#17#<P><f
ont face="Arial, Helvetica, sans-serif">17. Yavin E, Zutra A. Separation    and 
analysis of 32P-labeled phospholipids by a simple and rapid thin-layer chromatog
raphic    procedure and its application to cultured neuroblastoma cells. <I>Anal
 Biochem</I>    1977; 80: 430-437.    ^cY#6846.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#113#109#article#160# </font>      ^cY#68
46.htm##
00507000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704026200078002000900340#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#114#110#article#160#18#<P><f
ont face="Arial, Helvetica, sans-serif">18. Ruiz JL, Ochoa B. Quantification    
in the subnanomolar range of phospholipids and neutral lipids by nanodimensional
    thin layer chromatography and image analysis. <I>J Lipid Res</I> 1997; 38: 1
482-1489.    ^cY#6846.htm##
00251000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002100075002000900096#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#115#111#article#160#    </font>      ^cY
#6846.htm##
00452000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704020700078002000900285#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#116#112#article#160#19#<P><f
ont face="Arial, Helvetica, sans-serif">19. Dubois M, Gilles KA, Hamilton    JK,
 Rebers PA, Smith F. Colorimetric method for the determination of sugars.    <I>
Analyt Chem</I> 1956; 28: 350-354.    ^cY#6846.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#117#113#article#160# </font>      ^cY#68
46.htm##
00615000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704037000078002000900448#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#118#114#article#160#20#<P><f
ont face="Arial, Helvetica, sans-serif">20. Mourao PA, Pereira MS, Pavao    MS, 
Mulloy B, Tollefsen DM, Mowinckel MC, et al. Structure and anticoagulant    acti
vity of a fucosylated chondroitin sulfate from echinoderm. Sulfated fucose    br
anches on the polysaccharide account for its high anticoagulant action. <I>J    
Biol Chem</I> 1996; 271: 23973-23984.    ^cY#6846.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#119#115#article#160# </font>      ^cY#68
46.htm##
00491000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704024600078002000900324#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#120#116#article#160#21#<P><f
ont face="Arial, Helvetica, sans-serif">21. Coelho HS, Atella GC, Moreira    MF,
 Gondim KC, Masuda H. Lipophorin density variation during oogenesis on <I>Rhodni
us    prolixus</I>. <I>Arch Insect Biochem Physiol</I> 1997; 35: 301-313.    ^cY
#6846.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#121#117#article#160# </font>      ^cY#68
46.htm##
00549000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704030400078002000900382#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#122#118#article#160#22#<P><f
ont face="Arial, Helvetica, sans-serif">22. Martin-Nizard F, Richard B, Torpier 
   G, Nouvelot A, Fruchart JC, Duthilleul P, et al. Analysis of phospholipid tra
nsfer    during HDL binding to platelets using a fluorescent analog of phosphati
dylcholine.    <I>Thromb Res</I> 1987; 46: 811-825.    ^cY#6846.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#123#119#article#160# </font>      ^cY#68
46.htm##
00467000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704022200078002000900300#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#124#120#article#160#23#<P><f
ont face="Arial, Helvetica, sans-serif">23. Atella GC, Shahabuddin M. Differenti
al    partitioning of maternal fatty acid and phospholipid in neonate mosquito l
arvae.    <I>J Exp Biol</I> 2002; 205: 3623-3630.    ^cY#6846.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#125#121#article#160# </font>      ^cY#68
46.htm##
00481000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704023600078002000900314#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#126#122#article#160#24#<P><f
ont face="Arial, Helvetica, sans-serif">24. Goldstein JL, Basu SK, Brunschede   
 GY, Brown MS. Release of low density lipoprotein from its cell surface receptor
    by sulfated glycosaminoglycans. <I>Cell</I> 1976; 7: 85-95.    ^cY#6846.htm#
#
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#127#123#article#160# </font>      ^cY#68
46.htm##
00463000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704021800078002000900296#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#128#124#article#160#25#<P><f
ont face="Arial, Helvetica, sans-serif">25. Gondim KC, Oliveira PL, Masuda    H.
 Lipophorin and oogenesis in <I>Rhodnius prolixus</I>: transfer of phospholipids
.    <I>J Insect Physiol</I> 1989; 35: 19-27.    ^cY#6846.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#129#125#article#160# </font>      ^cY#68
46.htm##
00465000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704022000078002000900298#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#130#126#article#160#26#<P><f
ont face="Arial, Helvetica, sans-serif">26. Ryan RO, Schmidt JO, Law JH.    Chem
ical and immunological properties of lipophorin: an insect lipoprotein.    <I>Ar
ch Insect Biochem Physiol</I> 1984; 1: 375-383.    ^cY#6846.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#131#127#article#160# </font>      ^cY#68
46.htm##
00512000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704026700078002000900345#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#132#128#article#160#27#<P><f
ont face="Arial, Helvetica, sans-serif">27. Van der Horst DJ, Van Doorn JN,    B
eenakkers AMTh. Hormone induced rearrangement of locust haemolymph lipoproteins:
    the involvement of glycoprotein C<SUB>2</SUB>. <I>Insect Biochem</I> 1984; 1
4:    495-504.    ^cY#6846.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#133#129#article#160# </font>      ^cY#68
46.htm##
00441000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704019600078002000900274#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#134#130#article#160#28#<P><f
ont face="Arial, Helvetica, sans-serif">28. Ryan RO, van der Horst DJ. Lipid    
transport biochemistry and its role in energy production. <I>Annu Rev Entomol</I
>    2000; 45: 233-260.    ^cY#6846.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#135#131#article#160# </font>      ^cY#68
46.htm##
00463000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704021800078002000900296#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#136#132#article#160#29#<P><f
ont face="Arial, Helvetica, sans-serif">29. Schal C, Sevala VL, Young HP,    Bac
hmann JAS. Synthesis and transport of hydrocarbons: cuticle and ovary as    targ
et tissues. <I>Am Zool</I> 1998; 38: 382-393.    ^cY#6846.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#137#133#article#160# </font>      ^cY#68
46.htm##
00527000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704028200078002000900360#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#138#134#article#160#30#<P><f
ont face="Arial, Helvetica, sans-serif">30. Atella GC, Silva-Neto MA, Golodne   
 DM, Arefin S, Shahabuddin M. <I>Anopheles gambiae</I> lipophorin: characterizat
ion    and role in lipid transport to developing oocyte. <I>Insect Biochem Mol B
iol</I>    2006; 36: 375-386.    ^cY#6846.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#139#135#article#160# </font>      ^cY#68
46.htm##
00537000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704029200078002000900370#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#140#136#article#160#31#<P><f
ont face="Arial, Helvetica, sans-serif">31. Sevala VL, Shus S, Ramaswamy    SB, 
Schal C. Lipophorin of female <I>Blattella germanica</I> (L.): characterization 
   and relation to hemolymph titers of juvenile hormone and hydrocarbons. <I>J  
  Insect Physiol</I> 1999; 45: 431-441.    ^cY#6846.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#141#137#article#160# </font>      ^cY#68
46.htm##
00510000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704026500078002000900343#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#142#138#article#160#32#<P><f
ont face="Arial, Helvetica, sans-serif">32. Chino H, Katase H, Downer RG,    Tak
ahashi K. Diacylglycerol-carrying lipoprotein of hemolymph of the American    co
ckroach: purification, characterization, and function. <I>J Lipid Res</I>    198
1; 22: 7-15.    ^cY#6846.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#143#139#article#160# </font>      ^cY#68
46.htm##
00518000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704027300078002000900351#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#144#140#article#160#33#<P><f
ont face="Arial, Helvetica, sans-serif">33. Katagiri C, Sato M, de Kort S,    Ka
tsube Y. Structure of Colorado potato beetle lipophorin: differential scanning  
  calorimetric and small-angle X-ray scattering studies. <I>Biochemistry</I> 199
1;    30: 9675-9681.    ^cY#6846.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#145#141#article#160# </font>      ^cY#68
46.htm##
00437000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704019200078002000900270#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#146#142#article#160#34#<P><f
ont face="Arial, Helvetica, sans-serif">34. Katagiri C, Sato M, Tanaka N.    Sma
ll-angle X-ray scattering study of insect lipophorin. <I>J Biol Chem</I>    1987
; 262: 15857-15861.    ^cY#6846.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#147#143#article#160# </font>      ^cY#68
46.htm##
00426000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704018100078002000900259#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#148#144#article#160#35#<P><f
ont face="Arial, Helvetica, sans-serif">35. Jaenicke R. Protein stability    and
 molecular adaptation to extreme conditions. <I>Eur J Biochem</I> 1991; 202:    
715-728.    ^cY#6846.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#149#145#article#160# </font>      ^cY#68
46.htm##
00441000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704019600078002000900274#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#150#146#article#160#36#<P><f
ont face="Arial, Helvetica, sans-serif">36. Hussain MM, Strickland DK, Bakillah 
   A. The mammalian low-density lipoprotein receptor family. <I>Annu Rev Nutr</I
>    1999; 19: 141-172.    ^cY#6846.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#151#147#article#160# </font>      ^cY#68
46.htm##
00537000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704029200078002000900370#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#152#148#article#160#37#<P><f
ont face="Arial, Helvetica, sans-serif">37. Dantuma NP, Potters M, De Winther   
 MP, Tensen CP, Kooiman FP, Bogerd J, et al. An insect homolog of the vertebrate
    very low density lipoprotein receptor mediates endocytosis of lipophorins. <
I>J    Lipid Res</I> 1999; 40: 973-978.    ^cY#6846.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#153#149#article#160# </font>      ^cY#68
46.htm##
00570000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704032500078002000900403#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#154#150#article#160#38#<P><f
ont face="Arial, Helvetica, sans-serif">38. Lee CS, Han JH, Kim BS, Lee SM,    H
wang JS, Kang SW, et al. Wax moth, <I>Galleria mellonella</I>, high density    l
ipophorin receptor: alternative splicing, tissue-specific expression, and develo
pmental    regulation. <I>Insect Biochem Mol Biol</I> 2003; 33: 761-771.    ^cY#
6846.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#155#151#article#160# </font>      ^cY#68
46.htm##
00548000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704030300078002000900381#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#156#152#article#160#39#<P><f
ont face="Arial, Helvetica, sans-serif">39. Cheon HM, Seo SJ, Sun J, Sappington 
   TW, Raikhel AS. Molecular characterization of the VLDL receptor homolog media
ting    binding of lipophorin in oocyte of the mosquito <I>Aedes aegypti</I>. <I
>Insect    Biochem Mol Biol</I> 2001; 31: 753-760.    ^cY#6846.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#157#153#article#160# </font>      ^cY#68
46.htm##
00513000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704026800078002000900346#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#p#158#154#article#160#40#<P><f
ont face="Arial, Helvetica, sans-serif">40. van Hoof D, Rodenburg KW, van    der
 Horst DJ. Receptor-mediated endocytosis and intracellular trafficking of    lip
oproteins and transferrin in insect cells. <I>Insect Biochem Mol Biol</I>    200
5; 35: 117-128.    ^cY#6846.htm##
00282000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704005200075002000900127#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#159#155#article#160# </font>  <HR ALIGN=
LEFT WIDTH=100% SIZE=2>     ^cY#6846.htm##
00590000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704036000075002000900435#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#160#156#article#160#<P><font face="Arial
, Helvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT color="#00007F" SIZ
E=4><B>Acknowledgments</B></FONT></font>    <font size="4" face="Arial, Helvetic
a, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" 
ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0" width="12" height="12"></B></A>
</font></P>     ^cY#6846.htm##
00575000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704034500075002000900420#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#161#157#article#160#<P><font face="Arial
, Helvetica, sans-serif">We express our gratitude to Dr. Maur&iacute;cio    Sall
es, Universidade Federal do Rio Grande do Norte, for the insect donation    for 
starting our colony and to Lilian Soares da Cunha Gomes and Heloisa Coelho    fo
r excellent technical assistance. </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>    
 ^cY#6846.htm##
00591000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704036100075002000900436#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#162#158#article#160#<P><FONT SIZE=4 face
="Arial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F
><B>Correspondence    and Footnotes</B></FONT></FONT> <font size="4" face="Arial
, Helvetica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/
back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A
></font></P>     ^cY#6846.htm##
00725000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704049500075002000900570#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#163#159#article#160#<p><font face="Arial
, Helvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v41n1/
recor.gif" width="15" height="14" border="0"></a>    Address for correspondence:
 </b>G. C. Atella, Instituto de Bioqu&iacute;mica    M&eacute;dica, CCS, UFRJ, B
loco H, 2&#186; andar, Av. Bauh&iacute;nia, 400,    Ilha do Fund&atilde;o, 21941
-590 Rio de Janeiro, RJ, Brasil. Fax: +55-21-2270-8647.    E-mail: <a href="mail
to:atella@Bioqmed.ufrj.br">atella@Bioqmed.ufrj.br</a></font>  </p>     ^cY#6846.
htm##
00449000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704021900075002000900294#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6846.htm#S#p#164#160#article#160#<P><font face="Arial
, Helvetica, sans-serif">Research supported by CNPq, PADCT,    Pronex, Internati
onal Foudation for Science (IFS), and FAPERJ. Received April    2, 2007. Accepte
d September 24, 2007. </font>      ^cY#6846.htm##
00649000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100016000740100016000900100
01500106012013100121030002800252065000900280064000500289031000300294014000600297
865000900303002000900312035001000321801002800331#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6846.htm#S#c#165#1#article#40#1#^rND^sSilva^nCP#^rND^sTerra^nWR#^rND^
sLima^nRM#Differences in midgut serine proteinases from larvae of the bruchid be
etles Callosobruchus maculatus and Zabrotes subfasciatus^len#Arch Insect Biochem
 Physiol#20010000#2001#47#18-28#20080100#6846.htm#0739-4462#Arch Insect Biochem 
Physiol##
00612000000000301000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100024000740100018000980100
02400116010002000140012006200160030001700222065000900239064000500248031000400253
014000800257865000900265002000900274035001000283801001700293#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6846.htm#S#c#166#2#article#40#2#^rND^svan^nder Horst DJ#^
rND^svan^nHoof D#^rND^svan^nMarrewijk WJ#^rND^sRodenburg^nKW#Alternative lipid m
obilization: the insect shuttle system^len#Mol Cell Biochem#20020000#2002#239#11
3-119#20080100#6846.htm#0300-8177#Mol Cell Biochem##
00495000000000229000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720160015000740180122000890620
01500211066000700226065000900233064000500242865000900247002000900256#v41n1#v:\sc
ielo\serial\bjmbr\v41n1\markup\6846.htm#S#c#167#3#article#40#3#^rND^sChino^nH#Li
pid transport: biochemistry of hemolymph lipophorin. Comprehensive insect physio
logy, biochemistry and pharmacology^len#Pergamon Press#Oxford#19850000#1985#2008
0100#6846.htm##
00641000000000325000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100015000920100
01500107010001800122010002100140010001400161012005800175030001200233065000900245
06400050025403100040025901400120026386500090027500200090028403500100029380100120
0303#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#c#168#4#article#40#4#^
rND^sKawooya^nJK#^rND^sKeim^nPS#^rND^sRyan^nRO#^rND^sShapiro^nJP#^rND^sSamarawee
ra^nP#^rND^sLaw^nJH#Insect apolipophorin III: Purification and properties^len#J 
Biol Chem#19840000#1984#259#10733-10737#20080100#6846.htm#0021-9258#J Biol Chem#
#
00518000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100020000740100015000940120
03000109030002400139065000900163064000500172031000300177014000800180865000900188
002000900197035001000206801002400216#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
846.htm#S#c#169#5#article#40#5#^rND^sBlacklock^nBJ#^rND^sRyan^nRO#Hemolymph lipi
d transport^len#Insect Biochem Mol Biol#19940000#1994#24#855-873#20080100#6846.h
tm#0965-1748#Insect Biochem Mol Biol##
00576000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100019000740100016000930120
09000109030002400199065000900223064000500232031000300237014000600240865000900246
002000900255035001000264801002400274#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
846.htm#S#c#170#6#article#40#6#^rND^sSoulages^nJL#^rND^sWells^nMA#Metabolic fate
 and turnover rate of hemolymph free fatty acids in adult Manduca sexta^len#Inse
ct Biochem Mol Biol#19940000#1994#24#79-86#20080100#6846.htm#0965-1748#Insect Bi
ochem Mol Biol##
00530000000000265000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100019000740120081000930300
01900174065000900193064000500202031000300207014000700210865000900217002000900226
035001000235801001900245#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#c#
171#7#article#40#7#^rND^sEngelmann^nF#Insect vitellogenin: identification, biosy
nthesis and role in vitellogenesis^len#Adv Insect Physiol#19790000#1979#14#49-10
8#20080100#6846.htm#0567-9974#Adv Insect Physiol##
00613000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100015000740100017000890100
01900106012010200125030002100227065000900248064000500257031000400262014000800266
865000900274002000900283035001000292801002100302#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6846.htm#S#c#172#8#article#40#8#^rND^sChino^nH#^rND^sDowner^nRG#^rND^
sTakahashi^nK#The role of diacylglycerol-carrying lipoprotein I in lipid transpo
rt during insect vitellogenesis^len#Biochim Biophys Acta#19770000#1977#487#508-5
16#20080100#6846.htm#0006-3002#Biochim Biophys Acta##
00524000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100014000920120
06000106030001200166065000900178064000500187031000400192014001000196865000900206
002000900215035001000224801001200234#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
846.htm#S#c#173#9#article#40#9#^rND^sKawooya^nJK#^rND^sLaw^nJH#Role of lipophori
n in lipid transport to the insect egg^len#J Biol Chem#19880000#1988#263#8748-87
53#20080100#6846.htm#0021-9258#J Biol Chem##
00580000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100015000940100
01400109012008700123030001200210065000900222064000500231031000400236014001000240
865000900250002000900259035001000268801001200278#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6846.htm#S#c#174#10#article#40#10#^rND^sKawooya^nJK#^rND^sOsir^nEO#^r
ND^sLaw^nJH#Uptake of the major hemolymph lipoprotein and its transformation in 
the insect egg^len#J Biol Chem#19880000#1988#263#8740-8747#20080100#6846.htm#002
1-9258#J Biol Chem##
00581000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100022000920100
01500114010001800129012005400147030001200201065000900213064000500222031000400227
014000800231865000900239002000900248035001000257801001200267#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6846.htm#S#c#175#11#article#40#11#^rND^sLowry^nOH#^rND^sR
osenbrough^nNJ#^rND^sFarr^nAL#^rND^sRandall^nRJ#Protein measurement with the Fol
in phenol reagent^len#J Biol Chem#19510000#1951#193#265-275#20080100#6846.htm#00
21-9258#J Biol Chem##
00516000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760120088000940300
00700182065000900189064000500198031000400203014000800207865000900215002000900224
035001000233801000700243#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#c#
176#12#article#40#12#^rND^sLaemmli^nUK#Cleavage of structural proteins during th
e assembly of the head of bacteriophage T4^len#Nature#19700000#1970#227#680-685#
20080100#6846.htm#0028-0836#Nature##
00523000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760120077000920300
01700169065000900186064000500195031000400200014000800204865000900212002000900221
035001000230801001700240#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#c#
177#13#article#40#13#^rND^sDavis^nBJ#Disc electrophoresis II: Methods and applic
ation to human serum proteins^len#Ann N Y Acad Sci#19640000#1964#124#404-427#200
80100#6846.htm#0077-8923#Ann N Y Acad Sci##
00568000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940100
01900111012006200130030001600192065000900208064000500217031000400222014000800226
865000900234002000900243035001000252801001600262#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6846.htm#S#c#178#14#article#40#14#^rND^sNichols^nAV#^rND^sKrauss^nRM#
^rND^sMusliner^nTA#Nondenaturing polyacrylamide gradient gel electrophoresis^len
#Methods Enzymol#19860000#1986#128#417-431#20080100#6846.htm#0076-6879#Methods E
nzymol##
00502000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100015000920120
06200107030002200169710000200191065000900193064000500202031000300207014000800210
865000900218002000900227#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#c#
179#15#article#40#15#^rND^sBligh^nEG#^rND^sDyer^nWJ#A rapid method of total lipi
d extraction and purification^len#Can J Biochem Physiol#2#19590000#1959#37#911-9
17#20080100#6846.htm##
00584000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100018000920100
01500110012009300125030001200218065000900230064000500239031000200244014000800246
865000900254002000900263035001000272801001200282#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6846.htm#S#c#180#16#article#40#16#^rND^sVogel^nCW#^rND^sDoizaki^nWM#^
rND^sZieve^nL#Rapid thin-layer chromatographic separation of phospholipids and n
eutral lipids of serum^len#J Lipid Res#19620000#1962#3#138-140#20080100#6846.htm
#0022-2275#J Lipid Res##
00631000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100015000910120
16800106030001300274065000900287064000500296031000300301014000800304865000900312
002000900321035001000330801001300340#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
846.htm#S#c#181#17#article#40#17#^rND^sYavin^nE#^rND^sZutra^nA#Separation and an
alysis of 32P-labeled phospholipids by a simple and rapid thin-layer chromatogra
phic procedure and its application to cultured neuroblastoma cells^len#Anal Bioc
hem#19770000#1977#80#430-437#20080100#6846.htm#0003-2697#Anal Biochem##
00608000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100015000910120
14500106030001200251065000900263064000500272031000300277014001000280865000900290
002000900299035001000308801001200318#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
846.htm#S#c#182#18#article#40#18#^rND^sRuiz^nJL#^rND^sOchoa^nB#Quantification in
 the subnanomolar range of phospholipids and neutral lipids by nanodimensional t
hin layer chromatography and image analysis^len#J Lipid Res#19970000#1997#38#148
2-1489#20080100#6846.htm#0022-2275#J Lipid Res##
00575000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100017000920100
01900109010001700128010001500145012005600160030001200216710000200228065000900230
064000500239031000300244014000800247865000900255002000900264#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6846.htm#S#c#183#19#article#40#19#^rND^sDubois^nM#^rND^sG
illes^nKA#^rND^sHamilton^nJK#^rND^sRebers^nPA#^rND^sSmith^nF#Colorimetric method
 for the determination of sugars^len#Analyt Chem#2#19560000#1956#28#350-354#2008
0100#6846.htm##
00793000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100018000930100
01600111010001600127010002000143010002000163810000600183012018400189030001200373
06500090038506400050039403100040039901400120040386500090041500200090042403500100
0433801001200443#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#c#184#20#a
rticle#40#20#^rND^sMourao^nPA#^rND^sPereira^nMS#^rND^sPavao^nMS#^rND^sMulloy^nB#
^rND^sTollefsen^nDM#^rND^sMowinckel^nMC#et al#Structure and anticoagulant activi
ty of a fucosylated chondroitin sulfate from echinoderm: Sulfated fucose branche
s on the polysaccharide account for its high anticoagulant action^len#J Biol Che
m#19960000#1996#271#23973-23984#20080100#6846.htm#0021-9258#J Biol Chem##
00655000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100017000930100
01800110010001700128010001600145012007100161030002800232065000900260064000500269
031000300274014000800277865000900285002000900294035001000303801002800313#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#c#185#21#article#40#21#^rND^sCoelh
o^nHS#^rND^sAtella^nGC#^rND^sMoreira^nMF#^rND^sGondim^nKC#^rND^sMasuda^nH#Lipoph
orin density variation during oogenesis on Rhodnius prolixus^len#Arch Insect Bio
chem Physiol#19970000#1997#35#301-313#20080100#6846.htm#0739-4462#Arch Insect Bi
ochem Physiol##
00729000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100023000760100017000990100
01700116010001800133010001900151010002000170810000600190012012000196030001100316
06500090032706400050033603100030034101400080034486500090035200200090036103500100
0370801001100380#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#c#186#22#a
rticle#40#22#^rND^sMartin-Nizard^nF#^rND^sRichard^nB#^rND^sTorpier^nG#^rND^sNouv
elot^nA#^rND^sFruchart^nJC#^rND^sDuthilleul^nP#et al#Analysis of phospholipid tr
ansfer during HDL binding to platelets using a fluorescent analog of phosphatidy
lcholine^len#Thromb Res#19870000#1987#46#811-825#20080100#6846.htm#0049-3848#Thr
omb Res##
00567000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100021000930120
09700114030001100211065000900222064000500231031000400236014001000240865000900250
002000900259035001000268801001100278#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
846.htm#S#c#187#23#article#40#23#^rND^sAtella^nGC#^rND^sShahabuddin^nM#Different
ial partitioning of maternal fatty acid and phospholipid in neonate mosquito lar
vae^len#J Exp Biol#20020000#2002#205#3623-3630#20080100#6846.htm#0022-0949#J Exp
 Biol##
00611000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100015000960100
02100111010001600132012010100148030000500249065000900254064000500263031000200268
014000600270865000900276002000900285035001000294801000500304#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6846.htm#S#c#188#24#article#40#24#^rND^sGoldstein^nJL#^rN
D^sBasu^nSK#^rND^sBrunschede^nGY#^rND^sBrown^nMS#Release of low density lipoprot
ein from its cell surface receptor by sulfated glycosaminoglycans^len#Cell#19760
000#1976#7#85-95#20080100#6846.htm#0092-8674#Cell##
00580000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100019000930100
01600112012007700128030001700205065000900222064000500231031000300236014000600239
865000900245002000900254035001000263801001700273#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6846.htm#S#c#189#25#article#40#25#^rND^sGondim^nKC#^rND^sOliveira^nPL
#^rND^sMasuda^nH#Lipophorin and oogenesis in Rhodnius prolixus: transfer of phos
pholipids^len#J Insect Physiol#19890000#1989#35#19-27#20080100#6846.htm#0022-191
0#J Insect Physiol##
00600000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100018000910100
01400109012007900123030002800202065000900230064000500239031000200244014000800246
865000900254002000900263035001000272801002800282#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6846.htm#S#c#190#26#article#40#26#^rND^sRyan^nRO#^rND^sSchmidt^nJO#^r
ND^sLaw^nJH#Chemical and immunological properties of lipophorin: an insect lipop
rotein^len#Arch Insect Biochem Physiol#19840000#1984#1#375-383#20080100#6846.htm
#0739-4462#Arch Insect Biochem Physiol##
00620000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100024000760100020001000100
02300120012010400143030001500247065000900262064000500271031000300276014000800279
865000900287002000900296035001000305801001500315#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6846.htm#S#c#191#27#article#40#27#^rND^sVan^nder Horst DJ#^rND^sVan^n
Doorn JN#^rND^sBeenakkers^nAMTh#Hormone induced rearrangement of locust haemolym
ph lipoproteins: the involvement of glycoprotein C2^len#Insect Biochem#19840000#
1984#14#495-504#20080100#6846.htm#0020-1790#Insect Biochem##
00547000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100024000910120
06700115030001700182065000900199064000500208031000300213014000800216865000900224
002000900233035001000242801001700252#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
846.htm#S#c#192#28#article#40#28#^rND^sRyan^nRO#^rND^svan^nder Horst DJ#Lipid tr
ansport biochemistry and its role in energy production^len#Annu Rev Entomol#2000
0000#2000#45#233-260#20080100#6846.htm#0066-4170#Annu Rev Entomol##
00596000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100017000910100
01600108010002000124012008100144030000800225065000900233064000500242031000300247
014000800250865000900258002000900267035001000276801000800286#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6846.htm#S#c#193#29#article#40#29#^rND^sSchal^nC#^rND^sSe
vala^nVL#^rND^sYoung^nHP#^rND^sBachmann^nJAS#Synthesis and transport of hydrocar
bons: cuticle and ovary as target tissues^len#Am Zool#19980000#1998#38#382-393#2
0080100#6846.htm#0003-1569#Am Zool##
00684000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100021000930100
01800114010001600132010002100148012010000169030002400269065000900293064000500302
031000300307014000800310865000900318002000900327035001000336801002400346#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#c#194#30#article#40#30#^rND^sAtell
a^nGC#^rND^sSilva-Neto^nMA#^rND^sGolodne^nDM#^rND^sArefin^nS#^rND^sShahabuddin^n
M#Anopheles gambiae lipophorin: characterization and role in lipid transport to 
developing oocyte^len#Insect Biochem Mol Biol#20060000#2006#36#375-386#20080100#
6846.htm#0965-1748#Insect Biochem Mol Biol##
00669000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100014000930100
02000107010001500127012013800142030001700280065000900297064000500306031000300311
014000800314865000900322002000900331035001000340801001700350#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6846.htm#S#c#195#31#article#40#31#^rND^sSevala^nVL#^rND^s
Shus^nS#^rND^sRamaswamy^nSB#^rND^sSchal^nC#Lipophorin of female Blattella german
ica (L.): characterization and relation to hemolymph titers of juvenile hormone 
and hydrocarbons^len#J Insect Physiol#19990000#1999#45#431-441#20080100#6846.htm
#0022-1910#J Insect Physiol##
00644000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100016000910100
01700107010001900124012012500143030001200268065000900280064000500289031000300294
014000500297865000900302002000900311035001000320801001200330#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6846.htm#S#c#196#32#article#40#32#^rND^sChino^nH#^rND^sKa
tase^nH#^rND^sDowner^nRG#^rND^sTakahashi^nK#Diacylglycerol-carrying lipoprotein 
of hemolymph of the American cockroach: purification, characterization, and func
tion^len#J Lipid Res#19810000#1981#22#7-15#20080100#6846.htm#0022-2275#J Lipid R
es##
00653000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100014000940100
01700108010001700125012012800142030001300270065000900283064000500292031000300297
014001000300865000900310002000900319035001000328801001300338#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6846.htm#S#c#197#33#article#40#33#^rND^sKatagiri^nC#^rND^
sSato^nM#^rND^sde^nKort S#^rND^sKatsube^nY#Structure of Colorado potato beetle l
ipophorin: differential scanning calorimetric and small-angle X-ray scattering s
tudies^len#Biochemistry#19910000#1991#30#9675-9681#20080100#6846.htm#0006-2960#B
iochemistry##
00556000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100014000940100
01600108012006000124030001200184065000900196064000500205031000400210014001200214
865000900226002000900235035001000244801001200254#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6846.htm#S#c#198#34#article#40#34#^rND^sKatagiri^nC#^rND^sSato^nM#^rN
D^sTanaka^nN#Small-angle X-ray scattering study of insect lipophorin^len#J Biol 
Chem#19870000#1987#262#15857-15861#20080100#6846.htm#0021-9258#J Biol Chem##
00511000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760120069000940300
01400163065000900177064000500186031000400191014000800195865000900203002000900212
035001000221801001400231#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#c#
199#35#article#40#35#^rND^sJaenicke^nR#Protein stability and molecular adaptatio
n to extreme conditions^len#Eur J Biochem#19910000#1991#202#715-728#20080100#684
6.htm#0014-2956#Eur J Biochem##
00562000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100021000940100
01800115012005800133030001400191065000900205064000500214031000300219014000800222
865000900230002000900239035001000248801001400258#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6846.htm#S#c#200#36#article#40#36#^rND^sHussain^nMM#^rND^sStrickland^
nDK#^rND^sBakillah^nA#The mammalian low-density lipoprotein receptor family^len#
Annu Rev Nutr#19990000#1999#19#141-172#20080100#6846.htm#0199-9885#Annu Rev Nutr
##
00718000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940100
02100111010001700132010001800149010001600167810000600183012011400189030001200303
06500090031506400050032403100030032901400080033286500090034000200090034903500100
0358801001200368#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#c#201#37#a
rticle#40#37#^rND^sDantuma^nNP#^rND^sPotters^nM#^rND^sDe^nWinther MP#^rND^sTense
n^nCP#^rND^sKooiman^nFP#^rND^sBogerd^nJ#et al#An insect homolog of the vertebrat
e very low density lipoprotein receptor mediates endocytosis of lipophorins^len#
J Lipid Res#19990000#1999#40#973-978#20080100#6846.htm#0022-2275#J Lipid Res##
00756000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100014000900100
01400104010001400118010001600132010001500148810000600163012014800169030002400317
06500090034106400050035003100030035501400080035886500090036600200090037503500100
0384801002400394#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#c#202#38#a
rticle#40#38#^rND^sLee^nCS#^rND^sHan^nJH#^rND^sKim^nBS#^rND^sLee^nSM#^rND^sHwang
^nJS#^rND^sKang^nSW#et al#Wax moth, Galleria mellonella, high density lipophorin
 receptor: alternative splicing, tissue-specific expression, and developmental r
egulation^len#Insect Biochem Mol Biol#20030000#2003#33#761-771#20080100#6846.htm
#0965-1748#Insect Biochem Mol Biol##
00705000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100014000920100
01300106010002100119010001800140012013200158030002400290065000900314064000500323
031000300328014000800331865000900339002000900348035001000357801002400367#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6846.htm#S#c#203#39#article#40#39#^rND^sCheon
^nHM#^rND^sSeo^nSJ#^rND^sSun^nJ#^rND^sSappington^nTW#^rND^sRaikhel^nAS#Molecular
 characterization of the VLDL receptor homolog mediating binding of lipophorin i
n oocyte of the mosquito Aedes aegypti^len#Insect Biochem Mol Biol#20010000#2001
#31#753-760#20080100#6846.htm#0965-1748#Insect Biochem Mol Biol##
00641000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100020000940100
02400114012011200138030002400250065000900274064000500283031000300288014000800291
865000900299002000900308035001000317801002400327#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6846.htm#S#c#204#40#article#40#40#^rND^svan^nHoof D#^rND^sRodenburg^n
KW#^rND^svan^nder Horst DJ#Receptor-mediated endocytosis and intracellular traff
icking of lipoproteins and transferrin in insect cells^len#Insect Biochem Mol Bi
ol#20050000#2005#35#117-128#20080100#6846.htm#0965-1748#Insect Biochem Mol Biol#
#
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#o#1#1#article#1#20
080623#161508#6850.htm#172##
02976000000000649000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000700104030002000111
03100030013103200020013406500090013601400090014503500100015422300090016401201210
01730100026002940100027003200100024003470700122003710700200004930831321006930850
00802014085004102022085003302063085002902096085002102125085001702146117000602163
07200030216905800070217206000110217905800050219006000140219506000140220905800050
22230600014022281120009022421110014022511140009022651130019022748810024022930020
00902317#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#h#2#1#article#1#oa
#en#bjmbr#1#3.1#ILUS#09#BJMBR060#FAPESP#Braz J Med Biol Res#41#1#20080100#^f54^l
59#0100-879X#20071217#Differential response to gepirone but not to chlordiazepox
ide in malnourished rats subjected to learned helplessness^len#^rND^1A01^nL.M.M^
sCamargo#^rND^1A01^nA.B^sNascimento#^rND^1A02^nS.S^sAlmeida#Universidade Estadua
l de Londrina^iA01^1Departamento de Psicologia Geral e Análise do Comportamento^
cLondrina^sPR^pBrasil#Universidade de São Paulo^iA02^1Faculdade de Filosofia, Ci
ências e Letras de Ribeirão Preto^2Departamento de Psicologia e Educação^3Labora
tório de Nutrição e Comportamento^cRibeirão Preto^sSP^pBrasil#^len^aThe learned 
helplessness (LH) paradigm is characterized by learning deficits resulting from 
inescapable events. The aims of the present study were to determine if protein-c
alorie malnutrition (PCM) alters learning deficits induced by LH and if the neur
ochemical changes induced by malnutrition alter the reactivity to treatment with
 GABA-ergic and serotonergic drugs during LH. Well-nourished (W) and PCM Wistar 
rats (61 days old) were exposed or not to inescapable shocks (IS) and treated wi
th gepirone (GEP, 0.0-7.5 mg/kg, intraperitoneally, N = 128) or chlordiazepoxide
 (0.0-7.5 mg/kg, intraperitoneally, N = 128) 72 h later, 30 min before the test 
session (30 trials of escape learning). The results showed that rats exposed to 
IS had higher escape latency than non-exposed rats (12.6 ± 2.2 vs 4.4 ± 0.8 s) a
nd that malnutrition increased learning impairment produced by LH. GEP increased
 the escape latency of W animals exposed or non-exposed to IS, but did not affec
t the response of PCM animals, while chlordiazepoxide reduced the escape deficit
 of both W and PCM rats. The data suggest that PCM animals were more sensitive t
o the impairment produced by LH and that PCM led to neurochemical changes in the
 serotonergic system, resulting in hyporeactivity to the anxiogenic effects of G
EP in the LH paradigm.#^dnd^i1#^tm^len^kProtein-calorie malnutrition^i1#^tm^len^
kLearned helplessness^i1#^tm^len^kChlordiazepoxide^i1#^tm^len^kGepirone^i1#^tm^l
en^kRats^i1#other#37#FAPESP#02/05674-5#CNPq#470415/2003-7#411029/2003-7#CNPq#351
507/1996-5#20070404#April 4, 2007#20070913#September 13, 2007#S0100-879X20060050
00187#6850.htm##
02954000000000637000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000700104030002000111
03100030013103200020013406500090013601400090014503500100015422300090016401201280
01730100026003010100027003270100024003540700122003780700200005000831328007000850
00802028085004102036085003302077085002902110085002102139085001702160117000602177
07200030218305800070218606000110219305800050220406000140220906000140222305800050
2237060001402242112000902256111001402265114000902279113001902288002000902307#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#f#3#1#article#1#oa#en#bjmbr#1#
3.1#ILUS#09#BJMBR060#FAPESP#Braz J Med Biol Res#41#1#20080100#^f54^l59#0100-879X
#20071217#<B>Differential response to gepirone but not to chlordiazepoxide in ma
lnourished rats subjected to learned helplessness</B>^len#^rND^1A01^nL.M.M^sCama
rgo#^rND^1A01^nA.B^sNascimento#^rND^1A02^nS.S^sAlmeida#Universidade Estadual de 
Londrina^iA01^1Departamento de Psicologia Geral e Análise do Comportamento^cLond
rina^sPR^pBrasil#Universidade de São Paulo^iA02^1Faculdade de Filosofia, Ciência
s e Letras de Ribeirão Preto^2Departamento de Psicologia e Educação^3Laboratório
 de Nutrição e Comportamento^cRibeirão Preto^sSP^pBrasil#^len^aThe learned helpl
essness (LH) paradigm is characterized by learning deficits resulting from inesc
apable events. The aims of the present study were to determine if protein-calori
e malnutrition (PCM) alters learning deficits induced by LH and if the neurochem
ical changes induced by malnutrition alter the reactivity to treatment with GABA
-ergic and serotonergic drugs during LH. Well-nourished (W) and PCM Wistar rats 
(61 days old) were exposed or not to inescapable shocks (IS) and treated with ge
pirone (GEP, 0.0-7.5 mg/kg, intraperitoneally, N = 128) or chlordiazepoxide (0.0
-7.5 mg/kg, intraperitoneally, N = 128) 72 h later, 30 min before the test sessi
on (30 trials of escape learning). The results showed that rats exposed to IS ha
d higher escape latency than non-exposed rats (12.6 ± 2.2 <I>vs</I> 4.4 ± 0.8 s)
 and that malnutrition increased learning impairment produced by LH. GEP increas
ed the escape latency of W animals exposed or non-exposed to IS, but did not aff
ect the response of PCM animals, while chlordiazepoxide reduced the escape defic
it of both W and PCM rats. The data suggest that PCM animals were more sensitive
 to the impairment produced by LH and that PCM led to neurochemical changes in t
he serotonergic system, resulting in hyporeactivity to the anxiogenic effects of
 GEP in the LH paradigm.#^dnd^i1#^tm^len^kProtein-calorie malnutrition^i1#^tm^le
n^kLearned helplessness^i1#^tm^len^kChlordiazepoxide^i1#^tm^len^kGepirone^i1#^tm
^len^kRats^i1#other#37#FAPESP#02/05674-5#CNPq#470415/2003-7#411029/2003-7#CNPq#3
51507/1996-5#20070404#April 4, 2007#20070913#September 13, 2007#6850.htm##
03078000000000661000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000500100121000300105049000900108158000700117
03000240012403100030014803200020015106500090015301400090016203500100017122300090
01810120121001900100028003110100028003390100025003670700124003920700202005160831
32100718085000802039085004102047085003302088085002902121085002102150085001702171
11700060218807200030219405800070219706000110220405800050221506000140222006000140
22340580005022480600014022531120009022671110014022761140009022901130019022990020
00902318008008902327#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#l#4#1#
article#1#^mJan.^a2008#oa#en#bjmbr#1#3.1#ilus#09#BJMBR060#FAPESP#Braz. j. med. b
iol. res#41#1#20080100#^f54^l59#0100-879X#20071217#Differential response to gepi
rone but not to chlordiazepoxide in malnourished rats subjected to learned helpl
essness^len#^rND^1A01^nL. M. M^sCamargo#^rND^1A01^nA. B^sNascimento#^rND^1A02^nS
. S^sAlmeida#^iA01^1Universidade Estadual de Londrina^2Departamento de Psicologi
a Geral e Análise do Comportamento^cLondrina^sPR^pBrasil#^iA02^1Universidade de 
São Paulo^2Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto^3Departam
ento de Psicologia e Educação. Laboratório de Nutrição e Comportamento^cRibeirão
 Preto^sSP^pBrasil#^len^aThe learned helplessness (LH) paradigm is characterized
 by learning deficits resulting from inescapable events. The aims of the present
 study were to determine if protein-calorie malnutrition (PCM) alters learning d
eficits induced by LH and if the neurochemical changes induced by malnutrition a
lter the reactivity to treatment with GABA-ergic and serotonergic drugs during L
H. Well-nourished (W) and PCM Wistar rats (61 days old) were exposed or not to i
nescapable shocks (IS) and treated with gepirone (GEP, 0.0-7.5 mg/kg, intraperit
oneally, N = 128) or chlordiazepoxide (0.0-7.5 mg/kg, intraperitoneally, N = 128
) 72 h later, 30 min before the test session (30 trials of escape learning). The
 results showed that rats exposed to IS had higher escape latency than non-expos
ed rats (12.6 ± 2.2 vs 4.4 ± 0.8 s) and that malnutrition increased learning imp
airment produced by LH. GEP increased the escape latency of W animals exposed or
 non-exposed to IS, but did not affect the response of PCM animals, while chlord
iazepoxide reduced the escape deficit of both W and PCM rats. The data suggest t
hat PCM animals were more sensitive to the impairment produced by LH and that PC
M led to neurochemical changes in the serotonergic system, resulting in hyporeac
tivity to the anxiogenic effects of GEP in the LH paradigm.#^dnd^i1#^tm^len^kPro
tein-calorie malnutrition^i1#^tm^len^kLearned helplessness^i1#^tm^len^kChlordiaz
epoxide^i1#^tm^len^kGepirone^i1#^tm^len^kRats^i1#other#37#FAPESP#02/05674-5#CNPq
#470415/2003-7#411029/2003-7#CNPq#351507/1996-5#20070404#April 4, 2007#20070913#
September 13, 2007#6850.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci
_arttext&pid=S0100-879X2008000100009##
00375000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704014900071002000900220#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#5#1#article#131#<P> <font face="Arial, H
elvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med    Biol Res, January 2008
, Volume 41(1) 54-59</B> </font></P>     ^cY#6850.htm##
00426000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704020000071002000900271#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#6#2#article#131#<P><B><font size="5" fac
e="Arial, Helvetica, sans-serif">Differential response    to gepirone but not to
 chlordiazepoxide in malnourished rats subjected to learned    helplessness</fon
t></B>      ^cY#6850.htm##
00623000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704039700071002000900468#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#7#3#article#131#<P><font face="Arial, He
lvetica, sans-serif">L.M.M. Camargo<SUP>1</SUP>, A.B.    Nascimento<SUP>1</SUP> 
and <b><a href="#Correspondence"><img src="/img/revistas/bjmbr/v41n1/recor.gif" 
width="15" height="14" border="0"></a></b>    <a href="mailto:sebasalm@usp.br"><
img src="/img/revistas/bjmbr/v41n1/email-ca.gif" width="14" height="11" border="
0"></a>    S.S. Almeida<SUP>2</SUP> </font>      ^cY#6850.htm##
00708000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704048200071002000900553#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#8#4#article#131#<P><font face="Arial, He
lvetica, sans-serif"><SUP>1</SUP>Departamento de Psicologia    Geral e An&aacute
;lise do Comportamento, Universidade Estadual de Londrina,    Londrina, PR, Bras
il, <SUP>2</SUP>Laborat&oacute;rio de Nutri&ccedil;&atilde;o    e Comportamento,
 Departamento de Psicologia e Educa&ccedil;&atilde;o, Faculdade    de Filosofia,
 Ci&ecirc;ncias e Letras de Ribeir&atilde;o Preto, Universidade    de S&atilde;o
 Paulo, Ribeir&atilde;o Preto, SP, Brasil</font>      ^cY#6850.htm##
00442000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704021600071002000900287#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#9#5#article#131#<P> <font face="Arial, H
elvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v41n1/do
wn.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12">    <stro
ng>Abstract</strong></A>    ^cY#6850.htm##
00440000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704021300072002000900285#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#10#6#article#131#<BR>   <A HREF="#Introd
uction"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPA
CE=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Introduction"><strong>Int
roduction</strong></A>    ^cY#6850.htm##
00440000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704021300072002000900285#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#11#7#article#131#<BR>   <A HREF="#Materi
al"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0
 HSPACE=0 width="12" height="12"></A>    <A HREF="#Material"><strong>Material an
d Methods</strong></A>    ^cY#6850.htm##
00425000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704019800072002000900270#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#12#8#article#131#<BR>   <A HREF="#Result
s"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0 width="12" height="12"></A>    <A HREF="#Results"><strong>Results</stro
ng></A>    ^cY#6850.htm##
00434000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704020700072002000900279#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#13#9#article#131#<BR>   <A HREF="#Discus
sion"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Discussion"><strong>Discuss
ion</strong></A>    ^cY#6850.htm##
00422000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704019400073002000900267#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#14#10#article#131#<BR>   <A HREF="#Refer
ences"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#References"><strong>Refere
nces    ^cY#6850.htm##
00488000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704026000073002000900333#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#15#11#article#131#<br>   </strong></A> <
A HREF="#Correspondence"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOT
TOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Correspo
ndence"><strong>Correspondence and Footnotes</strong></A>    </font>      ^cY#68
50.htm##
00275000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704004700073002000900120#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#16#12#article#131#<P>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>     ^cY#6850.htm##
00563000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704033500073002000900408#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#17#13#article#131#<P> <font face="Arial,
 Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F>
<B>Abstract    </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1
/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></
A></FONT></font></P> <font face="Arial, Helvetica, sans-serif">      ^cY#6850.ht
m##
01620000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704139200073002000901465#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#18#14#article#131#<P>The learned helples
sness (LH) paradigm is characterized by learning deficits    resulting from ines
capable events. The aims of the present study were to determine    if protein-ca
lorie malnutrition (PCM) alters learning deficits induced by LH    and if the ne
urochemical changes induced by malnutrition alter the reactivity    to treatment
 with GABA-ergic and serotonergic drugs during LH. Well-nourished    (W) and PCM
 Wistar rats (61 days old) were exposed or not to inescapable shocks    (IS) and
 treated with gepirone (GEP, 0.0-7.5 mg/kg, intraperitoneally, N = 128)    or ch
lordiazepoxide (0.0-7.5 mg/kg, intraperitoneally, N = 128) 72 h later,    30 min
 before the test session (30 trials of escape learning). The results showed    t
hat rats exposed to IS had higher escape latency than non-exposed rats (12.6    
&#177; 2.2 <I>vs</I> 4.4 &#177; 0.8 s) and that malnutrition increased learning 
   impairment produced by LH. GEP increased the escape latency of W animals expo
sed    or non-exposed to IS, but did not affect the response of PCM animals, whi
le    chlordiazepoxide reduced the escape deficit of both W and PCM rats. The da
ta    suggest that PCM animals were more sensitive to the impairment produced by
 LH    and that PCM led to neurochemical changes in the serotonergic system, res
ulting    in hyporeactivity to the anxiogenic effects of GEP in the LH paradigm.
      ^cY#6850.htm##
00389000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704016100073002000900234#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#19#15#article#131#<P><B>Key words: </B>P
rotein-calorie malnutrition, Learned helplessness, Chlordiazepoxide,    Gepirone
, Rats  </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6850.htm##
00617000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038900073002000900462#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#20#16#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Introduction"></A><FONT color="#00007F" SIZE=4><
B>Introduction</B></FONT></font>    <font size="4" face="Arial, Helvetica, sans-
serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A></font></P> <font
 face="Arial, Helvetica, sans-serif">      ^cY#6850.htm##
01827000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704159900073002000901672#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#21#17#article#131#<P>Protein or protein-
calorie malnutrition (PCM) early in life produces morphological,    neurochemica
l and behavioral alterations in rats tested as adults (1,2). Behavioral    alter
ations following malnutrition cannot be attributed only to morphological    and/
or neurochemical changes in the central nervous system. Several lines of    expe
rimental evidence show that environmental changes concurrent with malnutrition  
  procedures may explain, in part, the behavioral alterations observed in malnou
rished    organisms (3-5). It has been shown that early protein malnutrition cha
nges mother-pup    and pup-pup interactions during lactation (6,7), promoting a 
drastic reduction    in social and environmental exploration early in life, a ph
enomenon described    as &quot;functional isolation&quot; (8). Although there ar
e no animal studies    showing that the isolation from the environment produced 
by malnutrition leads    to behavioral despair, a study on human malnutrition ha
s reported that depressive    symptoms, especially feelings of hopelessness, occ
ur more often among mothers    of malnourished children than among mothers of co
ntrol children (9). The hopelessness    feelings could be due to the absence of 
control on the part of the mothers of    the environmental variables that lead t
o miserable living conditions and eventually    to malnutrition. Thus, this unco
ntrollability of environmental variables may    alter the behavior of the mother
s and their interactions with the children,    possibly producing long-lasting e
motional alterations later in life in children.      ^cY#6850.htm##
01368000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704114000073002000901213#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#22#18#article#131#<P>In rats, it has bee
n described that early protein malnutrition also produces    changes in emotiona
lity, especially in the reaction of the animals to aversive    stimuli. It has b
een shown that malnutrition early in life produces increased    reactivity to el
ectric shocks (10) as well as increased inhibitory avoidance    in procedures us
ing painful stimuli (11-13). However, there are no reports in    the literature 
about the effects of inescapable shocks (IS) on the behavior    of malnourished 
animals. IS are extensively used in the classical model of learned    helplessne
ss (LH) (14). In this model, described as an experimental model of    depression
 (15), animals previously exposed to IS present a subsequent impairment    in th
e performance of an escape task (16,17). Given the reports showing the    partic
ipation of serotonergic and GABA-ergic neurotransmitter systems in the    develo
pment, maintenance, prevention, and reversal of LH (18-21) and the changes    in
 these neurotransmitter systems produced by early protein malnutrition (1,22,23)
,    it would be relevant to investigate LH in malnourished animals.      ^cY#68
50.htm##
00542000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704031400073002000900387#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#23#19#article#131#<P>Thus, the main obje
ctive of the present study was to investigate the effects    of early PCM and of
 acute treatment with serotonergic (gepirone) and benzodiazepine    (chlordiazep
oxide) drugs on the expression of escape deficit induced by the    LH paradigm. 
 </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6850.htm##
00621000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704039300073002000900466#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#24#20#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Material"></A><FONT color="#00007F" SIZE=4><B>Ma
terial    and Methods</B></FONT></font> <font size="4" face="Arial, Helvetica, s
ans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIG
N=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A></font></P> <
font face="Arial, Helvetica, sans-serif">      ^cY#6850.htm##
00264000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704003600073002000900109#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#25#21#article#131#<P><b>Animals</b>  </f
ont>      ^cY#6850.htm##
01194000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704096600073002000901039#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#26#22#article#131#<P><font face="Arial, 
Helvetica, sans-serif">Male Wistar rats from the animal    colony of the Londrin
a State University campus, Brazil, were used. On the day    of birth each litter
 was culled to 6 male pups. During the lactation period    (0-21 days of age), w
ell-nourished (W) pups were fed by mothers maintained on    an <I>ad libitum </I
>commercial diet (Purina, Cascav&eacute;l, PR, Brazil),    and malnourished pups
 were fed by mothers receiving 40% of the amount of diet    consumed by the <I>a
d libitum </I>control group. The litters were housed in    opaque plastic cages 
(40 x 30 x 20 cm). After weaning (22 days of age) the dams    were removed from 
the cages and the pups of both groups were given free access    to the diet up t
o the 60th day. The animals were kept on a 12-h light/dark cycle    with lights 
on at 7:00 am and room temperature kept at 23-25&#176;C. The experiment    was c
onducted during the dark portion of the cycle. </font>      ^cY#6850.htm##
00307000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704007900073002000900152#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#27#23#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><B>Apparatus</B> </font>      ^cY#6850.htm##
00563000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704033500073002000900408#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#28#24#article#131#<P><font face="Arial, 
Helvetica, sans-serif">During the training phase two shock    stimulators (model
 M-EP01, Funbec, S&atilde;o Paulo, SP, Brazil) and four Skinner    boxes (Funbec
) were used. During the testing phase a 50 x 25 x 25-cm shuttle-box    (Funbec) 
divided into two parts by a 5-cm sliding door was used. </font>      ^cY#6850.ht
m##
00307000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704007900073002000900152#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#29#25#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><B>Procedure</B> </font>      ^cY#6850.htm##
00624000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704039600073002000900469#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#30#26#article#131#<P><font face="Arial, 
Helvetica, sans-serif">At 61 days of age, W rats and rats    subjected to PCM we
re assigned to the IS or to the non-shock (NS) group, thereby    generating 4 ex
perimental groups for the LH paradigm: WIS (well-nourished, inescapable    shock
); WNS (well-nourished, non-shocked); MIS (malnourished, inescapable shock),    
and MNS (malnourished, non-shocked). </font>      ^cY#6850.htm##
00326000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704009800073002000900171#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#31#27#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><B>Inescapable shock session</B>    </font>      ^cY#6850
.htm##
00643000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704041500073002000900488#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#32#28#article#131#<P><font face="Arial, 
Helvetica, sans-serif">At 61 days of age, rats of the WIS    and MIS groups were
 placed individually in a Skinner box and exposed to 60 inescapable    8-s foots
hocks of 0.6 mA. Shocks were delivered according to a variable time    schedule,
 and the inter-shock interval averaged 60 s. WNS and MNS rats were    also place
d in Skinner boxes, but no shock was delivered to them. </font>      ^cY#6850.ht
m##
00310000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704008200073002000900155#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#33#29#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><B>Test session</B> </font>      ^cY#6850.htm##
01515000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704128700073002000901360#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#34#30#article#131#<P><font face="Arial, 
Helvetica, sans-serif">Seventy-two hours after the training    session and 30 mi
n before the test session rats received a single injection    of gepirone, chlor
diazepoxide, or vehicle (N = 8 for each group: WIS, WNS, MIS,    and MNS). Thus,
 there were 128 rats in the gepirone group (64 of them well-nourished    and 64 
malnourished) and 128 rats in the chlordiazepoxide group (64 of them    well-nou
rished and 64 malnourished). Rats were placed on side A of the shuttle-box    (w
here the shocks were delivered), and could escape to side B (where no shocks    
were delivered) by jumping through the middle sliding door. The intensity of    
the shock was the same as in the training session. If the animal did not escape 
   to side B, the shock was turned off after 30 s and the animal was removed by 
   the experimenter and placed on side B in which it remained for 30 s before be
ing    placed again on side A for the next trial. The test session consisted of 
30    trials. The experiments reported in the present paper were performed in co
mpliance    with the recommendations of the Brazilian Society of Neuroscience an
d Behavior    (SBNeC), which are based on the US National Institutes of Health G
uide for Care    and Use of Laboratory Animals. </font>      ^cY#6850.htm##
00303000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704007500073002000900148#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#35#31#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><B>Drugs</B> </font>      ^cY#6850.htm##
00716000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704048800073002000900561#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#36#32#article#131#<P><font face="Arial, 
Helvetica, sans-serif">Gepirone HCl (Bristol-Myers, Wallingford,    CT, USA) and
 chlordiazepoxide hydrochloride (Psicosedin&#153;, Farmasa, S&atilde;o    Paulo,
 SP, Brazil) were both dissolved in distilled water. Acute injections    of vehi
cle (distilled water), gepirone (2.5, 5.0, or 7.5 mg/kg) or chlordiazepoxide    
(2.5, 5.0, 7.5 mg/kg) were administered intraperitoneally (<I>ip</I>) in a volum
e    of 1 mL/kg, 30 min before the test session. </font>      ^cY#6850.htm##
00311000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704008300073002000900156#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#37#33#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><B>Data analysis</B> </font>      ^cY#6850.htm##
00667000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704043900073002000900512#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#38#34#article#131#<P><font face="Arial, 
Helvetica, sans-serif">Escape latency was analyzed by three-way    (diet conditi
on x shock procedure x dose of the drug) analysis of variance (ANOVA)    and rat
 body weight was analyzed by two-way ANOVA (diet condition x age). <I>Post    ho
c</I> comparisons were made using the Newman-Keuls test. The level of significan
ce    was set at P &lt; 0.05 in all analyses. </font>  <HR ALIGN=LEFT WIDTH=100%
 SIZE=2>     ^cY#6850.htm##
00563000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704033500073002000900408#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#39#35#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Results"></A><FONT color="#00007F" SIZE=4><B>Res
ults</B></FONT></font>    <font size="4" face="Arial, Helvetica, sans-serif"><A 
HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIGN=BOTTOM BORDE
R=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A></font></P>     ^cY#6850.ht
m##
00312000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704008400073002000900157#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#40#36#article#131#<P><b><font face="Aria
l, Helvetica, sans-serif">Body weight</font></b> </P>     ^cY#6850.htm##
00793000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704056500073002000900638#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#41#37#article#131#<P><font face="Arial, 
Helvetica, sans-serif">The body weight of the animals (<a href="#Fig1">Figure   
 1</a>) was affected by diet restriction, with W animals being heavier than PCM 
   animals as indicated by a significant effect of diet (F(1,179) = 448.8, P &lt
;    0.001). Animals of all groups significantly increased their body weights ac
ross    age (F(8,179) = 760.5, P &lt; 0.001). However, W animals had a greater i
ncrease    compared with PCM animals as indicated by a significant diet x age in
teraction    (F(8,179) = 26.5, P &lt; 0.001). </font>      ^cY#6850.htm##
00317000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704008900073002000900162#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#42#38#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><B>Behavioral measures</B> </font>      ^cY#6850.htm##
00938000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704071000073002000900783#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#43#39#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><I>Gepirone</I>. As shown in <a href="#Fig2">Figure    2<
/a>, there was a significant effect of procedure (F (1,674) = 193.8, P &lt;    0
.001), with IS animals presenting higher escape latencies compared with NS    an
imals. There was also a significant effect of dose (F(3,674), P &lt; 0.001),    
with <I>post hoc</I> analysis indicating a significant increase of escape latenc
y    at the dose of 5 mg/kg compared with saline (P &lt; 0.05). However, this in
crease    in escape latency was statistically significant only in W animals comp
ared with    PCM animals, leading to a significant diet x dose interaction (F(3,
674) = 18.2,    P &lt; 0.001). </font>      ^cY#6850.htm##
01790000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704156200073002000901635#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#44#40#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><I>Chlordiazepoxide</I>. As shown    in <a href="#Fig3">F
igure 3</a>, there was a significant effect of procedure    (F(1,673) = 198.5, P
 &lt; 0.001), with IS animals presenting higher escape latencies    compared wit
h NS animals. There was also a significant effect of dose (F(3,674),    P &lt; 0
.001), with <I>post hoc</I> analysis indicating a significant decrease    of esc
ape latency at the doses of 5.0 and 7.5 mg/kg as compared with saline    (P &lt;
 0.05). In addition, ANOVA showed a significant effect of diet (F(1,673)    = 15
.8, P &lt; 0.001), with PCM animals presenting higher escape latencies than    W
 animals. Finally, there was also a significant diet x shock procedure interacti
on    (F(1,673) = 8.62, P &lt; 0.01) and a significant shock procedure x drug do
se    interaction (F(3,673) = 8.17, P &lt; 0.001). <I>Post hoc</I> analysis show
ed    that the diet x shock interaction was due to greater increases (P &lt; 0.0
5)    in the escape latency for PCM animals exposed to IS, while the shock proce
dure    x drug dose interaction was due to a significant decrease in escape late
ncy    in IS compared with no effects in NS animals (P &lt; 0.05) following phar
macological    treatment.</font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2> <table width
="100%"  border="0">   <tr align="left" valign="top">      <td width="15%"><a hr
ef="/img/revistas/bjmbr/v41n1/html/6850i01.htm"><img src="/img/revistas/bjmbr/v4
1n1/6850i01peq.jpg" width="120" height="87" border="2"></a></td>     <td width="
85%">           ^cY#6850.htm##
00631000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704040300073002000900476#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#45#41#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig1" id="Fig1"></a>Figure          1. Body weig
ht of well-nourished (W) and malnourished (M) animals from          birth to age
 of testing. Data are reported as means &#177; SEM for N =          18 animals f
or each condition. *P &lt; 0.05 compared with malnourished          animals (New
man-Keuls test). </font>      </td>   </tr> </table>     ^cY#6850.htm##
00645000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704041700073002000900490#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#46#42#article#131#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image    (83 K JPG file)]</f
ont></P> <HR ALIGN=LEFT WIDTH=100% SIZE=2> <table width="100%"  border="0">   <t
r align="left" valign="top">      <td width="15%"><a href="/img/revistas/bjmbr/v
41n1/html/6850i02.htm"><img src="/img/revistas/bjmbr/v41n1/6850i02peq.jpg" width
="120" height="88" border="2"></a></td>     <td width="85%">           ^cY#6850.
htm##
00991000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704076300073002000900836#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#47#43#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig2"></a>Figure 2.          Latency of the esca
pe response of well-nourished and malnourished animals          after acute trea
tment with gepirone. Data are reported as means &#177;          SEM for N = 8 an
imals for each condition. WIS = well-nourished animals          exposed to inesc
apable shocks; WNS = well-nourished animals not exposed          to inescapable 
shocks; MIS = malnourished animals exposed to inescapable          shocks; MNS =
 malnourished animals not exposed to inescapable shocks.          *P &lt; 0.05 c
ompared with 0.0 mg/kg within the same group and <SUP>+</SUP>P          &lt; 0.0
5 compared with non-shocked animals (Newman-Keuls test). </font>      </td>   </
tr> </table>     ^cY#6850.htm##
01426000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704119800073002000901271#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#48#44#article#131#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image    (96 K JPG file)]</f
ont></P> <HR ALIGN=LEFT WIDTH=100% SIZE=2> <table width="100%"  border="0">   <t
r align="left" valign="top">      <td width="15%"><a href="/img/revistas/bjmbr/v
41n1/html/6850i03.htm"><img src="/img/revistas/bjmbr/v41n1/6850i03peq.jpg" width
="120" height="104" border="2"></a></td>     <td width="85%"><font face="Arial, 
Helvetica, sans-serif"><a name="Fig3"></a>Figure        3. Latency of the escape
 response of well-nourished and malnourished animals        after acute treatmen
t with chlordiazepoxide. Data are reported as means        &#177; SEM for N = 8 
animals for each condition. WIS = well-nourished animals        exposed to inesc
apable shocks; WNS = well-nourished animals not exposed        to inescapable sh
ocks; MIS = malnourished animals exposed to inescapable        shocks; MNS = mal
nourished animals not exposed to inescapable shocks. *P        &lt; 0.05 compare
d with 0.0 mg/kg within the same group, **P &lt; 0.05 compared        with non-s
hocked animals, and <SUP>+</SUP>P &lt; 0.05 compared with WIS        animals (Ne
wman-Keuls test). </font></td>   </tr> </table>     ^cY#6850.htm##
00347000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704011900073002000900192#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#49#45#article#131#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image    (98 K JPG file)]</f
ont></P>     ^cY#6850.htm##
00275000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704004700073002000900120#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#50#46#article#131#<P>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>     ^cY#6850.htm##
00523000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704029500073002000900368#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#51#47#article#131#<P> <font face="Arial,
 Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007
F><B>Discussion    </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v
41n1/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></
B></A></FONT></font></P>     ^cY#6850.htm##
00523000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704029500073002000900368#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#52#48#article#131#<P><font face="Arial, 
Helvetica, sans-serif">The nutritional manipulation imposed    on the dams direc
tly affected pup body weight. Early PCM produced a significant    decrease in th
e animal's body weight, a well-established result also reported    in previous s
tudies (24,25). </font>      ^cY#6850.htm##
00490000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704026200073002000900335#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#53#49#article#131#<P><font face="Arial, 
Helvetica, sans-serif">The behavioral data in the LH test    showed that animals
 exposed to IS present longer escape latencies compared with    animals not expo
sed to IS, in agreement with previous literature data (17).    </font>      ^cY#
6850.htm##
02096000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704186800073002000901941#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#54#50#article#131#<P><font face="Arial, 
Helvetica, sans-serif">Moreover, early PCM increased the    effects of the IS as
 demonstrated by longer escape latencies in PCM animals    compared with W anima
ls in the group treated with chlordiazepoxide, indicating    that the nutritiona
l insult increased the impairment of escape learning following    the helplessne
ss procedure. Although a similar result could be observed in the    gepirone gro
up (i.e., longer latencies in PCM rats compared with W rats), it    was not poss
ible to demonstrate a statistical effect since the strong response    of W anima
ls to the 5.0 mg/kg dose precluded the finding of a significant effect    of die
t. This result can be interpreted not only as an increased learning impairment  
  produced by the experience of inescapable shock, but also as a lower shock thr
eshold    in malnourished animals. A lower shock threshold produced by early mal
nutrition    has already been described (10). However, increased impairment of l
earning produced    by the uncontrollability of the shocks in PCM animals appear
s to be a more plausible    explanation since no differences due to diet were ob
served in the reactivity    to shock on escape latencies of the groups not expos
ed to IS before escape learning.    If this apparent increased sensitivity of PC
M animals to inescapable painful    aversive stimuli is due to environmental cha
nges produced by early malnutrition    (i.e., hopelessness of malnourished mothe
rs during lactation), similar results    can be expected in other experimental m
odels of behavioral despair. Since there    are reports in the literature showin
g that early malnutrition is a biological    risk factor for further affective d
isorders, including depression (26,27), it    would be interesting to investigat
e the effects of early malnutrition on behavioral    despair models. </font>    
  ^cY#6850.htm##
02851000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704262300073002000902696#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#55#51#article#131#<P><font face="Arial, 
Helvetica, sans-serif">The significant increase in escape    latency after acute
 gepirone treatment (5.0 mg/kg) in the present study agrees    with previously r
eported data comparing an anxiolytic profile after chronic    treatment (28). It
 has been reported that the 5-HT<SUB>1A</SUB> receptor subtype    is the primary
 site of action of the azaperone class of drugs such as buspirone,    ipsapirone
 and gepirone (28). These receptor subtypes are present on the soma    and dendr
ites of 5-HT neurons and on postsynaptic neurons in the brain (hippocampus,    s
eptum, neocortex, amygdala, and hypothalamus) and on the spinal cord (29).    Th
us, the present results showing anxiogenic effects of acute treatment compared  
  with an anxiolytic effect of chronic treatment (28) support the assumption tha
t    an anxiolytic effect of drugs acting on 5-HT<SUB>1A</SUB> receptors is only
    possible by the sustained presence of 5-HT<SUB>1A</SUB> agonists (30). The s
tronger    effect of gepirone at the dose of 5.0 mg/kg and the lower effect with
 2.5 and    7.5 mg/kg is an example of what is known as a non-monotonic dose-res
ponse curve.    In this condition the curves are shaped like inverted U's with t
he greatest    response in intermediate ranges. In addition, the effect of gepir
one could not    be attributed to effects on locomotor activity since this drug 
did not alter    locomotion in models of anxiety (28). The absence of gepirone e
ffects on the    malnourished animals is a pharmacological evidence that early p
rotein malnutrition    affects the serotonergic neurotransmitter system, especia
lly 5-HT<SUB>1A</SUB>    receptor subtypes. According to this interpretation, it
 has been shown that    5-HT<SUB>1A</SUB> receptors assayed with (3H)8-OH-DPAT w
ere decreased by 20%    in the hippocampal CA3 subfield of early protein-malnour
ished rats (31). Moreover,    it has also been reported that the sensitivity of 
5-HT receptors stimulated    with 8-OH-DPAT is increased in well-nourished anima
ls exposed to chronic stress    compared with no effect in malnourished animals 
(32), indicating a lack of adaptive    changes at serotonergic sites following e
arly malnutrition. In addition, hyporeactivity    to the effects of serotonergic
 drugs after early protein malnutrition has also    been reported, showing that 
malnourished animals have a lower response to ipsapirone    in the hypertonic sa
line ingestion test (33) and in the elevated plus-maze test    (34), indicating 
that the nutritional insult causes long-term alteration in    the serotonergic n
eurotransmitter system. </font>      ^cY#6850.htm##
01679000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704145100073002000901524#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#56#52#article#131#<P><font face="Arial, 
Helvetica, sans-serif">Treatment with chlordiazepoxide produced    a significant
 decrease in escape latency only in the group of IS animals, indicating    that 
this drug reversed, in part, the learning impairment produced by IS, especially 
   with the doses of 5.0 and 7.5 mg/kg. The reversal of this impairment after tr
eatment    with the GABA<SUB>A</SUB> receptor agonists muscimol and fengabine ha
s also    been reported (35), suggesting a participation of the GABA-benzodiazep
ine system    in the LH model (21). In agreement with these results are the repo
rts showing    that GABA microinjected into the hippocampus also reverses LH whe
n injected    after IS (36), while the GABA<SUB>A</SUB> receptor antagonist (bic
uculline)    injected into the same region induced LH (37). Early PCM did not ch
ange the    reactivity of the animals to the effects of chlordiazepoxide in the 
LH model.    This result contrasts with several reports showing hyporeactivity o
f malnourished    animals to treatment with benzodiazepines (for a review, see R
ef. 1). However,    the great majority of these reports were obtained in behavio
ral models without    the use of painful aversive stimuli or at least using cont
rollable shock procedures.    Thus, it is possible that the controllability of t
he aversive stimulus can play    an important role in the response of malnourish
ed organisms to benzodiazepine    anxiolytic drugs. </font>      ^cY#6850.htm##
01327000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704109900073002000901172#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#57#53#article#131#<P><font face="Arial, 
Helvetica, sans-serif">Finally, since the drugs were administered    before the 
behavioral test it is possible that the behavioral changes observed    were due 
to the action of these drugs on the expression of escape behavior rather    than
 on processes of learning and memory <I>per se</I>. Previous data from our    gr
oup using drugs of the same class in different experimental models (elevated    
plus-maze and hypertonic saline ingestion) have suggested a possible involvement
    of the drugs in the expression of the behavior rather than in the ability of
    the animals to learn a task (33,34). Future studies using experimental model
s    of painless stimuli such as the forced swimming test could definitely contr
ibute    to elucidate the effects of drugs acting on the serotonergic and GABA-e
rgic    neurotransmitter systems of early malnourished animals. The use of a pai
nless    stimulus prevents possible confounding factors due to the well-describe
d lower    shock threshold observed in malnourished animals (10). </font>  <HR A
LIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6850.htm##
00569000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704034100073002000900414#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#58#54#article#131#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><B>
References</B></FONT></font>    <font size="4" face="Arial, Helvetica, sans-seri
f"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIGN=BOTTOM
 BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A></font></P>     ^cY#6
850.htm##
00460000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704021800075002000900293#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#59#55#article#131#1#<P><font
 face="Arial, Helvetica, sans-serif">1. Almeida SS, Tonkiss J, Galler    JR. Mal
nutrition and reactivity to drugs acting in the central nervous system.    <I>Ne
urosci Biobehav Rev</I> 1996; 20: 389-402.    ^cY#6850.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#60#56#article#131# </font>      ^cY#6850
.htm##
00494000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704025200075002000900327#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#61#57#article#131#2#<P><font
 face="Arial, Helvetica, sans-serif">2. Morgane PJ, Austin-LaFrance R,    Bronzi
no J, Tonkiss J, D&iacute;az-Cintra S, Cintra L, et al. Prenatal malnutrition   
 and development of the brain.<I>Neurosci Biobehav Rev</I> 1993; 17: 91-128.    
^cY#6850.htm##
00249000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704002100073002000900094#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#62#58#article#131#    </font>      ^cY#6
850.htm##
00545000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704030300075002000900378#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#63#59#article#131#3#<P><font
 face="Arial, Helvetica, sans-serif">3. Levine S, Weiner SG. Malnutrition    and
 early environmental experience: possible interactive effects on later behavior.
    In: Walsh RN, Greenough WT (Editors), <I>Environment as therapy for brain dy
sfunction</I>.    New York: Plenum Press; 1976.    ^cY#6850.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#64#60#article#131# </font>      ^cY#6850
.htm##
00464000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704022200075002000900297#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#65#61#article#131#4#<P><font
 face="Arial, Helvetica, sans-serif">4. Levitsky DA, Barnes RH. Nutritional    a
nd environmental interactions in the behavioral development of the rat: long-ter
m    effects. <I>Science</I> 1972; 176: 68-71.    ^cY#6850.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#66#62#article#131# </font>      ^cY#6850
.htm##
00539000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704029700075002000900372#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#67#63#article#131#5#<P><font
 face="Arial, Helvetica, sans-serif">5. Santucci LB, Daud MM, Almeida    SS, de 
Oliveira LM. Effects of early protein malnutrition and environmental    stimulat
ion upon the reactivity to diazepam in two animal models of anxiety.    <I>Pharm
acol Biochem Behav</I> 1994; 49: 393-398.    ^cY#6850.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#68#64#article#131# </font>      ^cY#6850
.htm##
00480000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704023800075002000900313#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#69#65#article#131#6#<P><font
 face="Arial, Helvetica, sans-serif">6. Massaro TF, Levitsky DA, Barnes    RH. P
rotein malnutrition induced during gestation: its effect on pup development    a
nd maternal behavior. <I>Dev Psychobiol</I> 1977; 10: 339-345.    ^cY#6850.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#70#66#article#131# </font>      ^cY#6850
.htm##
00563000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704032100075002000900396#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#71#67#article#131#7#<P><font
 face="Arial, Helvetica, sans-serif">7. Riul TR, Carvalho AF, Almeida    PS, De-
Oliveira LM, Almeida SS. Ethological analysis of mother-pup interactions    and 
other behavioral reactions in rats: effects of malnutrition and tactile    stimu
lation of the pups. <I>Braz J Med Biol Res</I> 1999; 32: 975-983.    ^cY#6850.ht
m##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#72#68#article#131# </font>      ^cY#6850
.htm##
00428000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704018600075002000900261#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#73#69#article#131#8#<P><font
 face="Arial, Helvetica, sans-serif">8. Levitsky DA, Massaro TF, Barnes    RH. M
aternal malnutrition and the neonatal environment. <I>Fed Proc</I> 1975;    34: 
1583-1586.    ^cY#6850.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#74#70#article#131# </font>      ^cY#6850
.htm##
00501000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704025900075002000900334#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#75#71#article#131#9#<P><font
 face="Arial, Helvetica, sans-serif">9. Salt P, Galler JR, Ramsey FC.    The inf
luence of early malnutrition on subsequent behavioral development. VII.    The e
ffects on maternal depressive symptoms. <I>J Dev Behav Pediatr</I> 1988;    9: 1
-5.    ^cY#6850.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#76#72#article#131# </font>      ^cY#6850
.htm##
00450000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704020700076002000900283#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#77#73#article#131#10#<P><fon
t face="Arial, Helvetica, sans-serif">10. Smart JL, Whatson TS, Dobbing    J. Th
resholds of response to electric shock in previously undernourished rats.    <I>
Br J Nutr</I> 1975; 34: 511-516.    ^cY#6850.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#78#74#article#131# </font>      ^cY#6850
.htm##
00460000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704021700076002000900293#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#79#75#article#131#11#<P><fon
t face="Arial, Helvetica, sans-serif">11. Lynch A. Passive avoidance behavior   
 and response thresholds in adult male rats after early postnatal undernutrition
.    <I>Physiol Behav</I> 1976; 16: 27-32.    ^cY#6850.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#80#76#article#131# </font>      ^cY#6850
.htm##
00488000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704024500076002000900321#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#81#77#article#131#12#<P><fon
t face="Arial, Helvetica, sans-serif">12. Almeida SS, De-Oliveira LM, Bichuette 
   MZ, Graeff FG. Early malnutrition alters the effect of chlordiazepoxide on in
hibitory    avoidance. <I>Braz J Med Biol Res</I> 1988; 21: 1033-1036.    ^cY#68
50.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#82#78#article#131# </font>      ^cY#6850
.htm##
00509000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704026600076002000900342#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#83#79#article#131#13#<P><fon
t face="Arial, Helvetica, sans-serif">13. Almeida SS, Soares EG, Bichuette    MZ
, Graeff FG, de Oliveira LM. Effects of early postnatal malnutrition and chlordi
azepoxide    on experimental aversive situations. <I>Physiol Behav</I> 1992; 51:
 1195-1199.    ^cY#6850.htm##
00249000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704002100073002000900094#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#84#80#article#131#    </font>      ^cY#6
850.htm##
00416000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704017300076002000900249#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#85#81#article#131#14#<P><fon
t face="Arial, Helvetica, sans-serif">14. Hunziker MHL. O desamparo aprendido   
 revisitado: estudos com animais. <I>Psicol Teor Pesqui</I> 2005; 21: 131-139.  
  ^cY#6850.htm##
00249000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704002100073002000900094#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#86#82#article#131#    </font>      ^cY#6
850.htm##
00400000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704015700076002000900233#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#87#83#article#131#15#<P><fon
t face="Arial, Helvetica, sans-serif">15. Willner P. The validity of animal    m
odels of depression. <I>Psychopharmacology</I> 1984; 83: 1-16.    ^cY#6850.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#88#84#article#131# </font>      ^cY#6850
.htm##
00396000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704015300076002000900229#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#89#85#article#131#16#<P><fon
t face="Arial, Helvetica, sans-serif">16. Seligman ME, Maier SF. Failure    to e
scape traumatic shock. <I>J Exp Psychol</I> 1967; 74: 1-9.    ^cY#6850.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#90#86#article#131# </font>      ^cY#6850
.htm##
00411000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704016800076002000900244#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#91#87#article#131#17#<P><fon
t face="Arial, Helvetica, sans-serif">17. Maier SF, Seligman MEP. Learned    hel
plessness: Theory and evidence. <I>J Exp Psychol Gen</I> 1976; 105: 3-46.    ^cY
#6850.htm##
00249000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704002100073002000900094#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#92#88#article#131#    </font>      ^cY#6
850.htm##
00450000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704020700076002000900283#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#93#89#article#131#18#<P><fon
t face="Arial, Helvetica, sans-serif">18. Graeff EO, Hunziker MH, Graeff    FG. 
Effects of ipsapirone and BAY R 1531 on learned helplessness. <I>Braz J    Med B
iol Res</I> 1989; 22: 1141-1144.    ^cY#6850.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#94#90#article#131# </font>      ^cY#6850
.htm##
00531000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704028800076002000900364#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#95#91#article#131#19#<P><fon
t face="Arial, Helvetica, sans-serif">19. Maier SF, Grahn RE, Kalman BA,    Sutt
on LC, Wiertelak EP, Watkins LR. The role of the amygdala and dorsal raphe    nu
cleus in mediating the behavioral consequences of inescapable shock. <I>Behav   
 Neurosci</I> 1993; 107: 377-388.    ^cY#6850.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#96#92#article#131# </font>      ^cY#6850
.htm##
00444000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704020100076002000900277#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#97#93#article#131#20#<P><fon
t face="Arial, Helvetica, sans-serif">20. Petty F, Kramer G, Wilson L,    Jordan
 S. <I>In vivo</I> serotonin release and learned helplessness. <I>Psychiatry    
Res</I> 1994; 52: 285-293.    ^cY#6850.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#98#94#article#131# </font>      ^cY#6850
.htm##
00451000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704020800076002000900284#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#99#95#article#131#21#<P><fon
t face="Arial, Helvetica, sans-serif">21. Kram ML, Kramer GL, Steciuk M,    Rona
n PJ, Petty F. Effects of learned helplessness on brain GABA receptors.    <I>Ne
urosci Res</I> 2000; 38: 193-198.    ^cY#6850.htm##
00247000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070704001800074002000900092#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#100#96#article#131# </font>      ^cY#685
0.htm##
00544000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704030000077002000900377#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#101#97#article#131#22#<P><fo
nt face="Arial, Helvetica, sans-serif">22. Del Angel-Meza AR, Ramirez-Cortes    
L, Adame-Gonzalez IG, Gonzalez Burgos I, Beas-Zarate C. Cerebral GABA release   
 and GAD activity in protein- and tryptophan-restricted rats during development.
    <I>Int J Dev Neurosci</I> 2002; 20: 47-54.    ^cY#6850.htm##
00247000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070704001800074002000900092#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#102#98#article#131# </font>      ^cY#685
0.htm##
00459000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704021500077002000900292#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#103#99#article#131#23#<P><fo
nt face="Arial, Helvetica, sans-serif">23. Morgane PJ, Mokler DJ, Galler    JR. 
Effects of prenatal protein malnutrition on the hippocampal formation. <I>Neuros
ci    Biobehav Rev</I> 2002; 26: 471-483.    ^cY#6850.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#104#100#article#131# </font>      ^cY#68
50.htm##
00460000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704021500078002000900293#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#105#101#article#131#24#<P><f
ont face="Arial, Helvetica, sans-serif">24. Clarke KA, Parker AJ, Smart JL.    A
nalysis of walking locomotion in adult female rats undernourished as sucklings. 
   <I>Physiol Behav</I> 1992; 52: 823-826.    ^cY#6850.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#106#102#article#131# </font>      ^cY#68
50.htm##
00481000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704023600078002000900314#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#107#103#article#131#25#<P><f
ont face="Arial, Helvetica, sans-serif">25. Lago ES, Teodosio NR, Araujo    CR, 
Azevedo MC, Pessoa DC, Campos FA, et al. Rat models of protein and protein-energ
y    malnutrition. <I>Int J Vitam Nutr Res</I> 1993; 63: 52-56.    ^cY#6850.htm#
#
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#108#104#article#131# </font>      ^cY#68
50.htm##
00399000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704015400078002000900232#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#109#105#article#131#26#<P><f
ont face="Arial, Helvetica, sans-serif">26. Casper RC. Nutrients, neurodevelopme
nt,    and mood. <I>Curr Psychiatry Rep</I> 2004; 6: 425-429.    ^cY#6850.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#110#106#article#131# </font>      ^cY#68
50.htm##
00408000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704016300078002000900241#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#111#107#article#131#27#<P><f
ont face="Arial, Helvetica, sans-serif">27. Tiemeier H. Biological risk factors 
   for late life depression. <I>Eur J Epidemiol</I> 2003; 18: 745-750.    ^cY#68
50.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#112#108#article#131# </font>      ^cY#68
50.htm##
00509000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704026400078002000900342#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#113#109#article#131#28#<P><f
ont face="Arial, Helvetica, sans-serif">28. Silva RC, Brand&atilde;o ML.    Acut
e and chronic effects of gepirone and fluoxetine in rats tested in the elevated 
   plus-maze: an ethological analysis. <I>Pharmacol Biochem Behav</I> 2000; 65: 
   209-216.    ^cY#6850.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#114#110#article#131# </font>      ^cY#68
50.htm##
00435000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704019000078002000900268#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#115#111#article#131#29#<P><f
ont face="Arial, Helvetica, sans-serif">29. Blier P, Ward NM. Is there a    role
 for 5-HT1A agonists in the treatment of depression? <I>Biol Psychiatry</I>    2
003; 53: 193-203.    ^cY#6850.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#116#112#article#131# </font>      ^cY#68
50.htm##
00513000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704026800078002000900346#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#117#113#article#131#30#<P><f
ont face="Arial, Helvetica, sans-serif">30. Blier P, de Montigny C. Modification
    of 5-HT neuron properties by sustained administration of the 5-HT1A agonist 
   gepirone: electrophysiological studies in the rat brain. <I>Synapse</I> 1987;
    1: 470-480.    ^cY#6850.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#118#114#article#131# </font>      ^cY#68
50.htm##
00562000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704031700078002000900395#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#119#115#article#131#31#<P><f
ont face="Arial, Helvetica, sans-serif">31. Blatt GJ, Chen JC, Rosene DL,    Vol
icer L, Galler JR. Prenatal protein malnutrition effects on the serotonergic    
system in the hippocampal formation: an immunocytochemical, ligand binding,    a
nd neurochemical study. <I>Brain Res Bull</I> 1994; 34: 507-518.    ^cY#6850.htm
##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#120#116#article#131# </font>      ^cY#68
50.htm##
00522000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704027700078002000900355#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#121#117#article#131#32#<P><f
ont face="Arial, Helvetica, sans-serif">32. Keller EA, Cancela LM, Molina    VA,
 Orsingher OA. Lack of adaptive changes in 5-HT sites in perinatally undernouris
hed    rats after chronic stress: opioid influence. <I>Pharmacol Biochem Behav</
I>    1994; 47: 789-793.    ^cY#6850.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#122#118#article#131# </font>      ^cY#68
50.htm##
00479000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704023400078002000900312#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#123#119#article#131#33#<P><f
ont face="Arial, Helvetica, sans-serif">33. Almeida SS, de Oliveira LM, Graeff  
  FG. Decreased reactivity to anxiolytics caused by early protein malnutrition  
  in rats. <I>Pharmacol Biochem Behav</I> 1990; 36: 997-1000.    ^cY#6850.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#124#120#article#131# </font>      ^cY#68
50.htm##
00501000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704025600078002000900334#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#125#121#article#131#34#<P><f
ont face="Arial, Helvetica, sans-serif">34. Almeida SS, de Oliveira LM, Graeff  
  FG. Early life protein malnutrition changes exploration of the elevated plus-m
aze    and reactivity to anxiolytics. <I>Psychopharmacology </I>1991; 103: 513-5
18.    ^cY#6850.htm##
00251000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002100075002000900096#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#126#122#article#131#    </font>      ^cY
#6850.htm##
00551000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704030600078002000900384#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#127#123#article#131#35#<P><f
ont face="Arial, Helvetica, sans-serif">35. Lloyd KG, Zivkovic B, Sanger    D, D
epoortere H, Bartholini G. Fengabine, a novel antidepressant GABAergic agent.   
 I. Activity in models for antidepressant drugs and psychopharmacological profil
e.    <I>J Pharmacol Exp Ther</I> 1987; 241: 245-250.    ^cY#6850.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#128#124#article#131# </font>      ^cY#68
50.htm##
00450000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704020500078002000900283#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#129#125#article#131#36#<P><f
ont face="Arial, Helvetica, sans-serif">36. Sherman AD, Petty F. Neurochemical  
  basis of the action of antidepressants on learned helplessness. <I>Behav Neura
l    Biol</I> 1980; 30: 119-134.    ^cY#6850.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#130#126#article#131# </font>      ^cY#68
50.htm##
00424000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704017900078002000900257#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#p#131#127#article#131#37#<P><f
ont face="Arial, Helvetica, sans-serif">37. Petty F, Sherman AD. GABAergic    mo
dulation of learned helplessness. <I>Pharmacol Biochem Behav</I> 1981; 15:    56
7-570.    ^cY#6850.htm##
00281000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704005100075002000900126#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#132#128#article#131#</font>  <HR ALIGN=L
EFT WIDTH=100% SIZE=2>     ^cY#6850.htm##
00591000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704036100075002000900436#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#133#129#article#131#<P><FONT SIZE=4 face
="Arial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F
><B>Correspondence    and Footnotes</B></FONT></FONT> <font size="4" face="Arial
, Helvetica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/
back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A
></font></P>     ^cY#6850.htm##
00675000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704044500075002000900520#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#134#130#article#131#<p><font face="Arial
, Helvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v41n1/
recor.gif" width="15" height="14" border="0"></a>    Address for correspondence:
</b> S.S. Almeida, Departamento de Psicologia e Educa&ccedil;&atilde;o,    FFCLR
P, USP, Av. Bandeirantes, 3900, 14040-901 Ribeir&atilde;o Preto, SP, Brasil.    
Fax: +55-16-3602-4835. E-mail: <a href="mailto:sebasalm@usp.br">sebasalm@usp.br<
/a></font>  </p>     ^cY#6850.htm##
00535000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704030500075002000900380#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6850.htm#S#p#135#131#article#131#<P><font face="Arial
, Helvetica, sans-serif">Research supported by FAPESP (No.    02/05674-5) and CN
Pq (Nos. 470415/2003-7 and 411029/2003-7). S.S. Almeida was    the recipient of 
a research fellowship from CNPq (No. 351507/1996-5). Received    April 4, 2007. 
Accepted September 13, 2007 </font>      ^cY#6850.htm##
00591000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100017000920100
01700109012007800126030002200204065000900226064000500235031000300240014000800243
865000900251002000900260035001000269801002200279#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6850.htm#S#c#136#1#article#37#1#^rND^sAlmeida^nSS#^rND^sTonkiss^nJ#^r
ND^sGaller^nJR#Malnutrition and reactivity to drugs acting in the central nervou
s system^len#Neurosci Biobehav Rev#19960000#1996#20#389-402#20080100#6850.htm#01
49-7634#Neurosci Biobehav Rev##
00684000000000337000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100025000920100
01800117010001700135010002100152010001600173810000600189012005500195030002200250
06500090027206400050028103100030028601400070028986500090029600200090030503500100
0314801002200324#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#c#137#2#ar
ticle#37#2#^rND^sMorgane^nPJ#^rND^sAustin-LaFrance^nR#^rND^sBronzino^nJ#^rND^sTo
nkiss^nJ#^rND^sDíaz-Cintra^nS#^rND^sCintra^nL#et al#Prenatal malnutrition and de
velopment of the brain^len#Neurosci Biobehav Rev#19930000#1993#17#91-128#2008010
0#6850.htm#0149-7634#Neurosci Biobehav Rev##
00624000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100016000740100017000900120
10000107016001600207016002000223018004900243066000900292062001300301065000900314
064000500323865000900328002000900337#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
850.htm#S#c#138#3#article#37#3#^rND^sLevine^nS#^rND^sWeiner^nSG#Malnutrition and
 early environmental experience: possible interactive effects on later behavior^
len#^rND^sWalsh^nRN#^rND^sGreenough^nWT#Environment as therapy for brain dysfunc
tion^len#New York#Plenum Press#19760000#1976#20080100#6850.htm##
00563000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100019000740100017000930120
10700110030000800217065000900225064000500234031000400239014000600243865000900249
002000900258035001000267801000800277#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
850.htm#S#c#139#4#article#37#4#^rND^sLevitsky^nDA#^rND^sBarnes^nRH#Nutritional a
nd environmental interactions in the behavioral development of the rat: long-ter
m effects^len#Science#19720000#1972#176#68-71#20080100#6850.htm#0036-8075#Scienc
e##
00687000000000301000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100019000740100015000930100
01800108010002200126012013600148030002400284065000900308064000500317031000300322
014000800325865000900333002000900342035001000351801002400361#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6850.htm#S#c#140#5#article#37#5#^rND^sSantucci^nLB#^rND^s
Daud^nMM#^rND^sAlmeida^nSS#^rND^sde^nOliveira LM#Effects of early protein malnut
rition and environmental stimulation upon the reactivity to diazepam in two anim
al models of anxiety^len#Pharmacol Biochem Behav#19940000#1994#49#393-398#200801
00#6850.htm#0091-3057#Pharmacol Biochem Behav##
00604000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100019000920100
01700111012010300128030001500231065000900246064000500255031000300260014000800263
865000900271002000900280035001000289801001500299#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6850.htm#S#c#141#6#article#37#6#^rND^sMassaro^nTF#^rND^sLevitsky^nDA#
^rND^sBarnes^nRH#Protein malnutrition induced during gestation: its effect on pu
p development and maternal behavior^len#Dev Psychobiol#19770000#1977#10#339-345#
20080100#6850.htm#0012-1630#Dev Psychobiol##
00725000000000313000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100015000740100019000890100
01800108010002200126010001800148012015200166030002000318065000900338064000500347
031000300352014000800355865000900363002000900372035001000381801002000391#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#c#142#7#article#37#7#^rND^sRiul^nT
R#^rND^sCarvalho^nAF#^rND^sAlmeida^nPS#^rND^sDe-Oliveira^nLM#^rND^sAlmeida^nSS#E
thological analysis of mother-pup interactions and other behavioral reactions in
 rats: effects of malnutrition and tactile stimulation of the pups^len#Braz J Me
d Biol Res#19990000#1999#32#975-983#20080100#6850.htm#0100-879X#Braz J Med Biol 
Res##
00546000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100019000740100018000930100
01700111012005500128030000900183065000900192064000500201031000300206014001000209
865000900219002000900228035001000237801000900247#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6850.htm#S#c#143#8#article#37#8#^rND^sLevitsky^nDA#^rND^sMassaro^nTF#
^rND^sBarnes^nRH#Maternal malnutrition and the neonatal environment^len#Fed Proc
#19750000#1975#34#1583-1586#20080100#6850.htm#0014-9446#Fed Proc##
00627000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100014000740100017000880100
01700105012012700122030002000249065000900269064000500278031000200283014000400285
865000900289002000900298035001000307801002000317#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6850.htm#S#c#144#9#article#37#9#^rND^sSalt^nP#^rND^sGaller^nJR#^rND^s
Ramsey^nFC#The influence of early malnutrition on subsequent behavioral developm
ent. VII: The effects on maternal depressive symptoms^len#J Dev Behav Pediatr#19
880000#1988#9#1-5#20080100#6850.htm#0196-206X#J Dev Behav Pediatr##
00569000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100018000920100
01700110012007900127030001000206065000900216064000500225031000300230014000800233
865000900241002000900250035001000259801001000269#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6850.htm#S#c#145#10#article#37#10#^rND^sSmart^nJL#^rND^sWhatson^nTS#^
rND^sDobbing^nJ#Thresholds of response to electric shock in previously undernour
ished rats^len#Br J Nutr#19750000#1975#34#511-516#20080100#6850.htm#0007-1145#Br
 J Nutr##
00547000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760120111000910300
01400202065000900216064000500225031000300230014000600233865000900239002000900248
035001000257801001400267#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#c#
146#11#article#37#11#^rND^sLynch^nA#Passive avoidance behavior and response thre
sholds in adult male rats after early postnatal undernutrition^len#Physiol Behav
#19760000#1976#16#27-32#20080100#6850.htm#0031-9384#Physiol Behav##
00635000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100022000940100
02000116010001700136012008500153030002000238065000900258064000500267031000300272
014001000275865000900285002000900294035001000303801002000313#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6850.htm#S#c#147#12#article#37#12#^rND^sAlmeida^nSS#^rND^
sDe-Oliveira^nLM#^rND^sBichuette^nMZ#^rND^sGraeff^nFG#Early malnutrition alters 
the effect of chlordiazepoxide on inhibitory avoidance^len#Braz J Med Biol Res#1
9880000#1988#21#1033-1036#20080100#6850.htm#0100-879X#Braz J Med Biol Res##
00668000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940100
02000111010001700131010002200148012010100170030001400271065000900285064000500294
031000300299014001000302865000900312002000900321035001000330801001400340#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#c#148#13#article#37#13#^rND^sAlmei
da^nSS#^rND^sSoares^nEG#^rND^sBichuette^nMZ#^rND^sGraeff^nFG#^rND^sde^nOliveira 
LM#Effects of early postnatal malnutrition and chlordiazepoxide on experimental 
aversive situations^len#Physiol Behav#19920000#1992#51#1195-1199#20080100#6850.h
tm#0031-9384#Physiol Behav##
00472000000000253000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760120058000960300
01900154710000200173065000900175064000500184031000300189014000800192865000900200
002000900209#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#c#149#14#artic
le#37#14#^rND^sHunziker^nMHL#O desamparo aprendido revisitado: estudos com anima
is^len#Psicol Teor Pesqui#2#20050000#2005#21#131-139#20080100#6850.htm##
00495000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760120048000930300
01900141065000900160064000500169031000300174014000500177865000900182002000900191
035001000200801001900210#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#c#
150#15#article#37#15#^rND^sWillner^nP#The validity of animal models of depressio
n^len#Psychopharmacology#19840000#1984#83#1-16#20080100#6850.htm#0033-3158#Psych
opharmacology##
00504000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100016000950120
03800111030001400149065000900163064000500172031000300177014000400180865000900184
002000900193035001000202801001400212#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
850.htm#S#c#151#16#article#37#16#^rND^sSeligman^nME#^rND^sMaier^nSF#Failure to e
scape traumatic shock^len#J Exp Psychol#19670000#1967#74#1-9#20080100#6850.htm#0
022-1015#J Exp Psychol##
00523000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100020000920120
04600112030001800158065000900176064000500185031000400190014000500194865000900199
002000900208035001000217801001800227#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
850.htm#S#c#152#17#article#37#17#^rND^sMaier^nSF#^rND^sSeligman^nMEP#Learned hel
plessness: Theory and evidence^len#J Exp Psychol Gen#19760000#1976#105#3-46#2008
0100#6850.htm#0096-3445#J Exp Psychol Gen##
00579000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100019000930100
01700112012006500129030002000194065000900214064000500223031000300228014001000231
865000900241002000900250035001000259801002000269#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6850.htm#S#c#153#18#article#37#18#^rND^sGraeff^nEO#^rND^sHunziker^nMH
#^rND^sGraeff^nFG#Effects of ipsapirone and BAY R 1531 on learned helplessness^l
en#Braz J Med Biol Res#19890000#1989#22#1141-1144#20080100#6850.htm#0100-879X#Br
az J Med Biol Res##
00706000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100016000920100
01700108010001700125010002000142010001800162012011600180030001500296065000900311
06400050032003100040032501400080032986500090033700200090034603500100035580100150
0365#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#c#154#19#article#37#19
#^rND^sMaier^nSF#^rND^sGrahn^nRE#^rND^sKalman^nBA#^rND^sSutton^nLC#^rND^sWiertel
ak^nEP#^rND^sWatkins^nLR#The role of the amygdala and dorsal raphe nucleus in me
diating the behavioral consequences of inescapable shock^len#Behav Neurosci#1993
0000#1993#107#377-388#20080100#6850.htm#0735-7044#Behav Neurosci##
00579000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100016000910100
01600107010001600123012005500139030001500194065000900209064000500218031000300223
014000800226865000900234002000900243035001000252801001500262#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6850.htm#S#c#155#20#article#37#20#^rND^sPetty^nF#^rND^sKr
amer^nG#^rND^sWilson^nL#^rND^sJordan^nS#In vivo serotonin release and learned he
lplessness^len#Psychiatry Res#19940000#1994#52#285-293#20080100#6850.htm#0165-17
81#Psychiatry res##
00609000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100017000910100
01700108010001600125010001500141012006000156030001300216065000900229064000500238
031000300243014000800246865000900254002000900263035001000272801001300282#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#c#156#21#article#37#21#^rND^sKram^
nML#^rND^sKramer^nGL#^rND^sSteciuk^nM#^rND^sRonan^nPJ#^rND^sPetty^nF#Effects of 
learned helplessness on brain GABA receptors^len#Neurosci Res#20000000#2000#38#1
93-198#20080100#6850.htm#0168-0102#Neurosci Res##
00704000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100025000760100024001010100
02500125010002500150010002100175012010500196030001900301065000900320064000500329
031000300334014000600337865000900343002000900352035001000361801001900371#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#c#157#22#article#37#22#^rND^sDel^n
Angel-Meza AR#^rND^sRamirez-Cortes^nL#^rND^sAdame-Gonzalez^nIG#^rND^sGonzalez^nB
urgos I#^rND^sBeas-Zarate^nC#Cerebral GABA release and GAD activity in protein- 
and tryptophan-restricted rats during development^len#Int J Dev Neurosci#2002000
0#2002#20#47-54#20080100#6850.htm#0736-5748#Int J Dev Neurosci##
00589000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940100
01700111012007400128030002200202065000900224064000500233031000300238014000800241
865000900249002000900258035001000267801002200277#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6850.htm#S#c#158#23#article#37#23#^rND^sMorgane^nPJ#^rND^sMokler^nDJ#
^rND^sGaller^nJR#Effects of prenatal protein malnutrition on the hippocampal for
mation^len#Neurosci Biobehav Rev#20020000#2002#26#471-483#20080100#6850.htm#0149
-7634#Neurosci Biobehav Rev##
00581000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100017000930100
01600110012008400126030001400210065000900224064000500233031000300238014000800241
865000900249002000900258035001000267801001400277#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6850.htm#S#c#159#24#article#37#24#^rND^sClarke^nKA#^rND^sParker^nAJ#^
rND^sSmart^nJL#Analysis of walking locomotion in adult female rats undernourishe
d as sucklings^len#Physiol Behav#19920000#1992#52#823-826#20080100#6850.htm#0031
-9384#Physiol Behav##
00674000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100019000910100
01700110010001800127010001700145010001700162810000600179012005800185030002100243
06500090026406400050027303100030027801400060028186500090028700200090029603500100
0305801002100315#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#c#160#25#a
rticle#37#25#^rND^sLago^nES#^rND^sTeodosio^nNR#^rND^sAraujo^nCR#^rND^sAzevedo^nM
C#^rND^sPessoa^nDC#^rND^sCampos^nFA#et al#Rat models of protein and protein-ener
gy malnutrition^len#Int J Vitam Nutr Res#19930000#1993#63#52-56#20080100#6850.ht
m#0300-9831#Int J Vitam Nutr Res##
00453000000000253000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760120042000930300
02000135710000200155065000900157064000500166031000200171014000800173865000900181
002000900190#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#c#161#26#artic
le#37#26#^rND^sCasper^nRC#Nutrients, neurodevelopment, and mood^len#Curr Psychia
try Rep#2#20040000#2004#6#425-429#20080100#6850.htm##
00498000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760120053000940300
01600147065000900163064000500172031000300177014000800180865000900188002000900197
035001000206801001600216#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#c#
162#27#article#37#27#^rND^sTiemeier^nH#Biological risk factors for late life dep
ression^len#Eur J Epidemiol#20030000#2003#18#745-750#20080100#6850.htm#0392-2990
#Eur J Epidemiol##
00612000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100018000920120
12300110030002400233065000900257064000500266031000300271014000800274865000900282
002000900291035001000300801002400310#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
850.htm#S#c#163#28#article#37#28#^rND^sSilva^nRC#^rND^sBrandão^nML#Acute and chr
onic effects of gepirone and fluoxetine in rats tested in the elevated plus-maze
: an ethological analysis^len#Pharmacol Biochem Behav#20000000#2000#65#209-216#2
0080100#6850.htm#0091-3057#Pharmacol Biochem Behav##
00541000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100015000910120
07200106030001600178065000900194064000500203031000300208014000800211865000900219
002000900228035001000237801001600247#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
850.htm#S#c#164#29#article#37#29#^rND^sBlier^nP#^rND^sWard^nNM#Is there a role f
or 5-HT1A agonists in the treatment of depression?^len#Biol Psychiatry#20030000#
2003#53#193-203#20080100#6850.htm#0006-3223#Biol Psychiatry##
00607000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100021000910120
14900112030000800261065000900269064000500278031000200283014000800285865000900293
002000900302035001000311801000800321#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
850.htm#S#c#165#30#article#37#30#^rND^sBlier^nP#^rND^sde^nMontigny C#Modificatio
n of 5-HT neuron properties by sustained administration of the 5-HT1A agonist ge
pirone: electrophysiological studies in the rat brain^len#Synapse#19870000#1987#
1#470-480#20080100#6850.htm#0196-5565#SYNAPSE##
00717000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100015000920100
01700107010001700124010001700141012016200158030001500320065000900335064000500344
031000300349014000800352865000900360002000900369035001000378801001500388#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6850.htm#S#c#166#31#article#37#31#^rND^sBlatt
^nGJ#^rND^sChen^nJC#^rND^sRosene^nDL#^rND^sVolicer^nL#^rND^sGaller^nJR#Prenatal 
protein malnutrition effects on the serotonergic system in the hippocampal forma
tion: an immunocytochemical, ligand binding, and neurochemical study^len#Brain R
es Bull#19940000#1994#34#507-518#20080100#6850.htm#0361-9230#Brain Res Bull##
00668000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100018000930100
01700111010002000128012011700148030002400265065000900289064000500298031000300303
014000800306865000900314002000900323035001000332801002400342#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6850.htm#S#c#167#32#article#37#32#^rND^sKeller^nEA#^rND^s
Cancela^nLM#^rND^sMolina^nVA#^rND^sOrsingher^nOA#Lack of adaptive changes in 5-H
T sites in perinatally undernourished rats after chronic stress: opioid influenc
e^len#Pharmacol Biochem Behav#19940000#1994#47#789-793#20080100#6850.htm#0091-30
57#Pharmacol Biochem Behav##
00610000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100022000940100
01700116012008500133030002400218065000900242064000500251031000300256014000900259
865000900268002000900277035001000286801002400296#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6850.htm#S#c#168#33#article#37#33#^rND^sAlmeida^nSS#^rND^sde^nOliveir
a LM#^rND^sGraeff^nFG#Decreased reactivity to anxiolytics caused by early protei
n malnutrition in rats^len#Pharmacol Biochem Behav#19900000#1990#36#997-1000#200
80100#6850.htm#0091-3057#Pharmacol Biochem Behav##
00627000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100022000940100
01700116012011200133030001900245065000900264064000500273031000400278014000800282
865000900290002000900299035001000308801001900318#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6850.htm#S#c#169#34#article#37#34#^rND^sAlmeida^nSS#^rND^sde^nOliveir
a LM#^rND^sGraeff^nFG#Early life protein malnutrition changes exploration of the
 elevated plus-maze and reactivity to anxiolytics^len#Psychopharmacology#1991000
0#1991#103#513-518#20080100#6850.htm#0033-3158#Psychopharmacology##
00671000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100018000920100
01600110010002000126010002000146012005700166030010000223710000200323065000900325
064000500334031000400339014000800343865000900351002000900360#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6850.htm#S#c#170#35#article#37#35#^rND^sLloyd^nKG#^rND^sZ
ivkovic^nB#^rND^sSanger^nD#^rND^sDepoortere^nH#^rND^sBartholini^nG#Fengabine, a 
novel antidepressant GABAergic agent: I^len#Activity in models for antidepressan
t drugs and psychopharmacological profile. J Pharmacol Exp Ther#2#19870000#1987#
241#245-250#20080100#6850.htm##
00557000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100015000940120
08100109030001800190065000900208064000500217031000300222014000800225865000900233
002000900242035001000251801001800261#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
850.htm#S#c#171#36#article#37#36#^rND^sSherman^nAD#^rND^sPetty^nF#Neurochemical 
basis of the action of antidepressants on learned helplessness^len#Behav Neural 
Biol#19800000#1980#30#119-134#20080100#6850.htm#0163-1047#Behav Neural Biol##
00537000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100018000910120
04900109030002400158065000900182064000500191031000300196014000800199865000900207
002000900216035001000225801002400235#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
850.htm#S#c#172#37#article#37#37#^rND^sPetty^nF#^rND^sSherman^nAD#GABAergic modu
lation of learned helplessness^len#Pharmacol Biochem Behav#19810000#1981#15#567-
570#20080100#6850.htm#0091-3057#Pharmacol Biochem Behav##
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#o#1#1#article#1#20
080623#161511#6859.htm#102##
02179000000000541000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000900093158000300102030002000105
03100030012503200020012806500090013001400070013903500100014622300090015601201230
01650100025002880700150003130830889004630850008013520850042013600850025014020850
02201427085002901449085003501478085003001513117000601543072000301549112000901552
111001501561114000901576113001901585881002401604002000901628#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6859.htm#S#h#2#1#article#1#co#en#bjmbr#1#3.1#ND#01#BJMBR0
30#nd#Braz J Med Biol Res#41#1#20080100#^f1^l4#0100-879X#20071217#Connections: c
an the 20th century coronary heart disease epidemic reveal something about the 1
918 influenza lethality?^len#^rND^1A01^nM.I^sAzambuja#Universidade Federal do Ri
o Grande do Sul^iA01^1Programa de Pós-Graduação em Epidemiologia, Departamento d
e Medicina Social^cPorto Alegre^sRS^pBrasil#^len^aThis essay proposes that the e
cologic association shown between the 20th century coronary heart disease epidem
ic and the 1918 influenza pandemic could shed light on the mechanism associated 
with the high lethality of the latter. It suggests that an autoimmune interferen
ce at the apoB-LDL interface could explain both hypercholesterolemia and inflamm
ation (through interference with the cellular metabolism of arachidonic acid). A
utoimmune inflammation, then, would explain the 1950s-60s acute coronary events 
(coronary thrombosis upon influenza re-infection) and the respiratory failure se
en among young adults in 1918. This hypothesis also argues that the lethality of
 the 1918 pandemic may have not depended so much on the 1918 virus as on an immu
ne vulnerability to it, possibly resulting from an earlier priming of cohorts bo
rn around 1890 by the 1890 influenza pandemic virus.#^dnd^i1#^tm^len^kRespirator
y distress syndrome^i1#^tm^len^kAutoimmunity^i1#^tm^len^kInfluenza^i1#^tm^len^kC
oronary disease^i1#^tm^len^kDisease susceptibility^i1#^tm^len^kDisease outbreaks
^i1#other#29#20070413#April 13, 2007#20070917#September 17, 2007#S0100-879X20060
05000192#6859.htm##
02157000000000529000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000900093158000300102030002000105
03100030012503200020012806500090013001400070013903500100014622300090015601201370
01650100025003020700150003270830889004770850008013660850042013740850025014160850
02201441085002901463085003501492085003001527117000601557072000301563112000901566
111001501575114000901590113001901599002000901618#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6859.htm#S#f#3#1#article#1#co#en#bjmbr#1#3.1#ND#01#BJMBR030#nd#Braz J
 Med Biol Res#41#1#20080100#^f1^l4#0100-879X#20071217#<B>Connections</B>: <B>can
 the 20th century coronary heart disease epidemic reveal something about the 191
8 influenza lethality?</B>^len#^rND^1A01^nM.I^sAzambuja#Universidade Federal do 
Rio Grande do Sul^iA01^1Programa de Pós-Graduação em Epidemiologia, Departamento
 de Medicina Social^cPorto Alegre^sRS^pBrasil#^len^aThis essay proposes that the
 ecologic association shown between the 20th century coronary heart disease epid
emic and the 1918 influenza pandemic could shed light on the mechanism associate
d with the high lethality of the latter. It suggests that an autoimmune interfer
ence at the apoB-LDL interface could explain both hypercholesterolemia and infla
mmation (through interference with the cellular metabolism of arachidonic acid).
 Autoimmune inflammation, then, would explain the 1950s-60s acute coronary event
s (coronary thrombosis upon influenza re-infection) and the respiratory failure 
seen among young adults in 1918. This hypothesis also argues that the lethality 
of the 1918 pandemic may have not depended so much on the 1918 virus as on an im
mune vulnerability to it, possibly resulting from an earlier priming of cohorts 
born around 1890 by the 1890 influenza pandemic virus.#^dnd^i1#^tm^len^kRespirat
ory distress syndrome^i1#^tm^len^kAutoimmunity^i1#^tm^len^kInfluenza^i1#^tm^len^
kCoronary disease^i1#^tm^len^kDisease susceptibility^i1#^tm^len^kDisease outbrea
ks^i1#other#29#20070413#April 13, 2007#20070917#September 17, 2007#6859.htm##
02261000000000541000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640013000690710003000820400003000850010
00600088042000200094120000400096121000300100049000900103158000300112030002400115
03100030013903200020014206500090014401400070015303500100016022300090017001201230
01790100026003020700152003280830889004800850008013690850042013770850025014190850
02201444085002901466085003501495085003001530117000601560072000301566112000901569
111001501578114000901593113001901602002000901621008008901630#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6859.htm#S#l#4#1#article#1#^mJan.^a2008#co#en#bjmbr#1#3.1
#01#BJMBR030#nd#Braz. j. med. biol. res#41#1#20080100#^f1^l4#0100-879X#20071217#
Connections: can the 20th century coronary heart disease epidemic reveal somethi
ng about the 1918 influenza lethality?^len#^rND^1A01^nM. I^sAzambuja#^iA01^1Univ
ersidade Federal do Rio Grande do Sul^2Programa de Pós-Graduação em Epidemiologi
a, Departamento de Medicina Social^cPorto Alegre^sRS^pBrasil#^len^aThis essay pr
oposes that the ecologic association shown between the 20th century coronary hea
rt disease epidemic and the 1918 influenza pandemic could shed light on the mech
anism associated with the high lethality of the latter. It suggests that an auto
immune interference at the apoB-LDL interface could explain both hypercholestero
lemia and inflammation (through interference with the cellular metabolism of ara
chidonic acid). Autoimmune inflammation, then, would explain the 1950s-60s acute
 coronary events (coronary thrombosis upon influenza re-infection) and the respi
ratory failure seen among young adults in 1918. This hypothesis also argues that
 the lethality of the 1918 pandemic may have not depended so much on the 1918 vi
rus as on an immune vulnerability to it, possibly resulting from an earlier prim
ing of cohorts born around 1890 by the 1890 influenza pandemic virus.#^dnd^i1#^t
m^len^kRespiratory distress syndrome^i1#^tm^len^kAutoimmunity^i1#^tm^len^kInflue
nza^i1#^tm^len^kCoronary disease^i1#^tm^len^kDisease susceptibility^i1#^tm^len^k
Disease outbreaks^i1#other#29#20070413#April 13, 2007#20070917#September 17, 200
7#6859.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S010
0-879X2008000100001##
00410000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704018500070002000900255#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#5#1#article#69#<P class="style4"> <font 
face="Arial, Helvetica, sans-serif"><A NAME="Home"></A><B>Braz    J Med Biol Res
, January 2008, Volume 41(1) 1-4 (Concepts and Comments)</B></font></P>     ^cY#
6859.htm##
00446000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704022100070002000900291#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#6#2#article#69#<P class="style2"><B><fon
t size="5" face="Arial, Helvetica, sans-serif">Connections:    can the 20th cent
ury coronary heart disease epidemic reveal something about    the 1918 influenza
 lethality?</font></B> </P>     ^cY#6859.htm##
00626000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704040100070002000900471#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#7#3#article#69#<P><font face="Arial, Hel
vetica, sans-serif"><span class="style4"><a href="#Correspondence"><img src="/im
g/revistas/bjmbr/v41n1/recor.gif" width="15" height="14" border="0"></a>    <a h
ref="mailto:miazambuja@terra.com.br"><img src="/img/revistas/bjmbr/v41n1/email-c
a.gif" width="14" height="11" border="0"></a></span></font>    <font face="Arial
, Helvetica, sans-serif">M.I. Azambuja </font>      ^cY#6859.htm##
00459000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704023400070002000900304#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#8#4#article#69#<P><font face="Arial, Hel
vetica, sans-serif">Programa de P&oacute;s-Gradua&ccedil;&atilde;o    em Epidemi
ologia, Departamento de Medicina Social, Universidade Federal do Rio    Grande d
o Sul, Porto Alegre, RS, Brasil </font>      ^cY#6859.htm##
00525000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704030000070002000900370#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#9#5#article#69#<P class="style4"> <A HRE
F="#Abstract"><font face="Arial, Helvetica, sans-serif"><IMG SRC="/img/revistas/
bjmbr/v41n1/down.gif" ALIGN=BOTTOM WIDTH=12 HEIGHT=12 BORDER=0 VSPACE=0 HSPACE=0
></font></A>    <font face="Arial, Helvetica, sans-serif"><A HREF="#Abstract"><s
trong>Abstract</strong></A>    ^cY#6859.htm##
00415000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704018900071002000900260#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#10#6#article#69#<BR>   <A HREF="#Text"><
IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPA
CE=0 width="12" height="12"></A>    <A HREF="#Text"><strong>Text</strong></A>   
 ^cY#6859.htm##
00420000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704019400071002000900265#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#11#7#article#69#<BR>   <A HREF="#Referen
ces"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=
0 HSPACE=0 width="12" height="12"></A>    <A HREF="#References"><strong>Referenc
es    ^cY#6859.htm##
00520000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704029400071002000900365#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#12#8#article#69#<br>   </strong></A> <A 
HREF="#Correspondence"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTO
M BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Correspond
ence"><strong>Correspondence and Footnotes</strong></a>    </font>  <HR ALIGN=LE
FT WIDTH=100% SIZE=2>     ^cY#6859.htm##
00621000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704039500071002000900466#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#13#9#article#69#<P class="style4"> <A NA
ME="Abstract"></A><strong><span class="style3"><FONT COLOR=#00007F size="4" face
="Arial, Helvetica, sans-serif">Abstract    </FONT></span></strong><A HREF="#Hom
e"><FONT SIZE=4><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIGN=BOTTOM BO
RDER=0 VSPACE=0 HSPACE=0 LOOP="0" width="12" height="12"></B></FONT></A>  </P> <
font face="Arial, Helvetica, sans-serif">      ^cY#6859.htm##
01155000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704092800072002000901000#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#14#10#article#69#<P>This essay proposes 
that the ecologic association shown between the 20th century    coronary heart d
isease epidemic and the 1918 influenza pandemic could shed light    on the mecha
nism associated with the high lethality of the latter. It suggests    that an au
toimmune interference at the apoB-LDL interface could explain both    hyperchole
sterolemia and inflammation (through interference with the cellular    metabolis
m of arachidonic acid). Autoimmune inflammation, then, would explain    the 1950
s-60s acute coronary events (coronary thrombosis upon influenza re-infection)   
 and the respiratory failure seen among young adults in 1918. This hypothesis   
 also argues that the lethality of the 1918 pandemic may have not depended so   
 much on the 1918 virus as on an immune vulnerability to it, possibly resulting 
   from an earlier priming of cohorts born around 1890 by the 1890 influenza pan
demic    virus.      ^cY#6859.htm##
00412000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704018500072002000900257#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#15#11#article#69#<P>Key words: Respirato
ry distress syndrome; Autoimmunity; Influenza; Coronary    disease; Disease susc
eptibility; Disease outbreaks  </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^c
Y#6859.htm##
00613000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038600072002000900458#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#16#12#article#69#<P class="style4"><A NA
ME="Text"></A><strong><span class="style3"><FONT COLOR=#00007F size="4" face="Ar
ial, Helvetica, sans-serif">Text    </FONT></span></strong><A HREF="#Home"><FONT
 SIZE=4><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIGN=BOTTOM BORDER=0 V
SPACE=0 HSPACE=0 LOOP="0" width="12" height="12"></B></FONT></A>  </P> <font fac
e="Arial, Helvetica, sans-serif">      ^cY#6859.htm##
01932000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704170500072002000901777#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#17#13#article#69#<P>We may be living in 
revolutionary times in the field of biological sciences.    As stated by Goldenf
eld and Woese (1) referring to the evidence of horizontal    gene-swapping withi
n microbe collectives, &quot;molecular reductionism that    dominated the 20th c
entury biology will be superseded by an interdisciplinary    approach that embra
ces collective phenomena (p. 369)&quot;. Also the growing    recognition of the 
co-construction of both life and its environment at the molecular    (2), organi
sm (3-5) and population (6) levels, increasingly frames such collective    pheno
mena as contextual. According to Gould (6), the events of our complex natural   
 world always result from particular historical sequences that &quot;unfurl alon
g    the pathways actually followed, rather than along any of the myriad equally
    plausible alternatives (p. 36)&quot;. Science always mistrusted and downgrad
ed    contingent events. The experimental methodology and the &quot;laws of natu
re&quot;    type of explanations assumed such a paradigmatic strength in science
 as to be    considered the sole representatives of the true scientific endeavor
. But, according    to Gould, the contingency's domain needs to be recognized in
 its true dimension:    one as broad and important as anything deducible from na
tural law. &quot;Contingent    events, though unpredictable at the onset of a se
quence, are as explainable    as any other phenomena after they occur. The expla
nations as contingent rather    than law-based do require a knowledge of the par
ticular historical sequence    that generated the result, for such resolutions m
ust be in the narrative rather    than deductive model (6, p. 36)&quot;.      ^c
Y#6859.htm##
00755000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704052800072002000900600#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#18#14#article#69#<P>Traditional epidemio
logy - the one practiced until the 1940s-50s and defined    by Kuller (7) as &qu
ot;the study of epidemics and their prevention (p. 1051)&quot;    - was conceive
d as a way to investigate contingent events, with the purpose    of preventing s
imilar occurrences in the future: &quot;Epidemiology was 1) the    study of epid
emics (contingent events) in relation to time, place and person;    2) built on 
a strong biological rationale, and 3) the basic science of public    health (7, 
p. 1051)&quot;.      ^cY#6859.htm##
00676000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704044900072002000900521#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#19#15#article#69#<P>Epidemics are unique
 events with respect not only to the environmental challenge    initiating them,
 but also to the circumstantial pattern of resistance/vulnerability    (for the 
lack of a better concept) of the exposed population, built during the    course 
of all previous nature-nurture interactions taking place on and across    its se
veral levels of organization (molecular, individual and collective) along    tim
e (history) (8).      ^cY#6859.htm##
01055000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704082800072002000900900#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#20#16#article#69#<P>The 1918 influenza p
andemic was unusually severe, causing about 40 million    deaths around the worl
d. Its high level of lethality has been attributed to    the virus itself (9,10)
. However, this interpretation is not consistent with    the contextual nature o
f a new biology. If context is indeed important, the    1918 phenomenon must hav
e resulted from a convergence between the virus and    a particular pattern of p
opulation vulnerability to it. Supporting this claim    is the unusual concentra
tion of high rates of lethality among young adults found    during that period (
11). Since we would not know how to identify vulnerability    to the virus at th
e individual level, we would need to look for clues as to    its distribution at
 the only place they might be found, i.e., at the population    level (12).     
 ^cY#6859.htm##
00579000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704035200072002000900424#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#21#17#article#69#<P>Based on this ration
ale, it would make sense to investigate the mechanism resulting    in the 1918 i
nfluenza lethality by looking at another collective phenomenon    proposed to be
 associated with the vulnerability of the 1918 population to the    influenza vi
rus, i.e., the 20th century coronary heart disease (CHD) epidemic    (8,13-15). 
     ^cY#6859.htm##
01208000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704098100072002000901053#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#22#18#article#69#<P>Wade Hampton Frost (
16), a leading epidemiologist of the US Public Health Service,    wrote in 1927:
 &quot;The opinion is more or less prevalent that inferences based    upon epide
miological argument cannot be truly conclusive, because the evidence    is purel
y circumstantial. Such opinion has frequently failed to take account    of the w
hole mass of evidence, and to follow the argument which is necessary    built up
 step by step in a somewhat complex and perhaps tedious way. Given sufficient   
 scope and accuracy of observations, a conclusion as to the nature and spread   
 of a disease may often be established quite firmly by circumstantial evidence  
  well in advance of experimental confirmation... The weakness in conclusions   
 drawn from circumstantial studies is usually chargeable not to basic defects   
 in the methods of investigation, but more often to paucity or inaccuracy of    
data, or faults of logic in their interpretation (16, p. 190)&quot;.      ^cY#68
59.htm##
00630000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704040300072002000900475#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#23#19#article#69#<P>Following Frost's le
ad, the idea is that the clues regarding this epidemiologic    association toget
her with a strong biologic rationale - drawn, by analogy, from    evidence repor
ted in the literature - could shed light on the mechanism responsible    for the
 influenza lethality in advance of experimental confirmation. It is left    to t
he reader to judge the results of this enterprise.      ^cY#6859.htm##
00844000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704061700072002000900689#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#24#20#article#69#<P>It was first propose
d in 1994 (13) that a cohort association existed between    rates of vulnerabili
ty to influenza deaths in 1918 and CHD mortality among survivors    from those v
ulnerable birth cohorts. According to this hypothesis, hypercholesterolemia    -
 the hallmark of CHD cases in the 1950s and 60s - may have been an effect second
ary    to the influenza priming of 1918 vulnerable individuals for late developm
ent    of CHD. CHD deaths, however, were probably associated with bursts of auto
-immune    endothelial inflammation and thrombosis associated with influenza re-
infections    (8,14,15).      ^cY#6859.htm##
00538000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704031100072002000900383#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#25#21#article#69#<P>Mimicry between the 
amino acid sequences involved in cell attachment of the    viral hemagglutinin a
nd those of apolipoprotein B (apoB) involved in the low-density    lipoproteins 
(LDL) binding to high affinity LDL receptors (LDLR) has been described    in som
e strains of the influenza virus (17).      ^cY#6859.htm##
00592000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704036500072002000900437#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#26#22#article#69#<P>An autoimmune interf
erence at the apoB-LDLR interface might explain the development    of hyperchole
sterolemia. In familial hypercholesterolemia, raised serum LDL    cholesterol le
vels result from an interference in the LDLR pathway, commonly    caused by a lo
ss of function mutation in the LDLR gene or by a mutation in the    gene encodin
g apoB (18).      ^cY#6859.htm##
00644000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704041700072002000900489#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#27#23#article#69#<P>Also, cross-reactive
 auto-antibodies directed against the apoB-LDLR interface    could lead to sub-e
ndothelial co-accumulation of lipids and immune products,    and result in lipid
 peroxidation. This sequence of events has been fully demonstrated    in cases o
f Heymann nephritis, an autoimmune disease in which the main auto-antibodies    
target (megalin/gp330) is also a member of the LDLR family (19).      ^cY#6859.h
tm##
00729000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704050200072002000900574#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#28#24#article#69#<P>Thus, it would be po
ssible that, in vulnerable individuals, cross-reactive    auto-antibodies (and T
 cells) diverted to the apoB-LDLR interface, first elicited    by the 1918 influ
enza infection and recalled upon influenza reinfections of    1918 primed indivi
duals, resulted in elevated serum cholesterol levels (aggravated    by high-fat 
diets) and lipid deposits co-localized at sites of viral penetration:    the lef
t side of the heart, coronary arteries and the aortic arch (8,14,15).      ^cY#6
859.htm##
00554000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704032700072002000900399#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#29#25#article#69#<P>But what would the m
echanism initiating the autoimmune endothelial inflammation    and thrombosis re
sulting in the high CHD lethality observed during the 1950s    and 1960s influen
za epidemics be? And could it give us a clue as to the mechanism    responsible 
for the high lethality of the 1918 influenza pandemic?      ^cY#6859.htm##
00720000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704049300072002000900565#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#30#26#article#69#<P>The recent discussio
n about untoward cardiovascular effects of selective anti-inflammatory    drugs 
has taught us about an important group of inflammatory mediators associated    w
ith vascular homeostasis, i.e., the cyclooxygenase (COX) products (20). COX    i
s the rate-limiting enzyme in the synthesis of prostaglandins (PG) from free    
arachidonic acid (AA). It exists as two isoforms, COX-1 (mostly constitutive)   
 and COX-2 (mostly inducible in pathologic situations) (20).      ^cY#6859.htm##
00721000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704049400072002000900566#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#31#27#article#69#<P>In 1988, Krone et al
. (21) showed that PGE1, PGE2, and prostacyclin (PGI2)    affected the LDLR acti
vity and cholesterol synthesis in isolated mononuclear    leukocytes. In 2002, S
mith et al. (22) showed that, in cultured endothelial    cells, PGI2 formation i
s regulated by LDL cholesterol levels. Both findings    reinforce the suggestion
 made by Salbach et al. (23) in 1991 of a new role for    the LDLR, the regulati
on of cellular levels of free AA, and hence, of PG synthesis.      ^cY#6859.htm#
#
01001000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704077400072002000900846#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#32#28#article#69#<P>The LDLR AA pathway 
does appear to couple directly to the PGH synthase reaction,    but not to the 5
-lipoxygenase (5-LOX) reaction (24). Thus, upon re-infection,    an interference
 on this pathway could result in a LOX-COX products imbalance.    Interestingly,
 polymorphism studies of the gene ALOX5AP (which encodes the 5-LOX-activating   
 protein) have shown that variants of this gene are associated with twice the   
 risk of developing myocardial infarction and stroke. These high-risk variants  
  are associated with increased production of leukotriene B4 - a key product of 
   the 5-LOX pathway (25). It is possible that any imbalance in favor of 5-LOX  
  products, irrespective of its cause, increases the risk of vascular inflammati
on    and thrombosis.      ^cY#6859.htm##
01007000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704078000072002000900852#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#33#29#article#69#<P>If the experimental 
evidence suggests that: a) LDLR has a role both in the    cellular cholesterol m
etabolism (18,19) and in the regulation of PG synthesis    (21-23), b) cross-rea
ctive autoimmunity may target members of the LDLR family    (19), and c) mimicry
 may exist between amino acid sequences involved in cell    attachment of the vi
ral hemagglutinin and those of apoB involved in LDL binding    to high affinity 
LDLR (17), then a cross-reactive autoimmune response that targets    the LDLR-ap
oB interface could explain not only the cholesterol-related features    of the a
therosclerotic process, but also the thrombotic component of the atheroma,    wh
ich was proposed by Morris (26,27) in 1951 to be the main factor responsible    
for the CHD-related events.      ^cY#6859.htm##
01170000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704094300072002000901015#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#34#30#article#69#<P>Furthermore, as we w
ill see, the same interference could be implicated in the    immunopathogenic re
sponse to the 1918 influenza infection. Recently, COX-1 and    COX-2 enzyme conc
entrations were shown to have significant effects on the host    response to inf
luenza A viral infection (28). Among other findings, the authors    described a 
marked elevation of lung viral titers in COX-2<SUP>-/-</SUP> mice    relative to
 wild-type and COX-1<SUP>-/-</SUP> mice on day 4 of infection (28).    This rese
mbles the unabated load of viral antigens in lungs of 1918 virus-infected    mon
keys by day 6, compared to no viral antigen expression in K173 virus-infected   
 animals, recently described by Kobasa et al. (10). The whole picture of antivir
al    response dysregulation in macaques infected with the 1918 influenza virus 
(10)    is highly suggestive of an imbalance in COX products expected to modulat
e the    inflammatory process.      ^cY#6859.htm##
01053000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704082600072002000900898#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#35#31#article#69#<P>Thus, available expe
rimental evidence supports the epidemiologic hypothesis    of association betwee
n the 1918 influenza lethality and the 20th century CHD    mortality. Or, conver
sely, the (epidemiologic) cohort association shown to exist    between the 1918 
influenza lethality and the 20th century CHD mortality suggests    a common mech
anism for both events, i.e, an interference at the apoB-LDL interface,    possib
ly autoimmune and restricted to some particularly vulnerable birth cohorts.    S
uch interference would explain the high serum cholesterol levels characteristic 
   of CHD cases occurring at the height of the CHD epidemic, the thrombosis foun
d    in association with sudden unexpected CHD deaths in the 1950s (reinfection-
related?),    and also the high lethality of the 1918 influenza epidemic.      ^
cY#6859.htm##
01132000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704090500072002000900977#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#36#32#article#69#<P>The cause of the hig
h vulnerability of the 1918 young adults to autoimmunity    and high lethality i
n 1918 and to high CHD mortality in the years to come would    still remain unex
plained. An interesting possibility would be that their particular    cohort vul
nerability had been initiated many years earlier, when they first    encountered
 an influenza virus, which, in their case, was possibly the virus    associated 
with the 1890 influenza pandemic. Recently, it was shown that hidden    epitopes
 may emerge after a secondary challenge with an influenza virus, which    may sw
itch protective immunity to an alternative antibody-mediated pathway (29).    Th
us, it would be possible that the high pathogenicity of the influenza infection 
   registered among young adults in 1918 resulted from an immune response that  
  went awry among those individuals originally primed by the 1890 virus.      ^c
Y#6859.htm##
00527000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704030000072002000900372#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#37#33#article#69#<P>A historically built
 vulnerability of particular birth cohorts to death during    the 1918 influenza
 pandemic and, later on, to death from CHD (coronary thrombosis)    upon influen
za reinfection would be a strong argument in favor of a new biology,    understo
od as a contextual science.      ^cY#6859.htm##
00994000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704076700072002000900839#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#38#34#article#69#<P>This paper demonstra
tes the relevance of epidemiology, here understood as a    discipline engaged in
 the study of collective, contextual phenomena, either    as a source of hypothe
ses (like the association between the 1918 influenza pandemic    and the CHD epi
demic, and between the 1918 lethality and earlier priming by    the 1890 influen
za virus) or as a checking point to which knowledge produced    at the individua
l and sub-individual levels needs to conform (and vice versa).    Making connect
ions between the different levels of biologic organization and    knowledge with
in a contextual framework may be the formula needed to escape    the 20th centur
y reductionism and to advance biological knowledge.  </font>  <HR ALIGN=LEFT WID
TH=100% SIZE=2>     ^cY#6859.htm##
00588000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704036100072002000900433#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#39#35#article#69#<P class="style4"> <A N
AME="References"></A><FONT color="#00007F" SIZE=4 face="Arial, Helvetica, sans-s
erif"><B>References</B></FONT>    <A HREF="#Home"><FONT SIZE=4><B><IMG SRC="/img
/revistas/bjmbr/v41n1/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"
 width="12" height="12"></B></FONT></A>  </P> <font face="Arial, Helvetica, sans
-serif">      ^cY#6859.htm##
00337000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704009600074002000900170#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#p#40#36#article#69#1#<P>1. Gol
denfeld N, Woese C. Biology's next revolution. <I>Nature</I> 2007; 445:    369. 
   ^cY#6859.htm##
00347000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704010600074002000900180#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#p#41#37#article#69#2#<P>2. Kau
ffman SA. Prolegomenon to a general biology. <I>Ann N Y Acad Sci</I>    2001; 93
5: 18-36.    ^cY#6859.htm##
00369000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704012800074002000900202#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#p#42#38#article#69#3#<P>3. Lew
ontin R. <I>The triple helix. Gene, organism and environment</I>. Cambridge:    
Harvard University Press; 2001.    ^cY#6859.htm##
00357000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704011600074002000900190#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#p#43#39#article#69#4#<P>4. Mea
ney MJ. Nature, nurture, and the disunity of knowledge. <I>Ann NY Acad    Sci</I
> 2001; 935: 50-61.    ^cY#6859.htm##
00401000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704016000074002000900234#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#p#44#40#article#69#5#<P>5. Tau
ber AI. <I>The immune self: theory or metaphor? Cambridge studies in    philosop
hy and biology</I>. New York: Cambridge University Press; 1997.    ^cY#6859.htm#
#
00498000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704025700074002000900331#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#p#45#41#article#69#6#<P>6. Gou
ld SJ. &quot;What is life?&quot; as a problem in history. In: Murphy    MP, O'Ne
ill LAJ (Editors), <I>What is life? The next fifty years. Speculations    on the
 future of biology</I>. Cambridge: Cambridge University Press; 1995. p    25-39.
    ^cY#6859.htm##
00385000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704014400074002000900218#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#p#46#42#article#69#7#<P>7. Kul
ler LH. Epidemiology is the study of &quot;epidemics&quot; and their    preventi
on. <I>Am J Epidemiol</I> 1991; 134: 1051-1056.    ^cY#6859.htm##
00430000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704018900074002000900263#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#p#47#43#article#69#8#<P>8. Aza
mbuja MI, Levins R. Coronary heart disease (CHD) - one or several diseases?    C
hanges in the prevalence and features of CHD. <I>Perspect Biol Med</I> 2007;    
50: 228-242.    ^cY#6859.htm##
00467000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704022600074002000900300#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#p#48#44#article#69#9#<P>9. Kas
h JC, Tumpey TM, Proll SC, Carter V, Perwitasari O, Thomas MJ, et al.    Genomic
 analysis of increased host immune and cell death responses induced by    1918 i
nfluenza virus. <I>Nature</I> 2006; 443: 578-581.    ^cY#6859.htm##
00457000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704021500075002000900290#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#p#49#45#article#69#10#<P>10. K
obasa D, Jones SM, Shinya K, Kash JC, Copps J, Ebihara H, et al. Aberrant    inn
ate immune response in lethal infection of macaques with the 1918 influenza    v
irus. <I>Nature</I> 2007; 445: 319-323.    ^cY#6859.htm##
00471000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022900075002000900304#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#p#50#46#article#69#11#<P>11. C
ollins SD. Age and sex incidence of influenza and pneumonia morbidity    and mor
tality in the epidemic of 1928-29 with comparative data for the epidemic    of 1
918-19. <I>Public Health Rep</I> 1931; 46: 1909-1937.    ^cY#6859.htm##
00413000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704017100075002000900246#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#p#51#47#article#69#12#<P>12. E
vans AS. Viruses. In: Schottenfeld D, Fraumeni JF Jr (Editors), <I>Cancer    epi
demiology and prevention</I>. Philadelphia: W.B. Saunders; 1982. p 364-390.    ^
cY#6859.htm##
00457000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704021500075002000900290#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#p#52#48#article#69#13#<P>13. R
einert-Azambuja MI. Influenza pandemic and ischemic heart disease epidemic:    c
ause and effect? <I>Xth International Symposium on Atherosclerosis</I>. Montr&ea
cute;al:    1994. p 109-328 [Abstract].    ^cY#6859.htm##
00570000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704032800075002000900403#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#p#53#49#article#69#14#<P>14. A
zambuja MI, Duncan BB. Similarities in mortality patterns from influenza    in t
he first half of the 20th century and the rise and fall of ischemic heart    dis
ease in the United States: a new hypothesis concerning the coronary heart    dis
ease epidemic. <I>Cad Sa&uacute;de P&uacute;blica</I> 2002; 18: 557-566.    ^cY#
6859.htm##
00407000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704016500075002000900240#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#p#54#50#article#69#15#<P>15. A
zambuja MI. Spanish flu and early 20th-century expansion of a coronary    heart 
disease-prone subpopulation. <I>Tex Heart Inst J</I> 2004; 31: 14-21.    ^cY#685
9.htm##
00529000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704028700075002000900362#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#p#55#51#article#69#16#<P>16. F
rost WH. Epidemiology. In: Nelson Loose-Leaf System (Editor), <I>Public    Healt
h-Preventive Medicine</I>. New York: Thomas Nelson &amp; Sons; 1927. p    163-19
0 (quoted in Sartwell PE. The contribution of Wade Hampton Frost. Am J    Epidem
iol 1976; 104: 386-391, p 390).    ^cY#6859.htm##
00438000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704019600075002000900271#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#p#56#52#article#69#17#<P>17. P
leskov VM, Bannikov AI, Zaitsev I. The receptor-mediated endocytosis of    influ
enza viruses and low-density lipoproteins by tissue cells. <I>Vopr Virusol</I>  
  1994; 39: 121-125.    ^cY#6859.htm##
00410000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704016800075002000900243#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#p#57#53#article#69#18#<P>18. S
outar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial    hype
rcholesterolemia. <I>Nat Clin Pract Cardiovasc Med</I> 2007; 4: 214-225.    ^cY#
6859.htm##
00488000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704024600075002000900321#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#p#58#54#article#69#19#<P>19. K
erjaschki D, Exner M, Ullrich R, Susani M, Curtiss LK, Witztum JL, et    al. Pat
hogenic antibodies inhibit the binding of apolipoproteins to megalin/gp330    in
 passive Heymann nephritis. <I>J Clin Invest</I> 1997; 100: 2303-2309.    ^cY#68
59.htm##
00370000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704012800075002000900203#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#p#59#55#article#69#20#<P>20. S
ohn HY, Krotz F. Cyclooxygenase inhibition and atherothrombosis. <I>Curr    Drug
 Targets</I> 2006; 7: 1275-1284.    ^cY#6859.htm##
00477000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023500075002000900310#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#p#60#56#article#69#21#<P>21. K
rone W, Klass A, Nagele H, Behnke B, Greten H. Effects of prostaglandins    on L
DL receptor activity and cholesterol synthesis in freshly isolated human    mono
nuclear leukocytes. <I>J Lipid Res</I> 1988; 29: 1663-1669.    ^cY#6859.htm##
00498000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704025600075002000900331#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#p#61#57#article#69#22#<P>22. S
mith LA, Boutaud O, Breyer M, Morrow JD, Oates JA, Vaughan DE. Cyclooxygenase-2 
   dependent prostacyclin formation is regulated by low density lipoprotein chol
esterol    <I>in vitro</I>. <I>Arteriosc Thromb Vasc Biol</I> 2002; 22: 983-988.
    ^cY#6859.htm##
00429000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704018700075002000900262#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#p#62#58#article#69#23#<P>23. S
albach PB, Janssen-Timmen U, Blattner C, Ziegler R, Habenicht AJ. A new    role 
for the low density lipoprotein receptor. <I>Z Gastroenterol Verh</I> 1991;    2
6: 107-109.    ^cY#6859.htm##
00437000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704019500075002000900270#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#p#63#59#article#69#24#<P>24. J
anssen-Timmen U, Tomic I, Specht E, Beilecke U, Habenicht AJ. The arachidonic   
 acid cascade, eicosanoids, and signal transduction. <I>Ann N Y Acad Sci</I>    
1994; 733: 325-334.    ^cY#6859.htm##
00505000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704026300075002000900338#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#p#64#60#article#69#25#<P>25. H
elgadottir A, Manolescu A, Thorleifsson G, Gretarsdottir S, Jonsdottir    H, Tho
rsteinsdottir U, et al. The gene encoding 5-lipoxygenase activating protein    c
onfers risk of myocardial infarction and stroke. <I>Nat Genet</I> 2004; 36:    2
33-239.    ^cY#6859.htm##
00331000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704008900075002000900164#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#p#65#61#article#69#26#<P>26. M
orris JN. Recent history of coronary disease. <I>Lancet</I> 1951; 1: 1-7.    ^cY
#6859.htm##
00333000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704009100075002000900166#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#p#66#62#article#69#27#<P>27. M
orris JN. Recent history of coronary disease. <I>Lancet</I> 1951; 1: 69-73.    ^
cY#6859.htm##
00496000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704025400075002000900329#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#p#67#63#article#69#28#<P>28. C
arey MA, Bradbury JA, Seubert JM, Langenbach R, Zeldin DC, Germolec DR.    Contr
asting effects of cyclooxygenase-1 (COX-1) and COX-2 deficiency on the    host r
esponse to influenza A viral infection. <I>J Immunol</I> 2005; 175: 6878-6884.  
  ^cY#6859.htm##
00448000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704020600075002000900281#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#p#68#64#article#69#29#<P>29. T
homas PG, Brown SA, Keating R, Yue W, Morris MY, So J, et al. Hidden epitopes   
 emerge in secondary influenza virus-specific CD8+ T cell responses. <I>J Immuno
l</I>    2007; 178: 3091-3098.    ^cY#6859.htm##
00280000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704005300072002000900125#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#69#65#article#69#  </font>  <HR ALIGN=LE
FT WIDTH=100% SIZE=2>     ^cY#6859.htm##
00563000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033600072002000900408#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#70#66#article#69#<P class="style4"><A NA
ME="Correspondence"></A><FONT color="#00007F" SIZE=4 face="Arial, Helvetica, san
s-serif"><B>Correspondence    and Footnotes</B></FONT> <A HREF="#Home"><FONT SIZ
E=4><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0 LOOP="0" width="12" height="12"></B></FONT></A></P>     ^cY#6859.ht
m##
00734000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704050700072002000900579#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#71#67#article#69#<P class="style4"><B><a
 href="#Home"><img src="/img/revistas/bjmbr/v41n1/recor.gif" width="15" height="
14" border="0"></a>    Address for correspondence: </B><font face="Arial, Helvet
ica, sans-serif"> M.I.    Azambuja, Programa de P&oacute;s-Gradua&ccedil;&atilde
;o em Epidemiologia, Departamento    de Medicina Social, UFRGS, Rua Ramiro Barce
los, 2600, 4/420, 90035-003 Porto    Alegre, RS, Brasil. Fax: +55-51-3308-5291. 
E-mail: <a href="mailto:miazambuja@terra.com.br">miazambuja@terra.com.br</a>    
^cY#6859.htm##
00242000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704001500072002000900087#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#72#68#article#69#<br>       ^cY#6859.htm
##
00308000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704008100072002000900153#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6859.htm#S#p#73#69#article#69#<br>   Received April 1
3, 2007. Accepted September 17, 2007 </font> </P>     ^cY#6859.htm##
00480000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100020000730100015000930120
03000108030000700138065000900145064000500154031000400159014000400163865000900167
002000900176035001000185801000700195#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
859.htm#S#c#74#1#article#29#1#^rND^sGoldenfeld^nN#^rND^sWoese^nC#Biology's next 
revolution^len#Nature#20070000#2007#445#369#20080100#6859.htm#0028-0836#Nature##
00482000000000265000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100019000730120038000920300
01700130065000900147064000500156031000400161014000600165865000900171002000900180
035001000189801001700199#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#c#
75#2#article#29#2#^rND^sKauffman^nSA#Prolegomenon to a general biology^len#Ann N
 Y Acad Sci#20010000#2001#935#18-36#20080100#6859.htm#0077-8923#Ann N Y Acad Sci
##
00441000000000229000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710160018000730180053000910660
01000144062002500154065000900179064000500188865000900193002000900202#v41n1#v:\sc
ielo\serial\bjmbr\v41n1\markup\6859.htm#S#c#76#3#article#29#3#^rND^sLewontin^nR#
The triple helix. Gene, organism and environment^len#Cambridge#Harvard Universit
y Press#20010000#2001#20080100#6859.htm##
00455000000000253000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100017000730120051000900300
01600141710000200157065000900159064000500168031000400173014000600177865000900183
002000900192#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#c#77#4#article
#29#4#^rND^sMeaney^nMJ#Nature, nurture, and the disunity of knowledge^len#Ann NY
 Acad Sci#2#20010000#2001#935#50-61#20080100#6859.htm##
00473000000000229000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710160017000730180085000900660
00900175062002700184065000900211064000500220865000900225002000900234#v41n1#v:\sc
ielo\serial\bjmbr\v41n1\markup\6859.htm#S#c#78#5#article#29#5#^rND^sTauber^nAI#T
he immune self: theory or metaphor? Cambridge studies in philosophy and biology^
len#New York#Cambridge University Press#19970000#1997#20080100#6859.htm##
00600000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100016000730120044000890160
01700133016001900150018007800169066001000247062002700257065000900284064000500293
014000600298865000900304002000900313#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
859.htm#S#c#79#6#article#29#6#^rND^sGould^nSJ#"What is life?" as a problem in hi
story^len#^rND^sMurphy^nMP#^rND^sO'Neill^nLAJ#What is life? The next fifty years
. Speculations on the future of biology^len#Cambridge#Cambridge University Press
#19950000#1995#25-39#20080100#6859.htm##
00508000000000265000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100017000730120066000900300
01500156065000900171064000500180031000400185014001000189865000900199002000900208
035001000217801001500227#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#c#
80#7#article#29#7#^rND^sKuller^nLH#Epidemiology is the study of "epidemics" and 
their prevention^len#Am J Epidemiol#19910000#1991#134#1051-1056#20080100#6859.ht
m#0002-9262#Am J Epidemiol##
00582000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100019000730100016000920120
10700108030001800215065000900233064000500242031000300247014000800250865000900258
002000900267035001000276801001800286#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
859.htm#S#c#81#8#article#29#8#^rND^sAzambuja^nMI#^rND^sLevins^nR#Coronary heart 
disease (CHD) - one or several diseases?: Changes in the prevalence and features
 of CHD^len#Perspect Biol Med#20070000#2007#50#228-242#20080100#6859.htm#0031-59
82#Perspect Biol Med##
00690000000000337000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100015000730100017000880100
01600105010001600121010002100137010001700158810000600175012010300181030000700284
06500090029106400050030003100040030501400080030986500090031700200090032603500100
0335801000700345#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#c#82#9#art
icle#29#9#^rND^sKash^nJC#^rND^sTumpey^nTM#^rND^sProll^nSC#^rND^sCarter^nV#^rND^s
Perwitasari^nO#^rND^sThomas^nMJ#et al#Genomic analysis of increased host immune 
and cell death responses induced by 1918 influenza virus^len#Nature#20060000#200
6#443#578-581#20080100#6859.htm#0028-0836#Nature##
00680000000000337000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100016000750100016000910100
01600107010001500123010001500138010001700153810000600170012009800176030000700274
06500090028106400050029003100040029501400080029986500090030700200090031603500100
0325801000700335#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#c#83#10#ar
ticle#29#10#^rND^sKobasa^nD#^rND^sJones^nSM#^rND^sShinya^nK#^rND^sKash^nJC#^rND^
sCopps^nJ#^rND^sEbihara^nH#et al#Aberrant innate immune response in lethal infec
tion of macaques with the 1918 influenza virus^len#Nature#20070000#2007#445#319-
323#20080100#6859.htm#0028-0836#Nature##
00604000000000265000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100018000750120154000930300
01800247065000900265064000500274031000300279014001000282865000900292002000900301
035001000310801001800320#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#c#
84#11#article#29#11#^rND^sCollins^nSD#Age and sex incidence of influenza and pne
umonia morbidity and mortality in the epidemic of 1928-29 with comparative data 
for the epidemic of 1918-19^len#Public Health Rep#19310000#1931#46#1909-1937#200
80100#6859.htm#0033-3549#Public health rep##
00531000000000277000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100016000750120012000910160
02200103016002200125018003900147066001300186067001400199065000900213064000500222
014000800227865000900235002000900244#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
859.htm#S#c#85#12#article#29#12#^rND^sEvans^nAS#Viruses^len#^rND^sSchottenfeld^n
D#^rND^sFraumeni^nJF Jr#Cancer epidemiology and prevention^len#Philadelphia#W.B.
 Saunders#19820000#1982#364-390#20080100#6859.htm##
00491000000000241000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720160027000750180078001020560
01200180055001200192054000800204014000800212061001100220865000900231002000900240
#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#c#86#13#article#29#13#^rND
^sReinert-Azambuja^nMI#Influenza pandemic and ischemic heart disease epidemic: c
ause and effect?^len#Montréal^i1#19940000^i1#1994^i1#109-328#(Abstract)#20080100
#6859.htm##
00666000000000265000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100019000750100017000940120
22600111030001800337710000200355065000900357064000500366031000300371014000800374
865000900382002000900391#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#c#
87#14#article#29#14#^rND^sAzambuja^nMI#^rND^sDuncan^nBB#Similarities in mortalit
y patterns from influenza in the first half of the 20th century and the rise and
 fall of ischemic heart disease in the United States: a new hypothesis concernin
g the coronary heart disease epidemic^len#Cad Saúde Pública#2#20020000#2002#18#5
57-566#20080100#6859.htm##
00542000000000265000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100019000750120097000940300
01700191065000900208064000500217031000300222014000600225865000900231002000900240
035001000249801001700259#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#c#
88#15#article#29#15#^rND^sAzambuja^nMI#Spanish flu and early 20th-century expans
ion of a coronary heart disease-prone subpopulation^len#Tex Heart Inst J#2004000
0#2004#31#14-21#20080100#6859.htm#0730-2347#Tex Heart Inst J##
00664000000000349000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100016000750120017000910170
02500108018003800133066000900171062002100180065000900201064000500210014000800215
03000150022306500090023806400050024703100040025201400150025686500090027100200090
0280035001000289801001500299#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#
S#c#89#16#article#29#16#^rND^sFrost^nWH#Epidemiology^len#Nelson Loose-Leaf Syste
m#Public Health-Preventive Medicine^len#New York#Thomas Nelson & Sons#19270000#1
927#163-190#Am J Epidemiol#19760000#1976#104#386-391, p 390#20080100#6859.htm#00
02-9262#Am J Epidemiol##
00602000000000289000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100018000750100019000930100
01700112012010400129030001300233065000900246064000500255031000300260014000800263
865000900271002000900280035001000289801001300299#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6859.htm#S#c#90#17#article#29#17#^rND^sPleskov^nVM#^rND^sBannikov^nAI
#^rND^sZaitsev^nI#The receptor-mediated endocytosis of influenza viruses and low
-density lipoproteins by tissue cells^len#Vopr Virusol#19940000#1994#39#121-125#
20080100#6859.htm#0507-4088#Vopr Virusol##
00526000000000265000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100017000750100019000920120
07500111030003000186710000200216065000900218064000500227031000200232014000800234
865000900242002000900251#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#c#
91#18#article#29#18#^rND^sSoutar^nAK#^rND^sNaoumova^nRP#Mechanisms of disease: g
enetic causes of familial hypercholesterolemia^len#Nat Clin Pract Cardiovasc Med
#2#20070000#2007#4#214-225#20080100#6859.htm##
00718000000000337000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100020000750100015000950100
01700110010001600127010001800143010001800161810000600179012011100185030001400296
06500090031006400050031903100040032401400100032886500090033800200090034703500100
0356801001400366#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#c#92#19#ar
ticle#29#19#^rND^sKerjaschki^nD#^rND^sExner^nM#^rND^sUllrich^nR#^rND^sSusani^nM#
^rND^sCurtiss^nLK#^rND^sWitztum^nJL#et al#Pathogenic antibodies inhibit the bind
ing of apolipoproteins to megalin/gp330 in passive Heymann nephritis^len#J Clin 
Invest#19970000#1997#100#2303-2309#20080100#6859.htm#0021-9738#J Clin Invest##
00486000000000265000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100015000750100015000900120
05100105030001800156710000200174065000900176064000500185031000200190014001000192
865000900202002000900211#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#c#
93#20#article#29#20#^rND^sSohn^nHY#^rND^sKrotz^nF#Cyclooxygenase inhibition and 
atherothrombosis^len#Curr Drug Targets#2#20060000#2006#7#1275-1284#20080100#6859
.htm##
00676000000000313000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100015000750100015000900100
01600105010001600121010001600137012013000153030001200283065000900295064000500304
031000300309014001000312865000900322002000900331035001000340801001200350#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#c#94#21#article#29#21#^rND^sKrone^
nW#^rND^sKlass^nA#^rND^sNagele^nH#^rND^sBehnke^nB#^rND^sGreten^nH#Effects of pro
staglandins on LDL receptor activity and cholesterol synthesis in freshly isolat
ed human mononuclear leukocytes^len#J Lipid Res#19880000#1988#29#1663-1669#20080
100#6859.htm#0022-2275#J Lipid Res##
00676000000000313000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100016000750100017000910100
01600108010001700124010001600141010001800157012011500175030002700290710000200317
065000900319064000500328031000300333014000800336865000900344002000900353#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#c#95#22#article#29#22#^rND^sSmith^
nLA#^rND^sBoutaud^nO#^rND^sBreyer^nM#^rND^sMorrow^nJD#^rND^sOates^nJA#^rND^sVaug
han^nDE#Cyclooxygenase-2 dependent prostacyclin formation is regulated by low de
nsity lipoprotein cholesterol in vitro^len#Arteriosc Thromb Vasc Biol#2#20020000
#2002#22#983-988#20080100#6859.htm##
00637000000000313000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100018000750100024000930100
01800117010001700135010002000152012005600172030002100228065000900249064000500258
031000300263014000800266865000900274002000900283035001000292801002100302#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#c#96#23#article#29#23#^rND^sSalbac
h^nPB#^rND^sJanssen-Timmen^nU#^rND^sBlattner^nC#^rND^sZiegler^nR#^rND^sHabenicht
^nAJ#A new role for the low density lipoprotein receptor^len#Z Gastroenterol Ver
h#19910000#1991#26#107-109#20080100#6859.htm#0172-8504#Z Gastroenterol Verh##
00641000000000313000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100024000750100015000990100
01600114010001800130010002000148012007100168030001700239065000900256064000500265
031000400270014000800274865000900282002000900291035001000300801001700310#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#c#97#24#article#29#24#^rND^sJansse
n-Timmen^nU#^rND^sTomic^nI#^rND^sSpecht^nE#^rND^sBeilecke^nU#^rND^sHabenicht^nAJ
#The arachidonic acid cascade, eicosanoids, and signal transduction^len#Ann N Y 
Acad Sci#19940000#1994#733#325-334#20080100#6859.htm#0077-8923#Ann N Y Acad Sci#
#
00728000000000337000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100021000750100019000960100
02200115010002300137010002000160010002600180810000600206012010500212030001000317
06500090032706400050033603100030034101400080034486500090035200200090036103500100
0370801001000380#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#c#98#25#ar
ticle#29#25#^rND^sHelgadottir^nA#^rND^sManolescu^nA#^rND^sThorleifsson^nG#^rND^s
Gretarsdottir^nS#^rND^sJonsdottir^nH#^rND^sThorsteinsdottir^nU#et al#The gene en
coding 5-lipoxygenase activating protein confers risk of myocardial infarction a
nd stroke^len#Nat Genet#20040000#2004#36#233-239#20080100#6859.htm#1061-4036#Nat
 Genet##
00459000000000265000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100017000750120039000920300
00700131065000900138064000500147031000200152014000400154865000900158002000900167
035001000176801000700186#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#c#
99#26#article#29#26#^rND^sMorris^nJN#Recent history of coronary disease^len#Lanc
et#19510000#1951#1#1-7#20080100#6859.htm#0099-5355#Lancet##
00462000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760120039000930300
00700132065000900139064000500148031000200153014000600155865000900161002000900170
035001000179801000700189#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#c#
100#27#article#29#27#^rND^sMorris^nJN#Recent history of coronary disease^len#Lan
cet#19510000#1951#1#69-73#20080100#6859.htm#0099-5355#Lancet##
00712000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100019000920100
01800111010002000129010001700149010001900166012012500185030001000310065000900320
06400050032903100040033401400100033886500090034800200090035703500100036680100100
0376#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#c#101#28#article#29#28
#^rND^sCarey^nMA#^rND^sBradbury^nJA#^rND^sSeubert^nJM#^rND^sLangenbach^nR#^rND^s
Zeldin^nDC#^rND^sGermolec^nDR#Contrasting effects of cyclooxygenase-1 (COX-1) an
d COX-2 deficiency on the host response to influenza A viral infection^len#J Imm
unol#20050000#2005#175#6878-6884#20080100#6859.htm#0022-1767#J Immunol##
00675000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930100
01700109010001300126010001700139010001200156810000600168012008700174030001000261
06500090027106400050028003100040028501400100028986500090029900200090030803500100
0317801001000327#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6859.htm#S#c#102#29#a
rticle#29#29#^rND^sThomas^nPG#^rND^sBrown^nSA#^rND^sKeating^nR#^rND^sYue^nW#^rND
^sMorris^nMY#^rND^sSo^nJ#et al#Hidden epitopes emerge in secondary influenza vir
us-specific CD8+ T cell responses^len#J Immunol#20070000#2007#178#3091-3098#2008
0100#6859.htm#0022-1767#J Immunol##
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6876.htm#S#o#1#1#article#1#20
080623#161514#6876.htm#102##
03088000000000685000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000300104030002000107
03100030012703200020013006500090013201400090014103500100015022300090016001201290
01690100026002980100023003240100019003470100024003660100026003900700108004160700
08100524070010100605083128200706085000801988085002401996085002702020085003002047
08500440207708500320212111700060215307200030215906000090216205800060217106000100
21770580050021870600014022370580058022510600011023091120009023201110012023291140
00902341113001902350881002402369002000902393#v41n1#v:\scielo\serial\bjmbr\v41n1\
markup\6876.htm#S#h#2#1#article#1#sc#en#bjmbr#1#3.1#ILUS#03#BJMBR010#nd#Braz J M
ed Biol Res#41#1#20080100#^f12^l17#0100-879X#20071217#Isolation and characteriza
tion of a serine proteinase with thrombin-like activity from the venom of the sn
ake Bothrops asper^len#^rND^1A01 A02^nA.V^sPérez#^rND^1A01^nA^sRucavado#^rND^1A0
3^nL^sSanz#^rND^1A03^nJ.J^sCalvete#^rND^1A01^nJ.M^sGutiérrez#Universidad de Cost
a Rica^iA01^1Facultad de Microbiología^2Instituto Clodomiro Picado^cSan José^pCo
sta Rica#Universidad de El Salvador^iA02^1Facultad de Medicina^cSan Salvador^sEl
 Salvador#Instituto de Biomedicina de Valencia^iA03^1Laboratorio de Proteinómica
 Estructural^cValencia^pEspaña#^len^aA serine proteinase with thrombin-like acti
vity was isolated from the venom of the Central American pit viper Bothrops aspe
r. Isolation was performed by a combination of affinity chromatography on aminob
enzamidine-Sepharose and ion-exchange chromatography on DEAE-Sepharose. The enzy
me accounts for approximately 0.13% of the venom dry weight and has a molecular 
mass of 32 kDa as determined by SDS-PAGE, and of 27 kDa as determined by MALDI-T
OF mass spectrometry. Its partial amino acid sequence shows high identity with s
nake venom serine proteinases and a complete identity with a cDNA clone previous
ly sequenced from this species. The N-terminal sequence of the enzyme is VIGGDEC
NINEHRSLVVLFXSSGFL CAGTLVQDEWVLTAANCDSKNFQ. The enzyme induces clotting of plasm
a (minimum coagulant dose = 4.1 µg) and fibrinogen (minimum coagulant dose = 4.2
 µg) in vitro, and promotes defibrin(ogen)ation in vivo (minimum defibrin(ogen)a
ting dose = 1.0 µg). In addition, when injected intravenously in mice at doses o
f 5 and 10 µg, it induces a series of behavioral changes, i.e., loss of the righ
ting reflex, opisthotonus, and intermittent rotations over the long axis of the 
body, which closely resemble the `gyroxin-like' effect induced by other thrombin
-like enzymes from snake venoms.#^dnd^i1#^tm^len^kSnake venom^i1#^tm^len^kBothro
ps asper^i1#^tm^len^kSerine proteinase^i1#^tm^len^kThrombin-like serine proteina
se^i1#^tm^len^kDefibrin(ogen)ation^i1#other#20#2-N-2005#CYTED#206AC0281#Minister
io de Educación y Ciencia, Madrid, España#BFU2004-01432#Vicerrectoría de Investi
gación, Universidad de Costa Rica#741-A6-505#20070503#May 3, 2007#20070920#Septe
mber 20, 2007#S0100-879X2006005000189#6876.htm##
03108000000000673000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000300104030002000107
03100030012703200020013006500090013201400090014103500100015022300090016001201430
01690100026003120100023003380100019003610100024003800100026004040700108004300700
08100538070010100619083130300720085000802023085002402031085003402055085003002089
08500440211908500320216311700060219507200030220106000090220405800060221306000100
22190580050022290600014022790580058022930600011023511120009023621110019023711140
00902390113002602399002000902425#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6876.
htm#S#f#3#1#article#1#sc#en#bjmbr#1#3.1#ILUS#03#BJMBR010#nd#Braz J Med Biol Res#
41#1#20080100#^f12^l17#0100-879X#20071217#<B>Isolation and characterization of a
 serine proteinase with thrombin-like activity from the venom of the snake <I>Bo
throps asper</B></I>^len#^rND^1A01 A02^nA.V^sPérez#^rND^1A01^nA^sRucavado#^rND^1
A03^nL^sSanz#^rND^1A03^nJ.J^sCalvete#^rND^1A01^nJ.M^sGutiérrez#Universidad de Co
sta Rica^iA01^1Facultad de Microbiología^2Instituto Clodomiro Picado^cSan José^p
Costa Rica#Universidad de El Salvador^iA02^1Facultad de Medicina^cSan Salvador^s
El Salvador#Instituto de Biomedicina de Valencia^iA03^1Laboratorio de Proteinómi
ca Estructural^cValencia^pEspaña#^len^aA serine proteinase with thrombin-like ac
tivity was isolated from the venom of the Central American pit viper <I>Bothrops
 asper</I>. Isolation was performed by a combination of affinity chromatography 
on aminobenzamidine-Sepharose and ion-exchange chromatography on DEAE-Sepharose.
 The enzyme accounts for approximately 0.13% of the venom dry weight and has a m
olecular mass of 32 kDa as determined by SDS-PAGE, and of 27 kDa as determined b
y MALDI-TOF mass spectrometry. Its partial amino acid sequence shows high identi
ty with snake venom serine proteinases and a complete identity with a cDNA clone
 previously sequenced from this species. The N-terminal sequence of the enzyme i
s VIGGDECNINEHRSLVVLFXSSGFL CAGTLVQDEWVLTAANCDSKNFQ. The enzyme induces clotting
 of plasma (minimum coagulant dose = 4.1 µg) and fibrinogen (minimum coagulant d
ose = 4.2 µg) <I>in vitro</I>, and promotes defibrin(ogen)ation <I>in vivo </I>(
minimum defibrin(ogen)ating dose = 1.0 µg). In addition, when injected intraveno
usly in mice at doses of 5 and 10 µg, it induces a series of behavioral changes,
 i.e., loss of the righting reflex, opisthotonus, and intermittent rotations ove
r the long axis of the body, which closely resemble the `gyroxin-like' effect in
duced by other thrombin-like enzymes from snake venoms.#^dnd^i1#^tm^len^kSnake v
enom^i1#^tm^len^k<I>Bothrops asper</I>^i1#^tm^len^kSerine proteinase^i1#^tm^len^
kThrombin-like serine proteinase^i1#^tm^len^kDefibrin(ogen)ation^i1#other#20#2-N
-2005#CYTED#206AC0281#Ministerio de Educación y Ciencia, Madrid, España#BFU2004-
01432#Vicerrectoría de Investigación, Universidad de Costa Rica#741-A6-505#20070
503#<I>May 3, 2007</I>#20070920#<I>September 20, 2007</I>#6876.htm##
03198000000000697000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000500100121000300105049000900108158000300117
03000240012003100030014403200020014706500090014901400090015803500100016722300090
01770120129001860100027003150100023003420100019003650100025003840100027004090700
11000436070008300546070010300629083128900732085000802021085002402029085002702053
08500300208008500440211008500320215411700060218607200030219206000090219505800060
22040600010022100580050022200600014022700580058022840600011023421120009023531110
01202362114000902374113001902383002000902402008008902411#v41n1#v:\scielo\serial\
bjmbr\v41n1\markup\6876.htm#S#l#4#1#article#1#^mJan.^a2008#sc#en#bjmbr#1#3.1#ilu
s#03#BJMBR010#nd#Braz. j. med. biol. res#41#1#20080100#^f12^l17#0100-879X#200712
17#Isolation and characterization of a serine proteinase with thrombin-like acti
vity from the venom of the snake Bothrops asper^len#^rND^1A01 A02^nA. V^sPérez#^
rND^1A01^nA^sRucavado#^rND^1A03^nL^sSanz#^rND^1A03^nJ. J^sCalvete#^rND^1A01^nJ. 
M^sGutiérrez#^iA01^1Universidad de Costa Rica^2Facultad de Microbiología^3Instit
uto Clodomiro Picado^cSan José^pCosta Rica#^iA02^1Universidad de El Salvador^2Fa
cultad de Medicina^cSan Salvador^sEl Salvador#^iA03^1Instituto de Biomedicina de
 Valencia^2Laboratorio de Proteinómica Estructural^cValencia^pEspaña#^len^aA ser
ine proteinase with thrombin-like activity was isolated from the venom of the Ce
ntral American pit viper Bothrops asper. Isolation was performed by a combinatio
n of affinity chromatography on aminobenzamidine-Sepharose and ion-exchange chro
matography on DEAE-Sepharose. The enzyme accounts for approximately 0.13 percent
 of the venom dry weight and has a molecular mass of 32 kDa as determined by SDS
-PAGE, and of 27 kDa as determined by MALDI-TOF mass spectrometry. Its partial a
mino acid sequence shows high identity with snake venom serine proteinases and a
 complete identity with a cDNA clone previously sequenced from this species. The
 N-terminal sequence of the enzyme is VIGGDECNINEHRSLVVLFXSSGFL CAGTLVQDEWVLTAAN
CDSKNFQ. The enzyme induces clotting of plasma (minimum coagulant dose = 4.1 µg)
 and fibrinogen (minimum coagulant dose = 4.2 µg) in vitro, and promotes defibri
n(ogen)ation in vivo (minimum defibrin(ogen)ating dose = 1.0 µg). In addition, w
hen injected intravenously in mice at doses of 5 and 10 µg, it induces a series 
of behavioral changes, i.e., loss of the righting reflex, opisthotonus, and inte
rmittent rotations over the long axis of the body, which closely resemble the `g
yroxin-like' effect induced by other thrombin-like enzymes from snake venoms.#^d
nd^i1#^tm^len^kSnake venom^i1#^tm^len^kBothrops asper^i1#^tm^len^kSerine protein
ase^i1#^tm^len^kThrombin-like serine proteinase^i1#^tm^len^kDefibrin(ogen)ation^
i1#other#20#2-N-2005#CYTED#206AC0281#Ministerio de Educación y Ciencia, Madrid, 
España#BFU2004-01432#Vicerrectoría de Investigación, Universidad de Costa Rica#7
41-A6-505#20070503#May 3, 2007#20070920#September 20, 2007#6876.htm#Internet^iht
tp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2008000100003##
00395000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704017000070002000900240#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#5#1#article#78#<P> <font face="Arial, He
lvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med    Biol Res, January 2008,
 Volume 41(1) 12-17 (Short Communication)</B></font></P>     ^cY#6876.htm##
00441000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704021600070002000900286#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#6#2#article#78#<P><font size="5" face="A
rial, Helvetica, sans-serif"><B>Isolation and characterization    of a serine pr
oteinase with thrombin-like activity from the venom of the snake    <I>Bothrops 
asper</I></B> </font>      ^cY#6876.htm##
00731000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704050600070002000900576#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#7#3#article#78#<P><font face="Arial, Hel
vetica, sans-serif">A.V. P&eacute;rez<SUP>1,2</SUP>,    A. Rucavado<SUP>1</SUP>,
 L. Sanz<SUP>3</SUP>, J.J. Calvete<SUP>3</SUP> and <a href="#Correspondence"><im
g src="/img/revistas/bjmbr/v41n1/recor.gif" width="15" height="14" border="0"></
a>    <a href="mailto:jgutierr@icp.ucr.ac.cr"><img src="/img/revistas/bjmbr/v41n
1/email-ca.gif" width="14" height="11" border="0"></a></font>    <font face="Ari
al, Helvetica, sans-serif">J.M. Guti&eacute;rrez<SUP>1</SUP>    </font>      ^cY
#6876.htm##
00413000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704018800070002000900258#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#8#4#article#78#<P><font face="Arial, Hel
vetica, sans-serif"><SUP>1</SUP>Instituto Clodomiro Picado,    Facultad de Micro
biolog&iacute;a, Universidad de Costa Rica, San Jos&eacute;,    Costa Rica     ^
cY#6876.htm##
00331000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704010600070002000900176#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#9#5#article#78#<br>   <SUP>2</SUP>Facult
ad de Medicina, Universidad de El Salvador, San Salvador,    El Salvador     ^cY
#6876.htm##
00374000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704014800071002000900219#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#10#6#article#78#<br>   <SUP>3</SUP>Labor
atorio de Protein&oacute;mica Estructural, Instituto de Biomedicina    de Valenc
ia, Valencia, Espa&ntilde;a</font>      ^cY#6876.htm##
00462000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704023600071002000900307#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#11#7#article#78#<P> <font face="Arial, H
elvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v41n1/do
wn.gif" ALIGN=BOTTOM WIDTH=12 HEIGHT=12 BORDER=0 VSPACE=0 HSPACE=0></A>    <A HR
EF="#Abstract"><strong>Abstract</strong></A>    ^cY#6876.htm##
00415000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704018900071002000900260#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#12#8#article#78#<BR>   <A HREF="#Text"><
IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPA
CE=0 width="12" height="12"></A>    <A HREF="#Text"><strong>Text</strong></A>   
 ^cY#6876.htm##
00420000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704019400071002000900265#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#13#9#article#78#<BR>   <A HREF="#Referen
ces"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=
0 HSPACE=0 width="12" height="12"></A>    <A HREF="#References"><strong>Referenc
es    ^cY#6876.htm##
00462000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704023500072002000900307#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#14#10#article#78#<br>   </strong></A><A 
HREF="#Acknowledgments"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTT
OM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Acknowled
gments"><strong>Acknowledgments</strong></A>    ^cY#6876.htm##
00473000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704024600072002000900318#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#15#11#article#78#<BR>   <A HREF="#Corres
pondence"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Correspondence"><strong
>Correspondence and Footnotes</strong></a>    </font>      ^cY#6876.htm##
00274000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704004700072002000900119#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#16#12#article#78#<P>  <HR ALIGN=LEFT WID
TH=100% SIZE=2>     ^cY#6876.htm##
00550000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704032300072002000900395#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#17#13#article#78#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Abstract"></A><FONT COLOR=#00007F size="4"><stro
ng>Abstract</strong>    </FONT><A HREF="#Home"><FONT SIZE=4><B><IMG SRC="/img/re
vistas/bjmbr/v41n1/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0" wi
dth="12" height="12"></B></FONT></A>    </font></P>     ^cY#6876.htm##
01657000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704143000072002000901502#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#18#14#article#78#<P><font face="Arial, H
elvetica, sans-serif">A serine proteinase with thrombin-like    activity was iso
lated from the venom of the Central American pit viper <I>Bothrops    asper</I>.
 Isolation was performed by a combination of affinity chromatography    on amino
benzamidine-Sepharose and ion-exchange chromatography on DEAE-Sepharose.    The 
enzyme accounts for approximately 0.13% of the venom dry weight and has    a mol
ecular mass of 32 kDa as determined by SDS-PAGE, and of 27 kDa as determined    
by MALDI-TOF mass spectrometry. Its partial amino acid sequence shows high ident
ity    with snake venom serine proteinases and a complete identity with a cDNA c
lone    previously sequenced from this species. The N-terminal sequence of the e
nzyme    is VIGGDECNINEHRSLVVLFXSSGFL CAGTLVQDEWVLTAANCDSKNFQ. The enzyme induce
s clotting    of plasma (minimum coagulant dose = 4.1 &#181;g) and fibrinogen (m
inimum coagulant    dose = 4.2 &#181;g) <I>in vitro</I>, and promotes defibrin(o
gen)ation <I>in    vivo </I>(minimum defibrin(ogen)ating dose = 1.0 &#181;g). In
 addition, when    injected intravenously in mice at doses of 5 and 10 &#181;g, 
it induces a series    of behavioral changes, i.e., loss of the righting reflex,
 opisthotonus, and    intermittent rotations over the long axis of the body, whi
ch closely resemble    the `gyroxin-like' effect induced by other thrombin-like 
enzymes from snake    venoms. </font>      ^cY#6876.htm##
00455000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704022800072002000900300#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#19#15#article#78#<P><font face="Arial, H
elvetica, sans-serif"><B>Key words: </B>Snake venom; <I>Bothrops    asper</I>; S
erine proteinase; Thrombin-like serine proteinase; Defibrin(ogen)ation    </font
>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6876.htm##
00541000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704031400072002000900386#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#20#16#article#78#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Text"></A><FONT COLOR=#00007F size="4"><strong>Te
xt</strong>    </FONT><A HREF="#Home"><FONT SIZE=4><B><IMG SRC="/img/revistas/bj
mbr/v41n1/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0" width="12" 
height="12"></B></FONT></A>    </font></P>     ^cY#6876.htm##
00759000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704053200072002000900604#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#21#17#article#78#<P><font face="Arial, H
elvetica, sans-serif">Research supported by NeTropica (No.    2-N-2005), CYTED (
No. 206AC0281), Ministerio de Educaci&oacute;n y Ciencia,    Madrid, Espa&ntilde
;a (No. BFU2004-01432), and Vicerrector&iacute;a de Investigaci&oacute;n,    Uni
versidad de Costa Rica (No. 741-A6-505). This study was carried out in partial  
  fulfillment of the requirements for the M.Sc. degree of A.V. P&eacute;rez at  
  the University of Costa Rica. <I>Received May 3, 2007. Accepted September 20, 
   2007</I> </font>      ^cY#6876.htm##
01264000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704103700072002000901109#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#22#18#article#78#<P><font face="Arial, H
elvetica, sans-serif">Viperid snakes of the genus <I>Bothrops</I>    sp inflict 
the vast majority of snakebites in Central and South America (1,2).    In Centra
l America and parts of northern South America, the species <I>Bothrops    asper<
/I> is responsible for the majority of cases (2). Envenomation by this    specie
s is associated with prominent local pathological effects, i.e., myonecrosis,   
 hemorrhage, edema, dermonecrosis and blistering (3), as well as with systemic  
  alterations characterized by coagulopathy, hemorrhage, cardiovascular shock,  
  and acute renal failure (2,4,5). Alterations in hemostasis leading to thromboc
ytopenia,    platelet hypoaggregation, defibrin(ogen)ation and disseminated intr
avascular    coagulation are often observed in victims of <I>B. asper</I> bite e
nvenomation    (5-7). Such complex hemostatic disturbances potentiate the profus
e bleeding    initiated by the disruptive action of hemorrhagic metalloproteinas
es in the    microvasculature (7,8). </font>      ^cY#6876.htm##
01921000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704169400072002000901766#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#23#19#article#78#<P><font face="Arial, H
elvetica, sans-serif">Viperid venom-induced defibrin(ogen)ation    is the conseq
uence of the action of venom procoagulant components on the clotting    system <
I>in vivo</I>, since they cause the formation of microthrombi in the    circulat
ion, with the concomitant consumption of fibrinogen and the activation    of the
 fibrinolytic system, which results in the appearance of fibrin(ogen)-degradatio
n    products (9). These effects result in alteration of laboratory clotting tes
t    parameters, such as whole blood clotting time, prothrombin time and activat
ed    partial thromboplastin time (6,9). Procoagulant components in <I>Bothrops<
/I>    sp venoms include zinc-dependent metalloproteinases that activate factor 
X and    prothrombin, as well as serine proteinases that directly convert fibrin
ogen    into fibrin (10,11). In the case of <I>B. asper</I>, previous investigat
ions    have described a prothrombin activator, which is a class P-III metallopr
oteinase    named basparin A (12), and a thrombin-like serine proteinase, named 
asperase    (13,14); however, the characterization of the latter is limited to m
olecular    mass estimation and amino acid composition, with no sequence informa
tion available.    On the other hand, this venom is devoid of factor X activator
s (15). Owing to    the pathophysiological relevance of coagulant enzymes in thi
s medically relevant    snake venom, in the present paper we describe the isolat
ion of a thrombin-like    serine proteinase, the determination of its partial am
ino acid sequence, and    the characterization of its <I>in vitro</I> coagulant 
and <I>in vivo</I> defibrin(ogen)ating    activities. </font>      ^cY#6876.htm#
#
02260000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704203300072002000902105#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#24#20#article#78#<P><font face="Arial, H
elvetica, sans-serif">Serine proteinase was purified by    a two-step chromatogr
aphic protocol. Samples of 250 mg <I>B. asper</I> venom,    obtained from adult 
specimens collected in the Pacific region of Costa Rica,    were dissolved in 5 
mL 50 mM Tris-HCl, 0.4 M NaCl, pH 9.0. After centrifugation    at 500 <I>g</I> f
or 10 min, the supernatant was applied to a benzamidine-Sepharose    4 Fast Flow
 affinity chromatography column (3 x 12 cm; Amersham Biosciences,    Uppsala, Sw
eden), previously equilibrated with the same buffer. The sample was    passed se
veral times through the column in order to maximize binding. After    elution of
 the unbound fraction, a 0.1 M glycine-HCl, pH 3.0, buffer was applied    to the
 column and the absorbance of the eluting material was monitored at 280    nm. F
ractions of 3 mL were collected into tubes containing 0.5 mL 0.5 M Tris    buffe
r, pH 8.8. Throughout fractionation, fibrinogen-clotting activity was assessed  
  in order to identify fractions with thrombin-like activity. To this end, 200  
  &#181;L of a 4 mg/mL bovine fibrinogen (Sigma-Aldrich, St. Louis, MO, USA) in 
   0.12 M NaCl, 40 mM phosphate, pH 7.2 (PBS) was incubated with 100 &#181;L dil
utions    of the fractions. Proteins from the peaks showing fibrinogen-clotting 
activity    were diafiltered and concentrated by ultrafiltration against 50 mM T
ris-HCl,    50 mM KCl buffer, pH 9.0. The concentrated material was applied to a
 3 x 8 cm    DEAE-Sepharose column previously equilibrated with the dialysis buf
fer. After    elution of the unbound material, a linear KCl gradient (50 mM to 0
.75 M) in    the same Tris buffer was developed in a total volume of 500 mL. Act
ive peaks    were diafiltered against distilled water and lyophilized. Homogenei
ty was assessed    by reverse-phase HPLC on a C4 column (Vydac; 250 x 4.6 mm; fl
ow rate 1.0 mL/min)    using an Agilent 1100 instrument (Tokyo, Japan) and a lin
ear gradient from 0    to 60% acetonitrile in 0.1% trifluoroacetic acid. </font>
      ^cY#6876.htm##
01547000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704132000072002000901392#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#25#21#article#78#<P><font face="Arial, H
elvetica, sans-serif">For molecular mass analysis and amino    acid sequencing, 
the fibrinogen-clotting protein purified by DEAE-Sepharose    chromatography was
 submitted to reverse-phase HPLC using an ETTAN&#153; LC HPLC    system (Amersha
m Biosciences, Piscataway, NJ, USA) and a Lichrosphere RP100    C<SUB>18</SUB> c
olumn (250 x 4 mm, 5 &#181;m particle size) eluted at 1 mL/min    with a linear 
gradient of 0.1% TFA in water (solution A) and acetonitrile (solution    B) empl
oying the following chromatographic conditions: isocratically (5% B)    for 10 m
in, followed by linear gradients of 5-15% B over 20 min, 15-45% B over    120 mi
n, and 45-70% B over 20 min. Protein detection was at 215 nm. Fractions    were 
collected manually and dried in a Speed-Vac instrument (Savant, Ramsey,    MN, U
SA). The molecular mass of the purified protein was determined by SDS-PAGE    (1
6), run under reducing conditions on 12% polyacrylamide gels and by MALDI-TOF   
 mass spectrometry (using a Voyager DE-Pro&#153; instrument, Applied Biosystem, 
   Foster City, CA, USA, and sinapinic acid as the matrix) and electrospray ioni
zation    mass spectrometry using an Applied Biosystem Qtrap&#153; mass spectrom
eter (17)    operated in Enhanced Multiple Charge mode in a 600-1700-m/z range. 
</font>      ^cY#6876.htm##
01576000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704134900072002000901421#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#26#22#article#78#<P><font face="Arial, H
elvetica, sans-serif">The purified protein was subjected    to N-terminal sequen
ce analysis using a Procise instrument (Applied Biosystems)    following manufac
turer instructions. For internal sequence determination, the    protein band of 
~30 kDa was excised from a Coomassie brilliant blue-stained    SDS-PAGE and subj
ected to automated reduction with DTT and alkylation with iodoacetamide,    and 
in-gel digestion with sequencing grade bovine pancreas trypsin (Roche, San    Cu
gart del Vall&eacute;s, Barcelona, Spain) using a ProGest digestor (Genomic    S
olutions, Cambridgeshire, UK) following manufacturer instructions. A 0.65-&#181;
L    amount of the tryptic peptide mixtures (total volume of ~20 &#181;L) was sp
otted    onto a MALDI-TOF sample holder, mixed with an equal volume of a saturat
ed solution    of <font face="Symbol">a</font>-cyano-4-hydroxycinnamic acid (Sig
ma) in 50%    acetonitrile containing 0.1% TFA, dried, and analyzed with a Voyag
er-DE Pro    MALDI-TOF mass spectrometer (Applied Biosystems) operated in delaye
d extraction    and reflector modes. A tryptic peptide mixture of <I>Cratylia fl
oribunda</I>    seed lectin (SwissProt accession code P81517) prepared and previ
ously characterized    in our laboratory was used as mass calibration standard (
mass range, 450-3300    Da). </font>      ^cY#6876.htm##
01347000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704112000072002000901192#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#27#23#article#78#<P><font face="Arial, H
elvetica, sans-serif">For peptide sequencing, the protein    digest mixture was 
loaded onto a nanospray capillary column and subjected to    electrospray ioniza
tion tandem mass spectrometric analysis using a QTrap mass    spectrometer (Appl
ied Biosystems) (17) equipped with a nanospray source (Protana,    Odense, Denma
rk). Doubly- or triply-charged ions of selected peptides from the    MALDI-TOF m
ass fingerprint spectra were analyzed in Enhanced Resolution MS mode    and the 
monoisotopic ions were fragmented using the Enhanced Product Ion tool    with Q<
SUB>0</SUB> trapping. Enhanced Resolution was performed at 250 amu/s    across t
he entire mass range. Settings for MS/MS experiments were as follows:    Q1 - un
it resolution; Q1 to Q2 collision energy, 30-40 eV; Q3 entry barrier,    8 V; li
near ion trap Q3 fill time, 250 ms, and Q3 scan rate, 1000 amu/s. Collision-indu
ced    dissociation spectra were interpreted manually or using the on-line form 
of    the MASCOT program at <a href="http://www.matrixscience.com" target="_blan
k">http://www.matrixscience.com</a>.    </font>      ^cY#6876.htm##
01652000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704142500072002000901497#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#28#24#article#78#<P><font face="Arial, H
elvetica, sans-serif">The coagulant activity of fractions    and purified enzyme
 was assessed on citrated human plasma and on a 4 mg/mL solution    of bovine fi
brinogen, dissolved in PBS, as described above. Samples of 100 &#181;L    fracti
ons or various concentrations of the enzyme were added to 200 &#181;L    plasma 
or fibrinogen, previously incubated at 37&#176;C. Clotting times were    recorde
d, and the minimum coagulant doses (MCD) for plasma or fibrinogen were    determ
ined; MCD corresponds to the amount of enzyme that induces clotting in    60 s (
18). <I>In vivo</I> alterations were assessed by intravenous (<I>iv</I>)    inje
ction of various amounts of the enzyme dissolved in 100 &#181;L PBS, in    a gro
up of four CD-1 mice (18-20 g body weight); controls received the same    volume
 of PBS under otherwise identical conditions. One hour after injection,    mice 
were bled under anesthesia. Blood was placed in dry clean glass tubes and    lef
t at room temperature; the formation of clots was regularly assessed by tilting 
   the tubes, and clotting time was recorded (18). In addition, mice injected <I
>iv</I>    were observed for behavioral changes occurring during the first minut
es after    injection. Experiments involving mice were approved by the Instituti
onal Committee    for the Care and Use of Laboratory Animals (CICUA) of the Univ
ersity of Costa    Rica. </font>      ^cY#6876.htm##
01472000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704124500072002000901317#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#29#25#article#78#<P><font face="Arial, H
elvetica, sans-serif">Fractionation of <I>B. asper</I>    venom by affinity chro
matography on benzamidine-Sepharose yielded a peak, which    bound to the gel, h
aving fibrinogen-clotting activity (<a href="#Fig1">Figure    1A</a>). This frac
tion was separated into five peaks on a DEAE-Sepharose column    eluted with a l
inear KCl gradient (<a href="#Fig1">Figure 1B</a>). Only peak    1 showed fibrin
ogen-clotting activity. When analyzed by reverse-phase HPLC,    this peak had on
e main component (<a href="#Fig1">Figure 1C</a>). The yield    of this enzyme wa
s low, as only 2 mg was recovered from an initial amount of    1.5 g venom, thus
 corresponding to approximately 0.13% of <I>B. asper</I> venom.    The apparent 
molecular mass of this thrombin-like enzyme was 32 kDa (non-reduced)/24    kDa (
reduced), as determined by SDS-PAGE (<a href="#Fig1">Figure 1C</a>, inset).    M
ALDI-TOF mass spectrometry evidenced three molecular species of molecular masses
    27,067, 27,356, and 27,649 Da (&#177; 27 Da). The mass difference of 290-293
    Da may indicate that the purified enzyme is a mixture of glycoforms differin
g    in their degree of sialylation (mass increment due to sialylation = 292 Da)
.    </font>      ^cY#6876.htm##
01930000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704170300072002000901775#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#30#26#article#78#<P><font face="Arial, H
elvetica, sans-serif">N-terminal sequence analysis (<a href="#Fig2">Figure    2<
/a>) revealed 48 residues with high identity with previously characterized    th
rombin-like serine proteinases from viperid snake venoms (19). Moreover, the    
internal sequences of 14 peptides resulting from tryptic digestion also showed  
  characteristic sequences of venom serine proteinases. All the sequences determ
ined    showed 100% identity with a deduced amino acid sequence of a cDNA clone 
derived    from RNA isolated from the venom gland of <I>B. asper</I> from Costa 
Rica (UniProtKB/TrEMBL    entry Q072L6; <a href="#Fig2">Figure 2</a>). Therefore
, we may conclude that    this sequence corresponds to the thrombin-like serine 
proteinase described in    this communication. The cDNA-deduced sequence of <I>B
. asper</I> serine proteinase    exhibits a single potential N-glycosylation sit
e at position 20 of the mature    protein. The mass difference between the cDNA-
deduced sequence (isotope-averaged    molecular mass = 25308 Da, assuming that i
ts 12 cysteines are involved in the    formation of disulfide bonds) and the MAL
DI-TOF estimated molecular masses support    the hypothesis that each of the thr
ee purified thrombin-like enzyme glycoforms    bears a single di-, mono-, or non
-syalilated, fucosylated complex-type dianntenary    glycan chain (calculated ma
ss increments of 2352.1, 2060.1, and 1768.1 Da, respectively).    On the other h
and, the similarity in molecular mass with asperase, a thrombin-like    serine p
roteinase isolated from this venom by Ortiz and Gubensek (13), suggests    that 
the enzyme described here is likely to correspond to asperase. </font>      ^cY#
6876.htm##
01767000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704154000072002000901612#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#31#27#article#78#<P><font face="Arial, H
elvetica, sans-serif">The MCD of the serine proteinase    was 4.1 &#181;g for hu
man plasma and 4.2 &#181;g for bovine fibrinogen. When    the enzyme was incubat
ed with 20 mM PMSF for 30 min at room temperature before    addition to fibrinog
en, the clotting activity was abrogated. The MCD of crude    <I>B. asper</I> ven
om for plasma and fibrinogen are 0.5 &#181;g and 80 &#181;g,    respectively (15
). Taken together, these results clearly indicate that a) <I>B.    asper</I> ven
om contains other more active procoagulant components, which very    likely corr
espond to prothrombin-activating metalloproteinases (12,15), and    b) the amoun
t of thrombin-like serine proteinase in <I>B. asper</I> venom, and    thus its c
ontribution to the clotting activity is low, in agreement with the    low yield 
obtained with our fractionation protocol. Therefore, serine proteinases    play 
a secondary role in the clotting activity of <I>B. asper</I> venom. This    conc
lusion is supported by previous experiments in which metalloproteinases    were 
inhibited by the peptidomimetic hydroxamate batimastat. Under these conditions, 
   the MCD of <I>B. asper</I> venom increased from 0.5 &#181;g (uninhibited veno
m)    to 50 &#181;g (batimastat-inhibited venom) (15). Moreover, inhibition of v
enom    serine proteinases by PMSF had little effect on the coagulant activity o
f the    venom (15). Clearly, therefore, metalloproteinases constitute the most 
important    coagulant components of <I>B. asper </I>venom. </font>      ^cY#687
6.htm##
01350000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704112300072002000901195#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#32#28#article#78#<P><font face="Arial, H
elvetica, sans-serif">Upon <I>iv</I> injection in mice,    the serine proteinase
 induced defibrin(ogen)ation. Blood collected from control    mice injected with
 PBS clotted within 2 min, whereas blood collected from mice    injected with 10
, 5, 2.5, and 1.25 &#181;g of the enzyme were unclottable; blood    from mice re
ceiving 0.5 &#181;g showed normal clotting. The minimum defibrin(ogen)ating    d
ose, i.e., the minimum dose that induced defibrin(ogen)ation in all mice tested,
    corresponded to 1.0 &#181;g. Thus, this enzyme has a potent defibrin(ogen)at
ing    activity. The role of serine proteinases in defibrin(ogen)ation induced b
y <I>B.    asper </I> venom has been previously assessed in experiments in which
 venom    metalloproteinases were inhibited by batimastat (15). As in the case o
f <I>in    vitro</I> coagulant activity, inhibition of metalloproteinases greatl
y reduced    the defibrin(ogen)ating activity of this venom, further supporting 
the proposed    predominant role of metalloproteinases over serine proteinases i
n <I>B. asper</I>-induced    coagulopathy. </font>      ^cY#6876.htm##
01195000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704096800072002000901040#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#33#29#article#78#<P><font face="Arial, H
elvetica, sans-serif">Intravenous administration of doses    of 10 and 5 &#181;g
 of the serine proteinase induced a series of behavioral    changes in mice with
in the first 2-3 min after injection. These were characterized    by loss of the
 righting reflex, opisthotonus, and intermittent rotations over    the long axis
 of the body. These effects persisted during approximately 10 min,    after whic
h the animals apparently recovered. No such effect was observed with    doses be
low 5 &#181;g. This effect is very similar to that described for gyroxin,    a t
hrombin-like serine proteinase isolated from <I>Crotalus durissus terrificus</I>
    venom (20). Similar observations were made with thrombin-like serine protein
ases    from other venoms (20). It is likely that this `gyroxin-like' effect is 
typical    of thrombin-like serine proteinases from viperid snake venoms, althou
gh the    underlying mechanism remains unknown. </font>      ^cY#6876.htm##
01174000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704094700072002000901019#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#34#30#article#78#<P><font face="Arial, H
elvetica, sans-serif">In conclusion, a thrombin-like serine    proteinase, prese
nt in low concentration, was isolated from the venom of <I>B.    asper</I> from 
Costa Rica. It is likely that this enzyme corresponds to asperase,    isolated f
rom this venom (13,14), and to a previously described sequence (UniProtKB/TrEMBL
    entry Q072L6). The enzyme displays fibrinogen-clotting activity <I>in vitro<
/I>    and defibrin(ogen)ating activity <I>in vivo</I>, and is likely to play a 
role,    albeit not a predominant one, in the coagulopathy characteristic of env
enomation    inflicted by <I>B. asper</I> bites.</font>  <HR ALIGN=LEFT WIDTH=10
0% SIZE=2> <table width="100%"  border="0">   <tr align="left" valign="top">    
  <td width="12%"><a href="/img/revistas/bjmbr/v41n1/html/6876i01.htm"><img src=
"/img/revistas/bjmbr/v41n1/6876i01peq.jpg" width="120" height="100" border="2"><
/a></td>     <td width="88%">           ^cY#6876.htm##
01756000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704152900072002000901601#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#35#31#article#78#<P><font face="Arial, H
elvetica, sans-serif"><a name="Fig1"></a>Figure 1.          Isolation of a throm
bin-like serine proteinase from <I>Bothrops asper</I>          venom. <I>A</I>, 
Venom (250 mg) was dissolved in 50 mM Tris-HCl, 0.4 M          NaCl, pH 9.0, and
 applied to a benzamidine-Sepharose 4 Fast Flow column.          After elution o
f unbound material, a 0.1 M glycine-HCl buffer, pH 3.0,          was applied (ar
row) and the eluted material was collected into tubes containing          0.5 M 
Tris buffer, pH 8.8. <I>B</I>, The benzamidine-binding fraction          isolate
d in <I>A</I> was further fractionated by ion-exchange chromatography          o
n a DEAE-Sepharose column, equilibrated with 50 mM Tris-HCl, 50 mM KCl          
buffer, pH 9.0. After elution of unbound material, a linear gradient (G)        
  of KCl from 50 mM to 0.75 M was developed in the same Tris buffer. Only       
   the first peak collected after the onset of the gradient (discontinuous      
    arrow) had thrombin-like activity. <I>C</I>, Reverse-phase HPLC analysis    
      of the active peak after DEAE-Sepharose separation, carried out on a C4   
       column at a flow rate of 1.0 mL/min, using a linear gradient from 0 to   
       60% acetonitrile in 0.1% trifluoroacetic acid. The inset shows an SDS-PAG
E          of the purified protein run under reducing (R) and non-reducing (NR) 
conditions.          <I>D</I>, MALDI-TOF mass spectrum of the purified thrombin-
like enzyme.          </font>      </td>   </tr> </table>     ^cY#6876.htm##
01455000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704122800072002000901300#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#36#32#article#78#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image    (154 K JPG file)]</f
ont>  <HR ALIGN=LEFT WIDTH=100% SIZE=2> <table width="100%"  border="0">   <tr a
lign="left" valign="top">      <td width="12%"><a href="/img/revistas/bjmbr/v41n
1/html/6876i02.htm"><img src="/img/revistas/bjmbr/v41n1/6876i02peq.jpg" width="1
20" height="85" border="2"></a></td>     <td width="88%"><font face="Arial, Helv
etica, sans-serif"><a name="Fig2"></a>Figure        2. Alignment of the N-termin
al sequence of <I>Bothrops asper</I> serine        proteinase determined by auto
mated Edman degradation (N-terminal), and internal        amino acid sequences g
athered by collision-induced dissociation tandem mass        spectrometry of dou
bly- and triply-charged tryptic peptides (the m/z value        is indicated at t
he end of each peptide), with the deduced amino acid sequence        of a cDNA c
lone derived from RNA isolated from the venom gland of <I>B.        asper</I> (h
ighlighted in gray) (UniProtKB/TrEMBL entry Q072L6). The underlined        resid
ues correspond to the signal peptide. There is a 100% identity between        th
e sequenced peptides and the deduced sequence. </font></td>   </tr> </table>    
 ^cY#6876.htm##
00378000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704015100072002000900223#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#37#33#article#78#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image    (110 K JPG file)]</f
ont>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6876.htm##
00582000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704035500072002000900427#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#38#34#article#78#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><B>
References</B></FONT></font>    <font size="4" face="Arial, Helvetica, sans-seri
f"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIGN=BOTTOM
 BORDER=0 VSPACE=0 HSPACE=0 LOOP="0" width="12" height="12"></B></A>    </font><
/P>     ^cY#6876.htm##
00519000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704027800074002000900352#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6876.htm#S#p#39#35#article#78#1#<P><font 
face="Arial, Helvetica, sans-serif">1. Fan HW, Cardoso JL. Clinical toxicology  
  of snake bites in South America. In: Meier J, White J (Editors), <I>Handbook  
  of clinical toxicology of animal venoms and poisons</I>. Boca Raton: CRC Press
;    1995. p 667-688.    ^cY#6876.htm##
00245000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704001800072002000900090#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#40#36#article#78# </font>      ^cY#6876.
htm##
00520000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704027900074002000900353#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6876.htm#S#p#41#37#article#78#2#<P><font 
face="Arial, Helvetica, sans-serif">2. Guti&eacute;rrez JM. Clinical    toxicolo
gy of snakebite in Central America. In: Meier J, White J (Editors),    <I>Handbo
ok of clinical toxicology of animal venoms and poisons</I>. Boca Raton:    CRC P
ress; 1995. p 645-665.    ^cY#6876.htm##
00245000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704001800072002000900090#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#42#38#article#78# </font>      ^cY#6876.
htm##
00651000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704041000074002000900484#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6876.htm#S#p#43#39#article#78#3#<P><font 
face="Arial, Helvetica, sans-serif">3. Guti&eacute;rrez JM, Lomonte B.    Efecto
s locales en el envenenamiento of&iacute;dico en Am&eacute;rica Latina.    In: C
ardoso JLC, Fran&ccedil;a FOS, Wen FH, M&aacute;laque CMS, Haddad V (Editors),  
  <I>Animais pe&ccedil;onhentos no Brasil. Biologia, cl&iacute;nica e terap&ecir
c;utica    dos acidentes</I>. S&atilde;o Paulo: Sarvier; 2003. p 310-323.    ^cY
#6876.htm##
00245000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704001800072002000900090#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#44#40#article#78# </font>      ^cY#6876.
htm##
00536000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704029500074002000900369#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6876.htm#S#p#45#41#article#78#4#<P><font 
face="Arial, Helvetica, sans-serif">4. Bola&ntilde;os R. Las serpientes    venen
osas de Centroam&eacute;rica y el problema del ofidismo. Primera parte.    Aspec
tos zool&oacute;gicos, epidemiol&oacute;gicos y biom&eacute;dicos. <I>Rev    Cos
tarric Cienc Med</I> 1982; 3: 165-184.    ^cY#6876.htm##
00245000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704001800072002000900090#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#46#42#article#78# </font>      ^cY#6876.
htm##
00557000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704031600074002000900390#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6876.htm#S#p#47#43#article#78#5#<P><font 
face="Arial, Helvetica, sans-serif">5. Warrell DA. Epidemiology, clinical    fea
tures and management of snake bites in Central and South America. In: Campbell  
  JA, Lamar WW (Editors), <I>Venomous reptiles of the Western hemisphere</I>.   
 Vol. 2. Ithaca: Cornell University Press; 2004. p 709-761.    ^cY#6876.htm##
00245000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704001800072002000900090#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#48#44#article#78# </font>      ^cY#6876.
htm##
00476000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704023500074002000900309#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6876.htm#S#p#49#45#article#78#6#<P><font 
face="Arial, Helvetica, sans-serif">6. Barrantes A, Solis V, Bola&ntilde;os    R
. Alterations in the coagulation mechanisms of patients bitten by <I>Bothrops   
 asper</I> (Terciopelo). <I>Toxicon</I> 1985; 23: 399-407.    ^cY#6876.htm##
00245000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704001800072002000900090#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#50#46#article#78# </font>      ^cY#6876.
htm##
00610000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704036900074002000900443#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6876.htm#S#p#51#47#article#78#7#<P><font 
face="Arial, Helvetica, sans-serif">7. Rucavado A, Soto M, Escalante    T, Lor&i
acute;a GD, Arni R, Guti&eacute;rrez JM. Thrombocytopenia and platelet    hypoag
gregation induced by <I>Bothrops asper</I> snake venom. Toxins involved    and t
heir contribution to metalloproteinase-induced pulmonary hemorrhage. <I>Thromb  
  Haemost</I> 2005; 94: 123-131.    ^cY#6876.htm##
00245000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704001800072002000900090#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#52#48#article#78# </font>      ^cY#6876.
htm##
00526000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704028500074002000900359#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6876.htm#S#p#53#49#article#78#8#<P><font 
face="Arial, Helvetica, sans-serif">8. Guti&eacute;rrez JM, Rucavado    A, Escal
ante T, D&iacute;az C. Hemorrhage induced by snake venom metalloproteinases:    
biochemical and biophysical mechanisms involved in microvessel damage. <I>Toxico
n</I>    2005; 45: 997-1011.    ^cY#6876.htm##
00245000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704001800072002000900090#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#54#50#article#78# </font>      ^cY#6876.
htm##
00373000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704013200074002000900206#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6876.htm#S#p#55#51#article#78#9#<P><font 
face="Arial, Helvetica, sans-serif">9. White J. Snake venoms and coagulopathy.  
  <I>Toxicon</I> 2005; 45: 951-967.    ^cY#6876.htm##
00245000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704001800072002000900090#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#56#52#article#78# </font>      ^cY#6876.
htm##
00390000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704014800075002000900223#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6876.htm#S#p#57#53#article#78#10#<P><font
 face="Arial, Helvetica, sans-serif">10. Markland FS. Snake venoms and    the he
mostatic system. <I>Toxicon</I> 1998; 36: 1749-1800.    ^cY#6876.htm##
00245000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704001800072002000900090#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#58#54#article#78# </font>      ^cY#6876.
htm##
00470000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022800075002000900303#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6876.htm#S#p#59#55#article#78#11#<P><font
 face="Arial, Helvetica, sans-serif">11. Serrano SM, Maroun RC. Snake    venom s
erine proteinases: sequence homology <I>vs</I> substrate specificity,    a parad
ox to be solved. <I>Toxicon</I> 2005; 45: 1115-1132.    ^cY#6876.htm##
00245000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704001800072002000900090#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#60#56#article#78# </font>      ^cY#6876.
htm##
00641000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704039900075002000900474#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6876.htm#S#p#61#57#article#78#12#<P><font
 face="Arial, Helvetica, sans-serif">12. Lor&iacute;a GD, Rucavado A,    Kamigut
i AS, Theakston RD, Fox JW, Alape A, et al. Characterization of `basparin    A',
 a prothrombin-activating metalloproteinase, from the venom of the snake<I>    B
othrops asper</I> that inhibits platelet aggregation and induces defibrination  
  and thrombosis. <I>Arch Biochem Biophys</I> 2003; 418: 13-24.    ^cY#6876.htm#
#
00245000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704001800072002000900090#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#62#58#article#78# </font>      ^cY#6876.
htm##
00466000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022400075002000900299#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6876.htm#S#p#63#59#article#78#13#<P><font
 face="Arial, Helvetica, sans-serif">13. Ortiz FA, Gubensek F. Isolation    and 
some properties of blood clotting enzyme from the venom of <I>Bothrops asper</I>
.    <I>Bull Inst Pasteur</I> 1976; 74: 145-148.    ^cY#6876.htm##
00245000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704001800072002000900090#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#64#60#article#78# </font>      ^cY#6876.
htm##
00526000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704028400075002000900359#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6876.htm#S#p#65#61#article#78#14#<P><font
 face="Arial, Helvetica, sans-serif">14. Arag&oacute;n F, Gubensek F.    Charact
erization of thrombin-like proteinase from <I>Bothrops asper </I>venom.    In: R
osenberg P (Editor), <I>Toxins: animal, plant and microbial</I>. Oxford:    Perg
amon Press; 1978. p 107-111.    ^cY#6876.htm##
00244000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704001700072002000900089#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#66#62#article#78#</font>      ^cY#6876.h
tm##
00573000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704033100075002000900406#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6876.htm#S#p#67#63#article#78#15#<P><font
 face="Arial, Helvetica, sans-serif">15. Rucavado A, Escalante T, Guti&eacute;rr
ez    JM. Effect of the metalloproteinase inhibitor batimastat in the systemic t
oxicity    induced by <I>Bothrops asper </I>snake venom: understanding the role 
of metalloproteinases    in envenomation. <I>Toxicon</I> 2004; 43: 417-424.    ^
cY#6876.htm##
00245000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704001800072002000900090#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#68#64#article#78# </font>      ^cY#6876.
htm##
00435000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704019300075002000900268#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6876.htm#S#p#69#65#article#78#16#<P><font
 face="Arial, Helvetica, sans-serif">16. Laemmli UK. Cleavage of structural    p
roteins during the assembly of the head of bacteriophage T4. <I>Nature</I>    19
70; 227: 680-685.    ^cY#6876.htm##
00245000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704001800072002000900090#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#70#66#article#78# </font>      ^cY#6876.
htm##
00542000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704030000075002000900375#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6876.htm#S#p#71#67#article#78#17#<P><font
 face="Arial, Helvetica, sans-serif">17. Le Blanc JC, Hager JW, Ilisiu    AM, Hu
nter C, Zhong F, Chu I. Unique scanning capabilities of a new hybrid linear    i
on trap mass spectrometer (Q TRAP) used for high sensitivity proteomics applicat
ions.    <I>Proteomics</I> 2003; 3: 859-869.    ^cY#6876.htm##
00245000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704001800072002000900090#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#72#68#article#78# </font>      ^cY#6876.
htm##
00466000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022400075002000900299#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6876.htm#S#p#73#69#article#78#18#<P><font
 face="Arial, Helvetica, sans-serif">18. Theakston RD, Reid HA. Development    o
f simple standard assay procedures for the characterization of snake venom.    <
I>Bull World Health Organ</I> 1983; 61: 949-956.    ^cY#6876.htm##
00245000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704001800072002000900090#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#74#70#article#78# </font>      ^cY#6876.
htm##
00541000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704029900075002000900374#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6876.htm#S#p#75#71#article#78#19#<P><font
 face="Arial, Helvetica, sans-serif">19. Sant'Ana CD, Ticli FK, Oliveira    LL, 
Giglio JR, Rechia CG, Fuly AL, et al. BjussuSP-I: A new thrombin-like enzyme    
isolated from <I>Bothrops jararacussu</I> snake venom. <I>Comp Biochem Physiol  
  A Mol Integr Physiol</I> 2007 (in press).    ^cY#6876.htm##
00245000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704001800072002000900090#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#76#72#article#78# </font>      ^cY#6876.
htm##
00489000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704024700075002000900322#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6876.htm#S#p#77#73#article#78#20#<P><font
 face="Arial, Helvetica, sans-serif">20. Alexander G, Grothusen J, Zepeda    H, 
Schwartzman RJ. Gyroxin, a toxin from the venom of <I>Crotalus durissus terrific
us</I>,    is a thrombin-like enzyme. <I>Toxicon</I> 1988; 26: 953-960.    ^cY#6
876.htm##
00278000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704005100072002000900123#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#78#74#article#78#</font>  <HR ALIGN=LEFT
 WIDTH=100% SIZE=2>     ^cY#6876.htm##
00587000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704036000072002000900432#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#79#75#article#78#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT color="#00007F" SIZE=4
><B>Acknowledgments</B></FONT></font>    <font size="4" face="Arial, Helvetica, 
sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALI
GN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0" width="12" height="12"></B></A></f
ont></P>     ^cY#6876.htm##
00505000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704027800072002000900350#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#80#76#article#78#<P><font face="Arial, H
elvetica, sans-serif">The authors thank Teresa Escalante    and Bruno Lomonte fo
r their collaboration. A.V. P&eacute;rez was the recipient    of a scholarship f
rom NeTropica to perform her M.Sc. studies. </font>  <HR ALIGN=LEFT WIDTH=100% S
IZE=2>     ^cY#6876.htm##
00599000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704037200072002000900444#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#81#77#article#78#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Correspondence"></A><FONT color="#00007F" SIZE=4>
<B>Correspondence    and Footnotes</B></FONT></font> <font size="4" face="Arial,
 Helvetica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/b
ack.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0" width="12" height="12"
></B></A></font></P>     ^cY#6876.htm##
00675000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704044800072002000900520#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6876.htm#S#p#82#78#article#78#<P><font face="Arial, H
elvetica, sans-serif"><B><a href="#Home"><img src="/img/revistas/bjmbr/v41n1/rec
or.gif" width="15" height="14" border="0"></a>    Address for correspondence: </
B>J.M. Guti&eacute;rrez, Instituto Clodomiro Picado,    Facultad de Microbiolog&
iacute;a, Universidad de Costa Rica, San Jos&eacute;,    Costa Rica. Fax: +506-2
92-0485. E-mail: <a href="mailto:jgutierr@icp.ucr.ac.cr">jgutierr@icp.ucr.ac.cr<
/a></font>  </P>     ^cY#6876.htm##
00607000000000289000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100014000730100018000870120
05600105016001500161016001500176018006500191066001100256062001000267065000900277
064000500286014000800291865000900299002000900308#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6876.htm#S#c#83#1#article#20#1#^rND^sFan^nHW#^rND^sCardoso^nJL#Clinic
al toxicology of snake bites in South America^len#^rND^sMeier^nJ#^rND^sWhite^nJ#
Handbook of clinical toxicology of animal venoms and poisons^len#Boca Raton#CRC 
Press#19950000#1995#667-688#20080100#6876.htm##
00583000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100020000730120056000930160
01500149016001500164018006500179066001100244062001000255065000900265064000500274
014000800279865000900287002000900296#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
876.htm#S#c#84#2#article#20#2#^rND^sGutiérrez^nJM#Clinical toxicology of snakebi
te in Central America^len#^rND^sMeier^nJ#^rND^sWhite^nJ#Handbook of clinical tox
icology of animal venoms and poisons^len#Boca Raton#CRC Press#19950000#1995#645-
665#20080100#6876.htm##
00728000000000325000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100020000730100017000930120
06700110016001900177016001800196016001400214016001900228016001600247018008100263
06600100034406200080035406500090036206400050037101400080037686500090038400200090
0393#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6876.htm#S#c#85#3#article#20#3#^r
ND^sGutiérrez^nJM#^rND^sLomonte^nB#Efectos locales en el envenenamiento ofídico 
en América Latina^les#^rND^sCardoso^nJLC#^rND^sFrança^nFOS#^rND^sWen^nFH#^rND^sM
álaque^nCMS#^rND^sHaddad^nV#Animais peçonhentos no Brasil. Biologia, clínica e t
erapêutica dos acidentes^lpt#São Paulo#Sarvier#20030000#2003#310-323#20080100#68
76.htm##
00595000000000265000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100017000730120139000900300
02400229065000900253064000500262031000200267014000800269865000900277002000900286
035001000295801002400305#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6876.htm#S#c#
86#4#article#20#4#^rND^sBolaños^nR#Las serpientes venenosas de Centroamérica y e
l problema del ofidismo. Primera parte: Aspectos zoológicos, epidemiológicos y b
iomédicos^les#Rev Costarric Cienc Med#19820000#1982#3#165-184#20080100#6876.htm#
0253-2948#Rev Costarric Cienc Med##
00633000000000289000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100018000730120095000910160
01900186016001600205018004800221031000200269066000700271062002500278065000900303
064000500312014000800317865000900325002000900334#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6876.htm#S#c#87#5#article#20#5#^rND^sWarrell^nDA#Epidemiology, clinic
al features and management of snake bites in Central and South America^len#^rND^
sCampbell^nJA#^rND^sLamar^nWW#Venomous reptiles of the Western hemisphere^len#2#
Ithaca#Cornell University Press#20040000#2004#709-761#20080100#6876.htm##
00579000000000289000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100019000730100015000920100
01700107012009600124030000800220065000900228064000500237031000300242014000800245
865000900253002000900262035001000271801000800281#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6876.htm#S#c#88#6#article#20#6#^rND^sBarrantes^nA#^rND^sSolis^nV#^rND
^sBolaños^nR#Alterations in the coagulation mechanisms of patients bitten by Bot
hrops asper (Terciopelo)^len#Toxicon#19850000#1985#23#399-407#20080100#6876.htm#
0041-0101#Toxicon##
00761000000000325000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100018000730100014000910100
01900105010001600124010001400140010002000154012017800174030001500352065000900367
06400050037603100030038101400080038486500090039200200090040103500100041080100150
0420#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6876.htm#S#c#89#7#article#20#7#^r
ND^sRucavado^nA#^rND^sSoto^nM#^rND^sEscalante^nT#^rND^sLoría^nGD#^rND^sArni^nR#^
rND^sGutiérrez^nJM#Thrombocytopenia and platelet hypoaggregation induced by Both
rops asper snake venom: Toxins involved and their contribution to metalloprotein
ase-induced pulmonary hemorrhage^len#Thromb Haemost#20050000#2005#94#123-131#200
80100#6876.htm#0340-6245#Thromb Haemost##
00644000000000301000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100020000730100018000930100
01900111010001400130012012800144030000800272065000900280064000500289031000300294
014000900297865000900306002000900315035001000324801000800334#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6876.htm#S#c#90#8#article#20#8#^rND^sGutiérrez^nJM#^rND^s
Rucavado^nA#^rND^sEscalante^nT#^rND^sDíaz^nC#Hemorrhage induced by snake venom m
etalloproteinases: biochemical and biophysical mechanisms involved in microvesse
l damage^len#Toxicon#20050000#2005#45#997-1011#20080100#6876.htm#0041-0101#Toxic
on##
00457000000000265000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100015000730120034000880300
00800122065000900130064000500139031000300144014000800147865000900155002000900164
035001000173801000800183#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6876.htm#S#c#
91#9#article#20#9#^rND^sWhite^nJ#Snake venoms and coagulopathy^len#Toxicon#20050
000#2005#45#951-967#20080100#6876.htm#0041-0101#Toxicon##
00474000000000265000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100019000750120043000940300
00800137065000900145064000500154031000300159014001000162865000900172002000900181
035001000190801000800200#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6876.htm#S#c#
92#10#article#20#10#^rND^sMarkland^nFS#Snake venoms and the hemostatic system^le
n#Toxicon#19980000#1998#36#1749-1800#20080100#6876.htm#0041-0101#Toxicon##
00562000000000277000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100018000750100017000930120
10300110030000800213065000900221064000500230031000300235014001000238865000900248
002000900257035001000266801000800276#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
876.htm#S#c#93#11#article#20#11#^rND^sSerrano^nSM#^rND^sMaroun^nRC#Snake venom s
erine proteinases: sequence homology vs substrate specificity, a paradox to be s
olved^len#Toxicon#20050000#2005#45#1115-1132#20080100#6876.htm#0041-0101#Toxicon
##
00816000000000337000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100016000750100018000910100
01900109010002000128010001400148010001500162810000600177012020100183030002100384
06500090040506400050041403100040041901400060042386500090042900200090043803500100
0447801002100457#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6876.htm#S#c#94#12#ar
ticle#20#12#^rND^sLoría^nGD#^rND^sRucavado^nA#^rND^sKamiguti^nAS#^rND^sTheakston
^nRD#^rND^sFox^nJW#^rND^sAlape^nA#et al#Characterization of `basparin A', a prot
hrombin-activating metalloproteinase, from the venom of the snake Bothrops asper
 that inhibits platelet aggregation and induces defibrination and thrombosis^len
#Arch Biochem Biophys#20030000#2003#418#13-24#20080100#6876.htm#0003-9861#Arch B
iochem Biophys##
00568000000000277000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100016000750100018000910120
09200109030001800201065000900219064000500228031000300233014000800236865000900244
002000900253035001000262801001800272#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
876.htm#S#c#95#13#article#20#13#^rND^sOrtiz^nFA#^rND^sGubensek^nF#Isolation and 
some properties of blood clotting enzyme from the venom of Bothrops asper^len#Bu
ll Inst Pasteur#19760000#1976#74#145-148#20080100#6876.htm#0020-2452#Bull Inst P
asteur##
00583000000000277000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100016000750100018000910120
07500109016001900184018004000203067000700243062001500250065000900265064000500274
014000800279865000900287002000900296#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
876.htm#S#c#96#14#article#20#14#^rND^sAragón^nF#^rND^sGubensek^nF#Characterizati
on of thrombin-like proteinase from Bothrops asper venom^len#^rND^sRosenberg^nP#
Toxins: animal, plant and microbial^len#Oxford#Pergamon Press#19780000#1978#107-
111#20080100#6876.htm##
00673000000000289000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100018000750100019000930100
02000112012018200132030000800314065000900322064000500331031000300336014000800339
865000900347002000900356035001000365801000800375#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6876.htm#S#c#97#15#article#20#15#^rND^sRucavado^nA#^rND^sEscalante^nT
#^rND^sGutiérrez^nJM#Effect of the metalloproteinase inhibitor batimastat in the
 systemic toxicity induced by Bothrops asper snake venom: understanding the role
 of metalloproteinases in envenomation^len#Toxicon#20040000#2004#43#417-424#2008
0100#6876.htm#0041-0101#Toxicon##
00515000000000265000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100018000750120088000930300
00700181065000900188064000500197031000400202014000800206865000900214002000900223
035001000232801000700242#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6876.htm#S#c#
98#16#article#20#16#^rND^sLaemmli^nUK#Cleavage of structural proteins during the
 assembly of the head of bacteriophage T4^len#Nature#19700000#1970#227#680-685#2
0080100#6876.htm#0028-0836#Nature##
00682000000000313000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100019000750100016000940100
01700110010001600127010001500143010001300158012014200171030001100313710000200324
065000900326064000500335031000200340014000800342865000900350002000900359#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6876.htm#S#c#99#17#article#20#17#^rND^sLe^nBl
anc JC#^rND^sHager^nJW#^rND^sIlisiu^nAM#^rND^sHunter^nC#^rND^sZhong^nF#^rND^sChu
^nI#Unique scanning capabilities of a new hybrid linear ion trap mass spectromet
er (Q TRAP) used for high sensitivity proteomics applications^len#Proteomics#2#2
0030000#2003#3#859-869#20080100#6876.htm##
00582000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100015000960120
09200111030002400203065000900227064000500236031000300241014000800244865000900252
002000900261035001000270801002400280#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
876.htm#S#c#100#18#article#20#18#^rND^sTheakston^nRD#^rND^sReid^nHA#Development 
of simple standard assay procedures for the characterization of snake venom^len#
Bull World Health Organ#19830000#1983#61#949-956#20080100#6876.htm#0042-9686#Bul
l World Health Organ##
00736000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100016000950100
01900111010001700130010001700147010001500164810000600179012009000185030004200275
06500090031706400050032606100090033186500090034000200090034903500100035880100420
0368#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6876.htm#S#c#101#19#article#20#19
#^rND^sSant'Ana^nCD#^rND^sTicli^nFK#^rND^sOliveira^nLL#^rND^sGiglio^nJR#^rND^sRe
chia^nCG#^rND^sFuly^nAL#et al#BjussuSP-I: A new thrombin-like enzyme isolated fr
om Bothrops jararacussu snake venom^len#Comp Biochem Physiol A Mol Integr Physio
l#20070000#2007#in press#20080100#6876.htm#1095-6433#Comp Biochem Physiol A Mol 
Integr Physiol##
00618000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100019000950100
01600114010002200130012009500152030000800247065000900255064000500264031000300269
014000800272865000900280002000900289035001000298801000800308#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6876.htm#S#c#102#20#article#20#20#^rND^sAlexander^nG#^rND
^sGrothusen^nJ#^rND^sZepeda^nH#^rND^sSchwartzman^nRJ#Gyroxin, a toxin from the v
enom of Crotalus durissus terrificus, is a thrombin-like enzyme^len#Toxicon#1988
0000#1988#26#953-960#20080100#6876.htm#0041-0101#Toxicon##
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#o#1#1#article#1#20
080623#161518#6885.htm#178##
03315000000000673000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000400087121000300091049000900094158000300103030002000106
03100030012603200020012906500090013101400090014003500100014922300090015901201500
01680100022003180100026003400100023003660100020003890100030004090100022004390100
02400461070009600485070013100581083165700712085000802369085002102377085002602398
08500210242408500200244508500350246508500190250011700060251907200030252505800040
25280600008025320580005025400600014025451120009025591110012025681140009025801130
01902589881002402608002000902632#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.
htm#S#h#2#1#article#1#oa#en#bjmbr#1#3.1#TAB#08#BJMBR050#nd#Braz J Med Biol Res#4
1#1#20080100#^f47^l53#0100-879X#20071217#Association between the -174 G/C promot
er polymorphism of the interleukin-6 gene and cardiovascular disease risk factor
s in Brazilian older women^len#^rND^1A01^nA.C^sTonet#^rND^1A01^nM^sKarnikowski#^
rND^1A01^nC.F^sMoraes#^rND^1A01^nL^sGomes#^rND^1A01^nM.G.O^sKarnikowski#^rND^1A0
2^nC^sCórdova#^rND^1A01^nO.T^sNóbrega#Universidade Católica de Brasília^iA01^1Pr
ograma de Pós-Graduação Stricto Sensu em Gerontologia#Universidade Católica de B
rasília^iA02^1Programa de Pós-Graduação Stricto Sensu em Educação Física e Saúde
^cTaguatinga^sDF^pBrasil#^len^aIn worldwide studies, interleukin-6 (IL-6) is imp
licated in age-related disturbances. The aim of the present report was to determ
ine the possible association of IL-6 -174 C/G promoter polymorphism with the cyt
okine profile as well as with the presence of selected cardiovascular risk featu
res. This was a cross-sectional study on Brazilian women aged 60 years or older.
 A sample of 193 subjects was investigated for impaired glucose regulation, diab
etes, hypertension, and dyslipidemia. Genotyping was done by direct sequencing o
f PCR products. IL-6 and C-reactive protein were quantified by high-sensitivity 
assays. General linear regression models or the Student t-test were used to comp
are continuous variables among genotypes, followed by adjustments for confoundin
g variables. The chi-square test was used to compare categorical variables. The 
genotypes were consistent with Hardy-Weinberg equilibrium proportions. In a rece
ssive model, mean waist-to-hip ratio, serum glycated hemoglobin and serum glucos
e were markedly lower in C homozygotes (P = 0.001, 0.028, and 0.047, respectivel
y). In a dominant hypothesis, G homozygotes displayed a trend towards higher lev
els of circulating IL-6 (P = 0.092). Non-parametric analysis revealed that impai
red fasting glucose and hypertension were findings approximately 2-fold more fre
quent among G homozygous subjects (P = 0.042 and 0.043, respectively). Taken tog
ether, our results show that the IL-6 -174 G-allele is implicated in a greater c
ardiovascular risk. To our knowledge, this is the first investigation of IL-6 pr
omoter variants and age-related disturbances in the Brazilian elderly population
.#^dnd^i1#^tm^len^kCytokine^i1#^tm^len^kInterleukin-6^i1#^tm^len^kGenetics^i1#^t
m^len^kElderly^i1#^tm^len^kCardiovascular disease^i1#^tm^len^kBrazil^i1#other#39
#UCB#01/2005#CNPq#484318/2006-3#20070509#May 9, 2007#20070924#September 24, 2007
#S0100-879X2006005000190#6885.htm##
03335000000000661000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000400087121000300091049000900094158000300103030002000106
03100030012603200020012906500090013101400090014003500100014922300090015901201640
01680100022003320100026003540100023003800100020004030100030004230100022004530100
02400475070009600499070013100595083169900726085000802425085002102433085002602454
08500210248008500200250108500350252108500190255611700060257507200030258105800040
25840600008025880580005025960600014026011120009026151110012026241140009026361130
01902645002000902664#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#f#3#1#
article#1#oa#en#bjmbr#1#3.1#TAB#08#BJMBR050#nd#Braz J Med Biol Res#41#1#20080100
#^f47^l53#0100-879X#20071217#<B>Association between the -174 <I>G/C</I> promoter
 polymorphism of the interleukin-6 gene and cardiovascular disease risk factors 
in Brazilian older women</B>^len#^rND^1A01^nA.C^sTonet#^rND^1A01^nM^sKarnikowski
#^rND^1A01^nC.F^sMoraes#^rND^1A01^nL^sGomes#^rND^1A01^nM.G.O^sKarnikowski#^rND^1
A02^nC^sCórdova#^rND^1A01^nO.T^sNóbrega#Universidade Católica de Brasília^iA01^1
Programa de Pós-Graduação Stricto Sensu em Gerontologia#Universidade Católica de
 Brasília^iA02^1Programa de Pós-Graduação Stricto Sensu em Educação Física e Saú
de^cTaguatinga^sDF^pBrasil#^len^aIn worldwide studies, interleukin-6 (IL-6) is i
mplicated in age-related disturbances. The aim of the present report was to dete
rmine the possible association of IL-6 -174 <I>C/G</I> promoter polymorphism wit
h the cytokine profile as well as with the presence of selected cardiovascular r
isk features. This was a cross-sectional study on Brazilian women aged 60 years 
or older. A sample of 193 subjects was investigated for impaired glucose regulat
ion, diabetes, hypertension, and dyslipidemia. Genotyping was done by direct seq
uencing of PCR products. IL-6 and C-reactive protein were quantified by high-sen
sitivity assays. General linear regression models or the Student <I>t</I>-test w
ere used to compare continuous variables among genotypes, followed by adjustment
s for confounding variables. The chi-square test was used to compare categorical
 variables. The genotypes were consistent with Hardy-Weinberg equilibrium propor
tions. In a recessive model, mean waist-to-hip ratio, serum glycated hemoglobin 
and serum glucose were markedly lower in <I>C</I> homozygotes (P = 0.001, 0.028,
 and 0.047, respectively). In a dominant hypothesis, <I>G</I> homozygotes displa
yed a trend towards higher levels of circulating IL-6 (P = 0.092). Non-parametri
c analysis revealed that impaired fasting glucose and hypertension were findings
 approximately 2-fold more frequent among<I> G</I> homozygous subjects (P = 0.04
2 and 0.043, respectively). Taken together, our results show that the IL-6 -174 
<I>G</I>-allele is implicated in a greater cardiovascular risk. To our knowledge
, this is the first investigation of IL-6 promoter variants and age-related dist
urbances in the Brazilian elderly population.#^dnd^i1#^tm^len^kCytokine^i1#^tm^l
en^kInterleukin-6^i1#^tm^len^kGenetics^i1#^tm^len^kElderly^i1#^tm^len^kCardiovas
cular disease^i1#^tm^len^kBrazil^i1#other#39#UCB#01/2005#CNPq#484318/2006-3#2007
0509#May 9, 2007#20070924#September 24, 2007#6885.htm##
03442000000000685000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000400100121000300104049000900107158000300116
03000240011903100030014303200020014606500090014801400090015703500100016622300090
01760120150001850100023003350100026003580100024003840100020004080100032004280100
02200460010002500482070012200507070013300629083165700762085000802419085002102427
08500260244808500210247408500200249508500350251508500190255011700060256907200030
25750580004025780600008025820580005025900600014025951120009026091110012026181140
00902630113001902639002000902658008008902667#v41n1#v:\scielo\serial\bjmbr\v41n1\
markup\6885.htm#S#l#4#1#article#1#^mJan.^a2008#oa#en#bjmbr#1#3.1#tab#08#BJMBR050
#nd#Braz. j. med. biol. res#41#1#20080100#^f47^l53#0100-879X#20071217#Associatio
n between the -174 G/C promoter polymorphism of the interleukin-6 gene and cardi
ovascular disease risk factors in Brazilian older women^len#^rND^1A01^nA. C^sTon
et#^rND^1A01^nM^sKarnikowski#^rND^1A01^nC. F^sMoraes#^rND^1A01^nL^sGomes#^rND^1A
01^nM. G. O^sKarnikowski#^rND^1A02^nC^sCórdova#^rND^1A01^nO. T^sNóbrega#^iA01^1U
niversidade Católica de Brasília^2Programa de Pós-Graduação Stricto Sensu em Ger
ontologia^cTaguatinga^sDF^pBrasil#^iA02^1Universidade Católica de Brasília^2Prog
rama de Pós-Graduação Stricto Sensu em Educação Física e Saúde^cTaguatinga^sDF^p
Brasil#^len^aIn worldwide studies, interleukin-6 (IL-6) is implicated in age-rel
ated disturbances. The aim of the present report was to determine the possible a
ssociation of IL-6 -174 C/G promoter polymorphism with the cytokine profile as w
ell as with the presence of selected cardiovascular risk features. This was a cr
oss-sectional study on Brazilian women aged 60 years or older. A sample of 193 s
ubjects was investigated for impaired glucose regulation, diabetes, hypertension
, and dyslipidemia. Genotyping was done by direct sequencing of PCR products. IL
-6 and C-reactive protein were quantified by high-sensitivity assays. General li
near regression models or the Student t-test were used to compare continuous var
iables among genotypes, followed by adjustments for confounding variables. The c
hi-square test was used to compare categorical variables. The genotypes were con
sistent with Hardy-Weinberg equilibrium proportions. In a recessive model, mean 
waist-to-hip ratio, serum glycated hemoglobin and serum glucose were markedly lo
wer in C homozygotes (P = 0.001, 0.028, and 0.047, respectively). In a dominant 
hypothesis, G homozygotes displayed a trend towards higher levels of circulating
 IL-6 (P = 0.092). Non-parametric analysis revealed that impaired fasting glucos
e and hypertension were findings approximately 2-fold more frequent among G homo
zygous subjects (P = 0.042 and 0.043, respectively). Taken together, our results
 show that the IL-6 -174 G-allele is implicated in a greater cardiovascular risk
. To our knowledge, this is the first investigation of IL-6 promoter variants an
d age-related disturbances in the Brazilian elderly population.#^dnd^i1#^tm^len^
kCytokine^i1#^tm^len^kInterleukin-6^i1#^tm^len^kGenetics^i1#^tm^len^kElderly^i1#
^tm^len^kCardiovascular disease^i1#^tm^len^kBrazil^i1#other#39#UCB#01/2005#CNPq#
484318/2006-3#20070509#May 9, 2007#20070924#September 24, 2007#6885.htm#Internet
^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2008000100008
##
00375000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704014900071002000900220#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#5#1#article#135#<P> <font face="Arial, H
elvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med    Biol Res, January 2008
, Volume 41(1) 47-53</B> </font></P>     ^cY#6885.htm##
00462000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704023600071002000900307#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#6#2#article#135#<P><B><font size="5" fac
e="Arial, Helvetica, sans-serif">Association between the    -174 <I>G/C</I> prom
oter polymorphism of the interleukin-6 gene and cardiovascular    disease risk f
actors in Brazilian older women</font></B>      ^cY#6885.htm##
00737000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704051100071002000900582#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#7#3#article#135#<P><font face="Arial, He
lvetica, sans-serif">A.C. Tonet<SUP>1</SUP>, M. Karnikowski<SUP>1</SUP>,    C.F.
 Moraes<SUP>1</SUP>, L. Gomes<SUP>1</SUP>, M.G.O. Karnikowski<SUP>1</SUP>,    C.
 C&oacute;rdova<SUP>2</SUP> and <b><a href="#Correspondence"><img src="/img/revi
stas/bjmbr/v41n1/recor.gif" width="15" height="14" border="0"></a></b>    <a hre
f="mailto:nobrega@ucb.br"><img src="/img/revistas/bjmbr/v41n1/email-ca.gif" widt
h="14" height="11" border="0"></a>    O.T. N&oacute;brega<SUP>1</SUP> </font>   
   ^cY#6885.htm##
00601000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704037500071002000900446#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#8#4#article#135#<P><font face="Arial, He
lvetica, sans-serif"><SUP>1</SUP>Programa de P&oacute;s-Gradua&ccedil;&atilde;o 
   <I>Stricto Sensu</I> em Gerontologia, <SUP>2</SUP>Programa de P&oacute;s-Grad
ua&ccedil;&atilde;o    <I>Stricto Sensu</I> em Educa&ccedil;&atilde;o F&iacute;s
ica e Sa&uacute;de,    Universidade Cat&oacute;lica de Bras&iacute;lia, Taguatin
ga, DF, Brasil</font>      ^cY#6885.htm##
00442000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704021600071002000900287#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#9#5#article#135#<P> <font face="Arial, H
elvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v41n1/do
wn.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12">    <stro
ng>Abstract</strong></A>    ^cY#6885.htm##
00440000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704021300072002000900285#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#10#6#article#135#<BR>   <A HREF="#Introd
uction"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPA
CE=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Introduction"><strong>Int
roduction</strong></A>    ^cY#6885.htm##
00440000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704021300072002000900285#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#11#7#article#135#<BR>   <A HREF="#Materi
al"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0
 HSPACE=0 width="12" height="12"></A>    <A HREF="#Material"><strong>Material an
d Methods</strong></A>    ^cY#6885.htm##
00425000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704019800072002000900270#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#12#8#article#135#<BR>   <A HREF="#Result
s"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0 width="12" height="12"></A>    <A HREF="#Results"><strong>Results</stro
ng></A>    ^cY#6885.htm##
00434000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704020700072002000900279#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#13#9#article#135#<BR>   <A HREF="#Discus
sion"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Discussion"><strong>Discuss
ion</strong></A>    ^cY#6885.htm##
00422000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704019400073002000900267#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#14#10#article#135#<BR>   <A HREF="#Refer
ences"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#References"><strong>Refere
nces    ^cY#6885.htm##
00463000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704023500073002000900308#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#15#11#article#135#<br>   </strong></A><A
 HREF="#Acknowledgments"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOT
TOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Acknowle
dgments"><strong>Acknowledgments</strong></A>    ^cY#6885.htm##
00474000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704024600073002000900319#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#16#12#article#135#<BR>   <A HREF="#Corre
spondence"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 V
SPACE=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Correspondence"><stron
g>Correspondence and Footnotes</strong></A>    </font>      ^cY#6885.htm##
00275000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704004700073002000900120#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#17#13#article#135#<P>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>     ^cY#6885.htm##
00563000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704033500073002000900408#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#18#14#article#135#<P> <font face="Arial,
 Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F>
<B>Abstract    </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1
/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></
A></FONT></font></P> <font face="Arial, Helvetica, sans-serif">      ^cY#6885.ht
m##
01993000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704176500073002000901838#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#19#15#article#135#<P>In worldwide studie
s, interleukin-6 (IL-6) is implicated in age-related disturbances.    The aim of
 the present report was to determine the possible association of IL-6    -174 <I
>C/G</I> promoter polymorphism with the cytokine profile as well as with    the 
presence of selected cardiovascular risk features. This was a cross-sectional   
 study on Brazilian women aged 60 years or older. A sample of 193 subjects was  
  investigated for impaired glucose regulation, diabetes, hypertension, and dysl
ipidemia.    Genotyping was done by direct sequencing of PCR products. IL-6 and 
C-reactive    protein were quantified by high-sensitivity assays. General linear
 regression    models or the Student <I>t</I>-test were used to compare continuo
us variables    among genotypes, followed by adjustments for confounding variabl
es. The chi-square    test was used to compare categorical variables. The genoty
pes were consistent    with Hardy-Weinberg equilibrium proportions. In a recessi
ve model, mean waist-to-hip    ratio, serum glycated hemoglobin and serum glucos
e were markedly lower in <I>C</I>    homozygotes (P = 0.001, 0.028, and 0.047, r
espectively). In a dominant hypothesis,    <I>G</I> homozygotes displayed a tren
d towards higher levels of circulating    IL-6 (P = 0.092). Non-parametric analy
sis revealed that impaired fasting glucose    and hypertension were findings app
roximately 2-fold more frequent among<I> G</I>    homozygous subjects (P = 0.042
 and 0.043, respectively). Taken together, our    results show that the IL-6 -17
4 <I>G</I>-allele is implicated in a greater cardiovascular    risk. To our know
ledge, this is the first investigation of IL-6 promoter variants    and age-rela
ted disturbances in the Brazilian elderly population.      ^cY#6885.htm##
00338000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704011000073002000900183#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#20#16#article#135#<P>Key words: Cytokine
; Interleukin-6; Genetics; Elderly, Cardiovascular disease;    Brazil  </font>  
    ^cY#6885.htm##
00275000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704004700073002000900120#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#21#17#article#135#<P>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>     ^cY#6885.htm##
00617000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038900073002000900462#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#22#18#article#135#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Introduction"></A><FONT color="#00007F" SIZE=4><
B>Introduction</B></FONT></font>    <font size="4" face="Arial, Helvetica, sans-
serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A></font></P> <font
 face="Arial, Helvetica, sans-serif">      ^cY#6885.htm##
02105000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704187700073002000901950#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#23#19#article#135#<P>Inflammation is rec
ognized as a central component of cardiovascular disease    (CVD), even though t
he underlying regulation and molecular mechanisms remain    unclear (1). Interle
ukin-6 (IL-6) is a pleiotropic cytokine involved in a range    of immunological 
activities, especially the synthesis of acute-phase substances    by the liver. 
As its receptor subunit (gp130) is widely expressed, deregulated    high-level p
roduction of the cytokine combined with its agonistic soluble receptor    (sIL-6
R) may induce an undesired basal inflammatory state in many organs and    thus c
ause non-communicable diseases (2). It has been reported that the common    -174
 <I>C/G</I> polymorphism in the promoter region of human IL-6 regulates    its t
ranscription <I>in vitro</I>, with the <I>G</I> allele showing increased    tran
scriptional activity both under basal conditions and in response to inflammatory
    stimuli such as lipopolysaccharides or IL-1 (3-5). However, data on the effe
cts    of this polymorphism on IL-6 levels <I>in vivo</I> have led to conflictin
g results.    Most studies have shown that <I>G/G</I> individuals have an increa
sed IL-6 mRNA    expression (6) and higher circulating IL-6 levels (3,7), as wou
ld be expected    from <I>in vitro</I> data. Conversely, other studies have repo
rted no differences    among genotypes or increased levels of the cytokine among
 <I>C/C</I>-carrying    subjects (8,9). In addition to the issue of genotype-rel
ated expression levels,    it is also recognized that an age-related increase in
 serum IL-6 levels takes    place among men and women (10), beginning as early a
s at 30-40 years of age    (11), being prevalent even in people devoid of any ov
ert acute or chronic disease    (12), becoming prominent in later life (13,14), 
and acting as a predictor of    mortality independent of pre-existing morbidity 
(15).      ^cY#6885.htm##
01535000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704130700073002000901380#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#24#20#article#135#<P>By and large, eleva
ted levels of IL-6 are associated with an increased risk    of death from cardio
vascular causes in the elderly. Elevated levels of C-reactive    protein (CRP), 
an acute-phase reactant largely regulated by IL-6, are also independently    ass
ociated with a long-term risk for CVD (16). Our underlying hypothesis is    that
 IL-6 genotypes may predispose to risk factors for CVD (hypercholesterolemia,   
 hypertriglyceridemia, hypertension, diabetes, and impaired glycemic homeostasis
)    which would then be accompanied by a chronic inflammatory disorder. The exi
stence    of linkage disequilibrium between -174 <I>C/G</I> polymorphism and oth
er genotypes,    revealed by Western-based population haplotyping studies (5,17)
, demonstrates    that investigating solely the -174 <I>C/G</I> polymorphism is 
as informative    as investigating the entire promoter haplotype. Because a larg
e fraction of    cardiovascular events occurs in people aged 60 years or older a
nd the IL-6 promoter    polymorphism has not been studied extensively among aged
 women, we examined    the effects of the -174 <I>C/G</I> genotypes on CVD risk 
factors in a subset    of subjects from the Elderly Health Promotion Project hel
d in Bras&iacute;lia,    Brazil.  </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>    
 ^cY#6885.htm##
00577000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704034900073002000900422#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#25#21#article#135#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Material"></A><FONT color="#00007F" SIZE=4><B>Ma
terial    and Methods</B></FONT></font> <font size="4" face="Arial, Helvetica, s
ans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIG
N=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A></font></P>  
   ^cY#6885.htm##
00305000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704007700073002000900150#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#26#22#article#135#<P><b><font face="Aria
l, Helvetica, sans-serif">Subjects</font></b>      ^cY#6885.htm##
01880000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704165200073002000901725#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#27#23#article#135#<P><font face="Arial, 
Helvetica, sans-serif">Bras&iacute;lia is the administrative    capital of the B
razilian federation, located in Central West Brazil. Sampling    for the present
 study was based on preliminary genotyping of 30 subjects. A    minimum series o
f 175 subjects was determined for a frequency of risk allele    of 0.80, with a 
confidence level of 0.95 and an estimation error of 0.05 for    a finite populat
ion. Therefore, cross-sectional analyses were performed using    data obtained f
rom 224 apparently healthy, female outpatients from the urban    outskirts of th
e Brazilian Federal District, aged 60 years or older and recruited    to undergo
 health screenings and intervention (medical, nutritional and/or pharmacological
)    for the prevention of CVD at the Hospital of Universidade Cat&oacute;lica d
e    Bras&iacute;lia. For recruitment purposes, public invitations through mass 
communication    networks were broadcast early in 2005. Invitations were directe
d at aged women    from the outskirts of Bras&iacute;lia invited to join a unive
rsity research    project involving health promotion actions and ambulatory foll
ow-up. The project    became known as the Elderly Health Promotion Project, and 
this is the first    report of our activities in the project. The assessment on 
cardiovascular risk    reported in this study was performed from April to Octobe
r 2005. The study was    approved by the institutional Research Ethics Committee
 (CEP/UCB). Participation    was voluntary, and informed written consent was obt
ained from each participant    in accordance with the principles of the Helsinki
 Declaration.</font>      ^cY#6885.htm##
00318000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704009000073002000900163#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#28#24#article#135#<P><font face="Arial, 
Helvetica, sans-serif"><B>Clinical procedures </B> </font>      ^cY#6885.htm##
00898000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704067000073002000900743#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#29#25#article#135#<P><font face="Arial, 
Helvetica, sans-serif">Laboratory tests included serum liver    tests (aspartate
 aminotransferase, alanine aminotransaminase, and alkaline phosphatase),    cyto
megalovirus and Epstein-Barr IgM serology, and total blood count. Fasting    ser
um determinations of glucose, glycated hemoglobin (HbA1c), triglycerides,    tot
al cholesterol, and fractions (low- and high-density lipoprotein) were also    o
btained. All tests were performed following routine clinical analysis. CRP    wa
s measured using a high-sensitivity turbidimetric assay (BioT&eacute;cnica<SUP>&
#174;</SUP>,    Varginha, MG, Brazil) with a sensitivity of 0.05 mg/L. </font>  
    ^cY#6885.htm##
00891000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704066300073002000900736#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#30#26#article#135#<P><font face="Arial, 
Helvetica, sans-serif">For IL-6 measurement, whole blood    was collected into e
ndotoxin-free tubes. Serum was separated from whole blood    within 1 h of colle
ction, stored in aliquots at -80&#176;C and analyzed in batches    using a speci
fic enzyme-linked immunosorbent assay kit (GE Healthcare, Uppsala,    Sweden). S
amples for IL-6 quantification were analyzed in duplicate and their    coefficie
nt of variation (CV) were determined (CV<I><SUB>C/C</SUB></I> 11.7    <I>vs</I> 
15.6; CV<I><SUB>G/C</SUB></I> 29.6 <I>vs</I> 26.3; CV<I><SUB>G/G</SUB></I>    66
.4 <I>vs</I> 84.7). The minimum detectable dose was 0.10 pg/mL. </font>      ^cY
#6885.htm##
01170000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704094200073002000901015#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#31#27#article#135#<P><font face="Arial, 
Helvetica, sans-serif">On the occasion of the clinical visit,    blood pressure 
was measured after at least 10 min of rest in the sitting position.    The blood
 pressure value of each subject was the mean of three physician-obtained    meas
urements, recorded &gt;3 min apart. Body mass index (BMI; weight (kg)/height    
(m&#178;)) and waist-to-hip ratio (WHR; waist circumference/hip circumference)  
  were obtained for each patient. Body weight was measured to the nearest 0.1   
 kg with the subject using light clothing and without shoes and height was measu
red    to the nearest 0.1 cm. Waist circumference was measured midway between th
e iliac    crest and the lower costal margin, whereas hip circumference was meas
ured at    its maximum. Cases of active infection, inflammation or malignancies 
were assessed    by semiological criteria based on medical examination assisted 
by laboratory    data. </font>      ^cY#6885.htm##
01331000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704110300073002000901176#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#32#28#article#135#<P><font face="Arial, 
Helvetica, sans-serif">Hypertension was defined as systolic    blood pressure <f
ont face="Symbol">&#179;</font>135 or diastolic blood pressure    <font face="Sy
mbol">&#179;</font>85 mmHg, or current use of antihypertensive    medication, wh
ereas diabetes mellitus was characterized by fasting blood glucose    <font face
="Symbol">&#179;</font>126 mg/dL, or current use of insulin or oral    anti-diab
etic drugs. Impaired glucose regulation encompassed cases of diabetes    mellitu
s and any cases of fasting blood glucose <font face="Symbol">&#179;</font>110   
 mg/dL. Hypertriglyceridemia was defined as triglycerides <font face="Symbol">&#
179;</font>150    mg/dL and hypercholesterolemia was defined as total cholestero
l <font face="Symbol">&#179;</font>200    mg/dL or low-density lipoprotein <font
 face="Symbol">&#179;</font>130 mg/dL.    Current use of anti-lipemic medication
 was considered to represent either entity.    Dyslipidemia was defined as isola
ted or combined hypertriglyceridemia, hypercholesterolemia    and high-density l
ipoprotein &lt;50 mg/dL.</font>      ^cY#6885.htm##
00310000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704008200073002000900155#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#33#29#article#135#<P><font face="Arial, 
Helvetica, sans-serif"><B>DNA analysis</B> </font>      ^cY#6885.htm##
01635000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704140700073002000901480#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#34#30#article#135#<P><font face="Arial, 
Helvetica, sans-serif">Total DNA was isolated from peripheral    blood according
 to standard procedures. The -174<I> G/C</I> polymorphism in    the promoter of 
the human IL-6 gene (rs1800795) was determined by direct sequencing    of a poly
merase chain reaction product. A 628-bp region was amplified using    a pair of 
specific primers: 5'-GAACACAGAAGAACTCAGATG ACTGG-3' (sense) and 5'-AGGAGTTCATAGC
TGGGCTC    CTGGAG-3' (antisense), which flank the polymorphism. The reaction tub
es contained    100 ng DNA, 10 mM Tris-HCl, pH 9.2, 25 mM KCl, 1.5 mM MgCl<SUB>2
</SUB>, 0.2    mM dNTP, 20 pmol of each primer, 0.5 &#181;g purified chicken alb
umin, and 1    unit <I>Taq</I> DNA polymerase (Phoneutria<SUP>&#174;</SUP>, Belo
 Horizonte,    MG, Brazil) in a final volume of 50 &#181;L. After 1 min of hot s
tart at 80&#176;C    and an initial denaturation for 2 min at 94&#176;C, the amp
lifications were    carried out for 36 cycles of 40 s at 94&#176;C, 45 s at 64&#
176;C, and 50 s    at 72&#176;C followed by a final 5-min extension at 72&#176;C
. Each polymerase    chain reaction product was directly sequenced on an ABI PRI
SM 3700 DNA analyzer    (Applied Biosystems, Foster City, CA, USA), using the 5'
-GCCTCAGAGACATCTCCAGTCC-3'    primer. Each sequence obtained was examined using 
the Staden software package    (MRC, Cambridge, UK), and confirmed by visual ins
pection.</font>      ^cY#6885.htm##
00318000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704009000073002000900163#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#35#31#article#135#<P><font face="Arial, 
Helvetica, sans-serif"><B>Statistical analysis</B> </font>      ^cY#6885.htm##
01104000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704087600073002000900949#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#36#32#article#135#<P><font face="Arial, 
Helvetica, sans-serif">Violation of Hardy-Weinberg equilibrium    was tested usi
ng the Fisher exact test. The Kolmogorov-Smirnov test was used    to determine t
he distribution of data from continuous variables. Whenever appropriate,    data
 were reported as means &#177; SD. General linear regression models or the    St
udent-<I>t</I> test were used to compare means of continuous variables (levels  
  of fasting glycemic markers, blood pressure, white blood cell count, lipids,  
  liver markers, CRP, and IL-6) across genotypes using dominant, co-dominant and
    recessive comparison models. <I>Post hoc</I> comparisons were made using the
    Tukey test for pairwise comparisons. Phenotypic differences between genotype
s    were also tested for influence of co-variables by adjustment for confoundin
g    factors (age and BMI) by ANOVA. </font>      ^cY#6885.htm##
00748000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704052000073002000900593#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#37#33#article#135#<P><font face="Arial, 
Helvetica, sans-serif">Association of IL-6 genotypes with    categorical variabl
es representing CVD risk factor (states of impaired glucose    regulation, diabe
tes, hypertension, and dyslipidemia) was investigated by the    <font face="Symb
ol">c</font><SUP>2</SUP> test. All analyses were performed employing    the Stat
istical Package for Social Sciences (SPSS) for Windows (version 10.0).    A P va
lue &lt; 0.05 was considered to be significant.</font>  <HR ALIGN=LEFT WIDTH=100
% SIZE=2>     ^cY#6885.htm##
00563000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704033500073002000900408#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#38#34#article#135#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Results"></A><FONT color="#00007F" SIZE=4><B>Res
ults</B></FONT></font>    <font size="4" face="Arial, Helvetica, sans-serif"><A 
HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIGN=BOTTOM BORDE
R=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A></font></P>     ^cY#6885.ht
m##
00770000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704054200073002000900615#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#39#35#article#135#<P><font face="Arial, 
Helvetica, sans-serif">Data from 31 individuals enrolled    in the clinical scre
ening were eliminated from the databank due to exclusion    reasons described as
 follows: 17 for unavailability for laboratory testing,    12 for current use of
 anti-inflammatory drugs, and 2 for cytomegalovirus or    Epstein-Barr reactivit
y. No subjects were excluded based on the criteria of    active infection, infla
mmation or malignancy. Therefore, 193 subjects fulfilling    the inclusion crite
ria were included. </font> </P>     ^cY#6885.htm##
01821000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704159300073002000901666#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#40#36#article#135#<P><font face="Arial, 
Helvetica, sans-serif">The prevalence of the IL-6 -174 <I>G</I>    and <I>C</I> 
alleles was 78.9 and 21.1%, respectively. The genotypes were consistent    with 
Hardy-Weinberg equilibrium proportions (61.9% <I>G/G</I>, 34.0% <I>C/G</I>,    4
.1% <I>C/C</I>; P &gt; 0.05). The clinical and laboratory characteristics of    
the subjects analyzed are summarized in <a href="#Tab1">Table 1</a>. In a co-dom
inant    model, no significant differences in age, BMI, fasting glucose levels, 
HbA1c    levels, serum lipids, liver marker concentration, leukocyte count, or C
RP were    observed between subjects carrying the three genotypes. Nonetheless, 
the mean    WHR was significantly reduced in subjects carrying the -174 <I>C/C</
I> genotype    compared to carriers of the <I>G/G</I> (P = 0.004) and <I>C/G</I>
 (P = 0.001)    genotypes, concurring with a recessive model of genotype effect.
 In agreement,    homozygous carriers of the <I>C</I> allele also had significan
tly lower levels    of fasting serum glycated hemoglobin and glucose compared to
 carriers of the    <I>G</I> allele (<a href="#Tab1">Table 1</a>). To explore a 
dominant hypothesis,    analysis combining the <I>C/G</I> and <I>C/C</I> genotyp
es in one group was    also performed. In this scenario, the mean WHR and averag
e glycemic markers    did not differ significantly between the <I>G</I> homozygo
tes and the <I>C</I>    carriers. By contrast, a tendency towards higher serum I
L-6 levels was observed    among <I>G</I> homozygotes compared to carriers of th
e <I>C</I> allele (P =    0.092). </font>      ^cY#6885.htm##
01010000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704078200073002000900855#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#41#37#article#135#<P><font face="Arial, 
Helvetica, sans-serif">Because of the possible association    of IL-6 expression
, glycemic levels and WHR with variables such as age and adiposity,    differenc
es between genotypes were investigated by adjusting to these confounding    fact
ors. In brief, all significant differences described so far resisted adjustment 
   for age and BMI, while no other difference in biochemical or clinical quantit
ative    traits became significant after correction (data not shown). CRP levels
 showed    nonsignificant variance in either model, adjusted or not to age and a
diposity.    This homogeneity persisted after additional adjustment to markers o
f liver status    (aspartate aminotransferase, alanine aminotransaminase and alk
aline phosphatase).    </font>      ^cY#6885.htm##
01488000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704126000073002000901333#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#42#38#article#135#<P><font face="Arial, 
Helvetica, sans-serif">In order to study the association    of -174 <I>G/C</I> p
olymorphism with clinically established risk parameters    for CVD, we performed
 non-parametric analysis to evaluate the difference in    distribution of hyperc
holesterolemia, hypertriglyceridemia, hypertension, diabetes,    and impaired gl
ucose regulation among genotypes. Due to the low number of homozygous    individ
uals for the <I>C</I> allele, the genotype was merged with the heterozygous    s
ubjects for the categorical analysis. According to this dominant model (<I>GG</I
>    <I>vs</I> <I>GC</I> + <I>CC</I>), <I>G</I> homozygous subjects were roughly
    twice as much affected by impaired fasting glucose metabolism and hypertensi
on    compared to the <I>C</I>-carrier counterparts (<a href="#Tab2">Table 2</a>
).    In the present study, we did not observe a trend towards an association be
tween    genotypes and serum lipid disturbances.</font>  <HR ALIGN=LEFT WIDTH=10
0% SIZE=2> <table width="100%"  border="0">   <tr align="left" valign="top">    
  <td width="12%"><a href="/img/revistas/bjmbr/v41n1/html/6885t01.htm"><img src=
"/img/revistas/bjmbr/v41n1/table.jpg" width="100" height="65" border="2"></a></t
d>     <td width="88%">           ^cY#6885.htm##
00487000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704025900073002000900332#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#43#39#article#135#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Tab1"></a>Table 1.          Clinical and biochem
ical data as a function of the -174 <I>G/C</I> genotypes          of the IL-6 ge
ne in 193 older Brazilian women. </font>      </td>   </tr> </table>     ^cY#688
5.htm##
00925000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704069700073002000900770#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#44#40#article#135#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this table    (302 K JPG file)]</
font></P> <HR ALIGN=LEFT WIDTH=100% SIZE=2> <table width="100%"  border="0">   <
tr align="left" valign="top">      <td width="12%"><a href="/img/revistas/bjmbr/
v41n1/html/6885t02.htm"><img src="/img/revistas/bjmbr/v41n1/table.jpg" width="10
0" height="65" border="2"></a></td>     <td width="88%"><font face="Arial, Helve
tica, sans-serif"><a name="Tab2" id="Tab2"></a>Table        2. Frequency distrib
ution of the IL-6 -174 <i>G/C</i> genotypes in different        conditions that 
represent cardiovascular risk factors, according to a dominant        model. </f
ont></td>   </tr> </table>     ^cY#6885.htm##
00348000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704012000073002000900193#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#45#41#article#135#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this table    (152 K JPG file)]</
font></P>     ^cY#6885.htm##
00275000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704004700073002000900120#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#46#42#article#135#<P>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>     ^cY#6885.htm##
00523000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704029500073002000900368#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#47#43#article#135#<P> <font face="Arial,
 Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007
F><B>Discussion    </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v
41n1/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></
B></A></FONT></font></P>     ^cY#6885.htm##
00659000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704043100073002000900504#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#48#44#article#135#<P><font face="Arial, 
Helvetica, sans-serif">Increasing evidence suggests that    low-grade inflammati
on could be one of the determinants of an unbalanced glucose    handling capacit
y and blood pressure disorders (18,19). The implication of IL-6    promoter poly
morphisms in prominent transcriptional effects on the gene (3)    makes these va
riations credible candidates for association with chronic disorders.    </font> 
     ^cY#6885.htm##
01082000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704085400073002000900927#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#49#45#article#135#<P><font face="Arial, 
Helvetica, sans-serif">The aim of the present study was    to determine a possib
le association of the IL-6 -174 <I>C/G</I> promoter polymorphism    with the amo
unt of cytokine released in the serum of older female adults from    the Brazili
an population, as well as with the presence of selected biochemical    or clinic
al features representative of cardiovascular risk in this age stratum.    Regard
less of any age-related up-regulation of plasma IL-6 levels, the data    present
ed here suggest a tendency to greater <I>in vivo</I> release of the cytokine    
among aged individuals carrying the IL-6 -174 <I>G/G</I> genotype. Thus, an    u
nderlying lesson is that it may be important to take into account IL-6 genotypes
    whenever comparisons of cytokine production are performed between different 
   age strata. </font>      ^cY#6885.htm##
02055000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704182700073002000901900#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#50#46#article#135#<P><font face="Arial, 
Helvetica, sans-serif">We suggest that the quantitative    findings presented so
 far may be of physiological relevance. The association    between <I>G</I> homo
zygosis and CVD-prone conditions (impaired fasting glucose    and hypertension) 
is consistent with a dominant model of genotype effect. On    the other hand, th
e relationship of <I>C</I> homozygosis with lower WHR, HbA1c    and serum glucos
e suggests that a recessive model of genotype effect is advantageous    at clini
cal level. Regardless of the exact model, our results, taken together,    assign
 a determining effect to the <I>G</I> allele. Previous investigations    with We
stern populations also consider the -174<I> G</I> allele as the risk    allele. 
The largest meta-analysis on genetics of type 2 diabetes among Caucasians    pub
lished to date provides evidence for an association of the disorder with    the 
<I>G/G</I> genotype (20). In Pima Indians (21) and in Native American and    Spa
nish (22) admixed populations, the <I>G</I> allele was also associated with    t
ype 2 diabetes. Fernandez-Real and colleagues (23) found higher blood HbA1c    i
n carriers of the <I>G</I> allele, while other studies found that carriers    of
 the <I>G</I>-variant allele had lower glucose handling capacity in insulin    s
ensitivity assays (6,24). The present study also reveals a tendency to an increa
sed    frequency of the hypertensive phenotype among <I>G/G</I> homozygotes. To 
the    authors' knowledge, blood pressure might be influenced by IL-6 expression
 but    a smaller body of evidence is supportive for an association between hype
rtension    and low-grade inflammation in the female gender (25). Thus, the obse
rved association    may represent an accentuation of the phenotype due to the ag
e stratum of the    sample. </font>      ^cY#6885.htm##
01143000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704091500073002000900988#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#51#47#article#135#<P><font face="Arial, 
Helvetica, sans-serif">The lack of association between genotypes    and other ma
rkers of the acute phase response (namely CRP and peripheral leukocyte    count)
 suggests that clinical outcomes of IL-6 levels may derive from endocrine    rat
her than immunological effects of this pleiotropic cytokine. The mechanisms    b
y which the <I>G</I> allele might cause an increased WHR are unknown, but this  
  allele might act as a triggering agent of the dose-dependent lipolytic effect 
   of IL-6 on peripheral storages (26) driving to fat mobilization toward the ab
dominal    compartment. According to a vicious cycle hypothesis, IL-6 secreted f
rom the    abdominal adipose tissue in a non-inflammatory condition (27) would f
low by    venous drainage directly into the liver and drive a persistent increas
e in hepatic    triglyceride secretion (28,29), intensifying the phenotype. </fo
nt>      ^cY#6885.htm##
01172000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704094400073002000901017#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#52#48#article#135#<P><font face="Arial, 
Helvetica, sans-serif">Regarding the association between    <I>G</I> homozygotes
 and aspects of an unbalanced glucose regulation, it is    known that insulin at
tenuates several stimulatory effects of IL-6 (30,31). Thus,    the lack of a sig
nificant insulin action, as found in type 2 diabetes, would    lead to prolonged
 detrimental effects of the cytokine (32). In addition, it    has been demonstra
ted that increased levels of IL-6 impair insulin signaling    in models using hu
man cells, such as adipocytes and hepatocytes, by a mechanism    that involves a
t least in part an up-regulation of the inhibitory suppressor    of cytokine sig
naling-3 (33,34). Again, according to a vicious cycle hypothesis,    genetically
 prone producers of IL-6 such as <I>G/G </I>individuals may be predisposed    to
 intensification of an insulin-resistant state initiated by inappropriate    foo
d intake and life style. </font>      ^cY#6885.htm##
01537000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704130900073002000901382#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#53#49#article#135#<P><font face="Arial, 
Helvetica, sans-serif"> The present results are in contrast    to reports showin
g a significant relationship between the <I>G/G</I> genotype    and different li
pidemia-related (serum lipids and BMI) phenotypes (23,35). We    have no simple 
explanation for this discrepancy. Obviously, any apparent disparity    in result
s might be attributable in part to interethnic variation owing to the    remarka
ble Brazilian genetic admixture (36), as well as to food intake habits    not in
vestigated here. As stated before, no other inflammatory markers differed    amo
ng genotypes, in contrast to reports based on western elderly populations.    Re
garding total (<a href="#Tab1">Table 1</a>) and differential (not shown) white  
  blood cell counts, described elsewhere as genotype-influenced factors (23),   
 no higher or lower counts could be associated with either hereditary model unde
r    our conditions. Also in disagreement with the literature (37), no variance 
in    CRP levels was observed among genotypes. Although increased IL-6 levels we
re    not paralleled by CRP levels in the various genotypes, the present study y
ields    the assumption that baseline levels of the cytokine are more predictive
 of cardiovascular    events than levels of the acute-phase reactant. </font>   
   ^cY#6885.htm##
00782000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704055400073002000900627#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#54#50#article#135#<P><font face="Arial, 
Helvetica, sans-serif">The present study has limitations.    We have not been ab
le to genotype other potentially functional (coding and non-coding)    variation
s in the IL-6 locus so that such interference could be ruled out. Since    the s
tudy was carried out on a female series, the authors are reticent in extrapolati
ng    conclusions to male counterparts, since the literature demonstrates signif
icant    gender-dependent predisposition to increased IL-6 serum levels in aging
 women,    but not in men (38,39). </font>      ^cY#6885.htm##
01396000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704116800073002000901241#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#55#51#article#135#<P><font face="Arial, 
Helvetica, sans-serif">To our knowledge, this is the first    investigation of w
hether the IL-6 promoter variants _174 <I>G/C</I> are linked    to age-related m
etabolic disturbances in the Brazilian elderly population. Our    results sugges
t that this functional polymorphism influences circulating IL-6    levels, and i
ndicate a contribution of the <I>G</I> allele to a glucose-intolerant    and a h
ypertensive state as well to an increased WHR in postmenopausal women.    The pr
esent study does not support associations with further age-related disorders.   
 Whether this polymorphism is a risk factor for obesity or type 2 diabetes could
    be estimated only in prospective population-based studies. In conclusion, we
    demonstrated that the -174 <I>C/G</I> promoter polymorphism of the IL-6 gene
    is unequivocally associated with several features consistent with cardiovasc
ular    risk in apparently healthy elderly Brazilian females. Immunogerontologic
al avenues    of investigation on the effect of cytokine genes and levels in dis
eases of aging    are appropriate for this population. </font>  <HR ALIGN=LEFT W
IDTH=100% SIZE=2>     ^cY#6885.htm##
00569000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704034100073002000900414#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#56#52#article#135#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><B>
References</B></FONT></font>    <font size="4" face="Arial, Helvetica, sans-seri
f"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIGN=BOTTOM
 BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A></font></P>     ^cY#6
885.htm##
00420000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704017800075002000900253#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#57#53#article#135#1#<P><font
 face="Arial, Helvetica, sans-serif">1. Rink L, Cakman I, Kirchner H.    Altered
 cytokine production in the elderly. <I>Mech Ageing Dev</I> 1998; 102:    199-20
9.    ^cY#6885.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#58#54#article#135# </font>      ^cY#6885
.htm##
00477000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704023500075002000900310#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#59#55#article#135#2#<P><font
 face="Arial, Helvetica, sans-serif">2. Kamimura D, Ishihara K, Hirano    T. IL-
6 signal transduction and its physiological roles: the signal orchestration    m
odel. <I>Rev Physiol Biochem Pharmacol</I> 2003; 149: 1-38.    ^cY#6885.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#60#56#article#135# </font>      ^cY#6885
.htm##
00610000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704036800075002000900443#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#61#57#article#135#3#<P><font
 face="Arial, Helvetica, sans-serif">3. Fishman D, Faulds G, Jeffery R,    Moham
ed-Ali V, Yudkin JS, Humphries S, et al. The effect of novel polymorphisms    in
 the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels,    
and an association with systemic-onset juvenile chronic arthritis. <I>J Clin    
Invest</I> 1998; 102: 1369-1376.    ^cY#6885.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#62#58#article#135# </font>      ^cY#6885
.htm##
00524000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704028200075002000900357#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#63#59#article#135#4#<P><font
 face="Arial, Helvetica, sans-serif">4. Olivieri F, Bonafe M, Cavallone    L, Gi
ovagnetti S, Marchegiani F, Cardelli M, et al. The -174 <I>C/G</I> locus    affe
cts <I>in vitro</I>/<I>in vivo</I> IL-6 production during aging. <I>Exp    Geron
tol</I> 2002; 37: 309-314.    ^cY#6885.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#64#60#article#135# </font>      ^cY#6885
.htm##
00465000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704022300075002000900298#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#65#61#article#135#5#<P><font
 face="Arial, Helvetica, sans-serif">5. Rivera-Chavez FA, Peters-Hybki    DL, Ba
rber RC, O'Keefe GE. Interleukin-6 promoter haplotypes and interleukin-6    cyto
kine responses. <I>Shock</I> 2003; 20: 218-223.    ^cY#6885.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#66#62#article#135# </font>      ^cY#6885
.htm##
00525000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704028300075002000900358#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#67#63#article#135#6#<P><font
 face="Arial, Helvetica, sans-serif">6. Cardellini M, Perego L, D'Adamo    M, Ma
rini MA, Procopio C, Hribal ML, et al. C-174G polymorphism in the promoter    of
 the interleukin-6 gene is associated with insulin resistance. <I>Diabetes    Ca
re</I> 2005; 28: 2007-2012.    ^cY#6885.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#68#64#article#135# </font>      ^cY#6885
.htm##
00605000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704036300075002000900438#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#69#65#article#135#7#<P><font
 face="Arial, Helvetica, sans-serif">7. Hulkkonen J, Pertovaara M, Antonen    J,
 Pasternack A, Hurme M. Elevated interleukin-6 plasma levels are regulated    by
 the promoter region polymorphism of the IL6 gene in primary Sjogren's syndrome 
   and correlate with the clinical manifestations of the disease. <I>Rheumatolog
y</I>    2001; 40: 656-661.    ^cY#6885.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#70#66#article#135# </font>      ^cY#6885
.htm##
00517000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704027500075002000900350#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#71#67#article#135#8#<P><font
 face="Arial, Helvetica, sans-serif">8. Kubaszek A, Pihlajamaki J, Punnonen    K
, Karhapaa P, Vauhkonen I, Laakso M. The C-174G promoter polymorphism of the    
IL-6 gene affects energy expenditure and insulin sensitivity. <I>Diabetes</I>   
 2003; 52: 558-561.    ^cY#6885.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#72#68#article#135# </font>      ^cY#6885
.htm##
00637000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704039500075002000900470#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#73#69#article#135#9#<P><font
 face="Arial, Helvetica, sans-serif">9. Rea IM, Ross OA, Armstrong M,    McNerla
n S, Alexander DH, Curran MD, et al. Interleukin-6-gene <I>C/G</I> 174    polymo
rphism in nonagenarian and octogenarian subjects in the BELFAST study.    Recipr
ocal effects on IL-6, soluble IL-6 receptor and for IL-10 in serum and    monocy
te supernatants. <I>Mech Ageing Dev</I> 2003; 124: 555-561.    ^cY#6885.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#74#70#article#135# </font>      ^cY#6885
.htm##
00509000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704026600076002000900342#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#75#71#article#135#10#<P><fon
t face="Arial, Helvetica, sans-serif">10. Fagiolo U, Cossarizza A, Scala    E, F
anales-Belasio E, Ortolani C, Cozzi E, et al. Increased cytokine production    i
n mononuclear cells of healthy elderly people. <I>Eur J Immunol</I> 1993; 23:   
 2375-2378.    ^cY#6885.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#76#72#article#135# </font>      ^cY#6885
.htm##
00527000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704028400076002000900360#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#77#73#article#135#11#<P><fon
t face="Arial, Helvetica, sans-serif">11. Mysliwska J, Bryl E, Foerster    J, My
sliwski A. Increase of interleukin 6 and decrease of interleukin 2 production   
 during the ageing process are influenced by the health status. <I>Mech Ageing  
  Dev</I> 1998; 100: 313-328.    ^cY#6885.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#78#74#article#135# </font>      ^cY#6885
.htm##
00456000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704021300076002000900289#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#79#75#article#135#12#<P><fon
t face="Arial, Helvetica, sans-serif">12. Ershler WB, Keller ET. Age-associated 
   increased interleukin-6 gene expression, late-life diseases, and frailty. <I>
Annu    Rev Med</I> 2000; 51: 245-270.    ^cY#6885.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#80#76#article#135# </font>      ^cY#6885
.htm##
00514000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704027100076002000900347#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#81#77#article#135#13#<P><fon
t face="Arial, Helvetica, sans-serif">13. Baggio G, Donazzan S, Monti D,    Mari
 D, Martini S, Gabelli C, et al. Lipoprotein(a) and lipoprotein profile    in he
althy centenarians: a reappraisal of vascular risk factors. <I>FASEB J</I>    19
98; 12: 433-437.    ^cY#6885.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#82#78#article#135# </font>      ^cY#6885
.htm##
00472000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704022900076002000900305#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#83#79#article#135#14#<P><fon
t face="Arial, Helvetica, sans-serif">14. Forsey RJ, Thompson JM, Ernerudh    J,
 Hurst TL, Strindhall J, Johansson B, et al. Plasma cytokine profiles in elderly
    humans. <I>Mech Ageing Dev</I> 2003; 124: 487-493.    ^cY#6885.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#84#80#article#135# </font>      ^cY#6885
.htm##
00418000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704017500076002000900251#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#85#81#article#135#15#<P><fon
t face="Arial, Helvetica, sans-serif">15. Krabbe KS, Pedersen M, Bruunsgaard    
H. Inflammatory mediators in the elderly. <I>Exp Gerontol</I> 2004; 39: 687-699.
    ^cY#6885.htm##
00249000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704002100073002000900094#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#86#82#article#135#    </font>      ^cY#6
885.htm##
00604000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704036100076002000900437#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#87#83#article#135#16#<P><fon
t face="Arial, Helvetica, sans-serif">16. Tracy RP, Psaty BM, Macy E, Bovill    
EG, Cushman M, Cornell ES, et al. Lifetime smoking exposure affects the associat
ion    of C-reactive protein with cardiovascular disease risk factors and subcli
nical    disease in healthy elderly subjects. <I>Arterioscler Thromb Vasc Biol</
I> 1997;    17: 2167-2176.    ^cY#6885.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#88#84#article#135# </font>      ^cY#6885
.htm##
00491000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704024800076002000900324#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#89#85#article#135#17#<P><fon
t face="Arial, Helvetica, sans-serif">17. Christiansen L, Bathum L, Andersen-Ran
berg    K, Jeune B, Christensen K. Modest implication of interleukin-6 promoter 
polymorphisms    in longevity. <I>Mech Ageing Dev</I> 2004; 125: 391-395.    ^cY
#6885.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#90#86#article#135# </font>      ^cY#6885
.htm##
00475000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704023200076002000900308#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#91#87#article#135#18#<P><fon
t face="Arial, Helvetica, sans-serif">18. Pradhan AD, Manson JE, Rifai    N, Bur
ing JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing    
type 2 diabetes mellitus. <I>JAMA</I> 2001; 286: 327-334.    ^cY#6885.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#92#88#article#135# </font>      ^cY#6885
.htm##
00610000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704036700076002000900443#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#93#89#article#135#19#<P><fon
t face="Arial, Helvetica, sans-serif">19. Spranger J, Kroke A, Mohlig M,    Hoff
mann K, Bergmann MM, Ristow M, et al. Inflammatory cytokines and the risk    to 
develop type 2 diabetes: results of the prospective population-based European   
 Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. <I>Di
abetes</I>    2003; 52: 812-817.    ^cY#6885.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#94#90#article#135# </font>      ^cY#6885
.htm##
00533000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704029000076002000900366#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#95#91#article#135#20#<P><fon
t face="Arial, Helvetica, sans-serif">20. Huth C, Heid IM, Vollmert C,    Gieger
 C, Grallert H, Wolford JK, et al. IL6 gene promoter polymorphisms and    type 2
 diabetes: joint analysis of individual participants' data from 21 studies.    <
I>Diabetes</I> 2006; 55: 2915-2921.    ^cY#6885.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#96#92#article#135# </font>      ^cY#6885
.htm##
00484000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704024100076002000900317#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#97#93#article#135#21#<P><fon
t face="Arial, Helvetica, sans-serif">21. Wolford JK, Colligan PB, Gruber    JD,
 Bogardus C. Variants in the interleukin 6 receptor gene are associated with    
obesity in Pima Indians. <I>Mol Genet Metab</I> 2003; 80: 338-343.    ^cY#6885.h
tm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#98#94#article#135# </font>      ^cY#6885
.htm##
00559000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704031600076002000900392#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#99#95#article#135#22#<P><fon
t face="Arial, Helvetica, sans-serif">22. Vozarova B, Fernandez-Real JM,    Know
ler WC, Gallart L, Hanson RL, Gruber JD, et al. The interleukin-6 (-174)    G/C 
promoter polymorphism is associated with type-2 diabetes mellitus in Native    A
mericans and Caucasians. <I>Hum Genet</I> 2003; 112: 409-413.    ^cY#6885.htm##
00247000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070704001800074002000900092#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#100#96#article#135# </font>      ^cY#688
5.htm##
00496000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704025200077002000900329#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#101#97#article#135#23#<P><fo
nt face="Arial, Helvetica, sans-serif">23. Fernandez-Real JM, Broch M, Vendrell 
   J, Richart C, Ricart W. Interleukin-6 gene polymorphism and lipid abnormaliti
es    in healthy subjects. <I>J Clin Endocrinol Metab</I> 2000; 85: 1334-1339.  
  ^cY#6885.htm##
00247000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070704001800074002000900092#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#102#98#article#135# </font>      ^cY#688
5.htm##
00520000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704027600077002000900353#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#103#99#article#135#24#<P><fo
nt face="Arial, Helvetica, sans-serif">24. Grallert H, Huth C, Kolz M, Meisinger
    C, Herder C, Strassburger K, et al. IL-6 promoter polymorphisms and quantita
tive    traits related to the metabolic syndrome in KORA S4. <I>Exp Gerontol</I>
 2006;    41: 737-745.    ^cY#6885.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#104#100#article#135# </font>      ^cY#68
85.htm##
00442000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704019700078002000900275#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#105#101#article#135#25#<P><f
ont face="Arial, Helvetica, sans-serif">25. Chae CU, Lee RT, Rifai N, Ridker    
PM. Blood pressure and inflammation in apparently healthy men. <I>Hypertension</
I>    2001; 38: 399-403.    ^cY#6885.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#106#102#article#135# </font>      ^cY#68
85.htm##
00420000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704017500078002000900253#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#107#103#article#135#26#<P><f
ont face="Arial, Helvetica, sans-serif">26. Langhans W. Peripheral mechanisms   
 involved with catabolism. <I>Curr Opin Clin Nutr Metab Care</I> 2002; 5: 419-42
6.    ^cY#6885.htm##
00251000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002100075002000900096#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#108#104#article#135#    </font>      ^cY
#6885.htm##
00528000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704028300078002000900361#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#109#105#article#135#27#<P><f
ont face="Arial, Helvetica, sans-serif">27. Fried SK, Bunkin DA, Greenberg    AS
. Omental and subcutaneous adipose tissues of obese subjects release interleukin
-6:    depot difference and regulation by glucocorticoid. <I>J Clin Endocrinol M
etab</I>    1998; 83: 847-850.    ^cY#6885.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#110#106#article#135# </font>      ^cY#68
85.htm##
00491000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704024600078002000900324#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#111#107#article#135#28#<P><f
ont face="Arial, Helvetica, sans-serif">28. Nonogaki K, Fuller GM, Fuentes    NL
, Moser AH, Staprans I, Grunfeld C, et al. Interleukin-6 stimulates hepatic    t
riglyceride secretion in rats. <I>Endocrinology</I> 1995; 136: 2143-2149.    ^cY
#6885.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#112#108#article#135# </font>      ^cY#68
85.htm##
00492000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704024700078002000900325#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#113#109#article#135#29#<P><f
ont face="Arial, Helvetica, sans-serif">29. Stouthard JM, Romijn JA, Van    der 
Poll T, Endert E, Klein S, Bakker PJ, et al. Endocrinologic and metabolic    eff
ects of interleukin-6 in humans. <I>Am J Physiol</I> 1995; 268: E813-E819.    ^c
Y#6885.htm##
00251000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002100075002000900096#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#114#110#article#135#    </font>      ^cY
#6885.htm##
00479000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704023400078002000900312#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#115#111#article#135#30#<P><f
ont face="Arial, Helvetica, sans-serif">30. Campos SP, Baumann H. Insulin    is 
a prominent modulator of the cytokine-stimulated expression of acute-phase    pl
asma protein genes. <I>Mol Cell Biol</I> 1992; 12: 1789-1797.    ^cY#6885.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#116#112#article#135# </font>      ^cY#68
85.htm##
00528000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704028300078002000900361#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#117#113#article#135#31#<P><f
ont face="Arial, Helvetica, sans-serif">31. O'Riordain MG, Ross JA, Fearon    KC
, Maingay J, Farouk M, Garden OJ, et al. Insulin and counterregulatory hormones 
   influence acute-phase protein production in human hepatocytes. <I>Am J Physio
l</I>    1995; 269: E323-E330.    ^cY#6885.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#118#114#article#135# </font>      ^cY#68
85.htm##
00442000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704019700078002000900275#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#119#115#article#135#32#<P><f
ont face="Arial, Helvetica, sans-serif">32. Fernandez-Real JM, Ricart W.    Insu
lin resistance and chronic cardiovascular inflammatory syndrome. <I>Endocr    Re
v</I> 2003; 24: 278-301.    ^cY#6885.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#120#116#article#135# </font>      ^cY#68
85.htm##
00568000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704032300078002000900401#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#121#117#article#135#33#<P><f
ont face="Arial, Helvetica, sans-serif">33. Rotter V, Nagaev I, Smith U.    Inte
rleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is,    like
 IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells    from 
insulin-resistant subjects. <I>J Biol Chem</I> 2003; 278: 45777-45784.    ^cY#68
85.htm##
00251000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002100075002000900096#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#122#118#article#135#    </font>      ^cY
#6885.htm##
00558000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704031300078002000900391#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#123#119#article#135#34#<P><f
ont face="Arial, Helvetica, sans-serif">34. Senn JJ, Klover PJ, Nowak IA,    Zim
mers TA, Koniaris LG, Furlanetto RW, et al. Suppressor of cytokine signaling-3  
  (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance  
  in hepatocytes. <I>J Biol Chem</I> 2003; 278: 13740-13746.    ^cY#6885.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#124#120#article#135# </font>      ^cY#68
85.htm##
00540000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704029500078002000900373#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#125#121#article#135#35#<P><f
ont face="Arial, Helvetica, sans-serif">35. Hamid YH, Rose CS, Urhammer SA,    G
lumer C, Nolsoe R, Kristiansen OP, et al. Variations of the interleukin-6 promot
er    are associated with features of the metabolic syndrome in Caucasian Danes.
 <I>Diabetologia</I>    2005; 48: 251-260.    ^cY#6885.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#126#122#article#135# </font>      ^cY#68
85.htm##
00560000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704031500078002000900393#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#127#123#article#135#36#<P><f
ont face="Arial, Helvetica, sans-serif">36. Marrero AR, Das Neves Leite FP,    D
e Almeida Carvalho B, Peres LM, Kommers TC, Da Cruz I, et al. Heterogeneity    o
f the genome ancestry of individuals classified as White in the State of Rio    
Grande do Sul, Brazil. <I>Am J Hum Biol</I> 2005; 17: 496-506.    ^cY#6885.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#128#124#article#135# </font>      ^cY#68
85.htm##
00612000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704036700078002000900445#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#129#125#article#135#37#<P><f
ont face="Arial, Helvetica, sans-serif">37. Ferrari SL, Ahn-Luong L, Garnero    
P, Humphries SE, Greenspan SL. Two promoter polymorphisms regulating interleukin
-6    gene expression are associated with circulating levels of C-reactive prote
in    and markers of bone resorption in postmenopausal women. <I>J Clin Endocrin
ol    Metab</I> 2003; 88: 255-259.    ^cY#6885.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#130#126#article#135# </font>      ^cY#68
85.htm##
00537000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704029200078002000900370#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#131#127#article#135#38#<P><f
ont face="Arial, Helvetica, sans-serif">38. Bruunsgaard H, Pedersen AN, Schroll 
   M, Skinhoj P, Pedersen BK. Impaired production of proinflammatory cytokines  
  in response to lipopolysaccharide (LPS) stimulation in elderly humans. <I>Clin
    Exp Immunol</I> 1999; 118: 235-241.    ^cY#6885.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#132#128#article#135# </font>      ^cY#68
85.htm##
00537000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704029200078002000900370#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#p#133#129#article#135#39#<P><f
ont face="Arial, Helvetica, sans-serif">39. Bonafe M, Olivieri F, Cavallone    L
, Giovagnetti S, Mayegiani F, Cardelli M, et al. A gender-dependent genetic    p
redisposition to produce high levels of IL-6 is detrimental for longevity.    <I
>Eur J Immunol</I> 2001; 31: 2357-2361.    ^cY#6885.htm##
00281000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704005100075002000900126#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#134#130#article#135#</font>  <HR ALIGN=L
EFT WIDTH=100% SIZE=2>     ^cY#6885.htm##
00590000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704036000075002000900435#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#135#131#article#135#<P><font face="Arial
, Helvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT color="#00007F" SIZ
E=4><B>Acknowledgments</B></FONT></font>    <font size="4" face="Arial, Helvetic
a, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" 
ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0" width="12" height="12"></B></A>
</font></P>     ^cY#6885.htm##
00732000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704050200075002000900577#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#136#132#article#135#<P><font face="Arial
, Helvetica, sans-serif">Thanks are due to Elias Rosa de Souza    for technical 
support and logistic help in the laboratory. The authors are also    greatly ind
ebted to Dr. Clarice Sampaio Alho, Pontif&iacute;cia Universidade    Cat&oacute;
lica do Rio Grande do Sul, Brazil, and Professor Jo&atilde;o Lindolfo    Cunha B
orges, Universidade Cat&oacute;lica de Bras&iacute;lia, Brazil, for their    car
eful review of the manuscript. </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^c
Y#6885.htm##
00591000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704036100075002000900436#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#137#133#article#135#<P><FONT SIZE=4 face
="Arial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F
><B>Correspondence    and Footnotes</B></FONT></FONT> <font size="4" face="Arial
, Helvetica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/
back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A
></font></P>     ^cY#6885.htm##
00761000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704053100075002000900606#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#138#134#article#135#<p><font face="Arial
, Helvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v41n1/
recor.gif" width="15" height="14" border="0"></a>    Address for correspondence:
</b> O.T. N&oacute;brega, Programa de P&oacute;s-Gradua&ccedil;&atilde;o    <I>S
tricto Sensu</I> em Gerontologia, Universidade Cat&oacute;lica de Bras&iacute;li
a,    Q.S. 07, Lote 01, EPCT, &Aacute;guas Claras, 72030-170 Taguatinga, DF, Bra
sil.    Fax: +55-61-3356-3010. E-mail: <a href="mailto:nobrega@ucb.br">nobrega@u
cb.br</a></font>  </p>     ^cY#6885.htm##
00477000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704024700075002000900322#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6885.htm#S#p#139#135#article#135#<P><font face="Arial
, Helvetica, sans-serif">Research supported by UCB (SIGEP    No. 01/2005) and CN
Pq (No. 484318/2006-3). A.C. Tonet was the recipient of a    CAPES fellowship. R
eceived May 9, 2007. Accepted September 24, 2007. </font>      ^cY#6885.htm##
00545000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100014000740100016000880100
01800104012004700122030001600169065000900185064000500194031000400199014000800203
865000900211002000900220035001000229801001600239#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6885.htm#S#c#140#1#article#39#1#^rND^sRink^nL#^rND^sCakman^nI#^rND^sK
irchner^nH#Altered cytokine production in the elderly^len#Mech Ageing Dev#199800
00#1998#102#199-209#20080100#6885.htm#0047-6374#Mech Ageing Dev##
00616000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100018000920100
01600110012008900126030003000215065000900245064000500254031000400259014000500263
865000900268002000900277035001000286801003000296#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6885.htm#S#c#141#2#article#39#2#^rND^sKamimura^nD#^rND^sIshihara^nK#^
rND^sHirano^nT#IL-6 signal transduction and its physiological roles: the signal 
orchestration model^len#Rev Physiol Biochem Pharmacol#20030000#2003#149#1-38#200
80100#6885.htm#0303-4240#Rev Physiol Biochem Pharmacol##
00799000000000337000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740100016000910100
01700107010002100124010001700145010001900162010001300181012018300194030001400377
06500090039106400050040003100040040501400100040986500090041900200090042803500100
0437801001400447#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#c#142#3#ar
ticle#39#3#^rND^sFishman^nD#^rND^sFaulds^nG#^rND^sJeffery^nR#^rND^sMohamed-Ali^n
V#^rND^sYudkin^nJS#^rND^sHumphries^nS#^rND^set^nal#The effect of novel polymorph
isms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 leve
ls, and an association with systemic-onset juvenile chronic arthritis^len#J Clin
 Invest#19980000#1998#102#1369-1376#20080100#6885.htm#0021-9738#J Clin Invest##
00687000000000337000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100016000920100
01900108010002100127010002100148010001800169810000600187012007700193030001300270
06500090028306400050029203100030029701400080030086500090030800200090031703500100
0326801001300336#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#c#143#4#ar
ticle#39#4#^rND^sOlivieri^nF#^rND^sBonafe^nM#^rND^sCavallone^nL#^rND^sGiovagnett
i^nS#^rND^sMarchegiani^nF#^rND^sCardelli^nM#et al#The -174 C/G locus affects in 
vitro/in vivo IL-6 production during aging^len#Exp Gerontol#20020000#2002#37#309
-314#20080100#6885.htm#0531-5565#Exp Gerontol##
00598000000000301000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100024000740100023000980100
01700121010001800138012007500156030000600231065000900237064000500246031000300251
014000800254865000900262002000900271035001000280801000600290#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6885.htm#S#c#144#5#article#39#5#^rND^sRivera-Chavez^nFA#^
rND^sPeters-Hybki^nDL#^rND^sBarber^nRC#^rND^sO'Keefe^nGE#Interleukin-6 promoter 
haplotypes and interleukin-6 cytokine responses^len#Shock#20030000#2003#20#218-2
23#20080100#6885.htm#1073-2322#Shock##
00710000000000337000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100020000740100016000940100
01700110010001700127010001800144010001700162810000600179012010400185030001400289
06500090030306400050031203100030031701400100032086500090033000200090033903500100
0348801001400358#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#c#145#6#ar
ticle#39#6#^rND^sCardellini^nM#^rND^sPerego^nL#^rND^sD'Adamo^nM#^rND^sMarini^nMA
#^rND^sProcopio^nC#^rND^sHribal^nML#et al#C-174G polymorphism in the promoter of
 the interleukin-6 gene is associated with insulin resistance^len#Diabetes Care#
20050000#2005#28#2007-2012#20080100#6885.htm#0149-5992#Diabetes Care##
00757000000000313000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100019000740100020000930100
01700113010002000130010001500150012019900165030001300364065000900377064000500386
031000300391014000800394865000900402002000900411035001000420801001300430#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#c#146#7#article#39#7#^rND^sHulkkon
en^nJ#^rND^sPertovaara^nM#^rND^sAntonen^nJ#^rND^sPasternack^nA#^rND^sHurme^nM#El
evated interleukin-6 plasma levels are regulated by the promoter region polymorp
hism of the IL6 gene in primary Sjogren's syndrome and correlate with the clinic
al manifestations of the disease^len#Rheumatology#20010000#2001#40#656-661#20080
100#6885.htm#0080-2727#RHEUMATOLOGY##
00686000000000325000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100021000920100
01800113010001800131010001900149010001600168012010500184030000900289065000900298
06400050030703100030031201400080031586500090032300200090033203500100034180100090
0351#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#c#147#8#article#39#8#^
rND^sKubaszek^nA#^rND^sPihlajamaki^nJ#^rND^sPunnonen^nK#^rND^sKarhapaa^nP#^rND^s
Vauhkonen^nI#^rND^sLaakso^nM#The C-174G promoter polymorphism of the IL-6 gene a
ffects energy expenditure and insulin sensitivity^len#Diabetes#20030000#2003#52#
558-561#20080100#6885.htm#0012-1797#Diabetes##
00814000000000337000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100014000740100015000880100
01900103010001800122010002000140010001700160810000600177012020700183030001600390
06500090040606400050041503100040042001400080042486500090043200200090044103500100
0450801001600460#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#c#148#9#ar
ticle#39#9#^rND^sRea^nIM#^rND^sRoss^nOA#^rND^sArmstrong^nM#^rND^sMcNerlan^nS#^rN
D^sAlexander^nDH#^rND^sCurran^nMD#et al#Interleukin-6-gene C/G 174 polymorphism 
in nonagenarian and octogenarian subjects in the BELFAST study: Reciprocal effec
ts on IL-6, soluble IL-6 receptor and for IL-10 in serum and monocyte supernatan
ts^len#Mech Ageing Dev#20030000#2003#124#555-561#20080100#6885.htm#0047-6374#Mec
h Ageing Dev##
00694000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100020000930100
01500113010002500128010001800153010001500171810000600186012008100192030001400273
06500090028706400050029603100030030101400100030486500090031400200090032303500100
0332801001400342#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#c#149#10#a
rticle#39#10#^rND^sFagiolo^nU#^rND^sCossarizza^nA#^rND^sScala^nE#^rND^sFanales-B
elasio^nE#^rND^sOrtolani^nC#^rND^sCozzi^nE#et al#Increased cytokine production i
n mononuclear cells of healthy elderly people^len#Eur J Immunol#19930000#1993#23
#2375-2378#20080100#6885.htm#0014-2980#Eur J Immunol##
00667000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100014000950100
01800109010001900127012013300146030001600279065000900295064000500304031000400309
014000800313865000900321002000900330035001000339801001600349#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6885.htm#S#c#150#11#article#39#11#^rND^sMysliwska^nJ#^rND
^sBryl^nE#^rND^sFoerster^nJ#^rND^sMysliwski^nA#Increase of interleukin 6 and dec
rease of interleukin 2 production during the ageing process are influenced by th
e health status^len#Mech Ageing Dev#19980000#1998#100#313-328#20080100#6885.htm#
0047-6374#Mech Ageing Dev##
00560000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940120
09200111030001300203065000900216064000500225031000300230014000800233865000900241
002000900250035001000259801001300269#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
885.htm#S#c#151#12#article#39#12#^rND^sErshler^nWB#^rND^sKeller^nET#Age-associat
ed increased interleukin-6 gene expression, late-life diseases, and frailty^len#
Annu Rev Med#20000000#2000#51#245-270#20080100#6885.htm#0066-4219#Annu Rev Med##
00693000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100018000920100
01500110010001400125010001700139010001700156810000600173012010700179030000800286
06500090029406400050030303100030030801400080031186500090031900200090032803500100
0337801000800347#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#c#152#13#a
rticle#39#13#^rND^sBaggio^nG#^rND^sDonazzan^nS#^rND^sMonti^nD#^rND^sMari^nD#^rND
^sMartini^nS#^rND^sGabelli^nC#et al#Lipoprotein(a) and lipoprotein profile in he
althy centenarians: a reappraisal of vascular risk factors^len#FASEB J#19980000#
1998#12#433-437#20080100#6885.htm#0892-6638#FASEB j##
00662000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100019000930100
01800112010001600130010002000146010001900166810000600185012004700191030001600238
06500090025406400050026303100040026801400080027286500090028000200090028903500100
0298801001600308#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#c#153#14#a
rticle#39#14#^rND^sForsey^nRJ#^rND^sThompson^nJM#^rND^sErnerudh^nJ#^rND^sHurst^n
TL#^rND^sStrindhall^nJ#^rND^sJohansson^nB#et al#Plasma cytokine profiles in elde
rly humans^len#Mech Ageing Dev#20030000#2003#124#487-493#20080100#6885.htm#0047-
6374#Mech Ageing Dev##
00543000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100018000930100
02100111012004200132030001300174065000900187064000500196031000300201014000800204
865000900212002000900221035001000230801001300240#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6885.htm#S#c#154#15#article#39#15#^rND^sKrabbe^nKS#^rND^sPedersen^nM#
^rND^sBruunsgaard^nH#Inflammatory mediators in the elderly^len#Exp Gerontol#2004
0000#2004#39#687-699#20080100#6885.htm#0531-5565#Exp Gerontol##
00809000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100016000920100
01400108010001700122010001700139010001800156010001300174012016900187030003000356
06500090038606400050039503100030040001400100040386500090041300200090042203500100
0431801003000441#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#c#155#16#a
rticle#39#16#^rND^sTracy^nRP#^rND^sPsaty^nBM#^rND^sMacy^nE#^rND^sBovill^nEG#^rND
^sCushman^nM#^rND^sCornell^nES#^rND^set^nal#Lifetime smoking exposure affects th
e association of C-reactive protein with cardiovascular disease risk factors and
 subclinical disease in healthy elderly subjects^len#Arterioscler Thromb Vasc Bi
ol#19970000#1997#17#2167-2176#20080100#6885.htm#1079-5642#Arterioscler Thromb Va
sc Biol##
00652000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100022000760100016000980100
02600114010001500140010002100155012007600176030001600252065000900268064000500277
031000400282014000800286865000900294002000900303035001000312801001600322#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#c#156#17#article#39#17#^rND^sChris
tiansen^nL#^rND^sBathum^nL#^rND^sAndersen-Ranberg^nK#^rND^sJeune^nB#^rND^sChrist
ensen^nK#Modest implication of interleukin-6 promoter polymorphisms in longevity
^len#Mech Ageing Dev#20040000#2004#125#391-395#20080100#6885.htm#0047-6374#Mech 
Ageing Dev##
00625000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940100
01500111010001700126010001700143012008700160030000500247065000900252064000500261
031000400266014000800270865000900278002000900287035001000296801000500306#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#c#157#18#article#39#18#^rND^sPradh
an^nAD#^rND^sManson^nJE#^rND^sRifai^nN#^rND^sBuring^nJE#^rND^sRidker^nPM#C-react
ive protein, interleukin 6, and risk of developing type 2 diabetes mellitus^len#
JAMA#20010000#2001#286#327-334#20080100#6885.htm#0098-7484#JAMA##
00787000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100015000940100
01600109010001800125010001900143010001600162810000600178012019400184030000900378
06500090038706400050039603100030040101400080040486500090041200200090042103500100
0430801000900440#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#c#158#19#a
rticle#39#19#^rND^sSpranger^nJ#^rND^sKroke^nA#^rND^sMohlig^nM#^rND^sHoffmann^nK#
^rND^sBergmann^nMM#^rND^sRistow^nM#et al#Inflammatory cytokines and the risk to 
develop type 2 diabetes: results of the prospective population-based European Pr
ospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study^len#Diabe
tes#20030000#2003#52#812-817#20080100#6885.htm#0012-1797#Diabetes##
00713000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100015000900100
01800105010001600123010001800139010001800157810000600175012012100181030000900302
06500090031106400050032003100030032501400100032886500090033800200090034703500100
0356801000900366#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#c#159#20#a
rticle#39#20#^rND^sHuth^nC#^rND^sHeid^nIM#^rND^sVollmert^nC#^rND^sGieger^nC#^rND
^sGrallert^nH#^rND^sWolford^nJK#et al#IL6 gene promoter polymorphisms and type 2
 diabetes: joint analysis of individual participants' data from 21 studies^len#D
iabetes#20060000#2006#55#2915-2921#20080100#6885.htm#0012-1797#Diabetes##
00627000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100019000940100
01700113010001800130012009200148030001600240065000900256064000500265031000300270
014000800273865000900281002000900290035001000299801001600309#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6885.htm#S#c#160#21#article#39#21#^rND^sWolford^nJK#^rND^
sColligan^nPB#^rND^sGruber^nJD#^rND^sBogardus^nC#Variants in the interleukin 6 r
eceptor gene are associated with obesity in Pima Indians^len#Mol Genet Metab#200
30000#2003#80#338-343#20080100#6885.htm#1096-7192#Mol Genet Metab##
00740000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100025000940100
01800119010001700137010001700154010001700171810000600188012013400194030001000328
06500090033806400050034703100040035201400080035686500090036400200090037303500100
0382801001000392#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#c#161#22#a
rticle#39#22#^rND^sVozarova^nB#^rND^sFernandez-Real^nJM#^rND^sKnowler^nWC#^rND^s
Gallart^nL#^rND^sHanson^nRL#^rND^sGruber^nJD#et al#The interleukin-6 (-174) G/C 
promoter polymorphism is associated with type-2 diabetes mellitus in Native Amer
icans and Caucasians^len#Hum Genet#20030000#2003#112#409-413#20080100#6885.htm#0
340-6717#Hum Genet##
00664000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100025000760100015001010100
01800116010001700134010001600151012008000167030002400247065000900271064000500280
031000300285014001000288865000900298002000900307035001000316801002400326#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#c#162#23#article#39#23#^rND^sFerna
ndez-Real^nJM#^rND^sBroch^nM#^rND^sVendrell^nJ#^rND^sRichart^nC#^rND^sRicart^nW#
Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects^len#
J Clin Endocrinol Metab#20000000#2000#85#1334-1339#20080100#6885.htm#0021-972X#J
 Clin Endocrinol Metab##
00703000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100014000940100
01400108010001900122010001600141010002200157810000600179012010100185030001300286
06500090029906400050030803100030031301400080031686500090032400200090033303500100
0342801001300352#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#c#163#24#a
rticle#39#24#^rND^sGrallert^nH#^rND^sHuth^nC#^rND^sKolz^nM#^rND^sMeisinger^nC#^r
ND^sHerder^nC#^rND^sStrassburger^nK#et al#IL-6 promoter polymorphisms and quanti
tative traits related to the metabolic syndrome in KORA S4^len#Exp Gerontol#2006
0000#2006#41#737-745#20080100#6885.htm#0531-5565#Exp Gerontol##
00580000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100014000910100
01500105010001700120012006200137030001300199065000900212064000500221031000300226
014000800229865000900237002000900246035001000255801001300265#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6885.htm#S#c#164#25#article#39#25#^rND^sChae^nCU#^rND^sLe
e^nRT#^rND^sRifai^nN#^rND^sRidker^nPM#Blood pressure and inflammation in apparen
tly healthy men^len#Hypertension#20010000#2001#38#399-403#20080100#6885.htm#0194
-911X#Hypertension##
00474000000000253000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760120051000940300
03100145710000200176065000900178064000500187031000200192014000800194865000900202
002000900211#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#c#165#26#artic
le#39#26#^rND^sLanghans^nW#Peripheral mechanisms involved with catabolism^len#Cu
rr Opin Clin Nutr Metab Care#2#20020000#2002#5#419-426#20080100#6885.htm##
00656000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100017000920100
02000109012013600129030002400265065000900289064000500298031000300303014000800306
865000900314002000900323035001000332801002400342#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6885.htm#S#c#166#27#article#39#27#^rND^sFried^nSK#^rND^sBunkin^nDA#^r
ND^sGreenberg^nAS#Omental and subcutaneous adipose tissues of obese subjects rel
ease interleukin-6: depot difference and regulation by glucocorticoid^len#J Clin
 Endocrinol Metab#19980000#1998#83#847-850#20080100#6885.htm#0021-972X#J Clin En
docrinol Metab##
00677000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940100
01800111010001600129010001800145010001800163810000600181012006800187030001400255
06500090026906400050027803100040028301400100028786500090029700200090030603500100
0315801001400325#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#c#167#28#a
rticle#39#28#^rND^sNonogaki^nK#^rND^sFuller^nGM#^rND^sFuentes^nNL#^rND^sMoser^nA
H#^rND^sStaprans^nI#^rND^sGrunfeld^nC#et al#Interleukin-6 stimulates hepatic tri
glyceride secretion in rats^len#Endocrinology#19950000#1995#136#2143-2149#200801
00#6885.htm#0013-7227#Endocrinology##
00677000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100017000960100
02200113010001600135010001500151010001700166810000600183012006800189030001300257
06500090027006400050027903100040028401400100028886500090029800200090030703500100
0316801001300326#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#c#168#29#a
rticle#39#29#^rND^sStouthard^nJM#^rND^sRomijn^nJA#^rND^sVan^nder Poll T#^rND^sEn
dert^nE#^rND^sKlein^nS#^rND^sBakker^nPJ#et al#Endocrinologic and metabolic effec
ts of interleukin-6 in humans^len#Am J Physiol#19950000#1995#268#E813-E819#20080
100#6885.htm#0002-9513#Am J Physiol##
00582000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100017000930120
11100110030001400221065000900235064000500244031000300249014001000252865000900262
002000900271035001000280801001400290#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
885.htm#S#c#169#30#article#39#30#^rND^sCampos^nSP#^rND^sBaumann^nH#Insulin is a 
prominent modulator of the cytokine-stimulated expression of acute-phase plasma 
protein genes^len#Mol Cell Biol#19920000#1992#12#1789-1797#20080100#6885.htm#027
0-7306#Mol Cell Biol##
00710000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100021000760100015000970100
01700112010001700129010001600146010001700162810000600179012010500185030001300290
06500090030306400050031203100040031701400100032186500090033100200090034003500100
0349801001300359#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#c#170#31#a
rticle#39#31#^rND^sO'Riordain^nMG#^rND^sRoss^nJA#^rND^sFearon^nKC#^rND^sMaingay^
nJ#^rND^sFarouk^nM#^rND^sGarden^nOJ#et al#Insulin and counterregulatory hormones
 influence acute-phase protein production in human hepatocytes^len#Am J Physiol#
19950000#1995#269#E323-E330#20080100#6885.htm#0002-9513#Am J Physiol##
00542000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100025000760100016001010120
07200117030001100189065000900200064000500209031000300214014000800217865000900225
002000900234035001000243801001100253#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
885.htm#S#c#171#32#article#39#32#^rND^sFernandez-Real^nJM#^rND^sRicart^nW#Insuli
n resistance and chronic cardiovascular inflammatory syndrome^len#Endocr Rev#200
30000#2003#24#278-301#20080100#6885.htm#0163-769X#Endocr Rev##
00684000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100016000920100
01500108012018900123030001200312065000900324064000500333031000400338014001200342
865000900354002000900363035001000372801001200382#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6885.htm#S#c#172#33#article#39#33#^rND^sRotter^nV#^rND^sNagaev^nI#^rN
D^sSmith^nU#Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes
 and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat c
ells from insulin-resistant subjects^len#J Biol Chem#20030000#2003#278#45777-457
84#20080100#6885.htm#0021-9258#J Biol Chem##
00739000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100017000910100
01600108010001800124010001900142010002100161810000600182012013100188030001200319
06500090033106400050034003100040034501400120034986500090036100200090037003500100
0379801001200389#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#c#173#34#a
rticle#39#34#^rND^sSenn^nJJ#^rND^sKlover^nPJ#^rND^sNowak^nIA#^rND^sZimmers^nTA#^
rND^sKoniaris^nLG#^rND^sFurlanetto^nRW#et al#Suppressor of cytokine signaling-3 
(SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in 
hepatocytes^len#J Biol Chem#20030000#2003#278#13740-13746#20080100#6885.htm#0021
-9258#J Biol Chem##
00729000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100015000920100
01900107010001600126010001600142010002200158010001300180012011900193030001300312
06500090032506400050033403100030033901400080034286500090035000200090035903500100
0368801001300378#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#c#174#35#a
rticle#39#35#^rND^sHamid^nYH#^rND^sRose^nCS#^rND^sUrhammer^nSA#^rND^sGlumer^nC#^
rND^sNolsoe^nR#^rND^sKristiansen^nOP#^rND^set^nal#Variations of the interleukin-
6 promoter are associated with features of the metabolic syndrome in Caucasian D
anes^len#Diabetologia#20050000#2005#48#251-260#20080100#6885.htm#0012-186X#Diabe
tologia##
00709000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100026000940100
02900120010001600149010001800165010001700183810000600200012011800206030001400324
71000020033806500090034006400050034903100030035401400080035786500090036500200090
0374#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#c#175#36#article#39#36
#^rND^sMarrero^nAR#^rND^sDas^nNeves Leite FP#^rND^sDe^nAlmeida Carvalho B#^rND^s
Peres^nLM#^rND^sKommers^nTC#^rND^sDa^nCruz I#et al#Heterogeneity of the genome a
ncestry of individuals classified as White in the State of Rio Grande do Sul, Br
azil^len#Am J Hum Biol#2#20050000#2005#17#496-506#20080100#6885.htm##
00773000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100019000940100
01700113010002000130010002000150012018800170030002400358065000900382064000500391
031000300396014000800399865000900407002000900416035001000425801002400435#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#c#176#37#article#39#37#^rND^sFerra
ri^nSL#^rND^sAhn-Luong^nL#^rND^sGarnero^nP#^rND^sHumphries^nSE#^rND^sGreenspan^n
SL#Two promoter polymorphisms regulating interleukin-6 gene expression are assoc
iated with circulating levels of C-reactive protein and markers of bone resorpti
on in postmenopausal women^len#J Clin Endocrinol Metab#20030000#2003#88#255-259#
20080100#6885.htm#0021-972X#J Clin Endocrinol Metab##
00694000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100021000760100019000970100
01700116010001700133010001900150012012300169030001700292065000900309064000500318
031000400323014000800327865000900335002000900344035001000353801001700363#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#c#177#38#article#39#38#^rND^sBruun
sgaard^nH#^rND^sPedersen^nAN#^rND^sSchroll^nM#^rND^sSkinhoj^nP#^rND^sPedersen^nB
K#Impaired production of proinflammatory cytokines in response to lipopolysaccha
ride (LPS) stimulation in elderly humans^len#Clin Exp Immunol#19990000#1999#118#
235-241#20080100#6885.htm#0009-9104#Clin Exp Immunol##
00727000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100018000920100
01900110010002100129010001900150010001800169010001300187012010600200030001400306
06500090032006400050032903100030033401400100033786500090034700200090035603500100
0365801001400375#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6885.htm#S#c#178#39#a
rticle#39#39#^rND^sBonafe^nM#^rND^sOlivieri^nF#^rND^sCavallone^nL#^rND^sGiovagne
tti^nS#^rND^sMayegiani^nF#^rND^sCardelli^nM#^rND^set^nal#A gender-dependent gene
tic predisposition to produce high levels of IL-6 is detrimental for longevity^l
en#Eur J Immunol#20010000#2001#31#2357-2361#20080100#6885.htm#0014-2980#Eur J Im
munol##
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#o#1#1#article#1#20
080623#161523#6904.htm#199##
03185000000000637000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000300104030002000107
03100030012703200020013006500090013201400090014103500100015001201250016001000260
02850100025003110100021003360100020003570700099003770700120004760831628005960850
00802224085003002232085001802262085002002280085002802300085002202328085002002350
08500210237011700060239107200030239705800500240005800070245006000110245706000110
2468060001102479112000902490111001302499114000902512113001702521002000902538#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#h#2#1#article#1#oa#en#bjmbr#1#
3.1#ILUS#11#BJMBR060#nd#Braz J Med Biol Res#41#1#20080100#^f68^l77#0100-879X#Eff
ects of cocaine, methamphetamine and modafinil challenge on sleep rebound after 
paradoxical sleep deprivation in rats^len#^rND^1A01^nR.C.S^sMartins#^rND^1A01^nM
.L^sAndersen#^rND^1A02^nM.C^sShih#^rND^1A01^nS^sTufik#Universidade Federal de Sã
o Paulo^iA01^1Escola Paulista de Medicina^2Departamento de Psicobiologia#Univers
idade Federal de São Paulo^iA02^1Escola Paulista de Medicina^2Departamento de Ps
iquiatria^cSão Paulo^sSP^pBrasil#^len^aSleep loss is both common and critically 
relevant to our society and might lead to the abuse of psychostimulants such as 
amphetamines, cocaine and modafinil. Since psychoactive substance abuse often oc
curs within a scenario of sleep deficit, the purpose of this investigation was t
o compare the sleep patterns of rats challenged with cocaine (7 mg/kg, ip), meth
amphetamine (7 mg/kg, ip), or modafinil (100 mg/kg, ip) subsequent to paradoxica
l sleep deprivation (PSD) for 96 h. Our results show that, immediately after 96 
h of PSD, rats (10 per group) that were injected with a psychostimulant presente
d lower percentages of paradoxical sleep compared to those injected with saline 
(P < 0.01). Regarding slow wave sleep (SWS), rats injected with psychostimulants
 after PSD presented a late rebound (on the second night subsequent to the injec
tion) in the percentage of this phase of sleep when compared to PSD rats injecte
d with saline (P < 0.05). In addition, the current study has produced evidence o
f the characteristic effect of each drug on sleep architecture. Home cage contro
l rats injected with modafinil and methamphetamine showed a reduction in SWS com
pared with the saline group. Methamphetamine affected sleep patterns most, since
 it significantly reduced paradoxical sleep, SWS and sleep efficiency before and
 after PSD compared to control (P < 0.05). Cocaine was the psychostimulant causi
ng the least changes in sleep pattern in relation to those observed after saline
 injection. Therefore, our results suggest that abuse of these psychostimulants 
in a PSD paradigm aggravates their impact on sleep patterns.#^dnd^i1#^tm^len^kSl
eep deprivation^i1#^tm^len^kSleep^i1#^tm^len^kCocaine^i1#^tm^len^kMethamphetamin
e^i1#^tm^len^kModafinil^i1#^tm^len^kRebound^i1#^tm^len^kDopamine^i1#other#39#Ass
ociação Fundo de Incentivo à Psicofarmacologia#FAPESP#98/14303-3#01/04329-0#06/5
8276-8#20070521#May 21, 2007#20071026#October 26, 2007#6904.htm##
03222000000000637000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000300104030002000107
03100030012703200020013006500090013201400090014103500100015001201320016001000260
02920100025003180100021003430100020003640700099003840700120004830831658006030850
00802261085003002269085001802299085002002317085002802337085002202365085002002387
08500210240711700060242807200030243405800500243705800070248706000110249406000110
2505060001102516112000902527111001302536114000902549113001702558002000902575#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#f#3#1#article#1#oa#en#bjmbr#1#
3.1#ILUS#11#BJMBR060#nd#Braz J Med Biol Res#41#1#20080100#^f68^l77#0100-879X#<B>
Effects of cocaine, methamphetamine and modafinil challenge on sleep rebound aft
er paradoxical sleep deprivation in rats</B>^len#^rND^1A01^nR.C.S^sMartins#^rND^
1A01^nM.L^sAndersen#^rND^1A02^nM.C^sShih#^rND^1A01^nS^sTufik#Universidade Federa
l de São Paulo^iA01^1Escola Paulista de Medicina^2Departamento de Psicobiologia#
Universidade Federal de São Paulo^iA02^1Escola Paulista de Medicina^2Departament
o de Psiquiatria^cSão Paulo^sSP^pBrasil#^len^aSleep loss is both common and crit
ically relevant to our society and might lead to the abuse of psychostimulants s
uch as amphetamines, cocaine and modafinil. Since psychoactive substance abuse o
ften occurs within a scenario of sleep deficit, the purpose of this investigatio
n was to compare the sleep patterns of rats challenged with cocaine (7 mg/kg, <I
>ip</I>), methamphetamine (7 mg/kg, <I>ip</I>), or modafinil (100 mg/kg, <I>ip</
I>) subsequent to paradoxical sleep deprivation (PSD) for 96 h. Our results show
 that, immediately after 96 h of PSD, rats (10 per group) that were injected wit
h a psychostimulant presented lower percentages of paradoxical sleep compared to
 those injected with saline (P &lt; 0.01). Regarding slow wave sleep (SWS), rats
 injected with psychostimulants after PSD presented a late rebound (on the secon
d night subsequent to the injection) in the percentage of this phase of sleep wh
en compared to PSD rats injected with saline (P &lt; 0.05). In addition, the cur
rent study has produced evidence of the characteristic effect of each drug on sl
eep architecture. Home cage control rats injected with modafinil and methampheta
mine showed a reduction in SWS compared with the saline group. Methamphetamine a
ffected sleep patterns most, since it significantly reduced paradoxical sleep, S
WS and sleep efficiency before and after PSD compared to control (P &lt; 0.05). 
Cocaine was the psychostimulant causing the least changes in sleep pattern in re
lation to those observed after saline injection. Therefore, our results suggest 
that abuse of these psychostimulants in a PSD paradigm aggravates their impact o
n sleep patterns.#^dnd^i1#^tm^len^kSleep deprivation^i1#^tm^len^kSleep^i1#^tm^le
n^kCocaine^i1#^tm^len^kMethamphetamine^i1#^tm^len^kModafinil^i1#^tm^len^kRebound
^i1#^tm^len^kDopamine^i1#other#39#Associação Fundo de Incentivo à Psicofarmacolo
gia#FAPESP#98/14303-3#01/04329-0#06/58276-8#20070521#May 21, 2007#20071026#Octob
er 26, 2007#6904.htm##
03346000000000661000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000500100121000300105049000900108158000300117
03000240012003100030014403200020014706500090014901400090015803500100016701201250
01770100028003020100026003300100022003560100020003780700124003980700122005220831
62800644085000802272085003002280085001802310085002002328085002802348085002202376
08500200239808500210241811700060243907200030244505800500244805800070249806000110
25050600011025160600011025271120009025381110013025471140009025601130017025690020
00902586008008902595#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#l#4#1#
article#1#^mJan.^a2008#oa#en#bjmbr#1#3.1#ilus#11#BJMBR060#nd#Braz. j. med. biol.
 res#41#1#20080100#^f68^l77#0100-879X#Effects of cocaine, methamphetamine and mo
dafinil challenge on sleep rebound after paradoxical sleep deprivation in rats^l
en#^rND^1A01^nR. C. S^sMartins#^rND^1A01^nM. L^sAndersen#^rND^1A02^nM. C^sShih#^
rND^1A01^nS^sTufik#^iA01^1Universidade Federal de São Paulo^2Escola Paulista de 
Medicina^3Departamento de Psicobiologia^cSão Paulo^sSP^pBrasil#^iA02^1Universida
de Federal de São Paulo^2Escola Paulista de Medicina^3Departamento de Psiquiatri
a^cSão Paulo^sSP^pBrasil#^len^aSleep loss is both common and critically relevant
 to our society and might lead to the abuse of psychostimulants such as amphetam
ines, cocaine and modafinil. Since psychoactive substance abuse often occurs wit
hin a scenario of sleep deficit, the purpose of this investigation was to compar
e the sleep patterns of rats challenged with cocaine (7 mg/kg, ip), methamphetam
ine (7 mg/kg, ip), or modafinil (100 mg/kg, ip) subsequent to paradoxical sleep 
deprivation (PSD) for 96 h. Our results show that, immediately after 96 h of PSD
, rats (10 per group) that were injected with a psychostimulant presented lower 
percentages of paradoxical sleep compared to those injected with saline (P < 0.0
1). Regarding slow wave sleep (SWS), rats injected with psychostimulants after P
SD presented a late rebound (on the second night subsequent to the injection) in
 the percentage of this phase of sleep when compared to PSD rats injected with s
aline (P < 0.05). In addition, the current study has produced evidence of the ch
aracteristic effect of each drug on sleep architecture. Home cage control rats i
njected with modafinil and methamphetamine showed a reduction in SWS compared wi
th the saline group. Methamphetamine affected sleep patterns most, since it sign
ificantly reduced paradoxical sleep, SWS and sleep efficiency before and after P
SD compared to control (P < 0.05). Cocaine was the psychostimulant causing the l
east changes in sleep pattern in relation to those observed after saline injecti
on. Therefore, our results suggest that abuse of these psychostimulants in a PSD
 paradigm aggravates their impact on sleep patterns.#^dnd^i1#^tm^len^kSleep depr
ivation^i1#^tm^len^kSleep^i1#^tm^len^kCocaine^i1#^tm^len^kMethamphetamine^i1#^tm
^len^kModafinil^i1#^tm^len^kRebound^i1#^tm^len^kDopamine^i1#other#39#Associação 
Fundo de Incentivo à Psicofarmacologia#FAPESP#98/14303-3#01/04329-0#06/58276-8#2
0070521#May 21, 2007#20071026#October 26, 2007#6904.htm#Internet^ihttp://www.sci
elo.br/scielo.php?script=sci_arttext&pid=S0100-879X2008000100011##
00375000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704014900071002000900220#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#5#1#article#156#<P> <font face="Arial, H
elvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med    Biol Res, January 2008
, Volume 41(1) 68-77</B> </font></P>     ^cY#6904.htm##
00431000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704020500071002000900276#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#6#2#article#156#<P><font size="5" face="
Arial, Helvetica, sans-serif"><B>Effects of cocaine, methamphetamine    and moda
finil challenge on sleep rebound after paradoxical sleep deprivation    in rats<
/B> </font>      ^cY#6904.htm##
00647000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704042100071002000900492#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#7#3#article#156#<P><font face="Arial, He
lvetica, sans-serif">R.C.S. Martins<SUP>1</SUP>, <b><a href="#Correspondence"><i
mg src="/img/revistas/bjmbr/v41n1/recor.gif" width="15" height="14" border="0"><
/a></b>    <a href="mailto:mandersen@psicobio.epm.br"><img src="/img/revistas/bj
mbr/v41n1/email-ca.gif" width="14" height="11" border="0"></a>    M.L. Andersen<
SUP>1</SUP>, M.C. Shih<SUP>2</SUP> and S. Tufik<SUP>1</SUP> </font>      ^cY#690
4.htm##
00477000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704025100071002000900322#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#8#4#article#156#<P><font face="Arial, He
lvetica, sans-serif"><SUP>1</SUP>Departamento de Psicobiologia,    <SUP>2</SUP>D
epartamento de Psiquiatria, Escola Paulista de Medicina, Universidade    Federal
 de S&atilde;o Paulo, S&atilde;o Paulo, SP, Brasil</font>      ^cY#6904.htm##
00442000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704021600071002000900287#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#9#5#article#156#<P> <font face="Arial, H
elvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v41n1/do
wn.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12">    <stro
ng>Abstract</strong></A>    ^cY#6904.htm##
00440000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704021300072002000900285#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#10#6#article#156#<BR>   <A HREF="#Introd
uction"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPA
CE=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Introduction"><strong>Int
roduction</strong></A>    ^cY#6904.htm##
00440000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704021300072002000900285#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#11#7#article#156#<BR>   <A HREF="#Materi
al"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0
 HSPACE=0 width="12" height="12"></A>    <A HREF="#Material"><strong>Material an
d Methods</strong></A>    ^cY#6904.htm##
00425000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704019800072002000900270#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#12#8#article#156#<BR>   <A HREF="#Result
s"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0 width="12" height="12"></A>    <A HREF="#Results"><strong>Results</stro
ng></A>    ^cY#6904.htm##
00434000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704020700072002000900279#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#13#9#article#156#<BR>   <A HREF="#Discus
sion"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Discussion"><strong>Discuss
ion</strong></A>    ^cY#6904.htm##
00422000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704019400073002000900267#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#14#10#article#156#<BR>   <A HREF="#Refer
ences"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#References"><strong>Refere
nces    ^cY#6904.htm##
00463000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704023500073002000900308#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#15#11#article#156#<br>   </strong></A><A
 HREF="#Acknowledgments"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOT
TOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Acknowle
dgments"><strong>Acknowledgments</strong></A>    ^cY#6904.htm##
00474000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704024600073002000900319#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#16#12#article#156#<BR>   <A HREF="#Corre
spondence"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 V
SPACE=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Correspondence"><stron
g>Correspondence and Footnotes</strong></A>    </font>      ^cY#6904.htm##
00275000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704004700073002000900120#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#17#13#article#156#<P>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>     ^cY#6904.htm##
00563000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704033500073002000900408#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#18#14#article#156#<P> <font face="Arial,
 Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F>
<B>Abstract    </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1
/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></
A></FONT></font></P> <font face="Arial, Helvetica, sans-serif">      ^cY#6904.ht
m##
01952000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704172400073002000901797#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#19#15#article#156#<P>Sleep loss is both 
common and critically relevant to our society and might    lead to the abuse of 
psychostimulants such as amphetamines, cocaine and modafinil.    Since psychoact
ive substance abuse often occurs within a scenario of sleep deficit,    the purp
ose of this investigation was to compare the sleep patterns of rats    challenge
d with cocaine (7 mg/kg, <I>ip</I>), methamphetamine (7 mg/kg, <I>ip</I>),    or
 modafinil (100 mg/kg, <I>ip</I>) subsequent to paradoxical sleep deprivation   
 (PSD) for 96 h. Our results show that, immediately after 96 h of PSD, rats (10 
   per group) that were injected with a psychostimulant presented lower percenta
ges    of paradoxical sleep compared to those injected with saline (P &lt; 0.01)
. Regarding    slow wave sleep (SWS), rats injected with psychostimulants after 
PSD presented    a late rebound (on the second night subsequent to the injection
) in the percentage    of this phase of sleep when compared to PSD rats injected
 with saline (P &lt;    0.05). In addition, the current study has produced evide
nce of the characteristic    effect of each drug on sleep architecture. Home cag
e control rats injected with    modafinil and methamphetamine showed a reduction
 in SWS compared with the saline    group. Methamphetamine affected sleep patter
ns most, since it significantly    reduced paradoxical sleep, SWS and sleep effi
ciency before and after PSD compared    to control (P &lt; 0.05). Cocaine was th
e psychostimulant causing the least    changes in sleep pattern in relation to t
hose observed after saline injection.    Therefore, our results suggest that abu
se of these psychostimulants in a PSD    paradigm aggravates their impact on sle
ep patterns.      ^cY#6904.htm##
00378000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704015000073002000900223#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#20#16#article#156#<P>Key words: Sleep de
privation; Sleep; Cocaine; Methamphetamine; Modafinil; Rebound;    Dopamine  </f
ont>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6904.htm##
00617000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038900073002000900462#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#21#17#article#156#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Introduction"></A><FONT color="#00007F" SIZE=4><
B>Introduction</B></FONT></font>    <font size="4" face="Arial, Helvetica, sans-
serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A></font></P> <font
 face="Arial, Helvetica, sans-serif">      ^cY#6904.htm##
00662000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704043400073002000900507#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#22#18#article#156#<P>Despite the side ef
fects of psychostimulant drugs (PD) in medical and psychiatric    co-morbidity, 
illicit PD are broadly disseminated as an aid used by shift workers    to counte
r discomfort in their schedules. PD lead to various physiologic effects,    incl
uding hormonal (1), behavioral (2,3) and neurochemical (4) changes. Nevertheless
,    the problems most frequently reported by PD users are sleep disturbances (5
).      ^cY#6904.htm##
00955000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704072700073002000900800#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#23#19#article#156#<P>PD have acute and c
hronic effects on sleep architecture. Difficulty in initiating    and maintainin
g sleep as well as lower sleep efficiency (SE) and significant    sleep onset de
lay are common amongst cocaine users (6). Furthermore, in cocaine-dependent    i
ndividuals, alterations in objective sleep quality accompany their characteristi
c    binge-abstinence cycle (7). PD abusers often have increased propensity for 
rapid    eye movement (REM) sleep during periods of acute and subacute withdrawa
l from    cocaine and amphetamine (8). Indeed, studies on these signs and sympto
ms have    reported that they may reflect a state of relative functional dopamin
e (DA)    depletion in the brain during abstinence (8).      ^cY#6904.htm##
01119000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704089100073002000900964#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#24#20#article#156#<P>A recent study usin
g microdialysis coupled with electrophysiologic recordings    reported an increa
se in DA concentration during wakefulness and paradoxical    sleep (PS) compared
 to that during slow wave sleep (SWS) (9). Also reported    was an increased neu
ral activity of ventral tegmental area neurons during PS    (10) and a recent st
udy showed that mice with profound DA depletion display    a complete suppressio
n of REM sleep (4). Indeed, paradoxical sleep deprivation    (PSD) appears to en
hance DA concentrations and DA receptor sensitivity (11,12)    and these alterat
ions may be attributable to DA postsynaptic receptor supersensitivity    (11,13)
 and DA transporter (DAT) subsensitivity (11,14). The recovery period    after P
SD is marked by an increased pressure of REM sleep (15) and plays a role    in r
estoring the function of the catecholaminergic system (16).      ^cY#6904.htm##
00476000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704024800073002000900321#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#25#21#article#156#<P>PD abuse often occu
rs within a PSD scenario, the main effect of these drugs    being on the dopamin
ergic system (17). Internationally, amphetamine-type stimulants    and cocaine a
re among the three most common substances of abuse (18).      ^cY#6904.htm##
01514000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704128600073002000901359#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#26#22#article#156#<P>Cocaine primarily i
nhibits DAT (19) by causing a marked increase in the synaptic    cleft of striat
al DA concentrations. Amphetamines are far more effective in    binding DAT than
 cocaine, promoting a greater DA release (20). Amphetamines    release DA only i
n cells that express DAT (21); however, the release is greater    for cells that
 co-express vesicular monoamine transporter (VMAT). This indicates    that both 
plasmalemmal and vesicular components are involved in the DA-releasing    action
 of amphetamines, VMAT sequesters intraneuronal DA into vesicles for storage    
and subsequent release, and thus is an important regulator of cytolasmic DA    c
oncentrations and dopaminergic function. Cells that co-express DAT and VMAT    h
ave a higher capacity to retain accumulated DA by means of their vesicles,    wh
ereas the cytoplasmic pool of DA, the only one present in DAT cells, is more    
easily washed out by superfusion (22). The larger absolute amount of DA released
    by amphetamine from DAT/VMAT cells compared with DAT cells may be due to dir
ect    mobilization of VMAT and/or exchange diffusion from a cytoplasmic pool th
at    is, to a certain extent, fed by DA leaking out of the vesicles and is ther
efore    not as easily exhausted as in DAT cells (22).      ^cY#6904.htm##
01064000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704083600073002000900909#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#27#23#article#156#<P>Due to the undesire
d behavioral and cognitive effects observed after the use    of psychostimulants
 like cocaine and methamphetamine, an alternative non-illicit    drug that promo
tes wakefulness named modafinil has been approved by the Food    and Drug Admini
stration. This drug has been largely used to treat excessive    daytime sleepine
ss and is characterized by not causing rebound hypersomnolence    (23). Pharmaco
logical evidence is unclear, but some investigators suggest that    modafinil ac
ts through competitive binding to DAT (24) and provokes a surge    of extracellu
lar DA concentration (17,25). Although dopaminergic transmission    is an attrac
tive therapeutic approach, there is considerable pharmacological    evidence tha
t modafinil acts through noradrenergic mechanisms to promote wakefulness    (26,
27).      ^cY#6904.htm##
00574000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704034600073002000900419#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#28#24#article#156#<P>Since PSD plays a c
rucial role in the dopaminergic system, and substances that    increase the rele
ase of DA are commonly psychostimulants, the aim of the present    study was to 
compare the sleep patterns of rats challenged with different wake-promoting    d
rugs subsequent to 96 h of PSD.  </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     
^cY#6904.htm##
00621000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704039300073002000900466#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#29#25#article#156#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Material"></A><FONT color="#00007F" SIZE=4><B>Ma
terial    and Methods</B></FONT></font> <font size="4" face="Arial, Helvetica, s
ans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIG
N=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A></font></P> <
font face="Arial, Helvetica, sans-serif">      ^cY#6904.htm##
00264000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704003600073002000900109#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#30#26#article#156#<P><b>Animals</b>  </f
ont>      ^cY#6904.htm##
00639000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704041100073002000900484#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#31#27#article#156#<P><font face="Arial, 
Helvetica, sans-serif">Three-month-old male Wistar rats    bred in our facilitie
s (~300 g) were used in this experimental protocol. The    animals were maintain
ed at 22 &#177; 1&#176;C on a 12/12-h light/dark cycle    (lights on at 7:00 am)
, with free access to food and water. The research protocol    was approved by t
he local UNIFESP Ethics Committee (CEP No. 482/02). </font>      ^cY#6904.htm##
00318000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704009000073002000900163#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#32#28#article#156#<P><font face="Arial, 
Helvetica, sans-serif"><B>Surgical preparation</B> </font>      ^cY#6904.htm##
01261000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704103300073002000901106#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#33#29#article#156#<P><font face="Arial, 
Helvetica, sans-serif">The rats were anesthetized with ketamine    hydrochloride
 and diazepam (90 and 4.5 mg/kg body weight, <I>ip</I>). After    full induction
 of anesthesia, the animals were mounted in a stereotaxic frame    and their bod
y temperature was maintained at 36.5-37&#176;C with a homeothermic    blanket. T
o record the cortical electrocorticogram (ECoG), two pairs of screw    electrode
s were inserted through the skull ipsilaterally: 1 mm posterior to    the bregma
, 3 mm lateral to the central suture, and 1 mm anterior to lambda,    4 mm later
al to the central suture. Electromyogram (EMG) electrodes were implanted    in t
he neck muscles, soldered to a 6-pin socket and covered with dental acrylic    c
ement. After surgery, the rats were individually placed in transparent plastic  
  cages and allowed a 14-day period of recovery from surgery comprising 10 days 
   without the recording cable followed by a 3-day adaptation period with the po
lysomnography    cable connected. </font>      ^cY#6904.htm##
00313000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704008500073002000900158#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#34#30#article#156#<P><font face="Arial, 
Helvetica, sans-serif"><B>Sleep recording</B> </font>      ^cY#6904.htm##
01199000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704097100073002000901044#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#35#31#article#156#<P><font face="Arial, 
Helvetica, sans-serif">Electrophysiological signals were    recorded on a digita
l polygraph (Neurofax QP 223 A<SUP>&#174;</SUP> Nihon Kohden,    Tokyo, Japan) a
t a sampling rate of 200 Hz. recordings were visually scored    for 30-s epochs 
according to classical sleep-waking criteria as reflected either    in i) the wa
king state, which is characterized by low voltage, fast ECoG and    high EMG act
ivity; ii) SWS, characterized by continuous high amplitude, slow    ECoG activit
y and low EMG activity, or iii) PS, characterized by high ECoG activity    and a
bsence of EMG activity. Each 30-s epoch was defined by the wave pattern    (waki
ng state, SWS, PS), which occupied more than 50% of the time. When artifacts    
or noise did not allow characterization of an epoch, assessments were made based
    on immediate surrounding epochs. Animals were habituated to the recording sy
stem    before the rebound recording was performed. </font>      ^cY#6904.htm##
00331000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704010300073002000900176#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#36#32#article#156#<P><font face="Arial, 
Helvetica, sans-serif"><B>Paradoxical sleep deprivation    </B> </font>      ^cY
#6904.htm##
01082000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704085400073002000900927#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#37#33#article#156#<P><font face="Arial, 
Helvetica, sans-serif">The PSD method consists of placing    10 animals inside a
 tiled tank (123 x 44 x 44 cm) containing 14 narrow circular    platforms (6.5 c
m in diameter) filled with water to within 1 cm of the upper    surface of the p
latform. Such arrangement allows the animals to move around    by leaping from o
ne platform to another. One tank was used for each group. In    this procedure w
hen an animal reaches PS, the accompanying muscle atonia causes    it to touch t
he water and wake up. Under these conditions, the procedure causes    a complete
 loss of PS on each of the 4 days (27). Food and water were provided    <I>ad li
bitum</I> by placing chow pellets and water bottles on a grid located    on the 
top of the tank. The water in the tank was changed daily throughout the    96-h 
period of PSD. </font>      ^cY#6904.htm##
00304000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704007600073002000900149#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#38#34#article#156#<P><font face="Arial, 
Helvetica, sans-serif"><B>Groups</B> </font>      ^cY#6904.htm##
00662000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704043400073002000900507#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#39#35#article#156#<P><font face="Arial, 
Helvetica, sans-serif">After the PSD period, the rats were    randomly distribut
ed into 8 experimental groups of 10 animals each: saline (SAL)    home cage and 
PSD, cocaine (COC, 7 mg/kg, <I>ip</I>) home cage and PSD, methamphetamine    (ME
TH, 7 mg/kg, <I>ip</I>) home cage and PSD, or modafinil (MOD, 100 mg/kg,    <I>i
p</I>) home cage and PSD (as depicted in <a href="#Fig1">Figure 1</a>).    </fon
t>      ^cY#6904.htm##
00304000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704007600073002000900149#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#40#36#article#156#<P><font face="Arial, 
Helvetica, sans-serif"><B>Drugs </B> </font>      ^cY#6904.htm##
00677000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704044900073002000900522#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#41#37#article#156#<P><font face="Arial, 
Helvetica, sans-serif">The doses of each drug were chosen    on the basis of pre
vious studies and prepared immediately prior to testing by    dissolving in dist
illed water. Systemic injections were administered <I>ip</I>    in a volume of 1
 mL/kg: METH (7 mg/kg, <I>ip</I>) (28), COC (7 mg/kg, <I>ip</I>;    Sigma, St. L
ouis, MO, USA) (2), and MOD (100 mg/kg, <I>ip</I>; Laboratoire L.    Lafon, Fran
ce) (29). </font>      ^cY#6904.htm##
00318000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704009000073002000900163#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#42#38#article#156#<P><font face="Arial, 
Helvetica, sans-serif"><B>Statistical analysis</B> </font>      ^cY#6904.htm##
00675000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704044700073002000900520#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#43#39#article#156#<P><font face="Arial, 
Helvetica, sans-serif">Two-way analysis of variance (ANOVA)    was used to analy
ze group differences (treatment/sleep condition), period recordings    and inter
action between these two factors. For specific group comparisons, the    <I>post
 hoc </I>Duncan test was performed and values are reported as means &#177;    SE
M, with the level of significance set at P &lt; 0.05. </font>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>     ^cY#6904.htm##
00563000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704033500073002000900408#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#44#40#article#156#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Results"></A><FONT color="#00007F" SIZE=4><B>Res
ults</B></FONT></font>    <font size="4" face="Arial, Helvetica, sans-serif"><A 
HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIGN=BOTTOM BORDE
R=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A></font></P>     ^cY#6904.ht
m##
00352000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704012400073002000900197#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#45#41#article#156#<P><b><font face="Aria
l, Helvetica, sans-serif">Effects of drug treatment on basal    sleep values </f
ont></b> </P>     ^cY#6904.htm##
01507000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704127900073002000901352#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#46#42#article#156#<P><font face="Arial, 
Helvetica, sans-serif"><I>Sleep efficiency.</I> <I>Light    period</I>: ANOVA re
vealed a significant effect of group (F<SUB>(7,61)</SUB>    = 24.51; P &lt; 0.01
), time-points (F<SUB>(1,61)</SUB> = 11.45; P &lt; 0.01)    and an interaction e
ffect between these factors (F<SUB>(7,61)</SUB> = 25.74;    P &lt; 0.01). Rats i
njected with METH presented lower percentages of SE on the    first day of recor
ding (D1) than rats injected with SAL, COC, and MOD (P &lt;    0.01). On the sec
ond day of recording (D2), METH rats showed a significant increase    in the per
centages of SE compared with MOD animals (P &lt; 0.01). The administration    of
 MOD resulted in a statistical decrease of SE in relation to the SAL and COC    
groups at D2 (P &lt; 0.01; <a href="#Fig2">Figure 2</a>). <I>Dark period</I>:   
 Statistically significant differences were detected for groups (F<SUB>(7,61)</S
UB>    = 24.51; P &lt; 0.01) and time points (F<SUB>(1,61)</SUB> = 11.45; P &lt;
 0.01)    as was an interaction effect between these factors (F<SUB>(7,61)</SUB>
 = 25.74;    P &lt; 0.01). <I>Post hoc</I> analysis revealed a significant incre
ase of SE    in the METH group compared to SAL, COC (P &lt; 0.05), and MOD (P &l
t; 0.01 on    day 1) at both D1 and D2. </font>      ^cY#6904.htm##
01485000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704125700073002000901330#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#47#43#article#156#<P><font face="Arial, 
Helvetica, sans-serif"><I>Slow wave sleep</I>. <I>Light    period</I>: Statistic
ally significant differences were detected for group (F<SUB>(7,61)</SUB>    = 24
.51; P &lt; 0.01) and time points (F<SUB>(1,61)</SUB> = 11.45; P &lt; 0.01)    a
nd an interaction effect between these factors (F<SUB>(7,61)</SUB> = 25.74;    P
 &lt; 0.01) was verified. Acute administration of METH induced a significant    
decrease in SWS compared with the SAL, COC, and MOD groups (P &lt; 0.01) at    D
1. In contrast, at D2, rats injected with METH presented higher percentages    o
f SWS compared with MOD rats (P &lt; 0.05). The acute administration of MOD    i
nduced an increase of SWS compared with the SAL group and a decrease when compar
ed    with COC rats at D2 (P &lt; 0.05), as shown in <a href="#Fig2">Figure 2</a
>.    <I>Dark period</I>: Statistically significant differences were detected in
 groups    (F<SUB>(7,61)</SUB> = 24.51; P &lt; 0.01) and time points (F<SUB>(1,6
1)</SUB>    = 11.45; P &lt; 0.01). During the dark period, METH increased SWS wh
en compared    to the SAL group (P &lt; 0.01) at D1. No statistically significan
t differences    were observed in the remaining non-PSD groups (<a href="#Fig2">
Figure 2</a>).    </font>      ^cY#6904.htm##
00829000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704060100073002000900674#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#48#44#article#156#<P><font face="Arial, 
Helvetica, sans-serif"><I>Paradoxical sleep</I>. <I>Light    period</I>: As show
n in <a href="#Fig2">Figure 2</a>, the main effect of group    (F<SUB>(7,61)</SU
B> = 39.6; P &lt; 0.01), time points (F<SUB>(1,61)</SUB> =    75.74; P &lt; 0.01
) and interaction between group and rebound recordings (F<SUB>(7,61)</SUB>    = 
36.44; P &lt; 0.01) were observed. Rats injected with METH had lower percentages
    of PS at D1 when compared with all other groups (P &lt; 0.05). <I>Dark perio
d</I>:    There were no statistically significant differences in the dark period
. </font>      ^cY#6904.htm##
00362000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704013400073002000900207#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#49#45#article#156#<P><font face="Arial, 
Helvetica, sans-serif"><B>Effects of drug challenge after    paradoxical sleep d
eprivation</B> </font>      ^cY#6904.htm##
01117000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704088900073002000900962#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#50#46#article#156#<P><font face="Arial, 
Helvetica, sans-serif"><I>Saline</I>. <I>Light period</I>:    In the PSD group S
E was significantly higher and SWS lower on the first day    of rebound (R1) whe
n compared with the non-PSD group recordings (P &lt; 0.01).    Regarding SWS, th
e percentages of this stage were significantly higher on the    second day of re
bound (R2) in relation to R1 for the PSD group. PSD resulted    in a marked incr
ease of PS at R1 (P &lt; 0.01) that persisted until R2 in SAL-injected    rats (
P &lt; 0.01), as shown in <a href="#Fig3">Figure 3</a>. <I>Dark period</I>:    T
he Duncan test showed that, after PSD, rats injected with SAL presented increase
d    percentages of SE, SWS and PS compared to the non-PSD group at D1 (P &lt; 0
.01).    However, at R2, these percentages were not different from control and w
ere significantly    lower than R1 (P &lt; 0.05). </font>      ^cY#6904.htm##
01040000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704081200073002000900885#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#51#47#article#156#<P><font face="Arial, 
Helvetica, sans-serif"><I>Cocaine</I>. <I>Light period</I>:    After PSD, rats i
njected with COC presented a significant increase of SE at    R1 when compared w
ith the non-PSD group (P &lt; 0.01). The percentages of SWS    at D2/R2 were sig
nificantly higher than at D1/R1 in both the PSD and non-PSD    groups (P &lt; 0.
05). PSD resulted in a marked increase of PS at R1 (P &lt;    0.01) that persist
ed until R2 in COC-injected rats (P &lt; 0.01), as shown in    <a href="#Fig3">F
igure 3</a>. <I>Dark period</I>: The Duncan test showed that,    after PSD, rats
 injected with COC presented increased percentages of SE and    PS compared to t
he non-PSD group at R1 and R2 (P &lt; 0.01). However, at R2,    these percentage
s were significantly lower than at R1 (P &lt; 0.05). </font>      ^cY#6904.htm##
01127000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704089900073002000900972#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#52#48#article#156#<P><font face="Arial, 
Helvetica, sans-serif"><I>Methamphetamine</I>. <I>Light    period</I>: The Dunca
n test revealed that METH was the only drug that promoted    significant differe
nces between D1 and D2 in SE, SWS and PS in the non-PSD groups    (P &lt; 0.01).
 After PSD, rats injected with METH presented a decrease in SWS    at R1 that pe
rsisted until R2 compared with the non-PSD group (P &lt; 0.01).    However, when
 these days were compared, R2 was found to be significantly higher    than R1. I
ndeed, this drug promoted an increase of PS at R1 when compared with    the non-
PSD group (P &lt; 0.01). <I>Dark period</I>: After PSD, rats presented    increa
sed percentages of SE compared to the non-PSD group at R1 (P &lt; 0.01).    At R
2, the percentages of SE and PS were significantly lower at R2 compared    with 
R1 (P &lt; 0.05), as shown in <a href="#Fig3">Figure 3</a>. </font>      ^cY#690
4.htm##
01216000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704098800073002000901061#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#53#49#article#156#<P><font face="Arial, 
Helvetica, sans-serif"><I>Modafinil</I>. <I>Light period</I>:    After the admin
istration of MOD, SE and SWS were significantly reduced at R2    when compared t
o R1 in non-PSD rats (P &lt; 0.05). After PSD, SE and PS were    significantly h
igher at R1 and R2 when compared with the respective non-PSD    group recordings
 (P &lt; 0.01). PSD rats presented less PS at R2 compared with    R1 (P &lt; 0.0
5). PSD promoted an initial decrease of the SWS phase at R1 and    an increase a
t R2 compared with the non-PSD group (P &lt; 0.05). In this sleep    stage, PSD 
rats presented higher percentages at R2 compared with R1, as shown    in <a href
="#Fig3">Figure 3</a>. <I>Dark period</I>: The Duncan test showed    that, after
 PSD, rats injected with MOD presented increased percentages of SE,    SWS and P
S compared to the non-PSD group at R1 and R2 (P &lt; 0.01). The percentages    o
f SE and PS were significantly lower at R2 than at R1 (P &lt; 0.05). </font>    
  ^cY#6904.htm##
00376000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704014800073002000900221#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#54#50#article#156#<P><font face="Arial, 
Helvetica, sans-serif"><B>Comparisons among psychostimulant    drugs after parad
oxical sleep deprivation</B> </font>      ^cY#6904.htm##
01028000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704080000073002000900873#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#55#51#article#156#<P><font face="Arial, 
Helvetica, sans-serif"><I>Sleep efficiency</I>. <I>Light    period</I>: The PSD 
+ METH group had significantly lower SE at both R1 and R2    compared with the S
AL sleep-deprived group and with the rats challenged with    COC and MOD (P &lt;
 0.01), as shown in <a href="#Fig4">Figure 4</a>. <I>Dark    period</I>: At R1, 
METH resulted in a statistical increase in SE in PSD rats    compared with rats 
challenged with MOD (P &lt; 0.01), COC (P &lt; 0.05) and    SAL (P &lt; 0.01). A
t R2, the PSD + METH group presented a significant increase    in SE compared to
 the PSD + SAL (P &lt; 0.01) group. On both rebound days, MOD    led to a signif
icant increase in sleep time compared to SAL-challenged rats    (P &lt; 0.01), a
s shown in <a href="#Fig4">Figure 4</a>. </font>      ^cY#6904.htm##
00988000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704076000073002000900833#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#56#52#article#156#<P><font face="Arial, 
Helvetica, sans-serif"><I>Slow wave sleep</I>. <I>Light    period</I>: Compariso
n between the PSD groups indicated that on the first day    after sleep deprivat
ion PSD + METH produced significantly less SWS than PSD    + SAL, PSD + COC and 
PSD + MOD (P &lt; 0.01). At R2, rats injected with METH    presented lower perce
ntages of SWS compared with rats injected with COC (P &lt;    0.05). Indeed, the
 acute administration of MOD induced an increase of SWS compared    with the SAL
 group at R1 (P &lt; 0.05), as shown in <a href="#Fig4">Figure 4</a>.    <I>Dark
 period</I>: Rats injected with COC (P &lt; 0.05), METH (P &lt; 0.01)    and MOD
 (P &lt; 0.01) had more SWS compared with PSD + SAL rats at R2 (P &lt;    0.01).
 </font>      ^cY#6904.htm##
01287000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704105900073002000901132#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#57#53#article#156#<P><font face="Arial, 
Helvetica, sans-serif"><I>Paradoxical sleep</I>. <I>Light    period</I>: After P
SD, rats injected with COC, METH and MOD presented a significant    reduction of
 PS compared to SAL, and this reduction persisted until the second    day in the
 METH group (P &lt; 0.01). The Duncan test showed that at R1 this    sleep stage
 was significantly reduced in the MOD-challenged group when compared    with the
 PSD + COC group (P &lt; 0.05). Indeed, in both R1 and R2, PSD + METH    differe
d from PSD + COC and PSD + MOD (P &lt; 0.01). The reduction was due to    the lo
wer number of PS episodes in these groups compared to the others (P &lt;    0.01
; data not shown).<I> Dark period</I>: The groups challenged with psychostimulan
ts    presented an increase of PS compared to the PSD + SAL at R1 (P &lt; 0.01) 
and    this increase was observed even at R2 after MOD administration. Indeed, a
t R1,    rats injected with METH presented more PS that those injected with COC 
(P &lt;    0.05), as shown in <a href="#Fig4">Figure 4</a>. </font>      ^cY#690
4.htm##
00540000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704031200073002000900385#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#58#54#article#156#<P>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2> <table width="100%"  border="0">   <tr align="left" valign="top
">      <td width="12%"><a href="/img/revistas/bjmbr/v41n1/html/6904i01.htm"><im
g src="/img/revistas/bjmbr/v41n1/6904i01peq.jpg" width="120" height="124" border
="2"></a></td>     <td width="88%">           ^cY#6904.htm##
00707000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704047900073002000900552#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#59#55#article#156#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig1"></a>Figure 1.          Schematic represent
ation of the groups studied (panel A) and the protocol          (panel B). Each 
group contained 10 rats which received saline, cocaine          (7 mg/kg, <I>ip<
/I>), methamphetamine (7 mg/kg, <I>ip</I>), or modafinil          (100 mg/kg, <I
>ip</I>). L = light period; D = dark period; PSD = paradoxical          sleep-de
prived rats. </font>      </td>   </tr> </table>     ^cY#6904.htm##
00647000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704041900073002000900492#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#60#56#article#156#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image    (120 K JPG file)]</
font></P> <HR ALIGN=LEFT WIDTH=100% SIZE=2> <table width="100%"  border="0">   <
tr align="left" valign="top">      <td width="12%"><a href="/img/revistas/bjmbr/
v41n1/html/6904i02.htm"><img src="/img/revistas/bjmbr/v41n1/6904i02peq.jpg" widt
h="120" height="145" border="2"></a></td>     <td width="88%">           ^cY#690
4.htm##
01117000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704088900073002000900962#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#61#57#article#156#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig2"></a>Figure 2.          Percentage of each 
sleep parameter (sleep efficiency, SE; slow wave sleep,          SWS, and parado
xical sleep, PS) observed during the light (left panels)          and dark perio
ds (right panels) in home cage rats challenged with saline          (SAL), cocai
ne (COC, 7 mg/kg, <I>ip</I>), methamphetamine (METH, 7 mg/kg,          <I>ip</I>
) and modafinil (MOD, 100 mg/kg, <I>ip</I>) during two days of          recordin
g (D1 = open column and D2 = filled column). Data are reported          as means
 &#177; SEM. <SUP>#</SUP>P &lt; 0.05 compared to the saline group;          *P &
lt; 0.05 compared to the group challenged with cocaine;<SUP> +</SUP>P          &
lt; 0.05 compared to the group challenged with modafinil (ANOVA followed        
  by the Duncan test). </font>      </td>   </tr> </table>     ^cY#6904.htm##
00647000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704041900073002000900492#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#62#58#article#156#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image    (129 K JPG file)]</
font></P> <HR ALIGN=LEFT WIDTH=100% SIZE=2> <table width="100%"  border="0">   <
tr align="left" valign="top">      <td width="12%"><a href="/img/revistas/bjmbr/
v41n1/html/6904i03.htm"><img src="/img/revistas/bjmbr/v41n1/6904i03peq.jpg" widt
h="120" height="155" border="2"></a></td>     <td width="88%">           ^cY#690
4.htm##
01081000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704085300073002000900926#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#63#59#article#156#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig3"></a>Figure 3.          Percentage of each 
sleep parameter (sleep efficiency, SE; slow wave sleep,          SWS, and parado
xical sleep, PS) observed during the light (left panels)          and dark (righ
t panels) periods in home cage and paradoxical sleep-deprived          (PSD) rat
s challenged with saline (SAL), cocaine (COC, 7 mg/kg, <I>ip</I>),          meth
amphetamine (METH, 7 mg/kg, <I>ip</I>), and modafinil (MOD, 100 mg/kg,          
<I>ip</I>) during 2 days of recording (home cage group-D1/D2; PSD group-R1/R2). 
         Data are reported as means &#177; SEM. <SUP>+</SUP>P &lt; 0.05 compared
          to the first day of sleep recording; *P &lt; 0.05 compared to the non-
sleep-deprived          group (ANOVA followed by the Duncan test). </font>      
</td>   </tr> </table>     ^cY#6904.htm##
00647000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704041900073002000900492#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#64#60#article#156#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image    (186 K JPG file)]</
font></P> <HR ALIGN=LEFT WIDTH=100% SIZE=2> <table width="100%"  border="0">   <
tr align="left" valign="top">      <td width="12%"><a href="/img/revistas/bjmbr/
v41n1/html/6904i04.htm"><img src="/img/revistas/bjmbr/v41n1/6904i04peq.jpg" widt
h="120" height="127" border="2"></a></td>     <td width="88%">           ^cY#690
4.htm##
01121000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704089300073002000900966#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#65#61#article#156#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig4"></a>Figure 4.          Percentage of each 
sleep parameter (sleep efficiency, SE; slow wave sleep,          SWS, and parado
xical sleep, PS) during the light (left panels) and dark          (right panels)
 periods in paradoxical sleep-deprived rats (PSD) challenged          with salin
e (SAL), cocaine (COC, 7 mg/kg, <I>ip</I>), methamphetamine          (METH, 7 mg
/kg, <I>ip</I>) and modafinil (MOD, 100 mg/kg, <I>ip</I>) during          two da
ys of recording of PSD recovery (R1/R2). Data are reported as means          &#1
77; SEM. <SUP>#</SUP>Different from the group challenged with saline;          *
different from the group challenged with cocaine;<SUP> +</SUP>different         
 from the group challenged with modafinil (ANOVA followed by Duncan test,       
   see text for P values). </font>      </td>   </tr> </table>     ^cY#6904.htm#
#
00348000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704012000073002000900193#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#66#62#article#156#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image    (131 K JPG file)]</
font></P>     ^cY#6904.htm##
00275000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704004700073002000900120#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#67#63#article#156#<P>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>     ^cY#6904.htm##
00523000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704029500073002000900368#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#68#64#article#156#<P> <font face="Arial,
 Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007
F><B>Discussion    </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v
41n1/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></
B></A></FONT></font></P>     ^cY#6904.htm##
01244000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704101600073002000901089#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#69#65#article#156#<P><font face="Arial, 
Helvetica, sans-serif">The psychostimulants investigated    in the current study
 induced different patterns of sleep-wake cycle alterations    due to the effect
 of the drugs themselves and to their association with PSD.    Our results show 
that immediately after 96 h of PSD, rats injected with psychostimulants    prese
nted lower percentages of PS when compared to those injected with SAL solution  
  but, regarding SWS, after PSD rats injected with the three drugs showed a late
    rebound (on the second night after the injection) when compared to PSD + SAL
    rats. Among the drugs investigated, METH was the one that most affected slee
p    patterns since it significantly reduced PS, SWS and SE before and after PSD
    when compared with the respective SAL groups during the light period. Indeed
,    the four groups presented a significant increase in PS after PSD, but METH 
was    the only drug capable of inhibiting PS rebound on the second day after ad
ministration.    </font>      ^cY#6904.htm##
01528000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704130000073002000901373#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#70#66#article#156#<P><font face="Arial, 
Helvetica, sans-serif">Psychostimulant drugs such as amphetamines    or cocaine,
 which facilitate catecholamine release and/or block their uptake,    are common
ly used for psychostimulation. D<SUB>1</SUB> and D<SUB>2</SUB> DA    receptors a
re clearly implicated in the induction of hyperarousal (30) and it    has been s
uggested that presynaptic activation of DA transmission is a key pharmacologic  
  property mediating the wake-promoting effects of stimulants (31). The immediat
e    reduction in the percentage of PS observed subsequent to the injection of M
ETH,    COC and MOD when compared to the PSD + SAL group may have been due to a 
complex    relationship between brain dopaminergic and noradrenergic signaling s
ystems:    DA is the precursor of noradrenaline and could be a synergic ligand a
nd a substrate    for noradrenergic receptors (32). Interactions between these s
ystems have hampered    attempts to elucidate the exact target for the effects o
f stimulant drugs. Like    PS, psychostimulants are characterized by their prope
rty of increasing mesolimbic    DA neurons (9). Accordingly, rats submitted to P
SD for 96 h presented supersensitivity    of the postsynaptic D<SUB>2</SUB> rece
ptor (13) and subsensitivity of the presynaptic    DAT (14). </font>      ^cY#69
04.htm##
01248000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704102000073002000901093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#71#67#article#156#<P><font face="Arial, 
Helvetica, sans-serif">The neurotransmitter alterations    observed after PSD su
ggest that the loss of PS reduces the release of DA by    neurons. The present d
ata show that rats injected with psychostimulants after    PSD presented less PS
 immediately after the administration of the drugs when    compared to rats inje
cted with SAL solution, and this was most likely due to    the stimulating effec
ts of the drugs. However, during the subsequent dark period,    rats injected wi
th COC, METH and MOD presented increased PS compared to the    SAL group. These 
results suggest that, although the rat is more active during    the dark period,
 the excess DA released after administration of the psychostimulants    could ha
ve caused a late increase of PS in the drug groups in relation to the    vehicle
 group. If PSD promotes neurotransmitter changes that enhance the psychostimulan
t    effects, the combination of these two variables would promote a powerful wa
kefulness    effect. </font>      ^cY#6904.htm##
01350000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704112200073002000901195#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#72#68#article#156#<P><font face="Arial, 
Helvetica, sans-serif">In general, PS is more sensitive    than SWS to disruptio
n by manipulation of catecholaminergic transmission (33,34).    Our data show th
at, although acute COC and MOD administration to home cage groups    had no imme
diate effect on SWS, the PSD groups presented a significant increase    in SWS p
ercentages compared to PSD + SAL-challenged rats. Indeed, after PSD,    rats in 
the psychostimulant groups presented longer SWS than the SAL group during    the
 second dark period after PSD. MOD promoted an immediate reduction in SWS    in 
relation to the respective home cage group, followed by an exacerbated stimulato
ry    effect subsequent to PSD, whereas no changes were observed in the COC grou
p.    In contrast to these processes which are increased by psychostimulants, SW
S    is accompanied by a reduction of catecholamine release (35). The prolonged 
effects    of MOD on SWS may be attributed to its long half-life and in particul
ar to noradrenergic    transmission, since noradrenaline is a relevant regulatin
g agent for sleep-state    timing (36,37). </font>      ^cY#6904.htm##
00976000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704074800073002000900821#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#73#69#article#156#<P><font face="Arial, 
Helvetica, sans-serif">After PSD, the METH group showed    a significant reducti
on in SWS when compared to the other groups in the same    sleep condition. In c
ontrast, rats injected with COC and MOD presented higher    percentages of SWS c
ompared with the SAL and METH groups. Unlike the COC and    MOD groups, and with
in just the first 12 h, the home cage and PSD groups injected    with METH had a
 significant decrease in the light period of SWS compared with    the SAL group.
 The reduction observed in this phase may have been due to the    inactivation o
f the DA system by the drugs, so that the mechanism of action    of a high METH 
dose would remain effective even after a prolonged period of    PSD. </font>    
  ^cY#6904.htm##
01070000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704084200073002000900915#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#74#70#article#156#<P><font face="Arial, 
Helvetica, sans-serif">It is during the light period of    SWS that rat sleep be
comes concentrated and a rebound period of this sleep phase    was observed duri
ng the subsequent dark and light periods. On the basis of these    results, we s
uggest that the modulation of the sleep-wake response could depend    on the mon
oaminergic system, mainly if the dopaminergic system is involved.    Since the a
lterations in dopaminergic pathways resulting from PSD are mainly    marked by i
ncreased D<SUB>1</SUB> (38) and D<SUB>2</SUB> (14) receptors and    reduced DAT 
(responsible for the release and reuptake of DA from within the    synaptic clef
t) the most likely scenario is that dopaminergic drugs that lead    to the relea
se of DA, such as amphetamine, entail an increase in DA availability    after PS
D. </font>      ^cY#6904.htm##
01329000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704110100073002000901174#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#75#71#article#156#<P><font face="Arial, 
Helvetica, sans-serif">Recently, our group published that    the PSD method appl
ied in the present study completely abolishes PS during the    deprivation perio
d (39). After 96 h of PSD, both female (Antunes IB, Andersen    ML, Baracat EC, 
Tufik S, unpublished results) and male (39) rats presented significantly    incr
eased PS percentages. Our data corroborate with these previous studies showing  
  that all groups presented rebound of PS after PSD. Indeed, the group injected 
   with METH was the only where loss of PS did not persist until R2, suggesting 
   that this psychostimulant exerts marked long-term effects in sleep patterns. 
   SE observed during the second dark period was significantly lower than during
    the first, indicating a normalized sleep pattern. After 96 h of PSD, the COC
    and MOD challenge caused a significant reduction in PS compared with the PSD
    + SAL group which may have been due to the modulation of pharmacological int
eraction    since the sleep-wake cycle needs more time to regulate the equilibri
um of basal    sleep. </font>      ^cY#6904.htm##
00699000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704047100073002000900544#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#76#72#article#156#<P><font face="Arial, 
Helvetica, sans-serif">Our findings demonstrate that the    different pharmacolo
gical profiles of COC, METH and MOD lead to sleep rebound    after PSD. Overall,
 although the precise mechanisms underlying sleep rebound    remain obscure, our
 data suggest that its function is to enhance sleep recovery    by restoring the
 physiological and functional concentrations of catecholaminergic    neurons. </
font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6904.htm##
00569000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704034100073002000900414#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#77#73#article#156#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><B>
References</B></FONT></font>    <font size="4" face="Arial, Helvetica, sans-seri
f"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIGN=BOTTOM
 BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A></font></P>     ^cY#6
904.htm##
00532000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704029000075002000900365#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#78#74#article#156#1#<P><font
 face="Arial, Helvetica, sans-serif">1. Budziszewska B, Jaworska-Feil    L, Laso
n W. The effect of repeated amphetamine and cocaine administration on    adrenal
, gonadal and thyroid hormone levels in the rat plasma. <I>Exp Clin Endocrinol  
  Diabetes</I> 1996; 104: 334-338.    ^cY#6904.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#79#75#article#156# </font>      ^cY#6904
.htm##
00466000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704022400075002000900299#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#80#76#article#156#2#<P><font
 face="Arial, Helvetica, sans-serif">2. Andersen ML, Perry JC, Tufik S.    Acute
 cocaine effects in paradoxical sleep deprived male rats. <I>Prog Neuropsychopha
rmacol    Biol Psychiatry</I> 2005; 29: 245-251.    ^cY#6904.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#81#77#article#156# </font>      ^cY#6904
.htm##
00482000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704024000075002000900315#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#82#78#article#156#3#<P><font
 face="Arial, Helvetica, sans-serif">3. Andersen ML, Bignotto M, Tufik    S. Hor
mone treatment facilitates penile erection in castrated rats after sleep    depr
ivation and cocaine. <I>J Neuroendocrinol 2004;</I> 16: 154-159.    ^cY#6904.htm
##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#83#79#article#156# </font>      ^cY#6904
.htm##
00456000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704021400075002000900289#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#84#80#article#156#4#<P><font
 face="Arial, Helvetica, sans-serif">4. Dzirasa K, Ribeiro S, Costa R,    Santos
 LM, Lin SC, Grosmark A, et al. Dopaminergic control of sleep-wake states.    <I
>J Neurosci</I> 2006; 26: 10577-10589.    ^cY#6904.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#85#81#article#156# </font>      ^cY#6904
.htm##
00466000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704022400075002000900299#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#86#82#article#156#5#<P><font
 face="Arial, Helvetica, sans-serif">5. Johanson CE, Roehrs T, Schuh K,    Warba
sse L. The effects of cocaine on mood and sleep in cocaine-dependent males.    <
I>Exp Clin Psychopharmacol</I> 1999; 7: 338-346.    ^cY#6904.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#87#83#article#156# </font>      ^cY#6904
.htm##
00536000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704029400075002000900369#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#88#84#article#156#6#<P><font
 face="Arial, Helvetica, sans-serif">6. Morgan PT, Pace-Schott EF, Sahul    ZH, 
Coric V, Stickgold R, Malison RT. Sleep, sleep-dependent procedural learning    
and vigilance in chronic cocaine users: Evidence for occult insomnia. <I>Drug   
 Alcohol Depend</I> 2006; 82: 238-249.    ^cY#6904.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#89#85#article#156# </font>      ^cY#6904
.htm##
00517000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704027500075002000900350#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#90#86#article#156#7#<P><font
 face="Arial, Helvetica, sans-serif">7. Pace-Schott EF, Stickgold R, Muzur    A,
 Wigren PE, Ward AS, Hart CL, et al. Sleep quality deteriorates over a binge    
-abstinence cycle in chronic smoked cocaine users. <I>Psychopharmacology </I>200
5;    179: 873-883.    ^cY#6904.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#91#87#article#156# </font>      ^cY#6904
.htm##
00513000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704027100075002000900346#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#92#88#article#156#8#<P><font
 face="Arial, Helvetica, sans-serif">8. Gillin JC, Pulvirenti L, Withers    N, G
olshan S, Koob G. The effects of lisuride on mood and sleep during acute    with
drawal in stimulant abusers: a preliminary report. <I>Biol Psychiatry</I>    199
4; 35: 843-849.    ^cY#6904.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#93#89#article#156# </font>      ^cY#6904
.htm##
00617000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704037500075002000900450#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#94#90#article#156#9#<P><font
 face="Arial, Helvetica, sans-serif">9. Lena I, Parrot S, Deschaux O,    Muffat-
Joly S, Sauvinet V, Renaud B, et al. Variations in extracellular levels    of do
pamine, noradrenaline, glutamate, and aspartate across the sleep-wake cycle    i
n the medial prefrontal cortex and nucleus accumbens of freely moving rats.    <
I>J Neurosci Res</I> 2005; 81: 891-899.    ^cY#6904.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#95#91#article#156# </font>      ^cY#6904
.htm##
00528000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704028500076002000900361#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#96#92#article#156#10#<P><fon
t face="Arial, Helvetica, sans-serif">10. Maloney KJ, Mainville L, Jones    BE. 
c-Fos expression in dopaminergic and GABAergic neurons of the ventral mesencepha
lic    tegmentum after paradoxical sleep deprivation and recovery. <I>Eur J Neur
osci</I>    2002; 15: 774-778.    ^cY#6904.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#97#93#article#156# </font>      ^cY#6904
.htm##
00473000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704023000076002000900306#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#98#94#article#156#11#<P><fon
t face="Arial, Helvetica, sans-serif">11. Tufik S, Lindsey CJ, Carlini    EA. Do
es REM sleep deprivation induce a supersensitivity of dopaminergic receptors    
in the rat brain? <I>Pharmacology</I> 1978; 16: 98-105.    ^cY#6904.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#99#95#article#156# </font>      ^cY#6904
.htm##
00515000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704027100077002000900348#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#100#96#article#156#12#<P><fo
nt face="Arial, Helvetica, sans-serif">12. Andersen ML, Papale LA, Hipolide    D
C, Nobrega JN, Tufik S. Involvement of dopamine receptors in cocaine-induced    
genital reflexes after paradoxical sleep deprivation. <I>Behav Brain Res</I>    
2005; 160: 44-50.    ^cY#6904.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070704001700074002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#101#97#article#156#</font>      ^cY#6904
.htm##
00497000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704025300077002000900330#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#102#98#article#156#13#<P><fo
nt face="Arial, Helvetica, sans-serif">13. Nunes Junior GP, Tufik S, Nobrega    
JN. Autoradiographic analysis of D1 and D2 dopaminergic receptors in rat brain  
  after paradoxical sleep deprivation. <I>Brain Res Bull</I> 1994; 34: 453-456. 
   ^cY#6904.htm##
00250000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070704002100074002000900095#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#103#99#article#156#    </font>      ^cY#
6904.htm##
00542000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704029700078002000900375#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#104#100#article#156#14#<P><f
ont face="Arial, Helvetica, sans-serif">14. Tufik S, Troncone LR, Braz S,    Sil
va-Filho AR, Neumann BG. Does REM sleep deprivation induce subsensitivity    of 
presynaptic dopamine or postsynaptic acetylcholine receptors in the rat brain?  
  <I>Eur J Pharmacol</I> 1987; 140: 215-219.    ^cY#6904.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#105#101#article#156# </font>      ^cY#69
04.htm##
00405000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704016000078002000900238#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#106#102#article#156#15#<P><f
ont face="Arial, Helvetica, sans-serif">15. Benington JH. Debating how REM    sl
eep is regulated (and by what). <I>J Sleep Res</I> 2002; 11: 29-31.    ^cY#6904.
htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#107#103#article#156# </font>      ^cY#69
04.htm##
00471000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704022600078002000900304#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#108#104#article#156#16#<P><f
ont face="Arial, Helvetica, sans-serif">16. Stern WC, Morgane PJ. Theoretical   
 view of REM sleep function: maintenance of catecholamine systems in the central
    nervous system. <I>Behav Biol</I> 1974; 11: 1-32.    ^cY#6904.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#109#105#article#156# </font>      ^cY#69
04.htm##
00547000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704030200078002000900380#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#110#106#article#156#17#<P><f
ont face="Arial, Helvetica, sans-serif">17. Murillo-Rodriguez E, Haro R,    Palo
mero-Rivero M, Millan-Aldaco D, Drucker-Colin R. Modafinil enhances extracellula
r    levels of dopamine in the nucleus accumbens and increases wakefulness in ra
ts.    <I>Behav Brain Res</I> 2007; 176: 353-357.    ^cY#6904.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#111#107#article#156# </font>      ^cY#69
04.htm##
00446000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704020100078002000900279#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#112#108#article#156#18#<P><f
ont face="Arial, Helvetica, sans-serif">18. Costa e Silva JA. Evidence-based    
analysis of the worldwide abuse of licit and illicit drugs. <I>Hum Psychopharmac
ol</I>    2002; 17: 131-140.    ^cY#6904.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#113#109#article#156# </font>      ^cY#69
04.htm##
00420000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704017500078002000900253#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#114#110#article#156#19#<P><f
ont face="Arial, Helvetica, sans-serif">19. Johanson CE, Fischman MW. The    pha
rmacology of cocaine related to its abuse. <I>Pharmacol Rev</I> 1989; 41:    3-5
2.    ^cY#6904.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#115#111#article#156# </font>      ^cY#69
04.htm##
00491000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704024600078002000900324#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#116#112#article#156#20#<P><f
ont face="Arial, Helvetica, sans-serif">20. Ritz MC, Kuhar MJ. Relationship    b
etween self-administration of amphetamine and monoamine receptors in brain:    c
omparison with cocaine. <I>J Pharmacol Exp Ther</I> 1989; 248: 1010-1017.    ^cY
#6904.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#117#113#article#156# </font>      ^cY#69
04.htm##
00457000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704021200078002000900290#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#118#114#article#156#21#<P><f
ont face="Arial, Helvetica, sans-serif">21. Sulzer D, Sonders MS, Poulsen    NW,
 Galli A. Mechanisms of neurotransmitter release by amphetamines: a review.    <
I>Prog Neurobiol</I> 2005; 75: 406-433.    ^cY#6904.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#119#115#article#156# </font>      ^cY#69
04.htm##
00552000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704030700078002000900385#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#120#116#article#156#22#<P><f
ont face="Arial, Helvetica, sans-serif">22. Pifl C, Drobny H, Reither H,    Horn
ykiewicz O, Singer EA. Mechanism of the dopamine-releasing actions of amphetamin
e    and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine t
ransporter.    <I>Mol Pharmacol</I> 1995; 47: 368-373.    ^cY#6904.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#121#117#article#156# </font>      ^cY#69
04.htm##
00553000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704030800078002000900386#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#122#118#article#156#23#<P><f
ont face="Arial, Helvetica, sans-serif">23. Lin JS, Gervasoni D, Hou Y, Vanni-Me
rcier    G, Rambert F, Frydman A, et al. Effects of amphetamine and modafinil on
 the    sleep/wake cycle during experimental hypersomnia induced by sleep depriv
ation    in the cat. <I>J Sleep Res</I> 2000; 9: 89-96.    ^cY#6904.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#123#119#article#156# </font>      ^cY#69
04.htm##
00459000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704021400078002000900292#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#124#120#article#156#24#<P><f
ont face="Arial, Helvetica, sans-serif">24. Mignot E, Nishino S, Guilleminault  
  C, Dement WC. Modafinil binds to the dopamine uptake carrier site with low aff
inity.    <I>Sleep</I> 1994; 17: 436-437.    ^cY#6904.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#125#121#article#156# </font>      ^cY#69
04.htm##
00563000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704031800078002000900396#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#126#122#article#156#25#<P><f
ont face="Arial, Helvetica, sans-serif">25. de Saint Hilaire Z, Orosco M,    Rou
ch C, Blanc G, Nicolaidis S. Variations in extracellular monoamines in the    pr
efrontal cortex and medial hypothalamus after modafinil administration: a    mic
rodialysis study in rats. <I>NeuroReport</I> 2001; 12: 3533-3537.    ^cY#6904.ht
m##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#127#123#article#156# </font>      ^cY#69
04.htm##
00465000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704022000078002000900298#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#128#124#article#156#26#<P><f
ont face="Arial, Helvetica, sans-serif">26. Stone EA, Cotecchia S, Lin Y,    Qua
rtermain D. Role of brain alpha 1B-adrenoceptors in modafinil-induced behavioral
    activity. <I>Synapse</I> 2002; 46: 269-270.    ^cY#6904.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#129#125#article#156# </font>      ^cY#69
04.htm##
00546000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704030100078002000900379#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#130#126#article#156#27#<P><f
ont face="Arial, Helvetica, sans-serif">27. Gallopin T, Luppi PH, Rambert    FA,
 Frydman A, Fort P. Effect of the wake-promoting agent modafinil on sleep-promot
ing    neurons from the ventrolateral preoptic nucleus: an <I>in vitro</I> pharm
acologic    study. <I>Sleep</I> 2004; 27: 19-25.    ^cY#6904.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#131#127#article#156# </font>      ^cY#69
04.htm##
00481000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704023600078002000900314#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#132#128#article#156#28#<P><f
ont face="Arial, Helvetica, sans-serif">28. Levy Andersen M, Bignotto M,    Tufi
k S. Facilitation of ejaculation after methamphetamine administration in    para
doxical sleep deprived rats. <I>Brain Res</I> 2003; 978: 31-37.    ^cY#6904.htm#
#
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#133#129#article#156# </font>      ^cY#69
04.htm##
00492000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704024700078002000900325#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#134#130#article#156#29#<P><f
ont face="Arial, Helvetica, sans-serif">29. Edgar DM, Seidel WF. Modafinil    in
duces wakefulness without intensifying motor activity or subsequent rebound    h
ypersomnolence in the rat. <I>J Pharmacol Exp Ther</I> 1997; 283: 757-769.    ^c
Y#6904.htm##
00251000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002100075002000900096#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#135#131#article#156#    </font>      ^cY
#6904.htm##
00445000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704020000078002000900278#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#136#132#article#156#30#<P><f
ont face="Arial, Helvetica, sans-serif">30. Isaac SO, Berridge CW. Wake-promotin
g    actions of dopamine D1 and D2 receptor stimulation. <I>J Pharmacol Exp Ther
</I>    2003; 307: 386-394.    ^cY#6904.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#137#133#article#156# </font>      ^cY#69
04.htm##
00485000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704024000078002000900318#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#138#134#article#156#31#<P><f
ont face="Arial, Helvetica, sans-serif">31. Nishino S, Mao J, Sampathkumaran    
R, Shelton J. Increased dopaminergic transmission mediates the wake-promoting   
 effects of CNS stimulants. <I>Sleep Res Online</I> 1998; 1: 49-61.    ^cY#6904.
htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#139#135#article#156# </font>      ^cY#69
04.htm##
00483000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704023800078002000900316#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#140#136#article#156#32#<P><f
ont face="Arial, Helvetica, sans-serif">32. Zhang WP, Ouyang M, Thomas SA.    Po
tency of catecholamines and other L-tyrosine derivatives at the cloned mouse    
adrenergic receptors. <I>Neuropharmacology</I> 2004; 47: 438-449.    ^cY#6904.ht
m##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#141#137#article#156# </font>      ^cY#69
04.htm##
00446000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704020100078002000900279#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#142#138#article#156#33#<P><f
ont face="Arial, Helvetica, sans-serif">33. Nicholson AN, Pascoe PA. Dopaminergi
c    transmission and the sleep-wakefulness continuum in man. <I>Neuropharmacolo
gy</I>    1990; 29: 411-417.    ^cY#6904.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#143#139#article#156# </font>      ^cY#69
04.htm##
00503000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704025800078002000900336#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#144#140#article#156#34#<P><f
ont face="Arial, Helvetica, sans-serif">34. Pungor K, Hajnal A, Kekesi KA,    Ju
hasz G. Paradoxical sleep deprivatory effect of a single low dose of MPTP    whi
ch did not produce dopaminergic cell loss. <I>Exp Brain Res</I> 1993; 95:    473
-476.    ^cY#6904.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#145#141#article#156# </font>      ^cY#69
04.htm##
00524000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704027900078002000900357#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#146#142#article#156#35#<P><f
ont face="Arial, Helvetica, sans-serif">35. Ebert D, Berger M. Neurobiological  
  similarities in antidepressant sleep deprivation and psychostimulant use: a   
 psychostimulant theory of antidepressant sleep deprivation. <I>Psychopharmacolo
gy    </I>1998; 140: 1-10.    ^cY#6904.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#147#143#article#156# </font>      ^cY#69
04.htm##
00442000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704019700078002000900275#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#148#144#article#156#36#<P><f
ont face="Arial, Helvetica, sans-serif">36. Aston-Jones G, Chen S, Zhu Y,    Osh
insky ML. A neural circuit for circadian regulation of arousal. <I>Nat Neurosci<
/I>    2001; 4: 732-738.    ^cY#6904.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#149#145#article#156# </font>      ^cY#69
04.htm##
00497000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704025200078002000900330#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#150#146#article#156#37#<P><f
ont face="Arial, Helvetica, sans-serif">37. Berridge CW, Waterhouse BD. The    l
ocus coeruleus-noradrenergic system: modulation of behavioral state and state-de
pendent    cognitive processes. <I>Brain Res Brain Res Rev</I> 2003; 42: 33-84. 
   ^cY#6904.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#151#147#article#156# </font>      ^cY#69
04.htm##
00559000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704031400078002000900392#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#152#148#article#156#38#<P><f
ont face="Arial, Helvetica, sans-serif">38. Demontis MG, Fadda P, Devoto    P, M
artellotta MC, Fratta W. Sleep deprivation increases dopamine D1 receptor    ant
agonist [3H]SCH 23390 binding and dopamine-stimulated adenylate cyclase in    th
e rat limbic system. <I>Neurosci Lett</I> 1990; 117: 224-227.    ^cY#6904.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#153#149#article#156# </font>      ^cY#69
04.htm##
00510000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704026500078002000900343#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#p#154#150#article#156#39#<P><f
ont face="Arial, Helvetica, sans-serif">39. Machado RB, Hipolide DC, Benedito-Si
lva    AA, Tufik S. Sleep deprivation induced by the modified multiple platform 
technique:    quantification of sleep loss and recovery. <I>Brain Res </I>2004; 
1004: 45-51.    ^cY#6904.htm##
00285000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704005500075002000900130#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#155#151#article#156#    </font>  <HR ALI
GN=LEFT WIDTH=100% SIZE=2>     ^cY#6904.htm##
00590000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704036000075002000900435#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#156#152#article#156#<P><font face="Arial
, Helvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT color="#00007F" SIZ
E=4><B>Acknowledgments</B></FONT></font>    <font size="4" face="Arial, Helvetic
a, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" 
ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0" width="12" height="12"></B></A>
</font></P>     ^cY#6904.htm##
00502000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704027200075002000900347#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#157#153#article#156#<P><font face="Arial
, Helvetica, sans-serif">The authors would like to thank Waldemarks    Leite, To
me Pimentel, Alice Lima, Marilde Costa, Tathiana Alvarenga, and Juliana    Cini 
Perry for assistance during the project. </font>  <HR ALIGN=LEFT WIDTH=100% SIZE
=2>     ^cY#6904.htm##
00591000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704036100075002000900436#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#158#154#article#156#<P><FONT SIZE=4 face
="Arial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F
><B>Correspondence    and Footnotes</B></FONT></FONT> <font size="4" face="Arial
, Helvetica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/
back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A
></font></P>     ^cY#6904.htm##
00699000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704046900075002000900544#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#159#155#article#156#<p><font face="Arial
, Helvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v41n1/
recor.gif" width="15" height="14" border="0"></a>    Address for correspondence:
</b> M.L. Andersen, Departamento de Psicobiologia,    EPM, UNIFESP, Rua Napole&a
tilde;o de Barros, 925, Vila Clementino, 04024-002    S&atilde;o Paulo, SP, Bras
il. Fax: +55-11-5572-5092. E-mail: <a href="mailto:mandersen@psicobio.epm.br">ma
ndersen@psicobio.epm.br</a></font>  </p>     ^cY#6904.htm##
00569000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704033900075002000900414#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6904.htm#S#p#160#156#article#156#<P><font face="Arial
, Helvetica, sans-serif">Research supported by Associa&ccedil;&atilde;o    Fundo
 de Incentivo &agrave; Psicofarmacologia (AFIP) and FAPESP (CEPID No. 98/14303-3
    to S. Tufik, No. 01/04329-0 to M.L. Andersen, and No. 06/58276-8 to R.C.S. M
artins).    Received May 21, 2007. Accepted October 26, 2007. </font>      ^cY#6
904.htm##
00667000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100022000740100023000960100
01500119012013100134030002900265065000900294064000500303031000400308014000800312
865000900320002000900329035001000338801002900348#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6904.htm#S#c#161#1#article#39#1#^rND^sBudziszewska^nB#^rND^sJaworska-
Feil^nL#^rND^sLason^nW#The effect of repeated amphetamine and cocaine administra
tion on adrenal, gonadal and thyroid hormone levels in the rat plasma^len#Exp Cl
in Endocrinol Diabetes#19960000#1996#104#334-338#20080100#6904.htm#0947-7349#Exp
 Clin Endocrinol Diabetes##
00617000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100019000740100016000930100
01500109012006600124030004200190065000900232064000500241031000300246014000800249
865000900257002000900266035001000275801004200285#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6904.htm#S#c#162#2#article#39#2#^rND^sAndersen^nML#^rND^sPerry^nJC#^r
ND^sTufik^nS#Acute cocaine effects in paradoxical sleep deprived male rats^len#P
rog Neuropsychopharmacol Biol Psychiatry#20050000#2005#29#245-251#20080100#6904.
htm#0278-5846#Prog Neuropsychopharmacol Biol Psychiatry##
00609000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100019000740100018000930100
01500111012010400126030001800230065000900248064000500257031000300262014000800265
865000900273002000900282035001000291801001800301#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6904.htm#S#c#163#3#article#39#3#^rND^sAndersen^nML#^rND^sBignotto^nM#
^rND^sTufik^nS#Hormone treatment facilitates penile erection in castrated rats a
fter sleep deprivation and cocaine^len#J Neuroendocrinol#20040000#2004#16#154-15
9#20080100#6904.htm#0953-8194#J Neuroendocrinol##
00641000000000337000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740100017000910100
01500108010001700123010001400140010001800154810000600172012004600178030001100224
06500090023506400050024403100030024901400120025286500090026400200090027303500100
0282801001100292#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#c#164#4#ar
ticle#39#4#^rND^sDzirasa^nK#^rND^sRibeiro^nS#^rND^sCosta^nR#^rND^sSantos^nLM#^rN
D^sLin^nSC#^rND^sGrosmark^nA#et al#Dopaminergic control of sleep-wake states^len
#J Neurosci#20060000#2006#26#10577-10589#20080100#6904.htm#0270-6474#J Neurosci#
#
00618000000000301000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100019000740100016000930100
01500109010001800124012007200142030002500214065000900239064000500248031000200253
014000800255865000900263002000900272035001000281801002500291#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6904.htm#S#c#165#5#article#39#5#^rND^sJohanson^nCE#^rND^s
Roehrs^nT#^rND^sSchuh^nK#^rND^sWarbasse^nL#The effects of cocaine on mood and sl
eep in cocaine-dependent males^len#Exp Clin Psychopharmacol#19990000#1999#7#338-
346#20080100#6904.htm#1064-1297#Exp Clin Psychopharmacol##
00716000000000325000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740100022000910100
01600113010001500129010001900144010001800163012011600181030002000297065000900317
06400050032603100030033101400080033486500090034200200090035103500100036080100200
0370#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#c#166#6#article#39#6#^
rND^sMorgan^nPT#^rND^sPace-Schott^nEF#^rND^sSahul^nZH#^rND^sCoric^nV#^rND^sStick
gold^nR#^rND^sMalison^nRT#Sleep, sleep-dependent procedural learning and vigilan
ce in chronic cocaine users: Evidence for occult insomnia^len#Drug Alcohol Depen
d#20060000#2006#82#238-249#20080100#6904.htm#0376-8716#Drug Alcohol Depend##
00707000000000337000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100022000740100019000960100
01500115010001700130010001500147010001500162810000600177012009400183030001900277
06500090029606400050030503100040031001400080031486500090032200200090033103500100
0340801001900350#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#c#167#7#ar
ticle#39#7#^rND^sPace-Schott^nEF#^rND^sStickgold^nR#^rND^sMuzur^nA#^rND^sWigren^
nPE#^rND^sWard^nAS#^rND^sHart^nCL#et al#Sleep quality deteriorates over a binge 
-abstinence cycle in chronic smoked cocaine users^len#Psychopharmacology#2005000
0#2005#179#873-883#20080100#6904.htm#0033-3158#Psychopharmacology##
00671000000000313000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740100020000910100
01700111010001700128010001400145012011300159030001600272065000900288064000500297
031000300302014000800305865000900313002000900322035001000331801001600341#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#c#168#8#article#39#8#^rND^sGillin^
nJC#^rND^sPulvirenti^nL#^rND^sWithers^nN#^rND^sGolshan^nS#^rND^sKoob^nG#The effe
cts of lisuride on mood and sleep during acute withdrawal in stimulant abusers: 
a preliminary report^len#Biol Psychiatry#19940000#1994#35#843-849#20080100#6904.
htm#0006-3223#Biol Psychiatry##
00800000000000337000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100014000740100016000880100
01800104010002100122010001800143010001600161810000600177012019600183030001500379
06500090039406400050040303100030040801400080041186500090041900200090042803500100
0437801001500447#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#c#169#9#ar
ticle#39#9#^rND^sLena^nI#^rND^sParrot^nS#^rND^sDeschaux^nO#^rND^sMuffat-Joly^nS#
^rND^sSauvinet^nV#^rND^sRenaud^nB#et al#Variations in extracellular levels of do
pamine, noradrenaline, glutamate, and aspartate across the sleep-wake cycle in t
he medial prefrontal cortex and nucleus accumbens of freely moving rats^len#J Ne
urosci Res#20050000#2005#81#891-899#20080100#6904.htm#0360-4012#J Neurosci Res##
00649000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100019000940100
01600113012014700129030001500276065000900291064000500300031000300305014000800308
865000900316002000900325035001000334801001500344#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6904.htm#S#c#170#10#article#39#10#^rND^sMaloney^nKJ#^rND^sMainville^n
L#^rND^sJones^nBE#c-Fos expression in dopaminergic and GABAergic neurons of the 
ventral mesencephalic tegmentum after paradoxical sleep deprivation and recovery
^len#Eur J Neurosci#20020000#2002#15#774-778#20080100#6904.htm#0953-816X#Eur J N
eurosci##
00596000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100018000910100
01800109012010100127030001300228065000900241064000500250031000300255014000700258
865000900265002000900274035001000283801001300293#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6904.htm#S#c#171#11#article#39#11#^rND^sTufik^nS#^rND^sLindsey^nCJ#^r
ND^sCarlini^nEA#Does REM sleep deprivation induce a supersensitivity of dopamine
rgic receptors in the rat brain?^len#Pharmacology#19780000#1978#16#98-105#200801
00#6904.htm#0031-7012#Pharmacology##
00672000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100017000950100
01900112010001800131010001500149012011000164030001600274065000900290064000500299
031000400304014000600308865000900314002000900323035001000332801001600342#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#c#172#12#article#39#12#^rND^sAnder
sen^nML#^rND^sPapale^nLA#^rND^sHipolide^nDC#^rND^sNobrega^nJN#^rND^sTufik^nS#Inv
olvement of dopamine receptors in cocaine-induced genital reflexes after paradox
ical sleep deprivation^len#Behav Brain Res#20050000#2005#160#44-50#20080100#6904
.htm#0166-4328#Behav Brain Res##
00620000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100023000760100015000990100
01800114012011500132030001500247065000900262064000500271031000300276014000800279
865000900287002000900296035001000305801001500315#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6904.htm#S#c#173#13#article#39#13#^rND^sNunes^nJunior GP#^rND^sTufik^
nS#^rND^sNobrega^nJN#Autoradiographic analysis of D1 and D2 dopaminergic recepto
rs in rat brain after paradoxical sleep deprivation^len#Brain Res Bull#19940000#
1994#34#453-456#20080100#6904.htm#0361-9230#Brain Res Bull##
00699000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100019000910100
01400110010002200124010001800146012013500164030001600299065000900315064000500324
031000400329014000800333865000900341002000900350035001000359801001600369#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#c#174#14#article#39#14#^rND^sTufik
^nS#^rND^sTroncone^nLR#^rND^sBraz^nS#^rND^sSilva-Filho^nAR#^rND^sNeumann^nBG#Doe
s REM sleep deprivation induce subsensitivity of presynaptic dopamine or postsyn
aptic acetylcholine receptors in the rat brain?^len#Eur J Pharmacol#19870000#198
7#140#215-219#20080100#6904.htm#0014-2999#Eur J Pharmacol##
00491000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760120054000960300
01200150065000900162064000500171031000300176014000600179865000900185002000900194
035001000203801001200213#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#c#
175#15#article#39#15#^rND^sBenington^nJH#Debating how REM sleep is regulated (an
d by what)^len#J Sleep Res#20020000#2002#11#29-31#20080100#6904.htm#0962-1105#J 
Sleep Res##
00571000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100018000920120
11100110030001100221065000900232064000500241031000300246014000500249865000900254
002000900263035001000272801001100282#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
904.htm#S#c#176#16#article#39#16#^rND^sStern^nWC#^rND^sMorgane^nPJ#Theoretical v
iew of REM sleep function: maintenance of catecholamine systems in the central n
ervous system^len#Behav Biol#19740000#1974#11#1-32#20080100#6904.htm#0091-6773#B
ehav Biol##
00703000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100027000760100014001030100
02500117010002300142010002300165012011500188030001600303065000900319064000500328
031000400333014000800337865000900345002000900354035001000363801001600373#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#c#177#17#article#39#17#^rND^sMuril
lo-Rodriguez^nE#^rND^sHaro^nR#^rND^sPalomero-Rivero^nM#^rND^sMillan-Aldaco^nD#^r
ND^sDrucker-Colin^nR#Modafinil enhances extracellular levels of dopamine in the 
nucleus accumbens and increases wakefulness in rats^len#Behav Brain Res#20070000
#2007#176#353-357#20080100#6904.htm#0166-4328#Behav Brain Res##
00497000000000253000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100024000760120078001000300
02000178710000200198065000900200064000500209031000300214014000800217865000900225
002000900234#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#c#178#18#artic
le#39#18#^rND^sCosta^ne Silva JA#Evidence-based analysis of the worldwide abuse 
of licit and illicit drugs^len#Hum Psychopharmacol#2#20020000#2002#17#131-140#20
080100#6904.htm##
00523000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100019000950120
05300114030001400167065000900181064000500190031000300195014000500198865000900203
002000900212035001000221801001400231#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
904.htm#S#c#179#19#article#39#19#^rND^sJohanson^nCE#^rND^sFischman^nMW#The pharm
acology of cocaine related to its abuse^len#Pharmacol Rev#19890000#1989#41#3-52#
20080100#6904.htm#0031-6997#Pharmacol Rev##
00601000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100016000910120
11800107030002100225065000900246064000500255031000400260014001000264865000900274
002000900283035001000292801002100302#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
904.htm#S#c#180#20#article#39#20#^rND^sRitz^nMC#^rND^sKuhar^nMJ#Relationship bet
ween self-administration of amphetamine and monoamine receptors in brain: compar
ison with cocaine^len#J Pharmacol Exp Ther#19890000#1989#248#1010-1017#20080100#
6904.htm#0022-3565#J Pharmacol Exp Ther##
00597000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100018000920100
01800110010001500128012006900143030001500212065000900227064000500236031000300241
014000800244865000900252002000900261035001000270801001500280#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6904.htm#S#c#181#21#article#39#21#^rND^sSulzer^nD#^rND^sS
onders^nMS#^rND^sPoulsen^nNW#^rND^sGalli^nA#Mechanisms of neurotransmitter relea
se by amphetamines: a review^len#Prog Neurobiol#20050000#2005#75#406-433#2008010
0#6904.htm#0301-0082#Prog Neurobiol##
00706000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100016000900100
01700106010002200123010001700145012014900162030001400311065000900325064000500334
031000300339014000800342865000900350002000900359035001000368801001400378#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#c#182#22#article#39#22#^rND^sPifl^
nC#^rND^sDrobny^nH#^rND^sReither^nH#^rND^sHornykiewicz^nO#^rND^sSinger^nEA#Mecha
nism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal 
dopamine transporter versus vesicular monoamine transporter^len#Mol Pharmacol#19
950000#1995#47#368-373#20080100#6904.htm#0026-895X#Mol Pharmacol##
00734000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100019000900100
01300109010002300122010001700145010001700162810000600179012013700185030001200322
06500090033406400050034303100020034801400060035086500090035600200090036503500100
0374801001200384#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#c#183#23#a
rticle#39#23#^rND^sLin^nJS#^rND^sGervasoni^nD#^rND^sHou^nY#^rND^sVanni-Mercier^n
G#^rND^sRambert^nF#^rND^sFrydman^nA#et al#Effects of amphetamine and modafinil o
n the sleep/wake cycle during experimental hypersomnia induced by sleep deprivat
ion in the cat^len#J Sleep Res#20000000#2000#9#89-96#20080100#6904.htm#0962-1105
#J Sleep Res##
00590000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100017000920100
02300109010001700132012007400149030000600223065000900229064000500238031000300243
014000800246865000900254002000900263035001000272801000600282#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6904.htm#S#c#184#24#article#39#24#^rND^sMignot^nE#^rND^sN
ishino^nS#^rND^sGuilleminault^nC#^rND^sDement^nWC#Modafinil binds to the dopamin
e uptake carrier site with low affinity^len#Sleep#19940000#1994#17#436-437#20080
100#6904.htm#0161-8105#Sleep##
00715000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100026000760100016001020100
01500118010001500133010002000148012015400168030001200322065000900334064000500343
031000300348014001000351865000900361002000900370035001000379801001200389#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#c#185#25#article#39#25#^rND^sde^nS
aint Hilaire Z#^rND^sOrosco^nM#^rND^sRouch^nC#^rND^sBlanc^nG#^rND^sNicolaidis^nS
#Variations in extracellular monoamines in the prefrontal cortex and medial hypo
thalamus after modafinil administration: a microdialysis study in rats^len#Neuro
Report#20010000#2001#12#3533-3537#20080100#6904.htm#0959-4965#NeuroReport##
00598000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100019000920100
01300111010002100124012008200145030000800227065000900235064000500244031000300249
014000800252865000900260002000900269035001000278801000800288#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6904.htm#S#c#186#26#article#39#26#^rND^sStone^nEA#^rND^sC
otecchia^nS#^rND^sLin^nY#^rND^sQuartermain^nD#Role of brain alpha 1B-adrenocepto
rs in modafinil-induced behavioral activity^len#Synapse#20020000#2002#46#269-270
#20080100#6904.htm#0196-5565#SYNAPSE##
00685000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100016000940100
01800110010001700128010001400145012014900159030000600308065000900314064000500323
031000300328014000600331865000900337002000900346035001000355801000600365#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#c#187#27#article#39#27#^rND^sGallo
pin^nT#^rND^sLuppi^nPH#^rND^sRambert^nFA#^rND^sFrydman^nA#^rND^sFort^nP#Effect o
f the wake-promoting agent modafinil on sleep-promoting neurons from the ventrol
ateral preoptic nucleus: an in vitro pharmacologic study^len#Sleep#20040000#2004
#27#19-25#20080100#6904.htm#0161-8105#Sleep##
00598000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100023000760100018000990100
01500117012010400132030001000236065000900246064000500255031000400260014000600264
865000900270002000900279035001000288801001000298#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6904.htm#S#c#188#28#article#39#28#^rND^sLevy^nAndersen M#^rND^sBignot
to^nM#^rND^sTufik^nS#Facilitation of ejaculation after methamphetamine administr
ation in paradoxical sleep deprived rats^len#Brain Res#20030000#2003#978#31-37#2
0080100#6904.htm#0006-8993#Brain res##
00602000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100017000920120
11900109030002100228065000900249064000500258031000400263014000800267865000900275
002000900284035001000293801002100303#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
904.htm#S#c#189#29#article#39#29#^rND^sEdgar^nDM#^rND^sSeidel^nWF#Modafinil indu
ces wakefulness without intensifying motor activity or subsequent rebound hypers
omnolence in the rat^len#J Pharmacol Exp Ther#19970000#1997#283#757-769#20080100
#6904.htm#0022-3565#J Pharmacol Exp Ther##
00555000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100019000920120
07000111030002100181065000900202064000500211031000400216014000800220865000900228
002000900237035001000246801002100256#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
904.htm#S#c#190#30#article#39#30#^rND^sIsaac^nSO#^rND^sBerridge^nCW#Wake-promoti
ng actions of dopamine D1 and D2 receptor stimulation^len#J Pharmacol Exp Ther#2
0030000#2003#307#386-394#20080100#6904.htm#0022-3565#J Pharmacol Exp Ther##
00590000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100013000930100
02400106010001700130012009400147030001700241710000200258065000900260064000500269
031000200274014000600276865000900282002000900291#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6904.htm#S#c#191#31#article#39#31#^rND^sNishino^nS#^rND^sMao^nJ#^rND^
sSampathkumaran^nR#^rND^sShelton^nJ#Increased dopaminergic transmission mediates
 the wake-promoting effects of CNS stimulants^len#Sleep Res Online#2#19980000#19
98#1#49-61#20080100#6904.htm##
00608000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100016000920100
01700108012010400125030001800229065000900247064000500256031000300261014000800264
865000900272002000900281035001000290801001800300#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6904.htm#S#c#192#32#article#39#32#^rND^sZhang^nWP#^rND^sOuyang^nM#^rN
D^sThomas^nSA#Potency of catecholamines and other L-tyrosine derivatives at the 
cloned mouse adrenergic receptors^len#Neuropharmacology#20040000#2004#47#438-449
#20080100#6904.htm#0028-3908#Neuropharmacology##
00553000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100017000960120
07300113030001800186065000900204064000500213031000300218014000800221865000900229
002000900238035001000247801001800257#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
904.htm#S#c#193#33#article#39#33#^rND^sNicholson^nAN#^rND^sPascoe^nPA#Dopaminerg
ic transmission and the sleep-wakefulness continuum in man^len#Neuropharmacology
#19900000#1990#29#411-417#20080100#6904.htm#0028-3908#Neuropharmacology##
00639000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100016000920100
01700108010001600125012011500141030001400256065000900270064000500279031000300284
014000800287865000900295002000900304035001000313801001400323#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6904.htm#S#c#194#34#article#39#34#^rND^sPungor^nK#^rND^sH
ajnal^nA#^rND^sKekesi^nKA#^rND^sJuhasz^nG#Paradoxical sleep deprivatory effect o
f a single low dose of MPTP which did not produce dopaminergic cell loss^len#Exp
 Brain Res#19930000#1993#95#473-476#20080100#6904.htm#0014-4819#Exp Brain Res##
00629000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100016000910120
15500107030001900262065000900281064000500290031000400295014000500299865000900304
002000900313035001000322801001900332#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
904.htm#S#c#195#35#article#39#35#^rND^sEbert^nD#^rND^sBerger^nM#Neurobiological 
similarities in antidepressant sleep deprivation and psychostimulant use: a psyc
hostimulant theory of antidepressant sleep deprivation^len#Psychopharmacology#19
980000#1998#140#1-10#20080100#6904.htm#0033-3158#Psychopharmacology##
00547000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100021000760100014000970100
01300111010001900124012005700143030001300200710000200213065000900215064000500224
031000200229014000800231865000900239002000900248#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6904.htm#S#c#196#36#article#39#36#^rND^sAston-Jones^nG#^rND^sChen^nS#
^rND^sZhu^nY#^rND^sOshinsky^nML#A neural circuit for circadian regulation of aro
usal^len#Nat Neurosci#2#20010000#2001#4#732-738#20080100#6904.htm##
00610000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100021000950120
11700116030002400233065000900257064000500266031000300271014000600274865000900280
002000900289035001000298801002400308#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
904.htm#S#c#197#37#article#39#37#^rND^sBerridge^nCW#^rND^sWaterhouse^nBD#The loc
us coeruleus-noradrenergic system: modulation of behavioral state and state-depe
ndent cognitive processes^len#Brain Res Brain Res Rev#20030000#2003#42#33-84#200
80100#6904.htm#0165-0173#Brain Res Brain Res Rev##
00713000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100015000950100
01600110010002200126010001600148012015300164030001400317065000900331064000500340
031000400345014000800349865000900357002000900366035001000375801001400385#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6904.htm#S#c#198#38#article#39#38#^rND^sDemon
tis^nMG#^rND^sFadda^nP#^rND^sDevoto^nP#^rND^sMartellotta^nMC#^rND^sFratta^nW#Sle
ep deprivation increases dopamine D1 receptor antagonist [3H]SCH 23390 binding a
nd dopamine-stimulated adenylate cyclase in the rat limbic system^len#Neurosci L
ett#19900000#1990#117#224-227#20080100#6904.htm#0304-3940#Neurosci Lett##
00645000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100019000940100
02500113010001500138012011700153030001000270065000900280064000500289031000500294
014000600299865000900305002000900314035001000323801001000333#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6904.htm#S#c#199#39#article#39#39#^rND^sMachado^nRB#^rND^
sHipolide^nDC#^rND^sBenedito-Silva^nAA#^rND^sTufik^nS#Sleep deprivation induced 
by the modified multiple platform technique: quantification of sleep loss and re
covery^len#Brain Res#20040000#2004#1004#45-51#20080100#6904.htm#0006-8993#Brain 
res##
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#o#1#1#article#1#20
080623#161528#6914.htm#147##
03337000000000685000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000300108
03000200011103100030013103200020013406500090013601400090014503500100015422300090
01640120144001730100024003170100032003410100021003730100024003940100034004180700
17700452070013200629083158400761085000802345085002602353085002302379085002502402
08500250242708500410245211700060249307200030249905800070250206000110250906000110
25200580005025310600014025360580006025500600014025561120009025701110013025791140
00902592113001702601881002402618002000902642#v41n1#v:\scielo\serial\bjmbr\v41n1\
markup\6914.htm#S#h#2#1#article#1#oa#en#bjmbr#1#3.1#ILUS#TAB#06#BJMBR010#nd#Braz
 J Med Biol Res#41#1#20080100#^f34^l40#0100-879X#20071217#The MTR A2756G polymor
phism is associated with an increase of plasma homocysteine concentration in Bra
zilian individuals with Down syndrome^len#^rND^1A01^nJ.M^sBiselli#^rND^1A01^nE.M
^sGoloni-Bertollo#^rND^1A02^nR^sHaddad#^rND^1A02^nM.N^sEberlin#^rND^1A01^nE.C^sP
avarino-Bertelli#Faculdade de Medicina de São José do Rio Preto^iA01^1Departamen
to de Biologia Molecular^2Unidade de Pesquisa em Genética e Biologia Molecular^c
São José do Rio Preto^sSP^pBrasil#Universidade Estadual de Campinas^iA02^1Instit
uto de Química^2Laboratório ThoMSon de Espectrometria de Massas^cCampinas^sSP^pB
rasil#^len^aIndividuals with Down syndrome (DS) present decreased homocysteine (
Hcy) concentration, reflecting a functional folate deficiency secondary to overe
xpression of the cystathionine ß-synthase gene. Since plasma Hcy may be influenc
ed by genetic polymorphisms, we evaluated the influence of C677T and A1298C poly
morphisms in the methylenetetrahydrofolate reductase gene (MTHFR), of A2756G pol
ymorphism in the methionine synthase gene (MTR), and of A80G polymorphism in the
 reduced folate carrier 1 gene on Hcy concentrations in Brazilian DS patients. F
ifty-six individuals with free trisomy 21 were included in the study. Plasma Hcy
 concentrations were measured by liquid chromatography_tandem mass spectrometry 
with linear regression coefficient r² = 0.9996, average recovery between 92.3 to
 108.3% and quantification limits of 1.0 µmol/L. Hcy concentrations >15 µmol/L w
ere considered to characterize hyperhomocystinemia. Genotyping for the polymorph
isms was carried out by polymerase chain reaction followed by enzyme digestion a
nd allele-specific polymerase chain reaction. The mean Hcy concentration was 5.2
 ± 3.3 µmol/L. There was no correlation between Hcy concentrations and age, gend
er or MTHFR C677T, A1298C and reduced folate carrier 1 A80G genotype. However, H
cy concentrations were significantly increased in the MTR 2756AG heterozygous ge
notype compared to the MTR 2756AA wild-type genotype. The present results sugges
t that the heterozygous genotype MTR 2756AG is associated with the increase in p
lasma Hcy concentrations in this group of Brazilian patients with DS.#^dnd^i1#^t
m^len^kDown syndrome^i1#^tm^len^kTrisomy 21^i1#^tm^len^kPolymorphism^i1#^tm^len^
kHomocysteine^i1#^tm^len^kMass spectrometry (LC-MS/MS)^i1#other#39#FAPESP#04/159
44-5#03/09931-5#CNPq#302674/2005-5#CAPES#CGPP 046/2006#20070529#May 29, 2007#200
71018#October 18, 2007#S0100-879X2006005000195#6914.htm##
03322000000000673000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000300108
03000200011103100030013103200020013406500090013601400090014503500100015422300090
01640120151001730100024003240100032003480100021003800100024004010100034004250700
17700459070013200636083159800768085000802366085002602374085002302400085002502423
08500250244808500410247311700060251407200030252005800070252306000110253006000110
25410580005025520600014025570580006025710600014025771120009025911110013026001140
00902613113001702622002000902639#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.
htm#S#f#3#1#article#1#oa#en#bjmbr#1#3.1#ILUS#TAB#06#BJMBR010#nd#Braz J Med Biol 
Res#41#1#20080100#^f34^l40#0100-879X#20071217#<B>The MTR A2756G polymorphism is 
associated with an increase of plasma homocysteine concentration in Brazilian in
dividuals with Down syndrome</B>^len#^rND^1A01^nJ.M^sBiselli#^rND^1A01^nE.M^sGol
oni-Bertollo#^rND^1A02^nR^sHaddad#^rND^1A02^nM.N^sEberlin#^rND^1A01^nE.C^sPavari
no-Bertelli#Faculdade de Medicina de São José do Rio Preto^iA01^1Departamento de
 Biologia Molecular^2Unidade de Pesquisa em Genética e Biologia Molecular^cSão J
osé do Rio Preto^sSP^pBrasil#Universidade Estadual de Campinas^iA02^1Instituto d
e Química^2Laboratório ThoMSon de Espectrometria de Massas^cCampinas^sSP^pBrasil
#^len^aIndividuals with Down syndrome (DS) present decreased homocysteine (Hcy) 
concentration, reflecting a functional folate deficiency secondary to overexpres
sion of the cystathionine ß-synthase gene. Since plasma Hcy may be influenced by
 genetic polymorphisms, we evaluated the influence of C677T and A1298C polymorph
isms in the methylenetetrahydrofolate reductase gene (MTHFR), of A2756G polymorp
hism in the methionine synthase gene (MTR), and of A80G polymorphism in the redu
ced folate carrier 1 gene on Hcy concentrations in Brazilian DS patients. Fifty-
six individuals with free trisomy 21 were included in the study. Plasma Hcy conc
entrations were measured by liquid chromatography_tandem mass spectrometry with 
linear regression coefficient r<SUP>2</SUP> = 0.9996, average recovery between 9
2.3 to 108.3% and quantification limits of 1.0 µmol/L. Hcy concentrations &gt;15
 µmol/L were considered to characterize hyperhomocystinemia. Genotyping for the 
polymorphisms was carried out by polymerase chain reaction followed by enzyme di
gestion and allele-specific polymerase chain reaction. The mean Hcy concentratio
n was 5.2 ± 3.3 µmol/L. There was no correlation between Hcy concentrations and 
age, gender or MTHFR C677T, A1298C and reduced folate carrier 1 A80G genotype. H
owever, Hcy concentrations were significantly increased in the MTR 2756AG hetero
zygous genotype compared to the MTR 2756AA wild-type genotype. The present resul
ts suggest that the heterozygous genotype MTR 2756AG is associated with the incr
ease in plasma Hcy concentrations in this group of Brazilian patients with DS.#^
dnd^i1#^tm^len^kDown syndrome^i1#^tm^len^kTrisomy 21^i1#^tm^len^kPolymorphism^i1
#^tm^len^kHomocysteine^i1#^tm^len^kMass spectrometry (LC-MS/MS)^i1#other#39#FAPE
SP#04/15944-5#03/09931-5#CNPq#302674/2005-5#CAPES#CGPP 046/2006#20070529#May 29,
 2007#20071018#October 18, 2007#6914.htm##
03446000000000697000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000500100038000400105121000300109049000900112
15800030012103000240012403100030014803200020015106500090015301400090016203500100
01712230009001810120144001900100025003340100033003590100021003920100025004130100
03500438070017900473070013400652083159100786085000802377085002602385085002302411
08500250243408500250245908500410248411700060252507200030253105800070253406000110
25410600011025520580005025630600014025680580006025820600014025881120009026021110
01302611114000902624113001702633002000902650008008902659#v41n1#v:\scielo\serial\
bjmbr\v41n1\markup\6914.htm#S#l#4#1#article#1#^mJan.^a2008#oa#en#bjmbr#1#3.1#ilu
s#tab#06#BJMBR010#nd#Braz. j. med. biol. res#41#1#20080100#^f34^l40#0100-879X#20
071217#The MTR A2756G polymorphism is associated with an increase of plasma homo
cysteine concentration in Brazilian individuals with Down syndrome^len#^rND^1A01
^nJ. M^sBiselli#^rND^1A01^nE. M^sGoloni-Bertollo#^rND^1A02^nR^sHaddad#^rND^1A02^
nM. N^sEberlin#^rND^1A01^nE. C^sPavarino-Bertelli#^iA01^1Faculdade de Medicina d
e São José do Rio Preto^2Departamento de Biologia Molecular^3Unidade de Pesquisa
 em Genética e Biologia Molecular^cSão José do Rio Preto^sSP^pBrasil#^iA02^1Univ
ersidade Estadual de Campinas^2Instituto de Química^3Laboratório ThoMSon de Espe
ctrometria de Massas^cCampinas^sSP^pBrasil#^len^aIndividuals with Down syndrome 
(DS) present decreased homocysteine (Hcy) concentration, reflecting a functional
 folate deficiency secondary to overexpression of the cystathionine ß-synthase g
ene. Since plasma Hcy may be influenced by genetic polymorphisms, we evaluated t
he influence of C677T and A1298C polymorphisms in the methylenetetrahydrofolate 
reductase gene (MTHFR), of A2756G polymorphism in the methionine synthase gene (
MTR), and of A80G polymorphism in the reduced folate carrier 1 gene on Hcy conce
ntrations in Brazilian DS patients. Fifty-six individuals with free trisomy 21 w
ere included in the study. Plasma Hcy concentrations were measured by liquid chr
omatography_tandem mass spectrometry with linear regression coefficient r² = 0.9
996, average recovery between 92.3 to 108.3 percent and quantification limits of
 1.0 µmol/L. Hcy concentrations >15 µmol/L were considered to characterize hyper
homocystinemia. Genotyping for the polymorphisms was carried out by polymerase c
hain reaction followed by enzyme digestion and allele-specific polymerase chain 
reaction. The mean Hcy concentration was 5.2 ± 3.3 µmol/L. There was no correlat
ion between Hcy concentrations and age, gender or MTHFR C677T, A1298C and reduce
d folate carrier 1 A80G genotype. However, Hcy concentrations were significantly
 increased in the MTR 2756AG heterozygous genotype compared to the MTR 2756AA wi
ld-type genotype. The present results suggest that the heterozygous genotype MTR
 2756AG is associated with the increase in plasma Hcy concentrations in this gro
up of Brazilian patients with DS.#^dnd^i1#^tm^len^kDown syndrome^i1#^tm^len^kTri
somy 21^i1#^tm^len^kPolymorphism^i1#^tm^len^kHomocysteine^i1#^tm^len^kMass spect
rometry (LC-MS/MS)^i1#other#39#FAPESP#04/15944-5#03/09931-5#CNPq#302674/2005-5#C
APES#CGPP 046/2006#20070529#May 29, 2007#20071018#October 18, 2007#6914.htm#Inte
rnet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X200800010
0006##
00375000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704014900071002000900220#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#5#1#article#104#<P> <font face="Arial, H
elvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med    Biol Res, January 2008
, Volume 41(1) 34-40</B> </font></P>     ^cY#6914.htm##
00449000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704022300071002000900294#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#6#2#article#104#<P><B><font size="5" fac
e="Arial, Helvetica, sans-serif">The MTR A2756G polymorphism    is associated wi
th an increase of plasma homocysteine concentration in Brazilian    individuals 
with Down syndrome</font></B>      ^cY#6914.htm##
00685000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704045900071002000900530#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#7#3#article#104#<P><font face="Arial, He
lvetica, sans-serif">J.M. Biselli<SUP>1</SUP>, E.M. Goloni-Bertollo<SUP>1</SUP>,
    R. Haddad<SUP>2</SUP>, M.N. Eberlin<SUP>2</SUP> and <b><a href="#Corresponde
nce"><img src="/img/revistas/bjmbr/v41n1/recor.gif" width="15" height="14" borde
r="0"></a></b>    <a href="mailto:erika@famerp.br"><img src="/img/revistas/bjmbr
/v41n1/email-ca.gif" width="14" height="11" border="0"></a>    E.C. Pavarino-Ber
telli<SUP>1</SUP> </font>      ^cY#6914.htm##
00512000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704028600071002000900357#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#8#4#article#104#<P><font face="Arial, He
lvetica, sans-serif"><SUP>1</SUP>Unidade de Pesquisa em    Gen&eacute;tica e Bio
logia Molecular, Departamento de Biologia Molecular, Faculdade    de Medicina de
 S&atilde;o Jos&eacute; do Rio Preto, S&atilde;o Jos&eacute; do    Rio Preto, SP
, Brasil <SUP>    ^cY#6914.htm##
00400000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704017400071002000900245#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#9#5#article#104#<br>   2</SUP>Laborat&oa
cute;rio ThoMSon de Espectrometria de Massas, Instituto de    Qu&iacute;mica, Un
iversidade Estadual de Campinas, Campinas, SP, Brasil</font>      ^cY#6914.htm##
00443000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704021600072002000900288#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#10#6#article#104#<P> <font face="Arial, 
Helvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v41n1/d
own.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12">    <str
ong>Abstract</strong></A>    ^cY#6914.htm##
00440000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704021300072002000900285#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#11#7#article#104#<BR>   <A HREF="#Introd
uction"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPA
CE=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Introduction"><strong>Int
roduction</strong></A>    ^cY#6914.htm##
00440000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704021300072002000900285#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#12#8#article#104#<BR>   <A HREF="#Materi
al"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0
 HSPACE=0 width="12" height="12"></A>    <A HREF="#Material"><strong>Subjects an
d Methods</strong></A>    ^cY#6914.htm##
00425000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704019800072002000900270#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#13#9#article#104#<BR>   <A HREF="#Result
s"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0 width="12" height="12"></A>    <A HREF="#Results"><strong>Results</stro
ng></A>    ^cY#6914.htm##
00435000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704020700073002000900280#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#14#10#article#104#<BR>   <A HREF="#Discu
ssion"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Discussion"><strong>Discus
sion</strong></A>    ^cY#6914.htm##
00422000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704019400073002000900267#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#15#11#article#104#<BR>   <A HREF="#Refer
ences"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#References"><strong>Refere
nces    ^cY#6914.htm##
00463000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704023500073002000900308#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#16#12#article#104#<br>   </strong></A><A
 HREF="#Acknowledgments"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOT
TOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Acknowle
dgments"><strong>Acknowledgments</strong></A>    ^cY#6914.htm##
00474000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704024600073002000900319#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#17#13#article#104#<BR>   <A HREF="#Corre
spondence"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 V
SPACE=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Correspondence"><stron
g>Correspondence and Footnotes</strong></A>    </font>      ^cY#6914.htm##
00275000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704004700073002000900120#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#18#14#article#104#<P>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>     ^cY#6914.htm##
00563000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704033500073002000900408#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#19#15#article#104#<P> <font face="Arial,
 Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F>
<B>Abstract    </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1
/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></
A></FONT></font></P> <font face="Arial, Helvetica, sans-serif">      ^cY#6914.ht
m##
01918000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704169000073002000901763#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#20#16#article#104#<P>Individuals with Do
wn syndrome (DS) present decreased homocysteine (Hcy) concentration,    reflecti
ng a functional folate deficiency secondary to overexpression of the    cystathi
onine &szlig;-synthase gene. Since plasma Hcy may be influenced by genetic    po
lymorphisms, we evaluated the influence of C677T and A1298C polymorphisms    in 
the methylenetetrahydrofolate reductase gene (MTHFR), of A2756G polymorphism    
in the methionine synthase gene (MTR), and of A80G polymorphism in the reduced  
  folate carrier 1 gene on Hcy concentrations in Brazilian DS patients. Fifty-si
x    individuals with free trisomy 21 were included in the study. Plasma Hcy con
centrations    were measured by liquid chromatography_tandem mass spectrometry w
ith linear    regression coefficient r<SUP>2</SUP> = 0.9996, average recovery be
tween 92.3    to 108.3% and quantification limits of 1.0 &#181;mol/L. Hcy concen
trations &gt;15    &#181;mol/L were considered to characterize hyperhomocystinem
ia. Genotyping    for the polymorphisms was carried out by polymerase chain reac
tion followed    by enzyme digestion and allele-specific polymerase chain reacti
on. The mean    Hcy concentration was 5.2 &#177; 3.3 &#181;mol/L. There was no c
orrelation between    Hcy concentrations and age, gender or MTHFR C677T, A1298C 
and reduced folate    carrier 1 A80G genotype. However, Hcy concentrations were 
significantly increased    in the MTR 2756AG heterozygous genotype compared to t
he MTR 2756AA wild-type    genotype. The present results suggest that the hetero
zygous genotype MTR 2756AG    is associated with the increase in plasma Hcy conc
entrations in this group of    Brazilian patients with DS.      ^cY#6914.htm##
00381000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704015300073002000900226#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#21#17#article#104#<P>Key words: Down syn
drome; Trisomy 21; Polymorphism; Homocysteine; Mass spectrometry    (LC-MS/MS)  
</font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6914.htm##
00617000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038900073002000900462#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#22#18#article#104#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Introduction"></A><FONT color="#00007F" SIZE=4><
B>Introduction</B></FONT></font>    <font size="4" face="Arial, Helvetica, sans-
serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A></font></P> <font
 face="Arial, Helvetica, sans-serif">      ^cY#6914.htm##
01164000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704093600073002000901009#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#23#19#article#104#<P>Down syndrome (DS),
 or trisomy 21, results from the gene expression of an extra    chromosome 21, w
hich occurs in most cases due to the failure of normal chromosomal    segregatio
n during maternal meiosis (1). Individuals with DS present decreased    homocyst
eine (Hcy) concentrations (2). Hcy is an amino acid formed during folate    meta
bolism. It can be remethylated to methionine by the enzyme methionine synthase  
  (MTR), with transfer of the methyl group of methyltetrahydrofolate, formed by 
   the action of the enzyme methylenetetrahydrofolate reductase (MTHFR), or can 
   be converted to cysteine in the transsulfuration pathway, which requires the 
   enzyme cystathionine &szlig;-synthase (C&szlig;S) (3). The decreased Hcy conc
entration    observed in individuals with DS is consistent with the location of 
the C&szlig;S    gene on chromosome 21 and its overexpression (2) (<a href="#Fig
1">Figure 1</a>)    (4).      ^cY#6914.htm##
00631000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704040300073002000900476#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#24#20#article#104#<P>Plasma Hcy is influ
enced by modifiable and non-modifiable factors, such as    gender, vitamin statu
s and genetic factors (5,6). The C677T and A1298C polymorphisms    of the MTHFR 
gene are important genetic determinants of Hcy concentrations.    The polymorphi
c alleles result in an enzyme with reduced specific activity (7,8),    consequen
tly leading to increased Hcy concentrations (9,10).      ^cY#6914.htm##
00833000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704060500073002000900678#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#25#21#article#104#<P>Another polymorphis
m in the gene encoding protein involved in homocysteine-folate    metabolism is 
an adenine-to-guanine substitution in nucleotide 2756 of the MTR    gene. Some s
tudies (11,12) reported that this polymorphism had an effect in    increasing Hc
y concentration in the presence of the wild-type allele (A), whereas    others (
13,14) observed an association between elevated Hcy and this polymorphism    in 
the presence of the mutated allele (G). However, other studies did not observe  
  any association between this polymorphism and alterations in Hcy concentration
s    (15,16).      ^cY#6914.htm##
00563000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704033500073002000900408#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#26#22#article#104#<P>The A80G variant of
 the reduced folate carrier 1 (RFC1) gene may also contribute    to alterations 
in products derived from this metabolic pathway (11). The RFC1    protein is loc
ated in the intestinal mucosa membrane and plays a role in folic    acid absorpt
ion, transporting 5-methyltetrahydrofolate into the cells (17).      ^cY#6914.ht
m##
00475000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704024700073002000900320#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#27#23#article#104#<P>The aim of the pres
ent study was to evaluate the influence of the MTHFR C677T,    MTHFR A1298C, MTR
 A2756G, and RFC1 A80G polymorphisms on Hcy concentrations    in Brazilian patie
nts with DS.  </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6914.htm##
00621000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704039300073002000900466#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#28#24#article#104#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Material"></A><FONT color="#00007F" SIZE=4><B>Su
bjects    and Methods</B></FONT></font> <font size="4" face="Arial, Helvetica, s
ans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIG
N=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A></font></P> <
font face="Arial, Helvetica, sans-serif">      ^cY#6914.htm##
00461000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704023300073002000900306#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#29#25#article#104#<P>Fifty-six DS indivi
duals with full trisomy 21 were recruited at the General    Genetics Outpatient 
Service of Hospital de Base, S&atilde;o Jos&eacute; do Rio    Preto, SP, Brazil,
 after obtaining family informed consent.      ^cY#6914.htm##
01993000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704176500073002000901838#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#30#26#article#104#<P>After an overnight 
fast, blood samples from all 56 individuals were collected    into EDTA-containi
ng tubes, and genomic DNA was extracted from blood leukocytes    (18). Polymorph
isms were determined by the polymerase chain reaction with upstream    and downs
tream primers flanking the target sequence. Mutation C677T in the MTHFR    gene 
was detected using primer sequences described by Frosst et al. (8), followed    
by <I>Hinf</I>I digestion. The A1298C polymorphism was determined by allele-spec
ific    polymerase chain reaction using primers to separately amplify wild-type 
and    mutated alleles, as follows: forward: 5'- GGA GCT GAC CAG TGA AGA -3', an
d reverse:    5'- TGT GAC CAT TCC GGT TTG -3', to amplify a 77-base pair (bp) fr
agment corresponding    to allele A (wild type); forward: 5'- CTT TGG GGA GCT GA
A GGA -3', and reverse:    5'- AAG ACT TCA AAG ACA CTT G -3', to amplify a 120-b
p fragment corresponding    to allele C (mutated). A pair of primers was used to
 amplify a 198-bp segment    of the MTHFR gene as positive control of gene ampli
fication (8). Genotyping    for the MTR A2756G polymorphism was carried out usin
g specific primers (forward:    5'- CCA GGG TGC CAG GTA TAC AG -3', and reverse:
 5'- GCC TTT TAC ACT CCT CAA    AAC C -3') to amplify a 498-bp fragment spanning
 the polymorphism, followed    by digestion with enzyme<I> Hae</I>III, that dige
sts the fragment in the presence    of the mutated G allele. The RFC1 A80G polym
orphism was determined as described    by F&ouml;dinger et al. (19). This method
 for RFC1 A80G genotyping does not    distinguish individuals who have one (AAG)
 or two (AGG) polymorphic alleles,    since DS individuals present three alleles
 for this gene, which is located on    chromosome 21.      ^cY#6914.htm##
00979000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704075100073002000900824#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#31#27#article#104#<P>Blood samples colle
cted into EDTA-containing tubes were centrifuged at 3000    rpm for 10 min, at 1
8&#176;C. Plasma was then stored at -80&#176;C until assayed.    Total plasma Hc
y concentration was measured by mass spectrometry using the Q-TRAP,    triple_qu
adrupole mass spectrometer (Applied Biosystems-Canada_Perkin-Elmer    Sciex/QqQ-
Trap, Perkin-Elmer Sciex, Thornhill, ON, Canada) using positive electrospray    
in multiple reaction monitoring mode with internal standard, as previously repor
ted    (20-22). Linearity of the method was r<SUP>2</SUP> = 0.9996, average of r
ecovery    101.5% and quantification limits 1.0 &#181;mol/L. Hcy concentrations 
&gt;15    &#181;mol/L were considered to characterize hyperhomocystinemia (23). 
     ^cY#6914.htm##
00268000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704004000073002000900113#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#32#28#article#104#<P><B>Statistical anal
ysis</B>      ^cY#6914.htm##
00860000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704063200073002000900705#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#33#29#article#104#<P>Data are reported a
s means &#177; SD, number or frequency. The distribution    of Hcy values in rel
ation to age was analyzed using the Spearman correlation.    The <I>t</I>-test a
nd ANOVA were employed for the comparisons of Hcy concentrations    between gend
ers and between genotypes, respectively, using the logarithmic scale    of Hcy c
oncentrations. Hcy concentrations according to the combined MTHFR genotypes    (
677 and 1298) were evaluated by Mood's median test. MTHFR haplotypes were inferr
ed    using the Phase program (version 2.1), which creates population frequency 
estimates    of the haplotypes.  </font>      ^cY#6914.htm##
00716000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704048800073002000900561#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#34#30#article#104#<P><font face="Arial, 
Helvetica, sans-serif">The computer-assisted statistical    analyses were carrie
d out with the Minitab for Windows (Release 12.22) program.    Hardy-Weinberg eq
uilibrium was determined by the chi-square test using the BioEstat    program, e
xcept for RFC1 A80G, which presents three alleles in DS individuals.    Values o
f P <font face="Symbol">&#163;</font> 0.05 were considered to be statistically  
  significant. </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6914.htm##
00607000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704037900073002000900452#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#35#31#article#104#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Results"></A><FONT color="#00007F" SIZE=4><B>Res
ults</B></FONT></font>    <font size="4" face="Arial, Helvetica, sans-serif"><A 
HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIGN=BOTTOM BORDE
R=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A></font></P> <font face="Ari
al, Helvetica, sans-serif">      ^cY#6914.htm##
00403000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704017500073002000900248#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#36#32#article#104#<P>The study group con
sisted of 56 DS individuals (24 females and 32 males) ranging    in age between 
1 month and 30 years (mean age: 4.8 &#177; 6.7 years).  </font>      ^cY#6914.ht
m##
00814000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704058600073002000900659#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#37#33#article#104#<P><font face="Arial, 
Helvetica, sans-serif">The allele frequencies observed were    0.37 for MTHFR 67
7T, 0.21 for MTHFR 1298C, 0.18 for MTR 2756G, and 0.47 for    RFC1 80G. The alle
le distribution of the polymorphisms was in Hardy-Weinberg    equilibrium (<font
 face="Symbol">c</font><SUP>2</SUP> = 0.41; d.f. = 1; P =    0.521 for MTHFR C67
7T; <font face="Symbol">c</font><SUP>2</SUP> = 3.71; d.f.    = 1; P = 0.054 for 
MTHFR A1298C; <font face="Symbol">c</font><SUP>2</SUP> =    1.22; d.f. = 1; P = 
0.269 for MTR A2756G). </font>  <font face="Arial, Helvetica, sans-serif">      
^cY#6914.htm##
00659000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704043100073002000900504#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#38#34#article#104#<P>The MTHFR C677T and
 A1298C haplotype frequencies inferred by the Phase program    were 0.4116 for C
-A, 0.2134 for C-C, 0.3742 for T-A, and 0.0008 for T-C. However,    the T-C hapl
otype was not present in our sample of DS patients. Thus, the T-C    frequency i
n our population was lower than the expected allele combination frequency    cal
culated by the Phase program, confirming negative selection for this haplotype. 
     ^cY#6914.htm##
00460000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704023200073002000900305#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#39#35#article#104#<P>The mean Hcy concen
tration was 5.2 &#177; 3.3 &#181;mol/L. There was no correlation    between Hcy 
concentrations and age (Rs = 0.065; P = 0.633) and the Hcy concentrations    did
 not differ between genders (P = 0.627).      ^cY#6914.htm##
00726000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704049800073002000900571#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#40#36#article#104#<P>Mean Hcy concentrat
ions according to genotype for the polymorphisms studied    are presented in <a 
href="#Tab1">Table 1</a>. There was no association between    Hcy concentrations
 and genotypes MTHFR C677T (P = 0.110), MTHFR A1298C (P =    0.727), RFC1 A80G (
P = 0.769), or combined MTHFR 677/1298 genotypes (P = 0.135).    However, Hcy co
ncentrations were significantly increased in the MTR 2756AG heterozygous    geno
type as compared to the MTR 2756AA wild-type genotype (P = 0.025).      ^cY#6914
.htm##
00622000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704039400073002000900467#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#41#37#article#104#<P>Statistical analysi
s was also performed excluding the adults of the sample    (5 individuals). The 
mean Hcy concentration was 5.0 &#177; 3.3 &#181;mol/L.    The analysis of the me
an Hcy concentrations according to genotype for the polymorphisms    studied sho
wed the same results (increased Hcy concentration in the MTR 2756AG    genotype)
 compared for the total group (P = 0.029).      ^cY#6914.htm##
00818000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704059000073002000900663#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#42#38#article#104#<P>Only one individual
 (a 9-month-old female) presented hyperhomocystinemia (20.9    &#181;mol/L); she
 was the carrier of a heterozygous genotype for the MTR A2756G    polymorphism (
MTR 2756AG/MTHFR 677CC/MTHFR 1298AA/RFC1 80AAA).  </font>  <HR ALIGN=LEFT WIDTH=
100% SIZE=2> <table width="100%"  border="0">   <tr align="left" valign="top">  
    <td width="12%"><a href="/img/revistas/bjmbr/v41n1/html/6914i01.htm"><img sr
c="/img/revistas/bjmbr/v41n1/6914i01peq.jpg" width="120" height="86" border="2">
</a></td>     <td width="88%"><font face="Arial, Helvetica, sans-serif">        
    ^cY#6914.htm##
00936000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704070800073002000900781#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#43#39#article#104#<P><a name="Fig1"></a>
Figure 1. Folate metabolism in Down syndrome (DS)          individuals. Arrows i
ndicate direct and indirect alterations in metabolites          induced by cysta
thionine &szlig;<I>-</I>synthase (C&szlig;S) overexpression          in DS indiv
iduals (4). dTTP = thymine; dUTP = uracyl; DHF = dihydrofolate;          THF = t
etrahydrofolate; 5,10-CH<SUB>2</SUB>-THF = 5,10-methylenetetrahydrofolate;      
    5-CH<SUB>3</SUB>-THF = 5-methyltetrahydrofolate; 10-CHO-THF = 10-formyl     
     tetrahydrofolate; MTHFR = methylenetetrahydrofolate reductase; MS = methion
ine          synthase; SAM = S-adenosylmethionine; SAH = S-adenosylhomocysteine.
        </font></td>   </tr> </table>     ^cY#6914.htm##
00888000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704066000073002000900733#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#44#40#article#104#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image    (41 K JPG file)]</f
ont></P> <HR ALIGN=LEFT WIDTH=100% SIZE=2> <table width="100%"  border="0">   <t
r align="left" valign="top">      <td width="12%"><a href="/img/revistas/bjmbr/v
41n1/html/6914t01.htm"><img src="/img/revistas/bjmbr/v41n1/table.jpg" width="100
" height="65" border="2"></a></td>     <td width="88%"><font face="Arial, Helvet
ica, sans-serif"><a name="Tab1"></a>Table        1. Plasma homocysteine concentr
ations according to genotypes MTHFR C677T,        MTHFR A1298C, MTR A2756G, and 
RFC1 A80G in Down syndrome individuals. </font></td>   </tr> </table>     ^cY#69
14.htm##
00347000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704011900073002000900192#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#45#41#article#104#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this table    (76 K JPG file)]</f
ont></P>     ^cY#6914.htm##
00275000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704004700073002000900120#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#46#42#article#104#<P>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>     ^cY#6914.htm##
00567000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704033900073002000900412#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#47#43#article#104#<P> <font face="Arial,
 Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007
F><B>Discussion    </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v
41n1/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></
B></A></FONT></font></P> <font face="Arial, Helvetica, sans-serif">      ^cY#691
4.htm##
00907000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704067900073002000900752#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#48#44#article#104#<P>Previous studies ha
ve suggested that patients with DS have disturbed folate    metabolism (2,24). P
ogribna et al. (2) reported that the plasma profile of the    metabolites involv
ed in the methionine/homocysteine pathway in DS children,    including decreased
 Hcy concentrations, reflect a functional folate deficiency    secondary to over
expression of the C&szlig;S gene, present on chromosome 21.    The increase in t
he activity of the transsulfuration pathway of Hcy, which results    from the ov
erexpression of C&szlig;S<I>,</I> may promote a &quot;folate trap&quot;    by de
creasing the cellular concentration of Hcy and its subsequent remethylation    p
athway.      ^cY#6914.htm##
00722000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704049400073002000900567#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#49#45#article#104#<P>Several studies fai
led to confirm reduced Hcy concentrations in DS patients    (11,25,26). Furtherm
ore, in a study with elderly DS patients, Licastro et al.    (27) observed that 
their plasma Hcy was higher and their folate lower than in    controls; blood co
ncentrations of vitamin B12 were also lower in DS patients    than in controls. 
The authors attributed most of the cases of mild hyperhomocystinemia    in the e
lderly DS patients to a nutritional folate and B12 deficiency.      ^cY#6914.htm
##
00839000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704061100073002000900684#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#50#46#article#104#<P>In the present stud
y, the mean Hcy concentration of DS patients (5.2 &#177;    3.3 &#181;mol/L) was
 close to that observed by Pogribna et al. (2) in DS children    (5.1 &#177; 1.1
 &#181;mol/L), but lower than the observed by Fillon-Emery et    al. (11) (9.8 &
#177; 0.7 &#181;mol/L) and Licastro et al. (27) (12.51 &#177;    1.46 &#181;mol/
L) in adult and elderly DS patients, respectively, and by Bosco    et al. (26) (
8.5 &#181;mol/L) in a group of DS patients of various ages (median    age: 13 ye
ars). This may be due to the fact that in our study only 5 of the    56 DS indiv
iduals were adults.      ^cY#6914.htm##
01784000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704155600073002000901629#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#51#47#article#104#<P>MTHFR is one of the
 key enzymes in the folate-dependent remethylation of Hcy    to methionine. The 
C677T polymorphism was associated with increased concentrations    of Hcy in sev
eral studies (5,9,10,27). In DS patients, increased Hcy concentrations    were o
bserved in elderly DS subjects with an MTHFR 677TT genotype (27). However,    Fi
llon-Emery et al. (11) found no difference in Hcy concentrations according    to
 the MTHFR C677T genotype in adults with trisomy 21, but observed an increase   
 in Hcy concentrations in the presence of genotypes MTHFR 1298 AA and AC as comp
ared    to the mutated homozygote (CC) in a group of patients taking folic acid 
supplements.    Studies on other populations have not detected any significant d
ifferences in    Hcy concentrations between A1298C genotypes (28,29). However, e
levated Hcy concentrations    have been reported for the double heterozygote 677
CT/1298AC (30). In our study    on DS patients, the Hcy concentrations did not d
iffer among MTHFR genotypes,    in agreement with the results of a Brazilian stu
dy on healthy children (29).    However, the data about the influence of genetic
 polymorphisms on Hcy concentrations    provided by studies with healthy and DS 
individuals cannot be compared since    DS individuals present three copies of t
he C&szlig;S gene, a fact that increases    the transsulfuration pathway of Hcy 
and results in decreased Hcy concentration.    Thus, the contribution of genetic
 polymorphisms to the Hcy concentrations of    DS individuals may be underestima
ted.      ^cY#6914.htm##
00823000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704059500073002000900668#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#52#48#article#104#<P>The frequency of th
e MTHFR 677TT genotype observed by us (16.07%) was elevated    compared to other
 studies on the Brazilian population (~10%) (29,31), but close    to those obser
ved by Hobbs et al. (4) (15%) and Fillon-Emery et al. (11) (12.8%)    in America
n and French DS patients, respectively. Regarding the MTHFR A1298C    polymorphi
sm, the prevalence of homozygous 1298CC individuals in the present    study (8.9
3%) was higher than that observed in a large group of healthy Brazilian    child
ren (5.5%) (31) but close to the one observed in French DS patients (7.7%)    (1
1).      ^cY#6914.htm##
00614000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038600073002000900459#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#53#49#article#104#<P>Linkage disequilibr
ium between MTHFR 677T and 1298C alleles has been reported    (32,33). However, 
this linkage disequilibrium is not complete since there are    studies showing t
he presence of some individuals with the rare T-C haplotype    (34,35). In the p
resent study, no individual with a T-C haplotype was observed,    confirming neg
ative selection of this haplotype.      ^cY#6914.htm##
01957000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704172900073002000901802#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#54#50#article#104#<P>The frequency of th
e MTR 2756GG genotype (5.36%) in our DS patients was higher    than that observe
d in French DS patients (2.6%) (11). The contribution of the    MTR A2756G polym
orphism to Hcy concentrations has not been fully clarified.    This polymorphism
 has been investigated as a risk factor for some diseases,    such as vascular d
isease, neural tube defects, coronary artery disease and DS,    and the evaluati
on of its influence on Hcy concentrations becomes of great interest.    However,
 most of the studies did not find any relationship between this polymorphism    
and alterations in Hcy concentrations (15,16), and the few studies that observed
    this relationship are contradictory with regard to the allele involved. Harm
on    et al. (12) analyzed the relationship between MTR A2756G genotype and Hcy 
concentration    in a cohort of 625 working men aged 30-49 years and presented e
vidence that    the MTR 2756AA genotype was associated with a modest increase in
 plasma Hcy    concentrations. Similar results were observed in a prospective st
udy of myocardial    infarction (36). In a group of DS patients taking folic aci
d supplements, higher    Hcy concentrations were also observed in individuals wi
th the MTR 2756AA genotype    compared to the MTR 2756AG genotype (11). On the o
ther hand, Laraqui et al.    (13) recently observed a significant contribution o
f the MTR 2756G allele to    a moderate increase in Hcy concentrations in patien
ts with coronary artery disease.    In the present study, Hcy concentrations wer
e significantly increased in the    MTR 2756AG heterozygous genotype compared to
 the MTR 2756AA wild-type genotype,    in agreement with the observations of Lar
aqui et al. (13).      ^cY#6914.htm##
00566000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704033800073002000900411#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#55#51#article#104#<P>Genotype RFC1 80AAA
 was associated with elevated Hcy concentrations as compared    to RFC1 80AG in 
a group of DS patients using vitamin supplementation (11). The    influence of t
his polymorphism on Hcy concentrations was also observed in healthy    individua
ls, but only when combined with the MTHFR C677T polymorphism (37).      ^cY#6914
.htm##
00916000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704068800073002000900761#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#56#52#article#104#<P>Elevated Hcy concen
trations may be harmful since they have been associated    with elevated risk of
 cardiovascular disease, neurodegenerative disorders, psychiatric    disorders, 
and decline of cognitive performance (13,25,38). Gu&eacute;ant et    al. (25) ob
served that a lower intelligence quotient was associated with higher    Hcy conc
entrations in DS patients, and this association was also observed in    the pres
ence of the MTHFR 677T allele alone and in combination with the transcobalamin  
  776G polymorphic allele. However, they did not observe a relationship between 
   intelligence quotient and MTHFR A1298C, MTR A2756G and methionine synthase re
ductase    A66G.      ^cY#6914.htm##
01295000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704106700073002000901140#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#57#53#article#104#<P>According to Hobbs 
et al. (4), the presence of genetic variants involved in    folate metabolism in
 DS individuals may confer a survival advantage. These investigators    observed
 a preferential transmission of the MTHFR 677T allele from heterozygous    fathe
rs to DS children, and suggested that this may represent a metabolic advantage  
  since the overexpression of the C&szlig;S enzyme in these individuals is assoc
iated    with decreased Hcy, methionine and S-adenosylmethionine concentrations.
 Hcy    is essential for folate-dependent DNA synthesis and for cellular methyla
tion    reactions, which are important for fetal development. According to these
 investigators,    a maternal-fetal genotype interaction of the MTHFR C677T poly
morphism would    also provide a favorable balance of folate distribution betwee
n both DNA synthesis    and cellular methylation in DS individuals. The preferen
tial transmission of    the 677T allele from fathers to DS children was also obs
erved by Rai et al.    (39), confirming the hypothesis of Hobbs et al. (4).     
 ^cY#6914.htm##
00603000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704037500073002000900448#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#58#54#article#104#<P>In conclusion, our 
results suggest that the heterozygote genotype MTR 2756AG    is associated with 
the increase in plasma Hcy concentrations in this group of    Brazilian patients
 with DS. However, due to the contradictory results found    in different studie
s, this relationship should be confirmed in a larger sample.  </font>  <HR ALIGN
=LEFT WIDTH=100% SIZE=2>     ^cY#6914.htm##
00613000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038500073002000900458#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#59#55#article#104#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><B>
References</B></FONT></font>    <font size="4" face="Arial, Helvetica, sans-seri
f"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIGN=BOTTOM
 BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A></font></P> <font fac
e="Arial, Helvetica, sans-serif">      ^cY#6914.htm##
00447000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704020500075002000900280#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#60#56#article#104#1#<P>1. Jy
othy A, Kumar KS, Mallikarjuna GN, Babu Rao V, Uma Devi B, Sujatha M,    et al. 
Parental age and the origin of extra chromosome 21 in Down syndrome.    <I>J Hum
 Genet</I> 2001; 46: 347-350.    ^cY#6914.htm##
00444000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704020200075002000900277#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#61#57#article#104#2#<P>2. Po
gribna M, Melnyk S, Pogribny I, Chango A, Yi P, James SJ. Homocysteine    metabo
lism in children with Down syndrome: <I>in vitro</I> modulation. <I>Am    J Hum 
Genet</I> 2001; 69: 88-95.    ^cY#6914.htm##
00349000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704010700075002000900182#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#62#58#article#104#3#<P>3. Fi
nkelstein JD, Martin JJ. Homocysteine. <I>Int J Biochem Cell Biol</I>    2000; 3
2: 385-389.    ^cY#6914.htm##
00473000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704023100075002000900306#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#63#59#article#104#4#<P>4. Ho
bbs CA, Cleves MA, Lauer RM, Burns TL, James SJ. Preferential transmission    of
 the MTHFR 677 T allele to infants with Down syndrome: implications for a    sur
vival advantage. <I>Am J Med Genet</I> 2002; 113: 9-14.    ^cY#6914.htm##
00516000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704027400075002000900349#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#64#60#article#104#5#<P>5. Pa
poutsakis C, Yiannakouris N, Manios Y, Papaconstantinou E, Magkos F, Schulpis   
 KH, et al. The effect of MTHFR(C677T) genotype on plasma homocysteine concentra
tions    in healthy children is influenced by gender. <I>Eur J Clin Nutr</I> 200
6; 60:    155-162.    ^cY#6914.htm##
00495000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704025300075002000900328#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#65#61#article#104#6#<P>6. Se
lhub J, Jacques PF, Bostom AG, Wilson PW, Rosenberg IH. Relationship between    
plasma homocysteine and vitamin status in the Framingham study population. Impac
t    of folic acid fortification. <I>Public Health Rev</I> 2000; 28: 117-145.   
 ^cY#6914.htm##
00477000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704023500075002000900310#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#66#62#article#104#7#<P>7. We
isberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphis
m    in methylenetetrahydrofolate reductase (MTHFR) associated with decreased en
zyme    activity. <I>Mol Genet Metab</I> 1998; 64: 169-172.    ^cY#6914.htm##
00481000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704023900075002000900314#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#67#63#article#104#8#<P>8. Fr
osst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al.    A candi
date genetic risk factor for vascular disease: a common mutation in methylenetet
rahydrofolate    reductase. <I>Nat Genet</I> 1995; 10: 111-113.    ^cY#6914.htm#
#
00519000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704027700075002000900352#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#68#64#article#104#9#<P>9. Ul
vik A, Ueland PM, Fredriksen A, Meyer K, Vollset SE, Hoff G, et al. Functional  
  inference of the methylenetetrahydrofolate reductase 677 C &gt; T and 1298A   
 &gt; C polymorphisms from a large-scale epidemiological study. <I>Hum Genet</I>
    2007; 121: 57-64.    ^cY#6914.htm##
00247000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001900073002000900092#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#69#65#article#104#  </font>      ^cY#691
4.htm##
00598000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704035500076002000900431#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#70#66#article#104#10#<P><fon
t face="Arial, Helvetica, sans-serif">10. Castro R, Rivera I, Ravasco P,    Jako
bs C, Blom HJ, Camilo ME, et al. 5,10-Methylenetetrahydrofolate reductase    677
C <font face="Symbol">&#174;</font> T and 1298A <font face="Symbol">&#174;</font
>    C mutations are genetic determinants of elevated homocysteine. <I>QJM</I> 2
003;    96: 297-303.    ^cY#6914.htm##
00290000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704006200073002000900135#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#71#67#article#104# </font>  <font face="
Arial, Helvetica, sans-serif">      ^cY#6914.htm##
00484000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704024100076002000900317#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#72#68#article#104#11#<P>11. 
Fillon-Emery N, Chango A, Mircher C, Barbe F, Blehaut H, Herbeth B, et    al. Ho
mocysteine concentrations in adults with trisomy 21: effect of B vitamins    and
 genetic polymorphisms. <I>Am J Clin Nutr</I> 2004; 80: 1551-1557.    ^cY#6914.h
tm##
00508000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704026500076002000900341#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#73#69#article#104#12#<P>12. 
Harmon DL, Shields DC, Woodside JV, McMaster D, Yarnell JW, Young IS, et    al. 
Methionine synthase D919G polymorphism is a significant but modest determinant  
  of circulating homocysteine concentrations. <I>Genet Epidemiol</I> 1999; 17:  
  298-309.    ^cY#6914.htm##
00554000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704031100076002000900387#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#74#70#article#104#13#<P>13. 
Laraqui A, Allami A, Carrie A, Coiffard AS, Benkouka F, Benjouad A, et    al. In
fluence of methionine synthase (A2756G) and methionine synthase reductase    (A6
6G) polymorphisms on plasma homocysteine levels and relation to risk of coronary
    artery disease. <I>Acta Cardiol</I> 2006; 61: 51-61.    ^cY#6914.htm##
00528000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704028500076002000900361#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#75#71#article#104#14#<P>14. 
Feix A, Fritsche-Polanz R, Kletzmayr J, Vychytil A, Horl WH, Sunder-Plassmann   
 G, et al. Increased prevalence of combined MTR and MTHFR genotypes among indivi
duals    with severely elevated total homocysteine plasma levels. <I>Am J Kidney
 Dis</I>    2001; 38: 956-964.    ^cY#6914.htm##
00557000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704031400076002000900390#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#76#72#article#104#15#<P>15. 
Klerk M, Lievers KJ, Kluijtmans LA, Blom HJ, den Heijer M, Schouten EG,    et al
. The 2756A&gt;G variant in the gene encoding methionine synthase: its    relati
on with plasma homocysteine levels and risk of coronary heart disease    in a Du
tch case-control study. <I>Thromb Res</I> 2003; 110: 87-91.    ^cY#6914.htm##
00461000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704021800076002000900294#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#77#73#article#104#16#<P>16. 
Kluijtmans LA, Young IS, Boreham CA, Murray L, McMaster D, McNulty H, et    al. 
Genetic and nutritional factors contributing to hyperhomocysteinemia in    young
 adults. <I>Blood</I> 2003; 101: 2483-2488.    ^cY#6914.htm##
00463000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704022000076002000900296#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#78#74#article#104#17#<P>17. 
Nguyen TT, Dyer DL, Dunning DD, Rubin SA, Grant KE, Said HM. Human intestinal   
 folate transport: cloning, expression, and distribution of complementary RNA.  
  <I>Gastroenterology</I> 1997; 112: 783-791.    ^cY#6914.htm##
00432000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704018900076002000900265#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#79#75#article#104#18#<P>18. 
Abdel-Rahman SZ, Nouraldeen AM, Ahmed AE. Molecular interaction of [2,3-14C]    
acrylonitrile with DNA in gastric tissue of rat. <I>J Biochem Toxicol</I> 1994; 
   9: 191-198.    ^cY#6914.htm##
00539000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704029600076002000900372#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#80#76#article#104#19#<P>19. 
F&ouml;dinger M, Dierkes J, Skoupy S, Rohrer C, Hagen W, Puttinger H, et    al. 
Effect of glutamate carboxypeptidase II and reduced folate carrier polymorphisms
    on folate and total homocysteine concentrations in dialysis patients. <I>J A
m    Soc Nephrol</I> 2003; 14: 1314-1319.    ^cY#6914.htm##
00547000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704030400076002000900380#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#81#77#article#104#20#<P>20. 
de Andrade CR, Fukada SY, Olivon VC, de Godoy MA, Haddad R, Eberlin MN,    et al
. Alpha1D-adrenoceptor-induced relaxation on rat carotid artery is impaired    d
uring the endothelial dysfunction evoked in the early stages of hyperhomocystein
emia.    <I>Eur J Pharmacol</I> 2006; 543: 83-91.    ^cY#6914.htm##
00479000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704023600076002000900312#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#82#78#article#104#21#<P>21. 
Haddad R, Mendes MA, Hoehr NF, Eberlin MN. Amino acid quantitation in aqueous   
 matrices via trap and release membrane introduction mass spectrometry: homocyst
eine    in human plasma. <I>Analyst</I> 2001; 126: 1212_1215.    ^cY#6914.htm##
00466000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704022300076002000900299#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#83#79#article#104#22#<P>22. 
Vellasco AP, Haddad R, Eberlin MN, Hoehr NF. Combined cysteine &amp; homocystein
e    quantitation in plasma by trap and release membrane introduction mass spect
rometry.    <I>Analyst</I> 2002; 127: 1050-1053.    ^cY#6914.htm##
00471000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704022800076002000900304#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#84#80#article#104#23#<P>23. 
Measurement and use of total plasma homocysteine. American Society of Human    G
enetics/American College of Medical Genetics Test and Transfer Committee Working
    Group. <I>Am J Hum Genet</I> 1998; 63: 1541-1543.    ^cY#6914.htm##
00408000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704016500076002000900241#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#85#81#article#104#24#<P>24. 
Ueland PM, Refsum H, Christensen B. Methotrexate sensitivity in Down's    syndro
me: a hypothesis. <I>Cancer Chemother Pharmacol</I> 1990; 25: 384-386.    ^cY#69
14.htm##
00474000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704023100076002000900307#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#86#82#article#104#25#<P>25. 
Gu&eacute;ant JL, Anello G, Bosco P, Gueant-Rodriguez RM, Romano A, Barone    C,
 et al. Homocysteine and related genetic polymorphisms in Down's syndrome    IQ.
 <I>J Neurol Neurosurg Psychiatry</I> 2005; 76: 706-709.    ^cY#6914.htm##
00247000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001900073002000900092#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#87#83#article#104#  </font>      ^cY#691
4.htm##
00705000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704046200076002000900538#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#88#84#article#104#26#<P><fon
t face="Arial, Helvetica, sans-serif">26. Bosco P, Gueant-Rodriguez RM,    Anell
o G, Barone C, Namour F, Caraci F, et al. Methionine synthase (MTR) 2756    (A <
font face="Symbol">&#174;</font> G) polymorphism, double heterozygosity    methi
onine synthase 2756 AG/methionine synthase reductase (MTRR) 66 AG, and    elevat
ed homocysteinemia are three risk factors for having a child with Down    syndro
me. <I>Am J Med Genet A</I> 2003; 121: 219-224.    ^cY#6914.htm##
00290000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704006200073002000900135#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#89#85#article#104# </font>  <font face="
Arial, Helvetica, sans-serif">      ^cY#6914.htm##
00507000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704026400076002000900340#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#90#86#article#104#27#<P>27. 
Licastro F, Marocchi A, Penco S, Porcellini E, Lio D, Dogliotti G, et al.    Doe
s Down's syndrome support the homocysteine theory of atherogenesis? Experience  
  in elderly subjects with trisomy 21. <I>Arch Gerontol Geriatr</I> 2006; 43:   
 381-387.    ^cY#6914.htm##
00671000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704042800076002000900504#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#91#87#article#104#28#<P>28. 
Narayanan S, McConnell J, Little J, Sharp L, Piyathilake CJ, Powers H,    et al.
 Associations between two common variants C677T and A1298C in the methylenetetra
hydrofolate    reductase gene and measures of folate metabolism and DNA stabilit
y (strand breaks,    misincorporated uracil, and DNA methylation status) in huma
n lymphocytes <I>in    vivo</I>. <I>Cancer Epidemiol Biomarkers Prev</I> 2004; 1
3: 1436-1443.    ^cY#6914.htm##
00539000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704029600076002000900372#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#92#88#article#104#29#<P>29. 
Alessio AC, Annichino-Bizzacchi JM, Bydlowski SP, Eberlin MN, Vellasco    AP, Ho
ehr NF. Polymorphisms in the methylenetetrahydrofolate reductase and methionine 
   synthase reductase genes and homocysteine levels in Brazilian children. <I>Am
    J Med Genet A</I> 2004; 128: 256-260.    ^cY#6914.htm##
00517000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704027400076002000900350#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#93#89#article#104#30#<P>30. 
van der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes    TK, e
t al. A second common mutation in the methylenetetrahydrofolate reductase    gen
e: an additional risk factor for neural-tube defects? <I>Am J Hum Genet</I>    1
998; 62: 1044-1051.    ^cY#6914.htm##
00545000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704030200076002000900378#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#94#90#article#104#31#<P>31. 
Arruda VR, Siqueira LH, Goncalves MS, von Zuben PM, Soares MC, Menezes    R, et 
al. Prevalence of the mutation C677 <font face="Symbol">&#174;</font>    T in th
e methylene tetrahydrofolate reductase gene among distinct ethnic groups    in B
razil. <I>Am J Med Genet</I> 1998; 78: 332-335.    ^cY#6914.htm##
00530000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704028700076002000900363#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#95#91#article#104#32#<P>32. 
Stegmann K, Ziegler A, Ngo ET, Kohlschmidt N, Schroter B, Ermert A, et    al. Li
nkage disequilibrium of MTHFR genotypes 677C/T-1298A/C in the German population 
   and association studies in probands with neural tube defects (NTD). <I>Am J  
  Med Genet</I> 1999; 87: 23-29.    ^cY#6914.htm##
00538000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704029500076002000900371#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#96#92#article#104#33#<P>33. 
Shi M, Caprau D, Romitti P, Christensen K, Murray JC. Genotype frequencies    an
d linkage disequilibrium in the CEPH human diversity panel for variants in    fo
late pathway genes MTHFR, MTHFD, MTRR, RFC1, and GCP2. <I>Birth Defects Res    A
 Clin Mol Teratol</I> 2003; 67: 545-549.    ^cY#6914.htm##
00499000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704025600076002000900332#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#97#93#article#104#34#<P>34. 
Scala I, Granese B, Sellitto M, Salome S, Sammartino A, Pepe A, et al.    Analys
is of seven maternal polymorphisms of genes involved in homocysteine/folate    m
etabolism and risk of Down syndrome offspring. <I>Genet Med</I> 2006; 8: 409-416
.    ^cY#6914.htm##
00552000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704030900076002000900385#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#98#94#article#104#35#<P>35. 
Parle-McDermott A, Mills JL, Kirke PN, O'Leary VB, Swanson DA, Pangilinan    F, 
et al. Analysis of the MTHFR 1298A <font face="Symbol">&#174;</font> C and    67
7C <font face="Symbol">&#174;</font> T polymorphisms as risk factors for neural 
   tube defects. <I>J Hum Genet</I> 2003; 48: 190-193.    ^cY#6914.htm##
00523000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704028000076002000900356#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#99#95#article#104#36#<P>36. 
Chen J, Stampfer MJ, Ma J, Selhub J, Malinow MR, Hennekens CH, et al. Influence 
   of a methionine synthase (D919G) polymorphism on plasma homocysteine and fola
te    levels and relation to risk of myocardial infarction. <I>Atherosclerosis</
I>    2001; 154: 667-672.    ^cY#6914.htm##
00544000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704030000077002000900377#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#100#96#article#104#37#<P>37.
 Chango A, Emery-Fillon N, de Courcy GP, Lambert D, Pfister M, Rosenblatt    DS,
 et al. A polymorphism (80G<font face="Symbol">&#174;</font>A) in the reduced   
 folate carrier gene and its associations with folate status and homocysteinemia
.    <I>Mol Genet Metab</I> 2000; 70: 310-315.    ^cY#6914.htm##
00383000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704013900077002000900216#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#101#97#article#104#38#<P>38.
 Mattson MP, Kruman II, Duan W. Folic acid and homocysteine in age-related    di
sease. <I>Ageing Res Rev</I> 2002; 1: 95-111.    ^cY#6914.htm##
00450000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704020600077002000900283#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#p#102#98#article#104#39#<P>39.
 Rai AK, Singh S, Mehta S, Kumar A, Pandey LK, Raman R. MTHFR C677T and    A1298
C polymorphisms are risk factors for Down's syndrome in Indian mothers.    <I>J 
Hum Genet</I> 2006; 51: 278-283.    ^cY#6914.htm##
00282000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070704005300074002000900127#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#103#99#article#104#  </font>  <HR ALIGN=
LEFT WIDTH=100% SIZE=2>     ^cY#6914.htm##
00634000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704040400075002000900479#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#104#100#article#104#<P><font face="Arial
, Helvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT color="#00007F" SIZ
E=4><B>Acknowledgments</B></FONT></font>    <font size="4" face="Arial, Helvetic
a, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" 
ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0" width="12" height="12"></B></A>
</font></P> <font face="Arial, Helvetica, sans-serif">      ^cY#6914.htm##
00542000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704031200075002000900387#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#105#101#article#104#<P>The authors thank
 all the participants in this study, the Ding-Down workgroup    (multidisciplina
ry group of health professionals, FAMERP), Prof. Dr. Jos&eacute;    Ant&ocirc;ni
o Cordeiro for his help with the statistical analysis, and the FAMERP/FUNFARME. 
 </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6914.htm##
00591000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704036100075002000900436#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#106#102#article#104#<P><FONT SIZE=4 face
="Arial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F
><B>Correspondence    and Footnotes</B></FONT></FONT> <font size="4" face="Arial
, Helvetica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/
back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A
></font></P>     ^cY#6914.htm##
00665000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704043500075002000900510#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#107#103#article#104#<p><font face="Arial
, Helvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v41n1/
recor.gif" width="15" height="14" border="0"></a>    Address for correspondence:
</b> E.C. Pavarino-Bertelli, UPGEM, FAMERP, Bloco    U6, Av. Brigadeiro Faria Li
ma, 5416, 15090-000 S&atilde;o Jos&eacute; do Rio    Preto, SP, Brasil. Fax: +55
-17-3201-5708. E-mail: <a href="mailto:erika@famerp.br">erika@famerp.br</a></fon
t></p>     ^cY#6914.htm##
00509000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704027900075002000900354#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6914.htm#S#p#108#104#article#104#<P><font face="Arial
, Helvetica, sans-serif">Research supported by FAPESP (04/15944-5    and 03/0993
1-5) and CNPq (302674/2005-5). J.M. Biselli was the recipient of    a fellowship
 from CAPES (CGPP 046/2006). Received May 29, 2007. Accepted October    18, 2007
. </font>      ^cY#6914.htm##
00675000000000337000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100016000740100016000900100
02300106010001800129010001800147010001700165810000600182012007200188030001200260
06500090027206400050028103100030028601400080028986500090029700200090030603500100
0315801001200325#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#c#109#1#ar
ticle#39#1#^rND^sJyothy^nA#^rND^sKumar^nKS#^rND^sMallikarjuna^nGN#^rND^sBabu^nRa
o V#^rND^sUma^nDevi B#^rND^sSujatha^nM#et al#Parental age and the origin of extr
a chromosome 21 in Down syndrome^len#J Hum Genet#20010000#2001#46#347-350#200801
00#6914.htm#1434-5161#J Hum Genet##
00657000000000325000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100016000920100
01800108010001600126010001200142010001600154012008000170030001500250065000900265
06400050027403100030027901400060028286500090028800200090029703500100030680100150
0316#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#c#110#2#article#39#2#^
rND^sPogribna^nM#^rND^sMelnyk^nS#^rND^sPogribny^nI#^rND^sChango^nA#^rND^sYi^nP#^
rND^sJames^nSJ#Homocysteine metabolism in children with Down syndrome: in vitro 
modulation^len#Am J Hum Genet#20010000#2001#69#88-95#20080100#6914.htm#0002-9297
#Am J Hum Genet##
00509000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100022000740100017000960120
01700113030002400130065000900154064000500163031000300168014000800171865000900179
002000900188035001000197801002400207#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
914.htm#S#c#111#3#article#39#3#^rND^sFinkelstein^nJD#^rND^sMartin^nJJ#Homocystei
ne^len#Int J Biochem Cell Biol#20000000#2000#32#385-389#20080100#6914.htm#1357-2
725#Int J Biochem Cell Biol##
00675000000000313000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100016000740100017000900100
01600107010001600123010001600139012012500155030001500280065000900295064000500304
031000400309014000500313865000900318002000900327035001000336801001500346#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#c#112#4#article#39#4#^rND^sHobbs^n
CA#^rND^sCleves^nMA#^rND^sLauer^nRM#^rND^sBurns^nTL#^rND^sJames^nSJ#Preferential
 transmission of the MTHFR 677 T allele to infants with Down syndrome: implicati
ons for a survival advantage^len#Am J Med Genet#20020000#2002#113#9-14#20080100#
6914.htm#0148-7299#Am J Med Genet##
00745000000000337000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100021000740100022000950100
01600117010002600133010001600159010001900175810000600194012012200200030001600322
06500090033806400050034703100030035201400080035586500090036300200090037203500100
0381801001600391#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#c#113#5#ar
ticle#39#5#^rND^sPapoutsakis^nC#^rND^sYiannakouris^nN#^rND^sManios^nY#^rND^sPapa
constantinou^nE#^rND^sMagkos^nF#^rND^sSchulpis^nKH#et al#The effect of MTHFR(C67
7T) genotype on plasma homocysteine concentrations in healthy children is influe
nced by gender^len#Eur J Clin Nutr#20060000#2006#60#155-162#20080100#6914.htm#09
54-3007#Eur J Clin Nutr##
00700000000000313000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100016000740100018000900100
01700108010001700125010002000142012013500162030001800297065000900315064000500324
031000300329014000800332865000900340002000900349035001000358801001800368#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#c#114#6#article#39#6#^rND^sSelhub^
nJ#^rND^sJacques^nPF#^rND^sBostom^nAG#^rND^sWilson^nPW#^rND^sRosenberg^nIH#Relat
ionship between plasma homocysteine and vitamin status in the Framingham study p
opulation: Impact of folic acid fortification^len#Public Health Rev#20000000#200
0#28#117-145#20080100#6914.htm#0301-0422#Public Health Rev##
00680000000000313000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100014000920100
02100106010001600127010001500143012012300158030001600281065000900297064000500306
031000300311014000800314865000900322002000900331035001000340801001600350#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#c#115#7#article#39#7#^rND^sWeisber
g^nI#^rND^sTran^nP#^rND^sChristensen^nB#^rND^sSibani^nS#^rND^sRozen^nR#A second 
genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated w
ith decreased enzyme activity^len#Mol Genet Metab#19980000#1998#64#169-172#20080
100#6914.htm#1096-7192#Mol Genet Metab##
00714000000000337000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100016000740100015000900100
01500105010001700120010001900137010001900156010001300175012011500188030001000303
06500090031306400050032203100030032701400080033086500090033800200090034703500100
0356801001000366#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#c#116#8#ar
ticle#39#8#^rND^sFrosst^nP#^rND^sBlom^nHJ#^rND^sMilos^nR#^rND^sGoyette^nP#^rND^s
Sheppard^nCA#^rND^sMatthews^nRG#^rND^set^nal#A candidate genetic risk factor for
 vascular disease: a common mutation in methylenetetrahydrofolate reductase^len#
Nat Genet#19950000#1995#10#111-113#20080100#6914.htm#1061-4036#Nat Genet##
00743000000000337000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100015000740100017000890100
02000106010001500126010001800141010001400159010001300173012014700186030001000333
06500090034306400050035203100040035701400060036186500090036700200090037603500100
0385801001000395#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#c#117#9#ar
ticle#39#9#^rND^sUlvik^nA#^rND^sUeland^nPM#^rND^sFredriksen^nA#^rND^sMeyer^nK#^r
ND^sVollset^nSE#^rND^sHoff^nG#^rND^set^nal#Functional inference of the methylene
tetrahydrofolate reductase 677 C > T and 1298A > C polymorphisms from a large-sc
ale epidemiological study^len#Hum Genet#20070000#2007#121#57-64#20080100#6914.ht
m#0340-6717#Hum Genet##
00706000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100016000920100
01700108010001600125010001500141010001700156810000600173012012800179030000400307
06500090031106400050032003100030032501400080032886500090033600200090034503500100
0354801000400364#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#c#118#10#a
rticle#39#10#^rND^sCastro^nR#^rND^sRivera^nI#^rND^sRavasco^nP#^rND^sJakobs^nC#^r
ND^sBlom^nHJ#^rND^sCamilo^nME#et al#5,10-Methylenetetrahydrofolate reductase 677
C ® T and 1298A ® C mutations are genetic determinants of elevated homocysteine^
len#QJM#20030000#2003#96#297-303#20080100#6914.htm#0033-5622#QJM##
00715000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100022000760100016000980100
01700114010001500131010001700146010001700163810000600180012010600186030001500292
06500090030706400050031603100030032101400100032486500090033400200090034303500100
0352801001500362#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#c#119#11#a
rticle#39#11#^rND^sFillon-Emery^nN#^rND^sChango^nA#^rND^sMircher^nC#^rND^sBarbe^
nF#^rND^sBlehaut^nH#^rND^sHerbeth^nB#et al#Homocysteine concentrations in adults
 with trisomy 21: effect of B vitamins and genetic polymorphisms^len#Am J Clin N
utr#20040000#2004#80#1551-1557#20080100#6914.htm#0002-9165#Am J Clin Nutr##
00737000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100018000930100
01900111010001800130010001800148010001600166810000600182012012600188030001600314
06500090033006400050033903100030034401400080034786500090035500200090036403500100
0373801001600383#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#c#120#12#a
rticle#39#12#^rND^sHarmon^nDL#^rND^sShields^nDC#^rND^sWoodside^nJV#^rND^sMcMaste
r^nD#^rND^sYarnell^nJW#^rND^sYoung^nIS#et al#Methionine synthase D919G polymorph
ism is a significant but modest determinant of circulating homocysteine concentr
ations^len#Genet Epidemiol#19990000#1999#17#298-309#20080100#6914.htm#0741-0395#
Genet Epidemiol##
00780000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930100
01600109010001900125010001800144010001800162810000600180012017900186030001300365
06500090037806400050038703100030039201400060039586500090040100200090041003500100
0419801001300429#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#c#121#13#a
rticle#39#13#^rND^sLaraqui^nA#^rND^sAllami^nA#^rND^sCarrie^nA#^rND^sCoiffard^nAS
#^rND^sBenkouka^nF#^rND^sBenjouad^nA#et al#Influence of methionine synthase (A27
56G) and methionine synthase reductase (A66G) polymorphisms on plasma homocystei
ne levels and relation to risk of coronary artery disease^len#Acta Cardiol#20060
000#2006#61#51-61#20080100#6914.htm#0001-5385#Acta Cardiol##
00757000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100025000900100
01900115010001800134010001500152010002600167810000600193012013500199030001600334
06500090035006400050035903100030036401400080036786500090037500200090038403500100
0393801001600403#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#c#122#14#a
rticle#39#14#^rND^sFeix^nA#^rND^sFritsche-Polanz^nR#^rND^sKletzmayr^nJ#^rND^sVyc
hytil^nA#^rND^sHorl^nWH#^rND^sSunder-Plassmann^nG#et al#Increased prevalence of 
combined MTR and MTHFR genotypes among individuals with severely elevated total 
homocysteine plasma levels^len#Am J Kidney Dis#20010000#2001#38#956-964#20080100
#6914.htm#0272-6386#Am J Kidney Dis##
00778000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100018000910100
02100109010001500130010002000145010001900165810000600184012017600190030001100366
06500090037706400050038603100040039101400060039586500090040100200090041003500100
0419801001100429#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#c#123#15#a
rticle#39#15#^rND^sKlerk^nM#^rND^sLievers^nKJ#^rND^sKluijtmans^nLA#^rND^sBlom^nH
J#^rND^sden^nHeijer M#^rND^sSchouten^nEG#et al#The 2756A>G variant in the gene e
ncoding methionine synthase: its relation with plasma homocysteine levels and ri
sk of coronary heart disease in a Dutch case-control study^len#Thromb Res#200300
00#2003#110#87-91#20080100#6914.htm#0049-3848#Thromb Res##
00683000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100021000760100016000970100
01800113010001600131010001800147010001700165810000600182012008900188030000600277
06500090028306400050029203100040029701400100030186500090031100200090032003500100
0329801000600339#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#c#124#16#a
rticle#39#16#^rND^sKluijtmans^nLA#^rND^sYoung^nIS#^rND^sBoreham^nCA#^rND^sMurray
^nL#^rND^sMcMaster^nD#^rND^sMcNulty^nH#et al#Genetic and nutritional factors con
tributing to hyperhomocysteinemia in young adults^len#Blood#20030000#2003#101#24
83-2488#20080100#6914.htm#0006-4971#Blood##
00685000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100015000930100
01800108010001600126010001600142010001500158012009800173030001700271065000900288
06400050029703100040030201400080030686500090031400200090032303500100033280100170
0342#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#c#125#17#article#39#17
#^rND^sNguyen^nTT#^rND^sDyer^nDL#^rND^sDunning^nDD#^rND^sRubin^nSA#^rND^sGrant^n
KE#^rND^sSaid^nHM#Human intestinal folate transport: cloning, expression, and di
stribution of complementary RNA^len#Gastroenterology#19970000#1997#112#783-791#2
0080100#6914.htm#0016-5085#Gastroenterology##
00601000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100023000760100021000990100
01600120012008700136030001800223065000900241064000500250031000200255014000800257
865000900265002000900274035001000283801001800293#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6914.htm#S#c#126#18#article#39#18#^rND^sAbdel-Rahman^nSZ#^rND^sNoural
deen^nAM#^rND^sAhmed^nAE#Molecular interaction of [2,3-14C] acrylonitrile with D
NA in gastric tissue of rat^len#J Biochem Toxicol#19940000#1994#9#191-198#200801
00#6914.htm#0887-2082#J Biochem toxicol##
00764000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940100
01600111010001600127010001500143010001900158810000600177012015400183030001700337
06500090035406400050036303100030036801400100037186500090038100200090039003500100
0399801001700409#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#c#127#19#a
rticle#39#19#^rND^sFödinger^nM#^rND^sDierkes^nJ#^rND^sSkoupy^nS#^rND^sRohrer^nC#
^rND^sHagen^nW#^rND^sPuttinger^nH#et al#Effect of glutamate carboxypeptidase II 
and reduced folate carrier polymorphisms on folate and total homocysteine concen
trations in dialysis patients^len#J Am Soc Nephrol#20030000#2003#14#1314-1319#20
080100#6914.htm#1046-6673#J Am Soc Nephrol##
00776000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100021000760100017000970100
01700114010001900131010001600150010001800166810000600184012016400190030001600354
06500090037006400050037903100040038401400060038886500090039400200090040303500100
0412801001600422#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#c#128#20#a
rticle#39#20#^rND^sde^nAndrade CR#^rND^sFukada^nSY#^rND^sOlivon^nVC#^rND^sde^nGo
doy MA#^rND^sHaddad^nR#^rND^sEberlin^nMN#et al#Alpha1D-adrenoceptor-induced rela
xation on rat carotid artery is impaired during the endothelial dysfunction evok
ed in the early stages of hyperhomocysteinemia^len#Eur J Pharmacol#20060000#2006
#543#83-91#20080100#6914.htm#0014-2999#Eur J Pharmacol##
00656000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100017000920100
01600109010001800125012013900143030000800282065000900290064000500299031000400304
014001000308865000900318002000900327035001000336801000800346#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6914.htm#S#c#129#21#article#39#21#^rND^sHaddad^nR#^rND^sM
endes^nMA#^rND^sHoehr^nNF#^rND^sEberlin^nMN#Amino acid quantitation in aqueous m
atrices via trap and release membrane introduction mass spectrometry: homocystei
ne in human plasma^len#Analyst#20010000#2001#126#1212_1215#20080100#6914.htm#000
3-2654#Analyst##
00639000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100016000950100
01800111010001600129012012000145030000800265065000900273064000500282031000400287
014001000291865000900301002000900310035001000319801000800329#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6914.htm#S#c#130#22#article#39#22#^rND^sVellasco^nAP#^rND
^sHaddad^nR#^rND^sEberlin^nMN#^rND^sHoehr^nNF#Combined cysteine & homocysteine q
uantitation in plasma by trap and release membrane introduction mass spectrometr
y^len#Analyst#20020000#2002#127#1050-1053#20080100#6914.htm#0003-2654#Analyst##
00601000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100056000760120118001320300
01500250065000900265064000500274031000300279014001000282865000900292002000900301
035001000310801001500320#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#c#
131#23#article#39#23#^rND^sMeasurement^nand use of total plasma homocysteine#Ame
rican Society of Human Genetics/American College of Medical Genetics Test and Tr
ansfer Committee Working Group^len#Am J Hum Genet#19980000#1998#63#1541-1543#200
80100#6914.htm#0002-9297#Am J Hum Genet##
00589000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930100
02100109012006200130030002700192065000900219064000500228031000300233014000800236
865000900244002000900253035001000262801002700272#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6914.htm#S#c#132#24#article#39#24#^rND^sUeland^nPM#^rND^sRefsum^nH#^r
ND^sChristensen^nB#Methotrexate sensitivity in Down's syndrome: a hypothesis^len
#Cancer Chemother Pharmacol#19900000#1990#25#384-386#20080100#6914.htm#0344-5704
#Cancer Chemother Pharmacol##
00713000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930100
01500109010002700124010001600151010001600167810000600183012007300189030003000262
06500090029206400050030103100030030601400080030986500090031700200090032603500100
0335801003000345#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#c#133#25#a
rticle#39#25#^rND^sGuéant^nJL#^rND^sAnello^nG#^rND^sBosco^nP#^rND^sGueant-Rodrig
uez^nRM#^rND^sRomano^nA#^rND^sBarone^nC#et al#Homocysteine and related genetic p
olymorphisms in Down's syndrome IQ^len#J Neurol Neurosurg Psychiatry#20050000#20
05#76#706-709#20080100#6914.htm#0022-3050#J Neurol Neurosurg Psychiatry##
00818000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100027000910100
01600118010001600134010001600150010001600166810000600182012024100188030001700429
71000020044606500090044806400050045703100040046201400080046686500090047400200090
0483#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#c#134#26#article#39#26
#^rND^sBosco^nP#^rND^sGueant-Rodriguez^nRM#^rND^sAnello^nG#^rND^sBarone^nC#^rND^
sNamour^nF#^rND^sCaraci^nF#et al#Methionine synthase (MTR) 2756 (A ® G) polymorp
hism, double heterozygosity methionine synthase 2756 AG/methionine synthase redu
ctase (MTRR) 66 AG, and elevated homocysteinemia are three risk factors for havi
ng a child with Down syndrome^len#Am J Med Genet A#2#20030000#2003#121#219-224#2
0080100#6914.htm##
00742000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100018000940100
01500112010002000127010001300147010001900160810000600179012012200185030002200307
06500090032906400050033803100030034301400080034686500090035400200090036303500100
0372801002200382#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#c#135#27#a
rticle#39#27#^rND^sLicastro^nF#^rND^sMarocchi^nA#^rND^sPenco^nS#^rND^sPorcellini
^nE#^rND^sLio^nD#^rND^sDogliotti^nG#et al#Does Down's syndrome support the homoc
ysteine theory of atherogenesis? Experience in elderly subjects with trisomy 21^
len#Arch Gerontol Geriatr#20060000#2006#43#381-387#20080100#6914.htm#0167-4943#A
rch Gerontol Geriatr##
00907000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100019000950100
01600114010001500130010002200145010001600167810000600183012025900189030003300448
06500090048106400050049003100030049501400100049886500090050800200090051703500100
0526801003300536#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#c#136#28#a
rticle#39#28#^rND^sNarayanan^nS#^rND^sMcConnell^nJ#^rND^sLittle^nJ#^rND^sSharp^n
L#^rND^sPiyathilake^nCJ#^rND^sPowers^nH#et al#Associations between two common va
riants C677T and A1298C in the methylenetetrahydrofolate reductase gene and meas
ures of folate metabolism and DNA stability (strand breaks, misincorporated urac
il, and DNA methylation status) in human lymphocytes in vivo^len#Cancer Epidemio
l Biomarkers Prev#20040000#2004#13#1436-1443#20080100#6914.htm#1055-9965#Cancer 
Epidemiol Biomarkers Prev##
00721000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100030000940100
02000124010001800144010001900162010001600181012014700197030001700344710000200361
065000900363064000500372031000400377014000800381865000900389002000900398#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#c#137#29#article#39#29#^rND^sAless
io^nAC#^rND^sAnnichino-Bizzacchi^nJM#^rND^sBydlowski^nSP#^rND^sEberlin^nMN#^rND^
sVellasco^nAP#^rND^sHoehr^nNF#Polymorphisms in the methylenetetrahydrofolate red
uctase and methionine synthase reductase genes and homocysteine levels in Brazil
ian children^len#Am J Med Genet A#2#20040000#2004#128#256-260#20080100#6914.htm#
#
00745000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100022000760100018000980100
01800116010001900134010001900153010001600172810000600188012012800194030001500322
06500090033706400050034603100030035101400100035486500090036400200090037303500100
0382801001500392#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#c#138#30#a
rticle#39#30#^rND^svan^nder Put NM#^rND^sGabreels^nF#^rND^sStevens^nEM#^rND^sSme
itink^nJA#^rND^sTrijbels^nFJ#^rND^sEskes^nTK#et al#A second common mutation in t
he methylenetetrahydrofolate reductase gene: an additional risk factor for neura
l-tube defects^len#Am J Hum Genet#19980000#1998#62#1044-1051#20080100#6914.htm#0
002-9297#Am J Hum Genet##
00741000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100019000930100
02000112010002000132010001700152010001700169810000600186012012800192030001500320
06500090033506400050034403100030034901400080035286500090036000200090036903500100
0378801001500388#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#c#139#31#a
rticle#39#31#^rND^sArruda^nVR#^rND^sSiqueira^nLH#^rND^sGoncalves^nMS#^rND^svon^n
Zuben PM#^rND^sSoares^nMC#^rND^sMenezes^nR#et al#Prevalence of the mutation C677
 ® T in the methylene tetrahydrofolate reductase gene among distinct ethnic grou
ps in Brazil^len#Am J Med Genet#19980000#1998#78#332-335#20080100#6914.htm#0148-
7299#Am J Med Genet##
00758000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940100
01400111010002100125010001800146010001600164810000600180012015300186030001500339
06500090035406400050036303100030036801400060037186500090037700200090038603500100
0395801001500405#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#c#140#32#a
rticle#39#32#^rND^sStegmann^nK#^rND^sZiegler^nA#^rND^sNgo^nET#^rND^sKohlschmidt^
nN#^rND^sSchroter^nB#^rND^sErmert^nA#et al#Linkage disequilibrium of MTHFR genot
ypes 677C/T-1298A/C in the German population and association studies in probands
 with neural tube defects (NTD)^len#Am J Med Genet#19990000#1999#87#23-29#200801
00#6914.htm#0148-7299#Am J Med Genet##
00702000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100013000760100016000890100
01700105010002100122010001700143012015800160030003700318710000200355065000900357
064000500366031000300371014000800374865000900382002000900391#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6914.htm#S#c#141#33#article#39#33#^rND^sShi^nM#^rND^sCapr
au^nD#^rND^sRomitti^nP#^rND^sChristensen^nK#^rND^sMurray^nJC#Genotype frequencie
s and linkage disequilibrium in the CEPH human diversity panel for variants in f
olate pathway genes MTHFR, MTHFD, MTRR, RFC1, and GCP2^len#Birth Defects Res A C
lin Mol Teratol#2#20030000#2003#67#545-549#20080100#6914.htm##
00695000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100017000910100
01800108010001600126010002000142010001400162810000600176012013300182030001000315
71000020032506500090032706400050033603100020034101400080034386500090035100200090
0360#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#c#142#34#article#39#34
#^rND^sScala^nI#^rND^sGranese^nB#^rND^sSellitto^nM#^rND^sSalome^nS#^rND^sSammart
ino^nA#^rND^sPepe^nA#et al#Analysis of seven maternal polymorphisms of genes inv
olved in homocysteine/folate metabolism and risk of Down syndrome offspring^len#
Genet Med#2#20060000#2006#8#409-416#20080100#6914.htm##
00713000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100025000760100016001010100
01600117010001800133010001800151010002000169810000600189012010300195030001200298
06500090031006400050031903100030032401400080032786500090033500200090034403500100
0353801001200363#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#c#143#35#a
rticle#39#35#^rND^sParle-McDermott^nA#^rND^sMills^nJL#^rND^sKirke^nPN#^rND^sO'Le
ary^nVB#^rND^sSwanson^nDA#^rND^sPangilinan^nF#et al#Analysis of the MTHFR 1298A 
® C and 677C ® T polymorphisms as risk factors for neural tube defects^len#J Hum
 Genet#20030000#2003#48#190-193#20080100#6914.htm#1434-5161#J Hum Genet##
00752000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100019000900100
01200109010001600121010001800137010002000155810000600175012014700181030001600328
06500090034406400050035303100040035801400080036286500090037000200090037903500100
0388801001600398#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#c#144#36#a
rticle#39#36#^rND^sChen^nJ#^rND^sStampfer^nMJ#^rND^sMa^nJ#^rND^sSelhub^nJ#^rND^s
Malinow^nMR#^rND^sHennekens^nCH#et al#Influence of a methionine synthase (D919G)
 polymorphism on plasma homocysteine and folate levels and relation to risk of m
yocardial infarction^len#Atherosclerosis#20010000#2001#154#667-672#20080100#6914
.htm#0021-9150#Atherosclerosis##
00740000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100022000920100
02000114010001700134010001700151010002100168810000600189012012200195030001600317
06500090033306400050034203100030034701400080035086500090035800200090036703500100
0376801001600386#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#c#145#37#a
rticle#39#37#^rND^sChango^nA#^rND^sEmery-Fillon^nN#^rND^sde^nCourcy GP#^rND^sLam
bert^nD#^rND^sPfister^nM#^rND^sRosenblatt^nDS#et al#A polymorphism (80G®A) in th
e reduced folate carrier gene and its associations with folate status and homocy
steinemia^len#Mol Genet Metab#20000000#2000#70#310-315#20080100#6914.htm#1096-71
92#Mol Genet Metab##
00516000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940100
01400111012005500125030001500180710000200195065000900197064000500206031000200211
014000700213865000900220002000900229#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
914.htm#S#c#146#38#article#39#38#^rND^sMattson^nMP#^rND^sKruman^nII#^rND^sDuan^n
W#Folic acid and homocysteine in age-related disease^len#Ageing Res Rev#2#200200
00#2002#1#95-111#20080100#6914.htm##
00666000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100015000900100
01500105010001500120010001700135010001500152012009600167030001200263065000900275
06400050028403100030028901400080029286500090030000200090030903500100031880100120
0328#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6914.htm#S#c#147#39#article#39#39
#^rND^sRai^nAK#^rND^sSingh^nS#^rND^sMehta^nS#^rND^sKumar^nA#^rND^sPandey^nLK#^rN
D^sRaman^nR#MTHFR C677T and A1298C polymorphisms are risk factors for Down's syn
drome in Indian mothers^len#J Hum Genet#20060000#2006#51#278-283#20080100#6914.h
tm#1434-5161#J Hum Genet##
00264000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090005000597080002000640910009000660920007000750020009000827030
00300091#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6925.htm#S#o#1#1#text#1#20080
623#173901#6925.htm#17##
01069000000000457000450000400060000070200450000670500020005170600020005370000020
00557010002000577090005000597080002000640710003000660400003000690010006000720420
00200078120000400080038000300084121000300087049000900090158000300099030002000102
03100030012203200020012506500090012701400090013603500100014522300090015512300020
01640120099001660100025002650100020002900100018003100100019003280100023003470100
02100370070009200391070009500483881002400578002000900602#v41n1#v:\scielo\serial\
bjmbr\v41n1\markup\6925.htm#S#h#2#1#text#1#oa#en#bjmbr#1#3.1#ND#05#BJMBR010#nd#B
raz J Med Biol Res#41#1#20080100#^f26^l33#0100-879X#20071217#1#Niemann-Pick type
 C1 protein influences the delivery of cholesterol to the SREBP: SCAP complex^le
n#^rND^1A01 A02^nY.J.^sGuo#^rND^1A01^nW.H.^sLi#^rND^1A01^nR.^sWu#^rND^1A01^nQ.^s
Xie#^rND^1A02^nZ.H.^sZhang#^rND^1A02^nL.Q.^sCui#Fujian Medical University^iA01^1
Hospital of Xiamen^2Department of Cardiology^cXiamen^pChina#Shandong University^
iA02^1Shandong Provincial Hospital^2Department of Cardiology^cJinan^pChina#S0100
-879X2006005000005#6925.htm##
01047000000000445000450000400060000070200450000670500020005170600020005370000020
00557010002000577090005000597080002000640710003000660400003000690010006000720420
00200078120000400080038000300084121000300087049000900090158000300099030002000102
03100030012203200020012506500090012701400090013603500100014522300090015512300020
01640120113001660100025002790100020003040100018003240100019003420100023003610100
02100384070009200405070009500497002000900592#v41n1#v:\scielo\serial\bjmbr\v41n1\
markup\6925.htm#S#f#3#1#text#1#oa#en#bjmbr#1#3.1#ND#05#BJMBR010#nd#Braz J Med Bi
ol Res#41#1#20080100#^f26^l33#0100-879X#20071217#1#<b>Niemann-Pick type C1 prote
in influences the delivery of cholesterol to the SREBP</b>: <b>SCAP complex</b>^
len#^rND^1A01 A02^nY.J.^sGuo#^rND^1A01^nW.H.^sLi#^rND^1A01^nR.^sWu#^rND^1A01^nQ.
^sXie#^rND^1A02^nZ.H.^sZhang#^rND^1A02^nL.Q.^sCui#Fujian Medical University^iA01
^1Hospital of Xiamen^2Department of Cardiology^cXiamen^pChina#Shandong Universit
y^iA02^1Shandong Provincial Hospital^2Department of Cardiology^cJinan^pChina#692
5.htm##
01150000000000457000450000400060000070200450000670500020005170600020005370000020
00557010002000577090005000597080002000640640013000660710003000790400003000820010
00600085042000200091120000400093121000300097049000900100158000300109030002400112
03100030013603200020013906500090014101400090015003500100015922300090016912300020
01780120099001800100025002790100020003040100017003240100018003410100023003590100
02100382070009400403070009700497002000900594008008900603#v41n1#v:\scielo\serial\
bjmbr\v41n1\markup\6925.htm#S#l#4#1#text#1#^mJan.^a2008#oa#en#bjmbr#1#3.1#05#BJM
BR010#nd#Braz. j. med. biol. res#41#1#20080100#^f26^l33#0100-879X#20071217#1#Nie
mann-Pick type C1 protein influences the delivery of cholesterol to the SREBP: S
CAP complex^len#^rND^1A01 A02^nY. J^sGuo#^rND^1A01^nW. H^sLi#^rND^1A01^nR^sWu#^r
ND^1A01^nQ^sXie#^rND^1A02^nZ. H^sZhang#^rND^1A02^nL. Q^sCui#^iA01^1Fujian Medica
l University^2Hospital of Xiamen^3Department of Cardiology^cXiamen^pChina#^iA02^
1Shandong University^2Shandong Provincial Hospital^3Department of Cardiology^cJi
nan^pChina#6925.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext
&pid=S0100-879X2008000100005##
00371000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000500059708000300064704014900067002000900216#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6925.htm#S#p#5#1#text#13#<P> <font face="Arial, Helve
tica, sans-serif"><A NAME="Home"></A><B>Braz J Med    Biol Res, January 2008, Vo
lume 41(1) 26-33</B> </font></P>     ^cY#6925.htm##
00400000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000500059708000300064704017800067002000900245#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6925.htm#S#p#6#2#text#13#<P><font size="5" face="Aria
l, Helvetica, sans-serif"><B>Niemann-Pick type C1    protein influences the deli
very of cholesterol to the SREBP:SCAP complex</B>    </font>      ^cY#6925.htm##
00674000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000500059708000300064704045200067002000900519#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6925.htm#S#p#7#3#text#13#<P><font face="Arial, Helvet
ica, sans-serif">Y.J. Guo<SUP>1,2</SUP>, W.H. Li<SUP>1</SUP>,    R. Wu<SUP>1</SU
P>, Q. Xie<SUP>1</SUP>, Z.H. Zhang<SUP>2</SUP> and <b><a href="#Correspondence">
<img src="/img/revistas/bjmbr/v41n1/recor.gif" width="15" height="14" border="0"
></a></b>    <a href="mailto:lianqun_cui@hotmail.com"><img src="/img/revistas/bj
mbr/v41n1/email-ca.gif" width="14" height="11" border="0"></a>    L.Q. Cui<SUP>2
</SUP> </font>      ^cY#6925.htm##
00387000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000500059708000300064704016500067002000900232#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6925.htm#S#p#8#4#text#13#<p><font face="Arial, Helvet
ica, sans-serif"><SUP>1</SUP>Department of Cardiology,    The First Hospital of 
Xiamen, Fujian Medical University, Xiamen, China     ^cY#6925.htm##
00390000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000500059708000300064704016800067002000900235#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6925.htm#S#p#9#5#text#13#<br>   <SUP>2</SUP>Departmen
t of Cardiology, Shandong Provincial Hospital, Shandong    University, Jinan, Ch
ina</font><font face="Arial, Helvetica, sans-serif">    ^cY#6925.htm##
00250000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000500060708000300065704002700068002000900095#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6925.htm#S#p#10#6#text#13#<BR>   </font></p>     ^cY#
6925.htm##
00270000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000500060708000300065704004700068002000900115#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6925.htm#S#p#11#7#text#13#<P>  <HR ALIGN=LEFT WIDTH=1
00% SIZE=2>     ^cY#6925.htm##
00558000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000500060708000300065704033500068002000900403#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6925.htm#S#p#12#8#text#13#<P> <font face="Arial, Helv
etica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F><B>Ab
stract    </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back
.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A></F
ONT></font></P> <font face="Arial, Helvetica, sans-serif">      ^cY#6925.htm##
01475000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000500060708000300065704125200068002000901320#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6925.htm#S#p#13#9#text#13#<P>The proposed role of Nie
mann-Pick type C1 protein (NPC1) in the delivery of    low-density lipoprotein (
LDL) cholesterol to the sterol regulatory element binding    protein (SREBP):SRE
BP cleavage activation protein (SCAP) complex in the endoplasmic    reticulum ha
s been largely based on indirect studies and remains contentious.    The major a
im of the present study was to assess whether NPC1 is involved in    the deliver
y of LDL cholesterol to the SREBP:SCAP complex. A cell line stably    expressing
 green fluorescence protein-SCAP was cultured in the presence of U18666A,    whi
ch can induce a Niemann-Pick type C disease phenotype, in order to locate    the
 SREBP:SCAP complex by fluorescence microscopy. Our major finding was that    de
fective NPC1 caused a delay in the ability of LDL cholesterol to suppress    SRE
BP processing. This was shown in a time-course experiment by the effect of    LD
L on green fluorescence protein-SCAP movement when cells were treated with    ph
armacological agents to induce a Niemann-Pick type C disease phenotype. We    de
monstrated directly by fluorescence microscopy that defective NPC1 causes    a d
elay in LDL cholesterol delivery to the endoplasmic reticulum where SCAP    sens
es cholesterol.      ^cY#6925.htm##
00463000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000500061708000300066704023900069002000900308#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6925.htm#S#p#14#10#text#13#<P>Key words: Niemann-Pick
 type C1 protein; Low-density lipoprotein cholesterol;    Fluorescence microscop
y; Sterol regulatory element binding protein complex;    Cholesterol homeostasis
  </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6925.htm##
00346000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000500061708000300066704012200069002000900191#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6925.htm#S#p#15#11#text#13#<P><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b><font size="4">Retraction</font></b></fo
nt></P>     ^cY#6925.htm##
00486000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000500061708000300066704026200069002000900331#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6925.htm#S#p#16#12#text#13#<p><a href="http://www.sci
elo.br/scielo.php?script=sci_arttext&pid=S0100-879X2008000500014&lng=en&nrm=iso&
tlng=en"><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Braz    J M
ed Biol Res, May 2008, Volume 41(5) 437 (Retraction)</font></a></p>     ^cY#6925
.htm##
00240000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000500061708000300066704001600069002000900085#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6925.htm#S#p#17#13#text#13#<p></p>     ^cY#6925.htm##
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#o#1#1#article#1#20
080623#161533#6926.htm#189##
03073000000000577000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000300104030002000107
03100030012703200020013006500090013201400090014103500100015022300090016001201230
01690100024002920100021003160100022003370100024003590700105003830831696004880850
00802184085003702192085004402229085002702273085002402300085002902324117000602353
07200030235905800520236211200090241411100130242311400090243611300170244588100240
2462002000902486#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#h#2#1#arti
cle#1#oa#en#bjmbr#1#3.1#ILUS#07#BJMBR040#nd#Braz J Med Biol Res#41#1#20080100#^f
41^l46#0100-879X#20071217#In vitro modulation of alkaline phosphatase activity o
f Saccharomyces cerevisiae grown in low or high phosphate medium^len#^rND^1A01^n
J^sFernandes#^rND^1A01^nR^sAmorim#^rND^1A01^nI^sAzevedo#^rND^1A01^nM.J^sMartins#
Universidade do Porto^iA01^1Faculdade de Medicina (U38-FCT)^2Departamento de Bio
química^cPorto^pPortugal#^len^aOur objective was to characterize the modulation 
of the activity of Saccharomyces cerevisiae alkaline phosphatases (ALPs) by clas
sic inhibitors of ALP activity, cholesterol and steroid hormones, in order to id
entify catalytic similarities between yeast and mammalian ALPs. S. cerevisiae ex
presses two ALPs, coded for by the PHO8 and PHO13 genes. The product of the PHO8
 gene is repressible by Pi in the medium. ALP activity from yeast (grown in low 
or high phosphate medium) homogenates was determined with p-nitrophenylphosphate
 as substrate, pH 10.4 (lPiALP or hPiALP, respectively). Activation of hPiALP wa
s observed with 5 mM L-amino acids (L-homoarginine _ 186%, L-leucine _ 155% and 
L-phenylalanine - 168%) and with 1 mM levamisole (122%; percentage values, in co
mparison to control, of recovered activity). EDTA (5 mM) and vanadate (1 mM) dis
tinctly inhibited hPiALP (2 and 20%, respectively). L-homoarginine (5 mM) had a 
lower activating effect on lPiALP (166%) and was the strongest hPiALP activator.
 Corticosterone (5 mM) inhibited hPiALP to 90%, but no effect was observed in lo
w phosphate medium. Cholesterol, ß-estradiol and progesterone also had different
 effects on lPiALP and hPiALP. A concentration-dependent activation of lPiALP mi
nus hPiALP was evident with all three compounds, most especially with ß-estradio
l and cholesterol. These results do not allow us to identify similarities of the
 behavior of S. cerevisiae ALPs and any of the mammalian ALPs but allow us to ra
ise the hypothesis of differential regulation of S. cerevisiae ALPs by L-homoarg
inine, ß-estradiol and cholesterol and of using these compounds to discriminate 
between S. cerevisiae lPiALP and hPiALP.#^dnd^i1#^tm^len^kSaccharomyces cerevisi
ae^i1#^tm^len^kAlkaline phosphatase inhibitors^i1#^tm^len^kPHO8 and PHO13^i1#^tm
^len^kCholesterol^i1#^tm^len^kSteroid hormones^i1#other#40#FCT (POCI, FEDER and 
Programa Comunitário de Apoio)#20070609#June 9, 2007#20071105#November 5, 2007#S
0100-879X2006005000198#6926.htm##
03135000000000565000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000300104030002000107
03100030012703200020013006500090013201400090014103500100015022300090016001201440
01690100024003130100021003370100022003580100024003800700105004040831752005090850
00802261085004402269085004402313085004102357085002402398085002902422117000602451
07200030245705800520246011200090251211100130252111400090253411300170254300200090
2560#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#f#3#1#article#1#oa#en#
bjmbr#1#3.1#ILUS#07#BJMBR040#nd#Braz J Med Biol Res#41#1#20080100#^f41^l46#0100-
879X#20071217#<B><I>In vitro</I> modulation of alkaline phosphatase activity of 
<I>Saccharomyces cerevisiae</I> grown in low or high phosphate medium</B>^len#^r
ND^1A01^nJ^sFernandes#^rND^1A01^nR^sAmorim#^rND^1A01^nI^sAzevedo#^rND^1A01^nM.J^
sMartins#Universidade do Porto^iA01^1Faculdade de Medicina (U38-FCT)^2Departamen
to de Bioquímica^cPorto^pPortugal#^len^aOur objective was to characterize the mo
dulation of the activity of <I>Saccharomyces cerevisiae</I> alkaline phosphatase
s (ALPs) by classic inhibitors of ALP activity, cholesterol and steroid hormones
, in order to identify catalytic similarities between yeast and mammalian ALPs. 
<I>S. cerevisiae</I> expresses two ALPs, coded for by the <I>PHO8</I> and <I>PHO
13</I> genes. The product of the <I>PHO8</I> gene is repressible by Pi in the me
dium. ALP activity from yeast (grown in low or high phosphate medium) homogenate
s was determined with p-nitrophenylphosphate as substrate, pH 10.4 (lPiALP or hP
iALP, respectively). Activation of hPiALP was observed with 5 mM L-amino acids (
L-homoarginine _ 186%, L-leucine _ 155% and L-phenylalanine - 168%) and with 1 m
M levamisole (122%; percentage values, in comparison to control, of recovered ac
tivity). EDTA (5 mM) and vanadate (1 mM) distinctly inhibited hPiALP (2 and 20%,
 respectively). L-homoarginine (5 mM) had a lower activating effect on lPiALP (1
66%) and was the strongest hPiALP activator. Corticosterone (5 mM) inhibited hPi
ALP to 90%, but no effect was observed in low phosphate medium. Cholesterol, ß-e
stradiol and progesterone also had different effects on lPiALP and hPiALP. A con
centration-dependent activation of lPiALP minus hPiALP was evident with all thre
e compounds, most especially with ß-estradiol and cholesterol. These results do 
not allow us to identify similarities of the behavior of <I>S. cerevisiae</I> AL
Ps and any of the mammalian ALPs but allow us to raise the hypothesis of differe
ntial regulation of <I>S. cerevisiae</I> ALPs by L-homoarginine, ß-estradiol and
 cholesterol and of using these compounds to discriminate between <I>S. cerevisi
ae</I> lPiALP and hPiALP.#^dnd^i1#^tm^len^k<I>Saccharomyces cerevisiae</I>^i1#^t
m^len^kAlkaline phosphatase inhibitors^i1#^tm^len^k<I>PHO8</I> and <I>PHO13</I>^
i1#^tm^len^kCholesterol^i1#^tm^len^kSteroid hormones^i1#other#40#FCT (POCI, FEDE
R and Programa Comunitário de Apoio)#20070609#June 9, 2007#20071105#November 5, 
2007#6926.htm##
03219000000000589000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000500100121000300105049000900108158000300117
03000240012003100030014403200020014706500090014901400090015803500100016722300090
01770120123001860100024003090100021003330100022003540100025003760700107004010831
74500508085000802253085003702261085004402298085002702342085002402369085002902393
11700060242207200030242805800520243111200090248311100130249211400090250511300170
2514002000902531008008902540#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#
S#l#4#1#article#1#^mJan.^a2008#oa#en#bjmbr#1#3.1#ilus#07#BJMBR040#nd#Braz. j. me
d. biol. res#41#1#20080100#^f41^l46#0100-879X#20071217#In vitro modulation of al
kaline phosphatase activity of Saccharomyces cerevisiae grown in low or high pho
sphate medium^len#^rND^1A01^nJ^sFernandes#^rND^1A01^nR^sAmorim#^rND^1A01^nI^sAze
vedo#^rND^1A01^nM. J^sMartins#^iA01^1Universidade do Porto^2Faculdade de Medicin
a (U38-FCT)^3Departamento de Bioquímica^cPorto^pPortugal#^len^aOur objective was
 to characterize the modulation of the activity of Saccharomyces cerevisiae alka
line phosphatases (ALPs) by classic inhibitors of ALP activity, cholesterol and 
steroid hormones, in order to identify catalytic similarities between yeast and 
mammalian ALPs. S. cerevisiae expresses two ALPs, coded for by the PHO8 and PHO1
3 genes. The product of the PHO8 gene is repressible by Pi in the medium. ALP ac
tivity from yeast (grown in low or high phosphate medium) homogenates was determ
ined with p-nitrophenylphosphate as substrate, pH 10.4 (lPiALP or hPiALP, respec
tively). Activation of hPiALP was observed with 5 mM L-amino acids (L-homoargini
ne _ 186 percent, L-leucine _ 155 percent and L-phenylalanine - 168 percent) and
 with 1 mM levamisole (122 percent; percentage values, in comparison to control,
 of recovered activity). EDTA (5 mM) and vanadate (1 mM) distinctly inhibited hP
iALP (2 and 20 percent, respectively). L-homoarginine (5 mM) had a lower activat
ing effect on lPiALP (166 percent) and was the strongest hPiALP activator. Corti
costerone (5 mM) inhibited hPiALP to 90 percent, but no effect was observed in l
ow phosphate medium. Cholesterol, ß-estradiol and progesterone also had differen
t effects on lPiALP and hPiALP. A concentration-dependent activation of lPiALP m
inus hPiALP was evident with all three compounds, most especially with ß-estradi
ol and cholesterol. These results do not allow us to identify similarities of th
e behavior of S. cerevisiae ALPs and any of the mammalian ALPs but allow us to r
aise the hypothesis of differential regulation of S. cerevisiae ALPs by L-homoar
ginine, ß-estradiol and cholesterol and of using these compounds to discriminate
 between S. cerevisiae lPiALP and hPiALP.#^dnd^i1#^tm^len^kSaccharomyces cerevis
iae^i1#^tm^len^kAlkaline phosphatase inhibitors^i1#^tm^len^kPHO8 and PHO13^i1#^t
m^len^kCholesterol^i1#^tm^len^kSteroid hormones^i1#other#40#FCT (POCI, FEDER and
 Programa Comunitário de Apoio)#20070609#June 9, 2007#20071105#November 5, 2007#
6926.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-
879X2008000100007##
00375000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704014900071002000900220#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#5#1#article#145#<P> <font face="Arial, H
elvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med    Biol Res, January 2008
, Volume 41(1) 41-46</B> </font></P>     ^cY#6926.htm##
00478000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704025200071002000900323#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#6#2#article#145#<P><font face="Arial, He
lvetica, sans-serif"><B><I><font size="5">In vitro</font></I><font size="5">    
modulation of alkaline phosphatase activity of <I>Saccharomyces cerevisiae</I>  
  grown in low or high phosphate medium</font></B> </font>      ^cY#6926.htm##
00594000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704036800071002000900439#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#7#3#article#145#<P><font face="Arial, He
lvetica, sans-serif">J. Fernandes, R. Amorim, I. Azevedo    and <b><a href="#Cor
respondence"><img src="/img/revistas/bjmbr/v41n1/recor.gif" width="15" height="1
4" border="0"></a></b>    <a href="mailto:mmartins@med.up.pt"><img src="/img/rev
istas/bjmbr/v41n1/email-ca.gif" width="14" height="11" border="0"></a>    M.J. M
artins </font>      ^cY#6926.htm##
00397000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704017100071002000900242#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#8#4#article#145#<P><font face="Arial, He
lvetica, sans-serif">Departamento de Bioqu&iacute;mica,    Faculdade de Medicina
 (U38-FCT), Universidade do Porto, Porto, Portugal</font>      ^cY#6926.htm##
00442000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704021600071002000900287#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#9#5#article#145#<P> <font face="Arial, H
elvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v41n1/do
wn.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12">    <stro
ng>Abstract</strong></A>    ^cY#6926.htm##
00440000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704021300072002000900285#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#10#6#article#145#<BR>   <A HREF="#Introd
uction"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPA
CE=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Introduction"><strong>Int
roduction</strong></A>    ^cY#6926.htm##
00440000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704021300072002000900285#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#11#7#article#145#<BR>   <A HREF="#Materi
al"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0
 HSPACE=0 width="12" height="12"></A>    <A HREF="#Material"><strong>Material an
d Methods</strong></A>    ^cY#6926.htm##
00425000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704019800072002000900270#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#12#8#article#145#<BR>   <A HREF="#Result
s"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0 width="12" height="12"></A>    <A HREF="#Results"><strong>Results</stro
ng></A>    ^cY#6926.htm##
00434000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704020700072002000900279#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#13#9#article#145#<BR>   <A HREF="#Discus
sion"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Discussion"><strong>Discuss
ion</strong></A>    ^cY#6926.htm##
00422000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704019400073002000900267#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#14#10#article#145#<BR>   <A HREF="#Refer
ences"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#References"><strong>Refere
nces    ^cY#6926.htm##
00463000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704023500073002000900308#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#15#11#article#145#<br>   </strong></A><A
 HREF="#Acknowledgments"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOT
TOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Acknowle
dgments"><strong>Acknowledgments</strong></A>    ^cY#6926.htm##
00474000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704024600073002000900319#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#16#12#article#145#<BR>   <A HREF="#Corre
spondence"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 V
SPACE=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Correspondence"><stron
g>Correspondence and Footnotes</strong></A>    </font>      ^cY#6926.htm##
00275000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704004700073002000900120#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#17#13#article#145#<P>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>     ^cY#6926.htm##
00519000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704029100073002000900364#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#18#14#article#145#<P> <font face="Arial,
 Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F>
<B>Abstract    </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1
/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></
A></FONT></font></P>     ^cY#6926.htm##
02120000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704189200073002000901965#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#19#15#article#145#<P><font face="Arial, 
Helvetica, sans-serif">Our objective was to characterize    the modulation of th
e activity of <I>Saccharomyces cerevisiae</I> alkaline phosphatases    (ALPs) by
 classic inhibitors of ALP activity, cholesterol and steroid hormones,    in ord
er to identify catalytic similarities between yeast and mammalian ALPs.    <I>S.
 cerevisiae</I> expresses two ALPs, coded for by the <I>PHO8</I> and <I>PHO13</I
>    genes. The product of the <I>PHO8</I> gene is repressible by Pi in the medi
um.    ALP activity from yeast (grown in low or high phosphate medium) homogenat
es    was determined with p-nitrophenylphosphate as substrate, pH 10.4 (lPiALP o
r    hPiALP, respectively). Activation of hPiALP was observed with 5 mM L-amino 
acids    (L-homoarginine _ 186%, L-leucine _ 155% and L-phenylalanine - 168%) an
d with    1 mM levamisole (122%; percentage values, in comparison to control, of
 recovered    activity). EDTA (5 mM) and vanadate (1 mM) distinctly inhibited hP
iALP (2 and    20%, respectively). L-homoarginine (5 mM) had a lower activating 
effect on lPiALP    (166%) and was the strongest hPiALP activator. Corticosteron
e (5 mM) inhibited    hPiALP to 90%, but no effect was observed in low phosphate
 medium. Cholesterol,    &szlig;-estradiol and progesterone also had different e
ffects on lPiALP and    hPiALP. A concentration-dependent activation of lPiALP m
inus hPiALP was evident    with all three compounds, most especially with &szlig
;-estradiol and cholesterol.    These results do not allow us to identify simila
rities of the behavior of <I>S.    cerevisiae</I> ALPs and any of the mammalian 
ALPs but allow us to raise the    hypothesis of differential regulation of <I>S.
 cerevisiae</I> ALPs by L-homoarginine,    &szlig;-estradiol and cholesterol and
 of using these compounds to discriminate    between <I>S. cerevisiae</I> lPiALP
 and hPiALP. </font>      ^cY#6926.htm##
00466000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704023800073002000900311#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#20#16#article#145#<P><font face="Arial, 
Helvetica, sans-serif">Key words: <I>Saccharomyces cerevisiae</I>;    Alkaline p
hosphatase inhibitors; <I>PHO8</I> and <I>PHO13</I>; Cholesterol;    Steroid hor
mones</font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6926.htm##
00573000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704034500073002000900418#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#21#17#article#145#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Introduction"></A><FONT color="#00007F" SIZE=4><
B>Introduction</B></FONT></font>    <font size="4" face="Arial, Helvetica, sans-
serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A></font></P>     ^
cY#6926.htm##
00881000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704065300073002000900726#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#22#18#article#145#<P><font face="Arial, 
Helvetica, sans-serif">Alkaline phosphatase (ALP; orthophosphoric-monoester    p
hosphohydrolase, alkaline optimum) represents a family of several isoenzymes    
and isoforms whose expression depends on the species being considered and on    
physiological/pathological conditions (1-3). ALP substrates (either natural    o
r artificial) possess a phosphate residue (Pi) in a terminal position. Pi releas
ed    from an ALP substrate molecule is either released into the reaction medium
 (ALP    functioning as phosphohydrolase) or transferred to an appropriate accep
tor (ALP    functioning as phosphotransferase) (1-8). </font>      ^cY#6926.htm#
#
00709000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704048100073002000900554#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#23#19#article#145#<P><font face="Arial, 
Helvetica, sans-serif">The extent of natural ALP substrates    and <I>in vivo</I
> specific ALP functions are still unknown. ALP participates,    along with othe
r enzymes, in Pi homeostasis (in a cyclic pathway of polyphosphate    synthesis 
and degradation), a process including phosphorous acquisition and    metabolic i
ntegration of Pi in <I>Saccharomyces cerevisiae</I>, and eutopic    or ectopic b
one mineralization in mammals (1-3,5-18). </font>      ^cY#6926.htm##
00561000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704033300073002000900406#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#24#20#article#145#<P><font face="Arial, 
Helvetica, sans-serif">ALP has also been associated with    various fundamental 
cellular processes (differentiation, proliferation and cellular    signaling, me
iosis, mitosis, apoptosis, cell migration, immunological defense,    and DNA syn
thesis regulation) in several species (1-3,12,15-17). </font>      ^cY#6926.htm#
#
01511000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704128300073002000901356#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#25#21#article#145#<P><font face="Arial, 
Helvetica, sans-serif">In <I>S. cerevisiae</I>, ALPs are    the product of two s
tructural genes: <I>PHO8</I> and <I>PHO13</I>, both located    on chromosome IV.
 PHO8 ALP (E.C. 3.1.3.1) is an Mg<SUP>2+</SUP>/Zn<SUP>2+</SUP>-dependent    dime
ric protein similar to an ALP found in <I>Escherichia coli</I> and in mammalian 
   cells, is very unspecific in terms of substrates and is located in the cell  
  vacuole. The product of the <I>PHO13</I> gene (E.C. 3.1.3.41) is a monomeric  
  protein, is highly specific for p-nitrophenylphosphate (p-NPP) and histidinylp
hosphate    (not attacking other substrates at a significant rate), and, like PH
O8 ALP,    is also highly dependent on Mg<SUP>2+</SUP>. The nonspecific enzyme i
s repressible    by Pi in the medium, whereas the specific ALP is synthesized co
nstitutively    regardless of the Pi concentration in the medium. The repressibl
e ALP, however,    shows a significant level of activity even under repressible 
conditions. It    has been reported that repressible ALP activity, due to transc
ription of the    <I>PHO8</I> gene, is two to three times higher in low than in 
high Pi medium    (5-7,11,19-22). Both <I>S. cerevisiae</I> ALPs have protein an
d/or peptide phosphatase    activity (5-7). </font>      ^cY#6926.htm##
00728000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704050000073002000900573#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#26#22#article#145#<P><font face="Arial, 
Helvetica, sans-serif">The four ALP isoenzyme activities    expressed in mammals
, i.e., tissue-nonspecific, intestinal, placental, or germ-cell    ALP, with dif
ferent distributions among species, can be distinguished by their    differentia
l inhibition by several compounds such as L-amino acids or levamisole.    Unlike
 mammalian ALPs, bacterial ALPs are not stereospecifically inhibited by    L-ami
no acids through a non-competitive mechanism (1-3,17,23-25). </font>      ^cY#69
26.htm##
01184000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704095600073002000901029#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#27#23#article#145#<P><font face="Arial, 
Helvetica, sans-serif">Since we found no data about the    modulation of <I>S. c
erevisiae</I> ALP activity, in the present study we characterized    the modulat
ion of <I>S. cerevisiae</I> ALP activity by L-amino acids, cholesterol    and st
eroid hormones. This characterization will show the putatively different    cata
lytic behavior of PHO8 and PHO13 ALPs and possibly permit inferences about    AL
P functions in yeast. Our group has a large experience in comparative modulation
    of mammalian ALPs and has carried out extensive research on ALP function (3,
13-17,26-28).    Additionally, by also examining the modulation of <I>S. cerevis
iae</I> ALP activity    by levamisole, EDTA and vanadate, we set out to identify
 catalytic similarities    between yeast and mammalian ALPs in order to find out
 if <I>S. cerevisiae</I>    ALPs could be used as a study model of mammalian ALP
s. </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6926.htm##
00577000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704034900073002000900422#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#28#24#article#145#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Material"></A><FONT color="#00007F" SIZE=4><B>Ma
terial    and Methods</B></FONT></font> <font size="4" face="Arial, Helvetica, s
ans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIG
N=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A></font></P>  
   ^cY#6926.htm##
00789000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704056100073002000900634#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#29#25#article#145#<P><font face="Arial, 
Helvetica, sans-serif">p-NPP (Sigma 104D, St. Louis, MO,    USA), p-nitrophenol 
(p-NPL; Sigma 104-8), bovine serum albumin (BSA) (A-4503),    L-amino acids, lev
amisole (L-9756), orthovanadate (S-6508), cholesterol (C-8667),    and steroid h
ormones were purchased from Sigma (Sigma Alcobendas, Madrid, Spain).    Yeast gr
owth medium was purchased from Difco&#153; (YM Broth - 271120, yeast    malt, Vo
igt Global Distribution Inc., Lawrence, KS, USA). All other reagents    were of 
the highest quality and purity available. </font>      ^cY#6926.htm##
00334000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704010600073002000900179#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#30#26#article#145#<P><font face="Arial, 
Helvetica, sans-serif"><B>Yeast and yeast growth conditions</B>    </font>      
^cY#6926.htm##
00875000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704064700073002000900720#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#31#27#article#145#<P><font face="Arial, 
Helvetica, sans-serif"><I>S. cerevisiae</I> strain 3507    (wild type) from the 
Portuguese Yeast Cell Culture (Gulbenkian Institute of    Science, Lisbon, Portu
gal) was kindly provided by ESBUC, College of Biotechnology,    Portuguese Catho
lic University, Porto, Portugal. The strain was grown in 250-mL    Schott flasks
 with 150 mL medium under slow rotary agitation at 30&#176;C on    yeast malt me
dium supplemented with K<SUB>2</SUB>HPO<SUB>4</SUB> at two different    final co
ncentrations: 3000 mg/L (high phosphate medium) and 30 mg/L (low phosphate    me
dium) (11); the flasks were covered with gauze. </font>      ^cY#6926.htm##
00322000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704009400073002000900167#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#32#28#article#145#<P><font face="Arial, 
Helvetica, sans-serif"><B>Yeast sample collection </B> </font>      ^cY#6926.htm
##
00666000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704043800073002000900511#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#33#29#article#145#<P><font face="Arial, 
Helvetica, sans-serif">Yeast samples were collected from    the exponential phas
e. Yeast cells were separated by centrifugation at 6000    <I>g</I> for 10 min a
t 4&#176;C and washed once with 5 mL phosphate-buffered    saline (PBS), pH 7.4,
 also at 6000 <I>g</I> for 10 min at 4&#176;C. Then, the    yeast pellet was res
uspended in 1 mL PBS and stored at -80&#176;C for no longer    than one month. <
/font>      ^cY#6926.htm##
00341000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704011300073002000900186#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#34#30#article#145#<P><font face="Arial, 
Helvetica, sans-serif"><B>Alkaline phosphatase activity    modulation</B> </font
>      ^cY#6926.htm##
02867000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704263900073002000902712#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#35#31#article#145#<P><font face="Arial, 
Helvetica, sans-serif">On the day of the experiment, yeast    samples were homog
enized with a Heidolph homogenizer in PBS + 0.5% Triton X-100    (4:1) (13,14,20
,22) in a final volume of 1.25 mL and kept on ice. The final    concentration of
 Triton X-100 in the ALP sample incubation medium was lower    than its critical
 micellar concentration. The reaction mixtures (final volume    of 500 &#181;L) 
contained 80 mM Tris, pH 10.4, 0.4 mM MgCl<SUB>2</SUB>, 20 &#181;L    yeast samp
le from high or low phosphate growth medium, 0.3760 mg of p-NPP and    50 &#181;
L of the compound solution to be tested. The enzymatic reaction was    started b
y adding the ALP substrate. Incubation took place at 37&#176;C for    15 min, wa
s stopped by the addition of 2 mL 20 mM NaOH (ice-cold) and then the    reaction
 mixture was placed on ice for 10 min. At the end of this period, a    centrifug
ation was performed at 10,000 <I>g</I> for 16 min at 20&#176;C. The    supernata
nt was collected and the p-NPL released by ALP activity from yeast    homogenate
s (grown in low or high phosphate medium, lPiALP or hPiALP, respectively),    in
 the presence or absence of the compounds to be tested, was quantified by    abs
orbance measurements at 410 nm (Spectronic Genesys 5, Milton Roy, Rochester,    
NY, USA). For both lPiALP and hPiALP there was linearity with incubation time   
 from 5 to 20 min. A p-NPL calibration curve was performed in order to calculate
    ALP activity. L-amino acids with Sigma numbers given within parentheses (1 a
nd    5 mM: L-phenylalanine (P-2126), L-leucine (L-8912), and L-homoarginine (H-
1007)),    EDTA (1 and 5 mM), vanadate (0.1 and 1 mM), and levamisole (0.1 and 1
 mM) were    dissolved in water. Cholesterol (C-8667), progesterone (P-0130), co
rticosterone    (C-2505), and &szlig;-estradiol (E-8875) (0.01-5 mM) were dissol
ved in ethanol.    Controls for drugs were run in the presence of a correspondin
g volume of solvent.    All assays for each compound at the different concentrat
ions tested were always    carried out using the same homogenate batch (either l
PiALP or hPiALP homogenates).    The effect of each compound tested against ALP 
activity was determined as a    percentage of the corresponding control ALP acti
vity (representing the recovered    activity). The buffer pH value used in the p
resent study was chosen to ensure    that only ALP activity would be measured si
nce the ALP molecules were not isolated    but their activity was measured in ye
ast homogenates. All assays were performed    in triplicate (differences between
 replicates were always lower than 5%). </font>      ^cY#6926.htm##
00319000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704009100073002000900164#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#36#32#article#145#<P><font face="Arial, 
Helvetica, sans-serif"><B>Protein determination</B> </font>      ^cY#6926.htm##
00516000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704028800073002000900361#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#37#33#article#145#<P><font face="Arial, 
Helvetica, sans-serif">Protein concentration was determined    as described by B
radford (29), with BSA as standard. For each yeast growth condition    (low or h
igh phosphate medium), the protein concentration of the homogenates    used was 
similar. </font>      ^cY#6926.htm##
00318000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704009000073002000900163#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#38#34#article#145#<P><font face="Arial, 
Helvetica, sans-serif"><B>Statistical analysis</B> </font>      ^cY#6926.htm##
00479000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704025100073002000900324#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#39#35#article#145#<P><font face="Arial, 
Helvetica, sans-serif">Data are reported as means &#177;    SD and the significa
nce of differences between means was assessed by the paired    or unpaired Stude
nt <I>t</I>-test. </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6926.htm##
00563000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704033500073002000900408#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#40#36#article#145#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Results"></A><FONT color="#00007F" SIZE=4><B>Res
ults</B></FONT></font>    <font size="4" face="Arial, Helvetica, sans-serif"><A 
HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIGN=BOTTOM BORDE
R=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A></font></P>     ^cY#6926.ht
m##
00500000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704027200073002000900345#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#41#37#article#145#<P><font face="Arial, 
Helvetica, sans-serif">ALP activity was about 30% lower    in yeast homogenates 
obtained from <I>S. cerevisiae</I> grown in high phosphate    medium than in yea
st homogenates grown in low phosphate medium (results not    shown). </font> </P
>     ^cY#6926.htm##
01006000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704077800073002000900851#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#42#38#article#145#<P><font face="Arial, 
Helvetica, sans-serif">L-homoarginine, L-leucine and L-phenylalanine    signific
antly activated hPiALP and lPiALP in a concentration-dependent manner    (<a hre
f="#Fig1">Figures 1</a> and <a href="#Fig2">2</a>). For each of the tested    co
ncentrations (hPiALP), the results obtained with each L-amino acid were signific
antly    different (P = 0.002-0.03), except for L-phenylalanine versus L-leucine
 (5 mM)    and L-homoarginine versus the other two L-amino acids (1 mM; statisti
cal results    not shown in <a href="#Fig1">Figure 1</a>). L-homoarginine (5 mM)
 had a significantly    lower activating effect on lPiALP than on hPiALP (statis
tical result not shown,    comparison of <a href="#Fig1">Figures 1</a> and <a hr
ef="#Fig2">2</a>). </font>      ^cY#6926.htm##
00851000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704062300073002000900696#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#43#39#article#145#<P><font face="Arial, 
Helvetica, sans-serif">hPiALP and lPiALP were significantly    inhibited by both
 EDTA and vanadate, although with different potencies when    comparing both com
pounds, and in an apparently concentration-independent way    for EDTA (<a href=
"#Fig1">Figures 1</a> and <a href="#Fig2">2</a>). These inhibitory    effects we
re significantly different in each growth condition (statistical results    not 
shown in <a href="#Fig1">Figures 1</a> and <a href="#Fig2">2</a>; P &lt;    0.00
5; low and high EDTA concentrations compared to low and high vanadate concentrat
ions,    respectively). </font>      ^cY#6926.htm##
00842000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704061400073002000900687#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#44#40#article#145#<P><font face="Arial, 
Helvetica, sans-serif">Levamisole (1 mM) significantly activated    hPiALP and l
PiALP (<a href="#Fig1">Figures 1</a> and <a href="#Fig2">2</a>).    Levamisole e
ffect was significantly different from that of the L-amino acids    in each grow
th condition (P &lt; 0.005; low and high levamisole concentrations    compared t
o low and high L-amino acid concentrations, respectively, except for    lPiALP i
n levamisole versus L-leucine at the lower concentrations, where P &lt;    0.05;
 statistical results not shown in <a href="#Fig1">Figures 1</a> and <a href="#Fi
g2">2</a>).    </font>      ^cY#6926.htm##
01944000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704171600073002000901789#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#45#41#article#145#<P><font face="Arial, 
Helvetica, sans-serif">Regarding the steroid compounds tested    (cholesterol, &
szlig;-estradiol, progesterone, and corticosterone), only 5 mM    corticosterone
 had an effect on hPiALP, i.e., significant inhibition (statistical    result no
t shown; P <font face="Symbol">&#163;</font> 0.005). This effect was    only sig
nificantly different from that of 5 mM progesterone (statistical result    not s
hown; P = 0.002). The inhibition by 5 mM corticosterone observed in high    phos
phate medium was not observed when yeast was grown in low phosphate medium    (r
esult not shown). Cholesterol, &szlig;-estradiol and progesterone had different 
   effects on lPiALP and hPiALP activities (statistical results not shown for lP
iALP    minus hPiALP: significantly different for 5 mM for the first two compoun
ds and    for 1 mM for the last one; P <font face="Symbol">&#163;</font> 0.05). 
Among    these three steroid compounds, &szlig;-estradiol presented the stronges
t concentration-dependent    activation of lPiALP minus hPiALP and closely follo
wed by cholesterol (results    not shown). Progesterone and corticosterone (1 mM
) had significantly different    (P = 0.007) effects on lPiALP (statistical resu
lt not shown) and the same tendency    was observed at 5 mM for the same hormone
s (P = 0.059). Progesterone (1 mM)    activated lPiALP (statistical result not s
hown, P &lt; 0.05).</font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2> <table width="100%
"  border="0">   <tr align="left" valign="top">      <td width="13%"><a href="/i
mg/revistas/bjmbr/v41n1/html/6926i01.htm"><img src="/img/revistas/bjmbr/v41n1/69
26i01peq.jpg" width="120" height="62" border="2"></a></td>     <td width="87%"> 
          ^cY#6926.htm##
01415000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704118700073002000901260#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#46#42#article#145#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig1"></a>Figure 1.          Effect of L-amino a
cids, EDTA, orthovanadate, and levamisole on alkaline          phosphatase (ALP)
 activity from Saccharomyces cerevisiae homogenates.          Yeast was grown in
 high phosphate medium (3000 mg Pi/L YM medium, N =          5). Data are report
ed as arithmetic means &#177; SD and as percentage          of the corresponding
 control activity (= 100% (173.3 &#177; 48.83 nmol          p-nitrophenol releas
ed min<SUP>-1</SUP> mL homogenate<SUP>-1</SUP>); first          column of each s
et of results), determined as described in Material and          Methods. Assays
 were performed in triplicate. Symbols at the top of the          columns indica
te comparison to the respective control of each compound.          Symbols at th
e top of the horizontal bars indicate the comparison of the          two concent
rations. Circles indicate P <font face="Symbol">&#163;</font>          0.005 and
 squares indicate P <font face="Symbol">&#163;</font> 0.05. Leu          = L-leu
cine; Phe = L-phenylalanine; hArg = L-homoarginine; Van = orthovanadate.        
  </font>     </td>   </tr> </table>     ^cY#6926.htm##
00645000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704041700073002000900490#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#47#43#article#145#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image    (42 K JPG file)]</f
ont></P> <HR ALIGN=LEFT WIDTH=100% SIZE=2> <table width="100%"  border="0">   <t
r align="left" valign="top">      <td width="13%"><a href="/img/revistas/bjmbr/v
41n1/html/6926i02.htm"><img src="/img/revistas/bjmbr/v41n1/6926i02peq.jpg" width
="120" height="63" border="2"></a></td>     <td width="87%">           ^cY#6926.
htm##
01462000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704123400073002000901307#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#48#44#article#145#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig2"></a>Figure 2.          </font><font face="
Arial, Helvetica, sans-serif">Effect of L-amino acids,          EDTA, orthovanad
ate, and levamisole on alkaline phosphatase (ALP) activity          from Sacchar
omyces cerevisiae homogenates. Yeast was grown in low phosphate          medium 
(30 mg Pi/L YM medium, N = 7). Data are reported as arithmetic          means &#
177; SD and as percentage of the corresponding control activity          (= 100%
 (235.8 &#177; 56.33 nmol p-nitrophenol released min<SUP>-1</SUP>          mL ho
mogenate<SUP>-1</SUP>); first column of each set of results), determined        
  as described in Material and Methods. Assays were performed in triplicate.    
      Symbols at the top of the columns indicate comparison to the respective   
       control of each compound. Symbols at the top of the horizontal bars indic
ate          the comparison of the two concentrations. Circles indicate P <font 
face="Symbol">&#163;</font>          0.005 and squares indicate P <font face="Sy
mbol">&#163;</font> 0.05. Leu          = L-leucine; Phe = L-phenylalanine; hArg 
= L-homoarginine; Van = orthovanadate.          </font>      </td>   </tr> </tab
le>     ^cY#6926.htm##
00347000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704011900073002000900192#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#49#45#article#145#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image    (42 K JPG file)]</f
ont></P>     ^cY#6926.htm##
00275000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704004700073002000900120#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#50#46#article#145#<P>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>     ^cY#6926.htm##
00523000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704029500073002000900368#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#51#47#article#145#<P> <font face="Arial,
 Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007
F><B>Discussion    </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v
41n1/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></
B></A></FONT></font></P>     ^cY#6926.htm##
00713000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704048500073002000900558#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#52#48#article#145#<P><font face="Arial, 
Helvetica, sans-serif">In the present study, the yeast <I>S.    cerevisiae</I> w
as grown either in a low or high phosphate medium (30 or 3000    mg/L) (11). We 
observed that these distinct growth conditions induced a 30%    difference in to
tal ALP activity in the corresponding <I>S. cerevisiae</I> homogenates.    This 
level of reduction of ALP activity induced by Pi concentration in the growth    
medium agrees with data from Refs. 11 and 21. </font>      ^cY#6926.htm##
01150000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704092200073002000900995#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#53#49#article#145#<P><font face="Arial, 
Helvetica, sans-serif">Mammalian ALPs can be differentially    inhibited by L-am
ino acids, levamisole and EDTA. L-phenylalanine and L-leucine    strongly inhibi
t intestinal, placental and germ cell ALPs (tissue-specific ALPs).    Germ cell 
ALP is more sensitive to inhibition by L-leucine and EDTA than placental    ALP.
 L-homoarginine strongly inhibits tissue-nonspecific ALP and levamisole    inhib
its placental and tissue-nonspecific isoenzymes. Levamisole, L-phenylalanine    
and L-homoarginine, which permit discrimination between tissue-nonspecific and  
  tissue-specific ALPs, have been used for the clinical quantitation and identif
ication    of ALP isoenzymes for almost a century (2,24,25,30). Vanadate is an A
LP inhibitor    (12,17,31). Corticosterone (5 mM) inhibits rat renal ALP, but no
t rat liver    ALP, and progesterone has no effect on rat renal or liver ALP (13
). </font>      ^cY#6926.htm##
01162000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704093400073002000901007#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#54#50#article#145#<P><font face="Arial, 
Helvetica, sans-serif">To our knowledge, none of the compounds    used in this s
tudy, with the exception of EDTA, have been tested before in ALPs    from <I>S. 
cerevisiae</I>; EDTA has been described to also inhibit <I>Serratia    marcescen
s</I> ALP (5,7,32). The assay conditions used in the present study    (ALP sampl
e/homogenate preparation, p-NPP concentration, buffer (type, concentration    an
d pH value) as well as magnesium concentration) were the same as those we    hav
e been using with mammalian ALP homogenate samples (3,13,14,26,27) in order    t
o permit comparison of the results. The concentration ranges for L-amino acids, 
   levamisole, EDTA, vanadate, progesterone, and corticosterone chosen to be tes
ted    upon <I>S. cerevisiae </I>ALPs in the present study are the same as those
 tested    on mammalian ALPs either in our laboratory or by other authors (7,12,
 16,24,25).    </font>      ^cY#6926.htm##
01465000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704123700073002000901310#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#55#51#article#145#<P><font face="Arial, 
Helvetica, sans-serif">For L-amino acids, instead of their    reported inhibitio
n, we observed activation of ALP activity in both <I>S. cerevisiae</I>    homoge
nates. L-homoarginine (5 mM) was both the strongest activator of hPiALP    and t
he better discriminator between lPiALP and hPiALP. EDTA and vanadate strongly   
 inhibited lPiALP and hPiALP, each compound with the same potency in both types 
   of ALP samples. ALP inhibition by EDTA was not a surprise since ALP needs zin
c    and magnesium to perform catalysis and EDTA was tested in a concentration r
ange    higher than the Mg<SUP>2+</SUP> concentration in the incubation medium. 
The    similar effect of levamisole on either lPiALP or hPiALP was different fro
m that    described for tissue-nonspecific ALP. Progesterone and corticosterone 
acted    on hPiALP as described by our group for mammalian (rat) tissue-nonspeci
fic ALP    (13). &szlig;-estradiol, progesterone and cholesterol acted similarly
 on hPiALP    and lPiALP minus hPiALP, i.e., they had no significant effect on t
he former    ALP activity and induced a concentration-dependent activation of th
e latter    ALP activity (most especially &szlig;-estradiol and cholesterol). </
font>      ^cY#6926.htm##
00928000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704070000073002000900773#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#56#52#article#145#<P><font face="Arial, 
Helvetica, sans-serif">Under special conditions regarding    substrate and magne
sium, human ALP activation by L-phenylalanine (in a concentration    range simil
ar to that used in the present study) has been reported (23). Human    ALPs show
 different susceptibilities to inactivation or activation by 0.01 mM_0.1    M ED
TA (30) and calf intestinal ALP is activated by low EDTA concentrations,    20-4
00 &#181;M, and irreversibly inhibited by higher concentrations, 1 mM and    abo
ve (31). Levamisole inhibition of rat liver ALP decreases with increasing    lev
amisole concentration (Martins MJ, unpublished results). </font>  <font face="Ar
ial, Helvetica, sans-serif">      ^cY#6926.htm##
00745000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704051700073002000900590#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#57#53#article#145#<P>S. cerevisiae is a 
genetically well-defined organism, easy to manipulate, that    grows very fast, 
its growth and cell division being easily controlled by incubation    conditions
 (33). Thus, S. cerevisiae ALP (either in living cells or in yeast    homogenate
s or extracts) would be most useful as a model to study the modulation    of mam
malian ALPs. Unfortunately our results did not identify similarities between    
the behavior of S. cerevisiae lPiALP or hPiALP and any of the four mammalian    
ALPs.      ^cY#6926.htm##
00434000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704020600073002000900279#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#58#54#article#145#<P>However, our result
s allow us to raise the hypothesis of differential regulation    of S. cerevisia
e ALPs by L-homoarginine, cholesterol and &szlig;-estradiol,    all found in yea
st metabolism.      ^cY#6926.htm##
01319000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704109100073002000901164#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#59#55#article#145#<P>In S. cerevisiae, &
szlig;-estradiol can be obtained from estrones present in    the incubation medi
um and dehydrogenated by an S. cerevisiae peroxisomal multifunctional    enzyme 
that is homologous to a mammalian protein. S. cerevisiae possesses a    high-aff
inity estrogen-binding protein (34-36). The effect of this steroid compound    o
n ALP should be further studied. Estrogen has been suggested to cause shortening
    of the unbudded period of S. cerevisiae old cells by stimulating energy meta
bolism    (37). The PHO8 gene of S. cerevisiae also codes for the yeast fructose
-2,6-bisphosphate    6-phosphatase (5,38). On the other hand, ALP activity has b
een associated with    proliferation and differentiation in several species (1-3
,12). A truncated form    of PHO8 ALP (lacking 62 amino acids from the N-terminu
s) obtained from a cell-free    extract of S. cerevisiae has the ability to conv
ert farnesyl diphosphate into    E,E-farnesol (8), suggesting, in association wi
th our results, that this enzyme    activity might be involved in cholesterol sy
nthesis regulation.      ^cY#6926.htm##
00420000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704019200073002000900265#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#60#56#article#145#<P>Modulation of S. ce
revisiae PHO8 ALP may allow regulation of intracellular    levels of nickel, sin
ce this enzyme is located in the vacuole where the metal    is accumulated (11).
      ^cY#6926.htm##
00668000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704044000073002000900513#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#61#57#article#145#<P>ALP may remove Pi r
esidues from membrane phosphoproteins and from nucleotides    such as ATP and AM
P and may most probably be involved in transmembrane transport    system regulat
ion by modifying the phosphorylation level of transporters or    of molecules th
at regulate them. Supporting this idea is the fact that ALP is    an ubiquitous 
enzyme from humans to Dictyostelium discoideum (1,15-17,20-22),    located in me
mbranes.      ^cY#6926.htm##
00571000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704034300073002000900416#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#62#58#article#145#<P>ALP is associated w
ith lipid intestinal transport in mammals, is involved in    the modulation of o
rganic cation transport in rat isolated hepatocytes, Caco-2    and RBE4 cells, a
s well as in insulin internalization in RBE4 cells (1-3,15-17,39,40).    It also
 seems to modulate taurocholate uptake in rat isolated hepatocytes (3).      ^cY
#6926.htm##
00623000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704039500073002000900468#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#63#59#article#145#<P>Although in the pre
sent study only the acute effects of ALP modulatory compounds    on S. cerevisia
e homogenates were investigated, the observed differential modulation    of S. c
erevisiae ALPs might be used to test the hypothesis of yeast transport    system
 regulation by ALP activity since both PHO8 and PHO13 ALPs dephosphorylate    ph
osphoproteins and/or phosphopeptides (5-7).      ^cY#6926.htm##
00750000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704052200073002000900595#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#64#60#article#145#<P>The present results
 regarding in vitro lPiALP and hPiALP modulation did not    allow the identifica
tion of similarities in the behavior of S. cerevisiae ALPs    and of any of the 
mammalian ALPs. However, they allow us to raise the hypothesis    of differentia
l regulation of S. cerevisiae ALPs by L-homoarginine, &szlig;-estradiol    and c
holesterol and, consequently, to propose the use of these compounds to    discri
minate between S. cerevisiae lPiALP and hPiALP.  </font>  <HR ALIGN=LEFT WIDTH=1
00% SIZE=2>     ^cY#6926.htm##
00569000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704034100073002000900414#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#65#61#article#145#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><B>
References</B></FONT></font>    <font size="4" face="Arial, Helvetica, sans-seri
f"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIGN=BOTTOM
 BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A></font></P>     ^cY#6
926.htm##
00453000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704021100075002000900286#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#66#62#article#145#1#<P><font
 face="Arial, Helvetica, sans-serif">1. Van Hoof V, De Broe ME. Interpretation  
  and clinical significance of alkaline phosphatase isoenzyme patterns. Crit Rev
    Clin Lab Sci 1994; 31: 197-293.    ^cY#6926.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#67#63#article#145# </font>      ^cY#6926
.htm##
00437000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704019500075002000900270#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#68#64#article#145#2#<P><font
 face="Arial, Helvetica, sans-serif">2. Millan JL, Fishman WH. Biology    of hum
an alkaline phosphatases with special reference to cancer. Crit Rev Clin    Lab 
Sci 1995; 32: 1-39.    ^cY#6926.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#69#65#article#145# </font>      ^cY#6926
.htm##
00574000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704033200075002000900407#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#70#66#article#145#3#<P><font
 face="Arial, Helvetica, sans-serif">3. Martins MJ. Fosf&aacute;tase alcalina   
 - actividades em diversas situa&ccedil;&otilde;es fisiol&oacute;gicas e patol&o
acute;gicas.    Rela&ccedil;&atilde;o com sistemas de transporte membranar. [Doc
toral thesis].    Porto: Biochemistry Department, University of Porto; 2001.    
^cY#6926.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#71#67#article#145# </font>      ^cY#6926
.htm##
00451000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704020900075002000900284#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#72#68#article#145#4#<P><font
 face="Arial, Helvetica, sans-serif">4. McComb RB, Bowers GN Jr. Study    of opt
imum buffer conditions for measuring alkaline phosphatase activity in    human s
erum. Clin Chem 1972; 18: 97-104.    ^cY#6926.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#73#69#article#145# </font>      ^cY#6926
.htm##
00497000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704025500075002000900330#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#74#70#article#145#5#<P><font
 face="Arial, Helvetica, sans-serif">5. Donella-Deana A, Ostojic S, Pinna    LA,
 Barbaric S. Specific dephosphorylation of phosphopeptides by the yeast alkaline
    phosphatase encoded by PHO8 gene. Biochim Biophys Acta 1993; 1177: 221-228. 
   ^cY#6926.htm##
00249000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704002100073002000900094#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#75#71#article#145#    </font>      ^cY#6
926.htm##
00482000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704024000075002000900315#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#76#72#article#145#6#<P><font
 face="Arial, Helvetica, sans-serif">6. Tuleva B, Vasileva-Tonkova E,    Galabov
a D. A specific alkaline phosphatase from Saccharomyces cerevisiae with    prote
in phosphatase activity. FEMS Microbiol Lett 1998; 161: 139-144.    ^cY#6926.htm
##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#77#73#article#145# </font>      ^cY#6926
.htm##
00515000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704027300075002000900348#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#78#74#article#145#7#<P><font
 face="Arial, Helvetica, sans-serif">7. Galabova D, Tuleva B, Vasileva-Tonkova  
  E, Christova N. Purification and properties of alkaline phosphatase with prote
in    phosphatase activity from Saccharomyces cerevisiae. Z Naturforsch [C] 2000
;    55: 588-593.    ^cY#6926.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#79#75#article#145# </font>      ^cY#6926
.htm##
00475000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704023300075002000900308#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#80#76#article#145#8#<P><font
 face="Arial, Helvetica, sans-serif">8. Song L. A soluble form of phosphatase   
 in Saccharomyces cerevisiae capable of converting farnesyl diphosphate into    
E,E-farnesol. Appl Biochem Biotechnol 2006; 128: 149-158.    ^cY#6926.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#81#77#article#145# </font>      ^cY#6926
.htm##
00484000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704024200075002000900317#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#82#78#article#145#9#<P><font
 face="Arial, Helvetica, sans-serif">9. Hui M, Tenenbaum HC. New face    of an o
ld enzyme: alkaline phosphatase may contribute to human tissue aging    by induc
ing tissue hardening and calcification. Anat Rec 1998; 253: 91-94.    ^cY#6926.h
tm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#83#79#article#145# </font>      ^cY#6926
.htm##
00634000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704039100076002000900467#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#84#80#article#145#10#<P><fon
t face="Arial, Helvetica, sans-serif">10. Hui M, Li SQ, Holmyard D, Cheng    P. 
Stable transfection of nonosteogenic cell lines with tissue nonspecific alkaline
    phosphatase enhances mineral deposition both in the presence and absence of 
   beta-glycerophosphate: possible role for alkaline phosphatase in pathological
    mineralization. Calcif Tissue Int 1997; 60: 467-472.    ^cY#6926.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#85#81#article#145# </font>      ^cY#6926
.htm##
00477000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704023400076002000900310#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#86#82#article#145#11#<P><fon
t face="Arial, Helvetica, sans-serif">11. Nishimura K, Yasumura K, Igarashi    K
, Harashima S, Kakinuma Y. Transcription of some PHO genes in Saccharomyces    c
erevisiae is regulated by spt7p. Yeast 1999; 15: 1711-1717.    ^cY#6926.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#87#83#article#145# </font>      ^cY#6926
.htm##
00532000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704028900076002000900365#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#88#84#article#145#12#<P><fon
t face="Arial, Helvetica, sans-serif">12. Scheibe RJ, Kuehl H, Krautwald    S, M
eissner JD, Mueller WH. Ecto-alkaline phosphatase activity identified at    phys
iological pH range on intact P19 and HL-60 cells is induced by retinoic    acid.
 J Cell Biochem 2000; 76: 420-436.    ^cY#6926.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#89#85#article#145# </font>      ^cY#6926
.htm##
00460000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704021700076002000900293#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#90#86#article#145#13#<P><fon
t face="Arial, Helvetica, sans-serif">13. Martins MJ, Negr&atilde;o MR,    Hipol
ito-Reis C. Alkaline phosphatase from rat liver and kidney is differentially    
modulated. Clin Biochem 2001; 34: 463-468.    ^cY#6926.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#91#87#article#145# </font>      ^cY#6926
.htm##
00514000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704027100076002000900347#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#92#88#article#145#14#<P><fon
t face="Arial, Helvetica, sans-serif">14. Martins MJ, Negr&atilde;o MR,    Hipol
ito-Reis C, Azevedo I. Physiologic concentrations of bile salts inhibit    rat h
epatic alkaline phosphatase but not the intestinal isoenzyme. Clin Biochem    20
00; 33: 611-617.    ^cY#6926.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#93#89#article#145# </font>      ^cY#6926
.htm##
00531000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704028800076002000900364#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#94#90#article#145#15#<P><fon
t face="Arial, Helvetica, sans-serif">15. Calhau C, Martel F, Hipolito-Reis    C
, Azevedo I. Modulation of uptake of organic cationic drugs in cultured human   
 colon adenocarcinoma Caco-2 cells by an ecto-alkaline phosphatase activity.    
J Cell Biochem 2002; 87: 408-416.    ^cY#6926.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#95#91#article#145# </font>      ^cY#6926
.htm##
00564000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704032100076002000900397#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#96#92#article#145#16#<P><fon
t face="Arial, Helvetica, sans-serif">16. Calhau C, Martel F, Soares-da-Silva   
 P, Hipolito-Reis C, Azevedo I. Regulation of [(3)H]MPP(+) transport by phosphor
ylation/dephosphorylation    pathways in RBE4 cells: role of ecto-alkaline phosp
hatase. Naunyn Schmiedebergs    Arch Pharmacol 2002; 365: 349-356.    ^cY#6926.h
tm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#97#93#article#145# </font>      ^cY#6926
.htm##
00543000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704030000076002000900376#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#98#94#article#145#17#<P><fon
t face="Arial, Helvetica, sans-serif">17. Calhau C, Martel F, Pinheiro-Silva    
S, Pinheiro H, Soares-da-Silva P, Hipolito-Reis C, et al. Modulation of insulin 
   transport in rat brain microvessel endothelial cells by an ecto-phosphatase  
  activity. J Cell Biochem 2002; 84: 389-400.    ^cY#6926.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704001800073002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#99#95#article#145# </font>      ^cY#6926
.htm##
00490000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704024600077002000900323#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#100#96#article#145#18#<P><fo
nt face="Arial, Helvetica, sans-serif">18. Ciancaglini P, Simao AM, Camolezi    
FL, Millan JL, Pizauro JM. Contribution of matrix vesicles and alkaline phosphat
ase    to ectopic bone formation. Braz J Med Biol Res 2006; 39: 603-610.    ^cY#
6926.htm##
00247000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070704001800074002000900092#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#101#97#article#145# </font>      ^cY#692
6.htm##
00477000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704023300077002000900310#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#102#98#article#145#19#<P><fo
nt face="Arial, Helvetica, sans-serif">19. Mitchell JK, Fonzi WA, Wilkerson    J
, Opheim DJ. A particulate form of alkaline phosphatase in the yeast, Saccharomy
ces    cerevisiae. Biochim Biophys Acta 1981; 657: 482-494.    ^cY#6926.htm##
00246000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070704001700074002000900091#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#103#99#article#145#</font>      ^cY#6926
.htm##
00460000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704021500078002000900293#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#104#100#article#145#20#<P><f
ont face="Arial, Helvetica, sans-serif">20. Klionsky DJ, Emr SD. Membrane    pro
tein sorting: biosynthesis, transport and processing of yeast vacuolar alkaline 
   phosphatase. EMBO J 1989; 8: 2241-2250.    ^cY#6926.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#105#101#article#145# </font>      ^cY#69
26.htm##
00498000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704025300078002000900331#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#106#102#article#145#21#<P><f
ont face="Arial, Helvetica, sans-serif">21. Hayashi N, Oshima Y. Specific    cis
-acting sequence for PHO8 expression interacts with PHO4 protein, a positive    
regulatory factor, in Saccharomyces cerevisiae. Mol Cell Biol 1991; 11: 785-794.
    ^cY#6926.htm##
00251000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002100075002000900096#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#107#103#article#145#    </font>      ^cY
#6926.htm##
00482000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704023700078002000900315#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#108#104#article#145#22#<P><f
ont face="Arial, Helvetica, sans-serif">22. Spasova D, Galabova D. Yeast    perm
eabilization as a tool for measurement of in situ enzyme activity: localization 
   of alkaline phosphatase. Z Naturforsch [C] 1998; 53: 347-351.    ^cY#6926.htm
##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#109#105#article#145# </font>      ^cY#69
26.htm##
00429000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704018400078002000900262#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#110#106#article#145#23#<P><f
ont face="Arial, Helvetica, sans-serif">23. Tan I, Moss DW. The estimation    of
 intestinal alkaline phosphatase in human blood serum. Clin Chim Acta 1969;    2
5: 117-125.    ^cY#6926.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#111#107#article#145# </font>      ^cY#69
26.htm##
00493000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704024800078002000900326#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#112#108#article#145#24#<P><f
ont face="Arial, Helvetica, sans-serif">24. Sakiyama T, Robinson JC, Chou    JY.
 Multiple forms of alkaline phosphatase in untreated and 5-bromo-2'-deoxyuridine
-treated    choriocarcinoma cells. Arch Biochem Biophys 1978; 191: 782-791.    ^
cY#6926.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#113#109#article#145# </font>      ^cY#69
26.htm##
00479000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704023400078002000900312#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#114#110#article#145#25#<P><f
ont face="Arial, Helvetica, sans-serif">25. Hummer C, Millan JL. Gly429 is    th
e major determinant of uncompetitive inhibition of human germ cell alkaline    p
hosphatase by L-leucine. Biochem J 1991; 274 (Part 1): 91-95.    ^cY#6926.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#115#111#article#145# </font>      ^cY#69
26.htm##
00477000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704023200078002000900310#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#116#112#article#145#26#<P><f
ont face="Arial, Helvetica, sans-serif">26. Mota A, Calhau C, Martel F, Martins 
   MJ. Modulation of rat heart alkaline phosphatase activity by drugs, hormones 
   and nutrients. FASEB J 2006; 20: A897 (Abstract 588.12).    ^cY#6926.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#117#113#article#145# </font>      ^cY#69
26.htm##
00471000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704022600078002000900304#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#118#114#article#145#27#<P><f
ont face="Arial, Helvetica, sans-serif">27. Negr&atilde;o MR, Mota A, Azevedo   
 I, Martins MJ. Statins and tissue mineralization: putative involvement of alkal
ine    phosphatase. Med Hypotheses 2006; 67: 524-528.    ^cY#6926.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#119#115#article#145# </font>      ^cY#69
26.htm##
00536000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704029100078002000900369#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#120#116#article#145#28#<P><f
ont face="Arial, Helvetica, sans-serif">28. Negr&atilde;o MR, Keating E,    Fari
a A, Azevedo I, Martins MJ. Acute effect of tea, wine, beer, and polyphenols    
on ecto-alkaline phosphatase activity in human vascular smooth muscle cells.    
J Agric Food Chem 2006; 54: 4982-4988.    ^cY#6926.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#121#117#article#145# </font>      ^cY#69
26.htm##
00485000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704024000078002000900318#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#122#118#article#145#29#<P><f
ont face="Arial, Helvetica, sans-serif">29. Bradford MM. A rapid and sensitive  
  method for the quantitation of microgram quantities of protein utilizing the  
  principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.    ^cY#6926.
htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#123#119#article#145# </font>      ^cY#69
26.htm##
00461000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704021600078002000900294#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#124#120#article#145#30#<P><f
ont face="Arial, Helvetica, sans-serif">30. Conyers RA, Birkett DJ, Neale    FC,
 Posen S, Brudenell-Woods J. The action of EDTA on human alkaline phosphatases. 
   Biochim Biophys Acta 1967; 139: 363-371.    ^cY#6926.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#125#121#article#145# </font>      ^cY#69
26.htm##
00492000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704024700078002000900325#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#126#122#article#145#31#<P><f
ont face="Arial, Helvetica, sans-serif">31. Whisnant AR, Gilman SD. Studies    o
f reversible inhibition, irreversible inhibition, and activation of alkaline    
phosphatase by capillary electrophoresis. Anal Biochem 2002; 307: 226-234.    ^c
Y#6926.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#127#123#article#145# </font>      ^cY#69
26.htm##
00436000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704019100078002000900269#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#128#124#article#145#32#<P><f
ont face="Arial, Helvetica, sans-serif">32. Bhatti AR. Some distinctive characte
ristics    of the alkaline phosphatase of Serratia marcescens. Can J Biochem 197
5; 53:    819-822.    ^cY#6926.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#129#125#article#145# </font>      ^cY#69
26.htm##
00424000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704017900078002000900257#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#130#126#article#145#33#<P><f
ont face="Arial, Helvetica, sans-serif">33. Mager WH, Winderickx J. Yeast    as 
a model for medical and medicinal research. Trends Pharmacol Sci 2005; 26:    26
5-273.    ^cY#6926.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#131#127#article#145# </font>      ^cY#69
26.htm##
00509000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704026400078002000900342#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#132#128#article#145#34#<P><f
ont face="Arial, Helvetica, sans-serif">34. Feldman D, Tokes LG, Stathis    PA, 
Miller SC, Kurz W, Harvey D. Identification of 17 beta-estradiol as the    estro
genic substance in Saccharomyces cerevisiae. Proc Natl Acad Sci USA 1984;    81:
 4722-4726.    ^cY#6926.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#133#129#article#145# </font>      ^cY#69
26.htm##
00526000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704028100078002000900359#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#134#130#article#145#35#<P><f
ont face="Arial, Helvetica, sans-serif">35. Miller SC, Bottema CD, Stathis    PA
, Tokes LG, Feldman D. Unexpected presence of estrogens in culture medium    sup
plements: subsequent metabolism by the yeast Sacchromyces cerevisiae. Endocrinol
ogy    1986; 119: 1362-1369.    ^cY#6926.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#135#131#article#145# </font>      ^cY#69
26.htm##
00569000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704032400078002000900402#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#136#132#article#145#36#<P><f
ont face="Arial, Helvetica, sans-serif">36. Qin YM, Poutanen MH, Novikov    DK. 
Substrate specificities of peroxisomal members of short-chain alcohol dehydrogen
ase    superfamily: expression and characterization of dehydrogenase part of Can
dida    tropicalis multifunctional enzyme. J Lipid Res 2000; 41: 93-98.    ^cY#6
926.htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#137#133#article#145# </font>      ^cY#69
26.htm##
00482000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704023700078002000900315#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#138#134#article#145#37#<P><f
ont face="Arial, Helvetica, sans-serif">37. Motizuki M, Tsurugi K. Effect    of 
17 beta-estradiol on the generation time of old cells of the yeast Saccharomyces
    cerevisiae. Biochem Biophys Res Commun 1992; 183: 1191-1196.    ^cY#6926.htm
##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#139#135#article#145# </font>      ^cY#69
26.htm##
00498000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704025300078002000900331#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#140#136#article#145#38#<P><f
ont face="Arial, Helvetica, sans-serif">38. Plankert U, Purwin C, Holzer    H. Y
east fructose-2,6-bisphosphate 6-phosphatase is encoded by PHO8, the gene    for
 nonspecific repressible alkaline phosphatase. Eur J Biochem 1991; 196: 191-196.
    ^cY#6926.htm##
00251000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002100075002000900096#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#141#137#article#145#    </font>      ^cY
#6926.htm##
00485000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704024000078002000900318#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#142#138#article#145#39#<P><f
ont face="Arial, Helvetica, sans-serif">39. Narisawa S, Huang L, Iwasaki    A, H
asegawa H, Alpers DH, Millan JL. Accelerated fat absorption in intestinal    alk
aline phosphatase knockout mice. Mol Cell Biol 2003; 23: 7525-7530.    ^cY#6926.
htm##
00248000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704001800075002000900093#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#143#139#article#145# </font>      ^cY#69
26.htm##
00505000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704026000078002000900338#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#p#144#140#article#145#40#<P><f
ont face="Arial, Helvetica, sans-serif">40. Malo MS, Mozumder M, Zhang XB,    Bi
swas S, Chen A, Bai LC, et al. Intestinal alkaline phosphatase gene expression  
  is activated by ZBP-89. Am J Physiol Gastrointest Liver Physiol 2006; 290: G73
7-G746.    ^cY#6926.htm##
00285000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704005500075002000900130#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#145#141#article#145#    </font>  <HR ALI
GN=LEFT WIDTH=100% SIZE=2>     ^cY#6926.htm##
00590000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704036000075002000900435#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#146#142#article#145#<P><font face="Arial
, Helvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT color="#00007F" SIZ
E=4><B>Acknowledgments</B></FONT></font>    <font size="4" face="Arial, Helvetic
a, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" 
ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0" width="12" height="12"></B></A>
</font></P>     ^cY#6926.htm##
00711000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704048100075002000900556#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#147#143#article#145#<P><font face="Arial
, Helvetica, sans-serif">We would like to thank Dr. Jos&eacute;    Ant&oacute;ni
o Couto, ESBUC, College of Biotechnology, Portuguese Catholic University,    Por
to, Portugal, for kindly providing the Saccharomyces cerevisiae strain 3507    f
rom the Portuguese Yeast Cell Culture, Gulbenkian Institute of Science, Lisbon, 
   Portugal. We also thank Professor Rui Fontes for carefully reading this manus
cript.    </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6926.htm##
00591000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704036100075002000900436#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#148#144#article#145#<P><FONT SIZE=4 face
="Arial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F
><B>Correspondence    and Footnotes</B></FONT></FONT> <font size="4" face="Arial
, Helvetica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/
back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></B></A
></font></P>     ^cY#6926.htm##
01311000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704108100075002000901156#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6926.htm#S#p#149#145#article#145#<p><font face="Arial
, Helvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v41n1/
recor.gif" width="15" height="14" border="0"></a>    Address for correspondence:
</b> M.J. Martins, Departamento de Bioqu&iacute;mica,    Faculdade de Medicina (
U38-FCT), Universidade do Porto, Alameda Prof. Hern&acirc;ni    Monteiro, 4200-3
19 Porto, Portugal. Fax: +351-22-551-3624. E-mail: <a href="mailto:mmartins@med.
up.pt">mmartins@med.up.pt</a></font>  </p> <HR ALIGN=LEFT WIDTH=100% SIZE=2> <fo
nt face="Arial, Helvetica, sans-serif">A preliminary report of this manuscript  
was presented in abstract form at the Experimental Biology Meeting, San Francisc
o,  CA, USA, April 1-5, 2006. [Caldeira J, Amorim R, Azevedo I, Martins MJ. Modu
lation  of alkaline phosphatases from Saccharomyces cerevisiae. Faseb J 2006; 20
: A51  (Abstract 76.2)]. </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2> <font face="
Arial, Helvetica, sans-serif">Research supported by FCT (POCI, FEDER  and Progra
ma Comunit&aacute;rio de Apoio). Received June 9, 2007. Accepted November  5, 20
07. </font>      ^cY#6926.htm##
00573000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100018000920120
08800110030002200198065000900220064000500229031000300234014000800237865000900245
002000900254035001000263801002200273#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
926.htm#S#c#150#1#article#40#1#^rND^sVan^nHoof V#^rND^sDe^nBroe ME#Interpretatio
n and clinical significance of alkaline phosphatase isoenzyme patterns^len#Crit 
Rev Clin Lab Sci#19940000#1994#31#197-293#20080100#6926.htm#1040-8363#Crit Rev C
lin Lab Sci##
00557000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740100018000910120
07600109030002200185065000900207064000500216031000300221014000500224865000900229
002000900238035001000247801002200257#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
926.htm#S#c#151#2#article#40#2#^rND^sMillan^nJL#^rND^sFishman^nWH#Biology of hum
an alkaline phosphatases with special reference to cancer^len#Crit Rev Clin Lab 
Sci#19950000#1995#32#1-39#20080100#6926.htm#1040-8363#Crit Rev Clin Lab Sci##
00565000000000241000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720160018000740180132000920510
01600224046000600240050004500246045000900291044000500300865000900305002000900314
#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#c#152#3#article#40#3#^rND^
sMartins^nMJ#Fosfátase alcalina - actividades em diversas situações fisiológicas
 e patológicas: Relação com sistemas de transporte membranar^lpt#Doctoral thesis
#Porto#University of Porto^dBiochemistry Department#20010000#2001#20080100#6926.
htm##
00559000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740100020000910120
09800111030001000209065000900219064000500228031000300233014000700236865000900243
002000900252035001000261801001000271#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
926.htm#S#c#153#4#article#40#4#^rND^sMcComb^nRB#^rND^sBowers^nGN Jr#Study of opt
imum buffer conditions for measuring alkaline phosphatase activity in human seru
m^lpt#Clin Chem#19720000#1972#18#97-104#20080100#6926.htm#0009-9147#Clin Chem##
00652000000000301000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100023000740100017000970100
01600114010001800130012010500148030002100253065000900274064000500283031000500288
014000800293865000900301002000900310035001000319801002100329#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6926.htm#S#c#154#5#article#40#5#^rND^sDonella-Deana^nA#^r
ND^sOstojic^nS#^rND^sPinna^nLA#^rND^sBarbaric^nS#Specific dephosphorylation of p
hosphopeptides by the yeast alkaline phosphatase encoded by PHO8 gene^len#Biochi
m Biophys Acta#19930000#1993#1177#221-228#20080100#6926.htm#0006-3002#Biochim Bi
ophys Acta##
00618000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100016000740100026000900100
01800116012010000134030002000234065000900254064000500263031000400268014000800272
865000900280002000900289035001000298801002000308#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6926.htm#S#c#155#6#article#40#6#^rND^sTuleva^nB#^rND^sVasileva-Tonkov
a^nE#^rND^sGalabova^nD#A specific alkaline phosphatase from Saccharomyces cerevi
siae with protein phosphatase activity^len#FEMS Microbiol Lett#19980000#1998#161
#139-144#20080100#6926.htm#0378-1097#FEMS Microbiol Lett##
00664000000000301000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100016000920100
02600108010001900134012012000153030001800273065000900291064000500300031000300305
014000800308865000900316002000900325035001000334801001800344#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6926.htm#S#c#156#7#article#40#7#^rND^sGalabova^nD#^rND^sT
uleva^nB#^rND^sVasileva-Tonkova^nE#^rND^sChristova^nN#Purification and propertie
s of alkaline phosphatase with protein phosphatase activity from Saccharomyces c
erevisiae^len#Z Naturforsch [C]#20000000#2000#55#588-593#20080100#6926.htm#0341-
0382#Z Naturforsch [C]##
00579000000000265000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100014000740120123000880300
02400211065000900235064000500244031000400249014000800253865000900261002000900270
035001000279801002400289#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#c#
157#8#article#40#8#^rND^sSong^nL#A soluble form of phosphatase in Saccharomyces 
cerevisiae capable of converting farnesyl diphosphate into E,E-farnesol^len#Appl
 Biochem Biotechnol#20060000#2006#128#149-158#20080100#6926.htm#0273-2289#Appl B
iochem Biotechnol##
00591000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100013000740100020000870120
13600107030000900243065000900252064000500261031000400266014000600270865000900276
002000900285035001000294801000900304#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
926.htm#S#c#158#9#article#40#9#^rND^sHui^nM#^rND^sTenenbaum^nHC#New face of an o
ld enzyme: alkaline phosphatase may contribute to human tissue aging by inducing
 tissue hardening and calcification^len#Anat Rec#19980000#1998#253#91-94#2008010
0#6926.htm#0003-276X#Anat Rec##
00780000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100013000760100013000890100
01800102010001500120012025400135030001800389065000900407064000500416031000300421
014000800424865000900432002000900441035001000450801001800460#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6926.htm#S#c#159#10#article#40#10#^rND^sHui^nM#^rND^sLi^n
SQ#^rND^sHolmyard^nD#^rND^sCheng^nP#Stable transfection of nonosteogenic cell li
nes with tissue nonspecific alkaline phosphatase enhances mineral deposition bot
h in the presence and absence of beta-glycerophosphate: possible role for alkali
ne phosphatase in pathological mineralization^len#Calcif Tissue Int#19970000#199
7#60#467-472#20080100#6926.htm#0171-967X#Calcif Tissue Int##
00635000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100018000950100
01800113010001900131010001800150012008600168030000600254065000900260064000500269
031000300274014001000277865000900287002000900296035001000305801000600315#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#c#160#11#article#40#11#^rND^sNishi
mura^nK#^rND^sYasumura^nK#^rND^sIgarashi^nK#^rND^sHarashima^nS#^rND^sKakinuma^nY
#Transcription of some PHO genes in Saccharomyces cerevisiae is regulated by spt
7p^len#Yeast#19990000#1999#15#1711-1717#20080100#6926.htm#0749-503X#Yeast##
00696000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100015000940100
01900109010001900128010001800147012013400165030001500299065000900314064000500323
031000300328014000800331865000900339002000900348035001000357801001500367#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#c#161#12#article#40#12#^rND^sSchei
be^nRJ#^rND^sKuehl^nH#^rND^sKrautwald^nS#^rND^sMeissner^nJD#^rND^sMueller^nWH#Ec
to-alkaline phosphatase activity identified at physiological pH range on intact 
P19 and HL-60 cells is induced by retinoic acid^len#J Cell Biochem#20000000#2000
#76#420-436#20080100#6926.htm#0730-2312#J Cell Biochem##
00582000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940100
02300111012007900134030001300213065000900226064000500235031000300240014000800243
865000900251002000900260035001000269801001300279#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6926.htm#S#c#162#13#article#40#13#^rND^sMartins^nMJ#^rND^sNegrão^nMR#
^rND^sHipolito-Reis^nC#Alkaline phosphatase from rat liver and kidney is differe
ntially modulated^len#Clin Biochem#20010000#2001#34#463-468#20080100#6926.htm#00
09-9120#Clin Biochem##
00651000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940100
02300111010001700134012011900151030001300270065000900283064000500292031000300297
014000800300865000900308002000900317035001000326801001300336#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6926.htm#S#c#163#14#article#40#14#^rND^sMartins^nMJ#^rND^
sNegrão^nMR#^rND^sHipolito-Reis^nC#^rND^sAzevedo^nI#Physiologic concentrations o
f bile salts inhibit rat hepatic alkaline phosphatase but not the intestinal iso
enzyme^len#Clin Biochem#20000000#2000#33#611-617#20080100#6926.htm#0009-9120#Cli
n Biochem##
00677000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100016000920100
02300108010001700131012014400148030001500292065000900307064000500316031000300321
014000800324865000900332002000900341035001000350801001500360#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6926.htm#S#c#164#15#article#40#15#^rND^sCalhau^nC#^rND^sM
artel^nF#^rND^sHipolito-Reis^nC#^rND^sAzevedo^nI#Modulation of uptake of organic
 cationic drugs in cultured human colon adenocarcinoma Caco-2 cells by an ecto-a
lkaline phosphatase activity^len#J Cell Biochem#20020000#2002#87#408-416#2008010
0#6926.htm#0730-2312#J Cell Biochem##
00749000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100016000920100
02500108010002300133010001700156012013600173030003600309065000900345064000500354
031000400359014000800363865000900371002000900380035001000389801003600399#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#c#165#16#article#40#16#^rND^sCalha
u^nC#^rND^sMartel^nF#^rND^sSoares-da-Silva^nP#^rND^sHipolito-Reis^nC#^rND^sAzeve
do^nI#Regulation of [(3)H]MPP(+) transport by phosphorylation/dephosphorylation 
pathways in RBE4 cells: role of ecto-alkaline phosphatase^len#Naunyn Schmiedeber
gs Arch Pharmacol#20020000#2002#365#349-356#20080100#6926.htm#0028-1298#Naunyn S
chmiedebergs Arch Pharmacol##
00736000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100016000920100
02400108010001800132010002500150010002300175810000600198012011100204030001500315
06500090033006400050033903100030034401400080034786500090035500200090036403500100
0373801001500383#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#c#166#17#a
rticle#40#17#^rND^sCalhau^nC#^rND^sMartel^nF#^rND^sPinheiro-Silva^nS#^rND^sPinhe
iro^nH#^rND^sSoares-da-Silva^nP#^rND^sHipolito-Reis^nC#et al#Modulation of insul
in transport in rat brain microvessel endothelial cells by an ecto-phosphatase a
ctivity^len#J Cell Biochem#20020000#2002#84#389-400#20080100#6926.htm#0730-2312#
J Cell Biochem##
00661000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100021000760100016000970100
01900113010001700132010001800149012008700167030002000254065000900274064000500283
031000300288014000800291865000900299002000900308035001000317801002000327#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#c#167#18#article#40#18#^rND^sCianc
aglini^nP#^rND^sSimao^nAM#^rND^sCamolezi^nFL#^rND^sMillan^nJL#^rND^sPizauro^nJM#
Contribution of matrix vesicles and alkaline phosphatase to ectopic bone formati
on^len#Braz J Med Biol Res#20060000#2006#39#603-610#20080100#6926.htm#0100-879X#
Braz J Med Biol Res##
00631000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100016000950100
01900111010001700130012008600147030002100233065000900254064000500263031000400268
014000800272865000900280002000900289035001000298801002100308#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6926.htm#S#c#168#19#article#40#19#^rND^sMitchell^nJK#^rND
^sFonzi^nWA#^rND^sWilkerson^nJ#^rND^sOpheim^nDJ#A particulate form of alkaline p
hosphatase in the yeast, Saccharomyces cerevisiae^len#Biochim Biophys Acta#19810
000#1981#657#482-494#20080100#6926.htm#0006-3002#Biochim Biophys Acta##
00563000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100014000950120
10800109030000700217065000900224064000500233031000200238014001000240865000900250
002000900259035001000268801000700278#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
926.htm#S#c#169#20#article#40#20#^rND^sKlionsky^nDJ#^rND^sEmr^nSD#Membrane prote
in sorting: biosynthesis, transport and processing of yeast vacuolar alkaline ph
osphatase^len#EMBO J#19890000#1989#8#2241-2250#20080100#6926.htm#0261-4189#Embo 
J##
00608000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930120
14000109030001400249065000900263064000500272031000300277014000800280865000900288
002000900297035001000306801001400316#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
926.htm#S#c#170#21#article#40#21#^rND^sHayashi^nN#^rND^sOshima^nY#Specific cis-a
cting sequence for PHO8 expression interacts with PHO4 protein, a positive regul
atory factor, in Saccharomyces cerevisiae^len#Mol Cell Biol#19910000#1991#11#785
-794#20080100#6926.htm#0270-7306#Mol Cell Biol##
00596000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100018000930120
11800111030001800229065000900247064000500256031000300261014000800264865000900272
002000900281035001000290801001800300#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
926.htm#S#c#171#22#article#40#22#^rND^sSpasova^nD#^rND^sGalabova^nD#Yeast permea
bilization as a tool for measurement of in situ enzyme activity: localization of
 alkaline phosphatase^len#Z Naturforsch [C]#19980000#1998#53#347-351#20080100#69
26.htm#0341-0382#Z Naturforsch [C]##
00540000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100013000760100015000890120
07500104030001500179065000900194064000500203031000300208014000800211865000900219
002000900228035001000237801001500247#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
926.htm#S#c#172#23#article#40#23#^rND^sTan^nI#^rND^sMoss^nDW#The estimation of i
ntestinal alkaline phosphatase in human blood serum^len#Clin Chim Acta#19690000#
1969#25#117-125#20080100#6926.htm#0009-8981#Clin Chim Acta##
00628000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100019000940100
01500113012011400128030002100242065000900263064000500272031000400277014000800281
865000900289002000900298035001000307801002100317#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6926.htm#S#c#173#24#article#40#24#^rND^sSakiyama^nT#^rND^sRobinson^nJ
C#^rND^sChou^nJY#Multiple forms of alkaline phosphatase in untreated and 5-bromo
-2'-deoxyuridine-treated choriocarcinoma cells^len#Arch Biochem Biophys#19780000
#1978#191#782-791#20080100#6926.htm#0003-9861#Arch Biochem Biophys##
00576000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100017000920120
11700109030001000226065000900236064000500245031000400250014000600254865000900260
002000900269035001000278801001000288#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
926.htm#S#c#174#25#article#40#25#^rND^sHummer^nC#^rND^sMillan^nJL#Gly429 is the 
major determinant of uncompetitive inhibition of human germ cell alkaline phosph
atase by L-leucine^len#Biochem J#19910000#1991#274#91-95#20080100#6926.htm#0264-
6021#Biochem J##
00629000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100016000900100
01600106010001800122012009100140030000800231065000900239064000500248031000300253
014000500256061001800261865000900279002000900288035001000297801000800307#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#c#175#26#article#40#26#^rND^sMota^
nA#^rND^sCalhau^nC#^rND^sMartel^nF#^rND^sMartins^nMJ#Modulation of rat heart alk
aline phosphatase activity by drugs, hormones and nutrients^len#FASEB J#20060000
#2006#20#A897#(Abstract 588.12)#20080100#6926.htm#0892-6638#FASEB j##
00611000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100014000930100
01700107010001800124012008400142030001500226065000900241064000500250031000300255
014000800258865000900266002000900275035001000284801001500294#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6926.htm#S#c#176#27#article#40#27#^rND^sNegrão^nMR#^rND^s
Mota^nA#^rND^sAzevedo^nI#^rND^sMartins^nMJ#Statins and tissue mineralization: pu
tative involvement of alkaline phosphatase^len#Med Hypotheses#20060000#2006#67#5
24-528#20080100#6926.htm#0306-9877#Med Hypotheses##
00694000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100017000930100
01500110010001700125010001800142012012900160030001800289065000900307064000500316
031000300321014001000324865000900334002000900343035001000352801001800362#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#c#177#28#article#40#28#^rND^sNegrã
o^nMR#^rND^sKeating^nE#^rND^sFaria^nA#^rND^sAzevedo^nI#^rND^sMartins^nMJ#Acute e
ffect of tea, wine, beer, and polyphenols on ecto-alkaline phosphatase activity 
in human vascular smooth muscle cells^len#J Agric Food Chem#20060000#2006#54#498
2-4988#20080100#6926.htm#0021-8561#J Agric Food Chem##
00576000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760120136000950300
01300231065000900244064000500253031000300258014000800261865000900269002000900278
035001000287801001300297#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#c#
178#29#article#40#29#^rND^sBradford^nMM#A rapid and sensitive method for the qua
ntitation of microgram quantities of protein utilizing the principle of protein-
dye binding^len#Anal Biochem#19760000#1976#72#248-254#20080100#6926.htm#0003-269
7#Anal Biochem##
00632000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100018000940100
01600112010001500128010002500143012005400168030002100222065000900243064000500252
031000400257014000800261865000900269002000900278035001000287801002100297#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#c#179#30#article#40#30#^rND^sConye
rs^nRA#^rND^sBirkett^nDJ#^rND^sNeale^nFC#^rND^sPosen^nS#^rND^sBrudenell-Woods^nJ
#The action of EDTA on human alkaline phosphatases^len#Biochim Biophys Acta#1967
0000#1967#139#363-371#20080100#6926.htm#0006-3002#Biochim Biophys Acta##
00601000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100017000950120
13100112030001300243065000900256064000500265031000400270014000800274865000900282
002000900291035001000300801001300310#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
926.htm#S#c#180#31#article#40#31#^rND^sWhisnant^nAR#^rND^sGilman^nSD#Studies of 
reversible inhibition, irreversible inhibition, and activation of alkaline phosp
hatase by capillary electrophoresis^len#Anal Biochem#20020000#2002#307#226-234#2
0080100#6926.htm#0003-2697#Anal Biochem##
00528000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760120088000930300
01400181065000900195064000500204031000300209014000800212865000900220002000900229
035001000238801001400248#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#c#
181#32#article#40#32#^rND^sBhatti^nAR#Some distinctive characteristics of the al
kaline phosphatase of Serratia marcescens^len#Can J Biochem#19750000#1975#53#819
-822#20080100#6926.htm#0008-4018#Can J Biochem##
00541000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100020000920120
05600112030002100168065000900189064000500198031000300203014000800206865000900214
002000900223035001000232801002100242#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
926.htm#S#c#182#33#article#40#33#^rND^sMager^nWH#^rND^sWinderickx^nJ#Yeast as a 
model for medical and medicinal research^len#Trends Pharmacol Sci#20050000#2005#
26#265-273#20080100#6926.htm#0165-6147#Trends Pharmacol Sci##
00697000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930100
01800109010001700127010001400144010001600158012009600174030002300270065000900293
06400050030203100030030701400100031086500090032000200090032903500100033880100230
0348#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#c#183#34#article#40#34
#^rND^sFeldman^nD#^rND^sTokes^nLG#^rND^sStathis^nPA#^rND^sMiller^nSC#^rND^sKurz^
nW#^rND^sHarvey^nD#Identification of 17 beta-estradiol as the estrogenic substan
ce in Saccharomyces cerevisiae^len#Proc Natl Acad Sci USA#19840000#1984#81#4722-
4726#20080100#6926.htm#0027-8424#Proc Natl Acad Sci USA##
00687000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100018000930100
01800111010001600129010001700145012012700162030001400289065000900303064000500312
031000400317014001000321865000900331002000900340035001000349801001400359#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#c#184#35#article#40#35#^rND^sMille
r^nSC#^rND^sBottema^nCD#^rND^sStathis^nPA#^rND^sTokes^nLG#^rND^sFeldman^nD#Unexp
ected presence of estrogens in culture medium supplements: subsequent metabolism
 by the yeast Sacchromyces cerevisiae^len#Endocrinology#19860000#1986#119#1362-1
369#20080100#6926.htm#0013-7227#Endocrinology##
00692000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100019000900100
01800109012020000127030001200327065000900339064000500348031000300353014000600356
865000900362002000900371035001000380801001200390#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6926.htm#S#c#185#36#article#40#36#^rND^sQin^nYM#^rND^sPoutanen^nMH#^r
ND^sNovikov^nDK#Substrate specificities of peroxisomal members of short-chain al
cohol dehydrogenase superfamily: expression and characterization of dehydrogenas
e part of Candida tropicalis multifunctional enzyme^len#J Lipid Res#20000000#200
0#41#93-98#20080100#6926.htm#0022-2275#J Lipid Res##
00605000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940120
10600111030002700217065000900244064000500253031000400258014001000262865000900272
002000900281035001000290801002700300#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
926.htm#S#c#186#37#article#40#37#^rND^sMotizuki^nM#^rND^sTsurugi^nK#Effect of 17
 beta-estradiol on the generation time of old cells of the yeast Saccharomyces c
erevisiae^len#Biochem Biophys Res Commun#19920000#1992#183#1191-1196#20080100#69
26.htm#0006-291X#Biochem Biophys Res Commun##
00626000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100016000940100
01600110012012800126030001400254065000900268064000500277031000400282014000800286
865000900294002000900303035001000312801001400322#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6926.htm#S#c#187#38#article#40#38#^rND^sPlankert^nU#^rND^sPurwin^nC#^
rND^sHolzer^nH#Yeast fructose-2,6-bisphosphate 6-phosphatase is encoded by PHO8,
 the gene for nonspecific repressible alkaline phosphatase^len#Eur J Biochem#199
10000#1991#196#191-196#20080100#6926.htm#0014-2956#Eur J Biochem##
00667000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100015000940100
01700109010001800126010001700144010001700161012008000178030001400258065000900272
06400050028103100030028601400100028986500090029900200090030803500100031780100140
0327#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#c#188#39#article#40#39
#^rND^sNarisawa^nS#^rND^sHuang^nL#^rND^sIwasaki^nA#^rND^sHasegawa^nH#^rND^sAlper
s^nDH#^rND^sMillan^nJL#Accelerated fat absorption in intestinal alkaline phospha
tase knockout mice^len#Mol Cell Biol#20030000#2003#23#7525-7530#20080100#6926.ht
m#0270-7306#Mol Cell Biol##
00664000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100018000910100
01600109010001600125010001400141010001400155810000600169012007500175030004000250
71000020029006500090029206400050030103100040030601400100031086500090032000200090
0329#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6926.htm#S#c#189#40#article#40#40
#^rND^sMalo^nMS#^rND^sMozumder^nM#^rND^sZhang^nXB#^rND^sBiswas^nS#^rND^sChen^nA#
^rND^sBai^nLC#et al#Intestinal alkaline phosphatase gene expression is activated
 by ZBP-89^len#Am J Physiol Gastrointest Liver Physiol#2#20060000#2006#290#G737-
G746#20080100#6926.htm##
00267000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00300094#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#o#1#1#article#1#20
080623#161537#6929.htm#82##
02987000000000649000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000300108
03000200011103100030013103200020013406500090013601400090014503500100015401200760
01640100024002400100023002640100027002870100029003140100025003430100024003680100
02100392010002500413010002400438010002300462070012500485070013200610083139300742
08500080213508500310214308500350217408500250220908500230223411700060225707200030
22630580005022660580007022711120009022781110014022871140009023011130018023100020
00902328#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#h#2#1#article#1#sc
#en#bjmbr#1#3.1#ILUS#TAB#12#BJMBR080#nd#Braz J Med Biol Res#41#1#20080100#^f78^l
81#0100-879X#Sildenafil delays the intestinal transit of a liquid meal in awake 
rats^len#^rND^1A01^nJ.R.V^sGraça#^rND^1A01^nG.M^sMacedo#^rND^1A01^nR.C^sPalheta 
Jr#^rND^1A01^nF. de A.A^sGondim#^rND^1A01^nR.O^sNogueira#^rND^1A01^nJ.M^sCorreia
#^rND^1A01^nF.H^sRola#^rND^1A02^nR.B^sOliveira#^rND^1A01^nM.A.N^sSouza#^rND^1A01
^nA.A^sSantos#Universidade Federal do Ceará^iA01^1Faculdade de Medicina^2Departa
mento de Fisiologia e Farmacologia^cFortaleza^sCE,^pBrasil#Universidade de São P
aulo^iA02^1Faculdade de Medicina de Ribeirão Preto^2Departamento de Clínica Médi
ca^cRibeirão Preto^sSP^pBrasil#^len^aSildenafil slows down the gastric emptying 
of a liquid test meal in awake rats and inhibits the contractility of intestinal
 tissue strips. We studied the acute effects of sildenafil on in vivo intestinal
 transit in rats. Fasted, male albino rats (180-220 g, N = 44) were treated (0.2
 mL, iv) with sildenafil (4 mg/kg) or vehicle (0.01 N HCl). Ten minutes later th
ey were fed a liquid test meal (99m technetium-labeled saline) injected directly
 into the duodenum. Twenty, 30 or 40 min after feeding, the rats were killed and
 transit throughout the gastrointestinal tract was evaluated by progression of t
he radiotracer using the geometric center method. The effect of sildenafil on me
an arterial pressure (MAP) was monitored in a separate group of rats (N = 14). D
ata (medians within interquartile ranges) were compared by the Mann-Whitney U-te
st. The location of the geometric center was significantly more distal in vehicl
e-treated than in sildenafil-treated rats at 20, 30, and 40 min after test meal 
instillation (3.3 (3.0-3.6) vs 2.9 (2.7-3.1); 3.8 (3.4-4.0) vs 2.9 (2.5-3.1), an
d 4.3 (3.9-4.5) vs 3.4 (3.2-3.7), respectively; P < 0.05). MAP was unchanged in 
vehicle-treated rats but decreased by 25% (P < 0.05) within 10 min after sildena
fil injection. In conclusion, besides transiently decreasing MAP, sildenafil del
ays the intestinal transit of a liquid test meal in awake rats.#^dnd^i1#^tm^len^
kIntestinal transit^i1#^tm^len^kMean arterial pressure^i1#^tm^len^kScintigraphy^
i1#^tm^len^kSildenafil^i1#other#20#CNPq#FUNCAP#20070612#June 12, 2007#20071122#N
ovember 22, 2007#6929.htm##
03052000000000649000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000300108
03000200011103100030013103200020013406500090013601400090014503500100015401200830
01640100024002470100023002710100027002940100029003210100025003500100024003750100
02100399010002500420010002400445010002300469070012500492070013200617083145100749
08500080220008500310220808500350223908500250227408500230229911700060232207200030
23280580005023310580007023361120009023431110014023521140009023661130018023750020
00902393#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#f#3#1#article#1#sc
#en#bjmbr#1#3.1#ILUS#TAB#12#BJMBR080#nd#Braz J Med Biol Res#41#1#20080100#^f78^l
81#0100-879X#<b>Sildenafil delays the intestinal transit of a liquid meal in awa
ke rats</b>^len#^rND^1A01^nJ.R.V^sGraça#^rND^1A01^nG.M^sMacedo#^rND^1A01^nR.C^sP
alheta Jr#^rND^1A01^nF. de A.A^sGondim#^rND^1A01^nR.O^sNogueira#^rND^1A01^nJ.M^s
Correia#^rND^1A01^nF.H^sRola#^rND^1A02^nR.B^sOliveira#^rND^1A01^nM.A.N^sSouza#^r
ND^1A01^nA.A^sSantos#Universidade Federal do Ceará^iA01^1Faculdade de Medicina^2
Departamento de Fisiologia e Farmacologia^cFortaleza^sCE,^pBrasil#Universidade d
e São Paulo^iA02^1Faculdade de Medicina de Ribeirão Preto^2Departamento de Clíni
ca Médica^cRibeirão Preto^sSP^pBrasil#^len^aSildenafil slows down the gastric em
ptying of a liquid test meal in awake rats and inhibits the contractility of int
estinal tissue strips. We studied the acute effects of sildenafil on <i>in vivo<
/i> intestinal transit in rats. Fasted, male albino rats (180-220 g, N = 44) wer
e treated (0.2 mL, <i>iv</i>) with sildenafil (4 mg/kg) or vehicle (0.01 N HCl).
 Ten minutes later they were fed a liquid test meal (<b><sup>99m</sup></b>techne
tium-labeled saline) injected directly into the duodenum. Twenty, 30 or 40 min a
fter feeding, the rats were killed and transit throughout the gastrointestinal t
ract was evaluated by progression of the radiotracer using the geometric center 
method. The effect of sildenafil on mean arterial pressure (MAP) was monitored i
n a separate group of rats (N = 14). Data (medians within interquartile ranges) 
were compared by the Mann-Whitney U-test. The location of the geometric center w
as significantly more distal in vehicle-treated than in sildenafil-treated rats 
at 20, 30, and 40 min after test meal instillation (3.3 (3.0-3.6) <i>vs</i> 2.9 
(2.7-3.1); 3.8 (3.4-4.0) <i>vs</i> 2.9 (2.5-3.1), and 4.3 (3.9-4.5) <i>vs</i> 3.
4 (3.2-3.7), respectively; P &lt; 0.05). MAP was unchanged in vehicle-treated ra
ts but decreased by 25% (P &lt; 0.05) within 10 min after sildenafil injection. 
In conclusion, besides transiently decreasing MAP, sildenafil delays the intesti
nal transit of a liquid test meal in awake rats.#^dnd^i1#^tm^len^kIntestinal tra
nsit^i1#^tm^len^kMean arterial pressure^i1#^tm^len^kScintigraphy^i1#^tm^len^kSil
denafil^i1#other#20#CNPq#FUNCAP#20070612#June 12, 2007#20071122#November 22, 200
7#6929.htm##
03144000000000673000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000500100038000400105121000300109049000900112
15800030012103000240012403100030014803200020015106500090015301400090016203500100
01710120076001810100026002570100024002830100032003070100030003390100026003690100
02500395010002200420010002600442010002600468010002400494070012700518070013400645
08314000077908500080217908500310218708500350221808500250225308500230227811700060
23010720003023070580005023100580007023151120009023221110014023311140009023451130
01802354002000902372008008902381#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.
htm#S#l#4#1#article#1#^mJan.^a2008#sc#en#bjmbr#1#3.1#ilus#tab#12#BJMBR080#nd#Bra
z. j. med. biol. res#41#1#20080100#^f78^l81#0100-879X#Sildenafil delays the inte
stinal transit of a liquid meal in awake rats^len#^rND^1A01^nJ. R. V^sGraça#^rND
^1A01^nG. M^sMacedo#^rND^1A01^nR. C^sPalheta Júnior#^rND^1A01^nF. de A. A^sGondi
m#^rND^1A01^nR. O^sNogueira#^rND^1A01^nJ. M^sCorreia#^rND^1A01^nF. H^sRola#^rND^
1A02^nR. B^sOliveira#^rND^1A01^nM. A. N^sSouza#^rND^1A01^nA. A^sSantos#^iA01^1Un
iversidade Federal do Ceará^2Faculdade de Medicina^3Departamento de Fisiologia e
 Farmacologia^cFortaleza^sCE,^pBrasil#^iA02^1Universidade de São Paulo^2Faculdad
e de Medicina de Ribeirão Preto^3Departamento de Clínica Médica^cRibeirão Preto^
sSP^pBrasil#^len^aSildenafil slows down the gastric emptying of a liquid test me
al in awake rats and inhibits the contractility of intestinal tissue strips. We 
studied the acute effects of sildenafil on in vivo intestinal transit in rats. F
asted, male albino rats (180-220 g, N = 44) were treated (0.2 mL, iv) with silde
nafil (4 mg/kg) or vehicle (0.01 N HCl). Ten minutes later they were fed a liqui
d test meal (99m technetium-labeled saline) injected directly into the duodenum.
 Twenty, 30 or 40 min after feeding, the rats were killed and transit throughout
 the gastrointestinal tract was evaluated by progression of the radiotracer usin
g the geometric center method. The effect of sildenafil on mean arterial pressur
e (MAP) was monitored in a separate group of rats (N = 14). Data (medians within
 interquartile ranges) were compared by the Mann-Whitney U-test. The location of
 the geometric center was significantly more distal in vehicle-treated than in s
ildenafil-treated rats at 20, 30, and 40 min after test meal instillation (3.3 (
3.0-3.6) vs 2.9 (2.7-3.1); 3.8 (3.4-4.0) vs 2.9 (2.5-3.1), and 4.3 (3.9-4.5) vs 
3.4 (3.2-3.7), respectively; P < 0.05). MAP was unchanged in vehicle-treated rat
s but decreased by 25 percent (P < 0.05) within 10 min after sildenafil injectio
n. In conclusion, besides transiently decreasing MAP, sildenafil delays the inte
stinal transit of a liquid test meal in awake rats.#^dnd^i1#^tm^len^kIntestinal 
transit^i1#^tm^len^kMean arterial pressure^i1#^tm^len^kScintigraphy^i1#^tm^len^k
Sildenafil^i1#other#20#CNPq#FUNCAP#20070612#June 12, 2007#20071122#November 22, 
2007#6929.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S
0100-879X2008000100012##
00410000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704018500070002000900255#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#5#1#article#58#<P class="style4"> <A NAM
E="Home"></A><B>Braz J Med Biol Res, <font face="Arial, Helvetica, sans-serif">J
anuary    2008, Volume 41(1) 78-81</font> (Short Communication)</B></P>     ^cY#
6929.htm##
00378000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704015300070002000900223#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#6#2#article#58#<P><font size="5" face="A
rial, Helvetica, sans-serif"><B>Sildenafil delays the    intestinal transit of a
 liquid meal in awake rats</B> </font>      ^cY#6929.htm##
00856000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704063100070002000900701#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#7#3#article#58#<P><font face="Arial, Hel
vetica, sans-serif">J.R.V. Gra&ccedil;a<SUP>1</SUP>,    G.M. Macedo<SUP>1</SUP>,
 R.C. Palheta Jr.<SUP>1</SUP>, F. de A.A. Gondim<SUP>1</SUP>,    R.O. Nogueira<S
UP>1</SUP>, J.M. Correia<SUP>1</SUP>, F.H. Rola<SUP>1</SUP>,    R.B. Oliveira<SU
P>2</SUP>, M.A.N. Souza<SUP>1</SUP> and <span class="style2"><span class="style4
"><a href="#Correspondence"><img src="/img/revistas/bjmbr/v41n1/recor.gif" width
="15" height="14" border="0"></a>    <a href="meno@ufc.br"><img src="/img/revist
as/bjmbr/v41n1/email-ca.gif" width="14" height="11" border="0"></a></span></span
>    A.A. Santos<SUP>1</SUP> </font>      ^cY#6929.htm##
00422000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704019700070002000900267#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#8#4#article#58#<P><font face="Arial, Hel
vetica, sans-serif"><SUP>1</SUP>Departamento de Fisiologia    e Farmacologia, Fa
culdade de Medicina, Universidade Federal do Cear&aacute;,    Fortaleza, CE, Bra
sil     ^cY#6929.htm##
00429000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704020400070002000900274#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#9#5#article#58#<br>   <SUP>2</SUP>Depart
amento de Cl&iacute;nica M&eacute;dica, Faculdade de Medicina    de Ribeir&atild
e;o Preto, Universidade de S&atilde;o Paulo, Ribeir&atilde;o    Preto, SP, Brasi
l </font>      ^cY#6929.htm##
00510000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704028400071002000900355#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#10#6#article#58#<P><A HREF="#Abstract"><
font face="Arial, Helvetica, sans-serif"><IMG SRC="/img/revistas/bjmbr/v41n1/dow
n.gif" ALIGN=BOTTOM WIDTH=12 HEIGHT=12 BORDER=0 VSPACE=0 HSPACE=0></font></A>   
 <font face="Arial, Helvetica, sans-serif"><A HREF="#Abstract"><strong>Abstract<
/strong></A>    ^cY#6929.htm##
00415000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704018900071002000900260#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#11#7#article#58#<BR>   <A HREF="#Text"><
IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPA
CE=0 width="12" height="12"></A>    <A HREF="#Text"><strong>Text</strong></A>   
 ^cY#6929.htm##
00420000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704019400071002000900265#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#12#8#article#58#<BR>   <A HREF="#Referen
ces"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=
0 HSPACE=0 width="12" height="12"></A>    <A HREF="#References"><strong>Referenc
es    ^cY#6929.htm##
00461000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704023500071002000900306#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#13#9#article#58#<br>   </strong></A><A H
REF="#Acknowledgments"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTO
M BORDER=0 VSPACE=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Acknowledg
ments"><strong>Acknowledgments</strong></A>    ^cY#6929.htm##
00506000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704027900072002000900351#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#14#10#article#58#<BR>   <A HREF="#Corres
pondence"><IMG SRC="/img/revistas/bjmbr/v41n1/down.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0 width="12" height="12"></A>    <A HREF="#Correspondence"><strong
>Correspondence and Footnotes</strong></a></font></P> <HR ALIGN=LEFT WIDTH=100% 
SIZE=2>     ^cY#6929.htm##
00607000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038000072002000900452#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#15#11#article#58#<P class="style4"> <A N
AME="Abstract"></A><span class="style3"><font color="#00007F" size="4" face="Ari
al, Helvetica, sans-serif">Abstract    </font></span><A HREF="#Home"><FONT SIZE=
4><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=
0 HSPACE=0 LOOP="0" width="12" height="12"></B></FONT></A>  </P> <font face="Ari
al, Helvetica, sans-serif">      ^cY#6929.htm##
01738000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704151100072002000901583#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#16#12#article#58#<P>Sildenafil slows dow
n the gastric emptying of a liquid test meal in awake rats    and inhibits the c
ontractility of intestinal tissue strips. We studied the acute    effects of sil
denafil on <I>in vivo</I> intestinal transit in rats. Fasted,    male albino rat
s (180-220 g, N = 44) were treated (0.2 mL, <I>iv</I>) with sildenafil    (4 mg/
kg) or vehicle (0.01 N HCl). Ten minutes later they were fed a liquid    test me
al (<B><SUP>99m</SUP></B>technetium-labeled saline) injected directly    into th
e duodenum. Twenty, 30 or 40 min after feeding, the rats were killed    and tran
sit throughout the gastrointestinal tract was evaluated by progression    of the
 radiotracer using the geometric center method. The effect of sildenafil    on m
ean arterial pressure (MAP) was monitored in a separate group of rats (N    = 14
). Data (medians within interquartile ranges) were compared by the Mann-Whitney 
   U-test. The location of the geometric center was significantly more distal in
    vehicle-treated than in sildenafil-treated rats at 20, 30, and 40 min after 
   test meal instillation (3.3 (3.0-3.6) <I>vs</I> 2.9 (2.7-3.1); 3.8 (3.4-4.0) 
   <I>vs</I> 2.9 (2.5-3.1), and 4.3 (3.9-4.5) <I>vs</I> 3.4 (3.2-3.7), respectiv
ely;    P &lt; 0.05). MAP was unchanged in vehicle-treated rats but decreased by
 25%    (P &lt; 0.05) within 10 min after sildenafil injection. In conclusion, b
esides    transiently decreasing MAP, sildenafil delays the intestinal transit o
f a liquid    test meal in awake rats.      ^cY#6929.htm##
00361000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704013400072002000900206#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#17#13#article#58#<P>Key words: Intestina
l transit; Mean arterial pressure; Scintigraphy; Sildenafil </font>  <HR ALIGN=L
EFT WIDTH=100% SIZE=2>     ^cY#6929.htm##
00598000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704037100072002000900443#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#18#14#article#58#<P class="style4"><A NA
ME="Text"></A><span class="style3"><font color="#00007F" size="4" face="Arial, H
elvetica, sans-serif">Text    </font></span><A HREF="#Home"><FONT SIZE=4><B><IMG
 SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=
0 LOOP="0" width="12" height="12"></B></FONT></A>  </P> <font face="Arial, Helve
tica, sans-serif">      ^cY#6929.htm##
00926000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704069900072002000900771#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#19#15#article#58#<P>Sildenafil citrate b
elongs to a class of compounds called phosphodiesterase    (PDE) inhibitors. PDE
s constitute a family of enzymes that hydrolyze cyclic    nucleotides (cyclic ad
enosine monophosphate and cyclic guanosine monophosphate,    cGMP) and play a cr
itical role in the modulation of the second messenger pathway    (1). Sildenafil
 citrate is a selective PDE type 5 inhibitor widely used due    to its therapeut
ic efficacy in human erectile dysfunction and pulmonary hypertension.    It effe
ctively blocks the PDE 5-mediated hydrolysis of cGMP inside vascular    smooth m
uscle cells, relaxing the arterioles that supply the corpus cavernosum    (2) an
d the lung parenchyma (3).      ^cY#6929.htm##
00858000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704063100072002000900703#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#20#16#article#58#<P>Sildenafil increases
 the gastric resistance to injury by non-steroidal anti-inflammatory    drugs (4
), decreases the distal esophageal peristalsis (5), and inhibits the    gastric 
emptying of test meals both in humans and rats (6,7), and decreases    the contr
actility of isolated duodenal strips (8). Since the gastrointestinal    transit 
rate results from a complex interplay between gastric tonus, distal    stomach p
hasic activity and resistance and propulsion offered by the small intestine    (
9), we measured the effect of sildenafil on the small bowel intestinal transit  
  of a liquid test meal in awake rats.      ^cY#6929.htm##
01647000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704142000072002000901492#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#21#17#article#58#<P>Male albino rats (18
0-220 g, N = 58) were obtained from the animal house of    our institution. All 
animal handling and experimental protocols followed the    guidelines of the Bra
zilian College of Animal Experimentation and were approved    by local Research 
Ethics Committee. Rats were initially submitted to 24 h of    fasting in individ
ual Bowman cages. After anesthesia with tribromoethanol (250    mg/kg, <I>ip</I>
), the cervical vessels were cannulated with a polyethylene    catheter (PE 50) 
filled with saline and heparin (500 units/mL) that was tunneled    subcutaneousl
y to the back of the rats and then fixed with a silk ligature between    the sho
ulders. After laparotomy, a silastic tube (6 mm OD) was inserted through    a mi
dgastric incision and its distal end positioned in the proximal duodenum    (~1.
0 cm beyond the pylorus). The tube was fixed to the gastric wall with a    pouch
 suture and its proximal end tunneled subcutaneously to the interscapular    reg
ion, where it was externalized and occluded. After 3 days of recovery from    su
rgery, the animals were again submitted to fasting for 16 h with free access    
to an oral hydration solution (75 mM Na<SUP>+</SUP>, 65 mM Cl<SUP>-</SUP>, 20   
 mM K<SUP>+</SUP>, 75 mM glucose, and 10 mM citrate). All experiments were perfo
rmed    on awake, freely moving rats after a 30-min period for adaptation to the
 laboratory    environment.      ^cY#6929.htm##
01853000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704162600072002000901698#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#22#18#article#58#<P>First, the rats were
 randomly treated (0.2 mL, <I>iv</I>) with either sildenafil    (4 mg/kg, N = 21
) or vehicle (0.01 N HCl, N = 23). After 10 min, they were fed    a liquid test 
meal (10 MBq <SUP>99m</SUP>technetium coupled to phytate diluted    in 1.0 mL sa
line) injected via the tube directly into the proximal duodenum.    After 20, 30
, or 40 min, rats were killed by excess pentobarbital anesthesia    and then sub
mitted to gut exeresis. The stomach and the first 1.0 cm of the    proximal duod
enum that contained the cannula comprised segment 1. The remaining    intestine 
was carefully removed and slightly stretched. Obstructive ligatures    were perf
ormed to obtain five consecutive segments of the small bowel (about    20 cm lon
g) whereas the entire large bowel comprised segment 7. Radioactivity    was dete
rmined with a g-camera (Millennium MPR, General Electrics Inc., USA)    in each 
segment. Data were recorded by the Solaris 2.0 computer system (SUN    Microsyst
ems Inc., USA) as number of counts per minute, after discounting background    a
ctivity. To rule out eventual gut absorption of the marker, carcass radioactivit
y    was also obtained. Fractional marker retention was calculated for each gut 
segment    as a ratio between the counts obtained in this segment and the sum of
 counts    of all gastrointestinal segments, including the gastroduodenal one. T
he data    obtained for each individual segment were then multiplied by the numb
er of the    respective segment and summed up to calculate the geometric center 
of the marker    distribution throughout the gastrointestinal tract (10).      ^
cY#6929.htm##
00831000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704060400072002000900676#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#23#19#article#58#<P>Next, the rats were 
connected to a transducer coupled to a data acquisition    system (PowerLab<SUP>
&#174;</SUP>; AD Instruments, Australia). After a 30-min    period of stabilizat
ion, mean arterial pressure (MAP, in mmHg) was continuously    recorded on a mic
rocomputer for 1 h. The first 20 min were considered as a basal    period. Next,
 the rats were randomly treated (0.2 mL, <I>iv</I>) with sildenafil    (4 mg/kg,
 N = 8) or vehicle (0.01 N HCl, N = 6), as described before. MAP values    obtai
ned after vehicle or sildenafil treatment were pooled into consecutive    10-min
 intervals.      ^cY#6929.htm##
00595000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704036800072002000900440#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#24#20#article#58#<P>Intestinal transit i
ndexes were compared by the Mann-Whitney U-test and are    reported as medians w
ithin interquartile ranges. Differences between MAP values    are reported as me
an &#177; SEM and were compared by one-way ANOVA for repeated    measures and th
e Bonferroni test. P values lower than 0.05 were considered to    be statistical
ly significant.      ^cY#6929.htm##
01432000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704120500072002000901277#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#25#21#article#58#<P>Typical scintiscans 
of the intestinal transit obtained from vehicle- and sildenafil-treated    rats 
studied 40 min after meal gavage are shown in <strong><a href="#Fig1">Figure    
1A</a></strong>. On the sildenafil scintiscan, one can see that the foremost    
marker retention in proximal gut segments (2 and 3) was well behind when compare
d    to that obtained on the placebo scintiscan. In both groups, there was also 
radioactive    marker retention in segment 1 (corresponding to the stomach and d
uodenal stump),    probably due to duodenogastric reflux after intraduodenal adm
inistration.<strong><a href="#Fig1">Figure    1B</a></strong> shows that sildena
fil treatment induced a consistent delay in    intestinal transit. In the contro
l group, the radioactive marker progressed    throughout the gastrointestinal tr
act; i.e., the center of mass advanced gradually    over 20, 30, and 40 min afte
r the meal (3.3 (3.0-3.6), 3.8 (3.4-4.0), and 4.3    (3.9-4.5)), respectively. O
n the other hand, the center of mass of the sildenafil-treated    animals remain
ed behind, i.e., 2.9 (2.7-3.1); 2.9 (2.5-3.1) and 3.4 (3.2-3.7),    respectively
 at 20, 30, and 40 min after the meal (P &lt; 0.05).      ^cY#6929.htm##
01225000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704099800072002000901070#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#26#22#article#58#<P><strong><a href="#Ta
b1">Table 1</a></strong> compares the effects of sildenafil    or vehicle treatm
ent on the MAP of awake rats. In control rats, MAP remained    within stable lev
els (P &lt; 0.05) throughout the experiments (96.0 &#177; 3.5,    95.2 &#177; 3.
4, 90.1 &#177; 3.0, 98.0 &#177; 3.2, 97.4 &#177; 3.6, 98.0 &#177;    3.0 mmHg, r
espectively for basal, vehicle injection, gavage feeding, and 20-,    30-, and 4
0-min postprandial intervals). On the other hand, sildenafil treatment    induce
d a significant but short-lived arterial hypotension (a 25% drop at nadir)    fr
om the respective basal MAP values (100.2 &#177; 3.0 mmHg). After gavage there  
  was only a residual decrease (P &lt; 0.05) in MAP in sildenafil-treated rats  
  (85<I>.</I>9 &#177; 1<I>.</I>8 mmHg), with MAP reaching levels similar to basa
l    ones thereafter (96<I>.</I>2 &#177; 3<I>.</I>0, 97.3 &#177; 3.5, and 98.2 &
#177;    3.0 mmHg, respectively for the 20-, 30-, and 40-min postprandial interv
als).      ^cY#6929.htm##
00673000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704044600072002000900518#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#27#23#article#58#<P>In the present inves
tigation, intestinal transit was studied by scintigraphy,    which allows the de
termination of the fractional retention of a radioactive    marker throughout th
e gastrointestinal tract. This method has been extensively    employed due to it
s simplicity, ease-of-use, and accuracy (11). The present    indexes of intestin
al transit obtained from control rats were quite similar    to those reported by
 others (10).      ^cY#6929.htm##
00411000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704018400072002000900256#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#28#24#article#58#<P>In the present study
, we observed that sildenafil reduces the intestinal transit    of a radioactive
 liquid test meal directly injected into the duodenum of awake    rats.      ^cY
#6929.htm##
01434000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704120700072002000901279#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#29#25#article#58#<P>The remarkable reten
tion of an isotope marker in the proximal gut segments    and the delayed intest
inal transit in sildenafil-treated rats could be due to    intestinal myorelaxat
ion or increased segment contractions (12). We have previously    reported that 
sildenafil inhibits both spontaneous and cholinergic-induced duodenal    contrac
tions (8). In the same direction, drugs that inhibit gut contractility,    such 
as opioids, delay the intestinal transit of test meals in awake animals    (13,1
4). Since gastrointestinal smooth muscle cells also exhibit the PDE type    5 en
zyme (15), the increase in intracellular levels of cGMP presumably caused    by 
sildenafil could have induced myorelaxation that delayed the intestinal transit.
    The present data agree with previous reports of a gastrointestinal transit d
elay    induced by sildenafil both in humans and animals (7,16). Since sildenafi
l crosses    the blood brain barrier, this drug can also act on the central nerv
ous system    (17). Thus, one cannot rule out the possibility that the sildenafi
l-associated    intestinal transit delay could be secondary to a sympathetic ner
vous system    activation promoted by the drug (7,18).      ^cY#6929.htm##
00961000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704073400072002000900806#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#30#26#article#58#<P>As previously demons
trated (19), sildenafil induced arterial hypotension. However,    this effect wa
s short-lived compared to the delay of intestinal transit, which    persisted fo
r at least 50 min after drug administration. Thus, it seems that    the sildenaf
il-induced delay of the intestinal transit results from a direct    action of th
e drug on the gastrointestinal smooth muscle cells, instead of a    secondary he
modynamic effect (19). Interestingly, there was almost no retention    of the is
otope marker in the gastroduodenal stumps of the sildenafil-treated    rats. We 
wonder if this phenomenon could be related to a greater intestinal    compliance
 induced by sildenafil, decreasing the duodenogastric reflux.      ^cY#6929.htm#
#
00962000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704073500072002000900807#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#31#27#article#58#<P>Sildenafil transient
ly decreases MAP and delays the intestinal transit of a    liquid test meal in a
wake rats. The slowing down of both gastric emptying and    intestinal transit i
nduced by sildenafil could be related to the side effects    of the drug since a
s many as 3% of sildenafil users have reported gut dysmotility    complaints suc
h as dyspepsia and diarrhea (20). </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2> <ta
ble width="100%"  border="0">   <tr align="left" valign="top">      <td width="1
1%"><a href="/img/revistas/bjmbr/v41n1/html/6929i01.htm"><img src="/img/revistas
/bjmbr/v41n1/6929i01peq.jpg" width="120" height="48" border="2"></a></td>     <t
d width="89%"><font face="Arial, Helvetica, sans-serif">            ^cY#6929.htm
##
01417000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704119000072002000901262#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#32#28#article#58#<P><a name="Fig1"></a>F
igure 1. Comparison of <I>iv</I> treatment (0.2 mL)          with sildenafil (4 
mg/kg) or vehicle (0.01 N HCl) on the intestinal transit          of a liquid te
st meal in awake rats. Ten minutes after treatment, rats          were fed by in
traduodenal injection a 1.0-mL bolus of saline labeled with          <SUP>99m</S
UP>technetium and killed 20, 30, or 40 min later. <I>A</I>,          Typical rad
ioactivity scintiscans and plots of fractional retention of          the marker 
throughout the gut, from the stomach and proximal duodenum          (segment num
ber 1) to the large bowel (segment number 7) of sildenafil-          (full line)
 or vehicle (broken line)-treated rats, studied at 40 min after          the mea
l. GIT = gastrointestinal tract. <I>B</I>, Values of the geometric          cent
er of radioactivity distribution from the stomach and proximal duodenum         
 (segment number 1) to the large bowel (segment number 7) of awake rats         
 treated with sildenafil (filled squares) or vehicle (open squares). Horizontal 
         bars are medians. P &lt; 0.05 compared to control (Mann-Whitney U-test)
.       </font> </td>   </tr> </table>     ^cY#6929.htm##
00889000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704066200072002000900734#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#33#29#article#58#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image    (96 K JPG file)]</fo
nt>  <HR ALIGN=LEFT WIDTH=100% SIZE=2> <table width="100%"  border="0">   <tr al
ign="left" valign="top">      <td width="11%"><a href="/img/revistas/bjmbr/v41n1
/html/6929t01.htm"><img src="/img/revistas/bjmbr/v41n1/table.jpg" width="100" he
ight="65" border="2"></a></td>     <td width="89%"><font face="Arial, Helvetica,
 sans-serif"><a name="Tab1"></a>Table        1. Effects of <I>iv</I> treatment (
0.2 mL) withsildenafil (4 mg/kg) or vehicle        (0.01 N HCl) on the mean arte
rial pressure (MAP, mmHg) of awake rats. </font></td>   </tr> </table>     ^cY#6
929.htm##
00377000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704015000072002000900222#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#34#30#article#58#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table    (66 K JPG file)]</fo
nt>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6929.htm##
00552000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704032500072002000900397#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#35#31#article#58#<P class="style4"> <A N
AME="References"></A><FONT color="#00007F" SIZE=4><B>References</B></FONT>    <A
 HREF="#Home"><FONT SIZE=4><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALIG
N=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0" width="12" height="12"></B></FONT><
/A>  </P> <font face="Arial, Helvetica, sans-serif">      ^cY#6929.htm##
00397000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704015600074002000900230#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#p#36#32#article#58#1#<P>1. Gib
son A. Phosphodiesterase 5 inhibitors and nitrergic transmission - from    zapri
nast to sildenafil. <I>Eur J Pharmacol</I> 2001; 411: 1-10.    ^cY#6929.htm##
00453000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704021200074002000900286#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#p#37#33#article#58#2#<P>2. Gol
dstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral    silden
afil in the treatment of erectile dysfunction. Sildenafil Study Group.    <I>N E
ngl J Med</I> 1998; 338: 1397-1404.    ^cY#6929.htm##
00462000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704022100074002000900295#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#p#38#34#article#58#3#<P>3. Bar
reto AC, Franchi SM, Castro CR, Lopes AA. One-year follow-up of the effects    o
f sildenafil on pulmonary arterial hypertension and veno-occlusive disease.    <
I>Braz J Med Biol Res</I> 2005; 38: 185-195.    ^cY#6929.htm##
00485000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704024400074002000900318#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#p#39#35#article#58#4#<P>4. San
tos CL, Souza MH, Gomes AS, Lemos HP, Santos AA, Cunha FQ, et al. Sildenafil    
prevents indomethacin-induced gastropathy in rats: role of leukocyte adherence  
  and gastric blood flow. <I>Br J Pharmacol</I> 2005; 146: 481-486.    ^cY#6929.
htm##
00483000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704024200074002000900316#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#p#40#36#article#58#5#<P>5. Zha
ng X, Tack J, Janssens J, Sifrim DA. Effect of sildenafil, a phosphodiesterase-5
    inhibitor, on oesophageal peristalsis and lower oesophageal sphincter functi
on    in cats. <I>Neurogastroenterol Motil</I> 2001; 13: 325-331.    ^cY#6929.ht
m##
00439000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704019800074002000900272#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#p#41#37#article#58#6#<P>6. Sar
nelli G, Sifrim D, Janssens J, Tack J. Influence of sildenafil on gastric    sen
sorimotor function in humans. <I>Am J Physiol Gastrointest Liver Physiol</I>    
2004; 287: G988-G992.    ^cY#6929.htm##
00517000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704027600074002000900350#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#p#42#38#article#58#7#<P>7. de 
Rosalmeida MC, Saraiva LD, da Gra&ccedil;a JR, Ivo BB, da Nobrega MV,    Gondim 
FA, et al. Sildenafil, a phosphodiesterase-5 inhibitor, delays gastric    emptyi
ng and gastrointestinal transit of liquid in awake rats. <I>Dig Dis Sci</I>    2
003; 48: 2064-2068.    ^cY#6929.htm##
00513000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704027200074002000900346#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#p#43#39#article#58#8#<P>8. Ara
ujo PV, Clemente CM, da Gra&ccedil;a JR, Rola FH, de Oliveira RB, dos    Santos 
AA, et al. Inhibitory effect of sildenafil on rat duodenal contractility    <I>i
n vitro</I>: putative cGMP involvement. <I>Clin Exp Pharmacol Physiol</I>    200
5; 32: 191-195.    ^cY#6929.htm##
00530000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704028900074002000900363#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#p#44#40#article#58#9#<P>9. Mal
agelada JR, Aspiroz F. Determinants of gastric emptying and transit in    the sm
all intestine. In: Wood JD (Editor), <I>Handbook of physiology. The gastro-intes
tinal    system. Section VI, Volume 1, Part 2</I>. Bethesda: American Physiologi
cal Society;    1989. p 909-937.    ^cY#6929.htm##
00506000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704026400075002000900339#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#p#45#41#article#58#10#<P>10. T
roncon LE, Santos AA, Garbacio VL, Secaf M, Verceze AV, Cunha-Melo JR.    Inhibi
tion of gastric emptying and intestinal transit in anesthetized rats by    a <I>
Tityus serrulatus</I> scorpion toxin. <I>Braz J Med Biol Res</I> 2000;    33: 10
53-1058.    ^cY#6929.htm##
00393000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704015100075002000900226#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#p#46#42#article#58#11#<P>11. M
iller MS, Galligan JJ, Burks TF. Accurate measurement of intestinal transit    i
n the rat. <I>J Pharmacol Methods</I> 1981; 6: 211-217.    ^cY#6929.htm##
00410000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704016800075002000900243#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#p#47#43#article#58#12#<P>12. L
in HC, Prather C, Fisher RS, Meyer JH, Summers RW, Pimentel M, et al.    Measure
ment of gastrointestinal transit. <I>Dig Dis Sci</I> 2005; 50: 989-1004.    ^cY#
6929.htm##
00475000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023300075002000900308#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#p#48#44#article#58#13#<P>13. M
anara L, Bianchi G, Ferretti P, Tavani A. Inhibition of gastrointestinal    tran
sit by morphine in rats results primarily from direct drug action on gut    opio
id sites. <I>J Pharmacol Exp Ther</I> 1986; 237: 945-949.    ^cY#6929.htm##
00533000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704029100075002000900366#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#p#49#45#article#58#14#<P>14. P
ol O, Valle L, Sanchez-Blazquez P, Garzon J, Puig MM. Antibodies and antisense  
  oligodeoxynucleotides to mu-opioid receptors, selectively block the effects   
 of mu-opioid agonists on intestinal transit and permeability in mice. <I>Br    
J Pharmacol</I> 1999; 127: 397-404.    ^cY#6929.htm##
00464000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022200075002000900297#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#p#50#46#article#58#15#<P>15. K
aneda T, Yamamoto H, Azegami Y, Shimizu K, Urakawa N, Nakajyo S. Lack    of cycl
ic nucleotide regulation of MBCQ-induced relaxation of rat ileal smooth    muscl
e. <I>J Smooth Muscle Res</I> 2003; 39: 47-54.    ^cY#6929.htm##
00412000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704017000075002000900245#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#p#51#47#article#58#16#<P>16. B
ortolotti M, Mari C, Lopilato C, La Rovere L, Miglioli M. Sildenafil inhibits   
 gastroduodenal motility. <I>Aliment Pharmacol Ther</I> 2001; 15: 157-161.    ^c
Y#6929.htm##
00336000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704009400075002000900169#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#p#52#48#article#58#17#<P>17. V
obig MA. Retinal side-effects of sildenafil. <I>Lancet</I> 1999; 353:    1442.  
  ^cY#6929.htm##
00413000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704017100075002000900246#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#p#53#49#article#58#18#<P>18. P
hillips BG, Kato M, Pesek CA, Winnicki M, Narkiewicz K, Davison D, et    al. Sym
pathetic activation by sildenafil. <I>Circulation</I> 2000; 102: 3068-3073.    ^
cY#6929.htm##
00490000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704024800075002000900323#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#p#54#50#article#58#19#<P>19. G
ondim FA, de-Oliveira GR, Gra&ccedil;a JR, Cavalcante DI, Souza MA, Santos    AA
, et al. Variations in gastric emptying of liquid elicited by acute blood    vol
ume changes in awake rats. <I>Braz J Med Biol Res</I> 1998; 31: 967-973.    ^cY#
6929.htm##
00401000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704015900075002000900234#v41
n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#p#55#51#article#58#20#<P>20. G
oldenberg MM. Safety and efficacy of sildenafil citrate in the treatment    of m
ale erectile dysfunction. <I>Clin Ther</I> 1998; 20: 1033-1048.    ^cY#6929.htm#
#
00280000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704005300072002000900125#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#56#52#article#58#  </font>  <HR ALIGN=LE
FT WIDTH=100% SIZE=2>     ^cY#6929.htm##
00631000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704040400072002000900476#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#57#53#article#58#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT color="#00007F" SIZE=4
><B>Acknowledgments</B></FONT></font>    <font size="4" face="Arial, Helvetica, 
sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n1/back.gif" ALI
GN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0" width="12" height="12"></B></A></f
ont></P> <font face="Arial, Helvetica, sans-serif">      ^cY#6929.htm##
00365000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704013800072002000900210#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#58#54#article#58#<P>The authors wish to 
thank Mr. Haroldo Pinheiro for excellent technical assistance.  </font>  <HR ALI
GN=LEFT WIDTH=100% SIZE=2>     ^cY#6929.htm##
00527000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704030000072002000900372#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#59#55#article#58#<P class="style4"><A NA
ME="Correspondence"></A><FONT color="#00007F" SIZE=4><B>Correspondence    and Fo
otnotes</B></FONT> <A HREF="#Home"><FONT SIZE=4><B><IMG SRC="/img/revistas/bjmbr
/v41n1/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0" width="12" hei
ght="12"></B></FONT></A></P>     ^cY#6929.htm##
00743000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704051600072002000900588#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#60#56#article#58#<P class="style4"><B><a
 href="#Home"><img src="/img/revistas/bjmbr/v41n1/recor.gif" width="15" height="
14" border="0"></a>    Address for correspondence: </B><font face="Arial, Helvet
ica, sans-serif">A.A.    Santos, Laborat&oacute;rio Escola Prof. Luiz Capelo, De
partamento de Fisiologia    e Farmacologia, Faculdade de Medicina, Universidade 
Federal do Cear&aacute;,    60430-270 Fortaleza, CE, Brasil. Fax: +55-85-3366-83
33. E-mail: <strong><a href="mailto:meno@ufc.br">meno@ufc.br</a></strong></font>
</P>     ^cY#6929.htm##
00437000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704021000072002000900282#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#61#57#article#58#<P class="style4"><font
 face="Arial, Helvetica, sans-serif">Research supported    by CNPq and FUNCAP. P
ublication supported by FAPESP. Received June 12, 2007.    Accepted November 22,
 2007. </font></P>     ^cY#6929.htm##
00632000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704040500072002000900477#v41n1#v:\scielo
\serial\bjmbr\v41n1\markup\6929.htm#S#p#62#58#article#58#<P class="style4"><font
 face="Arial, Helvetica, sans-serif">This study is dedicated    to the memory of
 our colleague Dr. D.A.F. Queiroz.</font> <font face="Arial, Helvetica, sans-ser
if">    Part of a PhD thesis presented by J.R.V. Gra&ccedil;a to the Departament
o de    Fisiologia e Farmacologia, Faculdade de Medicina, Universidade Federal d
o Cear&aacute;,    Fortaleza, CE, Brasil. </font></P>     ^cY#6929.htm##
00531000000000265000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100016000730120093000890300
01600182065000900198064000500207031000400212014000500216865000900221002000900230
035001000239801001600249#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#c#
63#1#article#20#1#^rND^sGibson^nA#Phosphodiesterase 5 inhibitors and nitrergic t
ransmission - from zaprinast to sildenafil^len#Eur J Pharmacol#20010000#2001#411
#1-10#20080100#6929.htm#0014-2999#Eur J Pharmacol##
00671000000000325000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100019000730100014000920100
02200106010001600128010001700144010001700161012008500178030001300263065000900276
06400050028503100040029001400100029486500090030400200090031303500100032280100130
0332#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#c#64#2#article#20#2#^r
ND^sGoldstein^nI#^rND^sLue^nTF#^rND^sPadma-Nathan^nH#^rND^sRosen^nRC#^rND^sSteer
s^nWD#^rND^sWicker^nPA#Oral sildenafil in the treatment of erectile dysfunction:
 Sildenafil Study Group^len#N Engl J Med#19980000#1998#338#1397-1404#20080100#69
29.htm#0028-4793#N Engl J Med##
00651000000000301000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100018000730100018000910100
01700109010001600126012011400142030002000256065000900276064000500285031000300290
014000800293865000900301002000900310035001000319801002000329#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6929.htm#S#c#65#3#article#20#3#^rND^sBarreto^nAC#^rND^sFr
anchi^nSM#^rND^sCastro^nCR#^rND^sLopes^nAA#One-year follow-up of the effects of 
sildenafil on pulmonary arterial hypertension and veno-occlusive disease^len#Bra
z J Med Biol Res#20050000#2005#38#185-195#20080100#6929.htm#0100-879X#Braz J Med
 Biol Res##
00716000000000337000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100017000730100016000900100
01600106010001600122010001700138010001600155810000600171012011700177030001500294
06500090030906400050031803100040032301400080032786500090033500200090034403500100
0353801001500363#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#c#66#4#art
icle#20#4#^rND^sSantos^nCL#^rND^sSouza^nMH#^rND^sGomes^nAS#^rND^sLemos^nHP#^rND^
sSantos^nAA#^rND^sCunha^nFQ#et al#Sildenafil prevents indomethacin-induced gastr
opathy in rats: role of leukocyte adherence and gastric blood flow^len#Br J Phar
macol#20050000#2005#146#481-486#20080100#6929.htm#0007-1188#Br J Pharmacol##
00677000000000301000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100015000730100014000880100
01800102010001700120012013500137030002500272065000900297064000500306031000300311
014000800314865000900322002000900331035001000340801002500350#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6929.htm#S#c#67#5#article#20#5#^rND^sZhang^nX#^rND^sTack^
nJ#^rND^sJanssens^nJ#^rND^sSifrim^nDA#Effect of sildenafil, a phosphodiesterase-
5 inhibitor, on oesophageal peristalsis and lower oesophageal sphincter function
 in cats^len#Neurogastroenterol Motil#20010000#2001#13#325-331#20080100#6929.htm
#1350-1925#Neurogastroenterol Motil##
00588000000000289000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100018000730100016000910100
01800107010001400125012007100139030004000210710000200250065000900252064000500261
031000400266014001000270865000900280002000900289#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6929.htm#S#c#68#6#article#20#6#^rND^sSarnelli^nG#^rND^sSifrim^nD#^rND
^sJanssens^nJ#^rND^sTack^nJ#Influence of sildenafil on gastric sensorimotor func
tion in humans^len#Am J Physiol Gastrointest Liver Physiol#2#20040000#2004#287#G
988-G992#20080100#6929.htm##
00735000000000337000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100024000730100018000970100
01900115010001400134010002100148010001700169810000600186012012600192030001200318
06500090033006400050033903100030034401400100034786500090035700200090036603500100
0375801001200385#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#c#69#7#art
icle#20#7#^rND^sde^nRosalmeida MC#^rND^sSaraiva^nLD#^rND^sda^nGraça JR#^rND^sIvo
^nBB#^rND^sda^nNobrega MV#^rND^sGondim^nFA#et al#Sildenafil, a phosphodiesterase
-5 inhibitor, delays gastric emptying and gastrointestinal transit of liquid in 
awake rats^len#Dig Dis Sci#20030000#2003#48#2064-2068#20080100#6929.htm#0163-211
6#Dig Dis Sci##
00739000000000337000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100017000730100019000900100
01900109010001500128010002200143010002100165810000600186012010200192030002700294
06500090032106400050033003100030033501400080033886500090034600200090035503500100
0364801002700374#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#c#70#8#art
icle#20#8#^rND^sAraujo^nPV#^rND^sClemente^nCM#^rND^sda^nGraça JR#^rND^sRola^nFH#
^rND^sde^nOliveira RB#^rND^sdos^nSantos AA#et al#Inhibitory effect of sildenafil
 on rat duodenal contractility in vitro: putative cGMP involvement^len#Clin Exp 
Pharmacol Physiol#20050000#2005#32#191-195#20080100#6929.htm#0305-1870#Clin Exp 
Pharmacol Physiol##
00643000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100021000730100017000940120
07200111016001500183018008700198066000900285062003100294065000900325064000500334
014000800339865000900347002000900356#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6
929.htm#S#c#71#9#article#20#9#^rND^sMalagelada^nJR#^rND^sAspiroz^nF#Determinants
 of gastric emptying and transit in the small intestine^len#^rND^sWood^nJD#Handb
ook of physiology. The gastro-intestinal system. Section VI, Volume 1, Part 2^le
n#Bethesda#American Physiological Society#19890000#1989#909-937#20080100#6929.ht
m##
00721000000000325000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100018000750100017000930100
01900110010001500129010001800144010002100162012011700183030002000300065000900320
06400050032903100030033401400100033786500090034700200090035603500100036580100200
0375#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#c#72#10#article#20#10#
^rND^sTroncon^nLE#^rND^sSantos^nAA#^rND^sGarbacio^nVL#^rND^sSecaf^nM#^rND^sVerce
ze^nAV#^rND^sCunha-Melo^nJR#Inhibition of gastric emptying and intestinal transi
t in anesthetized rats by a Tityus serrulatus scorpion toxin^len#Braz J Med Biol
 Res#20000000#2000#33#1053-1058#20080100#6929.htm#0100-879X#Braz J Med Biol Res#
#
00567000000000289000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100017000750100019000920100
01600111012005800127030002000185065000900205064000500214031000200219014000800221
865000900229002000900238035001000247801002000257#v41n1#v:\scielo\serial\bjmbr\v4
1n1\markup\6929.htm#S#c#73#11#article#20#11#^rND^sMiller^nMS#^rND^sGalligan^nJJ#
^rND^sBurks^nTF#Accurate measurement of intestinal transit in the rat^len#J Phar
macol Methods#19810000#1981#6#211-217#20080100#6929.htm#0160-5402#J Pharmacol Me
thods##
00641000000000337000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100014000750100017000890100
01700106010001600123010001800139010001800157810000600175012004400181030001200225
06500090023706400050024603100030025101400090025486500090026300200090027203500100
0281801001200291#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#c#74#12#ar
ticle#20#12#^rND^sLin^nHC#^rND^sPrather^nC#^rND^sFisher^nRS#^rND^sMeyer^nJH#^rND
^sSummers^nRW#^rND^sPimentel^nM#et al#Measurement of gastrointestinal transit^le
n#Dig Dis Sci#20050000#2005#50#989-1004#20080100#6929.htm#0163-2116#Dig Dis Sci#
#
00665000000000301000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100016000750100017000910100
01800108010001600126012012500142030002100267065000900288064000500297031000400302
014000800306865000900314002000900323035001000332801002100342#v41n1#v:\scielo\ser
ial\bjmbr\v41n1\markup\6929.htm#S#c#75#13#article#20#13#^rND^sManara^nL#^rND^sBi
anchi^nG#^rND^sFerretti^nP#^rND^sTavani^nA#Inhibition of gastrointestinal transi
t by morphine in rats results primarily from direct drug action on gut opioid si
tes^len#J Pharmacol Exp Ther#19860000#1986#237#945-949#20080100#6929.htm#0022-35
65#J Pharmacol Exp Ther##
00732000000000313000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100013000750100015000880100
02600103010001600129010001500145012017400160030001500334065000900349064000500358
031000400363014000800367865000900375002000900384035001000393801001500403#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#c#76#14#article#20#14#^rND^sPol^nO
#^rND^sValle^nL#^rND^sSanchez-Blazquez^nP#^rND^sGarzon^nJ#^rND^sPuig^nMM#Antibod
ies and antisense oligodeoxynucleotides to mu-opioid receptors, selectively bloc
k the effects of mu-opioid agonists on intestinal transit and permeability in mi
ce^len#Br J Pharmacol#19990000#1999#127#397-404#20080100#6929.htm#0007-1188#Br J
 Pharmacol##
00689000000000325000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100016000750100018000910100
01700109010001700126010001700143010001700160012009500177030002000272065000900292
06400050030103100030030601400060030986500090031500200090032403500100033380100200
0343#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#c#77#15#article#20#15#
^rND^sKaneda^nT#^rND^sYamamoto^nH#^rND^sAzegami^nY#^rND^sShimizu^nK#^rND^sUrakaw
a^nN#^rND^sNakajyo^nS#Lack of cyclic nucleotide regulation of MBCQ-induced relax
ation of rat ileal smooth muscle^len#J Smooth Muscle Res#20030000#2003#39#47-54#
20080100#6929.htm#0916-8737#J Smooth Muscle Res##
00625000000000313000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100020000750100014000950100
01800109010001900127010001800146012004800164030002300212065000900235064000500244
031000300249014000800252865000900260002000900269035001000278801002300288#v41n1#v
:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#c#78#16#article#20#16#^rND^sBortol
otti^nM#^rND^sMari^nC#^rND^sLopilato^nC#^rND^sLa^nRovere L#^rND^sMiglioli^nM#Sil
denafil inhibits gastroduodenal motility^len#Aliment Pharmacol Ther#20010000#200
1#15#157-161#20080100#6929.htm#0269-2813#Aliment Pharmacol Ther##
00461000000000265000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100016000750120039000910300
00700130065000900137064000500146031000400151014000500155865000900160002000900169
035001000178801000700188#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#c#
79#17#article#20#17#^rND^sVobig^nMA#Retinal side-effects of sildenafil^len#Lance
t#19990000#1999#353#1442#20080100#6929.htm#0099-5355#Lancet##
00644000000000337000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100019000750100014000940100
01600108010001800124010002000142010001700162810000600179012004100185030001200226
06500090023806400050024703100040025201400100025686500090026600200090027503500100
0284801001200294#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#c#80#18#ar
ticle#20#18#^rND^sPhillips^nBG#^rND^sKato^nM#^rND^sPesek^nCA#^rND^sWinnicki^nM#^
rND^sNarkiewicz^nK#^rND^sDavison^nD#et al#Sympathetic activation by sildenafil^l
en#Circulation#20000000#2000#102#3068-3073#20080100#6929.htm#0009-7322#Circulati
on##
00719000000000337000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100017000750100022000920100
01600114010002100130010001600151010001700167810000600184012009800190030002000288
06500090030806400050031703100030032201400080032586500090033300200090034203500100
0351801002000361#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#c#81#19#ar
ticle#20#19#^rND^sGondim^nFA#^rND^sde-Oliveira^nGR#^rND^sGraça^nJR#^rND^sCavalca
nte^nDI#^rND^sSouza^nMA#^rND^sSantos^nAA#et al#Variations in gastric emptying of
 liquid elicited by acute blood volume changes in awake rats^len#Braz J Med Biol
 Res#19980000#1998#31#967-973#20080100#6929.htm#0100-879X#Braz J Med Biol Res##
00529000000000265000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100021000750120092000960300
01000188065000900198064000500207031000300212014001000215865000900225002000900234
035001000243801001000253#v41n1#v:\scielo\serial\bjmbr\v41n1\markup\6929.htm#S#c#
82#20#article#20#20#^rND^sGoldenberg^nMM#Safety and efficacy of sildenafil citra
te in the treatment of male erectile dysfunction^len#Clin Ther#19980000#1998#20#
1033-1048#20080100#6929.htm#0149-2918#Clin Ther##
